

Correspondence to: N I Kassebaum

Department of Health Metrics Sciences, Global Health, and Anesthesiology & Pain Medicine, Institute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA nickjk@uw.edu (ORCID 0000-0002-4299-9348)

Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2022;376:e068208 http://dx.doi.org/10.1136/ bmj-2021-068208

Accepted: 26 January 2022

Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study

on behalf of GBD 2019 Ageing Collaborators

ABSTRACT

OBJECTIVES

To use data from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) to estimate mortality and disability trends for the population aged ≥70 and evaluate patterns in causes of death, disability, and risk factors.

DESIGN Systematic analysis.

SETTING

Participants were aged ≥70 from 204 countries and territories, 1990-2019.

MAIN OUTCOMES MEASURES

Years of life lost, years lived with disability, disability adjusted life years, life expectancy at age 70 (LE-70), healthy life expectancy at age 70 (HALE-70), proportion of years in ill health at age 70 (PYIH-70), risk factors, and data coverage index were estimated based on standardised GBD methods.

RESULTS

Globally the population of older adults has increased since 1990 and all cause death rates have decreased for men and women. However, mortality rates due to falls increased between 1990 and 2019. The probability of death among people aged 70-90 decreased, mainly because of reductions in noncommunicable diseases. Globally disability burden was largely driven by functional decline, vision and hearing loss, and symptoms of pain. LE-70 and HALE-70 showed continuous increases since 1990 globally, with certain regional disparities. Globally higher LE-70 resulted in higher HALE-70 and slightly increased PYIH-70. Sociodemographic and healthcare access and quality indices were positively correlated with HALE-70 and LE-70. For high exposure risk factors,

WHAT IS ALREADY KNOWN ON THIS TOPIC

The global population is living longer and the health and wellbeing of older adults has become a major public health issue

While it is recognised that populations are ageing differently, global epidemiological data on the burden of diseases in adults aged ≥70 are lacking

WHAT THIS STUDY ADDS

In 2019, adults aged ≥70 were found to live more than two years longer compared with 1990 life expectancy estimates

Sociodemographic development and healthcare access and quality were major determinants of life expectancy and healthy life expectancy in adults aged \geq 70; disability burden followed a stable pattern across the development spectrum Specific healthy ageing policies are needed with targeted data coverage for adults aged \geq 70 and consistent collaboration among stakeholders

data coverage was moderate, while limited data were available for various dietary, environmental or occupational, and metabolic risks.

CONCLUSIONS

Life expectancy at age 70 has continued to rise globally, mostly because of decreases in chronic diseases. Adults aged ≥70 living in high income countries and regions with better healthcare access and quality were found to experience the highest life expectancy and healthy life expectancy. Disability burden, however, remained constant, suggesting the need to enhance public health and intervention programmes to improve wellbeing among older adults.

Introduction

For the first time in history, most newborns might live into their 70s and beyond.¹ With the global population experiencing extra years of life, the health and wellbeing of older adults is paramount so that they can continue to be actively engaged in society.² However, if added years are spent in poor health, health systems will face increased healthcare expenses due to increased demand.3 To conceptualise years of life spent in good health, a variety of ageing indicators have been developed. Healthy and successful ageing, and frailty, project high or low wellbeing in older people, respectively.⁴⁻⁶ Ageing research suggests that functional decline and health loss are more reflective of healthy ageing than chronological age.⁷ Consequently, surveillance of the older population's health is essential to capture its ageing status. Variations in the definition of old age exist that account for chronological age or for remaining life expectancy.⁸ Epidemiological data indicate that population ageing patterns are changing, with people aged ≥ 70 and ≥ 90 being the fastest growing segment in Europe, Asia, and the United States.⁹⁻¹¹ In 1950, older adults represented 5% of the global population; this estimate is projected to rise to 16% by 2050.¹² Consequently, the health and wellbeing of ageing populations have become important public health issues with wide reaching economic implications that affect medical care, inhome care and assistance, and healthcare staff.¹³

The projected ageing demographics are linked to increased burden and duration of non-communicable diseases.⁷ An analysis of the Global Burden of Disease (GBD) 2010 data established that the major causes of disability for adults aged ≥ 60 were musculoskeletal disorders, cardiovascular diseases, diabetes, and neurological disorders.¹⁴ In 2015, the World Health Organization declared that the rise in chronic conditions among older adults was a worldwide epidemic.⁷

9

The management of accumulated chronic conditions is likely to weigh upon healthcare financing over the next few decades in high income and in low to middle income regions.¹⁵⁻¹⁷ Low to middle income regions face an ongoing agenda of communicable diseases and will have to manage the added burden with limited resources and infrastructure. Understanding and reducing the burden of disease among older people is critical to mitigate the economic burden of ageing and build sustainability within the global health system for the next generations.¹³

While ageing draws increasing attention from policy makers and stakeholders, global epidemiological data on the burden of disease in older adults are limited. Studies from high life expectancy populations do exist,^{4 18 19} but most are based on localised sample populations without detailed analyses of adults older than 70.²⁰⁻²² Epidemiological studies from WHO.²³ including the recently published world report on ageing and health, have highlighted an increasingly ageing global population and the need for urgent public health changes.⁷ The GBD 2019 study provides annually updated global, regional, and national population data on mortality, 369 diseases and injuries, and 87 risk factors among 204 countries.²⁴⁻²⁶ Therefore, it provides an excellent opportunity for global and regional systematic analysis of causes of fatal and non-fatal health loss and risk factors in older adults.

The overall aim of the present study was to describe levels and trends in death and disability burden in the population aged ≥70 using GBD 2019 data. We approached this with several new metrics and assessments that leverage the GBD 2019 results. These assessments included life expectancy at age 70 (LE-70), the probability of death between ages 70 and 90 (20q70), assessment of diseases and injuries leading to changes in 20q70 through causal decomposition, calculating healthy life expectancy at age 70 (HALE-70), and the proportion of remaining vears in ill health at age 70 (PYIH-70). To provide context to these analyses, we further evaluated the historical relation between LE-70, HALE-70, and PYIH-70 with two societal proxies for development: the sociodemographic index (SDI) and the healthcare access and quality (HAQ) index. Data coverage underpinning the GBD estimates was also assessed. Overall, this study provides a comprehensive and detailed assessment of the health of older adults.

Methods

Extensive details on the methods used to derive each of the measures in GBD 2019 have been published previously.²⁴⁻²⁶ A brief summary of each component is presented, with emphasis on the metrics and analyses that are distinct to the present study to evaluate trends in epidemiological patterns and disease burden for people aged \geq 70. Reporting was performed with adherence to the guidelines for accurate and transparent health estimates reporting (GATHER) statement (supplementary table 1). Data inputs are downloadable from the Global Health Data Exchange (http://ghdx.healthdata.org/). Results are viewable online in GBD Compare (https://vizhub.healthdata. org/gbd-compare/).

Dimensions of GBD 2019

GBD 2019 includes estimates for 369 diseases and injuries, and 87 risk factors for 23 age groups and both sexes from 1990 to 2019 covering 204 countries and territories-22 of which were analysed subnationally-hierarchically arranged into 21 regions and 7 super regions (supplementary table 2). SDI is a composite indicator that uses the following components: country level income per capita, average educational attainment among people older than 15 years, and total fertility rate among women younger than 25 years.²⁴ SDI ranges from 0 (high fertility, low education, low income) to 1 (low fertility, high income, high education). Each GBD location was assigned to a single SDI group based on its SDI value in 2019.

All deaths were assigned a single underlying cause according to the international classification of diseases, and each was mapped according to a four level mutually exclusive and collectively exhaustive GBD cause list (supplementary table 3). Level 1 differentiates between communicable. maternal, neonatal, and nutritional disorders; noncommunicable diseases; and injuries. Level 2 covers 22 disease and injury aggregate clusters, such as cardiovascular diseases, respiratory diseases, and transport related injuries. Some level 2 disorders (maternal disorders, neonatal disorders, and congenital birth defects) do not cause death in adults aged \geq 70, but there is burden present for the first two arising from long term sequelae of neonatal disorders (eg, cerebral palsy) and long term complications of pregnancy (eg. severe preeclampsia and eclampsia). Level 3 (174 conditions) and level 4 (301 conditions) causes represent increasingly more specific diseases and injuries. Most causes were estimated as underlying causes of death and causes of disability burden. A few causes were assessed to cause either death or disability, but not both. Examples include aortic aneurysm (death only) and periodontal disease (disability only). The GBD 2019 comparative risk assessment framework classified each of 87 risk factors and clusters of risk factors into one of three categories: behavioural, environmental or occupational, and metabolic.²⁶

All cause mortality and cause specific mortality

Mortality estimation methods have been extensively described elsewhere.²⁴ ²⁵ Briefly, all available global data including vital registration, sample registration, household surveys, censuses, disease registries, notification systems, and police records were identified, extracted, and standardised. Standardised methods were then applied to produce internally consistent estimates of population, fertility, net migration, all cause mortality, and cause specific mortality. All cause mortality estimates for each location, sex, and year were inputs to the calculation of overall life expectancy

and LE-70. Years of life lost were the product of cause specific mortality rates and remaining GBD standard life expectancy at age of death.

Non-fatal disease burden and disability adjusted life years

Estimation methods for prevalence, incidence, years lived with disability, and disability adjusted life years have been described elsewhere.²⁵ Briefly, global datasets were assembled as for the mortality models with the addition of administrative datasets (hospital discharges and insurance claims) and published scientific studies. Data were standardised to a single reference definition using meta-regression-bayesian, regularised, trimmed (MR-BRT), a meta-regression framework developed for GBD 2019.27 Most causes used DisMod-MR 2.1, a bayesian meta-regression tool developed for GBD, to generate internally consistent models of prevalence, incidence, remission, and excess mortality. The proportion experiencing each type of non-fatal sequela were then calculated separately and paired with corresponding global GBD disability weights derived from worldwide population surveys to calculate years of life lived with disability.²⁸ Finally, a microsimulation adjusted for years lived with disability to account for comorbidity. The simulation assumed independent comorbidity between different diseases but was run separately for each age group, sex, location, and year based on extensive testing during GBD 2010, which revealed age and sex explained most comorbidities.²⁹ Disability adjusted life years were the sum of years of life lost and years lived with disability.

Specialised metrics of ageing

We calculated the probability of death between ages 70 and 90 (20q70) and paired this with cause specific mortality results in a decomposition analysis to understand how trends in 20q70 between 1990 and 2019 related to temporal trends in specific GBD causes. Next, we used previously described methods²⁴ to calculate HALE-70, evaluating age specific mortality and years lived with disability rates for each age group. Finally, we calculated PYIH-70: (LE-70–HALE-70)/LE-70.

Risk factor exposure and attributable burden

Risk factor exposure, relative risk, and population attributable fraction estimation methods have been extensively described previously.²⁶ Briefly, exposure models drew on similar data sources as non-fatal estimates. A continuous distribution of exposure was estimated for several risk factors (eg, high body mass index) known to have a spectrum of associated severity and outcome using ensemble distribution methods developed for GBD. For risk factors, exposure data were modelled by applying either spatiotemporal Gaussian process regression or DisMod-MR 2.1, bayesian statistical models.^{24 26} Quantitative relative risks were estimated for each risk-outcome pair, then paired with corresponding exposure estimates to calculate the population attributable fraction for each risk-outcome

pair. Population attributable fractions were multiplied by the outcome rates to calculate attributable years lived with disability, years of life lost, and disability adjusted life years.

Summary exposure value is a measure ranging from 0 (lowest) to 1 (highest) developed for GBD to capture exposure, magnitude of relative risk, and attributable burden in a single number. Summary exposure values allow comparison of intensity of exposure from the perspective of adverse health outcomes across risk factors and across different demographical groups. We evaluated the relation between total attributable disability adjusted life years to each risk factor in the population aged \geq 70 and the annualised rate of change in summary exposure values from 1990 to 2019 in those aged \geq 70. The annualised rate of change was calculated as log transformed (final estimates/initial estimates)/(No of years).

Epidemiological transition: historical relation with SDI and HAQ index

We assessed the epidemiological transition in ageing metrics (LE-70, HALE-70, and PYIH-70) as a function of summary measures of societal development and health system performance, including SDI and HAQ index. The HAQ index is a composite metric developed for GBD 2016 and subsequently updated. It is based on comparative risk standardised mortality rates for healthcare sensitive diseases, ranges from 0 (worst) to 100 (best), and represents a health centric assessment of development to complement SDI.30 For each metric, we incorporated all observed location specific estimates from 1990 to 2019 in MR-BRT,²⁷ including an intercept and a cubic spline on either SDI or HAQ index, depending on the model version, to predict the historical average relation between them. Models were fit in log space and an offset of 1×10^{-7} was used. The observed value for each location year was compared with the expected value, which was the result of the spline model, to calculate the observed to expected ratio.

Uncertainty and data coverage index for population aged ≥70

For all results, we report 95% uncertainty intervals derived from 1000 draws from the posterior distribution of each step in the estimation process according to established GBD methods.

The geographical and temporal representativeness of the data sources for non-fatal health outcomes were estimated through a measure we term the data coverage index (DCI). DCI was calculated in two ways for non-fatal disease burden and risk factor exposure. Firstly, we calculated the proportion of countries and territories with input data for each level 3 cause or risk factor (DCI by cause or risk). Secondly, we calculated the proportion of cause or risk factor with any input data for each country and territory (DCI by country). We compared the DCI for all ages with that for the population aged \geq 70 only to highlight potential data gaps.

Patient and public involvement

The GBD study is a global collaborative scientific endeavour involving more than 7500 people from around 150 countries. Enrolment as a GBD collaborator is a public facing process without specific limitations placed on educational degree or professional status. All collaborators were invited to review and comment on the manuscript according to their personal involvement and expertise.

Results

Demographics, mortality, and morbidity trends

From 1990 to 2019, the size of the global population aged ≥70 increased (fig 1). The 70-79 year old age group grew 115.4%, while the proportion of adults aged 80-94 increased by 164.7%. The population aged \geq 95 grew by 363.7%. These trends were consistent across all SDI groups and GBD super regions (supplementary figs 1-12). In 2019, there were 168.3 million more people aged 70-79, 90.1 million more people aged 80-94, and 3.7 million more people aged ≥95 than in 1990. Globally all cause deaths increased while death rates decreased for men and women aged \geq 70 between 1990 and 2019 (supplementary table 4), a pattern that was followed for nearly all specific causes of death. Globally during the same period, rates for years lived with disability increased only slightly in people aged ≥70 (+0.7%, 95% uncertainty interval 0.0% to 1.4%) and in all SDI groups. Globally all cause years lived with disability rates decreased for men but increased for women aged ≥70 between 1990 and 2019 (supplementary table 5).

LE-70, HALE-70, and PYIH-70

Globally LE-70 increased for men and women in 2019 (men: 12.88, 95% uncertainty level 12.53 to 13.26; women: 15.21, 14.88 to 15.55) compared with 1990 (men: 10.60, 10.43 to 10.80; women: 12.82, 12.68 to 12.99; table 1, supplementary tables 6-8). Globally HALE-70 increased for men (from 7.72 (6.92 to 8.42) healthy years in 1990 to 9.35 (8.43 to 10.27) in 2019) and women (from 9.10 (8.12 to 10.0) healthy years in 1990 to 10.69 (9.52 to 11.76) in 2019). Improvements in HALE-70 were slightly faster than LE-70 globally, which equated to a minimal increase in PYIH-70. All super regions saw improvements in LE-70, higher HALE-70, and a relatively stagnated PYIH-70 (fig 2, supplementary figs 13 and 14 by sex). We found associations between SDI, HAQ index, and each of LE-70, HALE-70, and PYIH-70 (fig 3; supplementary figs 15 and 16 by sex). Low regional variability was noted in LE-70, HALE-70, and PYIH-70 within countries of the same regional clusters.

More than 90% of the 204 countries and territories had increased LE-70 and HALE-70 between 1990 and 2019. The largest increases in LE-70 for men were in Singapore, South Korea, Bermuda, Maldives, and Luxembourg. In contrast, there were decreases of at least two years in LE-70 in Uzbekistan, Tajikistan, Nicaragua, Honduras, and Azerbaijan. Despite trends of slight PYIH-70 increases with increasing SDI and HAQ index, only 74 of 204 countries had decreased PYIH-70 between 1990 and 2019. The biggest improvements, in order, were seen in Côte d'Ivoire, Iraq, Singapore, Ukraine, and Kyrgyzstan, all of which saw declines of at least 1% in PYIH-70. In contrast, 64 countries had increases in PYIH-70 of at least 2%, including Sri Lanka, US, Seychelles, Georgia, Lebanon, and Syrian Arab Republic. LE-70 was higher in women than in men in 195 of 204 countries by an average of 1.89 years. The only exceptions were Afghanistan, Algeria, Egypt, Jordan, Marshall Islands, Mauritania, Qatar, Syrian Arab Republic, and Tokelau, where LE-70 was higher in men in 2019.

Causal decomposition of changes in probability of death

We performed causal decomposition of probability of death for the population aged 70-90 from 1990 to 2019 for level 2 GBD causes (fig 4; supplementary figs 17-19). Nearly all regions saw declines in probability of death from age 70 to 90 (thick black line on the left of dotted black line), with the only exceptions being Central Asia (83.2% probability of death in 1990 vs 89.0% in 2019) and southern sub-Saharan Africa (81.6% probability of death in 1990 vs 83.5% in 2019). Broad declines were mostly due to reductions in mortality from cardiovascular diseases and chronic respiratory diseases; declines would have been even greater if not for increases in mortality attributed to neoplasms, diabetes and kidney diseases, and neurological disorders in men and women. Trends in falls and unintentional injuries are important to highlight as proxies for frailty in older adults. In 121 countries, the probability of death by unintentional injury and falls decreased between 1990 and 2019.

Leading causes of mortality and morbidity

In 2019, the most notable causes of disease burden were cardiovascular diseases, neoplasms, and chronic respiratory diseases, while the least burden was caused by other infectious diseases and unintentional injuries (among other causes) for men and women (data given in online supplementary material). Globally the top five level 3 causes of death in people aged ≥70 in 2019 were ischaemic heart disease, stroke, chronic obstructive pulmonary disease, Alzheimer's disease and other dementias, and lower respiratory infections (fig 5; supplementary figs 20 and 21 by country and sex). Although ischaemic heart disease, stroke, colorectal cancer, diabetes, and chronic kidney disease remained among the leading causes of death globally, observed levels of deaths were generally lower than those expected based on SDI (ratio of observed to expected levels less than one; fig 5). Increases in death rates in people aged ≥70 from 1990 to 2019 were noted for Alzheimer's disease and other dementias (+29.28%), lung cancer (+11.74%), diabetes (+16.35%), and chronic kidney disease (+31.95%) (data given in online supplementary material). Based on the observed to expected mortality ratios, Alzheimer's disease and



Fig 1 | Global population, years lived with disability, and all-cause mortality transition by age group, 1990-2019. Distribution of global population by age group was estimated as simple difference from 1990 to 2019 (top panel), or as percentage change during the same period (second panel). Percentage differences in years lived with disability and all cause mortality as estimated by GBD 2019 are also provided for all age groups from 1990 to 2019 (lower two panels) to indicate quality of life lost due to illness before death and to quantify all cause mortality. All age groups have been included to provide a comparator when assessing health loss in older adults. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study; YLD=years lived with disability

> other dementias (ratio 1.05) was expected to have slightly higher estimates than the observed proportion of 29.28%, while for diabetes (ratio 0.82) the increase was expected to be a bit lower than 31.95%. Falls also increased 15.28% and were ranked 13th in 2019. Neoplasms showed heterogeneity, with half of cancers (15 of 30) increasing and half decreasing. The top two

neoplasms—tracheal, bronchus and lung cancer, and colorectal cancer—both increased (while lung cancer had an observed to expected ratio of 1.12 and the ratio for colorectal cancer was 0.83; fig 5), and the largest increase was in pancreatic cancer (+32.48%, ranked 18th overall). Cancers of the stomach (-33.34%), prostate (-3.74%), breast (-9.28%), oesophagus

Table 1 Life expectancy 2005, and 2019	/, healthy life expe	ctancy, and proport	ion of years spent i	n ill health for the p	opulation 70 years	and older by sociod	emographic index a	ind location for bot	n sexes in 1990,
	LE-70			HALE-70			РҮІН-70		
	1990	2005	2019	1990	2005	2019	1990	2005	2019
Global	11.8 (11.7 to 12)	12.8 (12.7 to 12.9)	14.1 (13.9 to 14.4)	8.48 (7.57 to 9.29)	9.18 (8.24 to 10)	10.1 (9.01 to 11)	0.28 (0.22 to 0.35)	0.28 (0.22 to 0.35)	0.29 (0.23 to 0.35)
Low SDI	9.53 (9.34 to 9.74)	10.3 (10.1 to 10.5)	11.5 (11.2 to 11.8)	6.79 (6.07 to 7.48)	7.32 (6.55 to 8.07)	8.2 (7.31 to 9.04)	0.29 (0.23 to 0.35)	0.29 (0.23 to 0.35)	0.29 (0.24 to 0.35)
Low-middle SD	10 (9.88 to 10.2)	11.1 (10.9 to 11.2)	12.3 (11.9 to 12.7)	7.09 (6.33 to 7.81)	7.8 (6.94 to 8.57)	8.62 (7.66 to 9.55)	0.29 (0.24 to 0.36)	0.3 (0.24 to 0.36)	0.3 (0.25 to 0.36)
Middle SDI	11.2 (10.9 to 11.5)	11.9 (11.7 to 12.1)	13.3 (12.8 to 13.7)	8.06 (7.19 to 8.83)	8.59 (7.72 to 9.39)	9.49 (8.54 to 10.4)	0.28 (0.23 to 0.34)	0.28 (0.22 to 0.34)	0.28 (0.24 to 0.34)
High-middle SDI	11.8 (11.7 to 12)	12.6 (12.5 to 12.7)	14.5 (14.1 to 14.8)	8.55 (7.66 to 9.35)	9.14 (8.21 to 9.97)	10.4 (9.38 to 11.4)	0.28 (0.22 to 0.34)	0.28 (0.22 to 0.34)	0.28 (0.23 to 0.34)
High SDI	13.8 (13.7 to 13.8)	15.5 (15.5 to 15.5)	16.7 (16.6 to 16.8)	9.81 (8.76 to 10.8)	11.1 (9.87 to 12.1)	11.8 (10.5 to 13)	0.29 (0.22 to 0.36)	0.29 (0.22 to 0.36)	0.29 (0.23 to 0.37)
Central Europe, Eastern Europe, and Central Asia	11.6 (11.6 to 11.6)	11.4 (11.4 to 11.4)	13.2 (12.8 to 13.6)	8.43 (7.55 to 9.22)	8.34 (7.48 to 9.1)	9.62 (8.59 to 10.5)	0.27 (0.21 to 0.35)	0.27 (0.2 to 0.34)	0.27 (0.23 to 0.33)
Central Asia	12.1 (12 to 12.2)	9.84 (9.76 to 9.93)	11 (10.6 to 11.4)	9.1 (8.27 to 9.86)	7.46 (6.8 to 8.07)	8.26 (7.49 to 9.04)	0.25 (0.19 to 0.31)	0.24 (0.19 to 0.3)	0.25 (0.21 to 0.29)
Central Europe	11.3 (11.2 to 11.3)	12.4 (12.4 to 12.4)	13.9 (13.2 to 14.6)	8.15 (7.3 to 8.9)	9.03 (8.1 to 9.85)	10.1 (8.97 to 11.2)	0.28 (0.21 to 0.35)	0.27 (0.21 to 0.34)	0.27 (0.23 to 0.32)
Eastern Europe	11.8 (11.7 to 11.8)	11.1 (11.1 to 11.1)	13.3 (12.8 to 13.9)	8.49 (7.59 to 9.29)	8.09 (7.24 to 8.83)	9.73 (8.62 to 10.7)	0.28 (0.21 to 0.35)	0.27 (0.21 to 0.35)	0.27 (0.22 to 0.33)
High income	13.8 (13.8 to 13.8)	15.6 (15.6 to 15.6)	16.7 (16.7 to 16.7)	9.87 (8.82 to 10.8)	11.1 (9.92 to 12.2)	11.8 (10.6 to 13)	0.29 (0.22 to 0.36)	0.29 (0.22 to 0.36)	0.29 (0.22 to 0.37)
Australasia	13.8 (13.7 to 13.8)	16.1 (16 to 16.1)	17.1 (17 to 17.2)	9.8 (8.74 to 10.8)	11.3 (10.1 to 12.5)	12 (10.6 to 13.2)	0.29 (0.22 to 0.36)	0.3 (0.23 to 0.37)	0.3 (0.23 to 0.37)
High income Asia Pacific	14.4 (14.4 to 14.4)	16.9 (16.9 to 16.9)	18.3 (18.3 to 18.4)	10.6 (9.53 to 11.5)	12.4 (11.2 to 13.5)	13.5 (12.2 to 14.7)	0.27 (0.2 to 0.34)	0.27 (0.2 to 0.34)	0.26 (0.2 to 0.33)
High income North America	14.3 (14.3 to 14.3)	15.2 (15.2 to 15.2)	16 (16 to 16.1)	9.72 (8.55 to 10.8)	10.3 (9.05 to 11.4)	10.5 (9.18 to 11.8)	0.32 (0.24 to 0.4)	0.32 (0.25 to 0.4)	0.34 (0.27 to 0.43)
Southern Latin America	12.8 (12.8 to 12.8)	14 (13.9 to 14)	14.6 (14.5 to 14.8)	9.56 (8.65 to 10.4)	10.4 (9.37 to 11.3)	10.8 (9.73 to 11.8)	0.25 (0.19 to 0.32)	0.26 (0.19 to 0.33)	0.26 (0.2 to 0.33)
Western Europe	13.5 (13.4 to 13.5)	15.4 (15.4 to 15.4)	16.5 (16.5 to 16.6)	9.81 (8.82 to 10.7)	11.2 (10 to 12.2)	12 (10.8 to 13.1)	0.27 (0.21 to 0.34)	0.27 (0.21 to 0.35)	0.28 (0.21 to 0.35)
Latin America and Caribbean	13.1 (13 to 13.1)	14.6 (14.5 to 14.6)	15.2 (14.7 to 15.7)	9.44 (8.45 to 10.3)	10.6 (9.51 to 11.6)	11 (9.91 to 12.1)	0.28 (0.21 to 0.35)	0.27 (0.21 to 0.34)	0.27 (0.23 to 0.33)
Andean Latin America	13.5 (13.1 to 13.9)	14.8 (14.4 to 15.2)	15.4 (1 4.4 to 1 6.5)	10.1 (9.05 to 11)	11 (9.89 to 12)	11.4 (10.1 to 12.7)	0.25 (0.21 to 0.31)	0.26 (0.21 to 0.31)	0.26 (0.23 to 0.3)
Caribbean	13.2 (13.1 to 13.3)	14.1 (13.9 to 14.3)	14.6 (13.8 to 15.4)	9.89 (8.95 to 10.7)	10.5 (9.48 to 11.4)	10.7 (9.54 to 11.8)	0.25 (0.19 to 0.32)	0.26 (0.2 to 0.32)	0.26 (0.23 to 0.31)
Central Latin America	13.3 (13.3 to 13.4)	14.7 (14.7 to 14.8)	15.4 (14.6 to 16.1)	9.55 (8.52 to 10.5)	10.7 (9.58 to 11.7)	11.1 (9.82 to 12.3)	0.28 (0.22 to 0.36)	0.27 (0.21 to 0.35)	0.28 (0.24 to 0.33)
Tropical Latin America	12.6 (12.5 to 12.6)	14.4 (14.4 to 14.5)	15.3 (15.1 to 15.4)	8.98 (8.01 to 9.86)	10.4 (9.32 to 11.4)	11.1 (9.94 to 12.1)	0.28 (0.22 to 0.36)	0.28 (0.21 to 0.35)	0.27 (0.22 to 0.34)
North Africa and Middle East	11.3 (11.1 to 11.5)	12.4 (12.2 to 12.7)	13 (12.5 to 13.4)	8.23 (7.38 to 9.04)	9.01 (8.11 to 9.88)	9.33 (8.35 to 10.3)	0.27 (0.21 to 0.33)	0.28 (0.22 to 0.33)	0.28 (0.23 to 0.33)
South Asia	9.49 (9.29 to 9.69)	10.8 (10.5 to 11)	12.4 (11.8 to 13)	6.51 (5.77 to 7.24)	7.37 (6.5 to 8.18)	8.46 (7.41 to 9.5)	0.31 (0.25 to 0.38)	0.31 (0.26 to 0.38)	0.32 (0.27 to 0.37)
South East Asia, East Asia, and Oceania	10.8 (10.5 to 11.2)	11.7 (11.5 to 12)	13.4 (12.8 to 14)	7.84 (7.02 to 8.62)	8.47 (7.63 to 9.26)	9.62 (8.62 to 10.6)	0.27 (0.23 to 0.33)	0.28 (0.23 to 0.33)	0.28 (0.24 to 0.33)
East Asia	10.6 (10.2 to 11.2)	11.6 (11.3 to 12)	13.5 (12.8 to 14.3)	7.76 (6.96 to 8.56)	8.45 (7.61 to 9.24)	9.76 (8.69 to 10.8)	0.27 (0.23 to 0.32)	0.27 (0.23 to 0.33)	0.28 (0.24 to 0.32)
Oceania	10.3 (9.83 to 10.8)	10.3 (9.7 to 10.9)	10.7 (9.82 to 11.5)	7.34 (6.51 to 8.14)	7.35 (6.47 to 8.19)	7.6 (6.58 to 8.6)	0.29 (0.24 to 0.34)	0.29 (0.25 to 0.33)	0.29 (0.25 to 0.33)
South East Asia	11.5 (11.3 to 11.7)	12 (11.8 to 12.2)	12.8 (12.4 to 13.3)	8.14 (7.26 to 8.94)	8.57 (7.68 to 9.42)	9.1 (8.08 to 10)	0.29 (0.24 to 0.36)	0.29 (0.23 to 0.35)	0.29 (0.25 to 0.35)
Sub-Saharan Africa	10.1 (9.88 to 10.3)	10.4 (10.1 to 10.6)	11.5 (11.1 to 11.8)	7.33 (6.59 to 8.04)	7.54 (6.79 to 8.24)	8.39 (7.55 to 9.2)	0.28 (0.22 to 0.33)	0.27 (0.22 to 0.33)	0.27 (0.22 to 0.32)
Central sub-Saharan Africa	9.32 (8.83 to 9.79)	9.83 (9.4 to 10.3)	10.9 (10.1 to 11.6)	6.73 (6 to 7.47)	7.13 (6.4 to 7.86)	7.96 (7.01 to 8.89)	0.28 (0.24 to 0.32)	0.27 (0.24 to 0.32)	0.27 (0.23 to 0.3)
Eastern sub-Saharan Africa	9.37 (9.16 to 9.59)	10.2 (10 to 10.4)	11.4 (11.1 to 11.7)	6.81 (6.11 to 7.45)	7.44 (6.68 to 8.12)	8.34 (7.51 to 9.1)	0.27 (0.22 to 0.33)	0.27 (0.22 to 0.33)	0.27 (0.22 to 0.32)
Southern sub-Saharan Africa	12.9 (12.7 to 13.1)	10.9 (10.8 to 11.1)	12.4 (12.2 to 12.6)	9.19 (8.24 to 10.1)	7.78 (6.99 to 8.55)	8.82 (7.92 to 9.71)	0.29 (0.23 to 0.35)	0.29 (0.23 to 0.35)	0.29 (0.23 to 0.35)
Western sub-Saharan Africa	10.2 (9.84 to 10.5)	10.4 (10 to 10.9)	11.5 (11 to 11.9)	7.4 (6.63 to 8.11)	7.65 (6.87 to 8.4)	8.42 (7.54 to 9.27)	0.27 (0.23 to 0.33)	0.27 (0.23 to 0.32)	0.27 (0.22 to 0.31)
2005 has been selected as mid LE-70=life expectancy at age 70	point of period 1990-20); HALE-70=healthy life	019, allowing comparisor expectancy at age 70; PY	is between almost equal t 1H-70=proportion of year:	ime periods. Data in pare s in ill health at age 70.	entheses are 95% uncerta	inty intervals.			

RESEARCH



Fig 2 | Life expectancy at age 70 (LE-70), healthy life expectancy at age 70 (HALE-70), and proportion of life years spent in ill health at age 70 (PYIH-70) by location for both sexes, 1990-2019. Shaded sections indicate 95% uncertainty intervals. GBD=Global Burden of Diseases, Injuries, and Risk **Factors Study**

> (-14.55%), and liver (-10.48%) all decreased from 1990 to 2019 in people aged ≥70 (data given in online supplementary material).

> Globally, the top 5 level 3 causes of years lived with disability in people aged ≥70 included age related hearing loss, diabetes, low back pain, blindness and

vision loss, and chronic obstructive pulmonary disease (fig 6, supplementary figs 22 and 23 by country and sex). Observed years lived with disability due to chronic obstructive pulmonary disease were almost two times (observed to expected ratio 1.8) higher than expected levels worldwide. Among all 10 leading causes of years

RESEARCH



Fig 3 | Epidemiological transition between life expectancy at age 70 (LE-70), healthy life expectancy at age 70 (HALE-70), proportion of years spent in ill health at age 70 (PYIH-70), and sociodemographic index (SDI) and healthcare access and quality (HAQ) index for both sexes, 2019. Dots represent countries and different colour coding indicates SDI categorisation

lived with disability, observed estimates were almost equal (observed to expected ratio >0.9) or exceeded the levels expected based on SDI (fig 6). Leading causes of disability in older people were largely consistent across locations, but with variations in ranking. Age related hearing loss was the leading cause in 47 countries, while diabetes ranked first in 98 countries. Notably, Alzheimer's disease and other dementias was in the top five in 51 countries, osteoarthritis in 28 countries, oral disorders in 29 countries, and chronic obstructive pulmonary disease in 50 countries (supplementary figs 22 and 23).

Attributable burden and risk factor exposure trends

In 2019, 280 million disability adjusted life years (95% uncertainty interval 261.3 to 297.9), or 57.7% of the total, were attributable to risk factors in people aged \geq 70; this includes 87.9 (79.4 to 95.8), 147.8 (134.8 to 163.4),

and 172.0 (155.4 to 189.3) million disability adjusted life years attributable to environmental, behavioural, and metabolic risks, respectively. This represents an increase in the total risk attributable disability adjusted life years from the estimated 165.3 million (157.8 to 172.5) in 1990, but a decrease in the proportion that were risk attributable in 1990 (61.9%). The top five risk factors in 2019 were high systolic blood pressure, high fasting plasma glucose, smoking, high low density lipoprotein cholesterol, and high body mass index. The only substantial change in ranking was a decline of 70.1% in burden attributable to household air pollution (data shown in online supplementary material).

A comparison of annualised rate of change in risk exposure measured by summary exposure values from 1990 to 2019 with total attributable disability adjusted life years in 2019 shows that the biggest risk factors for health loss were mainly those with the



Fig 4 | Relation between level 2 causes of death and changes in probability of death between ages 70 and 90 years (20q70) for both sexes by location, 1990-2019. Different colour bars represent different causes of death. All causes to the right of the dotted black line increased from 1990 to 2019, and all those to the left decreased over the same time period. At the global level, the probability of death decreased mainly due to reductions in cardiovascular diseases, chronic respiratory diseases, respiratory infections and tuberculosis, and enteric infections (-13.6% in total), while the probability of death increased due to increases in neoplasms, neurological disorders, diabetes, and kidney diseases (+4.3% in total). 20q70=probability 'q' of death for a period of 20 years starting at age 70

> largest cumulative improvements in exposure (fig 7, supplementary figs 24-36). Those with an annualised rate of change in summary exposure values of at least 2% decline and to which at least 100000 disability adjusted life years globally are attributed include household air pollution, unsafe water, low dietary fibre,

unsafe sanitation, low vegetables, poor handwashing, child wasting, and child underweight (which includes protein energy malnutrition in adults as well), and occupational injuries and asthmagens. Notable differences existed among diverse sociodemographic levels and super regions (supplementary figs 24-36).

g

	1	2	3	4	5	6	7	8	9	10
Global	Ischaemic heart disease	Stroke	COPD	Alzheimer's disease	Lower respiratory infection	Lung cancer	Diabetes	Hypertensive heart disease	Chronic kidney disease	Colorectal cancer
	0.81	0.97	1.86	1.010	1.00	1.12	0.82	1.19	0.99	0.83
Central Europe, Eastern	Ischaemic heart disease	Stroke	Alzheimer's disease	COPD	Colorectal cancer	Hypertensive heart disease	Lung cancer	Lower respiratory infection	Cardiomyopathy	Diabetes
Europe, and Central Asia	2.11	1.84	1.00	0.82	1.02	1.54	0.86	0.48	2.37	0.61
Central Asia	Ischaemic heart disease	Stroke	COPD	Hypertensive heart disease	Alzheimer's disease	Cirrhosis	Diabetes	Lower respiratory infection	Lung cancer	Stomach cancer
	2.45	1.64	1.40	1.98	1.02	2.52	0.74	0.61	0.85	1.29
Central Europe	Ischaemic heart disease	Stroke	Alzheimer's disease	Hypertensive heart disease	Lung cancer	Colorectal cancer	COPD	Cardiomyopathy	Lower respiratory infection	Diabetes
	1.46	1.59	1.04	2.65	1.12	1.23	0.83	3.39	0.68	0.91
Eastern Europe	Ischaemic heart disease 2.49	Stroke 2.04	Alzheimer's disease 0.97	COPD 0.72	Colorectal cancer 0.90	Lung cancer 0.66	Stomach cancer 1.16	Hypertensive heart disease 0.73	Cardiomyopathy 1.79	Lower respiratory infect 0.32
High income	Ischaemic heart disease	Stroke	Alzheimer's disease	COPD	Lung cancer	Lower respiratory infection	Chronic kidney disease	Colorectal cancer	Diabetes	Hypertensive heart dise
	0.63	0.67	1.05	1.10	0.97	1.01	1.30	0.79	0.87	1.10
Australasia	Ischaemic heart disease	Stroke	Alzheimer's disease	COPD	Lung cancer	Colorectal cancer	Chronic kidney disease	Lower respiratory infection	Prostate cancer	Diabetes
	0.63	0.61	1.03	1.10	0.83	0.80	1.19	0.56	0.93	0.91
High income Asia Pacific	Alzheimer's disease	Stroke	lschaemic heart disease	Lower respiratory infection	Lung cancer	Colorectal cancer	Stomach cancer	Chronic kidney disease	COPD	Liver cancer
	1.25	0.70	0.34	1.43	0.87	0.72	1.89	1.05	0.52	2.88
High income North	Ischaemic heart disease	Stroke	COPD	Alzheimer's disease	Lung cancer	Chronic kidney disease	Lower respiratory infection	Colorectal cancer	Diabetes	Prostate cancer
America	0.89	0.63	1.59	0.97	1.18	1.63	0.72	0.64	1.11	0.78
Southern Latin America	lschaemic heart disease	Lower respiratory infection	Stroke	COPD	Alzheimer's disease	Chronic kidney disease	Colorectal cancer	Hypertensive heart disease	Diabetes	Lung cancer
	0.49	2.61	0.55	1.25	0.94	1.80	1.35	1.31	0.90	1.00
Western Europe	Ischaemic heart disease	Stroke	Alzheimer's disease	COPD	Lung cancer	Lower respiratory infection	Colorectal cancer	Chronic kidney disease	Hypertensive heart disease	Prostate cancer
	0.64	0.70	0.99	1.08	0.89	0.87	0.89	1.18	1.44	0.91
Latin America and	Ischaemic heart disease	Stroke	Alzheimer's disease	Lower respiratory infection	COPD	Diabetes	Chronic kidney disease	Hypertensive heart disease	Prostate cancer	Cirrhosis
Caribbean	0.47	0.43	1.04	1.31	1.12	1.15	1.40	0.75	1.09	1.18
Andean Latin America	lschaemic heart disease	Lower respiratory infection	Stroke	Chronic kidney disease	Alzheimer's disease	Diabetes	COPD	Stomach cancer	Cirrhosis	Prostate cancer
	0.37	2.26	0.31	1.73	0.95	0.79	0.66	1.90	1.73	1.10
Caribbean	Ischaemic heart disease	Stroke	Lower respiratory infection	Diabetes	Alzheimer's disease	Prostate cancer	COPD	Chronic kidney disease	Hypertensive heart disease	Lung cancer
	0.71	0.69	1.21	1.32	0.90	1.80	0.76	1.03	1.11	1.04
Central Latin America	Ischaemic heart disease	Stroke	Diabetes	Chronic kidney disease	COPD	Alzheimer's disease	Lower respiratory infection	Cirrhosis	Hypertensive heart disease	Prostate cancer
	0.55	0.34	1.37	1.89	1.20	1.03	0.75	1.49	0.67	0.94
Tropical Latin America	Ischaemic heart disease	Stroke	Lower respiratory infection	Alzheimer's disease	COPD	Diabetes	Chronic kidney disease	Hypertensive heart disease	Prostate cancer	Lung cancer
	0.37	0.50	1.69	1.09	1.24	0.98	0.90	0.79	1.06	0.87
North Africa and Middle	Ischaemic heart disease	Stroke	Hypertensive heart disease	Alzheimer's disease	Chronic kidney disease	COPD	Cirrhosis	Diabetes	Lower respiratory infection	Lung cancer
East	1.32	0.91	2.27	1.14	1.67	0.97	2.52	1.02	0.83	0.77
North Africa and Middle	Ischaemic heart disease	Stroke	Hypertensive heart disease 2.27	Alzheimer's disease	Chronic kidney disease	COPD	Cirrhosis	Diabetes	Lower respiratory infection	Lung cancer
East	1.32	0.91		1.14	1.67	0.97	2.52	1.02	0.83	0.77
South Asia	Ischaemic heart disease	COPD	Stroke	Diarrheal diseases	Lower respiratory infection	Diabetes	Tuberculosis	Falls	Alzheimer's disease	Asthma
	0.76	2.84	0.63	11.42	0.97	0.85	3.14	4.41	0.81	2.23
South Asia	Ischaemic heart disease	COPD	Stroke	Diarrheal diseases	Lower respiratory infection	Diabetes	Tuberculosis	Falls	Alzheimer's disease	Asthma
	0.76	2.84	0.63	11.42	0.97	0.85	3.14	4.41	0.81	2.23
South East Asia, East Asia,	Stroke	Ischaemic heart disease	COPD	Lung cancer	Alzheimer's disease	Hypertensive heart disease	Lower respiratory infection	Stomach cancer	Diabetes	Chronic kidney diseas
and Oceania	1.39	0.74	2.82	1.85	1.01	1.56	0.90	1.67	0.62	0.81
East Asia	Stroke	Ischaemic heart disease	COPD	Lung cancer	Alzheimer's disease	Hypertensive heart disease	Stomach cancer	Lower respiratory infection	Colorectal cancer	Esophageal cancer
	1.42	0.77	3.17	2.00	1.01	1.65	1.95	0.66	0.90	5.18
Oceania	Ischaemic heart disease	Stroke	COPD	Diabetes	Asthma	Ischaemic heart disease	Lower respiratory infection	Hypertensive heart disease	Alzheimer's disease	Lung cancer
	1.08	1.07	2.96	3.23	4.24	2.39	0.84	1.10	0.92	1.43
South East Asia	Stroke	Ischaemic heart disease	COPD	Lower respiratory infection	Diabetes	Alzheimer's disease	Chronic kidney disease	Hypertensive heart disease	Tuberculosis	Cirrhosis
	1.27	0.62	1.56	1.74	1.21	1.02	1.24	1.26	7.68	1.88
Sub-Saharan Africa	Stroke	Ischaemic heart disease	Lower respiratory infection	Diarrheal diseases	Tuberculosis	Diabetes	Hypertensive heart disease	COPD	Alzheimer's disease	Chronic kidney diseas
	0.90	0.71	1.58	1.72	1.84	1.28	1.28	0.79	1.08	1.11
Central Sub-Saharan	Stroke	Ischaemic heart disease	Lower respiratory infection	Tuberculosis	Hypertensive heart disease 2.07	COPD	Diarrheal diseases	Diabetes	Alzheimer's disease	Chronic kidney diseas
Africa	0.99	0.81	1.81	2.71		1.15	1.73	1.10	1.11	0.97
Eastern Sub-Saharan	Stroke	Ischaemic heart disease	Lower respiratory infection	Tuberculosis	Diarrheal diseases	Hypertensive heart disease	Diabetes	COPD	Cirrhosis	Alzheimer's disease
Africa	0.95	0.66	1.42	1.69	1.41	1.50	1.13	0.75	1.49	1.11
Southern Sub-Saharan	Stroke	Ischaemic heart disease	Diabetes	Lower respiratory infection	COPD	Hypertensive heart disease	Chronic kidney disease	Alzheimer's disease	Diarrheal diseases	Tuberculosis
Africa	0.85	0.55	2.50	2.51	1.37	2.07	1.62	0.99	10.67	8.72
Western Sub-Saharan	Ischaemic heart disease 0.79	Stroke	Lower respiratory infection	Diarrheal diseases	Malaria	Tuberculosis	Diabetes	Alzheimer's disease	Chronic kidney disease	COPD
Africa		0.85	1.52	1.77	17.64	1.54	1.11	1.08	1.10	0.62
Values represent ratio of ol	oserved to estimated deaths	s based on sociodemograph	ic index rounded to two dec	imal places. Colour ranges	calculated to place a roughl	y equal number of cells in e	ach column			
	(0.00) 0.00	(0.((), 0.70))	(0.70 + 0.00)	(0.001 0.00)	(0.00) (0.00)	(4.00) (4.40)	(4.40) 4.40)	(4.40) (4.70)	(4.70) 0.45)	(0.45.1

Fig 5 | Ten leading causes of total deaths with ratio of observed to expected deaths in 2019 by location for population aged ≥70, both sexes. Causes are ranked according to global estimates of deaths and colour coded based on ratio of observed to expected rates. Shades of blue represent lower observed deaths than expected rates based on sociodemographic index whereas red indicates observed deaths exceeded expected rates. Ratios are listed in each cell; ratios greater than one indicate that observed levels exceeded expected levels based on sociodemographic index. COPD=chronic obstructive pulmonary disease

Analysing common risks among men and women in the high SDI group, drug use, followed by low birth weight or short gestation, had the highest increase in summary exposure values and attributable disability adjusted life years. In comparison, the middle SDI group had the highest increases for high temperature (one of two climate indicators, the other being low temperature) and high body mass index. The low-middle and low SDI groups noted the highest annualised rate of change in parallel with attributable disability adjusted life years related to ambient particulate matter air pollution and high body mass index.

DCI for population aged ≥70

Between 1990 and 2019, data coverage for all risks and non-fatal outcomes in the population aged ≥70 remained at low levels compared with that for all ages (supplementary tables 9-12). Across GBD locations, between 1990 and 2005, and between 2005 and 2019, 87 countries increased data completeness for risk factors for older adults and 117 countries increased DCI percentage for all ages. Meanwhile, the DCI percentage for non-fatal outcomes in adults aged ≥70 increased in 57 countries, while the DCI percentage for all ages increased in 198 countries. Non-fatal DCI percentage for the population aged ≥70 decreased in 125 countries. Analysing only risk factor data completeness between the same time periods and age groups showed that nine risk factors had 0% completeness for both periods among those aged \geq 70 (supplementary table 10). For the entire period, all risk factors completeness for older adults was at an equal or lower level compared with that of all ages. Additionally, for all ages and those aged ≥70, data completeness decreased between 1990 and 2005, and between 2005 and 2019 for 16 and 32 risks, respectively. Traditionally high burden modifiable risks, including dietary risks, high cholesterol levels, and high fasting plasma glucose, had low to moderate data availability for the population aged ≥70 (DCI range 29%-63%; supplementary table 10). Similar patterns were noted for environmental and occupational risks. Furthermore, when we analysed completeness for nonfatal causes, we found that 52 non-fatal causes had zero coverage for both periods for the population aged \geq 70, while 53 non-fatal causes had 100% completeness in all ages and the population aged \geq 70.

Discussion

Life expectancy, fatal and non-fatal causes, and risk factor patterns

Adults aged \geq 70 were more likely to live longer in 2019 than in 1990 in almost all countries. In the global

Global Age related hearing loss Diabetes Low back pain Bildness and vision loss COPD Stroke Alzheimer's disease Falls Ostecanthritis Central Europe, Eastern Low back pain Age related hearing loss Diabetes Alzheimer's disease 1.74 1.19 1.05 1.19 1.04 Central Europe, and Central Asia 1.19 1.18 0.92 1.13 1.49 1.18 1.07 1.17 0.98 Auge related hearing loss Low back pain Libre the stroke pain Diabetes Bindness and vision loss Stroke Falls Oral disorders Ostecanthritis Low back pain 1.18 0.92 1.13 1.49 1.18 1.07 1.17 0.98 Low back pain Diabetes Bindness and vision loss Oral disorders Alzheimer's disease Market 0.92 0.92 0.92 0.92 0.92 1.19 0.92 1.19 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.9	Oral disorders 0.90 Depressive disorders 1.14 COPD 1.01 COPD
Central Europe, Eastern Europe, and Central Asia Low back pain Age related hearing loss Diabetes Alzheimer's disease Blindness and vision loss Stroke Falls Oral disorders Osteoarthritis Europe, and Central Asia 1.19 1.18 0.92 1.13 1.49 1.18 1.07 1.17 0.98 Appendication Hearting Heartin	Depressive disorders 1.14 COPD 1.01 COPD
Age related hearing loss Low back pain Diabetes Blindness and vision loss Oral disorders Alzheimer's disease Stroke Depressive disorders Octaoarthritic	COPD 1.01 COPD
Central Asia 1.00 1.04 0.90 1.25 1.30 1.14 0.90 2.00 0.00 0.09 0.00 0.00 0.00 0.00	COPD
Diabetes Age related hearing loss Low back pain Falls Alzheimer's disase Stroke Oral disorders Blindness and vision loss Osteoarthritis Osteoa	0.89
Eastern Europe Low back pain Age related hearing loss Blindness and visionloss Alzheimer's disease Osteoarthritis Oral disorders Stroke Dishertes Osteoarthritis 1.3 1.20 1.12 0.65 0.90	Depressive disorders 1.25
High income Low back pain 1.06 Age related hearing loss Diabetes Fails COPD Alzheimer's disease Osteoarthritis Stroke Oral disorders 1.06 1.13 1.20 0.97 1.26 1.09 1.15 1.07 0.96	Other musculoskeleta 2.84
Australasia Age related hearing loss Fails Low back pain Dibetes COPD Oscoarthritis Alzheiner's diesse Oral disorders Other musculoseler 1.24 1.45 0.85 1.00 1.30 1.17 1.02 1.0	Atrial fibrillation 1.53
High Income Asia Pacific Age related hearing loss Low back pain Alzheimer's disease Oscontrintis Stroke Diabetes Falls Other musculoskeletal COPO 1,26 1,26 1,54 0,87 0,60 3,41 0,70	Oral disorders 0.93
High Income North Low back pain Age related hearing loss COPD Diabetes Falls Ostoarthritis Alzheimer's disease Stroke Other musculoseke America 1,23 1,99 1,56 1,05 1,29	Atrial fibrillation 1.74
Southern Latin America Age related hearing loss Diabetes Low back pain Other musculookeletal 1.39 0.95 0.81 0.05 0.95 0.81 1.00 0.95 0.95 0.81 1.00 0.95 0.95 0.81 0.00 0.95 0.95 0.94 1.00 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0	Blindness and vision lo 0.68
Western Europe Low back pain 0.99 Diabetes 1.18 Falls 1.12 Age related hearing loss 0.99 Alzheimer's disease 1.00 COPD 1.12 Ostaoathnitis 1.03 Oral disorders 1.03 Depressive disorders 1.21	Blindness and vision lo 1.03
Latin America and Caribbean Diabetes Age related hearing loss Blindness and visionloss Low back pain 0.80 Oral disorders Alzheimer's disease Osteoarthritis Other musculoskeletal Fails 1.20 0.80 1.20 0.80 1.15 3.44 1.40	Depressive disorders 1.05
Andean Latin America Age related hearing loss Bindness and vision loss Diabetes 014 and vision loss 1.05 1.05 1.05 0.88 0.08 0.85 vision 1.42 0.85 vision 1.42 0.85 vision 1.42 0.45 vision 1.42	Falls 0.88
Carlbbean Diabetes Age related hearing loss Low back pain Blindness and vision loss Oral disorders Falls Osteoarthritis Atzbeiner's disease Depressive disorder 1.00 1.32 1.01 1.26	Ischaemic heart disea 0.98
Central Latin America Diabetes Age related hearing loss Billndness and vision loss Lowak pain 0ther musculoskeletal Osteoarthritis 0ral disorders Alzheiner's disease Depressive disorder 0.75	Chronic kidney diseas 1.78
Tropical Latin America Diabetes Age notated hearing loss 0.98 0.96 0.96 0.95 1.17 1.43 0.055 1.13 1.270	Depressive disorders 1.05
North Africa and Middle Diabetes Age related hearing loss Blindness and vision loss Low back pain Stroke Alzheimer's disease Oral disorders COPD Osteoarthile 102 103 100 105 100 00100000000000000000000	Chronic kidney diseas
Zast horth Africa and Middle Diabetes Age related fearing loss Blindness and vision loss Low back pain Stroke Alzheimer's disease Oral disorders COPD Osteadminits	Chronic kidney diseas
Less de lindness and vision loss 3,67 Age related hearing loss 0,084 Low back pain 7 alis Dietary iron deficiency Road Puries Depressive disord 1,07 alis 1,	Other musculoskeleta
South Asia Blindness and vision loss COPD Age related hearing loss Dibetets Low back gain Falls Dietary inon deficiency Road Injuries Depressive disord	Other musculoskeleta
South Eart Asia, Eart Asia, Age related hearing loss Stroke Bindness and vision loss COPD Low back pain Diabetes Alzheimer's disease Ostavythitis Oral disorders and Openanic Copp Low back pain Diabetes Alzheimer's disease Ostavythitis Oral disorders 0.42	Falls 1.20
Esst Asia Age related hearing loss Stroke COPD Bindness and vision loss Low back pain Alzheiner's disease Diabetes Oscouthitis Oral disorders 119 0.78 1.078 0.54 0.98 0.92	Falls 1.22
Diabetes Low back pain Age related hearing loss Bildness and vision loss Stroke COPD Oral disorders Alzheiner's disease Osteonthilting 0.ceania 1.70 1.26 0.99 0.76 1.52 1.79 1.28 0.97 0.82	Ischaemic heart disea: 1.39
South East Asia Blindness and visionloss Diabetes Age related hearing loss Lovack pain 149 209 Alzheimer's disease 0ral disorders 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.87	I Neck pain 2.09
Sub-Saharan Africa Bindness and visionloss Age related hearing loss Diabetes Low back pain Depressive disorders Stroke Osteoarthritis COPP Alzheimer's disease 151 0.96 1.11 1.14 0.04	Road injuries 1.67
Certral Sub-Sharan Age related hearing loss Diabetes Low back pain Depressive disorders Bilindness and vision loss COPD Alzheimer's disease Onchoerclasis Stroke Africa 0.96 1.16 1.02 1.47 1.25 30.15 0.92	Osteoarthritis 1.07
Eastern Sub-Saharan Blindness and vision loss Age related hearing loss Low bock pain Diabetes Depressive disorders Stroke Osteoarthritis Alzheimer's disease COPD	Road injuries
Amda 1.0.3 0.00 biological dearing loss Blindness and vision loss Lowback pain COPB Stroke Depressive disorders Osteo-artinitis AlzheimerS disear	Oral disorders
Ausse Toto Toto Control Contro Control Control	Alzheimer's disease 0.81
Alues shown in brackets represent ratio of observed YLDs to estimated YLDs to estimated YLDs based on sociodemographic index rounded to two decimal places. Colour ranges calculated to place a rougbly equal number of cells in each column	
	(1.90 to _)

Fig 6 | Ten leading causes of total years lived with disability (YLDs) with ratio of observed to expected YLDs in 2019 by location for population aged ≥70, both sexes. Causes are ranked according to global estimates of YLDs and colour coded based on ratio of observed to expected rates. Shades of blue represent lower observed YLDs than expected rates based on sociodemographic index whereas red indicates observed YLDs exceeded expected rates. Ratios are listed in each cell; ratios greater than one indicate that observed levels exceeded expected levels based on sociodemographic index. COPD=chronic obstructive pulmonary disease

population aged ≥70, an extension of life was recorded of almost two years in total (LE-70) or almost 1.5 years free of disease (HALE-70). Disease burden was closely associated with societal development and aggregate healthcare quality, but starting at the age of 70, relatively low regional variability was found for LE-70, which could be attributed to a lack of variation in SDI and HAQ index within regions. Women generally lived longer but had a higher proportion of those years spent in ill health.

Steady increases in LE-70 have been described even before 1990,³¹ with variation of life expectancy thought to be a complex function of age specific mortality, risk factor exposures, and biomedical advances.³² This supports our findings of low regional variability in life expectancy beyond aged 70. Further, healthy ageing trends are not random³³ because evidence exists that determinants as diverse as lifestyle and socioeconomic development have predictable effects on healthy ageing.³⁴ Our study showed widespread decreases in cardiovascular and chronic respiratory diseases, and in some cancers. Nonetheless, increases in deaths were found to be caused by neurological disorders, falls, and some cancer types that have not been historically targeted by prevention programmes. The fatal and non-fatal burden of injuries due to falls increased in several countries, suggesting that functional

loss will have a role in the burden of disease among older adults.³⁵ Interventions targeting diseases that progressively impair physical functionality³⁶ might be required to alter this pattern. The main disability drivers globally were disorders related to functional status (eg, Alzheimer's disease and other dementias, and stroke), conditions associated with longstanding pain (eg, low back pain, neck pain, osteoarthritis, road injuries), deficits in sensory organ functioning (eg, age related hearing loss, blindness and vision loss), and oral disorders. Alzheimer's disease and other dementias have an important role in people's functional status, and based on our analysis, are contributing to higher mortality and morbidity rates than expected among older adults, a fact that is also supported by the literature.^{37 38} Projections suggest that the older population is expected to exceed 20% of the global population by 2050.³⁹ This growing number of older people is likely to present a challenge in terms of health needs and care costs.⁴⁰

Disability burden and functional loss among older adults

Conditions limiting physical function, pain symptoms, and sensory organ deficits were the main drivers of morbidity among the older population. Importantly,



Fig 7 | Comparison of annualised rate of change in risk exposure measured by summary exposure values (SEVs) for population aged ≥70 (both sexes) from 1990 to 2019 with total attributable disability adjusted life years (DALYs) for all risk factors in 2019. The fraction of disability adjusted life years attributed to each risk factor is depicted in relation to their corresponding population summary exposure values in 2019. Risk factors are colour coded by environmental or occupational (purple), behavioural (yellow), or metabolic (pink) risk factors, and different levels of the risk hierarchy are indicated by different shapes. LDL=low density lipoprotein; PUFA=polyunsaturated fat

our global analysis showed that among the 10 leading causes of death and disability, four were the same: blindness, hearing loss, low back pain, respiratory disease, oral disorders (total tooth loss), and falls represent a group of causes that feature direct functional decline,⁴¹ while other causes of years lived with disability, such as diabetes, are indirectly related to disability and functional loss.7 42 Sex stratified analysis showed a similar pattern, with differentiating drivers being falls for older women and strokes for older men.^{43 44} This information could help public health policy makers implement new tailored programmes to control and prevent functional loss and disability progression among older people.

Before this study, information was limited as to whether today's older adults live extra years of life in better health than their ancestors³⁴ or whether there is support for the theories of equilibrium of morbidity and delayed ageing.^{45 46} Under the compression of morbidity scenario, increases in life expectancy are coupled with decreases in the proportion of life spent in ill health because of shifts in future disease patterns that delay disease onset. However, the expansion of morbidity scenario supports a life expectancy increase coupled with increases in life spent in ill health occurring due to advances in medicine, while disease patterns remain similar.^{47 48} Our findings of a strong association between higher SDI and HAQ index levels with LE-70 and HALE-70 and relatively stagnated trends in PYIH-70 were consistent with previous regional analyses.¹⁴⁴⁹ Some reported relations were not as strong for some measures of health (PYIH-70); this could be attributed to a relatively similar experience of ageing across the development spectrum, with accumulation of deficits proceeding as a function of biology more than environment. Additionally, summary measures of development and healthcare quality might not be as closely associated with healthy ageing as they are for health outcomes in younger populations. The above findings might also reflect that comparatively fewer data are available to quantify epidemiology in older adults.

Policy implications

The present findings have three main implications for health policy and data collection. Firstly, country specific benchmarks can be used to develop and implement health intervention programmes to address and reduce the burden of disability in older adults while tracking regional estimates.⁵⁰ These programmes need to account for the increase in healthcare spending due to population ageing, particularly relating to long term healthcare.⁵¹⁻⁵³ Without preemptive planning, even among socioeconomically developed countries, a projected lack of long term care services might overwhelm the hospital system.⁵⁴ Secondly, the cause and risk specific insights from this analysis could help to draft policies focusing on prevention of functional loss and disability progression among older people, specifically targeting men and women, and different sociodemographic levels. Policy efforts to reduce exposure to smoking and ambient and household air pollution have paid dividends, and should continue and expand. With growing evidence showing that older people are particularly vulnerable to environmental risk factors,^{55 56} similar widespread efforts are needed to tackle increasing exposure to other risk factors, including the oncoming effects of climate change such as extreme weather events, natural disasters, and wildfires. While some accumulation of disease is related to altered biological metabolism and epigenetic signals,⁵⁷ other conditions are preventable. The degree of associated disability could be limited by a combination of healthy ageing surveillance at a population level and redevelopment of healthcare services towards sustainable development in a rapidly ageing societv.^{58 59}

Thirdly, evaluation of data coverage showed that categorically there are fewer health data available relating to older adults. Specifically, the coverage of risk factor data for the population aged \geq 70 decreased in almost 30% of the GBD locations, while since 1990 no information is available for nine risk factors in older adults. This comparative lack of data could represent an imminent threat and highlights the urgent need for surveillance mechanisms in locations with low coverage of risk factors and non-fatal disease burden data in older populations.⁶⁰

Because our analysis covers a period before the covid-19 pandemic, we were unable to analyse the effect of covid-19 on mortality. International studies indicate that most of the deaths have occurred in older adults, with a case fatality rate for the population aged \geq 70 of over 10%, which could even increase to 30%.⁶¹ Hospital admissions and mortality rates for covid-19 are also strongly associated with older age.⁶² Covid-19 will probably be one of the top ranked causes of death and disability adjusted life years in people aged ≥70 for 2020, with studies from high income countries having consistently reported that older adults are disproportionately affected by the ongoing pandemic. Additionally, covid-19 might have long term health implications related to functional decline and health related quality of life among older people.⁶³ Although exploring the impacts of covid-19 is beyond the scope of this study, our analysis should serve as a baseline for evaluating the impacts in the coming years.

Strengths and limitations of this study

This research has several strengths. It has added knowledge about the burden of disease and disability in older adults by analysing data for 204 countries and territories. It has also evaluated health data coverage at global and regional levels for the population aged \geq 70. However, this analysis has several limitations. Firstly, because it is based on GBD 2019, it shares the overall limitations described in previous publications, 2⁴⁻²⁶

including challenges in fully quantifying all sources of uncertainty, lags in data availability, and variation in coding practices and other biases. Secondly, overall input data were limited, especially in lower SDI settings. Thirdly, although we examined a number of associations between plausibly related factors such as SDI, conclusions cannot be drawn about causal relations. Fourthly, the GBD study treats conditions individually when determining mortality and morbidity estimates: however, because multimorbidity is highly prevalent in older populations, it is plausible that this approach leads to overestimation of total disability.⁶⁴ Therefore, individual cause risk might not be fully reflected in population level averages because when the cause manifests in people with a high burden, it could account for a higher proportion of ill health and premature mortality.

Conclusions

Globally adults aged ≥70 were found to live substantially longer in 2019 than in 1990, particularly owing to decreases in death due to cardiovascular diseases and chronic respiratory diseases. However, disability burden rates are following a stable pattern mostly attributable to functional decline, injuries due to falls, hearing loss, and back pain. Globally monitoring mortality and morbidity risk factors is crucial to sustain and advance research and health policy among older adults. Regions with lower sociodemographic development and healthcare quality performed at lower levels, highlighting the areas in greatest need. Our findings show we should develop and implement targeted strategies aimed at functional ability, sensory organ deficits, symptoms of pain, and unintentional falls. Programmes need to address country specific sociodemographic and cultural development because universal plans might be inefficient. Public health strategies will require a coherent ageing health policy, targeted data coverage, and consistent collaboration among stakeholders to succeed. The present estimates could serve as a healthy ageing benchmark for countries working to focus ageing policies on key risk factors and determinants, improve healthcare access and quality, and lower healthcare costs.

Contributors: ST is first author. GAK and NJK are joint senior authors. ST, GAK, AS, and NJK designed the study and drafted the initial manuscript. ST, GAK, VK, and NJK analysed the data. All other authors contributed data, interpreted the data, or revised the manuscript. All authors read and approved the final manuscript. NJK is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: GBD is supported by the Bill and Melinda Gates Foundation. This research work was supported by a Pilot Grants for Research on Subnational Burden of Disease, Center for Health Trends and Forecasts (CHTF) at IHME (National Institute on Ageing, National Institutes of Health) to GAK. ST was supported by the Foundation for Education and European Culture (IPEP), the Miguel Servet programme (reference No CP18/00006 from the Instituto de Salud Carlos III— Spain), the Fondos Europeo de Desarrollo Regional (FEDER), and awarded funding for a six month visiting fellowship at IHME from M-AES (reference No MV16/00035 from the Instituto de Salud Carlos III). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the article for publication. All authors had full access to the data in the study and had final responsibility for the decision to submit for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare support from CHTF, the Bill and Melinda Gates Foundation, IPEP, Instituto de Salud Carlos III—Spain, and FEDER for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The GBD study's protocol has been approved by the research ethics board at the University of Washington. The GBD shall be conducted in full compliance with University of Washington policies and procedures, as well as applicable federal, state, and local laws.

Data sharing: Data of the GBD study are publicly available at https://www.healthdata.org/results/data-visualizations.

The corresponding author (NJK) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The GBD study is compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).

Dissemination to participants and related patient and public communities: We plan to disseminate these research findings to a wider community via press releases, featuring on the healthdata.org website, via social media platforms, and presentation at international fora.

Provenance and peer review: Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.

- Development in an Ageing World. World Economic and Social Survey 2007. https://www.un.org/en/development/desa/policy/wess/ wess_archive/2007wess.pdf (accessed 27 Jan 2018).
- 2 European Commission. Population ageing in Europe: facts, implications and policies 2014. https://op.europa.eu/en/ publication-detail/-/publication/1e7549b4-2333-413b-972cf9f1bc70d4cf.
- 3 Knickman JR, Snell EK. The 2030 problem: caring for aging baby boomers. *Health Serv Res* 2002;37:849-84. doi:10.1034/j.1600-0560.2002.56.x
- 4 Crow RS, Lohman MC, Titus AJ, et al. Mortality risk along the frailty spectrum: data from the National Health and Nutrition Examination Survey 1999 to 2004. *J Am Geriatr Soc* 2018;66:496-502. doi:10.1111/jgs.15220
- 5 Rowe JW, Kahn RL. Successful Aging 2.0: conceptual expansions for the 21st century. J Gerontol B Psychol Sci Soc Sci 2015;70:593-6. doi:10.1093/geronb/gbv025
- 6 Caballero FF, Soulis G, Engchuan W, et al. Advanced analytical methodologies for measuring healthy ageing and its determinants, using factor analysis and machine learning techniques: the ATHLOS project. *Sci Rep* 2017;7:43955. doi:10.1038/srep43955
- 7 WHO. World report on ageing and health 2015. WHO. 2015. www. who.int/ageing/events/world-report-2015-launch/en/ (accessed 2 Nov 2018).
- 8 Scherbov S, Sanderson WC. New Approaches to the Conceptualization and Measurement of Age and Ageing. In: Mazzuco S, Keilman N, eds. Developments in Demographic Forecasting. The Springer Series on Demographic Methods and Population Analysis. Springer, 2020:49. https://doi.org/10.1007/978-3-030-42472-5_12
- 9 Population structure and ageing—statistics explained. http:// ec.europa.eu/eurostat/statistics-explained/index.php/Population_ structure_and_ageing#Further_Eurostat_information (accessed 27 Jan 2018).
- 10 Population Reference Bureau. Fact sheet: aging in the United States. https://www.prb.org/wp-content/uploads/2019/07/populationbulletin-2015-70-2-aging-us.pdf.
- 11 Population and aging in Asia: the growing elderly population. Asian Development Bank. https://www.adb.org/features/asia-s-growing-elderly-population-adb-s-take (accessed 27 Jan 2018).
- 12 European Environment Agency. Population trends 1950 2100: globally and within Europe. https://www.eea.europa.eu/dataand-maps/indicators/total-population-outlook-from-unstat-3/ assessment-1.

- 13 2018 Ageing report: policy challenges for ageing societies. European Commission. 2018. https://ec.europa.eu/info/news/economyfinance/policy-implications-ageing-examined-new-report-2018may-25_en (accessed 21 Aug 2019).
- 14 Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. *Lancet* 2015;385:549-62. doi:10.1016/S0140-6736(14)61347-7
- 15 de Nardi M, French E, Bailey Jones J, McCauley J. Medical spending of the US elderly. *Fiscal Studies* 2016;37:717-47.
- 16 Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. JAMA 2010;303:1303-4. doi:10.1001/ jama.2010.381
- 17 Lee JT, Hamid F, Pati S, Atun R, Millett C. Impact of Noncommunicable Disease Multimorbidity on Healthcare Utilisation and Out-OF-Pocket Expenditures in Middle-Income Countries: Cross Sectional Analysis. *PLoS One* 2015;10:e0127199. doi:10.1371/journal. pone.0127199
- 18 Olaya B, Moneta MV, Caballero FF, et al. Latent class analysis of multimorbidity patterns and associated outcomes in Spanish older adults: a prospective cohort study. *BMC Geriatr* 2017;17:186. doi:10.1186/s12877-017-0586-1
- 19 Freeman AT, Santini ZI, Tyrovolas S, Rummel-Kluge C, Haro JM, Koyanagi A. Negative perceptions of ageing predict the onset and persistence of depression and anxiety: findings from a prospective analysis of the Irish Longitudinal Study on Ageing (TILDA). *J Affect Disord* 2016;199:132-8. doi:10.1016/j.jad.2016.03.042
- 20 Tyrovolas S, Koyanagi A, Olaya B, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle 2016;7:312-21. doi:10.1002/jcsm.12076
- 21 Gijón-Conde T, Graciani A, López-García E, et al. Frailty, Disability, and ambulatory blood pressure in older adults. J Am Med Dir Assoc 2018;19:433-38. doi:10.1016/j.jamda.2017.11.014
- 22 Stenholm S, Alley D, Bandinelli S, et al. The effect of obesity combined with low muscle strength on decline in mobility in older persons: results from the InCHIANTI study. *Int J Obes (Lond)* 2009;33:635-44. doi:10.1038/ijo.2009.62
- 23 Stewart Williams J, Kowal P, Hestekin H, et al, SAGE collaborators. Prevalence, risk factors and disability associated with fall-related injury in older adults in low- and middle-incomecountries: results from the WHO Study on global AGEing and adult health (SAGE). BMC Med 2015;13:147. doi:10.1186/s12916-015-0390-8
- 24 GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1160-203. doi:10.1016/ S0140-6736(20)30977-6
- 25 Vos T, Lim SS, Abbafati C, et al, GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1204-22. doi:10.1016/S0140-6736(20)30925-9
- 26 Murray CJL, Aravkin AY, Zheng P, et al, GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;396:1223-49. doi:10.1016/ S0140-6736(20)30752-2
- 27 Zheng P, Barber R, Sorensen RJD, et al. Trimmed constrained mixed effects models: formulations and algorithms. J Comput Graph Stat 2021;30:544-56. doi:10.1080/10618600.2020.1868303
- 28 Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. *Lancet Glob Health* 2015;3:e712-23. doi:10.1016/S2214-109X(15)00069-8
- 29 Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96. doi:10.1016/S0140-6736(12)61729-2
- 30 GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet 2018;391:2236-71. doi:10.1016/S0140-6736(18)30994-2
- 31 Passarino G, De Rango F, Montesanto A. Human longevity: genetics or lifestyle? It takes two to tango. *Immun Ageing* 2016;13:12. doi:10.1186/s12979-016-0066-z.
- 32 Vaupel JW, Villavicencio F, Bergeron-Boucher M-P. Demographic perspectives on the rise of longevity. *Proc Natl Acad Sci U S* A 2021;118:e2019536118. doi:10.1073/pnas.2019536118
- 33 Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. *Lancet Public Health* 2019;4:e159-67. doi:10.1016/S2468-2667(19)30019-2

RESEARCH

- 34 Chatterji S, Byles J, Cutler D, Seeman T, Verdes E. Health, functioning, and disability in older adults--present status and future implications. *Lancet* 2015;385:563-75. doi:10.1016/S0140-6736(14)61462-8
- 35 Smee DJ, Anson JM, Waddington GS, Berry HL. Association between Physical functionality and falls risk in community-living older adults. *Curr Gerontol Geriatr Res* 2012;2012:864516. doi:10.1155/2012/864516
- 36 Ho S-H, Li C-S, Liu C-C. The influence of chronic disease, physical function, and lifestyle on health transition among the middleaged and older persons in Taiwan. J Nurs Res 2009;17:136-43. doi:10.1097/JNR.0b013e3181a53f94
- 37 Witthaus E, Ott A, Barendregt JJ, Breteler M, Bonneux L. Burden of mortality and morbidity from dementia. Alzheimer Dis Assoc Disord 1999;13:176-81. doi:10.1097/00002093-199907000-00011
- 38 Wolters FJ, Tinga LM, Dhana K, et al. Life expectancy with and without dementia: a population-based study of dementia burden and preventive potential. *Am J Epidemiol* 2019;188:372-81. doi:10.1093/aje/kwy234
- 39 United Nations. World Economic and Social Survey 2013: Sustainable Development Challenges. 2013. https://www.un.org/en/ development/desa/publications/world-economic-and-social-survey-2013-sustainable-development-challenges.html (accessed 2 Nov 2018).
- 40 Beard JR, Officer AM, Cassels AK. The World Report on Ageing and Health. Gerontologist 2016;56(Suppl 2):S163-6. doi:10.1093/ geront/gnw037
- 41 World Health Organization. Towards a common language for functioning, disability and health: ICF. WHO, 2002.
- 42 Colón-Emeric CS, Whitson HE, Pavon J, Hoenig H. Functional decline in older adults. *Am Fam Physician* 2013;88:388-94.
- 43 Gale CR, Cooper C, Aihie Sayer A. Prevalence and risk factors for falls in older men and women: The English Longitudinal Study of Ageing. *Aqe Ageing* 2016;45:789-94. doi:10.1093/ageing/afw129
- 44 Roy-O'Reilly M, McCullough LD. Age and sex are critical factors in ischemic stroke pathology. *Endocrinology* 2018;159:3120-31. doi:10.1210/en.2018-00465
- 45 Beltrán-Sánchez H, Soneji S, Crimmins EM. Past, present, and future of healthy life expectancy. *Cold Spring Harb Perspect Med* 2015;5:a025957. doi:10.1101/cshperspect.a025957
- 46 Manton KG. Changing concepts of morbidity and mortality in the elderly population. *Milbank Mem Fund Q Health Soc* 1982;60:183-244. doi:10.2307/3349767
- 47 Fries JF. Aging, natural death, and the compression of morbidity. N Engl J Med 1980;303:130-5. doi:10.1056/ NEJM198007173030304
- 48 Gruenberg EM. The failures of success. 1977. *Milbank* 0 2005;83;779-800. doi:10.1111/j.1468-0009.2005.00400.x
- 49 de la Fuente J, Caballero FF, Sánchez-Niubó A, et al. Determinants of health trajectories in England and the United States: an approach to identify different patterns of healthy aging. J Gerontol A Biol Sci Med Sci 2018;73:1512-8. doi:10.1093/gerona/gly006

- 50 WHO regional office for Europe. Policies and priority interventions for healthy ageing. https://www.euro.who.int/__data/assets/ pdf_file/0006/161637/WHD-Policies-and-Priority-Interventions-for-Healthy-Ageing.pdf
- 51 Dieleman JL, Squires E, Bui AL, et al. Factors associated with increases in US health care spending, 1996-2013. JAMA 2017;318:1668-78. doi:10.1001/jama.2017.15927
- 52 Reeves D, Pye S, Ashcroft DM, et al. The challenge of ageing populations and patient frailty: can primary care adapt?*BM*/ 2018;362:k3349. doi:10.1136/bmj.k3349
- 53 OECD. Aging and long-term care. https://www.oecd.org/els/healthsystems/long-term-care.htm (accessed 3 Sep 2019).
- 54 Hinde S, Bojke L, Richardson G, et al. Delayed transfers of care for older people: a wider perspective. Age Ageing 2021;50:1073-6. doi:10.1093/ageing/afab035
- 55 Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. *Nature* 2018;561:45-56. doi:10.1038/ s41586-018-0457-8.
- 56 Simoni M, Baldacci S, Maio S, Cerrai S, Sarno G, Viegi G. Adverse effects of outdoor pollution in the elderly. *J Thorac Dis* 2015;7:34-45. doi:10.3978/j.issn.2072-1439.2014.12.10
- 57 Longo VD, Antebi A, Bartke A, et al. Interventions to slow aging in humans: are we ready?*Aging Cell* 2015;14:497-510.
- 58 United Nations Developent Programme. Ageing, older persons and the 2030 agenda for sustainable development. New York. https:// www.undp.org/sites/g/files/zskgke326/files/publications/UNDP_ AARP_HelpAge_International_Ageing_Olderpersons%20and%20 2030%20Agenda_revOct2018.pdf (accessed 11 Aug 2021).
- 59 Mavrodaris Ä, Mattocks C, Brayne CE. Healthy ageing for a healthy planet: do sustainable solutions exist? The Lancet Healthy Longevity 2021;2:e10-1. doi:10.1016/S2666-7568(20)30067-2
- World Health Organization. UN Decade of healthy aging 2021-2030. 2020. https://www.who.int/initiatives/decade-of-healthy-ageing (accessed 29 Jun 2021).
- 61 Shahid Z, Kalayanamitra R, McClafferty B, et al. COVID-19 and older adults: what we know. *J Am Geriatr Soc* 2020;68:926-9. doi:10.1111/jgs.16472
- 62 Yanez ND, Weiss NS, Romand J-A, Treggiari MM. COVID-19 mortality risk for older men and women. *BMC Public Health* 2020;20:1742. doi:10.1186/s12889-020-09826-8
- 63 Walle-Hansen MM, Ranhoff AH, Mellingsæter M, Wang-Hansen MS, Myrstad M. Health-related quality of life, functional decline, and long-term mortality in older patients following hospitalisation due to COVID-19. BMC Geriatr 2021;21:199. doi:10.1186/s12877-021-02140-x
- 64 Garin N, Koyanagi A, Chatterji S, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci 2016;71:205-14. doi:10.1093/gerona/glv128

Web appendix: Supplementary material Web appendix: Acknowledgments and declarations

Supplementary Material (Appendix) for: Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study

This appendix provides specific methodological detail, supplemental figures, and more detailed results for "Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study."

Contents

GBD 2017 Ageing Collaborators
Global Burden of Disease overview
GATHER statement
GBD cause list and location hierarchy
Socio-demographic Index (SDI)
Data sources
Mortality and death cause-specific estimation process for those over 70 years old 32
Non-fatal modelling methods for those 70 years and older
Healthcare Access and Quality (HAQ) Index
References
Figure S1. Global population change by age group for both sexes combined (top panel), population percentagechange during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in Low Socio-demographic Index (SDI) regions
Figure S2. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in Low-middle Socio-demographic Index (SDI) regions
Figure S3. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lowermiddle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in Middle Socio-demographic Index (SDI) regions
Figure S4. Global population change by age group for both sexes combined (top panel), population percentagechange during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in High-middle Socio-demographic Index (SDI) regions
Figure S5. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in High Socio- demographic Index (SDI) regions
Figure S6. Global population change by age group for both sexes combined (top panel), population

percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the Central Europe, Eastern Europe and Central Asia GBD super-region.39

Figure S19. Decomposition of the probability of death, for all GBD locations, for the population aged 70 to 90 years old, from 1990 to 2019, in females
Figure S20. Leading ten causes of total deaths with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in males, for all GBD locations
Figure S21. Leading ten causes of total deaths with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in females, for all GBD locations
Figure S22. Leading ten causes of total years lived with disability with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in males, for all GBD locations.
Figure S23. Leading ten causes of total years lived with disability with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in females, for all GBD locations
Figure S24. Global annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019
Figure S25. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in Low SDI quintile
Figure S26. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in Low-middle SDI quintile
Figure S27. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in Middle SDI quintile
Figure S28. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in High-middle SDI quintile
Figure S29. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in High SDI quintile
Figure S30. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the Central Europe, Eastern Europe and Central Asia GBD super-region
Figure S31. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the High-income GBD super-region
Figure S32. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the Latin America and Caribbean GBD super-region
Figure S33. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the North Africa and Middle East super-region

Figure S34. Annualised rate of change in risk factors summary exposure values (SEV) in people ag 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by ris factor in 2019, in the South Asia GBD super-region	ged sk 78
Figure S35. Annualised rate of change in risk factors summary exposure values (SEV) in people ag 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by ris factor in 2019, in the Southeast Asia, East Asia and Oceania GBD super-region	ged sk 79
Figure S36. Annualised rate of change in risk factors summary exposure values (SEV) in people ag 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by ris factor in 2019, in the Sub-Saharan Africa GBD super-region	şed sk 80
Supplemental Tables	
Supplementary Table 1: GATHER checklist of information that should be included in reports of global health estimates, with description of compliance and location of information for "Global, regional, and national burden of diseases and injuries for adults 70 years and older: a systematic analysis for the Global Burden of Disease 2019 Study"	d obal 81
Supplementary Table 2. GBD location hierarchy, with SDI quintile	83
Supplementary Table 3: List of GBD causes, with levels	86
Supplementary Table 4: Cause-specific mortality rate for 70-79 years, 80-94 yearsand 95+ years in 20 and percentage change from 1990 to 2019 in death number and rate in 70+ years, global, for all GBD causes	19, 89
Supplementary Table 5. Cause-specific rate of YLDs for 70-79 years, 80-94 years,and 95+ years in 2019 and percentage change from 1990 to 2019 in YLD number and rate in 70+ years, global, for all GBD causes	∍, 96
Supplementary Table 6. Life expectancy, Health-adjusted life expectancy, and proportion of years spe ill health in all reporting locations, in 1990, 2005, 2019 for Both sexes combined	nt in 103
Supplementary Table 7. Life expectancy, Health-adjusted life expectancy, and proportion of years spe ill health in all reporting locations, in 1990, 2005, 2019 for Males	nt in 110
Supplementary Table 8. Life expectancy, Health-adjusted life expectancy, and proportion of years spe ill health in all reporting locations, in 1990, 2005, 2019 for Females	nt in 116
Supplementary Table 9. Data coverage index for all risk factorsfor 204 reporting locations, 1990–2005 2005–2019 and in total by all ages and for the 70+ age group, for both sexes	, 122
Supplementary Table 10. Data coverage index for all reporting locations for 69 risk factors, 1990–2005 2005–2019 and in total by all ages and for the 70+ age group, for both sexes	5, 128
Supplementary Table 11. Data coverage index for all non-fatal causes for 204 locations,among 1990–2 2005–2019 and in total by all ages and for the 70+ age group, for both sexes	2005, 130
Supplementary Table 12. Data coverage index for all locations for 286 non-fatal causes, among 1990–	

2005, 2005–2019 and in total by all ages and for the 70+ age group, for both sexes 135

GBD 2017 Ageing Collaborators

Stefanos Tyrovolas^{% 1 2 447}, Andy Stergachis^{4 5}, Varsha Sarah Krish⁶, Angela Y Chang⁷, Vegard Skirbekk⁸, Joseph L Dieleman⁶⁹, Somnath Chatterji¹⁰, Foad Abd-Allah¹¹, Mohammad Abdollahi¹²¹³, Aidin Abedi¹⁴, Hassan Abolhassani¹⁵¹⁶, Akine Eshete Abosetugn¹⁷, Lucas Guimarães Abreu¹⁸, Michael R M Abrigo¹⁹, Abdulaziz Khalid Abu Haimed²⁰, Maryam Adabi²¹, Oladimeji M Adebayo²², Isaac Akinkunmi Adedeji²³, Victor Adekanmbi²⁴, Olatunji O Adetokunboh^{25 26}, Davoud Adham²⁷, Shailesh M Advani^{28 29}, Mohsen Afarideh^{30 31}, Gina Agarwal³², Mohammad Aghaali³³, Seyed Mohammad Kazem Aghamir³⁴, Anurag Agrawal^{35 36}, Sohail Ahmad³⁷, Tauseef Ahmad³⁸, Keivan Ahmadi³⁹, Mehdi Ahmadi^{40 41}, Muktar Beshir Ahmed^{42 43}, Rufus Olusola Akinyemi^{44 45}, Ziyad Al-Aly^{46 47}, Khurshid Alam⁴⁸, Fahad Mashhour Alanezi⁴⁹, Turki M Alanzi⁵⁰, Jacqueline Elizabeth Alcalde-Rabanal⁵¹, Biresaw Wassihun Alemu^{52 53}, Samar Al-Haji^{54 55}, Robert Kaba Alhassan⁵⁶, Saqib Ali⁵⁷, Gianfranco Alicandro⁵⁸, Mehran Alijanzadeh⁵⁹, Vahid Alipour^{60 61}, Syed Mohamed Aljunid^{62 63}, François Alla⁶⁴, Majid Abdulrahman Hamad Almadi^{65 66}, Amir Almasi-Hashiani⁶⁷, Abdulaziz M Almulhim⁶⁸, Rajaa M Al-Raddadi⁶⁹, Arya Aminorroaya^{70 71}, Fatemeh Amiri⁷², Arianna Maever L Amit^{73 74}, Dickson A Amugsi⁷⁵, Etsay Woldu Anbesu⁷⁶, Robert Ancuceanu⁷⁷, Deanna Anderlini^{78 79}, Tudorel Andrei⁸⁰, Catalina Liliana Andrei⁸¹, Sofia Androudi⁸², Mina Anjomshoa⁸³, Fereshteh Ansari^{84 85}, Alireza Ansari-Moghaddam⁸⁶, Carl Abelardo T Antonio^{87 88}, Benny Antony⁸⁹, Davood Anvari^{90 91}, Razique Anwer⁹², Jalal Arabloo⁶⁰, Morteza Arab-Zozani⁹³, Johan Ärnlöv^{94 95}, Malke Asaad⁹⁶, Mehran Asadi-Aliabadi⁹⁷, Ali A Asadi-Pooya⁹⁸ ⁹⁹, Maha Moh'd Wahbi Atout¹⁰⁰, Marcel Ausloos¹⁰¹ ⁸⁰, Floriane Ausloos¹⁰², Beatriz Paulina Ayala Quintanilla¹⁰³, Getinet Ayano¹⁰⁴, Martin Amogre Ayanore¹⁰⁵, Yared Asmare Aynalem¹⁰⁶, Samad Azari⁶⁰, Zelalem Nigussie Azene¹⁰⁷, Ebrahim Babaee⁹⁷, Ashish D Badiye¹⁰⁸, Arun Balachandran^{109 110}, Maciej Banach¹¹¹¹¹², Srikanta K Banerjee¹¹³, Palash Chandra Banik¹¹⁴, Suzanne Lyn Barker-Collo¹¹⁵, Sanjay Basu¹¹⁶ ¹¹⁷, Bernhard T Baune¹¹⁸ ¹¹⁹, Mohsen Bayati¹²⁰, Bayisa Abdissa Baye¹²¹, Neeraj Bedi¹²² ¹²³, Ettore Beghi¹²⁴, Yannick Béjot^{125 126}, Michelle L Bell¹²⁷, Isabela M Bensenor¹²⁸, Akshaya Srikanth Bhagavathula^{129 130}, Pankaj Bhardwaj^{131 132}, Krittika Bhattacharyya^{133 134}, Suraj Bhattarai¹³⁵, Zulfiqar A Bhutta^{136 137}, Sadia Bibi¹³⁸, Ali Bijani¹³⁹, Boris Bikbov¹⁴⁰, Antonio Biondi¹⁴¹, Binyam Minuye Birihane¹⁴², Atanu Biswas¹⁴⁴, Tone Bjørge¹⁴⁵ ¹⁴⁶, Somayeh Bohlouli¹⁴⁷, Srinivasa Rao Rao Bolla¹⁴⁸, Archith Boloor¹⁴⁹, Soufiane Boufous¹⁵⁰, Dejana Braithwaite²⁹, Hermann Brenner¹⁵¹, Andrew M Briggs¹⁵², Nikolay Ivanovich Briko¹⁵³, Gabrielle B Britton¹⁵⁴ ¹⁵⁵, Sharath Burugina Nagaraja¹⁵⁶, Reinhard Busse¹⁵⁷, Zahid A Butt¹⁵⁸, Florentino Luciano Caetano dos Santos¹⁶⁰, Luis Alberto Cámera¹⁶¹¹⁶², Josip Car¹⁶³¹⁶⁴, Rosario Cárdenas¹⁶⁵, Giulia Carreras¹⁶⁶, Juan J Carrero¹⁶⁷, Felix Carvalho¹⁶⁸, Joao Mauricio Castaldelli-Maia¹⁶⁹, Carlos A Castañeda-Orjuela^{170 171}, Giulio Castelpietra^{172 173}, Franz Castro¹⁵⁵, Ester Cerin^{174 175}, Muge Cevik^{176 177}, Joht Singh Chandan¹⁷⁸, Alex R Chang¹⁷⁹, Jaykaran Charan¹⁸⁰, Vijay Kumar Chattu¹⁸¹, Pankaj Chaturvedi¹⁸², Sarika Chaturvedi¹⁸⁴, Prachi P Chavan¹⁸⁵, Simiao Chen¹⁸⁶, Nicolas Cherbuin¹⁸⁷, Ken Lee Chin¹⁸⁸, Daniel Youngwhan Cho¹⁹⁰, Mohiuddin Ahsanul Kabir Chowdhury^{191 192}, Dinh-Toi Chu¹⁹³, Sheng-Chia Chung^{194 195}, Michael T Chung¹⁹⁶, Liliana G Ciobanu^{197 198}, Vera Marisa Costa¹⁶⁸, Ewerton Cousin¹⁹⁹, Michael H Criqui²⁰⁰, Marita Cross²⁰¹, Saad M A Dahlawi²⁰², Giovanni Damiani^{203 204}, Lalit Dandona^{205 6 206}, Rakhi Dandona^{205 6 9}, Parnaz Daneshpajouhnejad^{207 208}, Jai K Das²⁰⁹, Rajat Das Gupta^{192 210}, Claudio Alberto Dávila-Cervantes²¹¹, Kairat Davletov²¹², Farah Deeba²¹³, Diego De Leo²¹⁴, Edgar Denova-Gutiérrez²¹⁵, Nikolaos Dervenis^{216 217}, Rupak Desai²¹⁸, Samath Dhamminda Dharmaratne^{219 9 6}, Govinda Prasad Dhungana²²⁰, Mostafa Dianatinasab²²¹ ²²², Diana Dias da Silva²²³, Daniel Diaz²²⁴ ²²⁵, Martin Dichgans²²⁶, Shirin Djalalinia²²⁷, Klara Dokova²²⁸, Fariba Dorostkar²²⁹, Leila Doshmangir²³⁰, Bruce B Duncan¹⁹⁹, Andre Rodrigues Duraes²³¹, Arielle Wilder Eagan²³³²³⁴, Mohammad Ebrahimi Kalan²³⁵, David Edvardsson²³⁶²³⁷, Andem Effiong²³⁸, Joshua R Ehrlich²³⁹ ²⁴⁰, Islam Y Elgendy²⁴¹ ²⁴², Shaimaa I El-Jaafary¹¹, Iman El Sayed²⁴³, Maysaa El Sayed Zaki²⁴⁴, Maha El Tantawi²⁴⁵, Babak Eshrati⁹⁷, Khalil Eskandari^{246 247}, Sharareh Eskandarieh²⁴⁸, Saman Esmaeilnejad^{249 250}, Atkilt Esaiyas Etisso²⁵¹, Pawan Sirwan Faris^{252 253}, Andre Faro²⁵⁴, Farshad Farzadfar⁷⁰, Mehdi Fazlzadeh²⁵⁵ ²⁵⁶, Valery L Feigin^{257 6 258}, Seyed-Mohammad Fereshtehnejad^{94 259}, Eduarda Fernandes²⁶⁰, Pietro Ferrara²⁶¹, Manuela L Ferreira²⁶², Irina Filip^{263 264}, Florian Fischer²⁶⁵, James L Fisher²⁶⁶, Nataliya A Foigt²⁶⁷,

Morenike Oluwatoyin Folayan²⁶⁸, Artem Alekseevich Fomenkov²⁶⁹, Masoud Foroutan²⁷⁰, Richard Charles Franklin²⁷¹, Marisa Freitas²⁶⁰, Mohamed M Gad^{272 273}, Silvano Gallus²⁷⁴, Amiran Gamkrelidze²⁷⁵, Abadi Kahsu Gebre^{276 277}, Leake G Gebremeskel^{278 279}, Fatemeh Ghaffarifar²⁸⁰, Mansour Ghafourifard²⁸¹, Mahsa Ghajarzadeh²⁸², Reza Ghanei Gheshlagh²⁸³, Ahmad Ghashghaee^{60 284}, Nermin Ghith²⁸⁵, Asadollah Gholamian^{286 287}, Tiffany K Gill¹⁹⁷, Richard F Gillum^{288 289}, Iago Giné-Vázquez^{290 2}, Giorgia Giussani²⁹¹, Mustefa Glagn²⁹², Elena V Gnedovskaya²⁹³, Myron Anthony Godinho²⁹⁴, Salime Goharinezhad⁹⁷, Sameer Vali Gopalani²⁹⁵ 296, Giuseppe Gorini²⁹⁷, Alessandra C Goulart²⁹⁸ 128, Michal Grivna²⁹⁹ 300, Harish Chander Gugnani^{301 302}, Rafael Alves Guimarães³⁰³, Yuming Guo^{188 304}, Rahul Gupta^{305 306}, Reyna Alma Gutiérrez³⁰⁷, Abdul Hafiz^{308 309}, Arvin Haj-Mirzaian^{310 311}, Arya Haj-Mirzaian³¹², Randah R Hamadeh³¹³, Samer Hamidi³¹⁴, Graeme J Hankey^{315 316}, Hamidreza Haririan³¹⁷, Josep Maria Haro^{318 319}, Ahmed I Hasaballah³²⁰, Maryam Hashemian^{321 322}, Abdiwahab Hashi³²³, Shoaib Hassan^{324 325}, Amr Hassan¹¹, Soheil Hassanipour³²⁶ ³²⁷, Simon I Hay^{6 9}, Khezar Hayat^{328 329}, Reza Heidari-Soureshjani³³⁰, Delia Hendrie¹⁰⁴, Claudiu Herteliu^{80 331}, Hung Chak Ho³³², Chi Linh Hoang³³³, Ramesh Holla³³⁴, Praveen Hoogar³³⁵, Naznin Hossain³³⁶, Mostafa Hosseini^{337 338}, Mehdi Hosseinzadeh^{339 340}, Mihaela Hostiuc³⁴¹, Sorin Hostiuc^{342 343}, Mowafa Househ³⁴⁴, Mohamed Hsairi³⁴⁵, Guoqing Hu³⁴⁶, Ayesha Humayun³⁴⁷, Bing-Fang Hwang³⁴⁸, Ivo Iavicoli³⁴⁹, Segun Emmanuel Ibitoye³⁵⁰, Olayinka Stephen Ilesanmi^{351 352}, Irena M Ilic³⁵³, Milena D Ilic³⁵⁴, Leeberk Raja Inbaraj³⁵⁵, Usman Iqbal³⁵⁶, Seyed Sina Naghibi Irvani³⁵⁷, Md.Mohaimenul Islam³⁵⁸, Hiroyasu Iso³⁵⁹, Rebecca Q Ivers³⁶⁰, Chinwe Juliana Iwu^{361 26}, Chidozie C D Iwu³⁶², Jalil Jaafari³⁶³, Mohammad Ali Jahani¹³⁹, Mihajlo Jakovljevic^{364 365}, Farzad Jalilian³⁶⁶, Hosna Janjani^{256 367}, Manthan Dilipkumar Janodia³⁶⁸, Tahereh Javaheri³⁶⁹, Ensiyeh Jenabi³⁷⁰, Ravi Prakash Jha^{371 372}, John S Ji^{373 374}, Oommen John^{375 376}, Jost B Jonas³⁷⁷ ³⁷⁸, Jacek Jerzy Jozwiak³⁷⁹, Mikk Jürisson³⁸⁰, Ali Kabir³⁸¹, Zubair Kabir³⁸², Rizwan Kalani³⁸³, Rohollah Kalhor³⁸⁴ ³⁸⁵, Tanuj Kanchan³⁸⁶, Neeti Kapoor¹⁰⁸, Behzad Karami Matin³⁸⁷, André Karch³⁸⁸, Ayele Semachew Kasa³⁸⁹, Gbenga A Kayode^{390 391}, Ali Kazemi Karyani³⁸⁷, Yousef Saleh Khader³⁹², Nauman Khalid³⁹³, Mohammad Khammarnia³⁹⁴, Maseer Khan³⁹⁵, Ejaz Ahmad Khan³⁹⁶, Khaled Khatab^{397 398}, Mahalagua Nazli Khatib³⁹⁹, Maryam Khayamzadeh^{400 401}, Habibolah Khazaie⁴⁰², Abdullah T Khoja^{403 404}, Young-Eun Kim⁴⁰⁵, Yun Jin Kim⁴⁰⁶, Ruth W Kimokoti⁴⁰⁷, Sezer Kisa⁴⁰⁸, Adnan Kisa^{409 410}, Mika Kivimäki^{411 412}, Cameron J Kneib¹⁹⁰, Sonali Kochhar^{4 413}, Ali Koolivand⁴¹⁴, Jacek A Kopec^{415 416}, Anirudh Kotlo⁴¹⁷, Ai Koyanagi^{418 419}, Kewal Krishan⁴²⁰, Barthelemy Kuate Defo^{421 422}, G Anil Kumar²⁰⁵, Nithin Kumar⁴²³, Manasi Kumar^{424 425}, Om P Kurmi^{426 427}, Dian Kusuma^{428 429}, Ben Lacey^{430 431}, Dharmesh Kumar Lal²⁰⁵, Ratilal Lalloo⁴³², Tea Lallukka⁴¹², Jennifer O Lam⁴³³, Faris Hasan Lami⁴³⁴, Iván Landires^{435 436}, Van Charles Lansingh^{437 438}, Anders O Larsson^{439 440}, Savita Lasrado⁴⁴¹, Paolo Lauriola⁴⁴², Carlo La Vecchia⁴⁴³, Janet L Leasher⁴⁴⁴, Georgy Lebedev^{445 446}, Paul H Lee⁴⁴⁷, Shaun Wen Huey Lee^{448 449}, James Leigh⁴⁵⁰, Matilde Leonardi⁴⁵¹, Andrew S Levey^{452 453}, Miriam Levi^{454 455}, Shanshan Li⁴⁵⁶, Shai Linn⁴⁵⁷, Xuefeng Liu⁴⁵⁸, Alan D Lopez⁴⁵⁹, Platon D Lopukhov¹⁵³, Stefan Lorkowski^{460 461}, Paulo A Lotufo⁴⁶², Rafael Lozano^{6 9}, Alessandra Lugo²⁷⁴, Raimundas Lunevicius^{463 464}, Mohammed Madadin⁴⁶⁵, Ralph Maddison⁴⁶⁶, Phetole Walter Mahasha⁴⁶⁷, Morteza Mahmoudi⁴⁶⁸, Azeem Majeed¹⁶⁴, Shokofeh Maleki⁴⁶⁹, Afshin Maleki⁴⁷⁰, Reza Malekzadeh^{322 471}, Deborah Carvalho Malta⁴⁷², Abdullah A Mamun⁴⁷³, Navid Manafi^{474 475}, Fariborz Mansour-Ghanaei^{326 327}, Borhan Mansouri⁴⁷⁶, Mohammad Ali Mansournia³³⁷, Santi Martini^{477 478}, Francisco Rogerlândio Martins-Melo⁴⁷⁹, Seyedeh Zahra Masoumi⁴⁸⁰, João Massano^{481 482}, Pallab K Maulik^{483 376}, Mohsen Mazidi⁴⁸⁴, John J McGrath^{485 486}, Martin McKee⁴⁸⁷, Man Mohan Mehndiratta⁴⁸⁸, Fereshteh Mehri⁴⁹⁰, Fabiola Mejia-Rodriguez²¹⁵, Walter Mendoza⁴⁹¹, Ritesh G Menezes⁴⁹², George A Mensah^{493 494}, Alibek Mereke^{495 212}, Tuomo J Meretoja^{496 497}, Atte Meretoja^{498 499}, Tomislav Mestrovic^{500 501}, Tomasz Miazgowski⁵⁰², Irmina Maria Michalek⁵⁰³, Ted R Miller^{504 104}, Edward J Mills⁵⁰⁵, Andreea Mirica⁸⁰, Erkin M Mirrakhimov^{506 507}, Hamed Mirzaei⁵⁰⁸, Maryam Mirzaei⁵⁰⁹, Mehdi Mirzaei-Alavijeh³⁶⁶, Philip B Mitchell⁵¹⁰, Babak Moazen^{186 511}, Masoud Moghadaszadeh^{512 513}, Efat Mohamadi⁵¹⁴, Yousef Mohammad⁵¹⁵, Dara K Mohammad^{516 517}, Shadieh Mohammadi^{470 518}, Abdollah Mohammadian-Hafshejani⁵¹⁹, Shafiu Mohammed^{520 186}, Ali H Mokdad^{6 9}, Alex Molassiotis⁴⁴⁷, Natalie C Momen⁴⁸⁶, Stefania Mondello⁵²¹, Masoud Moradi³⁸⁷, Maziar Moradi-Lakeh⁹⁷, Farhad Moradpour⁵²², Rahmatollah Moradzadeh⁶⁷, Paula Moraga⁵²³, Lidia Morawska⁵²⁴, Rintaro Mori^{525 526}, Seyyed Meysam

Mousavi⁵²⁷, Amin Mousavi Khaneghah⁵²⁸, Ulrich Otto Mueller^{529 530}, Satinath Mukhopadhyay⁵³¹, Moses K Muriithi⁵³², Mehdi Naderi⁴⁶⁹, Ahamarshan Jayaraman Nagarajan^{533 534}, Behshad Naghshtabrizi⁵³⁵, Mukhammad David Naimzada^{536 537}, Farid Najafi^{538 387}, Jobert Richie Nansseu^{539 540}, Rawlance Ndejjo⁵⁴¹, Ionut Negoi^{542 543}, Ruxandra Irina Negoi^{544 545}, Subas Neupane⁵⁴⁶, Georges Nguefack-Tsague⁵⁴⁰, Josephine W Ngunjiri⁵⁴⁷, Cuong Tat Nguyen⁵⁴⁸, Huong Lan Thi Nguyen⁵⁴⁸, Rajan Nikbakhsh³¹¹, Chukwudi A Nnaji^{361 549}, Marzieh Nojomi^{97 550}, Shuhei Nomura^{551 552}, Bo Norrving⁵⁵³, Jean Jacques Noubiap⁵⁵⁴, Christoph Nowak⁵⁵⁵, Virginia Nunez-Samudio^{556 557}, Felix Akpojene Ogbo⁵⁵⁸, In-Hwan Oh⁵⁵⁹, Morteza Oladnabi⁵⁶⁰, Andrew T Olagunju^{561 562}, Jacob Olusegun Olusanya⁵⁶³, Bolajoko Olubukunola Olusanya⁵⁶³, Muktar Omer Omer³²³, Obinna E Onwujekwe⁵⁶⁴, Sergej M Ostojic⁵⁶⁵, Adrian Oțoiu⁸⁰, Nikita Otstavnov⁵³⁶, Stanislav S Otstavnov⁵³⁶ ⁵⁶⁶, Mayowa O Owolabi^{567 568}, Mahesh P A⁵⁶⁹, Jagadish Rao Padubidri⁵⁷⁰, Songhomitra Panda-Jonas⁵⁷¹, Anamika Pandey⁵⁷², Carlo Irwin Able Panelo⁵⁷³, Deepak Kumar Pasupula⁵⁷⁴, Hamidreza Pazoki Toroudi⁵⁷⁵ ⁵⁷⁶, Jonathan Pearson-Stuttard¹¹⁷, Amy E Peden^{360 577}, Veincent Christian Filipino Pepito⁵⁷⁸, Emmanuel K Peprah⁵⁷⁹, Jeevan Pereira⁵⁸⁰, Konrad Pesudovs⁵⁸¹, Hai Quang Pham⁵⁴⁸, Michael R Phillips^{582 583}, Thomas Pilgrim⁵⁸⁴, Marina Pinheiro⁵⁸⁵, Michael A Piradov²⁵⁸, Meghdad Pirsaheb³⁸⁷, Roman V Polibin¹⁵³, Suzanne Polinder⁵⁸⁶, Maarten J Postma^{587 588}, Hadi Pourjafar^{589 590}, Akram Pourshams³²², Sergio I Prada^{591 592}, Sanjay Prakash⁵⁹³, Dimas Ria Angga Pribadi⁵⁹⁴, Elisabetta Pupillo¹²⁴, Zahiruddin Quazi Syed⁵⁹⁵, Navid Rabiee⁵⁹⁶, Amir Radfar⁵⁹⁷, Ata Rafiee⁵⁹⁸, Alberto Raggi⁴⁵¹, Fakher Rahim^{599 600}, Vafa Rahimi-Movaghar⁶⁰¹, Mohammad Hifz Ur Rahman⁶⁰², Muhammad Aziz Rahman^{603 236}, Kiana Ramezanzadeh⁶⁰⁴, Chhabi Lal Ranabhat^{605 606}, Annemarei Ranta^{607 608}, Sowmya J Rao⁶⁰⁹, Vahid Rashedi⁶¹⁰, Prateek Rastogi⁶¹¹, Priya Rathi³³⁴, Salman Rawaf¹⁶⁴ ⁶¹², David Laith Rawaf⁶¹³ ⁶¹⁴, Lal Rawal⁶¹⁵, Reza Rawassizadeh⁶¹⁶, Andre M N Renzaho⁶¹⁷ ⁶¹⁸, Bhageerathy Reshmi⁶¹⁹ ⁶²⁰, Serge Resnikoff⁵⁸¹ ⁶²¹, Nima Rezaei¹⁶ ⁶²², Negar Rezaei⁷⁰ ³¹, Aziz Rezapour⁶⁰, Seyed Mohammad Riahi⁶²³, Daniela Ribeiro⁶²⁴, Ana Isabel Ribeiro⁶²⁵, Jennifer Rickard⁶²⁶, Leonardo Roever⁶²⁸, Michele Romoli^{629 630}, Dietrich Rothenbacher⁶³¹, Enrico Rubagotti⁶³², Susan Fred Rumisha^{633 634}, Seyedmohammad Saadatagah⁶³⁵, Siamak Sabour⁶³⁶, Perminder S Sachdev^{637 638}, Masoumeh Sadeghi⁶³⁹, Ehsan Sadeghi³⁸⁷, Sahar Saeedi Moghaddam⁷⁰, Rajesh Sagar⁶⁴⁰, Mohammad Ali Sahraian²⁴⁸, S. Mohammad Sajadi^{641 642}, Nasir Salam⁶⁴³, Marwa Rashad Salem⁶⁴⁴, Hamideh Salimzadeh³²², Omar Mukhtar Salman⁶⁴⁵, Abdallah M Samy⁶⁴⁶, Juan Sanabria^{647 648}, Lidia Sanchez Riera^{649 262}, Itamar S Santos^{128 298}, Milena M Santric-Milicevic^{353 650}, Sivan Yegnanarayana Iyer Saraswathy^{651 652}, Arash Sarveazad⁶⁵³, Brijesh Sathian⁶⁵⁴ ⁶⁵⁵, Thirunavukkarasu Sathish⁶⁵⁶, Davide Sattin⁴⁵¹, Silvia Schiavolin⁴⁵¹, Maria Inês Schmidt¹⁹⁹, Aletta Elisabeth Schutte^{360 657}, David C Schwebel⁶⁵⁸, Falk Schwendicke⁶⁵⁹, Subramanian Senthilkumaran⁶⁶⁰, Sadaf G Sepanlou^{322 471}, Feng Sha⁶⁶¹, Omid Shafaat^{312 662}, Saeed Shahabi⁶⁶³, Amira A Shaheen⁶⁶⁴, Masood Ali Shaikh⁶⁶⁵, Marina Shakhnazarova⁶⁶⁶, Mehran Shams-Beyranvand⁶⁶⁷, MohammadBagher Shamsi⁵⁰⁹, Morteza Shamsizadeh⁶⁶⁸, Kiomars Sharafi³⁸⁷, B Suresh Kumar Shetty⁶¹¹, Kenji Shibuya⁶⁶⁹, Wondimeneh Shibabaw Shiferaw¹⁰⁶, Mika Shigematsu⁶⁷⁰, Jae II Shin⁶⁷¹, Rahman Shiri⁶⁷², Reza Shirkoohi^{673 674}, Kerem Shuval⁴⁵⁷, Inga Dora Sigfusdottir⁶⁷⁵, Rannveig Sigurvinsdottir⁶⁷⁵, João Pedro Silva¹⁶⁸, Biagio Simonetti⁶⁷⁷ ⁶⁷⁸, Jasvinder A Singh⁶⁷⁹, Pushpendra Singh⁶⁸¹, Ambrish Singh⁸⁹, Dhirendra Narain Sinha⁶⁸², Søren T Skou⁶⁸⁴ 685, Valentin Yurievich Skryabin⁶⁸⁶, Emma U R Smith⁶⁸⁷ 688, Mohammad Reza Sobhiyeh⁶⁸⁹, Amin Soheili⁶⁹⁰, Shahin Soltani³⁸⁷, Joan B Soriano^{691 692}, Ireneous N Soyiri⁶⁹³, Emma Elizabeth Spurlock⁶, Chandrashekhar T Sreeramareddy⁶⁹⁴, Dan J Stein⁶⁹⁵, Leo Stockfelt⁶⁹⁶, Mark A Stokes⁶⁹⁷, Saverio Stranges⁶⁹⁸ ⁶⁹⁹, Jacob L Stubbs⁷⁰⁰, Agus Sudaryanto⁷⁰¹, Mu'awiyyah Babale Sufiyan⁷⁰², Hafiz Ansar Rasul Suleria⁷⁰³, Rizwan Suliankatchi Abdulkader^{704 705}, Gerhard Sulo⁷⁰⁶, Rafael Tabarés-Seisdedos^{707 708}, Takahiro Tabuchi⁷⁰⁹, Biruk Wogayehu Taddele⁷¹⁰, Amir Taherkhani⁷¹¹, Masih Tajdini⁷¹, Md Ismail Tareque⁷¹², Yonas Getaye Tefera⁷¹³, Mohamad-Hani Temsah⁷¹⁴, Zemenu Tadesse Tessema⁷¹⁵, Kavumpurathu Raman Thankappan⁷¹⁶, Rekha Thapar⁴²³, Amanda G Thrift⁷¹⁷, Mariya Vladimirovna Titova^{718 719}, Hamid Reza Tohidinik^{720 337}, Marcello Tonelli⁷²¹, Mathilde Touvier^{722 723}, Marcos Roberto Tovani-Palone^{724 725}, Bach Xuan Tran⁷²⁶, Ravensara S Travillian⁶, Alexander C Tsai^{727 728}, Aristidis Tsatsakis⁷²⁹, Riaz Uddin^{730 731}, Saif Ullah¹³⁸, Chukwuma David Umeokonkwo⁷³², Bhaskaran Unnikrishnan⁷³³, Marco Vacante¹⁴¹, Pascual R Valdez⁷³⁴ ⁷³⁵, Aaron van Donkelaar⁷³⁶ ⁷³⁷, Santosh Varughese⁷³⁸, Tommi Juhani Vasankari⁷³⁹, Yasser

Vasseghian³³⁹, Yousef Veisani⁷⁴⁰, Narayanaswamy Venketasubramanian^{741 742}, Francesco S Violante^{743 744}, Vasily Vlassov⁷⁴⁵, Yasir Waheed⁷⁴⁶, Yanzhong Wang⁷⁴⁷, Fang Wang⁷⁴⁸, Yuan-Pang Wang¹⁶⁹, Jingkai Wei⁷⁴⁹, Robert G Weintraub^{750 751}, Jordan Weiss⁷⁵², Ronny Westerman⁷⁵³, Taweewat Wiangkham⁷⁵⁴, Charles D A Wolfe^{747 755}, Ai-Min Wu⁷⁵⁶, Seyed Hossein Yahyazadeh Jabbari⁷⁵⁷, Kazumasa Yamagishi^{758 759}, Yuichiro Yano⁷⁶⁰, Sanni Yaya^{761 762}, Vahid Yazdi-Feyzabadi^{763 764}, Yordanos Gizachew Yeshitila⁷⁶⁵, Mohammed Zewdu Yimmer⁷⁶⁶, Paul Yip^{767 768}, Naohiro Yonemoto^{769 770}, Seok-Jun Yoon⁴⁰⁵, Mustafa Z Younis^{771 772}, Zabihollah Yousefi⁷⁷³, Taraneh Yousefinezhadi⁷⁷⁴, Chuanhua Yu^{775 776}, Yong Yu⁷⁷⁷, Hasan Yusefzadeh⁷⁷⁸, Syed Saoud Zaidi⁷⁷⁹, Sojib Bin Zaman^{780 191}, Maryam Zamanian⁶⁷, Hadi Zarafshan⁷⁸¹, Mikhail Sergeevich Zastrozhin⁷⁸²⁷⁸³, Zhi-Jiang Zhang⁷⁸⁴, Jianrong Zhang^{785 786}, Yunquan Zhang^{787 788}, Xiu-Ju George Zhao^{789 748}, Cong Zhu⁷⁹⁰, Georgios A Kotsakis^{*3 4}, and Nicholas J Kassebaum*^{& 4 6 9 791}.

[%]First author *Co-senior authors [&]Corresponding author

- 1 St. John of God Health Park, San Juan de Dios Sanitary Park, Barcelona, Spain.
- 2 Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain.
- 3 Department of Periodontics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
- 4 Department of Global Health, University of Washington, Seattle, WA, USA.
- 5 Department of Pharmacy, University of Washington, Seattle, WA, USA.
- 6 Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA.
- 7 University of Washington, Seattle, WA, USA.
- 8 Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
- 9 Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA.
- 10 Division of Data, Analytics and Delivery for Impact, World Health Organization , Geneva, Switzerland.
- 11 Department of Neurology, Cairo University, Cairo, Egypt.
- 12 The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
- 13 School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
- 14 Department of Orthopaedic Surgery, University of Southern California, Los Angeles, CA, USA.
- 15 Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Sweden.
- 16 Research Center for Immunodeficiencies, Tehran University of Medical Sciences, Tehran, Iran.
- 17 Department of Public Health, Debre Berhan University, Debre Brehan, Ethiopia.
- 18 Department of Pediatric Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- 19 Department of Research, Philippine Institute for Development Studies, Quezon City, Philippines.
- 20 Internal Medicine Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 21 Hamadan University of Medical Sciences, Hamadan, Iran.
- 22 College of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria.
- 23 Department of Sociology, Olabisi Onabanjo University, Ago-Iwoye, Nigeria.
- 24 Department of Population Health Sciences, King's College London, London, England.
- 25 Centre of Excellence for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa.

- 26 Department of Global Health, Stellenbosch University, Cape Town, South Africa.
- 27 School of Health, Ardabil University of Medical Science, Ardabil, Iran.
- 28 Social Behavioral Research Branch, National Institute of Health, Bethesda, MD, USA.
- 29 Division of Hematology and Oncology, Georgetown University, Washington, DC, USA.
- 30 Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
- 31 Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 32 Department of Family Medicine, McMaster University, Hamilton, ON, Canada.
- 33 Department of Epidemiology and Biostatistics, Qom University of Medical Sciences, Qom, Iran.
- 34 Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 35 Institute of Genomics and Integrative Biology, Council of Scientific & Industrial Research, Delhi, India.
- 36 Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA.
- 37 Faculty of Pharmacy, MAHSA University, Kuala Langat, Malaysia.
- 38 Department of Epidemiology and Health Statistics, Southeast University, Nanjing, China.
- 29 Lincoln Medical School, Universities of Nottingham & Lincoln, Lincoln, UK.
- 40 Environmental Technologies Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- 41 Department of Environmental Health Engineering, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- 42 Department of Epidemiology, Jimma University, Jimma, Ethiopia.
- 43 Australian Center for Precision Health, University of South Australia, Adelaide, SA, Australia.
- 44 Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan, Nigeria.
- 45 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
- John T. Milliken Department of Internal Medicine, Washington University in St. Louis, St. Louis, MO, USA.
- 47 Clinical Epidemiology Center, Department of Veterans Affairs, St Louis, MO, USA.
- 48 Murdoch Business School, Murdoch University, Perth, WA, Australia.
- 49 Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 50 Health Information Management and Technology Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 51 Center for Health System Research, National Institute of Public Health, Cuernavaca, Mexico.
- 52 College of Medicine and Health Science, Arba Minch University, Arba Minch, Ethiopia.
- 53 Department of Midwifery, Arba Minch University, Injbara, Ethiopia.
- 54 Faculty of Health Sciences, Health Management and Policy, American University of Beirut, Beirut, Lebanon.
- 55 British Columbia Injury Research Prevention Unit, British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
- 56 Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana.
- 57 Department of Information Systems, Sultan Qaboos University, Muscat, Oman.
- 58 Directorate for Social Statistics and Population Census, Italian National Institute of Statistics, Rome, Italy.

- 59 Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
- 60 Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 61 Department of Health Economics, Iran University of Medical Sciences, Tehran, Iran.
- 62 Department of Health Policy and Management, Kuwait University, Safat, Kuwait.
- 63 International Centre for Casemix and Clinical Coding, National University of Malaysia, Bandar Tun Razak, Malaysia.
- 64 Bordeaux School of Public Health, University of Bordeaux, Bordeaux, France.
- 65 College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- 66 Division of Gastroenterology & Hepatology, McGill University, Montreal, QC, Canada.
- 67 Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran.
- 68 College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 69 Department of Community Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- 70 Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 71 Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
- 72 Department of Radiology and Nuclear Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 73 Department of Epidemiology and Biostatistics, University of the Philippines Manila, Manila, Philippines.
- 74 School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
- 75 Maternal and Child Wellbeing Unit, African Population and Health Research Center, Nairobi, Kenya.
- 76 Department of Public Health, Samara University, Samara, Ethiopia.
- 77 Department of Pharmacy, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 78 Centre for Sensorimotor Performance, The University of Queensland, Brisbane, Australia.
- 79 Neurology Department, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
- 80 Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania.
- 81 Department of Cardiology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 82 Department of Medicine, University of Thessaly, Volos, Greece.
- 83 Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
- 84 Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- 85 Razi Vaccine and Serum Research Institute, Agricultural Research, Education, and Extension Organization (AREEO), Tehran, Iran.
- 86 Department of Epidemiology and Biostatistics, Zahedan University of Medical Sciences, Zahedan, Iran.
- 87 Department of Health Policy and Administration, University of the Philippines Manila, Manila, Philippines.

- 88 Department of Applied Social Sciences, Hong Kong Polytechnic University, Hong Kong, China.
- 89 Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
- 90 Department of Parasitology, Mazandaran University of Medical Sciences, Sari, Iran.
- 91 Department of Parasitology, Iranshahr University of Medical Sciences, Iranshahr, Iran.
- 92 Department of Pathology, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
- 93 Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran.
- 94 Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
- 95 School of Health and Social Studies, Dalarna University, Falun, Sweden.
- 96 Department of Plastic Surgery, University of Texas, Houston, TX, USA.
- 97 Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 98 Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- 99 Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
- 100 Faculty of Nursing, Philadelphia University, Amman, Jordan.
- 101 School of Business, University of Leicester, Leicester, UK.
- 102 Gastro-enterology Department, University of Liège, Liège, Belgium.
- 103 The Judith Lumley Centre, La Trobe University, Melbourne, VIC, Australia.
- 104 School of Public Health, Curtin University, Perth, WA, Australia.
- 105 Department of Health Policy Planning and Management, University of Health and Allied Sciences, Ho, Ghana.
- 106 Department of Nursing, Debre Berhan University, Debre Berhan, Ethiopia.
- 107 Department of Reproductive Health, University of Gondar, Gondar, Ethiopia.
- 108 Department of Forensic Science, Government Institute of Forensic Science, Nagpur, India.
- 109 Department of Demography, University of Groningen, Groningen, Netherlands.
- 110 Population Research Centre, Institute for Social and Economic Change, Bengaluru, India.
- 111 Department of Hypertension, Medical University of Lodz, Lodz, Poland.
- 112 Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland.
- 113 School of Health Sciences, Walden University, Minneapolis, MN, USA.
- 114 Department of Non-communicable Diseases, Bangladesh University of Health Sciences, Dhaka, Bangladesh.
- 115 School of Psychology, University of Auckland, Auckland, New Zealand.
- 116 Center for Primary Care, Harvard University, Boston, MA, USA.
- 117 School of Public Health, Imperial College London, London, UK.
- 118 Department of Psychiatry, University of Münster, Münster, Germany.
- 119 Department of Psychiatry, Melbourne Medical School, Melbourne, Australia.
- 120 Health Human Resources Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- 121 Department of Public Health, Ambo University, Ambo, Ethiopia.
- 122 Department of Community Medicine, Gandhi Medical College Bhopal, Bhopal, India.
- 123 Jazan University, Jazan, Saudi Arabia.
- 124 Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy.

- 125 Department of Neurology, University Hospital of Dijon, Dijon, France.
- 126 Dijon Stroke Registry UFR Sciences Santé, University of Burgundy, Dijon, France.
- 127 School of the Environment, Yale University, New Haven, CT, USA.
- 128 Department of Internal Medicine, University of São Paulo, São Paulo, Brazil.
- 129 Department of Internal Medicine, United Arab Emirates University, Al Ain, United Arab Emirates.
- 130 Department of Social and Clinical Pharmacy, Charles University, Prague, Czech Republic.
- 131 Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India.
- 132 School of Public Health, All India Institute of Medical Sciences, Jodhpur, India.
- 133 Department of Statistical and Computational Genomics, National Institute of Biomedical Genomics, Kalyani, India.
- 134 Department of Statistics, University of Calcutta, Kolkata, India.
- 135 Department of Global Health, Global Institute for Interdisciplinary Studies, Kathmandu, Nepal.
- 136 Centre for Global Child Health, University of Toronto, Toronto, ON, Canada.
- 137 Centre of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan.
- 138 Institute of Soil and Environmental Sciences, University of Agriculture, Faisalabad, Faisalabad, Pakistan.
- 139 Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran.
- 140 Mario Negri Institute for Pharmacological Research, Ranica, Italy.
- 141 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
- 142 Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
- 143 Department of Nursing, Debre Tabor University, Debretabor, Ethiopia.
- 144 Department of Neurology, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India.
- 145 Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
- 146 Cancer Registry of Norway, Oslo, Norway.
- 147 Department of Veterinary Medicine, Islamic Azad University, Kermanshah, Iran.
- 148 Department of Biomedical Sciences, Nazarbayev University, Nur-Sultan City, Kazakhstan.
- 149 Department of Internal Medicine, Manipal Academy of Higher Education, Mangalore, India.
- 150 Transport and Road Safety (TARS) Research Centre, University of New South Wales, Sydney, NSW, Australia.
- 151 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany.
- 152 School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia.
- 153 Department of Epidemiology and Evidence-Based Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 154 Neuroscience Unit, Institute for Scientific Research and High Technology Services, Panama City, Panama.
- 155 Gorgas Memorial Institute for Health Studies, Panama City, Panama.
- 156 Department of Community Medicine, Employee State Insurance Post Graduate Institute of Medical Sciences and Research, Bangalore, India.
- 157 Department of Health Care Management, Technical University of Berlin, Berlin, Germany.

- 158 School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada.
- 159 Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan.
- 160 Institute of Microengineering, Federal Polytechnic School of Lausanne, Lausanne, Switzerland.
- 161 Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
- 162 Board of Directors, Argentine Society of Medicine, Buenos Aires, Argentina.
- 163 Centre for Population Health Sciences, Nanyang Technological University, Singapore, Singapore.
- 164 Department of Primary Care and Public Health, Imperial College London, London, UK.
- 165 Department of Health Care, Metropolitan Autonomous University, Mexico City, Mexico.
- 166 Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
- 167 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- 168 Research Unit on Applied Molecular Biosciences (UCIBIO), University of Porto, Porto, Portugal.
- 169 Department of Psychiatry, University of São Paulo, São Paulo, Brazil.
- 170 Colombian National Health Observatory, National Institute of Health, Bogota, Colombia.
- 171 Epidemiology and Public Health Evaluation Group, National University of Colombia, Bogota, Colombia.
- 172 Department of Medicine, University of Udine, Udine, Italy.
- 173 Department of Mental Health, Healthcare Agency 'Friuli Occidentale', Pordenone, Italy.
- 174 Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia.
- 175 School of Public Health, University of Hong Kong, Hong Kong, China.
- 176 Infection and Global Health Research, University of St Andrews, St Andrews, UK.
- 177 Regional Infectious Diseases Unit, NHS National Services Scotland, Edinburgh, UK.
- 178 Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
- 179 Kidney Health Research Institute, Geisinger Health System, Danville, PA, USA.
- 180 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India.
- 181 Department of Medicine, University of Toronto, Toronto, ON, Canada.
- 182 Center for Cancer Epidemiology, Tata Memorial Hospital, Navi Mumbai, India.
- 183 Department of Head Neck Surgery, Tata Memorial Hospital, Mumbai, India.
- 184 Research Department, Dr. D. Y. Patil University, Pune, India.
- 185 Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, TN, USA.
- 186 Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany.
- 187 Research School of Population Health, Australian National University, Canberra, ACT, Australia.
- 188 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
- 189 Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia.
- 190 Division of Plastic Surgery, University of Washington, Seattle, WA, USA.
- 191 Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh.
- 192 Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA.
- 193 Faculty of Biology, Hanoi National University of Education, Hanoi, Vietnam.
- 194 Department of Health Informatics, University College London, London, UK.
- 195 Health Data Research UK, London, UK.

- 196 Department of Otolaryngology, Wayne State University, Detroit, MI, USA.
- 197 Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
- 198 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia.
- 199 Postgraduate Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
- 200 Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA.
- 201 Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- 202 Environmental Health Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 203 Clinical Dermatology, IRCCS Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy.
- 204 Department of Dermatology, Case Western Reserve University, Cleveland, OH, USA.
- 205 Public Health Foundation of India, Gurugram, India.
- 206 Indian Council of Medical Research, New Delhi, India.
- 207 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- 208 Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
- 209 Division of Women and Child Health, Aga Khan University, Karachi, Pakistan.
- 210 James P Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
- 211 Department of Population and Development, Latin American Faculty of Social Sciences Mexico, Mexico City, Mexico.
- Health Research Institute, Al Farabi Kazakh National University, Almaty, Kazakhstan.
- 213 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Delhi, India.
- 214 Australian Institute for Suicide Research and Prevention, Griffith University, Mount Gravatt, QLD, Australia.
- 215 Center for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Mexico.
- 216 St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, UK.
- 217 Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- 218 Division of Cardiology, Atlanta Veterans Affairs Medical Center, Decatur, GA, USA.
- 219 Department of Community Medicine, University of Peradeniya, Peradeniya, Sri Lanka.
- 220 Department of Microbiology, Far Western University, Mahendranagar, Nepal.
- 221 Department of Epidemiology and Biostatistics, Shahroud University of Medical Sciences, Shahroud, Iran.
- 222 Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran.
- 223 Laboratory of Toxicology, University of Porto, Porto, Portugal.
- 224 Center of Complexity Sciences, National Autonomous University of Mexico, Mexico City, Mexico.
- 225 Faculty of Veterinary Medicine and Zootechnics, Autonomous University of Sinaloa, Culiacan Rosales, Mexico.
- 226 Institute for Stroke and Dementia Research, Ludwig Maximilians University, Munich, Germany.
- 227 Development of Research and Technology Center, Ministry of Health and Medical Education, Tehran, Iran.
- 228 Department of Social Medicine and Health Care Organisation, Medical University of Varna, Varna, Bulgaria.

- 229 Department of Medical Laboratory Sciences, Iran University of Medical Sciences, Tehran, Iran.
- 230 Department of Health Policy and Management, Tabriz University of Medical Sciences, Tabriz, Iran.
- 231 School of Medicine, Federal University of Bahia, Salvador, Brazil.
- 232 Department of Internal Medicine, Escola Bahiana de Medicina e Saúde Pública (Bahiana School of Medicine and Public Health), Salvador, Brazil.
- 233 Department of Global Health and Social Medicine, Harvard University, Boston, MA, USA.
- 234 Department of Social Services, Tufts Medical Center, Boston, MA, USA.
- 235 Department of Epidemiology, Florida International University, Miami, FL, USA.
- 236 School of Nursing and Midwifery, La Trobe University, Melbourne, VIC, Australia.
- 237 Department of Nursing, Umeå University, Umea, Sweden.
- 238 Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW, Australia.
- 239 Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA.
- 240 Institute for Health Care Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
- 241 Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
- 242 Division of Cardiology, Harvard University, Boston, MA, USA.
- 243 Biomedical Informatics and Medical Statistics Department, Alexandria University, Alexandria, Egypt.
- 244 Department of Clinical Pathology, Mansoura University, Mansoura, Egypt.
- 245 Pediatric Dentistry and Dental Public Health Department, Alexandria University, Alexandria, Egypt.
- 246 Department of Medicinal Chemistry, Kerman University of Medical Sciences, Kerman, Iran.
- 247 Pharmaceutics Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 248 Multiple Sclerosis Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 249 Department of Physiology, Tarbiat Modares University, Tehran, Iran.
- 250 Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
- 251 Unit of Medical Physiology, Hawassa University, Hawassa, Ethiopia.
- 252 Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, Pavia, Italy.
- 253 Department of Biology, Cihan University-Erbil, Erbil, Iraq.
- 254 Department of Psychology, Federal University of Sergipe, São Cristóvão, Brazil.
- 255 Department of Environmental Health Engineering, Ardabil University of Medical Science, Ardabil, Iran.
- 256 Department of Environmental Health Engineering, Tehran University of Medical Sciences, Tehran, Iran.
- 257 National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand.
- 258 Research Center of Neurology, Moscow, Russia.
- 259 Division of Neurology, University of Ottawa, Ottawa, ON, Canada.
- Associated Laboratory for Green Chemistry (LAQV), University of Porto, Porto, Portugal.
- 261 Research Center on Public Health, University of Milan Bicocca, Monza, Italy.
- 262 Institute of Bone and Joint Research (IBJR), University of Sydney, Sydney, NSW, Australia.
- 263 Psychiatry Department, Kaiser Permanente, Fontana, CA, USA.
- 264 School of Health Sciences, A.T. Still University, Mesa, AZ, USA.

- 265 Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany.
- 266 James Cancer Hospital, Ohio State University, Columbus, OH, USA.
- 267 Institute of Gerontology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine.
- 268 Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria.
- 269 Department of Cell Biology and Biotechnology, Timiryazev Institute of Plant Physiology, Moscow, Russia.
- 270 Department of Medical Parasitology, Abadan Faculty of Medical Sciences, Abadan, Iran.
- 271 School of Public Health, Medical, and Veterinary Sciences, James Cook University, Douglas, QLD, Australia.
- 272 Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
- 273 Gillings School of Global Public Health, University of North Carolina Chapel Hill, Chapel Hill, NC, USA.
- 274 Department of Environmental Health Sciences, Mario Negri Institute for Pharmacological Research, Milan, Italy.
- 275 National Center for Disease Control and Public Health, Tbilisi, Georgia.
- 276 School of Pharmacy, Mekelle University, Mekelle, Ethiopia.
- 277 School of Medical and Health Sciences, Edith Cowan University, Perth, Australia.
- 278 School of Pharmacy, Aksum University, Aksum, Ethiopia.
- 279 Department of Pharmacy, Mekelle University, Mekelle, Ethiopia.
- 280 Department of Parasitology and Entomology, Tarbiat Modares University, Tehran, Iran.
- 281 Department of Medical Surgical Nursing, Tabriz University of Medical Sciences, Tabriz, Iran.
- 282 Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran.
- 283 Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- 284 Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.
- 285 Research Group for Genomic Epidemiology, Technical University of Denmark, Copenhagen, Denmark.
- 286 Young Researchers and Elite Club, Islamic Azad University, Rasht, Iran.
- 287 Department of Biology, Islamic Azad University, Tehran, Iran.
- 288 Division of General Internal Medicine, Howard University, Washington, DC, USA.
- 289 Department of Community and Family Medicine, Howard University, Washington, DC, USA.
- 290 Research, Innovation and Teaching Unit, San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain.
- 291 Laboratory of Neurological Disorders, Mario Negri Institute for Pharmacological Research, Milan, Italy.
- 292 Department of Public Health, Arba Minch University, Arba Minch, Ethiopia.
- 293 Third Department of Neurology, Research Center of Neurology, Moscow, Russia.
- 294 School of Public Health and Community Medicine, University of New South Wales, Kensington, NSW, Australia.
- 295 Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
- 296 Department of Health and Social Affairs, Government of the Federated States of Micronesia, Palikir, Federated States of Micronesia.

- 297 Oncological Network, Prevention and Research Institute, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
- 298 Center for Clinical and Epidemiological Research, University of São Paulo, São Paulo, Brazil.
- 299 Institute of Public Health Department, United Arab Emirates University, Al Ain, United Arab Emirates.
- 300 Department of Public Health and Preventive Medicine, Charles University, Prague, Czech Republic.
- 301 Department of Microbiology, Saint James School of Medicine, The Valley, Anguilla.
- 302 Department of Epidemiology, Saint James School of Medicine, The Valley, Anguilla.
- 303 Institute of Tropical Pathology and Public Health (IPTSP), Federal University of Goias, Goiânia, Brazil.
- 304 Department of Epidemiology, Binzhou Medical University, Yantai City, China.
- 305 Medical Resources Department, March of Dimes, Arlington, VA, USA.
- 306 Department of Health Policy, Management and Leadership, West Virginia University School of Public Health, Morgantown, WV.
- 307 Department of Epidemiology and Psychosocial Research, Ramón de la Fuente Muñiz National Institute of Psychiatry , Mexico City, Mexico.
- 308 College of Medicine, Umm Al Qura University, Makkah, Saudi Arabia.
- 309 MSc Epidemiology Programme, London School of Hygiene & Tropical Medicine, London, UK.
- 310 Department of Pharmacology, Tehran University of Medical Sciences, Tehran, Iran.
- 311 Obesity Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 312 Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.
- 313 Department of Family and Community Medicine, Arabian Gulf University, Manama, Bahrain.
- 314 School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates.
- 315 Medical School, University of Western Australia, Perth, WA, Australia.
- Department of Neurology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
- 317 Tabriz University of Medical Sciences, Tabriz, Iran.
- Research Unit, University of Barcelona, Sant Boi de Llobregat, Barcelona, Spain.
- 319 Biomedical Research Networking Center for Mental Health Network (CiberSAM), Barcelona, Spain.
- 320 Department of Zoology and Entomology, Al Azhar University, Cairo, Egypt.
- 321 Biology Department, Utica College, Utica, NY, USA.
- 322 Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- 323 Department of Public Health, Jigjiga University, Jijiga, Ethiopia.
- Center for International Health (CIH), University of Bergen, Bergen, Norway.
- Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen, Norway.
- 326 Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
- 327 Caspian Digestive Disease Research Center, Guilan University of Medical Sciences, Rasht, Iran.
- 328 Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan.

- 329 Department of Pharmacy Administration and Clinical Pharmacy, Xian Jiaotong University, Xian, China.
- 330 School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran.
- 331 School of Business, London South Bank University, London, UK.
- 332 Department of Urban Planning and Design, University of Hong Kong, Hong Kong, China.
- 333 Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
- 334 Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
- Centre for Bio Cultural Studies (CBiCS), Manipal Academy of Higher Education, Manipal, India.
- 336 Department of Pharmacology, Bangladesh Industrial Gases Limited, Tangail, Bangladesh.
- 337 Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
- 338 Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 339 Institute of Research and Development, Duy Tan University, Da Nang, Vietnam.
- 340 Department of Computer Science, University of Human Development, Sulaymaniyah, Iraq.
- 341 Department of Internal Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 342 Department of Legal Medicine and Bioethics, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 343 Clinical Legal Medicine Department, National Institute of Legal Medicine Mina Minovici, Bucharest, Romania.
- College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar.
- 345 Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia.
- 346 Department of Epidemiology and Health Statistics, Central South University, Changsha, China.
- 347 Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan.
- 348 Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan.
- 349 Department of Public Health, University of Naples Federico II, Naples, Italy.
- 350 Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria.
- 351 Department of Community Medicine, University of Ibadan, Ibadan, Nigeria.
- 352 Department of Community Medicine, University College Hospital, Ibadan, Ibadan, Nigeria.
- 353 Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- 354 Department of Epidemiology, University of Kragujevac, Kragujevac, Serbia.
- Division of Community Health and Family Medicine, Bangalore Baptist Hospital, Bangalore, India.
- 356 College of Public Health, Taipei Medical University, Taipei, Taiwan.
- 357 Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 358 Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan.
- 359 Department of Social Medicine, Osaka University, Suita-city, Japan.
- 360 School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia.
- 361 South African Medical Research Council, Cape Town, South Africa.

- 362 Department of Biochemistry and Microbiology, University of Fort Hare, Alice, South Africa.
- 363 Department of Environmental Health Engineering, Guilan University of Medical Sciences, Rasht, Iran.
- 364 N.A. Semashko Department of Public Health and Healthcare, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 365 Department of Global Health, Economics and Policy, University of Kragujevac, Kragujevac, Serbia.
- 366 Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 367 Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 368 Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.
- 369 Health Informatic Lab, Boston University, Boston, MA, USA.
- 370 Autism Spectrum Disorders Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
- 371 Department of Community Medicine, Dr. Baba Saheb Ambedkar Medical College & Hospital, Delhi, India.
- 372 Department of Community Medicine, Banaras Hindu University, Varanasi, India.
- 373 Environmental Research Center, Duke Kunshan University, Kunshan, China.
- 374 Nicholas School of the Environment, Duke University, Durham, NC, USA.
- Renal and Cardiovascular Division, The George Institute for Global Health, New Delhi, India.
- 376 School of Medicine, University of New South Wales, Sydney, NSW, Australia.
- 377 Department of Ophthalmology, Heidelberg University, Mannheim, Germany.
- Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Beijing, China.
- 379 Department of Family Medicine and Public Health, University of Opole, Opole, Poland.
- 380 Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
- 381 Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 382 School of Public Health, University College Cork, Cork, Ireland.
- 383 Department of Neurology, University of Washington, Seattle, WA, USA.
- 384 Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
- Health Services Management Department, Qazvin University of Medical Sciences, Qazvin, Iran.
- 386 Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Jodhpur, India.
- 387 Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 388 Institute for Epidemiology and Social Medicine, University of Münster, Münster, Germany.
- 389 Department of Adult Health Nursing, Bahir Dar University, Bahir Dar, Ethiopia.
- 390 International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
- 391 Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, Netherlands.
- 392 Department of Public Health, Jordan University of Science and Technology, Irbid, Jordan.
- 393 School of Food and Agricultural Sciences, University of Management and Technology, Lahore, Pakistan.
- Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.

- 395 Epidemiology Department, Jazan University, Jazan, Saudi Arabia.
- 396 Department of Epidemiology and Biostatistics, Health Services Academy, Islamabad, Pakistan.
- 397 Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK.
- College of Arts and Sciences, Ohio University, Zanesville, OH, USA.
- 399 Center of Global Evidence Synthesis Initiative, Datta Meghe Institute of Medical Sciences, Wardha, India.
- 400 Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 401 The Iranian Academy of Medical Sciences, Tehran, Iran.
- 402 Department of Psychiatry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 403 Department of Public Health, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia.
- 404 Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA.
- 405 Department of Preventive Medicine, Korea University, Seoul, South Korea.
- 406 School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia.
- 407 Department of Nutrition, Simmons University, Boston, MA, USA.
- 408 Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway.
- 409 School of Health Sciences, Kristiania University College, Oslo, Norway.
- 410 Global Community Health and Behavioral Sciences, Tulane University, New Orleans, LA, USA.
- 411 Department of Epidemiology and Public Health, University College London, London, UK.
- 412 Department of Public Health, University of Helsinki, Helsinki, Finland.
- 413 Global Healthcare Consulting, New Delhi, India.
- 414 Department of Environmental Health Engineering, Arak University of Medical Sciences, Arak, Iran.
- 415 School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
- 416 Arthritis Research Canada, Richmond, BC, Canada.
- 417 Global Health Department, Vancouver Virology Centre, Vancouver, BC, Canada.
- 418 Biomedical Research Networking Center for Mental Health Network (CiberSAM), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain.
- 419 Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
- 420 Department of Anthropology, Panjab University, Chandigarh, India.
- 421 Department of Demography, University of Montreal, Montreal, QC, Canada.
- 422 Department of Social and Preventive Medicine, University of Montreal, Montreal, QC, Canada.
- 423 Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India.
- 424 Department of Psychiatry, University of Nairobi, Nairobi, Kenya.
- 425 Division of Psychology and Language Sciences, University College London, London, UK.
- 426 Department of Medicine, McMaster University, Hamilton, ON, Canada.
- 427 Institute of Occupational and Environmental Medicine, University of Birmingham, Birmingham, UK.
- 428 Imperial College Business School, Imperial College London, London, UK.
- 429 Faculty of Public Health, University of Indonesia, Depok, Indonesia.
- 430 Nuffield Department of Population Health, University of Oxford, Oxford, UK.
- 431 National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford, UK.
- 432 School of Dentistry, The University of Queensland, Brisbane, QLD, Australia.
- 433 Division of Research, Kaiser Permanente, Oakland, CA, USA.

- 434 Department of Community and Family Medicine, University of Baghdad, Baghdad, Iraq.
- 435 Unit of Genetics and Public Health, Institute of Medical Sciences, Las Tablas, Panama.
- 436 Ministry of Health, Herrera, Panama.
- 437 HelpMeSee, New York, NY, USA.
- 438 General Director, Mexican Institute of Ophthalmology, Queretaro, Mexico.
- 439 Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- 440 Department of Clinical Chemistry and Pharmacology, Uppsala University Hospital, Uppsala, Sweden.
- 441 Department of Otorhinolaryngology, Father Muller Medical College, Mangalore, India.
- 442 Institute of Clinical Physiology, National Research Council, Pisa, Italy.
- 443 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- 444 College of Optometry, Nova Southeastern University, Fort Lauderdale, FL, USA.
- 445 Department of Information and Internet Technologies, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
- 446 Federal Research Institute for Health Organization and Informatics of the Ministry of Health (FRIHOI), Moscow, Russia.
- 447 School of Nursing, Hong Kong Polytechnic University, Hong Kong, China.
- 448 School of Pharmacy, Monash University, Bandar Sunway, Malaysia.
- 449 School of Pharmacy, Taylor's University Lakeside Campus, Subang Jaya, Malaysia.
- 450 Asbestos Diseases Research Institute, University of Sydney, Sydney, NSW, Australia.
- 451 Neurology, Public Health and Disability Unit, Carlo Besta Neurological Institute IRCCS, Milan, Italy.
- 452 Division of Nephrology, Tufts Medical Center, Boston, MA, USA.
- 453 School of Medicine, Tufts University, Boston, MA, USA.
- 454 Department of Prevention, USL Tuscany Center, Firenze, Italy.
- 455 Department of Health Sciences, University of Florence, Florence, Italy.
- 456 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
- 457 School of Public Health, University of Haifa, Haifa, Israel.
- 458 Department of Systems, Populations, and Leadership, University of Michigan, Ann Arbor, MI, USA.
- 459 School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
- 460 Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, Germany.
- 461 Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany.
- 462 Department of Medicine, University of São Paulo, São Paulo, Brazil.
- 463 Department of General Surgery, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
- 464 Department of Surgery, University of Liverpool, Liverpool, UK.
- 465 Pathology Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 466 Institute for Physical Activity and Nutrition, Deakin University, Burwood, VIC, Australia.
- 467 Grants, Innovation and Product Development Unit, South African Medical Research Council, Cape Town, South Africa.
- 468 Radiology and Precision Health Program, Michigan State University, East Lansing, MI, USA.
- 469 Clinical Research Development Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 470 Environmental Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- 471 Non-communicable Disease Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- 472 Department of Maternal and Child Nursing and Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil.
- 473 Institute for Social Science Research, The University of Queensland, Indooroopilly, QLD, Australia.
- 474 School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- 475 School of Medicine, University of Manitoba, Winnipeg, MB, Canada.
- 476 Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 477 Faculty of Public Health, Universitas Airlangga (Airlangga University), Surabaya, Indonesia.
- 478 Indonesian Public Health Association, Surabaya, Indonesia.
- 479 Campus Caucaia, Federal Institute of Education, Science and Technology of Ceará, Caucaia, Brazil.
- 480 Department of Midwifery, Hamadan University of Medical Sciences, Hamadan, Iran.
- 481 Department of Neurology, University Hospital Center de Sao Joao, Porto, Portugal.
- 482 Department of Clinical Neurosciences and Mental Health, University of Porto, Porto, Portugal.
- 483 Research Division, The George Institute for Global Health, New Delhi, India.
- 484 Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.
- 485 Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
- 486 National Centre for Register-based Research, Aarhus University, Aarhus, Denmark.
- 487 Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
- 488 Neurology Department, Janakpuri Super Specialty Hospital Society, New Delhi, India.
- 489 Department of Neurology, Govind Ballabh Institute of Medical Education and Research, New Delhi, India.
- 490 Nutrition Health Research Center, Iran University of Medical Sciences, Hamadan, Iran.
- 491 Peru Country Office, United Nations Population Fund (UNFPA), Lima, Peru.
- 492 Forensic Medicine Division, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
- 493 Center for Translation Research and Implementation Science, National Institutes of Health, Bethesda, MD, USA.
- 494 Department of Medicine, University of Cape Town, Cape Town, South Africa.
- 495 Department of Cardiovascular Surgery, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
- 496 Breast Surgery Unit, Helsinki University Hospital, Helsinki, Finland.
- 497 University of Helsinki, Helsinki, Finland.
- 498 Neurology Unit, Helsinki University Hospital, Helsinki, Finland.
- 499 School of Health Sciences, University of Melbourne, Parkville, VIC, Australia.
- 500 Clinical Microbiology and Parasitology Unit, Dr. Zora Profozic Polyclinic, Zagreb, Croatia.
- 501 University Centre Varazdin, University North, Varazdin, Croatia.
- 502 Department of Propedeutics of Internal Diseases & Arterial Hypertension, Pomeranian Medical University, Szczecin, Poland.
- 503 Woman-Mother-Child Department, Lausanne University Hospital, Lausanne, Switzerland.
- 504 Pacific Institute for Research & Evaluation, Calverton, MD, USA.

- 505 Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
- 506 Internal Medicine Programme, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan.
- 507 Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan.
- 508 Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
- 509 Department of Sports Medicine and Rehabilitation, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 510 School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.
- 511 Institute of Addiction Research (ISFF), Frankfurt University of Applied Sciences, Frankfurt, Germany.
- 512 Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- 513 Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Health Equity Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 515 Internal Medicine Department, King Saud University, Riyadh, Saudi Arabia.
- 516 Department of Forestry, Salahaddin University-Erbil, Erbil, Iraq.
- 517 Department of Medicine-Huddinge, Karolinska Institutet, Stockholm, Sweden.
- 518 Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj City, Iran.
- 519 Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran.
- 520 Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria.
- 521 Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina University, Messina, Italy.
- 522 Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- 523 Department of Mathematical Sciences, University of Bath, Bath, UK.
- 524 International Laboratory for Air Quality and Health, Queensland University of Technology, Brisbane, QLD, Australia.
- 525 Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- 526 Asia-Pacific Regional Office, United Nations Population Fund (UNFPA), Bangkok, Thailand.
- 527 Department of Health Policy, Management, and Economics, Tehran University of Medical Sciences, Tehran, Iran.
- 528 Department of Food Science, University of Campinas (Unicamp), Campinas, Brazil.
- 529 Federal Institute for Population Research, Wiesbaden, Germany.
- 530 Center for Population and Health, Wiesbaden, Germany.
- 531 Department of Endocrinology & Metabolism, Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India.
- 532 School of Economics, University of Nairobi, Nairobi, Kenya.
- 533 Research and Analytics Department, Initiative for Financing Health and Human Development, Chennai, India.
- 534 Department of Research and Analytics, Bioinsilico Technologies, Chennai, India.

- 535 Department of Cardiology, Hamedan University of Medical Sciences, Hamadan, Iran.
- 536 Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia.
- 537 Experimental Surgery and Oncology Laboratory, Kursk State Medical University, Kursk, Russia.
- 538 Department of Epidemiology and Biostatistics, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 539 Department for the Control of Disease, Epidemics, and Pandemics, Ministry of Public Health, Yaoundé, Cameroon.
- 540 Department of Public Health, University of Yaoundé I, Yaoundé, Cameroon.
- 541 Department of Disease Control and Environmental Health, Makerere University, Kampala, Uganda.
- 542 Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 543 Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania.
- 544 Department of Anatomy and Embryology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- 545 Cardio-Aid, Bucharest, Romania.
- 546 Department of Health Sciences, University of Tampere, Tampere, Finland.
- 547 Department of Biological Sciences, University of Embu, Embu, Kenya.
- 548 Institute for Global Health Innovations, Duy Tan University, Hanoi, Vietnam.
- 549 School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
- 550 Department of Community and Family Medicine, Iran University of Medical Sciences, Tehran, Iran.
- 551 Department of Health Policy and Management, Keio University, Tokyo, Japan.
- 552 Department of Global Health Policy, University of Tokyo, Tokyo, Japan.
- 553 Department of Clinical Sciences, Lund University, Lund, Sweden.
- 554 Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, SA, Australia.
- 555 Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.
- 556 Unit of Microbiology and Public Health, Institute of Medical Sciences, Las Tablas, Panama.
- 557 Department of Public Health, Ministry of Health, Herrera, Panama.
- 558 Translational Health Research Institute, Western Sydney University, Sydney, NSW, Australia.
- 559 Department of Preventive Medicine, Kyung Hee University, Dongdaemun-gu, South Korea.
- 560 Gorgan Congenital Malformations Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
- 561 Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
- 562 Department of Psychiatry, University of Lagos, Lagos, Nigeria.
- 563 Centre for Healthy Start Initiative, Lagos, Nigeria.
- 564 Department of Pharmacology and Therapeutics, University of Nigeria Nsukka, Enugu, Nigeria.
- 565 Department of Biomedical Sciences, University of Novi Sad, Novi Sad, Serbia.
- 566 Department of Project Management, National Research University Higher School of Economics, Moscow, Russia.
- 567 Department of Medicine, University of Ibadan, Ibadan, Nigeria.

- 568 Department of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria.
- 569 Department of Respiratory Medicine, Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India.
- 570 Department of Forensic Medicine, Manipal Academy of Higher Education, Mangalore, India.
- 571 Department of Ophthalmology, Heidelberg University, Heidelberg, Germany.
- 572 Department of Research, Public Health Foundation of India, Gurugram, India.
- 573 Department of Clinical Epidemiology, University of the Philippines Manila, Manila, Philippines.
- 574 Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- 575 Department of Physiology, Iran University of Medical Sciences, Tehran, Iran.
- 576 Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 577 School of Public Health, Medical, and Veterinary Sciences, James Cook University, Townsville, NSW, Australia.
- 578 Center for Research and Innovation, Ateneo De Manila University, Pasig City, Philippines.
- 579 School of Global Public Health, New York University, New York, NY, USA.
- 580 Department of Orthopedics, Yenepoya Medical College, Mangalore, India.
- 581 School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia.
- 582 Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China.
- 583 Department of Psychiatry, Columbia University, New York City, NY, USA.
- 584 Department of Cardiology, University of Bern, Bern, Switzerland.
- 585 Department of Chemistry, University of Porto, Porto, Portugal.
- 586 Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands.
- 587 University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
- 588 School of Economics and Business, University of Groningen, Groningen, Netherlands.
- 589 Department of Nutrition and Food Sciences, Maragheh University of Medical Sciences, Maragheh, Iran.
- 590 Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran.
- 591 Clinical Research Center, Fundación Valle del Lili, Cali, Colombia.
- 592 Center for Studies in Social Protection and Health Economics, ICESI University, Cali, Colombia.
- 593 Department of Neurology, Smt. B.K.S. Medical Institute and Research Center, Vadodara, India.
- Health Sciences Department, Muhammadiyah University of Surakarta, Sukoharjo, Indonesia.
- 595 Department of Community Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India.
- 596 Department of Chemistry, Sharif University of Technology, Tehran, Iran.
- 597 College of Medicine, University of Central Florida, Orlando, FL, USA.
- 598 Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- 599 Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- 600 Metabolomics and Genomics Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 601 Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 602 Department of Community Medicine, Maharishi Markandeshwar Institute of Medical Sciences & Research, Ambala, India.

- 603 School of Nursing and Healthcare Professions, Federation University Australia, Berwick, VIC, Australia.
- 604 Department of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 605 Research Department, Policy Research Institute, Kathmandu, Nepal.
- 606 Health and Public Policy Department, Global Center for Research and Development, Kathmandu, Nepal.
- 607 Department of Medicine, University of Otago, Wellington, New Zealand.
- 608 Department of Neurology, Capital & Coast District Health Board, Wellington, New Zealand.
- 609 Department of Oral Pathology, Srinivas Institute of Dental Sciences, Mangalore, India.
- 610 Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, Iran.
- 611 Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Mangalore, India.
- 612 Academic Public Health England, Public Health England, London, UK.
- 613 WHO Collaborating Centre for Public Health Education and Training, Imperial College London, London, UK.
- 614 University College London Hospitals, London, UK.
- 615 School of Health, Medical and Applied Sciences, CQ University, Sydney, NSW, Australia.
- 616 Department of Computer Science, Boston University, Boston, MA, USA.
- 617 School of Social Sciences and Psychology, Western Sydney University, Penrith, NSW, Australia.
- 618 Translational Health Research Institute, Western Sydney University, Penrith, NSW, Australia.
- 619 Department of Health Information Management, Manipal Academy of Higher Education, Manipal, India.
- 620 Manipal Academy of Higher Education, Manipal, India.
- 621 Brien Holden Vision Institute, Sydney, Australia.
- 622 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
- 623 Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
- 624 Department of Chemical Sciences, University of Porto, Porto, Portugal.
- 625 Epidemiology Research Unit Institute of Public Health (EPIUnit-ISPUP), University of Porto, Porto, Portugal.
- 626 Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
- 627 Department of Surgery, University Teaching Hospital of Kigali, Kigali, Rwanda.
- 628 Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil.
- 629 Department of Neuroscience, University of Perugia, Perugia, Italy.
- 630 Department of Neurology, Rimini 'Infermi' Hospital AUSL Romagna, Rimini, Italy.
- 631 Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
- 632 Agrosavia, Palmira, Colombia.
- 633 Malaria Atlas Project, University of Oxford, Oxford, UK.
- 634 Department of Health Statistics, National Institute for Medical Research, Dar es Salaam, Tanzania.
- 635 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
- 636 Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 637 School of Psychiatry, University of New South Wales, Kensington, NSW, Australia.
- 638 Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, NSW, Australia.

- 639 Cardiac Rehabilitation Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
- 640 Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.
- 641 Department of Phytochemistry, Soran University, Soran, Iraq.
- 642 Department of Nutrition, Cihan University-Erbil, Kurdistan Region, Iraq.
- 643 Department of Microbiology, Central University of Punjab, Bathinda, India.
- 644 Department of Public Health and Community Medicine , Cairo University, Giza, Egypt.
- 645 Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK.
- 646 Department of Entomology, Ain Shams University, Cairo, Egypt.
- 647 Department of Surgery, Marshall University, Huntington, WV, USA.
- 648 Department of Nutrition and Preventive Medicine, Case Western Reserve University, Cleveland, OH, USA.
- 649 Rheumatology Department, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
- 650 School of Public Health and Health Management, University of Belgrade, Belgrade, Serbia.
- 651 Department of Community Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India.
- 652 PSG-FAIMER South Asia Regional Institute, Coimbatore, India.
- 653 Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
- 654 Department of Geriatrics and Long Term Care, Hamad Medical Corporation, Doha, Qatar.
- Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK.
- 656 Population Health Research Institute, McMaster University, Hamilton, ON, Canada.
- The George Institute for Global Health, Sydney, NSW, Australia.
- 658 Department of Psychology, University of Alabama at Birmingham, Birmingham, AL, USA.
- 659 Oral Diagnosis, Digital Health and Health Services Research, Charité University Medical Center Berlin, Berlin, Germany.
- 660 Emergency Department, Manian Medical Centre, Erode, India.
- 661 Center for Biomedical Information Technology, Shenzhen Institutes of Advanced Technology, Shenzhen, China.
- 662 Department of Radiology and Interventional Neuroradiology, Isfahan University of Medical Sciences, Isfahan, Iran.
- 663 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- 664 Public Health Division, An-Najah National University, Nablus, Palestine.
- 665 Independent Consultant, Karachi, Pakistan.
- 666 National Centre for Disease Control (NCDC), Tbilisi, Georgia.
- 667 School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
- 668 Faculty of Caring Science, Work Life, and Social Welfare, University of Borås, Borås, Sweden.
- 669 Institute for Population Health, King's College London, London, UK.
- 670 National Institute of Infectious Diseases, Tokyo, Japan.
- 671 College of Medicine, Yonsei University, Seoul, South Korea.
- Finnish Institute of Occupational Health, Helsinki, Finland.
- 673 Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
- 674 Cancer Biology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

- 675 Department of Psychology, Reykjavik University, Reykjavik, Iceland.
- 676 Department of Health and Behavior Studies, Columbia University, New York, NY, USA.
- 677 Department of Law, Economics, Management and Quantitative Methods, University of Sannio, Benevento, Italy.
- 678 WSB University in Gdańsk, Gdansk, Poland.
- 679 School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
- 680 Medicine Service, US Department of Veterans Affairs (VA), Birmingham, AL, USA.
- 681 Department of Humanities and Social Sciences, Indian Institute of Technology, Roorkee, Roorkee, India.
- 682 Department of Epidemiology, School of Preventive Oncology, Patna, India.
- 683 Department of Epidemiology, Healis Sekhsaria Institute for Public Health, Mumbai, India.
- 684 Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.
- 685 Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Slagelse, Denmark.
- 686 Department No.16, Moscow Research and Practical Centre on Addictions, Moscow, Russia.
- 687 Institute of Bone and Joint Research (IBJR), University of Sydney, St Leonards, NSW, Australia.
- 688 Australian New Zealand Clinical Trials Registry (ANZCTR), NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
- 689 Department of Vascular and Endovascular Surgery, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- 690 Nursing Care Research Center, Semnan University of Medical Sciences, Semnan, Iran.
- 691 Hospital Universitario de La Princesa (Princess University Hospital), Autonomous University of Madrid, Madrid, Spain.
- 692 Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES-Center for Biomedical Research in Respiratory Diseases Network), Madrid, Spain.
- 693 Hull York Medical School, University of Hull, Hull City, UK.
- Division of Community Medicine, International Medical University, Kuala Lumpur, Malaysia.
- 695 Risk and Resilience in Mental Disorders Unit, South African Medical Research Council, Cape Town, South Africa.
- 696 Occupational and Environmental Medicine Department, University of Gothenburg, Gothenburg, Sweden.
- 697 Department of Psychology, Deakin University, Burwood, VIC, Australia.
- 698 Department of Epidemiology & Biostatistics, The University of Western Ontario, London, ON, Canada.
- 699 Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg.
- 700 Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
- 701 Nursing Department, Muhammadiyah University of Surakarta, Surakarta, Indonesia.
- 702 Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria.
- 703 Department of Agriculture and Food Systems, University of Melbourne, Melbourne, VIC, Australia.
- 704 Department of Statistics, Manonmaniam Sundaranar University, Abishekapatti, Tirunelveli, India.
- National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India.

- Norwegian Institute of Public Health, Bergen, Norway.
- 707 Department of Medicine, University of Valencia, Valencia, Spain.
- 708 Carlos III Health Institute, Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain.
- 709 Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
- 710 Department of Pharmacy, Arbaminch College of Health Sciences, Arbaminch, Ethiopia.
- 711 Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
- 712 Department of Population Science and Human Resource Development, University of Rajshahi, Rajshahi, Bangladesh.
- 713 Department of Clinical Pharmacy, University of Gondar, Gondar, Ethiopia.
- 714 Pediatric Intensive Care Unit, King Saud University, Riyadh, Saudi Arabia.
- 715 Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia.
- 716 Department of Public Health and Community Medicine, Central University of Kerala, Kasaragod, India.
- 717 Department of Medicine, Monash University, Melbourne, VIC, Australia.
- 718 K.A. Timiryazev Institute of Plant Physiology, Russian Academy of Sciences, Moscow, Russia.
- 719 Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Moscow, Russia.
- 720 HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Kerman University of Medical Sciences, Kerman, Iran.
- 721 Department of Medicine, University of Calgary, Calgary, AB, Canada.
- 722 Nutritional Epidemiology Research Team (EREN), National Institute for Health and Medical Research (INSERM), Paris, France.
- Health, Medicine and Human Biology, Sorbonne Paris Nord University, Bobigny, France.
- 724 Department of Pathology and Legal Medicine, University of São Paulo, Ribeirão Preto, Brazil.
- 725 Modestum LTD, London, UK.
- 726 Department of Health Economics, Hanoi Medical University, Hanoi, Vietnam.
- 727 Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
- 728 Mbarara University of Science and Technology, Mbarara, Uganda.
- 729 Department of Medicine, University of Crete, Heraklion, Greece.
- 730 Institute for Physical Activity and Nutrition, Deakin University, Melbourne, QLD, Australia.
- 731 School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia.
- 732 Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Nigeria.
- 733 Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India.
- 734 Argentine Society of Medicine, Buenos Aires, Argentina.
- 735 Velez Sarsfield Hospital, Buenos Aires, Argentina.
- 736 Department of Physics and Atmospheric Science, Dalhousie University, Halifax, NS, Canada.
- 737 Department of Energy, Environmental and Chemical Engineering, Washington University in St. Louis, St. Louis, MO, USA.
- 738 Department of Nephrology, Christian Medical College and Hospital (CMC), Vellore, India.
- 739 UKK Institute, Tampere, Finland.

- 740 Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran.
- 741 Raffles Neuroscience Centre, Raffles Hospital, Singapore, Singapore.
- 742 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- 743 Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- 744 Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy.
- 745 Department of Health Care Administration and Economics, National Research University Higher School of Economics, Moscow, Russia.
- Foundation University Medical College, Foundation University Islamabad, Islamabad, Pakistan.
- 747 School of Population Health and Environmental Sciences, King's College London, London, UK.
- 748 School of Health Sciences, Wuhan University, Wuhan, China.
- 749 Department of Epidemiology and Biostatistics, George Washington University, Washington, DC, USA.
- 750 Cardiology Department, Royal Children's Hospital, Melbourne, VIC, Australia.
- 751 Critical Care and Neurosciences, Murdoch Childrens Research Institute, Melbourne, VIC, Australia.
- 752 Department of Demography, University of California Berkeley, Berkley, CA, USA.
- 753 Competence Center of Mortality-Follow-Up of the German National Cohort, Federal Institute for Population Research, Wiesbaden, Germany.
- 754 Department of Physical Therapy, Naresuan University, Phitsanulok, Thailand.
- 755 National Institute for Health Research (NIHR) Biomedical Research Centre, Guy's and St.Thomas' Hospital and Kings College London, London, UK.
- 756 Department of Orthopaedics, Wenzhou Medical University, Wenzhou, China.
- 757 Clinical Cancer Research Center, Milad General Hospital, Tehran, Iran.
- 758 Research and Development Center for Health Services, University of Tsukuba, Tsukuba, Japan.
- 759 Graduate School of Medicine, Osaka University, Suita, Japan.
- 760 Department of Family Medicine and Community Health, Duke University, Durham, NC, USA.
- 761 School of International Development and Global Studies, University of Ottawa, Ottawa, ON, Canada.
- 762 The George Institute for Global Health, University of Oxford, Oxford, UK.
- 763 Health Services Management Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- 764 Department of Health Management, Policy, and Economics, Kerman University of Medical Sciences, Kerman, Iran.
- 765 Department of Nursing, Arba Minch University, Arba Minch, Ethiopia.
- 766 Department of Anatomy, Mekelle University, Mekelle, Ethiopia.
- 767 Centre for Suicide Research and Prevention, University of Hong Kong, Hong Kong, China.
- 768 Department of Social Work and Social Administration, University of Hong Kong, Hong Kong, China.
- 769 Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan.
- 770 Department of Public Health, Juntendo University, Tokyo, Japan.
- 771 Department of Health Policy and Management, Jackson State University, Jackson, MS, USA.
- 772 School of Medicine, Tsinghua University, Beijing, China.

- 773 Department of Environmental Health, Mazandaran University of Medical Sciences, Sari, Iran.
- 774 Injury Prevention and Safety Promotion Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- 775 Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China.
- 776 Global Health Institute, Wuhan University, Wuhan, China.
- 577 School of Public Health and Management, Hubei University of Medicine, Shiyan, China.
- 778 Department of Healthcare Management and Economics, Urmia University of Medical Science, Urmia, Iran.
- 779 Department of Pharmaceutics, Dow University of Health Sciences, Karachi, Pakistan.
- 780 The School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia.
- 781 Psychiatry and Psychology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- 782 Laboratory of Genetics and Genomics, Moscow Research and Practical Centre on Addictions, Moscow, Russia.
- 783 Addictology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia.
- 784 School of Medicine, Wuhan University, Wuhan, China.
- 785 Department of General Practice, University of Melbourne, Melbourne, Australia.
- 786 Victorian Comprehensive Cancer Centre, Melbourne, Australia.
- 787 School of Public Health, Wuhan University of Science and Technology, Wuhan, China.
- 788 Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China.
- 789 School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, China.
- 790 Department of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.
- 791 Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA, USA.

Global Burden of Disease overview

GATHER statement

This study is in compliance with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement. The GBD 2019 capstone papers^{1–3} and their respectivesupplementary documents contain the general methods, data sources, model selection information, performance and limitation information for the GBD 2019 analyses including detailed GATHER documentation. Supplementary table 1 contains GATHER compliance information for this publication.

GBD cause list and location hierarchy

The GBD cause list can be found in the supplementary table 2, consisting of a hierarchy that ismutually exclusive and collectively exhaustive. The GBD location hierarchy, including levels, for GBD superregions, regions, countries and sub-country analysis is presented in supplementary table 3. Details on the overall GBD 1990–2019 cause list have been documented and can be found elsewhere^{1,3}. This paper uses the same cause list in the populationaged 70 years and older.

Socio-demographic Index (SDI)

The Socio-demographic Index (SDI) is a composite indicator of development status initially constructed for

GBD 2015 whose components are strongly correlated with health outcomes. SDI in GBD 2019 incorporated changes that replaced the total fertility rate (TRF) compoment with the total fertility rate (TFU25) in females under the age of 25 years from previous GBD cycles. Specific SDI methodology information is described elsewhere.⁴

Data sources

A complete list of sources used in the GBD 2019 analyses is available from the GBD 2019 DataInput Sources Tool (<u>http://ghdx.healthdata.org/gbd-2019/data-input-sources</u>).

Mortality and death cause-specific estimation process for those over 70 years old

Mortality and death cause estimates for the population aged 70 years and older had followed the standard procedure methodology of GBD 2019 and were generated using Cause of Death Ensemble modelling (CODEm). The CODEm approach has been described elsewhere^{1,3}.

The cause of death (CoD) database contains seven types of data sources: vital registration (VR), verbal autopsy (VA), cancer registry (CR), police records, sibling history, surveillance, and survey/census. When all the types of data are collected in various formats, then the input data are standardised to run through central CoD machinery to then to be uploaded to the database. A specific tool has been developed through GBD called age-sex splitting, that takes aggregated age groups, and likewise the "both sexes combined" grouping, and divides them into what their constituent age groups would likely have been using respective cause-specific and country- specific age distributions. This allows the GBD study to include age categories from early neonatal (0-6 days) to the age group of 95 years and older. This calculation formula is described in detailed elsewhere.^{1,3}

For certain causes of death, mortality rates reported in vital registration systems are impossible to reconcile with observed trends in disease prevalence and excess mortality. These include dementia, Parkinson's disease, and atrial fibrillation and flutter. It is well known that dementiasand Parkinson's disease are highly prevalent in the older population, starting mildy even from the age of 70.^{5,1} GBD 2017 as well as 2019 made an effort to calculate the known bias regardingthese causes of death data by detecting the proportion of deaths that had to be assigned to these causes, and after that, to assess the GBD causes and garbage codes to which these kind of deathswere inaccurately assigned. As described in the past GBD methodologies (GBD 2017 and 2015),^{1,6} the aforementioned causes of death were processed in CODCorrect in a manner that inappropriately led to changes in mortality estimates for causes that were not related to dementia,Parkinson's, and atrial fibrillation and flutter. In GBD 2016, a huge literature review⁷ was applied to assess the causes of death mostly related to Parkinson's and Alzheimer's diseases, helping in further CodCorrect adjustments, while in GBD 2017 and 2019 a more refined process, even further limiting bias, was used.^{1,5} The current study, by applying this miscoding correction for the aforementioned diseases, is calibrating the mortality rates for those 70 years and older with the minimum possible bias.

Non-fatal modelling methods for those 70 years and older

Non-fatal estimates for the population aged 70 years and older were modelled using the DisMod-MR 2.1 tool. Morbidity modelling methods used in the same manner as described in detail in theGBD 2019 methodology have been documented elsewhere.^{2,8}

A group of behavioural, environmental and occupational, and metabolic risks that contribute todisease burden were evaluated in GBD 2019. The same group of risk factors was used in the current analysis to identify those that are closely related to the ageing population. The methodology regarding risk factor estimation and evaluation is described in detail elsewhere.^{2,4}

Healthcare Access and Quality (HAQ) Index

The HAQ Index in GBD 2016 used 32 causes for which death should not occur in the presence of effective care to approximate personal health-care access and quality by location and over time. A risk-standardised cause-specific death methodology due to non-cancers by location-year, replaced the local combined exposure of environmental and behavioural risks with the global level of exposure applied, to isolate potential effects of personal health-care access and quality from underlying risk factor patterns. Each cause transformed to a scale of 0–100, with 0 as the first percentile (worst) observed between 1990 and 2016, and 100 as the 99th percentile (best); these thresholds were set at the country level, and then applied to subnational locations. The rest of the HAQ Index methodology is described in detail elsewhere.⁹

References

- GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1160–203.
- 2. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223–49.
- 3. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet 2020; 396: 1204–22.
- 4. Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018; 392: 1923–94.
- 5. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018; 392: 1736–88.
- 6. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980- 2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459–544.
- GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1151–210.
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted lifeyears (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1859–922.
- 9. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet 2018; 391: 2236–71.

Figure S1. Global population change by age group for both sexes combined (top panel), population percentagechange during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in Low Socio-demographic Index (SDI) regions.



Figure S2. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in Low-middle Socio-demographic Index (SDI) regions.



Figure S3. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lowermiddle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in Middle Socio-demographic Index (SDI) regions.



Figure S4. Global population change by age group for both sexes combined (top panel), population percentagechange during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in High-middle Socio-demographic Index (SDI) regions.



Figure S5. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in High Socio- demographic Index (SDI) regions.



Figure S6. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the Central Europe, Eastern Europe and Central Asia GBD super-region.



Figure S7. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the High- income GBD super-region.





Figure S8. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the Latin America and Caribbean GBD super-region.





Figure S9. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the North Africa and Middle East super-region.



42

Figure S10. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the South Asia GBD super-region.





Figure S11. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the Southeast Asia, East Asia and Oceania GBD super-region.



Figure S12. Global population change by age group for both sexes combined (top panel), population percentage change during the same period (upper middle panel), rate of change in years lived with disability (YLDs; lower middle panel), and rate of change in All-cause mortality (bottom panel) between 1990 and 2019 in the Sub-Saharan Africa GBD superregion



Figure S13. Life expectancy at 70+ (LE-70), healthy life expectancy at 70+ (HALE-70), and proportion of life- years spent in ill health (PYIH-70) at age 70+ GBD by super-region between 1990 and 2019, in males.



Supplementary Figure 13. LE, HALE and proportion of life years spend in ill health at the population 70+ years old, by super-regions, between 1990 and 2019, males Figure S14. Life expectancy at 70+ (LE-70), healthy life expectancy at 70+ (HALE-70), and proportion of life- years spent in ill health (PYIH-70) at age 70+ GBD by super-region between 1990 and 2019, in females.



47



Figure S15. Life expectancy (LE-70), healthy life expectancy (HALE-70) and proportion of life-years spent in ill health at age 70+ (PYIH-70) versus Socio-demographic Index (SDI) and Healthcare Access and Quality (HAQ) Index in 2019, in males.

SDI Group • Low SDI • Low-middle SDI • Middle SDI • High-middle SDI • High SDI



Figure S16. Life expectancy (LE-70), healthy life expectancy (HALE-70) and proportion of life-years spent in ill health at age 70+ (PYIH-70) versus Socio-demographic Index (SDI) and Healthcare Access and Quality (HAQ) Index in 2019, in females.

SDI Group • Low SDI • Low-middle SDI • Middle SDI • High-middle SDI • High SDI

Figure S17. Decomposition of the probability of death, for all GBD locations, for the population aged 70to 90 years old, from 1990 to 2019, in both sexes.

Both sexes refer to combined estimates for males and females. Probability of death between 70 and 90 years of age (denoted using standard demographer notation as 20q70, the probability 'q' of death for a period of 20 years starting at age 70) is plotted globally and by Global Burden of Disease super-region and region for 1990 (dashed vertical line) and 2019 (solid vertical line). The relative contribution of that change due to different causes is indicated by different coloured bars. All causes to the right of the dashed line increased from 1990 to 2019 and all those to the left decreased over the same time period. As can be seen at the global level, the probability of death for those 70 to 90 years decreased mainly due to cardiovascular diseases, chronic respiratory diseases, respiratory infections and tuberculosis and enteric infections (-13.6% in aggregate), while probability of death increased owing to increases in neoplasms, neurological disorders, and diabetes and kidney diseases (+4.3% in aggregate). **COLOR LEGEND:**



Republic of Korea	-35.9%	+11.9%
Singapore	-26.6%	+2.1%
Australasia	-20.8%	+5.7%
Australia	-21.2%	+5.9%
New Zealand	-18.4%	+4.6%
Western Europe	-19.3%	+4.2%
Andorra	-10.6%	+0.8%
Austria	-21.1%	+4.6%
Belgium	-17.6%	+3.5%
Cyprus	-24.7%	+7.1%
Denmark	-22.7%	+11.1%
Finland	-19.9%	+4.4%
France	-20.2%	+1.9%
Germany	-20.6%	+6.9%
Greece	-17.0%	+4.8%
Iceland	-20.5%	+2.5%
Ireland	-23.8%	+5.5%
Israel	-23.1%	+7.6%
Italy	-19.5%	+4.3%
Luxembourg	-22.9%	+2.5%
Malta	-20.8%	+2.3%
Netherlands	-16.1%	+5.7%
Norway	-24.0%	+8.6%
Portugal	-27.0%	+7.5%
Spain	-20.8%	+3.6%
Sweden	-19.7%	+7.0%
Switzerland	-19.0%	+3.7%
United Kingdom	-20.2%	+7.3%
Southern Latin America	-15.6%	+8.2%
Argentina	-15.9%	+10.8%
Chile	-20.6%	+6.9%
Uruguay	-14.8%	+6.8%
High-income North America	-14.3%	+6.4%
Canada	-17.0%	+3.8%
United States of America	-13.9%	+6.6%

Latin America and Caribbean	14.9%
Antigua and Barbuda	-7.3%
Bahamas Barbados	-7.3% +3.2% -11.3% +8.5%
Belize	-11.7%
Dominica	-8.9%
Dominican Republic Grenada	-3.8%
Guyana	-13.5%
Jamaica	-10.1%
Saint Lucia	-17,2%
Suriname	-11.1%
Trinidad and Tobago	-18.4%
Bolivia (Plurinational State of)	-13.0%
Ecuador	13.5%
Peru Central Latin America	-17.5%
Colombia	-18.8%
El Salvador	-12.9%
Guatemala	-26.5%
Mexico	-5.4%
Nicaragua	-2.4% +15.1%
enezuela (Bolivarian Republic of)	-13.7%
Tropical Latin America	-17.9%
Paraguay	-9.9%
North Africa and Middle East	-10.1%
Algeria	-10.1%
Bahrain	-22.5%
Egypt Iran (Islamic Republic of)	-15.7%
Iraq	-5.6%
Jordan Kuwait	-16.4%
Lebanon	-12.9%
Libya	-5.3% +2.1%
Palestine	-9.3%
Oman	
Saudi Arabia	13.0%
Syrian Arab Republic	-8.6%
Turkey	-10.1%
United Arab Emirates	-14.4%
South Asia	-0.5%
South Asia	-18.4%
Bangladesh	-12.3% +9.7%
Bhutan	-18.2%
Nepal	-14.8%
Pakistan	13.9%
Sub-Saharan Africa Central Sub-Saharan Africa	-10.4%
Angola	-17.1% +11.0%
Central African Republic	-3.6%
Democratic Republic of the Congo	-7.4%
Equatorial Guinea	-24.0% +16.6%
Eastern Sub-Saharan Africa	-13.8%
Burundi Comoros	-9.4% +3.8% -11.4% +5.3%
Djibouti	-11.3%
Eritrea	-20.6%
Kenya	-8.3% +7.5%
Madagascar Malawi	-12 7%
Mauritius	-27.2%
Mozambique Bwanda	-14.5%
Seychelles	-11.7%
Somalia United Republic of Tanzania	-7.5%
Uganda	-13.1%
Zambia Southern Sub-Sabaran Africa	-15.2%
Botswana	-12.3%
Lesotho	-8.5%
South Africa	-11.8%
Eswatini	-10.4%
∠imbabwe Western Sub-Saharan Africa	-11.1%
Benin Burking Free	-11.7%
Cameroon	-11.9% +10.2%
Cabo Verde	-7.4%
Chad Côte d'Ivoire	-9.5%
Gambia	-10.5%
Ghana Guinea	-12.7% +9.3%
Guinea-Bissau	-13.1%
Liberia	-11.7%
Mauritania	-15.3%
Niger	
Sao Tome and Principe	-9.2%
Senegal	-12.7%
Sierra Leone Togo	-10.4%
American Samoa	-9.0%
Bermuda Cook Islands	-21.1%
Greenland	-16.1%
Guam	-19.8%
Monaco	-7.3%
Monaco Nauru	-9.9%
Monaco Nauru Niue Northern Mariana Islands	.8 5%,
Monaco Nauru Niue Northern Mariana Islands Palau	-8.5% +4.5%
Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico	-8.5% +4.5% -19.9% +3.2%
Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino	-8.5% +4.5% -8.5% +6.5% -19.9% -18.0% -18.0% +8.2%
Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino Tokelau	-8.5% -19.9% -19.9% -18.0% -18.0% -11.1% +6.5% +8.2% -9.6% -11.1% +6.6%
Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino Tokelau Tukelau United States Virgin Islands	-19.9% -19.9% -18.0% -18.0% -11.1% -11.1% -11.5% -11.5% +5.3%
Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino Tokelau Tuvalu United States Virgin Islands South Sudan	-19.9% -19.9% -18.0% -18.0% -18.0% -11.1% -11.1% -11.5% -11.5% -11.5% -11.5% -14.0% -11.4%

Figure S18. Decomposition of the probability of death, for all GBD locations, for the population aged 70 to 90 years old, from 1990 to 2019, in males

Probability of death between 70 and 90 years of age (denoted using standard demographer notation as 20q70, the probability 'q' of death for a period of 20 years starting at age 70) is plotted globally and by Global Burden of Disease super-region and region for 1990 (dashed vertical line) and 2019 (solid vertical line). The relative contribution of that change due to different causes is indicated by different coloured bars. All causes to the right of the dashed line increased from 1990 to 2019 and all those to the left decreased over the same time period. As can be seen at the global level, the probability of death for the males 70 to 90 years decreased mainly due to cardiovascular diseases, chronic respiratory diseases, respiratory infections and tuberculosis and enteric infections (-12.7% in aggregate), while probability of death increased owing to increases in neoplasms, neurological disorders, and diabetes and kidney diseases (+4.8% in aggregate). **COLOR LEGEND:**



Australasia	-22.170	+0.0%
Australia	-22.5%	+6.2%
New Zealand	-20.0%	+4.7%
Western Europe	-19.6%	+4.6%
Andorra	-10.7%	+0.9%
Austria	-21.3%	+5.7%
Belgium	-19.2%	+4.7%
Cyprus	-19.7%	+7.5%
Denmark	-23.1%	+10.7%
Finland	-19.1%	+3.7%
France	-20.5%	+2.5%
Germany	-22.1%	+7.5%
Greece	-15.1%	+4.7%
Iceland	-18.5%	+4.0%
Ireland	-23.8%	+6.4%
Israel	-22.5%	+8.8%
Italy	-18.6%	+4.6%
Luxembourg	-24.1%	+3.5%
Malta	-19.0%	+2.7%
Netherlands	-17.7%	+5.4%
Norway	-25.5%	+9.2%
Portugal	-25.9%	+9.9%
Spain	-18.5%	+3.7%
Sweden	-21.6%	+7.4%
Switzerland	-20.5%	+3.3%
United Kingdom	-20.2%	+5.7%
Southern Latin America	-14.7%	+9.0%
Argentina	-15.2%	+11.5%
Chile	-19.5%	+8.6%
Uruguay	-13.6%	+7.6%
High-income North America	-15.7%	+5.8%
Canada	-18.8%	+3.7%
United States of America	-15.4%	+6.2%

Latin America and Caribbean	-13.7%
Caribbean	-9.1%
Antigua and Barbuda Bahamas	-11.1% +0.6%
Barbados	-12.3%
Belize	-8.9% +9.8%
Cuba	-11.0% +6.1%
Dominica Dominican Bepublic	-9.4%
Grenada	-14.5%
Guyana	-13.2%
Haiti	-8.7%
Jamaica Saint Lucia	-9.6%
Saint Vincent and the Grenadines	-16.0%
Suriname	-10,4%
Trinidad and Tobago	-18.6%
Andean Latin America	-14.2%
Bolivia (Plurinational State of)	-12.5% +9.3%
Peru	-17.4%
Central Latin America	-13.0%
Colombia	-16.8%
El Salvador	-12.0%
Guatemala	-22,4%
Honduras	-3.7%
Mexico	-13.3%
Nicaragua	-5.9% +9.3%
Venezuela (Bolivarian Benublic of)	-12.5%
Tropical Latin America	-16.7%
Brazil	-16.9%
Paraguay	-8.5%
North Africa and Middle East	-10.5%
Algeria	-14.2%
Bahrain	-22.8%
Egypt	-8.4%
Iran (Islamic Republic of)	-16.4%
lordan	-13.9%
Kuwait	-6.2%
Lebanon	-9.2%
Libya	-4.8%
Morocco	-4.5%
Oman	-10,1%
Qatar	-13.5%
Saudi Arabia	-11.8%
Syrian Arab Republic	-9.4%
Turkey	-0.4 %
United Arab Emirates	-13.0%
Yemen	-7.5%
South Asia	-17.1%
Afghanistan	-17.1%
Bangladesh	-25.8%
Bhutan	-18.1% +13.7%
India	-17.3%
Pakistan	-14.3%
Sub-Saharan Africa	-10.4%
Central Sub-Saharan Africa	-7.7% +4.0%
Angola	-15.8%
Central African Republic	-3.6%
Democratic Republic of the Congo	-9.3%
Equatorial Guinea	-24.1%
Gabon	-10.0%
Eastern Sub-Saharan Africa	-12.8%
Burundi	-8.6%
Djibouti	-11.9%
Eritrea	-15.8%
Ethiopia	-18.5%
Kenya	-8.2%
Malawi	-11.4%
Mauritius	-27.8%
Mozambique	-13.9%
Rwanda	-14.0%
Seychelles	-14.9%
United Republic of Tanzania	-13.6%
Uganda	-14.6%
Zambia	-14.5%
Southern Sub-Saharan Africa	-6.7%
Lesotho	-14.270 +12.2%
Namibia	-12.5%
South Africa	-6.1% +7.9%
Eswatini	-12.6%
Zimbabwe Western Sub-Sabaran Africa	-5.1% +3.9%
Benin	-11.2%
Burkina Faso	-11.7%
Cameroon	-11.4%
Cabo Verde	-8.1%
Côte d'Ivoire	-3.4%
Gambia	-11.2%
Ghana	-11.4%



Figure S19. Decomposition of the probability of death, for all GBD locations, for the population aged 70 to 90 years old, from 1990 to 2019, in females.

Probability of death between 70 and 90 years of age (denoted using standard demographer notation as 20q70, the probability 'q' of death for a period of 20 years starting at age 70) is plotted globally and by Global Burden of Disease super-region and region for 1990 (dashed vertical line) and 2019 (solid vertical line). The relative contribution of that change due to different causes is indicated by different coloured bars. All causes to the right of the dashed line increased from 1990 to 2019 and all those to the left decreased over the same time period. As can be seen at the global level, the probability of death for those 70 to 90 years decreased mainly due to cardiovascular diseases, chronic respiratory diseases, respiratory infections and tuberculosis and enteric infections (-14.6% in aggregate), while probability of death increased owing to increases in neoplasms, neurological disorders, and diabetes and kidney diseases (+3.6% in aggregate). **COLOR LEGEND:**



New Zealand	-10.470	+ 5.070
Western Europe	-20.0%	+3.9%
Andorra	-9.4%	+0.7%
Austria	-22.8%	+4.3%
Belgium	-18.1%	+3.4%
Cyprus	-	28.5%
Denmark	-22.8%	+11.2%
Finland	-21.7%	+4.3%
France	-21.2%	+1.9%
Germany	-20.7%	+5.9%
Greece	-18.8%	+4.9%
Iceland	-24.0%	+2.0%
Ireland	-24.3%	+5.0%
Israel	-23.7%	+6.9%
Italy	-20.7%	+4.0%
Luxembourg	-23.1%	+2.1%
Malta	-22.5%	+2.2%
Netherlands	-16.6%	+7.0%
Norway	-23.1%	+8.1%
Portugal	-28.2%	+ 5.8%
Spain	-22.7%	+3.1%
Sweden	-18.3%	+6.5%
Switzerland	-18.8%	+4.4%
United Kingdom	-20.9%	+8.2%
Southern Latin America	-16.4%	+7.8%
Argentina	-16.6%	+10.5%
Chile	-21.7%	+5.7%
Uruguay	-15.9%	+6.9%
High-income North America	-14.0%	+6.7%
Canada	-17.0%	+4.8%
United States of America	-13.6%	+6.9%

Latin America and Caribbean	-15.8%
Antigua and Barbuda	-4.9%
Bahamas Barbados	-5.1% +2.8%
Belize	-14.6%
Cuba Dominica	-13.3%
Dominican Republic Grenada	-3.3% +4.9%
Guyana	-12.2%
Haiti	-6.3%
Jamaica Saint Lucia	-10.5% +7.2%
Saint Vincent and the Grenadines	-8.3% +3.6%
Trinidad and Tobago	-11.9%
Andean Latin America	-15.8%
Bolivia (Plurinational State of)	-11.0% +10.0%
Peru	-17.6%
Central Latin America Colombia	-16.0%
Costa Rica	-13.7%
El Salvador	-10.7%
Honduras	-3.4%
Mexico	-17.0%
Panama	-1.2%
Venezuela (Bolivarian Republic of)	-12.2%
Tropical Latin America	-18.7%
Paraguay	-11.5%
North Africa and Middle East	-9.7%
North Africa and Middle East Algeria	-9.7%
Bahrain	-23.2% +16.9
Egypt	-4.4%
Iran (Islamic Republic of)	-14.0%
Jordan	-18.4%
Kuwait	-19.6%
Libya	-5.8%
Morocco	-5.7%
Palestine Oman	-8.3% +4.7%
Qatar	-7.1% +12.4%
Saudi Arabia Svrian Arab Republic	-14.9%
Tunisia	-8.4%
Turkey	-9.7%
United Arab Emirates Yemen	-16.5%
South Asia	-19.9%
South Asia	-19.9%
Bangladesh	-11.2% +10.1%
Bhutan	-19.5%
India	-21.3%
Pakistan	-14.2%
Sub-Saharan Africa	-10.2%
Central Sub-Sanaran Africa Angola	-17.7%
Central African Republic	-4.1%
Congo	-9.3%
Equatorial Guinea	-5.1% +1.9%
Gabon	-10.6% +6.9%
Eastern Sub-Saharan Africa	-14.3%
Comoros	-11.3%
Djibouti	11.3%
Eritrea	-23.5%
Kenya	-7.6%
Madagascar	-5.8% +5.1%
Mauritius	-12.7%
Mozambique	14.0%
Rwanda	-16.9%
Somalia	-9.1%
United Republic of Tanzania	-12.3%
Uganda Zambia	-13.0% +9.1%
Southern Sub-Saharan Africa	-4.6%
Botswana	-11.4% +9.7%
Lesotho	-7.6%
South Africa	-4.1%
Eswatini	-8.7%
Western Sub-Saharan Africa	-11.4%
Benin	-11.4%
Burkina Faso Cameroon	-12.5%
Cabo Verde	7.5%
Côte d'Ivoire	-10.2%
Gambia	-9.8%
Ghana	-12.9%
Guinea-Bissau	-12.1%
Liberia	-12.1%
Mali	-14.9%
Niger	-12.6%
Nigeria	-13.5%
Sao Tome and Principe	-8.4%
Sierra Leone	-9.8%
Togo	-9.1%
Bermuda	-27.0%
Cook Islands	-15.3%
	-20.8%
Greenland	-14.9%
Greenland Guam Monaco	-7.5% +7.3%
Greenland Guam Monaco Nauru	
Greenland Guam Monaco Nauru Niue Northern Mariana Jelanda	-10.2%
Greenland Guam Monaco Nauru Niue Northern Mariana Islands Palau	-10.2% -11.8\% -11.8\% -1
Greenland Guam Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico	-10.2%
Greenland Guam Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino	-10.2% -11.8% -11.8% -8.4% -19.4% -19.4% -17.5% -19.6%
Greenland Guam Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino To kelau	-10.2% -11.8% -11.8% -11.8% -8.4% -19.4% -17.5% -9.9% +0.6% -10.1%
Greenland Guam Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino Tokelau Tuvalu	-10.2% -11.8% -11.8% -11.8% -8.4% -19.4% -17.5% -9.9% -10.1% -10.1% -10.1% -10.1% -10.1% -10.1% -10.1% -10.2% -10.2% -10.1% -10.2%
Greenland Guam Monaco Nauru Niue Northern Mariana Islands Palau Puerto Rico Saint Kitts and Nevis San Marino Tokelau Tuvalu United States Virgin Islands South Surdan	-10.2% -11.8% -11.8% -11.8% -19.4% -19.4% -17.5% -10.1%

Figure S20. Leading ten causes of total deaths with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in males, for all GBD locations.

Causes are ranked based on global estimates of deaths. Causes are color coded (shown in color key) based on the ratio of observed to expected (O:E) rates on that basis of SDI from the epidemiologic transition analysis. Shades of blue represent much lower observed deaths and YLDs than expected levels based on SDI, whereas red shows that observed deaths and YLDs exceed expected levels. When the ratio exceeds 1 means that observed levels exceeded the expected levels on the basis of SDI. O:E ratios are listed in each cell.

Global	1 Ischemic heart disease	2 Total cancers	3 Stroke	4 COPD	5 Lung cancer	6 Lower respiratory infect	7 Alzheimer's disease	8 Chronickidney disease	9 Prosto te sancer	10 Diabetes
Central Europe, Eastern	0.8 Ischemic heart disease	0.88 Total cancers	1.04 Stroke	1.69 Lung cancer	L04 COPD	1 Alzheimer's disease	1 Colorectal cancer	0.97 Prostate cancer	Notes Hypertensive heart disease	0.87 Lower respiratory intest
Europe, and Central Asia Central Asia	2.01 Ischemic heart disease	0.89 Stroke	1.85 Total cancers	COPD	0.91 Hypertensive heart disease	L 08 Cirrhosis	1.15 Lung cancer	0.74 Alzheimer's disease	Stomach cancer	0.57 Diabetes
Armenia	2.48 Ischemic heart disease	1.76 Total cancers	0,85 Stroke	1.31 COPD	2.35 Lung cancer	2,26 Alzheimer's disease	0,91 Cinthosis	1.08 Diabetes	1.42 Hypertensive heart disease	0.78 Prostate cancer
Azerbaijan	1.52 Ischenic heart disease	0.99 Stroke	0.73 Total cancers	1.3 COPD	1.48 Hypertensive heart disease	1.14 Cimbusis	2.58 Stomach cancer	1.02 Lung cancer	1.65 Alzheimer's disease	0.7 Diabetes
Georgia	Ischemic heart disease	1.79 Stroke	Total cancers	0.93 Hypertensive heart disease	Alzheimer's disease	Lung cancer	COPD	0.85 Prostate ianger	1.11 Diabetes	Cirrhosis
Kazakhstan	Ischemic heart disease	Stroke	Total cancers	COPD	Lung cander	Cintosis	Alzheimer's disease	Lower respiratory infect	Stomach cancer	Colorectal cancer
Kyrgyzstan	Ischemic heart disease	Stroke	Total Lancers	COPD	Alzheimer's disease	Cirrhosis	Stomach cancer	Hypertensive heart disease	Long tancer	Prostate cancer
Mongolia	Ischemic heart disease	Total cancers	Stroke	Uyer cancer	Stomach cancer	Lung cancer	Cirrhosis	Total burden related to hep	Excepting and carrier	Total burden related to hep
Tajikistan	Behavić heart disease	Stroke	Total cancers	Hypertensive heart disease	COPD	Lower respiratory infect	Stomach cancer	Diabetes	Cirrhosis 1.41	Alzheimer's disease
Turkmenistan	bchemic heart disease	Stroke	Total concern	Alzheimer's disease	Cirrhosis	Hypertensive heart disease	COPD	Chronizkkinsy diverse	Lung concer	Prostate concer
Uzbekistan	Ischemic heart disease 4.36	Stroke	Total cancers 0.72	Circhosis 2.42	Diabetes	Hypertensive heart disease	COPD	Lower respiratory infect 0.79	Chronic kidney disease 0.85	Lung canter 0.61
Central Europe	lschemic heart disease 1.39	Total cancers 1.03	Stroke 1.62	Lung cancer 1.15	COPD 0.87	Colorectal cancer 1.4	Alzheimer's disease 1.11	Prostate cancer 0.89	Hypertensive heart disease 3.01	Lower respiratory intest (176
Albania	Ischemic heart disease 1.03	Stroke 1.74	Total cancers 0.9	Lung cancer 1.31	COPD 12.7	Alzheimer's disease 1.1	Prostate cancer 0.86	Lower respire tory infect.	Stomach cancer 0.98	Other cardiovascular 2.9.3
Bosnia and Herzegovina	Ischemic heart disease 1.09	Total cancers 1.17	Stroke 1,75	Lung cancer 1.59	Diabetes 2.01	COPD 0.95	Colorectal cancer 1.65	Prostate cancer 0.85	Alzheimer's disease 1.04	Cardiomyopathy 3.6
Bulgaria	lschemic heart disease 1.83	Stroke 2.97	Total cancers 0.91	Hypertensive heart disease 9.43	lung cancer 0.87	COPD 0.87	Colorectal cancer 1.47	Prostate cancer 0,89	Alzheimer's disease 1.08	Other cardi ovasculat 4.89
Croatia	Total cancers 1.14	Ischemicheart disease	Stroke 1.46	Lung cancer 1.1	COPD 1.07	Colorectal cancer 1.68	Prostate cancer 1.07	Alzheimer's disease 1.11	Hypertensive heart disease 2.46	Fails 213
Czechia	Ischemic heart disease	Total cancers 0.95	Stroke 1.03	Lung cancer 0.91	Colorectal cancer 1.21	0.82	Prostate cancer 0.88	Alzheimer's disease 1.12	Lower respiratory infect 0.93	Diabetes 1.54
Hungary	Ischemic heart disease	Total cancers 1.09	Stroke 1.09	Lung cancer 1.21	COPD 118	Colored al cancer 1.72	Hypertonsive heart disease 3.80	Alzheimer's disease 1.08	Prostate cancer 0.86	Diabetes 0.92
Montenegro	3.45	ISChemicheart disease 1.51	1.08	Lung cancer 1.52	Prostate cancer 1.13	6.43	Alzheimers disease	3.87	0.99	L24
North Macedonia	3.81	1.47	1.14 Stroke	1.25	16 Coloradal social	2 Altroimpris disarca	1 Prostate cancer	1	1.33	0.61
Poland	1.16	1.25 Strake	1 Total cancers	1/46	145	1.19	0.98 Alabaimer's disease	0,79 Cardiogramathy	0.98 Colorectal cancer	357 Brostata cancer
Romania	1.4 Ischemic heart disease	2.01 Stroke	0.83 Total cancers	4 1 Lung cancer	0.86	0:85 Colorect al cancer	1.05 Prostate cancer	4.95 Diabetes	1.21 Alzheimer's disease	0,67 Chronic kidney disease
Serbia	1.45 Ischemic heart disease	2.51 Total cancers	1.05 Stroke	1.18 Lung cancer	1.02 Colorectal cancer	1.52 Lower respiratory infect	0.92 Alzheimer's disease	1.38 Prostate cancer	1.02 CDPD	141 Hypertensive heart disease
Slovakia	1.83 Total cancers	1 Ischemicheart disease	1.25 Stroke	0.94 Prostate cancer	1.58 lung cancer	1.28 Alzheimer's disease	1.09 Colorectal cancer	0.85 COPD	0.54 Lower respiratory infect	1.92 Hypertensive heart disease
Fast on Europa	1.02 Ischemic heart disease	G.67 Stroke	0.96 Total cancers	1.21 Lung cancer	0.86 COPD	1.22 Alzheimer's disease	1.14 Colorectal cancer	0.75 Prostate cander	0.99 Stomach cancer	102 Lower respiratory infest
Relarus	2.43 Ischemic heint divense	2.07 Total cancers	CL.78 Stroke	0.83 Lung cancer	0.87 COPD	1.05 Alzheimer's disease	0.97 Prostate cancer	0.66 Colorectal cancer	1.27 Stomach cancer	0.41 Alcohol use disorders
Estonia	2 st Ischemic heart disease	0.86 Total cancers	1.44 Hypertensive heart disease	0.96 Stroke	0.78 Lung cancer	1.04 Prostate cancer	0,76 Alzheimer's disease	1.15 Colorectal cancer	1.33 COPD	Li Li Chronic kidney disease
Latvia	1.54 Ischemic heart disease	1 Total cancers	lti 79 Stroke	0.81 Lung cancer	1.01 Prostate cancer	1.17 Alzheimer's disease	1.16 Colorectal cancer	1 COPD	053 Hypertensive heart disease	1.08 Stomach cancer
Uthuania	I So Ischemic heart disease	Total cancers	Stroke	Lung cancer	Prostate cancer	Alzheimer's disease	COPD	Colorectal cancer	Stomach cancer	Bladder cancer
Republic of Moldova	Ischemic heart disease	Stroke	Total sancers	Hypertensive heart disease 7.51	Alzheimer's disease	0400	Cirrhosis 1 84	Colorectal cancer	Prodate cancer	Ling carrier (151
Russian Federation	Ischemic heart disease	Stroke 2.42	Total cancers	Lung cancer 0.84	COPD	Alzheimer's disease	Colorectal cancer	Prostate tander	Stomach cancer	Lower regulationy infect
Ukraine	Ischemic heart disease	Stroke 1.59	Total cancers 0.74	COPD 0.73	Alzheimer's disease 1.07	Lung cancer 0.75	Colorectal cancer	Prostate cander	Stomach cancer 1.01	Parkinson's disease
High-income	Total cancers 0.85	Nchemicheart disease	Stroke 11.67	Lung cancer 0.87	COPD 1	Alzheimer's disease 1.05	Lower respiratory infect 1.06	Prostate cancer 0.76	Colorectal cancer 0.75	Chronic kidney disease 1.28
Australasia	Total cancers 0.82	Bahlemichean disease	Straine LLS6	COPD 0.97	Prostate cancer 0.93	Lung cancer 0.89	Alzheimer's disease 1	Coloractal cancer 0.73	Chronic kidney disease 1.15	Lower respiratory infert URB
Australia	Total cancers 0.82	Kahvori z neart disease -0.6	Strake U.S/	COPD 0.94	Lung canter 0.7	Prostate cancer 0.92	Alzheimer's disease 1	Colorectal cancer Q.7	Chronic kidney disease 1.17	Diabetes 1.01
New Zealand	Total cancers 0.82	Bohemicheart disease 0.79	Straine di S2	COPD 1.11	Prostate cancer 0.96	Alzheimer's disease	Lung cancer.	Colorectal cancer 0.93	Chronic kidney disease 1.07	Lower regiritury infert 0.53
High-income Asia Padific	O.82	Lower respiratory infect 1.81	5 trinko (1. 78	US3	Ung cander 0.86	Alzheimer's disease 1.32	Stomach cancer 2.1	COPD 0.58	Colorectal cancer 0.68	Chronic kidney disease 1.09
Brunei Darussalam	L 36	1.45	7.99	1.85 Stroke	2.5 Aizhaimar's disasca	4.18	Lung cancer 1.45	4 62 Coloractal cancer	Loopo	101
Japan	0.81 Total cancers	1.82 Stroke	U 33	U.73	1.35	0,83 COPD	2.14 Alzheimer's disease	0,69 Stomach cancer	0.53 Liver capaze	107 Diabetes
Republic of Korea	0.88 Tetal.commy	1.15 Lower respiratory infect	1.03 bohemis neart diverse	0.35 Lung cáncer	153 Stroke	0.91 Al theimer's disease	1.15 COPD	2.04 Colorectal canaer	3.94 Liver cancer	1.84 Chronic kidney disease
Singapore High-income North	U.b Total cancers	3.33 Ischemicheart disease	D.35- COPD	0.71 Lung cancer	GA7 Simila	1.05 Alzheimer's disease	0.55 Prostate cancer	0 85 Chronickidney disease	2.51 Lower respiratory infect	0.91 Coloredal caneer
America	0.8 Total cancers	0.9 Ischemicheart disease	1.3 Lung cancer	0.91 COPD	0.59 Simbe	0.96 Prostate cancer	0.78 Alzheimer's disease	1.66 Colorectal cancer	0.58 Univer resplitatory infect	0.5 f Chronic kidney disease
Greenland	0.79 Total cancers	(1.71 Ischemitheart disease	0.84 Stroke	Lung cancer	COPD	0.84 Lower respiratory infect	0.95 Colorectal cancer	Alzheimer's disease	Fails	1.11 Chronic kidney disease
United States of	14 Total cancers	0.74 Ischemicheart disease	1.22 COPD	2.25 Lung cancer	151 Struke	1,35 Alzheimer's disease	1.5 Prostate cancer	0.97 Chronickidney disease	3,2 Lower respiratory infect	12 Coloreddil canser
America Southern Latin America	0.8 Total cancers	0.93 Rohemicheart disease	1.33 Lower respiratory infect	0.91 Stroke	COPD	0.96 Prostate cancer	0,77 Chronickidney disease	1,73 Lung cancer	0.69 Alzheimer's disease	Colorectal cancer
Argentina	Total cancers	hchemichant disease	Lower respiratory infact	5 mile	COPD	Chronic kidney disease	1,84 Prostate cancer	Lung cancer	Colorectal cancer	Alzheimer's disease
Chile	Total cancers	behumicnicart direase	Stroke	Prostate cancer	COPD	Lower respiratory infect	Chronickidney disease	Alzheimer's disease	Stomach rancer	Lung cunter
Uruguay	Total cancers	Behendensert ührense 17.48	Strike (1.53	COPD 149	Prostate cancer	Lung cancer	Lower respiratory infect	Colorectal cancer	Alzheimer's disease	Chronic kidney disease
WesternEurope	Total canders	Bishemishwart disease 0.65	Stroke 0.68	Lung cancer 0.85	COPD 101	Prostate cancer 0.91	Alzheimer's disease	Lower respiratory infect 0.84	Colorectal cancer 0.87	Chronic kidney disease
Andorra	Total cancers 1.07	Ischemicheart direise 7.53	Lung cancer 0.95	COPD 1.35	Colorectal cancer 1.26	Strake C.D.	Prostate cancer 0.92	Alzheimer's disease 0.98	Lower respiratory infect 0.66	Chronic kidney disease 1.12
Austria	Total cancers IL 76	Ischemicheart disease 0.94	Strowe U.56	Prostate cancer 0.86	Lung Länder Ööl	COPD 0.75	Alzheimer's disease 0,9	Chronickidney disease 1.58	Colorectal cancer 0.7	Diabetes 128
Belgium	Total cancers 0.95	techemichean disease 0.52	Lung cancer 1.11	COPD 1.33	Stroke 0.72	Lower respiratory infect 1.36	Prostate cancer 0.98	Alzheimer's disease 0.94	Colorectal cancer 0.85	Chronic kidney disease 111
Cyprus	Total cancers 0.8	Bchemicheart disease 0.88	Stroke 0.82	COPD 13	Ung cancer 0.81	Distietes 2.83	Prostate cancer 0.99	Chronickidney disease 2.11	Atzheimer's disease 0.96	Colorettal cancer 0.71
Denmark	O.98	U.69	L 53	Stroke 0.92	Ung cancer 0.82	Prostate cancer 1.3	Lower respiratory infect 1.19	Colorectal cancer 0.91	Alzheimer's disease	Diabetes 148
Finland	1.18	101a tantor s (1.74	0.82	0.95	0.65 Destate cancer	0.9 Al facimer's disease	67 Colorected cancer	E SZ	1.48	1.05
France	0.92 Total cancers	2 49 kchemicheart disease	0.53 Stroke	0.84	0.94	0.99 Prostate cancer	0.88 Alzheimer's disease	0.75 Colorectal cancer	0.56 Chronic kidney disease	149
Germany	0.81 Total cancers	1 Ischemicheart disease	0.79 Stroke	U.65 Lung cancer	0.9 COPD	0,89 Al zheimer's disease	0.92 Lower respiratory infect	0,76 Prostate cancer	1.76 Chronic kidney disease	0.72 Coloredal cancer
isoland	0.99 Total campais	0.68 Ischemicheart disease	1.04 Stroke	1.37 Prostate cancer	0.89 Alzheimer's disease	0.92 Lung gancer	0.96 Lower respiratory infect	0.88	1.3 Coloractal cause	0.86 Parkinson's disease
Ireland	0.73 Total cancers	0.9 Ischemicheart disease	COPD	0.99 Stroke	0.95 Lung canoer	0.57 Prostate cancer	0.88 Lower respiratory infect	0.67 Colorectal cancer	057 Alzheimer's disease	1.24 Chronic kidney disease
Israel	0.85 Total cancers	0.87 Isoliterriciteart disease	1.38 Chronic kidney disease	0.59 Stroke	0.73 Alzheimer's disease	1 Diabetes	1.23 Lung sancer	0.8/	0.95 Lower respiratory infect	1.15 Colorectal cancer
Italy	0.79 Total cancers	8 sherisheart disease	2.18 Stroke	Lung cancer	0.9 Alzheimer's disease	L 79 COPD	0 68 Prostate canser	Colorectal cancer	Hypertensive heart disease	0.89 Diabetes
luxembourg	0.94 Tobal cancers	Ischemichean disease	Stroke	1.03 Long concer	COPD	Prostate cancer	Alzheimer's disease	Colorectal cringer	2,09 Lower respiratory intect	1.1 Chronic kidney disease
Malta	Ischemic heart disease	Total cancers	Stroke	Lung cancer	COPD	Lower respiratory infect	Alzheimer's disease	Colorectal cancer	Prostrite cancer.	Diabetes
Monaco	Total cancers	Ischemicheart disease	Lung cancer	Stroke	Lower respiratory infect	Prostate cancer	Colorectal cancer	Alzheimer's disease	COPD 0.76	Bladder cancer
Netherlands	Total cancers	bannmicheart diverse	Lung cancer	COPD 142	Stroke	Prostate cancer	Colorectal cancer	Alzheimer's disease	Lower respiratory infect	Falls 138
Norway	Total cancers (1.77)	bthemitheart disease (1.72	Stroke 0.81	Prostate cancer 1.27	COPD 1.14	Lower respiratory infect 1.11	Lung Lance+	Alzheimer's disease 0.97	Colorectal cancer 0.75	Falls 1.4
Portugal	Total cancers 0.99	Stroke 0.9	Behemieheart rikease 70.35	Lower respiratory infect 1.75	COPD 1.07	Prostate cancer 1.02	Colorectal cancer 1.47	Alzheimer's disease 0.88	Lung cancer 0.78	Chronic kidney disease 1.18
San Marino	Total cancers 1.18	Bchomicheart disease 0.54	Stroke 0.9	Lung cancer 0.91	Prostate cancer 1.15	Colorectal cancer 1.02	Alzheimer's disease 1	Stomach cancer 2.65	COP0 0.56	Lower respiratory infect (167
Spain	Total cancers 0.98	Rehemicheart disease 0.39	COPD 1.56	Strow U a 9	Lung cancer 1.08	Colorectal cancer 1,32	Aizheimer's disease 0,86	Prostate cancer 0,70	Lower respiratory infect 0.68	Chronic kidney disease 1.05
Sweden	1 otal candos 11 74 Total canders	0.88 Ushemisheart disease	St/OKE 0.78 Nityake	1.16 Prostate cancer	Alzheimer's disease 0.91 Alzheimer's disease	UGPD UGS Lung dinger	0.45 COPD	Colonictal candin 0.67 Colonictal candin	0.67 Chronic kidney disease	Chronic kidney disease 0.99 Falls
switzenand	10.66 Total cancers	0.78 Ischemicheart disease	COPD	0.94 Stroke	0.99 Lower respiratory infect	CLES Lung cancer	0.72 Prostate cancer	0.46 Alzheimer's disease	1.28 Colorectal cancer	1.15 Parkinson's disease
omited kingdom	0.96	0.71	1.36	0,7	154	0.9	11	1	0.86	1.08

Latin America and Caribbean	Total cancers	Nchemicteart disease	Stroke 0.95	COPD	Lower respiratory infect	Chronickidney disease	Alzheimer's disease	Prostate cancer	Diabetes	Lime Cahcer
Andean Latin America	Total cancers	Datient charact	Lower respiratory infect	Stroke	Chronic kidney disease	Prostate cancer	Alzheimer's disease	COPD	Stomach cancer	Cirrhosis
Bolivia (Plurinational	Total cancers	behendeneart divense	Lower respiratory infect	8 timber	Chronic Kidney disease	Prostate cancer	COPD	Stomach dancer	Diabetes	Cirriosia
State of)	1.33 Total cancers	0.52 Behvmiensart disease	2.15 Chronickidney disease	0.5.4 Stevice	2.15 Lower respiratory infect	1.79 Prostate cancer	0.96 COPD	2.75 Diabetes	1.16 Alzheimer's disease	194 Stomach cancer
Ecuador	0.87 Total cancers	0 M Retrumicheart disease	2.1/ Lower respiratory infect	4 15 Alzheimer's disease	149	1.18 Prostate cancer	0.81 Chronickidney disease	1.1 Stomach cancer	1.03 Cirrhosis	173 Intertitial long disease
Peru	0.7	0.8	2.15	0.94	0.24	0.94	1.06	1.26	1.37	42.57
Caribbean	1.01	0.7	0.67	Prostate cancer 1.8	Lower respiratory infect 1.15	0.71	Authermen's disease 0.97	1.21	0.91	Chronic kidney disease
Antigua and Barbuda	Total cancers 1.15	Prostate cancer 3.49	Bchemicheart disease	Stroke 0.87	Diabetes 306	Lower respiratory infect 1.68	Chronickidney disease 2.44	Hypertensive heart disease 2.85	Alzheimer's disease 1.03	Stomach cancer 1.12
Bahamas	Total cancers 1.06	Ischemicheart disease	Prostate cancer 3.04	Stroke 0.91	Hypertansive haart disease 715	Diabetes 2.34	Lower respiratory infect	Chronickidney disease	Alzheimer's disease	Coloredal cancer 0.85
Barbados	Total cancers	Prestal e cancer	benemie neart diresse	Stroke	Disisetes	Lower respiratory infect	Alzheimer's disease	Chronickidney disease	Colorectal cancer	Uninary diseases
Belize	Total cancers	benemicheart diresse	Strake	Prostate cancer	Lower respiratory infect	Diabetes	Chronickidney disease	COPD	Alzheimer's disease	Hypertensive heart disease
Bermiida	Total cancers	li da Ischemicheart disease	Prostate cancer	1.69 Strake	147 lung cancer	1.45 Alzheimer's disease	L 32 Colorectal cancer	Diabetes	0.99 Chronic kidney disease	Lower respiratory infect
C.L.	1.09 Total cancers	0.89 Boitemis heart tilseave	2.07 Strmao	U.72 Lower respiratory infect	0.84 Prostate cancer	1.08 Lung cancer	1.01 Alzheimer's disease	1.63 COPD	1.32 Fails	(174 Colorectal cancer
Cuba	1.13 Total cancers	1.54 Prostate cancer	0.54	1.72 Strake	L57	L44 Puranteri live heart dive me	0.97 Chronickidney disease	0.74	3,64	111 Abheimer's disease
Dominica	1.79	5.26	L.53	0.85	274	4.34	2.57	1.65	0.85	101
Dominican Republic	Bichemic heart disease	Total cancers 1.01	Stroke	Prostate cancer	177	Augheimer's disease 0,89	Hypertensive heart disease 1.29	0,83	0.46	Lower respiratory intect
Grenada	Total cancers 1.52	Bahemianeen disease 0.65	Prostate cancer	Stroke 0.86	Diabetes 264	Chronickidney disease 2.44	Lower respiratory infect 2.13	Hypertensive heart disease 1.71	COPD Q 51	Colorectal cancer 1.25
Guyana	Ischemic heart disease	Stroke	Total cancers	Prostate cancer 3.7	Diabetes 251	Hypertensive heart disease	Lower respiratory infect	Chronic kidney disease	COPD	Alzheimer's disease
Haiti	Ischemic heart disease	Total cancers	Stroke	Frostate cancer	COPD	Lower respiratory infect	Diabetes	Hypertensive heart disease	Chronic kidney disease	Alzheimer's disease
Jamaica	Total cancers	Stroke	Ischemic heart disease	Prostate cancer	Diabetes	COPD	Alzheimer's disease	Chronickidney disease	Hypertensive heart disease	Lung cancer
Ruesta Rica	1.09 Total canaeri	0.89 Rehemic heart disease	Diatietes	2.51 Prostate cancer	307 Alzheimer's disease	Chronic kidney disease	0.96 Stroke	L5 COPD	1.87 Lower respiratory infect	0.79 Coloreda) cander
Puerto Neo	0.52 Total cancers	015 Stroke	3 19 Ischemic heart disease	1.05 Prostate cancer	L04 Disbetes	1.97 Chronickidney disease	C.41 Lower respiratory infect	0.78 Hypertensive heart disease	0.7 COPD	Colorectal cancer
Saint Kitts and Nevis	1.34 Total cancers	1.6 Product of contrast	U,78 Stonke	4.05	11 Diabates	1.42	21 Chronickidney disease	3 21 Lower respiratory infect	0.7 Alzheimer's disease	107
Saint Lucia	1.31	3 79	0.85	().4	241	1.06	1.68	1.29	1.02	162
Saint Vincent and the Grenadines	Total cancers 1.33	haneniansart disease 0.35	Finistate cancer 3.42	Stroke 0.7	Diabetes 2.41	Lower respiratory infect 1.32	Hypertensive heart disease 1.91	Chronic kidney disease 1.36	Alzheimer's disease 0.93	0.47
Suriname	Total cancers	Benenik neart Olsease	Stroke 0.87	Prostate cancer 1.82	Chronic kidney disease	Diabetes	Lower respiratory infect	Alzheimer's disease	CORD	Hypertensive heart disease
Trinidad and Tobago	schemic heart disease	Total rangers	Diabetics	Stroke	Prostate cancer	Chronic kidney disease	Alzheimer's disease	Lower respiratory infect	Hypertensive heart disease	COPD
United States Virgin	Total cancers	Ischemicheart disease	Prostate cancer	0.95 Stroke	Diabetes	Chronic kidney disease	0.99 Hypertensive heart disease	Colorectal cancer	Lung cances	Lower respiratory infect
Islands	1.38 Reference on the second	1.56 Total cancers	3.7 Chronic kidney disease	1.07 COPD	315 Strake	2.49 Diabetes	4.67 Alzheimer's disease	1.34 Prostate cancer	0.69 Lower respiratory infert	101 Cinhosis
Central Latin America	U.56	0.71 Total reserves	1.85	0.98 Alzheimer seliterer	9.35 Smile	1.46 Prostate concern	1.08 Chronick kinger die	0,94	0.72 Stomach concer	1.5
Colombia	U.M	1.66	1.02	1.02	927	0.79	0.9	0.45	0.98	Q69
Costa Rica	Total canders. 0.91	banenicheart disease 0.46	0.95	Atzheimer's disease	5 miles 932	Prostate cancer 1.11	L41	Stomach cander 1.75	tower dispiratory infect	Colorectal cancer 0.98
El Salvador	Bisherinis Instart diversion 0.61	Total cancers (L7A	Chronic Kidney disease 2.49	Lower respiratory infect 1.18	Strake 031	Alzheimer's disease 1.07	Prostate cancer 0.97	COPD 0.51	Diabetes 0.9	Stomach cancer 126
Guatemala	Behemic heart disease	Total cancers	Lower respiratory infect	Chronic kidney disease	Simble	Diabetes	Prostate canoer	COPO	Alzheimer's disease	Cirrhosis
Honduras	Ischemic heart disease	Total cancers	Stroke	COPD	Chronic kidney disease	Cinthosis	Alzheimer's disease	Prostate cancer	Lower respiratory infect	Ever cancer
Maulan	1.08 Butternic heart disease	1.03 Total samours	0.91 Diabetes	1.31 Chronic ki dney disease	1.76 COPD	17 Stroke	1.28 Alzheimer's disease	1.11 Cirrhosis	0.58 Prostate cancer	3.89 Lower respiratory infect
MEXICO	0.55 Ischemic heart disarra	U at Total canners	2.16 Chronic Minar displace	2.38	113	0.41 Olabetes	1.12 Prostate carrier	2,22 Cinhosis	0.81 Alzheimer's disease	0.7
Nicaragua	1.13	1.07	1.52	0.56	1	1.53	1.62	1.83	1.12	0.5a
Panama	L 69	U.37	Showe 0.51	Authermer's disease	Prostate cancer 1.09	Linconic xi diney di sease 1.51	Life	9.61	0.72	Lutig carnest
Venezuela (Bolivarian Republicof)	bithemic heart disease 0.74	Total cancers 0.95	Stroke 0.51	Prostate cancer 1.51	Chronic kidney disease 1.5	Diabetes 1.28	COPD 0.72	Alzheimer's disease 1.06	Hypertensive heart disease 1.41	Lower respiratory intest 0.65
Tropical Latin America	Total cancers	Benemit neart disease	Struke	COPD	Lower respiratory infect	Alzheimer's disease	Prostate cancer	Diabetes	Cleonic kidney disease	Lung cancer
Brazil	Total cancers	Benemicheart rikeave	Strake	COPD	Lower respiratory infect	Alzheimer's disease	Prostate cancer	Diabetes	Chronic kidney disease	Lung cancer:
Baraniumi	0.85 Total cancers	12.99 Bohemisheart disease	10.56 Stroke	1.1 Diabetes	1.56 Chronic kidney disease	1.16 COPD	1.06 Alzheimer's disease	1 Lower respiratory infect	0.88 Prostate cancer	(171 Lung cancer
North Africa and Middle	0.85 Ischemic heart disease	0.51 Total rangers	0.6 Stroke	1.47 COPD	L51 Hypertensive heart disease	0.82 Alzheimer's disease	1.1 Chronickidney disease	1.1 Cirrhods	1.08 Lower respiratory infect	0.89 Diabetes
East	12	14.67	0.82	0.87	223	1.14	1,39	2.18	0.78	09
Fast	1.2	Total cancers U.67	0.82	0.87	Avpertensive heart disease 223	Alzheimer's disease	L 39	2.13	0.78	0.9
Afghanistan	I 179	Stroke 1.06	Total cancers 1.08	Conflict & terror 1658.3	Hypertensive heart disease 281	Lower respiratory infect	Chronickidney disease 1.48	COPD 0.72	Alzheimer's disease 1.39	Stomach cancer 202
Algeria	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Alzheimer's disease	Chronic kidney disease	COPD	Lower respiratory infect	Diabetes	Long conter
Bahrain	Ischemic heart disease	Diabetos	Total rancers	Stroke	COPD	Chronic kidney disease	Lung cancer	Alzheimer's disease	Lower respiratory infect	Prostate sancer
	1.06 Ischemic heart disease	R.21 Cirrhosis	0.81 Total sancers	0.67 Stroke	1.14 Total borden related to hep	2.47 Hypertensive heart disease	0.98 Chronickidney disease	1.28 Total burden related to hep	1.06 COPD	(169 Alzheimer's disease
tgypt	1.49 Isothemic beautidicense	9.09	0.42	0.53 Abhaimarta disease	15 A7	2.77	1.58 Chronick Manu disease	9,84	0.76 Stomach.concer	105
of)	0.88	LT7	0.54	1.13	215	0,68	0.97	0.82	1.44	U.56
Iraq	Ischemic heart disease 1.47	Stroke 1.44	Total cancers 0.74	Chronic kidney disease 2,4	Diabetes 1.78	Alzheimer's disease 1.16	Lung cancer 0.93	Hypertensive heart disease 1.34	COPD 0.4	Prostate cancer 0.5
Jordan	Ischemic heart disease 0.74	Total cancers 0.52	Stroke	Diabetes 2.09	Hypertensive heart disease 3.57	Chronic kidney disease 1.99	Alzheimer's disease	Lung cancer	COPD	Lower respiratory infect
Kuwalt	Bchemic heart disease	Total mnours	Stroke	Lower respiratory infect	Alzheimer's disease	Diabetes	Hypertensive heart disease	Chronic kidney disease	Lung bancer	COPD
lebanon	0.92 Ischemic heart disease	Total cancers	1.04 Stroke	2.04 Prostate cancer	1.26 Lung cancer	1.88 Hypertensive heart disease	Alzheimer's disease	1.34 Lower respiratory infect	COPD	Chronic kidney disease
arbandir	1.69 Ischemic heart disease	1.04 Total mnours	11.43 Strake	1.12 Alzheimer's disease	1.13 Hypertensive heart disease	2.67 Chronic kidney disease	1.16 COPD	1.06 Lung cancer	0.71 tower respiratory infect	13 Diabetes
UDya	0.96 Ischanic heart disease	il 35 Stroke	0.71 Total company	1.29	2.33 Chronic kidney disease	1.44	0,66	0.84	0.75	0.78
Morpeco	1.64	1.05	4.57	2.2	137	0.67	1.14	0,69	0,67	0.95
Oman	Ischemic heart disease 2.77	Stroke 1.88	Total cancers	Diabetes 4.57	Lower respiratory infect	Road Injuries	COPD 1.03	Alzheimer's disease 1.41	Orronic kidney disease 1,72	Hypertensive heart disease 2.82
Palestine	Ischemic heart disease	Total cancers	Stroke 1.09	Diabetes 2,47	Hypertensive heart disease 203	Lung cancer 1.6	Chronickidney disease 1.49	Lower respiratory infect 1.04	COPD.	Alzheimer's disease 115
Qatar	Ischemic heart disease	Total cancers	Diabetes	Stroke	Chronic Midney disease	Lung canter	Circlinasis	Road Injuries	Liver cancer	Total bunden related to hep
Saudi Arabia	Ischemic heart disease	Stroke	Total sancers	Chronic ki diney disease	Cinhosis	Lower respiratory infect	Alzheimer's disease	COPD	Diabetes	Total burden related to her
Sudan	1.43 Ischemic heart disease	1.58 Stroke	0 58 Total sancers	4/13 Hypertensive heart disease	3.9 COPD	1.41 Chronic kidney disease	1 31 Alzheimer's disease	0.7 Lower respire tony integt	1.42 Cirrhosis	533 Stomach cancer
Jugan	1.56 Ischemic heart disease	1.02 Stroke	(1.76 Total concern	2.54 Conflict & terror	0.7 Alzheimer's disease	1.05 Chronic kidney disease	1.05	0 El	1.04 Cirrhosis	131 Disbeter
Syrian Arab Republic	1.64	0.73	0.5	Zind 5	114	1.01	0.56	0.75	1.14	051
Tunisia	1.22	0.86	U 63	1.2	197	1.03	0,68	1.23	0.82	0.68
Turkey	Ischemic heart disease 0.85	Total cancers 0.81	Stroke 0.8	COPD 1.64	Lung cancer 1.26	Alzheimer's disease 1.15	Chronickidney disease 1.52	Lower respiratory infect 0.91	Hypertensive heart disease 2.18	Diabetes 121
United Arab Emirates	Ischemic heart disease	Total cantars	Stroke 2.05	Diabates 5.31	Lower respiratory infect	Hypertensive heart disease	Chronickidney disease	COPD	Ling tassee	Road Injuries
Yemen	Bchemic heart disease	Stroke	Total cancers	Hypertensive heart disease	COPD	Lower respiratory infact	Alzheimer's disease	Chronickidney disease	Stomach cancer	Asthma
South Asia	I di Ischemic heart disease	COPD	0.86 Strake	Total sancers	-Diarmeal diseases	Lower respiratory infect	Diabetes	Tuberculosis	Alzheimer's disease	L.54 Chronic kidney disease
South Asia	0.8 Ischemic heart disease	Z.4 COPD	U.St Strake	0.59 Total sancers	7.99 Diamboal diseases	0.87 Lower respiratory infect	0.95 Diabetes	2.89 Tuberculosis	0.83 Alzheimer's disease	(121 Chronic kidney disease
South Asia	0.8 Stroke	2.4 Millionic board citization	0.61 Total causars	COPD	7.99 Diabetes	0.87 Dianteal diseases	0.95	2.89 Tuberculosia	0.83 Alzheimer's disease	0,71 Cighasis
Bangladesh	115	1.9	Lial	1.18	0.92	1.77	0.49	1.23	0.8	8.0
Bhutan	0.92	2.03	LTZ	0.61	1.07	1,71	0.51	C,88	1.11	0.91
India	Ischemić heart disease	26	0.55	Total cancers 0.54	triaminal di seasos 14.3	Lower respiratory infect 0.99	Diabetes 0.93	Tubirnaul osis 3 85	Falls 4.26	Chronic kidney disease 0.75
Nepal	COPD	bchemicheart disease	Stroke 0.79	Total cancers 0.85	Tuberculosis	Lower respiratory infect	Cinhosis	Asthma 2.02	Other malignant neoplasms	Chronic kidney disease
Pakistan	Ischemic heart disease	COPD	Total cancers	Stroke	Diameal diseases	Diabetes	Tuberculosis	Chronickidney disease	kower econicatory infest	Alzheimer's disease
Southeast Asia, East Asia,	1.12 Stroke	Total cancers	0.94 Ischemichwart disease	COPD	Lung cancer	1.36 Stomadi cancer	1.56 Hypertensive heart disease	Lower respiratory infect	Alzheimer's disease	Colorectal cancer
and Oceania	1.65 Stroke	1.07 Total cancers	0.73 Ischemicheart disease	2.59 COPD	L67 Lung cancer	1.85 Stomach cancer	1.9 Hypertensive heart disease	0.98 Biophagesi cancer	0.95 Alzheimer's disease	1.04 Colorectal cancer
Cast Asia	1.74 Stroke	1.14 Total cancars	0.78 Ischemicheart diserve	2.84	1.8	2.17 Stomach catror	2.06 Hypertensive heart illinger	5,18 Esophanial cases	0.95 Alzheimer's disease	105 Colorectal career
China	175	1.15	0.79	2.86	1.83	2.19	2.08	5.32	0.96	105
Republic of Korea	1.81	3.41	0.77	1.05	Ling canter 171	0,87	1.88	1.25	0.81	0.5
Taiwan (Province of China)	Total cancers 0.81	Baheminian disease	Lower respiratory infect	Stroke 0.5	COPD 138	Lung cancer	Diabetes 2.53	Colorectal cancer 1.06	Alzheimer's disease	Chronic kidney disease 174
Oceania	Ischemic heart disease	COPD	Stroke	Diabetes	Total cancers	Diamical diseases	Asthma	Lower respiratory infect	Lung cancer	Prostate cancer
American Samoa	Total cancers	ischemicheart disease	Stroke	Diabetes	COPD	Chronickianey disease	Prostate cancer	Lung cancer	Lower respiratory infect	Alzheimer's disease
Ford Island	1.01 Total cancers	(1.77 Beitemi chwart filsoane	1.02 Diabetes	4/14 Prostate cancer	172 Stroke	3.17 Hypertensive heart disease	1.95 Lower respiratory infect	1.13 Lung cancer	1.02 Chronic kidney disease	COPD
Look Isrands	1 Ischemic heart discourse	U SI	5.58 Stocke	2.49	0.82	7.1 Chronic Mitnau disease	1.95	1.22 Hypertensiste haart diagonal	198 lower respiratory infort	0.84 Prostate concer
Fiji	14	9.21	0.97	0\67	15 44	2.64	12	2.09	1.26	101
Guam	Ischemic heart disease 1, 19	Tobil camages 0.62	Stroke 0.73	Lung cancer 0.9	COPD 095	Alzheimer's disease 0.93	Chronickidney disease 1.69	Prostate cancer 0,7	Diabetes 1.29	Lower near initiary Infect 0.63
Kiribati	Stroke	Ischemicheart disease	Diabetes	Total cancers	COPD	Asthma 7.11	Tuberculosis	Diamheal diseases	Chronic kidney disease	Lower respiratory infect
Marshall Islands	Ischemic heart disease	Stroke	Total cancers	COPD	Diabetes	Lower respiratory infect	Chronic kidney disease	Lung cancer	Prostate cancer	Hypertensive heart disease
Micronesia (Federated	1.17 Ischemic heart disease	1.31 Stroke	Total cancers	1.63 Diabotes	COPD	1.22 Chronic kidney disease	L51 Lower respiratory infect	L 74 Lung cancer	1.34 Prostate cancer	1.5 Hypertensive heart disease
States of)	1.18 Ischemic heart disease	1.38 Stroke	1.16 Total cancers	4.04 Dispetor	204 COPD	2.52 Chronic kidney disease	1.61 Lower respiratory infect	1.8 Lung cancer	1.46 Prostate cancer	1.76 Hypertensive heart disease
Nauru	1.41	144	1.2	89.6	215	2.36	1.89	1.95	1.44	153 Abbalmada di
Niue	1.17	0.96	1.31	5,19	1.8	2.67	1.58	1.37	1.34	1
Northern Mariana Islands	Total cancers 1.12	Schemicheart disease 0.95	Stroke 1.44	Lung cancer 1.82	COPD 183	Diabetes 3.54	Chronickidney disease 3.59	Prostate cancer 1.18	lower respiratory infect 1.38	Alzheimer's disease 104
Palau	Ischemic heart disease	Total cancers	Stroke	Diabotes 4.25	Lower reginitory infect	COPD 2.22	Chronickidney disease	Prostate cancer	Lung cancer	Astirma 9.74
	COPD	ischemicheart disease	Stroke	Disbetts	Total cancers	Diambeal diseases	Asthmu	Lower orspiratory inferr	Lung cancer	Prostate cancer
Papua New Guinea		0.00	1.12	3.35	0.93	211	3.01	V 50	1.77	1.1
Papua New Guinea	2.58 Ischemic heart disease	Stroke	Total cancers	COPD	Diabetes	Lower respiratory infect	Chronickidney disease	Alzheimer's disease	Hypertensive heart disease	Prostant caroor
Solomon Islands	lichemic heart disease 2.19	Stroke 1.97	Total cancers 1.18	COPD 2.27	Lower respiratory infect	Diabetes 2.56	Diarmeal dispases 2.85	Lung cancer 2.29	Asthma 2.43	Prostate cancer 128
-------------------------------------	----------------------------------	----------------------------------	----------------------------------	-----------------------------------	-----------------------------------	-----------------------------------	------------------------------------	------------------------------------	------------------------------------	-----------------------------------
Tokelau	Ischemic heart disease 0.67	Total cancers 0.75	Strake 0.71	Diabetes 2.03	COPD 124	Chronic kidney disease 1,35	Lower respiratory infect 1.06	Alzheimer's disease 0.96	Prostate cancer 0.99	Lung canter 1.15
Tonga	Total cancers 1.32	Ischemicheart disease 0.75	Diabetes 3.85	COPD 1.96	Strake 064	Lower respiratory infect 1.76	Chronickidney disease 1,94	Lung cancer 1.82	Prostate cancer 1.48	Alzheimer's disease 094
Tuvalu	Ischemic heart disease	Stroke 1.07	Total cancers 0.96	Diabetes 2.57	COPD 165	Chronic kidney disease 1.67	Lower respiratory infect 1.34	Prostate cancer 1.29	Lung cancer 1.46	Alzheimer's disease 1
Vanuatu	Ischemic heart disease 1.49	Stroke 1.42	Total cancers 1.06	COPD 1.86	Diabetes 1.69	Lower respiratory infect 0.98	Diarrheal diseases 2.0	Lung cancer 1.75	Chronic kidney disease 1.17	Prostate cancer 1.3
Southeast Asia	Stroke 1.31	hthem/theart disease 0.60	Total cancers 0.78	COPD 1.65	Lower respiratory infect 173	Diabetes 1.25	Lung cancer 1.07	Tuberculusis 7.32	Chronic kidney disease	Alzheimer's disease 0.92
Cambodia	Stroke 1.3	Ischemicheart disease 0.87	Total cancers 1.23	Lower respiratory infect 2.17	COPD 1.21	Tuberculosis 2.81	Lung cancer 2.25	Cinhosis 1.94	Upper digest diseases 4.46	Diabetes 0.93
Indonesia	Stroke 1.73	Ischemicheart obease (1.73	Total cancers XL78	COPD. 2	Diarriteal diseases 52.59	Diabetes 1.5	Tober culosis 14 37	Cinnosis 2.86	Lung cancer 1.12	Hypertensive heart disease 203
Lao People's Democratic Republic	Stroke 15	Ischemicheart disease	Total cancers 0.94	COPD 1.54	Lower respiratory infect 142	Tuberculosis 2.69	Chronickidney disease 1.32	Lung cancer 1.68	Diabetes 0.92	Asthma 2.19
Malaysia	Ischemic heart disease	Lower respiratory infect	Total cancers	Stroke 1.05	COPD 13	Lung cancer	Alzheimer's disease	Chronickidney disease	Colorectal cancer	Cirrhosis 1.51
Maldives	Ischemic heart disease 0.79	Stroke	Total cancers	COPD 0.95	Chronic kidney disease 1.25	Alzheimer's disease 0.91	Diabetes	Lower respiratory infect	Lung cancer 0.75	Prostané panoén
Mauritius	Bahamic meant disease	Diabetes A.R.	Total sancers	Stroke 0.8	Chronic Milmey disease	COPD 0.97	Hypertensive heart disease 2.18	Lower respiratory infect	Alzheimer's disease	Prostate cancer
Myanmar	Stroke	COPD 2.57	Total cancers	Ischemik heart illsenise	Diabetes	Lower respiratory infect	Asthma	Tuberculosis	Lung cancer	Hypertensive heart disease
Philippines	Ischemic heart disease	Stroke	Lower respiratory infect	Total sancers	COPD	Chronic kidney disease	Hypertensive heart disease	Tuberculosis	Diabetes	Alzheimer's disease
Seychelles	Total cancers	Indiemisheart disease	Lower respiratory infect	Stroke	Prostate cancer	COPD	Hypertensive heart disease	Chronickidney disease	Lung cancer	Coloredal cancer
Sri Lanka	Ischemic heart disease	Stroke	Total cancers	Diabetes	Astima	COPD	Chronickidney disease	Lower respiratory infect	Alzheimer's disease	Hypertensive heart disease
Thailand.	Total cancers	Mohemichean disease	Stroke	Lower respiratory infect	COPD	Lung cancer	Aizheimer's disease	Chronickidney disease	Liver campor	Diabetes
Timor-Leste	Stroke	Ischemicheart disease	Total cancers	COPD	Lower respiratory infect	Tuberculosis	Diartheal diseases	Chronickidney disease	Lung cancer	Hypertensive heart disease
VietNam	Stroke	bahemicheart disease	Total cancers	COPD	Lower respiratory infect	Tubertulosis	Diabetes	Lung cancer	Alzheimer's disease	Chronic kidney disease
Sub-Saharan Africa	Total cancers	Ischemicheart disease	Stroke	Lower respiratory infect	Tuberculosis	Diarrheal diseases	COPD	Diabetes	Prostate cancer	Chronic kidney disease
Central Sub-Saharan	Stroke	Lower respiratory infect	Total cancers	1.58 Ischemic heart disease	Tuberculosis	COPD	Diarrheal diseases	Diabetes	1.04 Hypertensive heart disease	Prostate cancer
Africa	0.98 Stroke	1.38 Total cancers	1 Isthemicheart disease	Lower respiratory infect	7.78 Tuberculosis	0.94 Diamheal diseases	2,24 Diabetes	L58 Cirrhosis	1.81 Prostate cancer	COPD
Central African	1.06 Tuberculosis	0.09 Olamina I diseases	Stroke	2.14 Lower respiratory infect.	167 Ischemic heart disease	3,79 Total cancers	1.71 COPD	Z Diabetes	1.55 Hypertensive heart disease	Chronic kidney disease
Republic	Z-98 Total cancers	2 Stroke	1.21 Dehemicheett disease	1.54 Lower respiratory infect	0.92 Diabetes	1.07 Tubarculosis	1.21 Diambaal diseases	1.67 COPD	2.17 Prostate cancer	127 Hypertensive heart disease
Democratic Republic of	1.03 Lower respiratory infact	0.96 Stroke	Total cancers	2.66 Uschumic heart disease	179 Tuberculosis	COPD	14 51 Diamheal diseases	0,9 Diabetes	1.52 Hypertensive heart disease	1.91 Prostate cancer
the Congo	19 Total cancers	0.95 Stroke	0.96 Lower respiratory infect	0.66 Dahemik hepri illienie:	2.5 Diabetes	1 Prostate cancer	1.75 COPD	1.46 Chronic kidney disease	1.82 Malanta	135 Tuberculosis
Gabon	0.97 Total cancers	0.96 Ischemichnart disease	3 79 Stroke	0.4a lower respiratory infect	3.07 Diabetes	1.53 Prostate cancer	1.15 Chronickidney disease	2.02 Tuberculosis	R517 Hyportonsive heart disease	13.62 COPD
Eastern Sub-Saharan	1.12 Stroke	d 98 Ischemicheart disease	1.02 Total cancers	3.89 Lower respiratory infect	131 Tuberculosis	1.62 Diarrheal diseases	2.14 COPD	15.35 Diabetes	2.75 Cirrhosis	1 Chronic kidney disease
Africa	0.94 Stroke	0.66 Ischemicheart disease	0.91 Tuberculosis	1.45 Lower respiratory infect	L69 Total cancers	1.7 Diamheal diseases	0.79 COPD	1.37 Diabetes	1.51 Prostate cancer	1.04 Chronic kidney disease
Company	0,96 Bichemit beart disease	0.81 Total cancers	1.66 Stroke	1.19 Lower respiratory infect	0.91 Tuberculosis	1.24 COPD	1.05 Diarmeal diseases	1.16 Diabetes	1.24 Prostate cancer	0.93 Chronic kidney disease
Compros	U IS- Total cancers	0.89 Ischemicheart disease	0.8 Stroke	1.61 Lower respiratory infect	2.56 Tuberculosis	0.73 Diabetes	2.49 Prostate cancer	1.25 Diartheal diseases	1.35 COPD	1.02 Chronic kidney disease
Dipouti	1.06 Lower respiratory infect	0.74 Stroke	0.93 Tubergilosis	1.85 Ischemic heart disease	2.5 Total cancers	1.51 Diamteal diseases	1.59 COPD	2.25 Diabetes	0.58 Cirihosis	1.13 Prostate cancer
Entrea	2.62 Stroke	1.02 Lower respiratory infect	A 132 Noticemil heart disease	0.75 Total saucers	0.95 Diambeal diseases	3.85 Tuberculosis	0.9 Cirrhosis	1.38 COPD	1.56 Diabetes	1.35 Chronic kidney disease
Ethiopia	(1.74 Stroke	1.29 Lower respiratory infed	U.SI Total cancers	0.69 Ischemic heart nilware	1.72 Diamheal diseases	1.11 Toberbulcsis	1.75 Cinhosis	0.13 - COPD	1.31 Diabetes	1.05 Prostate cancer
Kenya	0.98 Ischemic heart disease	2.52 Stroke	0.88 Lower respiratory infect	0.53 Total cancers	557 Tuberculosis	3 99 COPD	2.48 Diambeal diseases	0.88 Hypertensive heart disease	1.36 Diabetes	131 Cimbosis
Madagascar	0.94 Stroke	1.19 Total cancers	138	G 72	2.21 Tuberrulosis	11 Diamboal diteases	1,75 Diabates	1.88	0.96 Circhosis	1.12 Chronic kidney disease
Malawi	1.02 Stroke	1.03	1.67	1.66	194 Total cancer	2 38 Diabatas	1.56 Narthaal diseases	0.77	1.71 Monortangius heart disease	111
Mozambique	148	2.39	0.84	1.38	0.97	17	104	0.75	1.87	449
Rwanda	0.98	1.04	0.57 kohoni ohaat disaxa	1.6	103	2.03	146	2.03	1.51	155
Somalia	(Lee	1.02	L 07	0.2	097	0 32.	1.06	13	0.96	164
South Sudan	1.78	0.92	Le.	271	Lower respiratory intect 1.24	2.07	0.75	1.21	135	L05
Uganda	1.42	0.93	D 53	Lower respiratory intect 1.58	2.53	2.71	0.96	Lis8	1.89	L18
Tanzania	Ischemic heart disease	0.93	1.03	Lower respiratory intect 1.46	2.13	2 18	1.33	Prostate cancer 1,48	0.55	Chronic kidney disease
Zambia	Stroke 1.47	Total cancers 1.09	This heart disease	Lower respiratory infect 2.11	Tuberculosis 452	Diabetes 1.67	2.43	0,83	Hypertensive heart disease 2.29	Diambeal diseases 3.0
Southern Sub-Saharan Africa	Total cancers 1.03	D.52	Stroke 0.77	Lower respiratory infact 2.55	Diabetes 2.5	COPD 1.37	Prostate cancer 1.8	Tuberadusis 9 Bi	Chronic kidney disease 1.75	Diamheal diseases 11.36
Botswana	Total cancers 12	ischemicheart disease (1.71	Stroke 1.14	Lower respiratory infect 3.37	Dianetes 3.15	COPD 1.86	Prostate cancer 2.14	Chroniskidney disease 1.92	Tuberculosia 10.01	HIV/AIDS 38(2)
Eswatini	Total cancers 1.59	Diabetes A 34	Stroke 1.13	US3	Lower respiratory infect. .296	COPD 19	Chronickidney disease 2.79	Tubercuicsès 9.60	Prostate cancer 2.28	Diarmeal diseases 21.04
lasotho	Total cancers 1.64	Stroke 1.37	Tubernafosis 8.76	COPD 2.11	Ischemic heart disease 067	Lower respiratory infect. 2.72	Diamheal diseases 10.94	Diabetes. 3,24	Prostate cancer 2.6	Chronic kidney disease 2.15
Namibia	Stroke 1.19	ischemicheart disease 0.69	Total cancers 0,89	Lower respiratory infect 3 89	COPD 2	Diabetes 2 31	Prostate cancer 1,77	Diartheal diseases 30,58	Tuberculus/s 9.29	Chronic kidney disease 1.58
South Africa	Total cancers 0.96	lichemicheart Gisease	Stroke 0.72	Diabetes 2.66	Lower respiratory infect. 243	COPD 1.45	Prostate cancer 1.66	Chronickidney disease 1,76	Hypertensive heart disease 2.04	Tuberculosis 12.09
Zimbabwe	Total cancers 1.47	Ischemic heart disease 0.88	Tubercalosis 7.89	Lower respiratory infact 2.73	Stroke 0.77	Prostate cancer 2.85	Diarrheal diseases 4.65	Chronic kidney disease 1.54	COPD 0.66	Diabetes 1.2
Western Sub-Saharan Africa	Ischemic heart disease (1.73	Total cancers 1.03	Struke (1.78	Lower respiratory infect 1.49	Prostate cancer 199	Malaria 1622	Tuberculosis 1.48	Diamheal diseases 1.76	0.65	Diabetes 1.18
Benin	Ischemic heart disease 0.81	Stroke 0.96	Total cancers 1.1	Lower respiratory infect 1.53	Malaria 12.7	Diarrheal diseases 1.31	Tuberculosis 0.99	COPD	Prostate cancer 1.58	Chronic kidney disease 1.19
Burkina Faso	Ischemic heart disease 1.17	Lower respiratory infect 1.32	Total cancers 1.09	Stroke 0.71	Diarrheal diseases 0.88	Malaria 5,52	Tuber culosis 0.65	Diabetes 1.17	Prostate cancer 1.5	Chronic kidney disease 103
Cabo Verde	Total cancers 2.16	Ischemicheart disease	Stroke 0.94	Lower respiratory infect. 2.35	Prostate cancer 3.33	Stomach cancer 3.14	Chronickidney disease 1.26	Alzheimer's disease 0.96	COPD	Diabetes 1.01
Cameroon	Total cancers	Ischemicheart disease	Stroke 0.92	Lower respiratory infect	Malaria 423.2	Diabetes 15	Prostate cancer	Chronic kidney disease	Tuberculosis 2.44	COPD U65
Chad	Ischemic heart disease	Lower respiratory infect	Total cancers	Stroke 0.81	Diantheal diseases	Tuberculosis	COPD 0.72	Prostate cancer	Chronic kidney disease	Diabetes 0.82
Côte d'ivoire	bchemic heart disease	Total cancers	Lower respiratory infect	Stroke	Malarta 55.91	Tuberculosis	Prostate cancer	Chronickidney disease	COPD	Diabetes
Gambia	Ischemic heart disease	Lower respiratory infect	Stroke 0.88	Total cancers	Tuberculosis	COPD	Chronickidney disease	Diamheal diseases	Liver cancer 7.35	Diabetes
Ghana	Lower respiratory infect	Total cancers	Ischemicheart disease	Stroke	Tuberculosis	Prostate cancer	COPD	Diabetes	Malana as a po	Chronic kidney disease
Guinea	Total cancers	Lower respiratory infect	Ischemic heart disease	Stroke	Tuberculosis	Diantheal diseases	Prostate cancer	COPD	Liver cancer	Chronic kidney disease
Guinea-Bissau	Ischemic heart disease	Lower respiratory infed	Total cancers	Stroke	Tuberculosis	Diambeal diseases.	COPD	Chronickidney disease	Prostate cancer	Diabetes
Uberia	1.12 Ischemic heart disease	2.18 Total cancers	1.24 Stroke	Lower respiratory infect	1.8 Malaria	Diamheal diseases	0.91 Tuber culosis	Prostate cancer	1.66 Chronic kidney disease	L24 Diabetes
Mali	schemic heart disease	0.99 Stroke	(L/ Total cancers	1.24 Diarrheal diseases	18 3 Tubersulosis	1.27 Lower peoplitatory infect	LOS COPD	1.48 Chronickidney disease	1.07 Alzheimer's disease	0.91 Diabetes
Mauritania	0.87 Ischemic heart disease	0.8 Total cancers	0.94 Lower respiratory infect	1.27 Struke	067 Malatia	Prostate cancer	Diameat diseases	0.97 Alzheimer's disease	1.08 Chronic kidney disease	077 Diabetes
Niger	lischemic heart disease	0.92 Lower respiratory infect	1.78 Stroke	Total cancers	01armeat diseases	1.45 Malaria	7.097 Tuberculanti	LOS COPD	0.99 Prostate cancer	0.88 Chronic kidney disease
Nigeria	0.95 Total cancers	0.81 banemichast disease	0,74 Stroke	0.95 Lower respiratory infect	0.51 Prostate cancer	2.65 Malaria	Diameal diseases	0,68 Tulsenaviosis	1.35 Diabetes	0.94 COPD
San Toma and Brinder	0.99 Bchemic heart disease	U.sa Total cancers	0.75 Lower respiratory infect	1.48 Stroke	2.45 COPD	604.77 Chronic kidney disease	4.34 Cirrhosis	3.29 Prostate cancer	1.28 Lung cancer	1039 Falls

Senegal	Bichemic heart disease	Total cancers	Strake	Lower respiratory infect	Diarriteal diseases	Prostate cancer	COPD	Chronickidney disease	Mataria	Tuberculosis		
Serregar	0.8	1.12	0.72	1.15	197	1.74	0.86	1.27	16.19	1.12		
Sierra Leone	Ischemic heart disease	Lower respiratory infect	Total cancers	Strake	Diarmeal diseases	Malaria	Tuberaulosis	COPU	Prostate cancer	Chronic kidney disease		
	0.87	1.54	0.98	10.22	2.03	12.7	1	2.64	1.43	0.93		
7. in	Ischemic heart disease	Total cancers	Lower respiratory infect	Stroke	Malaria	Tuberculosis	Diarrheal diseases	COPD	Prostate cancer	Chronic kidney disease		
1080	1	1.11	2.21	0.89	52.27	2.1	2.18	0,79	1.65	119		
Values shown in brackets rep.	/alues shown in brackets represent the ratio of observed deaths to predicted deaths on the basis of Socio-Demographic Index (SDI), rounded to two (2) digits. Color ranges (shown below) were calculated to place a roughly equal number of cells into each bin.											
COLOR KEY:	0.000.651	(0,65,0,78)	(0.78,0.9)	[0.9,0,99]	[0.99,1.09)	[1.09, 1.25]	[1.25,1.5]	[1.5, 1.87]	[1.87,2.69]	[269,]		

Figure S21. Leading ten causes of total deaths with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in females, for all GBD locations.

Causes are ranked based on global estimates of deaths. Causes are color coded (shown in color key) based on the ratio of observed to expected (O:E) rates on that basis of SDI from the epidemiologic transition analysis. Shades of blue represent much lower observed deaths and YLDs than expected levels based on SDI, whereas red shows that observed deaths and YLDs exceed expected levels. When the ratio exceeds 1 means that observed levels exceeded the expected levels on the basis of SDI. O:E ratios are listed in each cell.

	1	2	3	4	5	6	7	8	9	10
Global	0.82	Stroke 0.92	Total cancers 0.89	2.12	Alzheimer's disease	Lower respiratory infect 0.99	Hypertensive heart disease 1.15	Diabotes 0.79	Chronic kidney disease 1.02	Diarrheal diseases 5:39
Central Europe, Eastern	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Hypertensive heart disease	Colorectal cancer	COPD	Breast cancer	Diabetes	Cardiomyopathy
Europe, and Central Asia	2.17 Ischemic heart disease	1.83 Stroke	0.79 Total cancers	0.97 Hypertensive heart disease	1.4 Alzheimer's disease	COPD	0.72 Cirrhosis	D.7E Diabetes	Lower respiratory infact	2.44 Chronic kidney disease
Central Asia	2,44	1.56	0.83	1.81	1	1.5	2.78	0.71	0,58	0.6
Armenia	Ischemic heart disease 1.69	Stroke D.79	Total cancers 0.98	Alzheimer's disease 1.04	1.83	Diabetes 1.21	Hypertensive heart disease 1.45	Girrhosis 3.65	Uninary diseases 5.19	Breast cancer 1.09
Azerbaijan	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Cirrhosis	Alzheimer's disease	COPD	Diabetes	Stomach cancer	Chronic kidney disease
	1.27 Ischemic heart disease	2.02 Stroke	0.87 Hypertensive heart disease	2.52 Total cancers	4.66 Alzheimer's disease	1.07 Diabetes	1.35 COPD	0.8 Breast cancer	Lower respiratory infact	0.98 Atrial fibrillation
Georgia	1.29	1.54	4.22	0.71	0.98	0.7	0.64	0.99	eis,o	1.05
Kazakhstan	Ischemic heart disease	Stroke 2 M	Total cancers	COPD	Alzheimer's disease	Diabetes	Cirrhosis 2.75	Lower respiratory infect	Hypertensive heart disease	Cardiomyopathy 2.94
Kurmutetan	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	COPD	Hypertensive heart disease	Cirrhosis	Colorectal cancer	Stomach cancer	Lower respiratory infect
NAIRASSOUL	1.99	0.77	0.67	0.99	1.52	0.52	1.37	0.73	0.83	0.22
Mongolia	1.49	2.35	1.3	32.42	16.05	5.49	0.98	3.07	13.24	8.94
Tajikistan	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Alzheimer's disease	COPD	Lower respiratory infect	Diabetes	Cirrhosis	Stomach cancer
	2.86 Ischemic heart disease	1.52 Stroke	1 Total cancers	2.24 Alzheimer's disease	1 Hypertensive heart disease	1.05 Cirrhosis	0.73 COPD	0.65 Diabetes	1.86 Etiropic kitoev disease	1.89 Atrial fibrillation
Turkmenistan	2.03	1.07	0,49	0.98	0.89	1.98	0.5	0.3	0.48	0.87
Uzbekistan	Ischemic heart disease	Stroke	Total cancers	Diabetes	Hypertensive heart disease	Circhosis	Alzheimer's disease	COPD	Chronickidney disease	Lower respiratory infect
Control Europa	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Hypertensive heart disease	Colorectal cancer	Cardiomyopathy	Diabetes	Breast cancer	COPD
central corope	1.52	1.58	0.96	1.01 Alabeironia diserva	25	1.09	3.58 Others configuration	0.91	0.98	0,77
Albania	1,53	0.92	0.72	1.04	0.68	0.46	2.17	1.11	0,49	0.68
Bosnia and Herzegovina	Ischemic heart disease	Stroke	Total cancers	Diabetes	Alzheimer's disease	Colorectal cancer	Cardiomyopathy	COPD	Hypertensive heart disease	Breast cancer
	1,55 Ischemic heart disease	1.95 Stroke	1.14 Hypertensive heart disease	2.3/ Total cancers	0.98 Alzheimer's disease	1.24 Colorectal cancer	4.45 Diabetes	COPD	1.01 Breast cancer	1.14 Other cardiovascular
Bulgaria	2.02	2.85	7.36	0.83	0.99	1.11	0.93	0.87	0.96	2.83
Croatia	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Hypertensive heart disease	Falls 2.87	Colorectal cancer	COPD 0.95	Breast cancer	Diabetes
Crechia	Ischemic heart disease	Total cancers	Stroke	Alzheimer's disease	Diabetes	Lower respiratory infect	Colorectal cancer	Breast cancer	COPD	Lung cancer
Caecina	1.66 Instantis heart discuss	0.95	1.07	1.02 Alsheimerik disease	1.47	0.87	0.97	0.91	0.79	0.95
Hungary	1.67	1.06	1.01	1.01	3,18	1.22	1.26	1.52	1.01	0.86
Montenegro	Stroke	Ischemic heart disease	Total cancers	Cardiomyopathy	Alzheimer's disease	Diabetes	Breast cancer	Lung cancer	Atrial fibrillation	Colorectal cancer
	3.94 Stroke	1.38 Ischemic heart disease	0.91 Total cancers	9.4 Hypertensive beart disease	1.07 Diabetes	1.22 Alzheimer's disease	1.17 Cardiomyopathy	1.29 COPD	2.13 Breast cancer	0.81 Colorectal cancer
North Macedonia	4.46	1.74	1.13	5.05	2.63	1.07	6.57	1.2	1.34	1.25
Poland	Ischemic heart disease	Total cancers	Stroke	Alzheimer's disease	Colorectal cancer	Cardiomyopathy	Hypertensive heart disease	Lower respiratory infect	Lung cancer	Breast cancer
Romania	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Alzheimer's disease	Cardiomyopathy	COPD	Colorectal cancer	Breast cancer	Lower respiratory infect
ine ing ing	1.55	1.99 technolic hand di	0.76	3.35	0.97	5.4 Alzbeimert die	0.76	0.85	0.81	000
Serbia	3.47	2	1.16	3.03	1.79	D.93	6.06	1.51	1.21	1.09
Slovakia	Ischemic heart disease	Total cancers	Stroke	Alzheimer's disease	Lower respiratory infect	Colorectal cancer	Hypertensive heart disease	Breast cancer	Diabetes	Chronic kidney disease
4	Z.19 Total cancers	0.92 Ischemic heart disease	1.13 Stroke	1.02 Alzheimer's disease	1.06 Hypertensive heart disease	1.15 Cardiomyopathy	1.5 Lower respiratory infect	0.95 Falls	Colorectal cancer	0.77 Breast cancer
Slovenia	0.88	0.6	0.78	1.04	2.82	5.69	0.78	1.69	0.87	0.98
Eastern Europe	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Colorectal cancer	COPO	Breastconcer	Hyperanasive heart disease	Cardiomyopathy	Atrial fibrillation
Belanis	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Colorectal cancer	COPD	Stomach cancer	Atrial fibrillation	Breast cancer	Alcohol use disorders
SALIDIUS	2.58	1.3	0.54 Total and	0.97	0.83	0.56	1.08	0.88	0,51	\$1,65 Ramonali
Estonia	1.63	Rypertensive heart disease 8.44	0.88	0.72	1.01	0.98	1.29	0.74	0.73	1.04
Latvia	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Hypertensive heart disease	Colorectal cancer	Breast cancer	Diabetes	Pancreatic cancer	COPD
	2.04 Ischemic heart disease	. 2.02 Stroke	0.8- Total cantorn	0.94 Alzheimer's disease	1.75 Colorectal cancer	0.88 Breast concer	0.76 Hyportensive heart disease	0,62	1.01 Pancreatic cancer	D.42 Atrial fibrillation
Lithuania	2.56	1.47	0.71	0.98	0.74	0.63	0.89	0,47	0.8	0.79
Republic of Moldova	Ischemic heart disease	Stroke	Total canses	Alzheimer's disease	Hypertensive heart disease	Cirrhosis	COND	Colorectal cancer	Bhrast cancer	Atrial fibrillation
Durrise Enderstion	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Colorectal cancer	COPD.	Breast cancer	Hypertensive heart disease	Diabetes	Cardiomyopathy
Russian Federation	2.27	2.4	0.7	0.93	0.9	0.62	0 đã	0.79	0.63	1.98
Ukraine	3,24	1.45	Total cancers i 0.57	Alzheimer's disease 0.97	Colorectal cancer 0.75	0,54	Atrial fibrillation	Breast cancer 0.65	Cardiomyopathy 2.11	0.74
High-income	Total cancers	Inchemic heart disease	Alzheimer's disease	Stroke	Lower respiratory infect	COPD	Lung cancer	Chronic kidney disease	Colorectal cancer	Hypertensive heart disease
	0.91 Total cancers	0.62	1.05 Alzheimer's disease	0.67 Stool/a	0.97	1.24	1.2 Colorectal concer	1.31 Chronic kidney disease	0.83	1.1 Atrial fibrillation
Australasia	0.91	D.64	1.04	0.65	1.33	1.19	0.87	1.23	D.65	1.48
Australia	Total cancers	Ischemic heart disease	Alzheimer's disease	Stroke	COPD	Lung cancer	Chronic kidney disease	Colorectal cancer	Lower respiratory infect	Atrial fibrillation
New Zealand	Total cancers	Ischemic heart disease	Stroka	Alzheimer's disease	COPD	Colorectal cancer	Lung cancer	Lower respiratory infect	Atrial fibrillation	Breast cancer
New Zealand	0.97	8.0	0.76	1.05	1.6	1.13	1.35	0,76	1.5	0.86
High-income Asia Pacific	Total cancers 0.76	Alzheimer's disease	Stroke 0.65	lischemic heart disease 0.34	Lower respiratory infect	Cotorectal cancer 0.75	Lung cancer 0.88	Chronic kidney disease 1.03	Stomach cancer 1.63	Pancreatic cancer 0.92
Brunei Darussalam	Total cancers	Ischemic heart disease	Stroke	Diabetus	COPD	Lower respiratory infect	Lung cancer	Chronic kidney disease	Alzheimer's disease	Colorectal cancer
	1.46 Total ranges	1.26 Alzheimer's disease	1.43 Stroke	6,03 Ischemic bear disease	3.14 Lower respiratory infect	3:13 Colorectal cancer	2.62 Chronic kidney disease	3,19 Lunx cancer	1.11 Stomach cancer	1.47 Papermatic ranger
Japan	0.76	1.24	0.6	U.SZ.	1.09	0.76	1.02	0.87	1.63	0.95
Republic of Korea	Total cancers	Stroke	Ischemic heart disease	Alzheimer's disease	Lower respiratory infect	Diabetes	Lung cancer	Colorectul cancer	COPD	Hypertensive heart disease
	Total canpers	Lower respiratory infect	Ischemic heart disease	1.1 Alzheimer's disease	1.25 Stroke	Lung cancer	Colorectal cancer	Chronic kidney disease	Hypertensive heart disease	1.45 Urinary diseases
Singapore	0.67	3.09	0.52	1	0,49	0.97	0.81	1.21	1.08	2.54
America	0.95	0.88	Alzheimer's disease	Jin	2.03	1.82	Lhronic kidney disease	Lower respiratory Infect 0.75	Breast cancer 0.89	0.71
Canada	Total cancers	Ischemic heart disease	Alzheimer's disease	Stroke	Lung cancer	COPD	Lower respiratory infect	Colorectal cancer	Breast cancer	Falls
	0.95 Total cancers	0.71 Ischemic bean disease	0.95 Stroke	COPD	1.66	1.41 Alzbeimer's disease	0.79 Colorectal cancer	0.81 Lower respiratory infect	0.92 Falls	1.29 Pancreatic cancer
Greenland	1.77	0.66	1.01	3,98	4.67	1.03	1.91	1.31	4.01	2.64
United States of	Total cancers	Ischemic heart disease	Alzheimer's disease	Stroke	COPD	Lung cancer	Chronic kidney disease	Lower respiratory infect	Breast cancer	Colorectal cancer
Couthorn Latin America	Total cancers	Iszbernic heart disease	Lower respiratory infect	Strake	Alzheimer's disease	Chronic kidney disease	COPD	Hypertensive heart disease	Colorectal cancer	Breast cancer
Southern Laun America	1.2	0.48	2.69	0.52	0.95	1.77	1.38	1.24	1.32	1.38
Argentina	1.21	U.53	3.38	0.47	0.96	1.47	1.81	1.24	1.59	1.4
Chile	Total cancers	Stroke	Ischemic heart disease	Alzheimer's disease	Lower respiratory infect	Chronic kidney disease	COPD	Hypertensive heart disease	Diabetes	Colorectal cancer
	1.13 Total rancers	0.63 Strake	1 58 Ischemic heart disease	0.93 Alzheimer's disease	1.27 Lower respiratory infect	1.87 Colorectal captor	1.21 COPD	1,44 Breast cancer	1.06 Chronic kidney disease	1.01 Hypertensive heart disease
oruguay	1.43	0,66	10.59	0.95	1.38	1.86	1.14	1.76	1.06	0.83
Western Europe	Total cancers 0.95	Distremic heart disease	Stroke 0.71	Alzheimer's disease	COPD 1.18	Lower respiratory infect 0.89	hypertensive heart disease 1.48	Colorectal cancer 0.92	Chronic kidney disease 1.25	Breast cancer 1.06
Andorra	Total cancers	ischemic heart disease	Alzheimer's disease	Stroko	Falls	Hypertensive heart disease	Lower respiratory infect	COPD	Chronic kidney disease	Colorectal cancer
	0.8 Ischemic heart disease	Total cancers	0.97 Alzheimer's disease	Stroke	2.16 Hypertensive heart disease	2/21 Chronic kidney disease	COPD	1.11 Breast cancer	1.37 Diabetes	Cardiemvosorhy
Austria	0.98	0.83	0.95	0.55	2.33	2,06	0.84	0.99	1.19	2.85
Belgium	Total cancers 0.96	Ischnmic heart disease	Stroke 0.73	Alzheimer's disease	Lower respiratory infect 1.39	L 32	Breast cancer 1.24	Colorectal cancer 0.94	Chronic kidney disease 1.33	Falls 1.5
Cyprus	Total cancers	Ischemic heart disease	Stroke	Qiabetes.	Alzheimer's disease	COPD	Chronic kidney disease	Hypertensive heart disease	Breast cancer	Nonrheum valv diseases
	0.9 Total cancers	0.99 Ischemic heart disease	1.1 Stroke	1-29 COPD	1.05 Alzheimer's disease	1.69 Lung cancer	2.41 Lower respiratory infect	2.43 Colorectal cancer	1.2 Breast cancer	Diabetes
Denmark	1.13	0.69	0.85	2.48	0.93	1.73	1.3	1.12	1.24	1.24
Finland	Ischemic heart disease	Total cancers	Stroke	Alzheimer's disease	Hypertensive heart disease	Breast cancer	Colorectal concer	Lung cancer	Falls	Pancreatic cancer
France	Total cancers	Alzheimer's disease	lichemic heart disease	Stroke	Lower respiratory infect	Colorectal cancer	Falls	Breast cancer	COPD	Chronic kidney disease
- and the	0.9 Ischemichent diagon	1.03	D.B.	R.52 Alzhalmar's discours	0.8	0.91	1.61	1.06	0.61 Broast control	D.75
Germany	1.05	0.91	0.ST	0.95	3.15	2.18	1.07	0.9	1.07	D.64.
Greece	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Lower respiratory infect	COPD	Chronic kidney disease	Hypertensive heart disease	Breast cancer	Colorectal cancer
Icolored	Total cancers	1.39 Tachemic beart disease	0.99 Alzheimer's disease	0.96 Stroke	1.33 Lower respiratory infect	1.38 COPD	1.66 Lung cancer	1.4 Breast cancer	1.3 Colorestal cancer	Atrial fibrillation
icerand	0.76	Pa.0	0.96	0.53	1	1.26	1.35	0,71	0.55	1.02
Ireland	Total cancers	Ischemic heart disease 0.83	Stroke 0.76	Alzheimer's disease	Lower respiratory infect	2.09	Lung cancer 1.48	Colorectal cancer 0.86	Breast cancer 1.05	Chronic kidney disease 1.05
Israel	Total cancers	In charged or has not officer on on	Alzheimer's disease	Stroke	Diabetes	Chronic kidney disease	Lower respiratory infect	Colorectal cancer	Breast cancer	COPD
		incherine mean unseuse	realized in a subscript.		1.98	2.17	0.88	1.06	1.22	0.9
italy	1.04 Total campur	0.48	0.96	0.51 Alzheimer's disease	Hypertencius his sit elles se	Diaboter	CT (D) I	1.1	Broact cancer	Chropic kidnou director
	1.04 Total cancers 0.93	0.48 Ischemic heart disease 0.36	0.96 Strake 0.71	0.51 Alzheimer's disease 1.05	Hypertensive heart disease 2.15	Diabetes 1.14	0.88	0.85	Breast cancer	Chronic kidney disease 0.97
Luxembourg	1.04 Total cancers 0.93 Total cancers	0.45 Ischemic heart disease 0.36 Ischemic heart disease	0.96 Stroke 0.71 Stroke	0.51 Alzheimer's disease 1.05 Alzheimer's disease	Hypertensive heart disease 2.15 COPD	Diabetes 1.14 Lower respiratory infect	0.88 Chronic kidney disease	0.85 Colorectal cancer	Breast cancer 1 Breast cancer	0.97
Luxembourg	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease	Asthemic near disease 0.48 Ischemic heart disease 0.36 Ischemic heart disease 0.67 Total sancers	0.96 Stroke 0.71 Stroke 0.77 Stroke	0.51 Alzheimer's disease 1.05 Alzheimer's disease 0.91 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes	0.88 Chronic kidney disease 1.39 Breast cancer	0.85 Colorectal cancer 0.81 Chronic kidney disease	Breast cancer 1 Breast cancer 1.01 Colorectal cancer	Chronic Kidney disease 0.97 Lung concer 0.8 Hypertensive heart disease
Luxembourg Malta	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85	Adventic near advesse 0.36 Ischemic huar disease 0.36 Ischemic heart disease 0.67 Total cancers 0.74	0.96 Stroke 0.71 Strokn 0.77 Stroke. 0.59	0.51 Alzheimer's disease 1.05 Alzheimer's disease 0.91 Alzheimer's disease 0.94	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02	0.88 Chronic kidney disease 1.39 Breast cancer 1.03	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 0.73	Chronic kidney disease 0.97 Lung concer 0.8 Hypertensive heart disease D.65
Luxembourg Malta Monaco	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54	0.48 Ischemic heart disease 0.57 Total cancers 0.74 Ischemic heart disease 0.57 Total cancers 0.74 Ischemic heart disease 0.88	0.96 Stroke 0.71 Strokn 0.77 Strokn 0.50 Stroke 1.05	0.53 Alzheimer's disease 1.05 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19 Lung cancer 1.99	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31	0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.57	Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 0.73 Pancreatic cancer 2	Chronic kidney disease 0.97 Lung cancer 0.8 Hypertensive heart disease East COPD 0.92
Luxembourg Malta Monaco Netherlands	1.04 Total cancers 0.93 Total cancers 0.85 Ischemich eart disease 0.85 Total cancers 1.54 Total cancers	0.48 0.48 Ischemic heart disease 0.37 Total cancers 0.74 Ischemic heart disease 0.74 Ischemic heart disease 0.88 Bischemic heart disease	0.96 Stroke 0.71 Stroke 0.77 Stroke 0.76 Stroke 1.05 Stroke	0.51 Atzheimer's disease 1.05 Atzheimer's disease 0.94 Atzheimer's disease 0.94 Atzheimer's disease 0.98 Atzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19 Lung cancer 1.99 COPD	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect	0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 0.73 Pancreatic cancer 2 Breast cancer	Chronic kidney disease 0.97 Lung cancer 0.8 Hypertensive hoart disease 0.85 COPD 0.92 Falls
Luxembourg Malta Monaco Netherlands	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.65 Total cancers 1.54 Total cancers 1.13 Total cancers	0.48 0.48 Ischemic heart disease 0.37 Total cancers 0.74 Ischemic heart disease 0.74 Ischemic heart disease 0.78 Ischemic heart disease 0.55 Ischemic heart disease	0.96 Stroke 0.71 Stroke 0.77 Stroke 0.76 Stroke 1.05 Stroke 0.87 Code	0.53 Alzheimer's disease 1.05 Alzheimer's disease 0.94 Alzheimer's disease 0.94 Alzheimer's disease 1.01 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19 Lung cancer 1.99 COPD 1.74 Lower recontance infect	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect 1.15 Cone	COPD 0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.3 Falle	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 0.73 Pancreatic cancer 2 Breast cancer 1.26 Ling cancer	Chronic kidney disease 0.97 Lung cancer 0.8 Hypertensive heart disease 5.05 COPD 0.92 Fails 1.68 Act of fibellation
Luxembourg Malta Monaco Netherlands Norway	1.04 Total cancers 0.83 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54 Total cancers 1.13 Total cancers 0.89	0.48 0.48 Ischemic heart disease 0.37 Total cancers 0.74 Ischemic heart disease 0.88 Ischemic heart disease 0.55 Ischemic heart disease 0.55 Ischemic heart disease 0.74	0.96 Stroke 0.71 Stroke 0.77 Stroke 0.69 Stroke 0.87 Stroke 0.83	0.53 Alzheimer's disease 0.03 Alzheimer's disease 0.94 Alzheimer's disease 0.98 Alzheimer's disease 1.01 Alzheimer's disease 1.01	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19 Lung cancer 1.99 COPD 1.74 Lower respiratory infect 1.25	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.15 COPD 1.61	Corro Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.31 Falls 1.44	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 0.73 Pancreatic cancer 2 Breast cancer 1.26 Lung cancer 1.03	Chronic kidney disease 0.97 Lung cancer 0.8 Hypertensive heart disease ELGS COPD 0.92 Fails 1.68 Atrial fibrillation 1.28
Luxembourg Malta Monaco Netherlands Norway Portugal	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54 Total cancers 0.89 Stroke	0.54 Octav 0.54 Sincere 0.56 Ischemic heart disease 0.67 Total cancers 0.74 Ischemic heart disease 0.58 Rchemic heart disease 0.55 Ischemic heart disease 0.55 Ischemic heart disease 0.74 Total cancers 0.74	0.96 Stroke 0.71 Stroke 0.77 Stroke 1.05 Stroke 0.87 Stroke 0.87 Stroke 0.83 Stroke	0.51 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 1.05 Alzheimer's disease 1.01 Alzheimer's disease 1.01 Alzheimer's disease 1.01 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.9 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect 1.15 COPD 1.61 COPD	Corro 0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02 Diabetes 1.02	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.3 Fails 1.44 Chronic kidney disease	Breast cancer 1 Breast cancer 0,73 Pancreati cancer 2 Breast cancer 1,26 Lung cancer 1,03 Colorectal cancer	Chronic kidney disease 0.97 Lung cancer 0.8 Hypernenske heart disease 1.65 COPD 0.92 Falls 1.68 Attal fibrillation 1.28 Hypertensive heart disease
Luxembourg Malta Monaco Netherlands Norway Portugal	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54 Total cancers 1.13 Total cancers 0.89 Stroke 0.86 Total cancers	bichemic Incar disease 0 36 Ischemic Invart disease 0 37 Total cancers 0.74 Ischemic heart disease 0.88 Bichemic heart disease 0.88 Bichemic heart disease 0.74 Total cancers 0.74 Total cancers 0.74 Total cancers 0.94 Ischemic heart disease	0.96 Stroke 0.71 Stroke 0.77 Stroke 1.05 Stroke 0.87 Stroke 0.83 (schemic hunt disease 0.83 (schemic hunt disease 0.83 Stroke	0.53 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 1.03 Alzheimer's disease 1.01 Alzheimer's disease 0.95 Alzheimer's disease 0.95 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.9 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect 1.57 Colorectal cancer	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.5 COPD 1.61 COPD 1.25 Hypertensive heart disease	Corro 0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02 Diabetes 1.08 Other cancievascular.	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.3 Falls 1.44 Chronic kidney disease 1.34 Stomath cancer	Breast cancer 1 Breast cancer 0.73 Pancreati cancer 2 Breast cancer 1.26 Lung cancer 1.03 Colorectal cancer 1.09 COPD	Chronic kidney disease 0.97 Lung cancer 0.8 Hypernenske heart disease 1.65 COPD 0.92 Falls 1.68 Atrial fibrillation 1.28 Hypertensive heart disease 0.83 Breast cancer
Luxembourg Malta Monacó Netherlands Norway Portugal San Marino	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54 Total cancers 1.13 Total cancers 0.89 Stroke 0.89 Stroke 0.85 Total cancers 1.1	0.45 - 0.43 Canada Cana	0.96 Stroke 0.71 Stroke 0.77 Stroke 1.05 Stroke 0.87 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83	0.53 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 0.98 Alzheimer's disease 1.01 Alzheimer's disease 0.95 Alzheimer's disease 0.95 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.99 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect 1.57 Colorect Cancer	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.5 COPD 1.61 COPD 1.25 Hypertensive heart disease 1.54	Coronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02 Diabetes 1.08 Other cardioyascalar 3.99	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.3 Fails 1.44 Chronic kidney disease 1.34 Stomach cancer 2.56	Breast cancer 1 Breast cancer 0.73 Pancreatic cancer 0.73 Pancreatic cancer 1.25 Lung cancer 1.03 Colorectal cancer 1.09 COPP 0.85	Chronic kidney disease 0.97 Lung cancer 0.8 Hypernetwice finant disease 1.65 COPD 0.92 Falls 1.68 Atrial fibrillation 1.28 Hypertensive heart disease 0.81 Breast cancer 0.95
Luxembourg Malta Monacó Netherlands Norway Portugal San Marino Spain	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54 Total cancers 0.89 Stroke 0.86 Total cancers 1.13 Total cancers 0.89 Stroke 0.85	0.85 0.25 0.74 1schemic heart disease 0.77 Total cancers 0.74 1schemic heart disease 0.88 1schemic heart disease 0.75 1schemic heart disease 0.75 1schemic heart disease 0.75 1schemic heart disease 0.77 Total cancers 0.9 1schemic heart disease 0.77 1schemic heart disease 0.77 1schemic heart disease 0.77 1schemic heart disease 0.77 1schemic heart disease 0.77 1schemic heart disease 0.77 1schemic heart disease 0.79	0.96 Stroke 0.71 Stroke 0.77 Stroke 1.05 Stroke 0.87 Stroke 0.83 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.33 Stroke 0.35 Stroke 0.	0.53 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 0.98 Alzheimer's disease 1.01 Alzheimer's disease 0.95 Alzheimer's disease 1.05 Alzheimer's disease 0.95 Alzheimer's disease 0.99	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.99 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect 1.57 Colorectal cancer 1.04 COPD 1.32	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect 1.5 COPD 1.61 COPD 1.25 Hypertensive heart disease 1.54 Chronic kidney disease 1.32	0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02 Diabetes 1.08 Other cardioyasolar 3.99 Lower respiratory fullect 0.67	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.3 Falls 1.44 Chronic kidney disease 1.34 Stomach cancer 2.56 Colorectal cancer 1.04	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 0.73 Pancreatic cancer 2 Breast cancer 1.25 Lung cancer 1.03 Colorectal cancer 1.09 COPD 0.85 Hypertensive heart disease 0.97	Chronic kidney disease 0.97 Lung cancer 0.8 Hypertensive finant disease 1.65 COPD- 0.92 Fails 1.68 Atrial fibrillation 1.28 Hypertensive heart disease 0.81 Breast cancer 0.96 Diabetes 0.77
Luxembourg Malta Monaco Netherlands Norway Portugal San Marino Spain Sweden	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.85 Total cancers 1.54 Total cancers 0.89 Stroke 0.86 Total cancers 1.13 Total cancers 0.89 Stroke 0.85 Total cancers 0.85 Total cancers	0.44 Strategy 0.45 States 0.56 States 0.67 States 0.67 States 0.67 States 0.74 States 0.55 States 0.55 Ischemic heart disease 0.74 States 0.55 Ischemic heart disease 0.74 States 0.55 Ischemic heart disease 0.57 Ischemic heart disease 0.59 Ischemic heart disease 0.59 Ischemic heart disease 0.59 Ischemic heart disease	0.96 Stroke 0.71 Stroles 0.77 Stroke 1.05 Stroke 0.87 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.35 Stroke 0.35 Stroke 0.35 Stroke 0.35 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.37 Stroke 0.35 Stroke 0.55 Stroke Stroke 0.55 Stroke Stroke 0.55 Stroke 0.55 Stroke 0.55 Stroke Stroke 0.55	0.51 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 1.03 Alzheimer's disease 1.01 Alzheimer's disease 1.05 Alzheimer's disease 1.03 Alzheimer's disease 1.01 Alzheimer's disease 0.95 Alzheimer's disease 0.99 Alzheimer's disease	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.39 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect 1.57 Colorectal cancer 1.04 COPD 1.32 COPD	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect 1.51 COPD 1.61 COPD 1.25 Hypertensive heart disease 1.52 Chronic kidney disease 1.52 Atrial fibrillation	0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02 Diabetes 1.08 Other cardiovosoular 3.99 Lower oventratury funct 0.67 Lung cancer	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.3 Falls 1.44 Chronic kidney disease 1.34 Stomoth cancer 2.56 Colorectal cancer 1.04 Colorectal cancer	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 2 Breast cancer 1.26 Lung cancer 1.03 Colorectal cancer 1.09 Colorectal cancer 1.09 0.85 Hypertensive heart disease 0.97 Lower respiratory infect	Chronic kidney disease 0.97 Lung cancer 0.8 Flypementue finant disease E 65 COPD- 0.92 Fails 1.68 Atrial fibrillation 1.28 Hypertensive heart disease 0.81 Breast cancer 0.96 Diabetes 0.77 Breast cancer
Luxembourg Malta Monaco Netherlands Norway Portugal San Marino Spain Sweden	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.65 Total cancers 1.54 Total cancers 1.3 Total cancers 0.89 Stroke 0.86 Total cancers 1.1 Total cancers 0.89 Stroke 0.86 Total cancers 0.89 Total cancers 0.89 Total cancers 0.89 Total cancers 0.89 Total cancers 0.89 Total cancers 0.92 Total cancers 0.92	0.48 minute interaction 0.48 minute interaction 0.56 minute interaction 0.57 minute interaction 0.58 minute interaction 0.55 lischemic heart disease 0.74 minute interaction 0.55 lischemic heart disease 0.74 minute interaction 0.57 lischemic heart disease 0.57 lischemic heart disease 0.39 lischemic heart disease 0.39 lischemic heart disease 0.39 minute interaction	0.96 Stroke 0.71 Strole 0.77 Strole 1.05 Stroke 0.87 Stroke 0.83 Stroke 0.83 Stroke 0.83 Stroke 0.89 Stroke 0.89 Stroke 0.23 Stroke 0.43 Stroke 0.89 Stroke 0.80 Stroke 0.89 Stroke 0.80 Stroke 0.	0.51 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 1.03 Alzheimer's disease 1.01 Alzheimer's disease 0.95 Alzheimer's disease 0.95 Alzheimer's disease 0.93 Alzheimer's disease 0.93 Simile	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19 Lung cancer 1.39 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect 1.57 Colorectal cancer 1.04 COPD 1.32 COPD 1.32 COPD	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect 1.5 COPD 1.5 Hypertensive heart disease 1.52 Chronic kidney disease 1.52 Chronic kidney disease 1.53 Chronic kidney disease 1.53 Chronic kidney disease 1.53 Chronic kidney disease 1.53 Chronic kidney disease 1.53 Chronic kidney disease	0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.13 Colorectal cancer 1.02 Diabetes 1.08 Other cardiovascular 3.09 Lower reginatory inflect 0.07 Lung cancer 1.1 Falls	0.85 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.31 Falls 1.44 Chronic kidney disease 1.34 Stomath cancer 2.56 Colorectal cancer 1.04 Colorectal cancer 0.66 Perset sourcer	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 2 Breast cancer 1.25 Lung cancer 1.25 Lung cancer 1.03 Colorectal cancer 1.09 COPO 0.85 Hypertensive heart disease 0.97 Lower respiratory infect 0.7 Lower respiratory infect	Chronic kidney disease 0.97 Lung cancer 0.8 Flyperensive heart disease E 65 COPD 0.92 Falls 1.68 Atrial fibrillation 1.28 Hypertensive heart disease 0.81 Breast cancer 0.96 Diabetes 0.77 Breast cancer 0.94 COPD
Luxembourg Malta Monaco Netherlands Norway Portugal San Marino Spain Sweden Switzerland	1.04 Total cancers 0.93 Total cancers 0.85 Ischemic heart disease 0.65 Total cancers 1.54 Total cancers 0.89 Stroke 0.86 Total cancers 1.1 Total cancers 0.89 Stroke 0.86 Total cancers 0.89 Stroke 0.85 Total cancers 0.26 Total cancers 0.39 Stroke 0.85 Total cancers 0.39 Stroke 0.35 Total cancers 0.39 Stroke 0.35 Total cancers 0.39 Stroke 0.35 Total cancers 0.37 Total cancers 0.37	0.48 minute interaction 0.36 minute interaction 0.37 minute interaction 0.37 minute interaction 0.38 minute interaction 0.38 minute interaction 0.35 minute interaction 0.35 ischemic heart disease 0.74 minute interaction 0.39 ischemic heart disease 0.39 ischemic heart disease 0.39 ischemic heart disease 0.39 ischemic heart disease 0.38 ischemic heart disease 0.38 ischemic heart disease 0.34	0.96 Stroke 0.71 Strole 0.77 Stroke 1.05 Stroke 0.87 Stroke 0.83 Ischewic heard disease 0.43 Stroke 0.89 Stroke 0.89 Stroke 0.23 Stroke 0.43 Stroke 0.89 Stroke 0.23 Stroke 0.44 Stroke 0.44 Stroke 0.44 Stroke 0.45 Stroke	0.51 Alzheimer's disease 0.91 Alzheimer's disease 0.94 Alzheimer's disease 1.03 Alzheimer's disease 1.01 Alzheimer's disease 0.95 Alzheimer's disease 0.95 Alzheimer's disease 0.95 Alzheimer's disease 0.93 Alzheimer's disease 0.93 Stroke 0.69	Hypertensive heart disease 2.15 COPD 1.2 Lower respiratory infect 1.19 Lung cancer 1.39 COPD 1.74 Lower respiratory infect 1.25 Lower respiratory infect 1.57 Colorectal cancer 1.04 COPD 1.32 COPD 1.2 Hypertensive heart disease 2.34	Diabetes 1.14 Lower respiratory infect 0.8 Diabetes 1.02 Lower respiratory infect 1.31 Lower respiratory infect 1.31 COPD 1.61 COPD 1.54 Chronic kidney disease 1.54	COPD 0.88 Chronic kidney disease 1.39 Breast cancer 1.03 Breast cancer 1.52 Colorectal cancer 1.52 Colorectal cancer 1.02 Diabetes 1.08 Other cardiovascular 3.09 Lower respiratory inflect 0.67 Lung cancer 1.1 Falls 1.19	0.48 0.48 Colorectal cancer 0.81 Chronic kidney disease 1.03 Colorectal cancer 1.1 Lung cancer 1.31 Falls 1.44 Chronic kidney disease 1.34 Stomach cancer 1.04 Colorectal cancer 1.04 Colorectal cancer 0.86 Bretast cancer 0.9	Breast cancer 1 Breast cancer 1.01 Colorectal cancer 2.73 Prancreatic cancer 2.2 Breast cancer 1.25 Lung cancer 1.03 Colorectal cancer 1.09 COPO 0.85 Hypertensive heart disease 0.97 Lower respiratory infect 0.7 Lower respiratory infect	Chronic kidney disease 0.97 Lung cancer 0.8 Flyperensive finant disease E 65 COPD 0.92 Fails 1.68 Atrial fibrillation 1.28 Hypertensive heart disease 0.81 Breast cancer 0.96 Diabetes 0.77 Breast cancer 0.94 COPD 0.83

Latin America and	Ischemic heart disease	Total cancers	Stroke	Alzheimer's disease	Diabetes	Lower respiratory infect	COPD 1 39	Chronic kidney disease	Hypertensive heart disease	Colorectal cancer
Andean Latin America	Total cancers	Ischemic heart disease	Lower respiratory infect	Strake	Chronic kidney disease	Alzheimer's disease	Diabetes	Stomach cancer	COPD	Cirrhosis
Bolivia (Plurinational	Total cancers	Ischemic heart disease	Lower respiratory infect	Stroke	Diabetes	Chronic kidney disease	COPD	Stomach cancer	Alzheimer's disease	Cirrhosis
State of) Ecuador	1.85 Total cancers	15chemic Neart disease	292 Stroke	0.6 Chronic kidney disease	1.56 Lower respiratory infect	2.59 Diabetes	1.59 Alzheimer's disease	4.01 Hypertensive heart disease	COPD	2.38 Cirrhosis
Peru	1.23 Total cancers	Lower respiratory infect	0.58 Ischemic heart disease	2.68 Alzheimer's disease	1.87 Stroke	1.17 Chronic kidney disease	0.95 Stomach cancer	1.29 Diabetes	1.17 Interstitial lung disease	2,39 Cirrhosis
Caribbana	1.05 Ischemic heart disease	2.75 Total cancers	0.79 Stroke	0.9 Diabetes	0.25 Alzheimer's disease	1.58 Lower respiratory infect	2.09 Hypertensive heart disease	0.49 COPD	13.73 Chronic kidney disease	1.67 Falls
Cariobean	0.72 Ischemic heart disease	0.98 Total cancers	0.7 Stroke	1.4 Diabetes	0.86 Lower respiratory infect	1.27 Hypertensive heart disease	1.02 Chronic kidney disease	0.85 Alzheimer's disease	1.05 Breast cancer	2.88 Colorectal cancer
Antigua and Barbuda	0.77 Total cancers	1.13 Ischemic heart disease	1.02 Stroke	3.84 Hupertensive heart disease	2.14 Dishates	2.86 Alzheimer's disease	2.52	0.93 Chronic kidney disease	1.61 Breast cancer	1.36 Colorectal cancer
Bahamas	0.87	0,71	0.91	5.14	2.81	0,89	1.38	1.83	1.47	0,92
Barbados	1.32	0.98	USD 0.59	4.13	2.1	0.9	Breast cancer 1.87	1.68	1.62	52.36
Belize	Exclusion heart disease	Total cancers 0.81	Diabetes 1.71	Stroke 0.43	Lower respiratory infect 1.66	Alzheimer's disease 0.89	Chronic kidney disease 1.46	Hypertensive heart disease 0.93	0.54	Other cardiovascular 2.1
Bermuda	Total cancers 0.91	lischemichean disease 0,63	Alzheimer's disease 0.92	Stroke (1.49	Colorectal cancer 1.1	Diabetes 1.27	Lower respiratory infect 0.76	Breast cancer 1.17	Lung cancer 1.02	Chronic kidney disease 0,99
Cuba	Ischemic heart disease 0.67	Total cancers 1.13	Stroke 0.53	Lower respiratory infect 1.79	Alzheimer's disease 0.85	Falls 6.8	Colorectal cancer 1.54	COPD 0.94	Lung cancer 2 39	Hypertensive heart disease 0.67
Dominica	Total cancers 1.34	Uschemic heart disease 0.75	Stroke 0.99	Diabetes 3.73	Hypertensive heart disease	Chronic kidney disease 2.77	Alzheimer's disease	Lower respiratory infect 1.64	Other cardiovascular 5:06	Breast cancer 1.62
Dominican Republic	Ischemic heart disease	Stroke	Total cancers	Alzheimer's disease	Diabetes	Hypertensive heart disease	Lower respiratory infect	Chronic kidney disease	Cirrhosis	COPD
Grenada	Stroke	Total cancers	Ischemic heart disease	Diabetes	Lower respiratory infect	Chronic kidney disease	Alzheimer's disease	Hypertensive heart disease	Breast cancer	Colorectal cancer
Guyana	Ischemic heart disease	Stroke	Diabetes	Total cancers	Hypertensive heart disease	Lower respiratory infect	Chronic kidney disease	Alzheimer's disease	Breast cancer	Colorectal cancer
Haiti	Ischemic heart disease	1.21 Stroke	Total cancers	Diabetes	Lower respiratory infect	Hypertensive heart disease	COPD	0.86 Alzheimer's disease	L 12 Chronic kidney disease	1.06 Breast cancer
lamaica	1.41 Stroke	1.58 Diabetes	1.23 Ischemic heart disease	2.38 Total cancers	1.27 Alzheimer's disease	1.46 Hypertensive heart disease	0.86 Lower respiratory infect	0.83 Chronic kidney disease	0.98 Breast cancer	1.59 Colorectal cancer
Ruarto Pico	0.92 Ischemic heart disease	3,61 Total cancers	0.39 Diabetes	0.94 Alzheimer's disease	0.84 Stroke	1.49 Chronic kidney disease	COPD	1.09 Lower respiratory infect	1.25 Hypertensive heart disease	1.01 Colorectal cancer
Foliat Vites and Marile	0.51 Stroke	0.65 Ischemic heart disease	3.32 Total cancers	0.88 Diabetes	0,38 Lower respiratory infect	1.94 Chronic kidney disease	1.25 Alzheimer's disease	0.8 Hypertensive heart disease	1.07 Breast cancer	0.74 Colorectal cancer
Saint Kitts and Nevis	1.75 Stroke	0.77 Total cancers	1.16 Ischemic heart disease	2.99 Diabetes	2.11 Alpheimer's disease	3.1 Lower respiratory infect	0.87 Hypertensive heart disease	1.97 Chronic kidney disease	1.61	1.08 Breast cancer
Saint Lucia	0.83	0.96	0.36	2.37 Dishotor	0.91	1.32	1.5	1.49 Chronic kidney disease	0.66	1.06
Grenadines	0.85	0.84	1.25	2.8	2.08	1.52	0.86	1.58	1.66	3,08
Suriname	U.8	0.5	0.93	1.23	Alzheimer's disease	LATONIC Kidney disease	Lower respiratory infect	Hypertensive heart disease 1.22	0.64	Lolorectal cancer 1.12
Trinidad and Tobago	Ischemic heart disease 0.86	Diabetes 5.05	Stroke 0.9	Total cancers 0.75	Alzheimer's disease 0.86	Chronic kidney disease 1.6	Hypertensive heart disease 1.35	Lower respiratory infect 0.76	Breast cancer 1.05	Colorectal cancer 0.8
United States Virgin Islands	Ischemic heart disease 1.51	Total cancers	Stroke 0.84	Diabetes 3.18	Alzheimer's disease 0.94	Hypertensive heart disease 2.66	Chronic kidney disease 2.13	Colorectal cancer 1.4	Breast cancer 1.43	Lung cancer 1.11
Central Latin America	Ischemic heart disease 0.55	Total cancers 0.86	Stroke 0.34	Diabetes 1.31	Alzheimer's disease 0.99	Chronic kidney disease 1.94	COPD 1.56	Lower respiratory infect 0.77	Hypertensive heart disease 0.67	Cirrhosis 1.47
Colombia	Inchantic heart disease	Total cancers	Alzheimer's disease	COPD 17	Stroke	Chronic kidney disease	Hypertensive heart disease	Diabetes	Lower respiratory intect	Stomach cancer
Costa Rica	Total cancers	Ischemic heart disease	Alzheimer's disease	Stroke	COPD	Chronic kidney disease	Hypertensive heart disease	Colorectal cancer	Stomach cancer	Lower respiratory infect
El Salvador	Ischemic heart disease	Total cancers	Alzheimer's disease	Stroke	Chronic kidney disease	Lower respiratory infect	Diabetes	COPD	Stomach cancer	Cirrhosis
Guatemala	ischemic heart disease	0.93 Total cancers	0.96 Lower respiratory infect	Diabetes	1.68 Stroke	1.09 Chronic kidney disease	0.95 Alzheimer's disease	0.87 Stomach cancer	1:49 COPD	L15 Cirrhosis
Honduras	11.62 Ischemic heart disease	1.08 Stroke	2.03 Total cancers	1.48 COPD	0.38 Chronic kidney disease	1.8 Cirrhosis	0.98 Alzheimer's disease	2.83 Lung cancer	0.68 Hypertensive heart disease	1.42 Upper digest diseases
Manufas	0.97 Ischemit heart disease	0.94 Total cancers	1.4 Diabetes	1.79 Chronic kidney disease	2.07 Stroke	2.57 COPD	1.08 Alzheimer's disease	3.28 Lower respiratory infect	0.69 Cirrhosis	3.36 Hypertensive heart disease
Mexico	0.50 Ischemic heart disease	0.79 Total cancers	1.95	2.82 Chronic kidney disease	0.32 Diabetes	1.87 COPD	1.01 Alzbeimer's disease	0.79 Hypertensive heart disease	2.17 Cirrhosis	0.65
Nicaragua	0.95	1.07	0.49 Stroke	2.29 Alzheimer's disease	1.34 Dishetes	1.17	1 Chronic kidney disease	0.83	1.31 Coloractal cancer	0.49 Himentensive heart disease
Panama Manamala (Rollingian	0.36:	0.76	0.43	0.98	1.28	1.13	1.29	0.72	0.77	n.5
Republic of)	U,6	0.98	U.44	0.99	1.01	1.36	1.04	1.04	0.68	1.63
Tropical Latin America	Total cancers 0.9	0.35	Stroke D.45	Lower respiratory infect 1.81	Alzheimer's disease	Diabetes 0.97	COPD 1.46	Hypertensive heart disease 0.75	Chronic kidney disease 0.9	Urinary diseases 5.26
Brazil	Total cancers 0.9	Uschemic heart disease 0.34	Stroke B.45	Lower respiratory infect 1.82	Alzheimer's disease 1.06	COPD 1.48	Diabetes 0.95	Hypertensive heart disease 0.74	Chronic kidney disease 0.88	Urinary diseases 5.37
Paraguay	Ischemic heart disease 0.42	Total cancers 0.88	Stroke 0.5	Diabetes 1.56	Alzheimer's disease 1.03	Lower respiratory infect 1.15	Chronic kidney disease 1.44	Hypertensive heart disease 0.94	COPD 0.67	Colorectal cancer 0.9
North Africa and Middle East	Ischemic heart disease 1.47	Stroke 1.01	Total cancers 0.75	Hypertensive heart disease 2.31	Alzheimer's disease 1.13	Chronic kidney disease 2.05	Diabetes 1.13	Cirrhosis 3.1	COPD 1.21	Lower respiratory infect 0.92
North Africa and Middle	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Alzheimer's disease	Chronic kidney disease	Diabetes	Cirrhosis	COPD 1.31	Lower respiratory infect
Afghanistan	Ischemic heart disease	Stroke	Total cancers	Conflict & terror	Hypertensive heart disease	Diabetes	Chronic kidney disease	COPD	Lower respiratory infect	Alzheimer's disease
Algeria	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Chronic kidney disease	Alzheimer's disease	Diabetes	Lower respiratory infect	COPD	Cirrhosis
Bahrain	Ischemic heart disease	Diabetes	Total cancers	Stroke	Chronic kidney disease	COPD	Alzheimer's disease	Lower respiratory infect	Breast cancer	Circhosts
Egypt	1.52 Ischemic heart disease	9.01 Cirrhosis	1.02 Stroke	0.93 Hypertensive heart disease	3.47 Total burden related to hep	2.01 Chronic kidney disease	1.27 Total cancers	1.44 Diabetes	1.46 Total burden related to hep	Lower respiratory infect
Iran (Islamic Republic	2:79 Ischemic heart disease	19.78 Stroke	1.04 Total cancers	3,83 Hypertensive heart disease	22.35 Alzheimer's disease	3.8 Diabetes	0.68 Chronic kidney disease	1.29 COPD	20.47 Lower respiratory infect	1.74 Stomach cancer
of)	1.14 Ischemic heart disease	0.78 Stroke	0.79 Total canters	2.32 Diabetes	1.12 Chronic kidney disease	1.02 Alzheimer's disease	1.42 Hypertensive heart disease	1.16 Breast cancer	0.85 Lowel respiratory infect	1.53 Lung cancer
iraq	1.44 Ischemic heart disease	1.35 Stroke	0.67 Total cancers	1.56 Hypertensive heart disease	2.3 Diabetes	1.09 Chronic kidney disease	1.3 Alzheimer's disease	0.69 Lower respiratory infect	0.43 Breast cancer	0.96 Colorectal cancer
Jordan	1 Ischemic heart disease	1.24	0.72	4 49 Altheimer's disease	2.5	3.45 Humantansiya boart disease	1.11 Dishetes	1.03 Chronic kidney disease	0.9 Brand Course	0,8
Kuwait	0,74	U.S	0.79	1.1	1.81	2.98	2.01	1.82	061	0,49
Lebanon	Ischemic heart disease 1.41	Total cancers 1.1	Stroke 0,46	Alzheimer's disease 1.21	Hypertensive heart disease 2.12	Chronic kidney disease 1.8	Breast cancer 1,63	Colorectal cancer 1.16	Lower respiratory infect 0.76	0.81
Libya	Ischemic heart disease 1.08	Stroke 0.82	Total cancers 0.65	Alzheimer's disease 1.26	Chronic kidney disease 2.32	Hypertensive heart disease 1.92	Diabetes 0.85	Lower respiratory infect 0.85	0,8	Cirrhosis 1.82
Morocco	Ischemic heart disease 1.61	Stroke 1.07	Hypertensive heart disease 1.81	Total cancers 0.67	Chronic kidney disease 1.71	Alzheimer's disease 1.03	Diabetes 0.7	Lower respiratory infect 0.67	COPD 10.68	Tuberculosis 3.29
Oman	Ischemic heart disease	Stroke	Total cancers	Diabetes	Lower respiratory infect 2.77	Hypertensive heart disease	Alzheimer's disease	Chronic kidney disease 2.75	COPD 1.46	Other cardiovascular
Palestine	Ischemic heart disease	Stroke	Total cancers	Diabetes	Hypertensive heart disease	Alzheimer's disease	Chronic kidney disease	Lower respiratory infect	Cirrhosis	Colorectal cancer
Qatar	Ischemic heart disease	Diabetes	Total cancers	Chronic kidney disease	Stroke	Cirrhosis	Lower respiratory infect	Breast cancer	Colorectal cancer	COPD
Saudi Arabia	Ischemic heart disease	Stroke	Chronic kidney disease	Total cancers	Alzheimer's disease	Lower respiratory infect	Circhosis	COPD	Diabetes	Total burden related to hep
Sudan	1.74 Ischemic heart disease	1.82 Stroke	5.17 Hypertensive heart disease	0.56 Total cancers	1.19 Alzheimer's disease	1.68 Chronic kidney disease	5,88 Lower respiratory infect	L.34 COPD	1.39 Dinbotes	6.22 Cirrhosis
Syrian Arab Republic	1.65 Ischemic heart disease	1.23 Stroke	1.87 Conflict & terror	0.69 Total canters	0.98 Chronic kidney disease	1.22 Alzheimer's disease	Disi Diabetes	COPD	L48 Lower respiratory infect	L18 Cirrhosis
Tupicia	2.21 Ischemic heart disease	0.98 Stroke	4346.82 Total cancers	0.66 Alzheimer's disease	1.69 Hypertensive heart disease	1.18 Chronic kidney disease	D.G3 Lower respiratory infect	1.06 Diabetes	0.99 COPD	1.99 Colorectal cancer
Turkey	1.14 Ischemic heart disease	0.84 Stroke	0.56 Total cancers	1.14 Alzheimer's disease	1.89 Hypertensive heart disease	1.64 COPD	0.79 Diabetes	0.58 Chronic kidney disease	0.78 Lower respiratory Infect	0.71 Colorectal cancer
Holitad Arch Fart	1 Ischemic heart disease	0.95 Total cancers	0.79 Stroke	1.17 Diabetes	2.52 Chronic kidney disease	1.83 Lower respiratory infect	1.71 Hypertensive heart disease	2.08 Alzheimer's disease	0.98 COPD	0.79 Colorectal cancer
United Arab Emirates	2.61 Ischemic heart disease	0.87 Stroke	2.53 Hypertensive heart disease	7,35 Total cancers	7.71 Alzheimer's disease	4.46 COPD	7.92 Lower respiratory intert	1.27 Chronic kidney disease	1.61 Asthma	0.87 Diatieties
reinen	1.9 Ischemic heart disease	1.21 COPP	2.06 Diambeal diseases	0.74 Stroke	1.05 Total cancers	0.88 Lower respiratory infect	0.56 Diabetes	0.9 Fails	1.22 Alzheimer's disease	0.48 Asthma
South Asia	0.72 Ischamic haart die	3.62	14.84 Diarthe at diarant	0.61.	0.75	1.1	0.77 Diabatest	5.51	0.79 Altheory's dream	2.8
South Asia	0.72 Strate	3.62	14,84	0.61	0.75	1.1 Dishara	0.77	5.51 Alphalator's disc	0.79	2.8
Bangladesh	1.24	0.64	0.65	3.21	1.3	Liabertes 1	D.59	0.73	0.7	1.26
Bhutan	4.14	Ischemic heart disease 0.81	Stroke 0.63	Total cancers 0.86	Diabetes 1.02	Lower respiratory infect 0.69	Aizheimer's disease 0.92	Diarrheal diseases	Chronic kidney disease 1.09	Fails 3.91
India	ischemic heart disease 0.71	60PD 4.05	Diarrheal diseases 24.57	Stroke 0.52	Total cancers 0.71	Lower respiratory infect 1.28	Falls 6.85	Diabetes 0.7	Aizheimer's disease 0:8	Asthma 3.37
Nepal	COPD 6,24	Ischemic heart disease 0.58	Stroke 0.59	Total cancers 0.84	Diarrheal diseases 2.13	Asthma 3.27	Lower respiratory infect 0.78	Alzheimer's disease 0.86	Diabetes 0.68	Chronic kidney disease 0.89
Pakistan	Ischemic heart disease	Stroke 1.07	Total cancers 1.43	Diarrheal diseases 3.8	COPD 1.75	Diabetes 1.59	Hypertensive heart disease 0.98	Cirrhosis 1.91	Chronic kidney disease 1.24	Breast cancer 3.05
Southeast Asia, East Asia, and Oceania	Stroke	Ischemic heart disease	Total cancers	COPD	Alzheimer's disease	Hypertensive heart disease	Lung cancer	Lower respiratory infect	Diabetes	Chronic kidney disease
East Asia	Stroke	Ischemic heart disease	Total cancers	COPD	Alzheimer's disease	Hypertensive heart disease	Lung cancer	Lower respiratory Infect	Stomach cancer	Chronic kidney disease
China	1.17 Stroke	0.75 Ischemic heart disease	0.96 Total cancers	GOPD	1.03 Alzheimer's disease	1.4 Hypertensive heart disease	2.58 Lung cancer	0.62 Stomach cancer	1.62 Lower respiratory infact	Chronic kldney disease
Democratic People's	1.17 Stroke	0.75 Ischemichean disease	0.97 COPD	3.76 Total cancers	1.04 Alzheimer's disease	1.41 Lower respiratory infect	2.65 Hypertensive heart disease	1.64 Lung cancer	0.58 Diabetas	Stomach cancer
Republic of Korea Taiwan (Province of	1.32 Total cancers	0.67 Ischemic heart disease	3.89 Stroke	0.81 Alzheimer's disease	0.94 Lower respiratory infect	0.86 Diabetes	0.97 Chronic kidney disease	1.79 Colorectal cancer	0.32 Lung cancer	1.24 COPD
China)	0.88 Ischemic heart disease	0.45 Stroke	COPD	0.97 Diabetes	1.78 Total cancers	3.34 Asthma	2.47 Diambeal diseases	1.17 Lower respiratory infect	1.32 Alzheimer's disease	1.12 Hypertensive heart disease
Oceania	1.06 Ischemic heart disease	1 Total cancers	3.64 Stroke	2.73 Diabetes	0.95 Chropic kidney disease	5.11 Alzheimer's disease	2.49 COPD	0.97	0.93 Breast cancer	0.96
American Samoa	0.91	1.22	1.09	4.03	3.10	1.08	1.95	1.36	1.72	1.58
Cook Islands	6.59	0.69	0.83	0.8	4.97	1.99	0.98	2.2	1.59	1.79
Fiji	Diabetes 7.46	Ischemic heart disease	Stroke 1	Total cancers 0.99	Asthma 10.56	Chronic kidney disease 1.94	hypertensive heart disease 1.61	Alžheimer's disease 1.01	Breast cancer 1.87	Lower respiratory infect 1.19
Guam	Ischemic heart disease	fotal cancers 0.6	Stroke 0,61	Alzheimer's disease 0.89	Chronic kidney disease 1.93	Diabetes 1.51	COPD 0.91	Lower respiratory infect 0.69	Lung cancer 1.19	Hypertensive heart disease 0.91
Kiribati	Ischemic heart disease 1.18	Stroke 1.39	Diabetes 3.78	Total cancers 1.58	Diambeal diseases 14.59	Asthma 9,48	Tuberculosis 9.8	Chronic kidney disease 1.92	Lower respiratory infect 1.37	Cervical cancer 6,04
Marshall Islands	Ischemic heart disease 1.49	Stroke 1.43	Diabetes 3.31	Total cancers 1.35	COPD 1.97	Lower respiratory infect	Hypertensive heart disease 1.69	Chronic kidney disease 1.83	Diamheal diseases	Asthima 3.5
Micronesia (Federated States of)	Ischemic heart disease	Stroke	Diabetes 405	Total cancers	COPD 2.52	Chronic kidney disease	Lower respiratory infect	Hypertensive heart disease	Alzheimer's disease	Asthma
Nauru	Ischemic heart disease	Stroke	Diabetes	Total cancers	COPD	Chronic kidney disease	Lower respiratory infect	Hypertensive heart disease	Breast cancer	Alzheimer's disease
Niue	Ischemic heart disease	Diabetos	Stroke	Total cancers	Alzheimer's disease	Lower respiratory infect	COPD	Chronic kidney disease	Hypertensive heart disease	Breast cancer
Northern Mariana	1.18 Ischemic heart disease	Total cancers	1.06 Stroke	1.05 Diabetes	1.14 Chronic kidney disease	1.75 Alzheimer's disease	L98 COPD	2.37 Lower respiratory infect	1.31 Lung cancer	1.53 Breast cancer
Islands Palau	1.11 Ischemic heart disease	1.14 Total cancers	1.22 Diabetes	3:31 Lower respiratory infect	4.01 Stroke	1.09 COPD	1.53 Chronic kidney disease	1.25 Lung cancer	1.69 Alzheimer's disease	1.43 Breast cancer
Dagenting	1.43 COPD	1.63 Ischemic heart disease	5.89 Stroke	6.42 Asthma	1.06 Total cancers	4.47 Diabetes	3.35 Diarrheal diseases	3.61 Lower respiratory infect	0.94 Falls	1.72 Hypertensive heart disease
rapua New Guinea	10.05	0.96	0.9	5.05	0.91	1 70	2.05	0.78	517	0.95

Samoa	Ischemic heart disease	Stroke	Diabetes 2.55	Total cancers	COPD 2.66	Lower respiratory infect	Alzheimer's disease	Chronic kidney disease	Hypertensive heart disease	Asthma 6.41
Solomon Islands	Stroke 2.61	Ischemic heart disease	Lower respiratory infect	Diarrheal diseases	Total cancers	Diabetes 2.91	COPD 2.13	Asthma 2.48	Hypertensive heart disease	Falls 5.75
Tokelau	Ischemic heart disease	Stroke	Diabetes 3.29	Total cancers	COPD 2.3	Lower respiratory infect	Alzheimer's disease	Chronic kidney disease	Hypertensive heart disease	Asthma 5.06
Tonga	Ischemic fieart disease	Diabetés 0 98	Suoke 0.57	Total cancers	Alzheimer's disease	Lower respiratory infect	Chronic kidney disease	COPD 11	Breast cancer	Asthma 3.98
Tuvalu	Ischemic heart disease	Stroke	Diabetes 3.15	Total cancers	COPD 2.22	Lower respiratory infect	Chronic kidney disease	Alzheimer's disease	Hypertensive heart disease	Asthma
Vanuatu	Ischemic heart disease	Stroke	Total cancers	Diabetes 2.16	COPD 1.73	Diarrheal diseases	Lower respiratory infect	Chronic kidney disease	Asthma 2.85	Hypertensive heart disease
Southeast Asia	Stroke	Ischemic heart disease	Total cancers	Lower respiratory infect	Diabetes	Alzheimer's disease	COPD 143	Hypertensive heart disease	Chronic kidney disease	Cirrhosis
Cambodia	Stroke	tschemic heart disease	Lower respiratory infect	Total cancers	Cirrhosis	Alzheimer's disease	Diabetes	COPD	Hypertensive heart disease	Tuberculosis
Indonesia	Stroke	Ischemic heart disease	Total cancers	Diabetes	Hypertensive heart disease	Diarmeal diseases	Cirrhosis	COPD	Alzheimer's disease	Lower respiratory infect
Lao People's	Stroke	Ischemic heart disease	Total cancers	Lower respiratory infect	Diabetes	COPD	Hypertensive heart disease	Chronic kidney disease	Alzheimer's disease	Diarrheal diseases
Malaysia	Ischemic heart disease	Lower respiratory infect	Stroke	Total cancers	Alzheimer's disease	Chronic kidney disease	COPD	Colorectal cancer	Urinary diseases	Diabetes
Maldives	Ischemic heart disease	Total cancers	Stroke	COPD	Chronic kidney disease	Alzheimer's disease	Diabetes	Lower respiratory infect	Hypertensive heart disease	Colorectal cancer
Mauritius	Ischemic heart disease	Diabetes	Stroke	Total cancers	1.95 Chronic kidney disease	Alzheimer's disease	Hypertensive heart disease	Lower respiratory infect	COPD	1.22 Breast cancer
Myanmar	0.64 Stroke	4.34 Ischemic heart disease	Total cancers	COPD	3.74 Diabetes	1 Lower respiratory infect	2.13 Alzheimer's disease	0.84 Hypertensive heart disease	0.82 Asthma	0.89 Chronic kidney disease
Philippines	1.78 Ischemic heart disease	0.64 Stroke	0.99 Lower respiratory infect	2/18 Total cancers	1.29 Hypertensive heart disease	1 Diabetes	0.99 Chronic kidney disease	0.93 Alzheimer's disease	COPD	0.91 Tuberculosis
Sevchelles	0.75 Ischemic heart disease	0.81 Total cancers	4.17 Lower respiratory infect	0.78 Stroke	1.75 Hypertensive heart disease	1.03 Chronic kidney disease	1.82 Alzheimer's disease	1.02 Diabetes	1.06 COPD	9.7 Colorectal cancer
Scilanka	0.74 Ischemic heart disease	1.15 Stroke	3.79 Diabetes	0.78 Total cancers	4.05 Asthma	3.23 Alzheimer's disease	1.03 Chronic kidney disease	1.39 Hypertensive heart disease	1.23 Lower respiratory infect	1.62 COPD
Thailand	0.69 Total cancers	0.74 Ischemic heart disease	2.57 Stroke	0.66 Alzheimer's disease	17.02 Lower respiratory infect	1.07 Chronic kidney disease	1.45 Diabetes	1.26 COPD	1.02 Lung cancer	1.13 Liver cancer
Times Locks	0.87 Stroke	0.32 Ischemic heart disease	0.47 Total cancers	1.02 Lower respiratory infect	1.42 COPD	1.87 Hypertensive heart disease	0.77 Diabetes	0.77 Alzheimer's disease	1.69 Chronic kidney disease	5.2 Tuberculosis
Wet New	1.5 Stroke	0.99 Ischemic heart ilisease	0.91 Total cancers	1.92 Alzheimer's disease	1.38 Diabetes	1.32 COPD	0.83 Chronic kidney disease	1.03 Lower respiratory infect	1.19 Hypertensive heart disease	3.05 Falls
Viet Nam	1.23 Stroke	0,64 Ischemic heart disease	0.86 Total cancers	1.27 Lower respiratory infect	1.23 Hypertensive heart disease	1.41 Diarrheal diseases	1.55 Diabetes	1.06 Alzheimer's disease	1.11 Tuberculosis	5.03 COPD
Sub-Saharan Africa Central Sub-Saharan	0.94 Ischemic heart disease	0.74 Stroke	1.01 Lower respiratory infect	1.58 Hypertensive heart disease	1.41 Total cancers	1.59 Tuberculosis	1.18 COPD	1.09 Diarrheal diseases	1.88 Alzheimer's disease	0.8 Diabetes
Africa	0.91 Ischemic heart disease	0.99 Stroke	1.68 Total cancers	2.18 Lower respiratory infect	0.91 Hypertensive heart disease	2.64 Diambeal diseases	L4 COPD	1.43 Alzheimer's disease	1.11 Tuberculosis	0.81 Diabetes
Angola Central African	0.83 Stroke	0.98 Ischemic heart disease	0.89 Diarcheal diseases	1.55 Tutherruleris	2.04	323	0.98	1.12	3.06	0.86 Diabates
Republic	1.17	1.15	2.11	2.25	1.33	2.14	0.92	1.5	1.78	1.04
Congo	lschemic heart disease 0.98	Stroke 1.15	Total cancers 1.09	Hypertensive heart disease 3.12	Lower respiratory infect 2.83	Diabetes 1.2	COPD 1.35	Alzheimer's disease 1.17	Tuberculosis 9.2	Diarrheal diseases 8.71
Democratic Republic of the Congo	Ischemic heart disease 0.92	Stroke 0.97	Lower respiratory infect 1.66	Hypertensive heart disease 2,14	Total cancers 0.9	Tuberculosis 2.52	COPD 1.5	Alzheimer's disease 1.1	Diarrheal diseases 1.06	Asthma 1.74
Equatorial Guinea	Ischemic heart disease 0.8	Stroke 1.08	Total cancers 1.06	Lower respiratory infect 3.74	Hypertensive heart disease 3.63	Diabetes 1.78	Alzheimer's disease 1.21	COPD 1.78	Chronic kidney disease 1.98	Breast cancer 1.54
Gabon	Ischemic heart disease	Stroke	Total cancers	Hypertensive heart disease	Lower respiratory infect	Diabetes	Alzheimer's disease	Chronic kidney disease	COPD	Breast cancer
Eastern Sub-Saharan	Stroke	Ischemic heart disease	Lower respiratory infect	Total cancers	Hypertensive heart disease	Diarrheal diseases	Tuberculosis	Alzheimer's disease	Diabetes	Cirrhosis
Burundi	Stroke	Ischemic heart disease	Lower respiratory infect	Tuberculosis	Total cancers	Diarrheal diseases	Hypertensive heart disease	Alzheimer's disease	COPD	Diabetes
Comoros	0.98 Stroke	0.85 Ischemic heart disease	Lower respiratory infect	1.89 Total cancers	0.98 Hypertensive heart disease	0.96 Alzheimer's disease	1.26 Tuberculosis	L06 Diabetes	1 Diarrheal diseases	0.98 Chronic kidney disease
Diibouti	1.01 Stroke	0.77 Ischemic heart disease	1.77 Total cancers	1.03 Lower respiratory infect	1.77 Hypertensive heart disease	1.14 Diabetes	3.22 Alzheimer's disease	1.02 Tuberculosis	1.92 Diarrheal diseases	1.07 Chronic kidney disease
Silves	0.98 Stroke	0.79 Lower respiratory infect	1.11 Ischemic heart disease	1.7 Total cancers	1.76 Hypertensive heart disease	1.08 Tuberculosis	1.18 Diarrheal diseases	2.69 Diabetes	1.66 Cirrhosis	1.07 Alzheimer's disease
Entrea	1.09 Stroke	2.27 Ischemic heart disease	0.77 Lower respiratory infect	1.19 Total cancers	2.22 Diarrheal diseases	3.37 Hypertensive heart disease	2.3 Alzheimer's disease	1.23 Tuberculosis	1.84 Cirrhosis	1.16 Diabetes
Ethiopia	0.79 Stroke	0.71 Netromic heart disease	1.17 Lower respiratory infect	0.94 Total cancers	1.25 Hypertensive heart disease	1.27 Diambeal diseases	1.21 Cirrhosis	1.32 Alzheimer's disease	1.72 Tuberculosis	0.93 Diabetes
Kenya	0.88 Stroke	0.54	2.18 Munortensius heart disease	0.96	1.6	3.79 Diarrhaal diseases	2.62 Tubarradoris	1.11	E32	0.73 Alabaimar's disease
Madagascar	1.46	0.82	2:67	1.62	0.85	1.85	2.58	1.02	0.83 Disheter	0.85
Malawi	0.87	0.59	1.18	1.32	1.71	1.39	2.18	1.13	0.91	1.41
Mozambique	1.2	0.55	1.16	1.05	1.7	1.87	1.23	0.98	5.31	0.44
Rwanda	Stroke 1.02	Ascheinic heart disease	Total cancers 1.08	Lower respiratory infect 1.54	Hypertensive heart disease 1.48	Alzheimer's disease 1.16	0.99	Z.26	0.91	Diarrheal diseases 1.38
Somalia	Stroke 0.97	Tuberçülasis 0.63	Ischemic heart disease 1.02	Diarrhual diseasus 0.36	Lower respiratory intect 0.73	Hypertensive heart disease 1.19	Total cancers 1.02	Diabetes 1.25	0.94	Cirrhosis 0.87
South Sudan	Stroke 0.85	Ischemic heart disease 0.64	Diarrheal diseases 2.25	Lower respiratory infect 1.23	Total cancers 0.97	Hypertensive heart disease 1.37	Tuberculosis 2.13	Alzheimer's disease 1	Diabetes 0.94	Cirrhosis 1.36
Uganda	Stroke 0.88	Uschemic heart disease 0.63	Total cancers 1.22	Lower respiratory infect 1.52	Hypertensive heart disease 1.33	Tuberculosis 2.33	Alzheimer's disease	Diabetes 1	Diarrheal diseases 1.3	COPD 0.66
United Republic of Tanzania	Stroke	Aschomic heart disease	Total cancers	Lower respiratory infect	Hypertensive heart disease	Diarrheal diseases	Alzheimer's disease	Tuberculosis 2.51	Diabetes 1	Chronic kidney disease
Zambia	Stroke	Total cancers	Hypertensive heart disease	Ischemic heart disease	Lower respiratory infect	Diamheal diseases	Diabetes 0.93	Tuberculosis	Alzheimer's disease	Cirrhosis 213
Southern Sub-Saharan	Stroke	Ischemic hears disease	Total cancers	Diabetes	Lower respiratory infect	Hypertensive heart disease	Alzheimer's disease	COPD	Chronic kidney disease	Diarrheal diseases
Botswana	Stroke	Ischemic heart disease	Total cancers	Diabetes	Lower respiratory infect	Hypertensive heart disease	Alzheimer's disease	COPD	Chronic kidney disease	Breast cancer
Eswatini	Stroke	Diabétes	Ischemic heart disease	Total cancers	Lower respiratory infect	Hypertensive heart disease	Diarrheal diseases	Chronic kidney disease	COPD	Alzheimer's disease
Lesotho	1.15 Stroke	Ischemic heart disease	Diabetes	1.25 Total cancers	2.34 Lower respiratory infect	2.15 Hypertensive heart disease	Diarrheal diseases	L.47 COPD	1.25 HIV/AID5	0.95 Tuberculosis
Namibia	1.56 Stroke	0.75 Inchemic heart disease	3 Total cancers	1.39 Lower respiratory infect	2.21 Diabetes	2.45 Hypertensive heart disease	6.24 Alzheimer's disease	1.92 COPD	436.75 Diamheal diseases	S:35 Chronic kidney disease
South Africa	1.11 Stroke	0,6	0.91	2.82	1.78	2.31	1.08	1.59	14.45 Chronic kidney disease	1.03 Diambeal diseases
South Affica		Total cancers	tschemic heart disease	Diabetes	Lower respiratory infect	Hypertensive heart disease	Alzheimer's disease	COPD	antonic mane y about	
Zimbabwe Western Sub-Saharan	0.86 Ischemic heart disease	Total cancers 0.99 Total cancers	0.49 Stroke	2.63 Lower respiratory infect	Lower respiratory infect 2.43 Diabetes	Hypertensive heart disease 2.42 Alzheimer's disease	Alzheimer's disease 0.99 Tuberculosis	COPD 1.47 Hypertensive heart disease	1.61 Chronic kidney disease	27.4 Diarrheal diseases
	0,86 Ischemic heart disease 1.15 Ischemic heart disease	Total cancers 0.99 Total cancers 1.74 Stroke	tschemic heart disease 0.49 Stroke 0.9 Lower respiratory infect	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers	Lower respiratory infect 2.43 Diabetes 1.7 Diarrheal diseases	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Malaria	Alzheimer's disease 0.99 Tuberculosis 3.07 Diabetes	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease	1.61 Chronic kidney disease 1.16 Tuberculosis	27.4 Diarrheal diseases 1.81 Hypertensive be art disease
Africa	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.86 Stroke	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic hand disease	Ischemic heart disease 0.45 Stroke 0.9 Lower respiratory infect 1.55	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers	Lower respiratory infect 2.43 Diabetes 1.7 Diarrheal diseases 1.78 Malagia	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Malaria 19.44 Diarthaal disease	Alzheimer's disease 0.99 Tuberculosis 3:07 Diabetes 1:05 Diabetes	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.1 Alzheimar's disease	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kideav disease
Africa Benin	0,86 Ischemic heart disease 1.15 Ischemic heart disease 0.96 Stroke 0.99	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.88	Lower respiratory infect 149 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers	Lower respiratory infect 2.43 Diabetes 1.7 Diarrheal diseases 1.78 Malarta 10.79 Diagnati diseases	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Malaria 15.44 Diarrheat diseases 1.09 Malaria	Alzheimer's disease 0.99 Tuberculosis 3.07 Diabetes 1.05 Diabetes 1.09	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.0 Alzheimer's disease 1.09	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Disease
Africa Benin Burkina Faso	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.86 Stroke 0.99 Ischemic heart disease 1.03	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.88 Stroke 0.54	techemic haard disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.18	Diabetes 2,63 Lower respiratory infect 2,61 Total cancers 0,97 Total cancers 1 Total cancers 1 1 Total cancers 1,11	Lower respiratory infect 2.43 Diabetes 1.7 Diarrheal diseases 1.78 Malaria 10.79 Diarrheal diseases 0.8	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Malaria 19.44 Diarrheal diseases 1.09 Malaria 6.27	Alzheimer's disease 0.99 Tuberculosis 3.07 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.09 Alzheimer's disease 1.15	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71	27.4 Diartheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83
Africa Benin Burkina Faso Cabo Verde	0.86 Ischemich eart disease 1.15 Ischemicheart disease 0.86 Stroke 0.99 Ischemicheart disease 1.03 Ischemicheart disease 0.91	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.88 Stroke 0.54 Total cancers 1.53	ttchemic heart disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.18 Stroke 0.62	Diabetes 2.63 Lower respiratory Infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 1.66	Lower respiratory infect 2.43 Diabetes 1.7 Diarbeal diseases 1.78 Malaria 10.79 Diarrheal diseases 0.8 Alzheimr* disease 1	Hypertensive heart disease 2.42 Alzheimer's disease 1.05 Malaria 19.44 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2	Alzheimer's disease 0.99 Tuberculosis 3.07 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 0.92	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.0 Alzheimer's disease 1.15 Hypertensive heart disease 2.65	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27	27.4 Diamheal diseases 181 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52
Africa Benin Burkina Faso Cabo Verde Cameroon	0.86 Ischemich eart disease 1.15 Ischemicheart disease 0.99 Ischemicheart disease 1.03 Ischemicheart disease 0.91 Ischemicheart disease 0.74	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.88 Stroke 0.64 Total cancers 1.53 Stroke 0.9	techemic heard disease 0.49 Stroke 0.5 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.8 Stroke 0.62 Total cancers 1.09	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1.1 Total cancers 1.11 Lower respiratory infect 1.66 Lower respiratory infect 2.06	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Alzheimer's disease 1 Diabetes 1.42	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Malaria 25.44 Diarrheal diseases 1.09 Malaria 5.27 Diabetes. 1.2 Malaria 437.05	Altheimer's disease 0.99 Tuberculosis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 0.92 Chronic kidney disease 1.58	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.1 Alzheimer's disease 1.09 Alzheimer's disease 1.15 Hypertensive heart disease 0.65 Alzheimer's disease 1.1	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27 Diarcheal diseases 2.41	27.4 Diamheal diseases 1.81 Hypertensive heard disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52 Tuberculosis 2.87
Africa Benin Burkina Faso Cabo Verde Cameroon Chad	0.86 Ischemich eart disease 1.15 Ischemic heart disease 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemic heart disease 0.74 Ischemic heart disease 1.01	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.68 Stroke 0.54 Total cancers 1.53 Stroke 0.9 Stroke 0.87	techemic haard disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.18 Suroke 0.62 Total cancers 1.09 Lower respiratory infect 1.27	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 1.66 Lower respiratory infect 2.06 Diarrheal diseases 0.33	Lowr 7:espiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Alzheimer's disease 1 Diabetes 1.42 Total cancers 1.08	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Malaria 19.44 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 432.05 Tuberculosis 0.92	Alzheimer's disease 0.99 Tuberculoais 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.92 Chronic kidney disease 1.58 Diabetes 1.19	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.09 Alzheimer's disease 1.15 Hypertensive heart disease 0.65 Alzheimer's disease 1.1 Alzheimer's disease 1.1 Alzheimer's disease 1.1 Alzheimer's disease 1.1 Alzheimer's disease 1.1	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27 Diarthead diseases 2.41 Hypertensive heart disease 0.74	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52 Tuberculosis 2.87 Cirrhosis 1.07
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire	0.86 Ischmich eart disease 1.15 Ischmich eart disease 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemich eart disease 0.74 Ischemich eart disease 1.01 Ischemich eart disease 0.74	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.88 Stroke 0.84 Total cancers 1.53 Stroke 0.9 Stroke 0.87 Stroke 0.87	techemic heard disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.8 Surbse 0.62 Total cancers 1.09 Lower respiratory infect 1.27 Lower respiratory infect 1.27 Lower respiratory infect 1.65	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 2.06 Diartheal diseases 0.93 Total cancers 1.02	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Alzheimer's disease 1 Diabetes 1.42 Total cancers 1.08 Malaria 5.76	Hypertensive heart disease 2.42 Alzheimer's disease 1.05 Malaria 19.44 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 432.05 Tuberculosis 0.92 Diabetes 1.2	Alzheimer's disease 0.99 Tuberculiatis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heard disease 0.92 Chronic kidney disease 1.58 Diabetes 1.59 Diabetes 1.59 Diabetes 1.19 Alzheimer's disease 1.06	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.09 Alzheimer's disease 1.15 Hypertensive heart disease 1.3 Alzheimer's disease 1.1 Alzheimer's disease 1.3	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.75 Diarrhead diseases 2.41 Hypertensive heart disease 0.74 Tuberculosis 1.8	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52 Tuberculosis 2.87 Cirrhosis 1.07 Chronic kidney disease 1.18
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.99 Ischemic heart disease 0.91 Ischemic heart disease 0.91 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.04 Ischemic heart disease 1.04 Ischemic heart disease 1.04 Ischemic heart disease 1.04	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemich eart disease 0.88 Stroke 0.59 Total cancers 1.53 Stroke 0.9 Stroke 0.87 Stroke 0.87 Stroke 0.8 Stroke 0.8 Stroke 0.8 Stroke 0.9	techemic heard disease 049 Stroke 0,9 Lower respiratory infect 1.55 Lower respiratory infect 1.8 Stroke 0.62 Total cancers 1.09 Lower respiratory infect 1.27 Lower respiratory infect 1.25 Lower respiratory infect 1.27 Lower respiratory infect 1.25 Lower respiratory infect 1.20	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 2.06 Diarrheal diseases 0.93 Total cancers 1.02 Total cancers 1.02	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diarrhaal diseases 0.8 Alzheimer's disease 1 Diabetes 1.42 Total cancers 1.08 Malaria 55.76 Diabetes 1.2	Hypertensive heart disease 2.42 Alzheimer's disease 1.05 Malaria 19:34 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 427.05 Tuberculosis 0.92 Diabetes 1.2 Tuberculosis 2.32	Alzheimer's disease 0.99 Tuberculiatis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 0.9 Chronic kidney disease 1.58 Diabetes 1.19 Alzheimer's disease 1.06 Alzheimer's disease 1.13	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.0 Alzheimer's disease 1.5 Hypertensive heart disease 1.1 Alzheimer's disease 1.1 Hypertensive heart disease 1.3 Hypertensive heart disease 0.9 Diarrheal disease 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27 Diarrheal diseases 2.41 Hypertensive heart disease 0.74 Tuberculosis 1.8 Diarrheal diseases 1.16	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.85 COPD 0.52 Tuberrulosis 2.87 Cirrhosis 1.07 Chronic kidney disease 1.18 Chronic kidney disease 1.12
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Ghana	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.96 Stroke 0.99 Ischemic heart disease 0.91 Ischemic heart disease 0.94 Ischemic heart disease 0.94 Ischemic heart disease 0.84 Ischemic heart disease 1.11 Stroke 1.37	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischenic heart disease 0.88 Stroke 0.91 Total cancers 1.53 Stroke 0.9 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87	techemic haard disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.8 3troke 0.52 Total cancers 1.09 Lower respiratory infect 1.27 Lower respiratory infect 1.65 Lower respiratory infect 2.02 Total cancers non	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 2.06 Diarrhead diseases 0.93 Total cancers 1.02 Total cancers 0.87 Lower respiratory infect	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Alzheimer's disease 1 Diabetes 1.42 Total cancers 1.08 Malaria 55.76 Diabetes 1.2 Diabetes 1.2 Diabetes	Hypertensive heart disease 2.42 Alzheimer's disease 1.05 Malaria 19:34 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 437.05 Diabetes 1.2 Diabetes 1.2 Tuberculosis 2.32 Chronic kidney disease 1.4 disease	Alzheimer's disease 0.99 Tuberculosis 3.07 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 1.9 Chronic kidney disease 1.58 Diabetes 1.19 Alzheimer's disease 1.05 Alzheimer's disease 1.05 Alzheimer's disease	COPD 1.47 Hypertensive heart disease 0.92 Altheimer's disease 1.1 Alzheimer's disease 1.5 Hypertensive heart disease 1.5 Alzheimer's disease 1.1 Alzheimer's disease 1.3 Hypertensive heart disease 0.93 Maiania disa 1.3	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27 Diartheal disease 0.74 Hypertensive heart disease 1.16 Hypertensive heart disease 1.16	27.4 Diamheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52 Tuberculosis 2.87 Clirrhosis 1.07 Chronic kidney disease 1.18 Chronic kidney disease 1.22 Diamheal diseases
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Ghana Guinea	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.86 Stroke 0.99 Ischemic heart disease 0.91 Ischemic heart disease 0.94 Ischemic heart disease 0.84 Ischemic heart disease 1.01 Ischemic heart disease 1.03 Ischemic heart disease 1.04 Ischemic heart disease 1.01 Stroke 1.01 Note	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.69 Total cancers 1.53 Stroke 0.9 Stroke 0.87 Stroke 0.88 Stroke 0.86 Stroke 0.96 Stroke 0.96 Stroke 0.96 Stroke 0.96 Stroke 0.96	techemic heard disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.18 Stroke 0.62 Total cancers 1.09 Lower respiratory infect 1.55 Lower respiratory infect 2.02 Total cancers 0.99 Lower respiratory infect	Diabetes 2.63 Lower respiratory infest 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 1.66 Lower respiratory infect 2.06 Diarrhead diseases 0.93 Total cancers 1.02 Total cancers 0.67 Lower respiratory infect 1.97 Total cancers 1.97 Total cancers 1.97	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Alzheimer's disease 1.68 Malaria 55.76 Diabetes 1.2 Diabetes 1.2 Diabetes 1.2 Diabetes 1.2 Diabetes 1.2 Diabetes 1.2 Diabetes 1.2 Diabetes 1.2	Hypertensive heart disease 2.42 Altheimer's disease 1.06 Malaria 1.94 Diartheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 437.05 Tuberculosis 0.32 Diabetes 1.2 Tuberculosis 2.32 Chronic kidney disease 1.36 Diabetes 1.37	Alzheimer's disease 0.99 Tuberculosis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 0.92 Chronic kidney disease 1.58 Diabetes 1.19 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Alzheimer's disease 0.95 Alzheimer's disease	COPD 1.47 Hypertensive heart disease 0.92 Altheimer's disease 1.1 Altheimer's disease 1.09 Altheimer's disease 1.15 Hypertensive heart disease 1.65 Diartheal diseases 1.3 Hypertensive heart disease 0.93 Malaria 083.74 Tuberculosis 1.38	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.72 Diarrheal diseases 0.74 Hypertensive heart disease 1.16 Hypertensive heart disease 1.16 Hypertensive heart disease 1.16 Hypertensive heart disease 1.27 Hypertensive heart disease 1.28 Diarrheal disease 1.20 Hypertensive heart disease 1.20 Hypertensive heart disease 1.20 Hypertensive heart disease 1.20 Hypertensive heart disease	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52 Tubercalosis 1.57 Chronic kidney disease 1.18 Chronic kidney disease 1.22 Diarrheal diseases 4.73 Chronic kidney disease 1.2
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Ghana Guinea Guinea	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.86 Stroke 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemic heart disease 0.94 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.03 Ischemic heart disease 1.01 Ischemic heart disease 1.03 Ischemic heart disease 1.03 Ischemic heart disease 1.03 Ischemic heart disease 1.03 Ischemic heart disease 1.03 Ischemic heart disease 1.27 Ischemic heart disease 0.98 Ischemic heart disease	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heard tisease 0.83 Stroke 0.99 Stroke 0.9 Stroke 0.9 Stroke 0.87 Stroke 0.95 Ischemic heard disease 0.96 Ischemic heard disease 0.97 Stroke 0.96 Ischemic heard disease 0.87 Stroke 0.96 Ischemic heard disease 0.87 Stroke 0.96 Ischemic heard disease 0.87 Stroke 0.96 Ischemic heard disease 0.87 Stroke 0.96 Ischemic heard disease 0.87 Stroke 0.96 Ischemic heard disease 0.87 Ischemic heard disease 0.87 Ischemic heard disease 0.87 Ischemic heard disease 0.87 Ischemic heard disease 0.87 Ischemic heard disease 0.96 Ischemic heard disease 0.96 Ischemic heard disease 0.87 Ischemic heard disease 0.96 Ischemic heard disease Ischemic heard disease Is	techemic heard disease 049 Stroke 0,9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.18 Stroke 062 Total cancers 1.09 Lower respiratory infect 1.25 Lower respiratory infect 2.02 Total cancers 0.99 Lower respiratory infect 1.74 Lower respiratory infect 1.74	Diabetes 2.63 Lower respiratory infest 2.61 Total cancers 0.97 Total cancers 1 Lower respiratory infect 1.66 Lower respiratory infect 0.63 Diarrheal diseases 0.93 Total cancers 1.02 Total cancers 1.02 Lower respiratory infect 1.97 Total cancers 1.97	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Atzheimer's disease 0.8 Atzheimer's disease 1.42 Diabetes 1.42 Total cancers 1.08 Malaria 55.76 Diabetes 1.2 Diabetes 0.94 Diartheal diseases 1.2 Diartheal diseases	Hypertensive heart disease 2.42 Altheimer's disease 1.06 Malaria 25.44 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 417.05 Tuberculosis 0.92 Diabetes 1.2 Tuberculosis 2.32 Chronic kidney disease 1.35 Diabetes 1.32 Diabetes 1.32 Diabetes	Alzheimer's disease 0.99 Tuberculosis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 0.92 Chronic kidney disease 1.58 Diabetes 1.19 Alzheimer's disease 1.05 Alzheimer's disease 1.03 Alzheimer's disease 1.13 Tuberculosis	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.1 Alzheimer's disease 1.09 Alzheimer's disease 1.65 Alzheimer's disease 1.3 Hypertensive heart disease 0.9 Diarrheal diseases 1.3 Hypertensive heart disease 0.9 Maiaria disa.24 Tuberculosis 1.28 Hypertensive heart disease	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27 Diartheal diseases 2.41 Hypertensive heart disease 0.74 Tuberculosis 1.8 Diartheal diseases 1.16 Hypertensive heart disease 1.02 Hypertensive heart disease 0.79 Alzheimer's disease	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 COPD 0.52 Tuberculosis 2.87 Cirrhosis 1.07 Chronic kidney disease 1.18 Chronic kidney disease 1.22 Diarrheal disease 4.73 Chronic kidney disease 1.2 Chronic kidney disease
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Ghana Guinea Guinea Guinea Liberia	0.86 Ischemic heart disease 1.15 Ischemic heart disease 0.86 Stroke 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.02 Ischemic heart disease 1.03 Ischemic heart disease 1.04 Ischemic heart disease	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.68 Stroke 0.91 Total cancers 1.53 Stroke 0.9 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.9 Stroke 0.8 Stroke 0.9 Stroke 0.8 Stroke 0.9 Stroke 0.9 Stroke 0.9 Stroke 0.8 Stroke 0.9 Stroke	techemic heard disease 0.49 Stroke 0.9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.8 Total cancers 1.09 Lower respiratory infect 1.55 Lower respiratory infect 2.02 Total cancers 0.99 Lower respiratory infect 1.72 Lower respiratory infect 1.74 Lower respiratory infect 1.74 Lower respiratory infect 1.74	Diabetes 2.63 Lower respiratory infest 2.51 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 1.66 Lower respiratory infect 0.93 Total cancers 0.93 Lower respiratory infect 1.02 Total cancers 0.87 Lower respiratory infect 1.97 Total cancers 1.19 Total cancers 1.15	Lower respiratory infect 2.43 Diabetes 1.7 Diarrheal diseases 1.78 Malaria 10.79 Diarrheal diseases 1 Diabetes 1.42 Total cancers 1.08 Malaria 55.76 Diabetes 1.2 Diabetes	Hypertensive heart disease 2.42 Altheimer's disease 1.06 Malaria 25.44 Diarrheal diseases 1.09 Malaria 5.27 Diabetes 1.2 Malaria 417.05 Tuberculosis 0.92 Diabetes 1.2 Chronic kidney disease 1.36 Diabetes 1.35 Diabetes 1.35 Diabetes 1.36 Diabetes	Alzheimer's disease 0.99 Tuberculosis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 1.08 Diabetes 1.19 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Diabetes 1.11 Tuberculosis 1.64 Diabetes	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.0 Alzheimer's disease 1.0 Hypertensive heart disease 1.3 Hypertensive heart disease 0.93 Maiaría 093.74 Tuberculosis 1.28 Hypertensive heart disease 0.97 Alzheimer's disease	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.47 Diartheal diseases 2.41 Hypertensive heart disease 1.16 Hypertensive heart disease 1.02 Hypertensive heart disease 0.99 Alzheimer's disease 1.05 Chronic kidney disease	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 CoPD 0.52 Tuberralosis 2.87 Cirrhosis 1.07 Chronic kidney disease 1.22 Diarrheal diseases 1.22 Diarrheal diseases 1.22 Chronic kidney disease 1.23 Chronic kidney disease 1.23 Tuberculosis
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Ghana Guinea Guinea Guinea Liberia Mali	0.86 Ischemic heart disease 0.36 Stroke 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemic heart disease 0.91 Ischemic heart disease 0.94 Ischemic heart disease 0.84 Ischemic heart disease 1.01 Ischemic heart disease 1.27 Ischemic heart disease 1.27 Ischemic heart disease 1.27 Ischemic heart disease 0.98 Ischemic heart disease 0.99 Ischemic heart disease 0.95 Ischemic heart disease 0.95 Ischemic heart disease	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.88 Total cancers 1.53 Stroke 0.9 Stroke 0.9 Stroke 0.87 Stroke 0.96 Ischemic heart disease 0.87 Stroke 0.96 Stroke 1.02 Stroke 1.02 Stroke 1.02 Stroke 0.93 Stroke	techemic heard disease 049 Stroke 0,9 Lower respiratory infect 1.55 Lower respiratory infect 1.8 Stroke 0,9 Lower respiratory infect 1.9 Lower respiratory infect 1.65 Lower respiratory infect 1.65 Lower respiratory infect 1.74 Lower res	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 2.06 Diartheal diseases 0.93 Total cancers 1.02 Total cancers 0.87 Lower respiratory infect 1.97 Total cancers 0.87 Lower respiratory infect 1.97 Total cancers 1.19 Total cancers 1.15 Total cancers 1.15 Total cancers 1.02	Lower respiratory infect 2.43 Diabetes 1.7 Diarrheal diseases 1.78 Malaria 10.79 Diarrheal diseases 1 Diabetes 1.42 Total cancers 1.08 Malaria 55.76 Diabetes 1.22 Diarrheal diseases 1.22 Diarrheal diseases 2.11 Malaria Barrheal diseases 2.11 Malaria Barrheal diseases 2.11 Malaria Barrheal diseases 2.11 Malaria	Hypertensive heart disease 2.42 Alzheimer's disease 1.06 Milaria 39.44 Diarrheal diseases 1.09 Malaria 5.27 Diabetes 1.2 Malaria 432.05 Tuberculosis 0.32 Diabetes 1.2 Tuberculosis 2.32 Chronic kidney disease 1.36 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes	Alzheimer's disease 0.99 Tuberculosis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.9 Chronic kidney disease 0.92 Chronic kidney disease 1.58 Diabetes 1.58 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Alzheimer's disease 0.95 Alzheimer's disease 1.11 Tuberculosis 1.64 Diabetes 1.21 Lower responsery infect	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.09 Alzheimer's disease 1.15 Hypertensive heart disease 1.3 Hypertensive heart disease 0.93 Mianim 083.74 Tuberculosis 1.28 Hypertensive heart disease 0.93 Mianim 083.74 1.28 Hypertensive heart disease 0.93 Mianim 083.74 1.28 Hypertensive heart disease 0.93 Mianim 083.74 1.28 Hypertensive heart disease 0.93 Mianim 1.28 Hypertensive heart disease 0.93 Mianim 1.28 Hypertensive heart disease 0.97 Mianim	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach carcier 2.27 Diartheal diseases 2.41 Hypertensive heart disease 0.74 Toberculosis 1.8 Diartheal diseases 1.16 Hypertensive heart disease 1.02 Hypertensive heart disease 1.02 Hypertensive heart disease 1.05 Chronic kidney disease 1.34 Alzheimer's disease	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 Corbo 0.52 Tuberculosis 2.87 Cirrhosis 1.07 Chronic kidney disease 1.22 Diarrheal diseases 4.73 Chronic kidney disease 1.23 Tuberculosis 1.23 Tuberculosis 1.23 Tuberculosis 1.23 Tuberculosis 1.23
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Ghana Guinea Guinea Guinea-Bissau Liberia Mali	0.86 Ischemic heart disease 0.36 Stroke 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemic heart disease 0.91 Ischemic heart disease 0.91 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.11 Stroke 1.27 Ischemic heart disease 1.14 Ischemic heart disease 0.95 Ischemic heart disease 1.14 Ischemic heart disease 1.14 Ischemic heart disease 1.14 Ischemic heart disease 1.14 Ischemic heart disease 0.95 Ischemic heart disease 1.14 Ischemic heart disease 1.14 Is	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemich eart disease 0.88 Stroke 0.99 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.85 Stroke 0.95 Ischemic heart disease 0.95 Ischemic heart disease 0.95 Stroke 0.93 Stroke 0.93 Stroke 0.93 Stroke 0.93 Stroke	techemic heard disease 049 Stroke 0,9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.65 Lower respiratory infect 1.65 Lower respiratory infect 2.02 Total cancers 0.99 Lower respiratory infect 1.74 Lower respiratory infect 1.88 Lower respiratory infect 1.44 Diarrhead diseases 1 Lower respiratory infect	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 2.06 Diartheal diseases 0.93 Total cancers 1.02 Total cancers 1.03 Lower respiratory infect 1.97 Total cancers 1.19 Total cancers 1.19 Total cancers 1.19 Total cancers 1.19 Total cancers 1.19 Total cancers 1.02 Total cancers 1.02 Total cancers 1.02 Total cancers 1.19 Total cancers 1.02 Total cancers 1.02 Total cancers 0.97 Total cancers 0.97 Total cancers 0.97 Total cancers	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 0.8 Alzheimer's diseases 1.42 Total cancers 1.08 Malaria 5.76 Diabetes 1.42 Total cancers 1.08 Malaria 5.76 Diabetes 1.2 Diabetes 1.3 Diabetes 1.3 Diabetes	Hypertensive heart disease 2.42 Alzheimer's disease 1.05 Malaria 193.44 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Malaria 432.05 Tuberculosis 0.92 Diabetes 1.2 Tuberculosis 2.32 Chronic Kidney disease 1.35 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.44 Diartheal diseases 1.47 Diabetes 1.43 Malaria	Alzheimer's disease 0.99 Tuberculoais 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.92 Chronic kidney disease 0.92 Chronic kidney disease 0.92 Chronic kidney disease 1.58 Diabetes 1.19 Alzheimer's disease 1.13 Alzheimer's disease 0.95 Alzheimer's disease 1.11 Tuberculosis 1.64 Diabetes 1.21 Iower regularizing prifect 1.20	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.0 Alzheimer's disease 1.0 Alzheimer's disease 1.1 Hypertensive heart disease 1.3 Alzheimer's disease 1.1 Alzheimer's disease 1.3 Hypertensive heart disease 0.93 Malarla 061.74 Tuberculosis 1.28 Hypertensive heart disease 0.93 Malarla 061.74 Tuberculosis 1.28 Hypertensive heart disease 0.97 Alzheimer's disease 0.97 Alzheimer's disease 0.97 Loss 1.28 Hypertensive disease 0.97 Alzheimer's disease 0.97 0	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Stomach cancer 2.27 Diartheal diseases 2.41 Hypertensive heart disease 0.74 Tuberculosis 1.8 Diartheal diseases 1.16 Hypertensive heart disease 1.02 Hypertensive heart disease 1.02 Hypertensive heart disease 1.04 Alzheimer's disease 1.34 Alzheimer's disease	27.4 Diamheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.83 Corb 0.52 Tubercalosis 2.87 Cirrhosis 1.07 Chronic kidney disease 1.23 Diamheal disease 4.23 Chronic kidney disease 1.2 Diamheal disease 1.2 Chronic kidney disease
Africa Benin Burkina Faso Cabo Verde Cameroon Chad Côte d'Ivoire Gambia Guinea Guinea Guinea Guinea Liberia Mali Mauritania	0.86 Ischemic heart disease 0.36 Stroke 0.99 Ischemic heart disease 1.03 Ischemic heart disease 0.91 Ischemic heart disease 0.91 Ischemic heart disease 0.94 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Ischemic heart disease 1.01 Stroke 1.27 Ischemic heart disease 1.11 Stroke 1.27 Ischemic heart disease 0.93 Ischemic heart disease 1.12 Ischemic heart disease 0.95 Ischemic heart dis	Total cancers 0.99 Total cancers 1.74 Stroke 0.91 Ischemic heart disease 0.83 Stroke 0.9 Stroke 0.87 Stroke 0.87 Stroke 0.87 Stroke 0.85 Stroke 0.9 Ischemic heart disease 0.86 Ischemic heart disease 0.86 Stroke 0.95 Ischemic heart disease 0.87 Stroke 0.95 Ischemic heart disease 0.87 Stroke 0.95 Ischemic heart disease 0.87 Stroke 0.95 Ischemic heart disease 0.87 Stroke 0.95 Ischemic heart disease 0.87 Stroke 0.95 Ischemic heart disease 0.87 Stroke 0.95 Stroke 0.95 Stroke 0.93 Stroke 0.93 Stroke	techemic haard disease 049 Stroke 0,9 Lower respiratory infect 1.55 Lower respiratory infect 1.43 Lower respiratory infect 1.65 Lower respiratory infect 1.65 Lower respiratory infect 2.02 Total cancers 0.99 Lower respiratory infect 1.54 Lower respiratory infect 1.74 Lower respiratory infect 1.74 Lower respiratory infect 1.88 Lower respiratory infect 1.44 Diarrheal diseases 1 Lower respiratory infect 2.09	Diabetes 2.63 Lower respiratory infect 2.61 Total cancers 0.97 Total cancers 1 Total cancers 1.11 Lower respiratory infect 2.06 Diarrhead diseases 0.93 Total cancers 1.02 Total cancers 1.03 Lower respiratory infect 1.97 Total cancers 1.15 Total cancers 1.15 Total cancers 1.15 Total cancers 1.02 Total cancers 0.97	Lower respiratory infect 2.43 Diabetes 1.7 Diartheal diseases 1.78 Malaria 10.79 Diartheal diseases 1.08 Alzheimer's disease 1.03 Alzheimer's disease 1.42 Diabetes 1.42 Total cancers 1.08 Malaria 55.76 Diabetes 1.2 Diabetes	Hypertensive heart disease 2.42 Alzheimer's disease 1.05 Milaria 193.44 Diarrheal diseases 1.09 Malaria 6.27 Diabetes 1.2 Tuberculosis 0.392 Diabetes 1.2 Tuberculosis 2.32 Chronic kidney disease 1.35 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.32 Diabetes 1.33 Milaria 420.05 Diabetes 1.44 Diarrheal diseases 1.47 Diabetes 1.47 Diabetes 1.47 Diabetes 1.47 Diabetes 1.47 Diabetes	Alzheimer's disease 0.99 Tuberculosis 307 Diabetes 1.05 Diabetes 1.09 Hypertensive heart disease 0.92 Chronic kidney disease 0.92 Chronic kidney disease 1.58 Diabetes 1.59 Diabetes 1.19 Alzheimer's disease 0.95 Alzheimer's disease 1.13 Alzheimer's disease 1.13 Tuberculosis 1.64 Diabetes 1.21 Tuberculosis 1.64 Diabetes 1.21 Diabetes 1.21 Diabetes 1.21 Diabetes 1.21 Diabetes 1.21 Diabetes 1.21 Diabetes 1.21 Diabetes 1.21 Diabetes	COPD 1.47 Hypertensive heart disease 0.92 Alzheimer's disease 1.0 Alzheimer's disease 1.0 Alzheimer's disease 1.5 Hypertensive heart disease 1.1 Alzheimer's disease 1.0 Diarrheal disease 1.3 Hypertensive heart disease 0.93 Malarle 0.93 Malarle 0.93 Hypertensive heart disease 0.93 Hypertensive heart disease 0.93 Malarle 0.93 Hypertensive heart disease 0.93 Malarle 0.93 Hypertensive heart disease 0.93 Chronickidney disease 1.07 Tuberculosis 0.81 Chronickidney disease 1.51 Tuberculosis	1.61 Chronic kidney disease 1.16 Tuberculosis 1.65 Hypertensive heart disease 0.75 Tuberculosis 0.71 Stomach cancer 2.27 Diartheal diseases 2.41 Hypertensive heart disease 0.74 Tuberculosis 1.8 Diartheal diseases 1.16 Hypertensive heart disease 0.29 Hypertensive heart disease 0.20 Hypertensive heart disease 0.89 Chronic kidney disease 1.05 Chronic kidney disease 1.34 Alzheimer's disease 1.35 Diartheal diseases 2.38 Alzheimer's disease 1.36	27.4 Diarrheal diseases 1.81 Hypertensive heart disease 0.83 Chronic kidney disease 1.14 Diabetes 0.852 Tuberculosis 2.85 Cirrhosis 1.07 Chronic kidney disease 1.18 Chronic kidney disease 1.22 Diarrheal diseases 4.73 Chronic kidney disease 1.23 Chronic kidney disease 1.23 Chronic kidney disease 1.23 Chronic kidney disease 1.23 Tuberculosis 1.42 Hypertensive heart disease 0.62 COPD

0.78 0.9 0.8/ 1.8 5.62 850.47 1.12 0.92	1.85
See Tyme and Reinder Stohemic heart disease Stroke Lower respiratory Infect Total cancers Chronic kidney disease COPD Alzheimer's disease Other cardiovascular Ar	thma Cirrhosis
sao lone and rindpe 1.08 1.14 2.8 1.26 2.26 1.43 1 5.95	2.55 1.5
Separal Ischemic heart disease Stroke Total cancers Lower respiratory infect Diabetes Alzheimer's disease Diarrheal diseases Tuberculosis Chronic ki	dney disease Malaria
0.93 0.81 1.08 1.33 1.31 1.15 1.29 1.93	1.3 15.95
Sierra Leone Ischemic heart disease Stroke Lower respiratory infect Total cancers Malaria Diarrheal diseases Diabetes Tuberculosis Alzheim	er's disease Hypertensive heart disease
11 0.96 1.64 1.02 14,27 1.26 1.19 1.43	1.05 0.69
Tono Ischemic heart disease Stroke Lower respiratory infect Total cancers Diarrheal diseases Malaria Diabetes Alzheimer's disease Tuber	rculosis Hypertensive heart disease
10g0 0.91 0.85 1.88 0.99 1.81 43,43 0.98 1.07	1.94 0.8
Values shown in brackets represent the ratio of observed deaths to predicted deaths on the basis of Socio-Demographic Index (SDI), rounded to two (2) digits. Color ranges (shown below) were calculated to place a raughly equal number of cells into each bin.	
COLOR KEY: (0.00.0.69) (0.68,0.83) (0.83,0.93) (0.93,1.02) (1.02,1.13) (1.13,1.28) (1.28,1.55) (1.55,1.94) [1.4	4,2.83) [2.83,)

Figure S22. Leading ten causes of total years lived with disability with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in males, for all GBD locations.

Causes are ranked based on global estimates of YLDs. Causes are color coded (shown in color key) based on observed to expected (O:E) rate ratio on the basis of SDI from the epidemiologic transition analysis. Shades of blue represent much lower observed deaths and YLDs than expected levels based on SDI, whereas red shows that observed deaths and YLDs exceed expected levels. When the ratio exceeds 1 means that observed levels exceeded the expected levels on the basis of SDI. O:E ratios are listed in each cell. YLDs = years of life lived with disability.

rigore i.e. ceating to causes	1	2	3	4	5	6	7	8	9	10
Global	Age-related hearing loss	Diabetes	COPD	Low back pain	Blindness and vision loss	Stroke	Falls	Alzheimer's disease	Osteoarthritis	Oral disorders
Central Europe, Eastern	1.09 Age-related bearing loss	0.97 Low back pain	1.51 Diabetes	0.9 Falls	1.28 Blindness and vision loss	1.16 Alzheimer's disease	1.12 Oral disorders	1.04 Osteoarthritis	1.01 Stroke	0.87
Europe, and Central Asia	1.09	1.22	0.93	1.45	1.46	1.18	1.12	1.06	1.12	0.79
Central Asia	Age-related hearing loss	Diabotes	Low back pain	Blindness and vision loss	Oral disorders	Alzheimer's disease	COPD	Stroke	Osteoarthritis	Falls
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Age-related hearing loss	Low back pain	1.09 Diabetes	1.25 Blindness and vision loss	1.55 Oral disorders	1.19 Alzheimer's disease	COPD	Osteparthritis	0.99 Ischemic heart disease	Atrial fibrillation
Armenia	0.98	1.15	0.83	1.33	1.35	1.22	1.19	0.97	1.09	1.39
Azerbaijan	Age-related hearing loss	Low back pain	Diabetes	Blindness and vision loss	Oral disorders	Alzheimer's disease	Stroke	COPD	Osteoarthritis	Ischemic heart disease
	Diabetes	Age-related hearing loss	Low back pain	1.35 Blindness and vision loss	1.51 Alzheimer's disease	0ral disorders	0.88 Falls	Depressive disorders	0.96 Stroke	COPD
Georgia	1.06	0.99	0.99	1.43	1.19	1.21	1,53	1.6	0.91	0.85
Kazakhstan	Age-related hearing loss	Low back pain	Diabetes	Blindness and vision loss	Oral disorders	COPD	Alzheimer's disease	Stroke	Falls	Osteoarthritis
	1.01 Age-related hearing loss	1.13 Low back pain	0.89 Blindness and vision loss	1.57 Oral disorders	L43 COPD	1.28 Alzheimer's disease	1,15 Diabetes	1.04 Osteoarthritis	1.09 Depressive disorders	0,95 Ischemic heart disease
Kyrgyzstan	0.95	1.12	0.9	1.35	1.57	1.25	0,49	1.06	1.18	0.91
Mongolia	Age-related hearing loss	Blindness and vision loss	Low back pain	Oral disorders	Alzheimer's disease	Falls	Diabetes	Osteoarthritis	Ischemic heart disease	Depressive disorders
	0,93 Ana. colated bearing loss	1.16	11 Jow back pain	1.27 Blindness and vision loss	1.2 Deal disordary	1.7 Alzhoimor's diseasee	036 Octoopthritic	1.04	1.09 Atrial Elizabetian	1.26
Tajikistan	Age-related hearing loss 0.96	0.63	LOW Dack pain 1.09	Dindness and vision loss	1.42	Alzheimer's disease	L03	ischemic heart disease	Athai fibriliation	1.36
Turkmanistan	Age-related hearing loss	Low back pain	Blindness and vision loss	Diabetes	Oral disorders	Alzheimer's disease	Stroke	Osteoarthritis	Ischemic heart disease	Atrial fibrillation
Turkinenstan	0.96	1.09	1.34	0.66	1.27	1.22	0.98	1.04	0.98	1.44
Uzbekistan	Age-related hearing loss	Diabetes	Low back pain	Blindness and vision loss	Oral disorders	Stroke 0.97	Osteoarthritis	Alzheimer's disease	Atrial fibrillation	Depressive disorders
Control Common	Diabetes	Low back pain	Age-related hearing loss	Falls	COPD	Stroke	Alzheimer's disease	Oral disorders	Mechanical forces	Blindness and vision loss
Central Europe	1,33	1,3	1.08	1.56	1.01	1.28	1.18	1,06	254	1.17
Albania	Low back pain	Age-related hearing loss	Disbetes	Mechanical forces	Oral disorders	Alzheimer's disease	Blindnest and vision loss	Stroke	COPD 1.07	Falls
	Diabetes	Age-related hearing loss	Low back pain	Stroke	Falls	COPD	Oral disorders	Alzheimer's disease	Blindness and vision loss	Mechanical forces
Bosnia and Herzegovina	1.5	0.98	1.22	1.56	1.44	1.17	1.08	1.14	0.9	2.67
Bulgaria	Low back pain	Diabetes	Age-related hearing loss	Stroke	Falls	Mechanical forces	COPD	Alzheimer's disease	Oral disorders	Blindness and vision loss
	Diabetes	Low back pain	Age-related hearing loss	Falls	COPD	Total cancers	Alzheimer's disease	Stroke	Oral disorders	Blindness and vision loss
Croatia	1.45	1.25	1.06	1.97	1.25	1.18	1.17	1.22	1.14	1.21
Czechia	Diabetes	Low back pain	Age-related hearing loss	Falls	COPD	Alzheimer's disease	Total cancers	Oral disorders	Stroke	Ischemic heart disease
	Diahetes	1.28 Low back nain	LU8 Age-related hearing loss	1.4/ Falls	COPD	1.18 Stroke	0.92 Alzheimer's disease	1.11 Oral disorders	1.15 Blindness and vision loss	L03
Hungary	1.46	1.43	1.05	1.75	1.31	1.38	1.18	1.08	1.27	0.88
Montenegro	Diabetes	Low back pain	Age-related hearing loss	Falls	Stroke	Oral disorders	Alzheimer's disease	Ischemic heart disease	Blindness and vision loss	Mechanical forces
	1.53 Dishutar	13 Ann related hearing loss	1.06	1.46	1.33 Oral disordars	1.17 Falls	1.18	1.43 Alshaimar's disaasa	1.23 Blindness and vision loss	2.29 Machanical forces
North Macedonia	1.57	1.01	1.19	1.89	1.16	1.09	10.91	1.12	1.02	2.53
Poland	Diabetes	Age-related hearing loss	Low back pain	Falls	COPD	Alzheimer's disease	Ischemic heart disease	Oral disorders	Osteoarthritis	Mechanical forces
	1.3	1.17	1.25	1.66	0.96	1.2	1.5	1	0.87	2.32
Romania	Low back pain	Agentelated hearing loss	0.87	1.48	1.5	1.17	0.99	2.9	1.09	1
Sarbia	Diabetes	Low back pain	Age-related hearing loss	Stroke	COPD	Falls	Oral disorders	Alzheimer's disease	Blindness and vision loss	Mechanical forces
	1.48	1.33	1.03	1.66	1.19	1.16	1.15	1.12	1.12	2.47
Slovakia	Low back pain	Falls	Age-related hearing loss	Diabetes	Stroke	Total cancers	Oral disorders	Alzheimer's disease	Mechanical forces	Ischemic heart disease
	1.34 Falls	Low back pain	Diabetes	Age-related hearing loss	Alzheimer's disease	Mechanical forces	1.16	Oral disorders	Total cancers	Blindness and vision loss
Slovenia	1.83	1.28	1.23	1	1.21	3.05	0.84	1.27	18.0	1.47
Eastern Europe	Age-related hearing loss	Low back pain	Falls	Blindness and vision loss	Osteoarthritis	Diabetes	Alzheimer's disease	Oral disorders	Urinary diseases	Stroke
	1.13 Age-related hearing for	1.16	14 Falls	1.75 Blindpess and vision lare	1.24 Alzheimer's disease	U.61	1.18	1.13 Alcohol use disperten	2.80 Osteoarthritis	1.02 Oral disordary
Belarus	1.06	1.22	1.9	1.37	1.21	0.52	2.72	6.51	1.02	0.97
Estonia	Age-related hearing loss	Low back pain	Falls	Diabetes	Total cancers	Alzheimer's disease	Urinary diseases	Depressive disorders	Osteoarthritis	Oral disorders
	1.16	1.19	1.2	0.86	1.13	1.24	2.97	1.87	0.91	1.04
Latvia	Age-related hearing loss	1.17	1.31	0.79	1.91	1.19	3.19	1.92	0.92	1.01
Lithunnia	Age-related hearing loss	Low back pain	Falls	Blindness and vision loss	Diabetes	Alzheimer's disease	Urinary diseases	Total cuncers	Depressive disorders	Discourtbritis
Licitarina	1.16	1.2	1.43	2.11	0.7	1.19	3.27	0.84	1.8	0.79
Republic of Moldova	Age-related hearing loss	Low back pain	Blindness and vision loss	Diabetes:	Alzheimer's disease	Falls	Urinary diseases	Oral disorders	Osteoarthritis	Ischemic heart disease
Duration Federation	Age-related hearing loss	Low back pain	Falls	Blindness and vision loss	Osteoarthritis	Diabetes	Alzheimer's disease	Oral disorders	Urinary diseases	Stroke
Russian repetation	1.15	1.12	1,29	2.01	1.35	0.62	1.18	1.18	2.92	1.1
Ukraine	Age-related hearing loss	Low back pain	Falls	Blindness and vision loss	Diabetes	Alzheimer's disease	Oral disorders	Uninary diseases	Depressive disorders.	Osteoarthritis
	Age-related hearing loss	Diabetes	Low back pain	COPD	Falls	Total cancers	Alzheimer's disease	Osteoarthritis	Stroke	Oral disorders
High-Income	1.16	1.25	1.04	1.2	0.94	1.01	1.09	1.05	1.06	0.95
Australasia	Age-related hearing loss	Falls	Diabetes	Low back pain	Total cancers	COPD	Osteoarthritis	Mechanical forces	Oral disorders	Alzheimer's disease
Constant of the second	Age-related hearing loss	1.43 Diabetes	Falls	Low back pain	Total cancers	COPD	Osteoarthritis	Mechanical forces	0ral disorders	Alzbeimer's disease
Australia	1.34	1.07	1.43	0.92	1.26	0.99	1.04	2.68	1.1	0.93
New Zealand	Age-related hearing loss	Falls	Low back pain	Diabetes	Total cancers	COPD	Mechanical forces	Osteoarthritis	Oral disorders	Alzheimer's disease
and the first	1.34 Age, related hearing loss	1.44	0.89 Diabates	0.88	1.25 Stroke	1.02 Alzheimer's disease	S.L.	1.05	1.22 Osteoarthritis	L03 Oral disorders
High-income Asia Pacific	1.28	0.94	0,93	0.97	1.49	1.11	0.74	0.79	0.91	0.94
Brunei Darussalam	Diabetes	Age-related hearing loss	COPD.	Low back pain	Stroke	Osteoarthritis	Falls.	Total cancers	Other musculoskeletal	Asthma
	2.86	1.19	1.67.	0.86	1.81	0.97 Alabaimas's disabsa	U.B.I	A.S.	1.95	3.02 Oral disorders
Japan	Age-related hearing loss	0.95	0.89	0.91	1.5	1.13	0.81	0.72	0.9	0.98
Republic of Korea	Age-related hearing loss	COPD	Diabetes	Low back pain	Falls	Stroke	Osteoarthritis	Total cancers	Alzheimer's disease	Other musculoskeletal
Republic of Korea	1.27	1.35	1.11	0.88	0.89	1.42	0.94	0.7	0.98	1.94
Singapore	Age-related hearing loss	Diabetes	COPD	Low back pain	Osteoarthritis	Stroke	Alzheimer's disease	Other musculoskeletal	Falls	Total cancers
High-income North	Diabetes	Age-related hearing loss	COPD	Low back pain	Total cancers	Osteoarthritis	Falls	Alzheimer's disease	Stroke	Atrial fibrillation
America	1.69	1.39	1.68	1.34	1.17	1.26	0.94	1.24	1.38	1.72
Canada	Age-related hearing loss	Total cancers	Low back pain	Diabetes	Falls	COPD	Alzheimer's disease	Stroke	Atrial fibrillation	Other musculoskeletal
1.	Age-related hearing loss	Low back pain	Falls	Stroke	Diabetes	COPD	Total cancers	Osteoarthritis	Alzheimer's disease	Atrial fibrillation
Greenland	1.13	1.15	2.12	2.22	0.93	1.48	1.31	1.12	1.2	1.81
United States of	Diabetes	Age-related hearing loss	COPD	Low back pain	Total cancers	Osteoarthritis	Falls	Alzheimer's disease	Stroke	Atrial fibrillation
America	1.77 Age, calated hearing loss	1.43 Dishatar	1.79	1.39 Other musculockeland	1.14 Octoorthritic	1.3 Alzhaimar's disaasa	0.93	1.26	1.39 Plindness and vision lass	1.73 Total cancers
Southern Latin America	1.16	0.96	U.S	4.16	1.22	1.08	1	0.83	0.89	0.99
Argentina	Age-related hearing loss	Diabetes	Low back pain	Other musculoskeletal	Osteoarthritis	Alzheimer's disease	COPD	Oral disorders	Blindness and vision loss	Total cancers
	1.13 Age-related heading large	0.91 Diabatas	0.2	4.31 Other muscularity to total	1.24 Osteoarthritic	1.08	1.1	0.84	0.68 Oral dissetters	1.01
Chile	1.22	1.15	0.78	3,87	1.16	1.08	0.92	0.74	().82	0.88
Uruguay	Age-related hearing loss	Diabotes	Low back pain	COPD	Alzheimer's disease	Osteoarthritis	Other musculoskeletal	Mechanical forces	Total cancers	Oral disorders
	1.12	U.3	0.82	1.34	1.08	1.27	4.68	2.8	1.42	0.89
Western Europe	1.17	0.95	0.93	1.03	1.04	1.01	0.99	0.99	1.02	1.07
Andorra	Diabetes	Age-related hearing loss	Low back pain	COPD	Osteoarthritis	Total cancers	Falls	Alzheimer's disease	Oral disorders	Atrial fibrillation
	1.08 Disbates	0.93	0.91	0.98	1.35	1	0.83 Oral disordars	0.98	1.06	0.94
Austria	1.06	1.28	C.84	1.35	0.81	0.93	1.22	0.87	2.54	0.95
Belgium	Diabetes	Age-related hearing loss	COPD	Falls	Low back pain	Osteoarthritis	Total cancers	Oral disorders	Alzheimer's disease	Ischemic heart disease
	1.12 Diabatai	0.95	1.28	1.31	0.91 Osteoarthritir	1.2 Total cancer	0.97 Falls	1.22 Oral disordar	0.95 Alzheimer's disease	1.01 Atrial fibritation
Cyprus	1.55	0.98	0.87	1.17	1.29	1.09	0.96	1.07	0.97	0.99
Denmark	Low back pain	COPD	Age-related hearing loss	Total cancers	Diabetes	Osteoarthritis	Falls	Oral disorders	Alzheimer's disease	Stroke
	1.17	1.15 Dishara	18.0	0.86	0.77	1.09	072	1.08	0.92	0.74
Finland	1.68	1.21	0.87	0.86	1.04	0.79	1.13	0.94	0.84	1.28
France	Age-related hearing loss	Falls	Low back pain	Total cancers	Alzheimer's disease	Osteoarthritis	Diabetes	Oral disorders	COPD	Atrial fibrillation
- sulles	0.98	1.4	0,89	1.04	0.98	1	0.56	1.04	0.51	1.05
Germany	Lister 1.5	LOW Dack pain	0.94	0.93	0.84	0.81	1.05	Difeoantinitis	1.05	1.03
Greece	Age-related hearing loss	Diabetes	COPD	Low back pain	Alzheimer's disease	Total cancers	Oral disorders	Depressive disorders	Ealls	Osteoarthritis
	0.99	1.07	1.49	0.88	0.96	1.13	1.03	1.81	0.79	0.89
Iceland	Diabetes	Age-related hearing loss	Low back pain	Osteoarthritis	Fails	COPD	Total cancers	Alzneimer's disease	Oral disorders	Atrial fibrillation
Imland	Diabetes	Low back pain	Age-related hearing loss	COPD	Total cancers	Falls	Osteoarthritis	Oral disorders	Alzheimer's disease	Atrial fibrillation
rreland	1.13	1.07	0.9	1.15	0.99	5./9	1.01	1.19	0.98	1.04
Israel	Diabetes	Age-related hearing loss	Low back pain	Osteoarthritis	Oral disorders	Alzheimer's disease	CORD	Total cancers	Palls	Depressive disorders
14-14	Diabetes	Age-related hearing loss	Low back pain	COPD	Falls	Total cancers	Alzheimer's disease	Osteoarthritis	Blindness and vision loss	Oral disorders
Italy	1.21	1.07	0.94	1.06	1.16	1.23	1.12	1.02	1.2	0.94
Luxembourg	Diabetes	Falls	Age-related hearing loss	COPD	Low back pain	Total cancers	Osteoarthritis	Oral disorders	Alzheimer's disease	Atrial fibrillation
	1.71 Diabetes	1.02 Low back nain	0.84 Age-related hearing loss	0.95	U.85 Falls	0.72 Osteoarthritie	0.96 Total cancers	1.21 Alzbeimer's disease	0.84 Oral disorder	1.05 Ischemic heart disease
Malta	1.2	1.08	0.36	1.17	1.18	1.11	0.91	0.96	0.89	1.17
Monaco	Total cancers	Age-related hearing loss	Diabetes	Low back pain	COPD	Osteoarthritis	Falls	Alzheimer's disease	Oral disorders	Stroke
Wielder	1.23	0.93	1.04	0.9	0.89	0.98	8.64	0.96	0.99	6.81
Netherlands	COPD 135	Diabetes	Age-related hearing loss	Total cancers	Low back pain	Falls	Oral disorders	Osteoarthritis	Atzheimer's disease	Afrial fibrillation
Norway	Age-related hearing loss	Falls	Diabetes	Low back pain	COPD	Total cancers	Stroke	Osteoarthritis	Alzheimer's disease	Oral disorders
Norway	1.2	1.12	1.22	0,84	0.89	0.83	1.36	0.97	0.96	1.05
Portugal	Diabetes	Age-related hearing loss	Low back pain	COPD	Total cancers	Alzheimer's disease	Osteoarthritis	Falls	Oral disorders	Depressive disorders
Constant.	Diabetes	Age-related hearing loss	Total cancers	Low back pain	COPD	Palls	Osteoarthritis	Alzheimer's disease	Oral disorders	Atrial fibrillation
San Marino	111	0.92	1.18	0.91	0.95	U.76	0.99	0.96	1.06	0.96
Spain	and a second sec			The second second second	I nut had not	Blindness and vision loss	Falls	Osteoarthritis	Althoimer's disease	Depressive disorders
a province	Diabetes	Age-related hearing loss	COPD	Total cancers	CON INC. PART	bindiess and vision toss	1.00		TANK BAR	Depressive disorders
	Diabetes 1.28 Falls	Age-related hearing loss 0.95 Low back pain	L53 Diabetes	1.47	0.71 Total cancers	1.26 Appropriated hearing loss	1.04 Atrial fibrillation	1.12 Oral disorders	C 88 Osteoarthotis	1.46 Ischemic heart disease
Sweden	Diabetes 1.28 Falls 1.21	Age-related hearing loss 0.95 Low back pain 0.97	COPD 1.53 Diabetes 0.97	L47 COPD 0.82	0.71 Total cancers 0.86	1.26 Age-related hearing loss 0.59	1.04 Atrial fibrillation 1.46	1.12 Oral disorders 1.04	0.83 Osteoarthritis 0.82	1.46 Ischemic heart disease 1.55
Sweden	Diabetes 1.28 Falls 1.21 Falls	Age-related hearing loss 0.95 Low back pain 0.97 Low back pain	COPD 1.53 Diabetes 0.97 Diabetes	1.47 COPD 0.82 Age-related hearing loss	0.71 Total cancers 0.86 Total cancers	1.26 Age-related hearing loss 0.59 COPD	1.04 Atrial fibrillation 1.46 Osteoarthritis	1.12 Oral disorders 1.04 Alzheimer's disease	0.88 Osteoarthntis 0.82 Oral disorders	1.46 Ischemic heart disease 1.55 Urinary diseases
Sweden Switzerland	Diabetes 1.28 Falls 1.21 Falls 1.03 Diabates	Age-related hearing loss 0.95 Low back pain 0.97 Low back pain 1.04 Age-related hearing loss	COPD 1:53 Diabetes 0:97 Diabetes 1:2 COPD	1.47 COPD 0.82 Age-related hearing loss 0.86 0.86	0.71 Total cancers 0.36 Total cancers 0.7 Total cancers	Age-related hearing loss 0.59 COPD 0.56 5-311-	1.04 Atrial fibrillation 1.46 Osteoarthritis 0.89 Osteoarthritis	1.12 Oral disorders 1.04 Alzheimer's disease 0.98 Drad disorder	0.88 Osteoarthritis 0.82 Oral disorders 0.94 Alabaimer's discuss	1.46 Ischemic heart disease 1.55 Unnary diseases 2.25 Atrial faultation

Latin America and Caribbean	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Oral disorders	Alzheimer's disease	Osteoarthritis	Other musculoskeletal	Falls	Ischemic heart disease
Andean Latin America	Age-related hearing loss	Diabetes 0.85	Blindness and vision loss	Oral disorders	Low back pain	Atzheimer's disease	Osteoarthritis	Other musculoskeletal	Falls 0.95	Urinary diseases
Bolivia (Plurinational	Age-related hearing loss	Diabetes	Blindness and vision loss	Oral disorders	Low back pain	Osteoarthritis	Alzheimer's disease	Other musculoskeletal	Depressive disorders	Falls
Ecuador	Age-related hearing loss	Diabetes	Blindness and vision loss	Oral disorders	Low back pain	Osteoarthritis	Alzheimer's disease	Other musculoskeletal	Falls	Urinary diseases
Peru	1.11 Age-related hearing loss	1.09 Blindness and vision loss	1.04 Diabetes	1.34 Oral disorders	Low back pain	1.15 Alzheimer's disease	0.91 Osteoarthritis	2.94 Other musculoskeletal	1.21 Inchemic heart disease	1.75 Falls
Caribbaan	1.04 Diabetes	1.5 Age-related hearing loss	0.72 Blindness and vision loss	1.46 Low back pain	0.76 Oral disorders	0.88 Alzheimer's disease	1.07 Osteoarthritis	3.28 Total cancers	0.75 Falls	0.8 Depressive disorders
Antigue and Parbude	1.54 Diabetes	1.07 Age-related hearing loss	1.09 Low back pain	0.7 Total cancers	0.96 Blindness and vision loss	0,86 Prostate cancer	1.04 Oral disorders	1.35 Osteoarthritis	1,04 Alzheimer's disease	1.29 Mechanical forces
Antigua anu barbuua	1.87 Diabetes	1.13 Age-related hearing loss	0.68 Low back pain	1.49 Blindness and vision loss	1.27 Total cancers	3.18 Ostecarthritis	0.91 Oral disorders	0.94 Alzheimer's disease	0.85 Prostatu cancer	1.96 Other musculoskeletal
Banamas	1.8 Diabetes	1.21 Age-related hearing loss	0.67 Total cancers	1.64 Low back pain	0.99 Prostate cancer	0.9 Oral disorders	0.93 Osteoarthritis	0.87 Alzheimer's disease	2.01 Other musculoskeletal	2.3 Ischemic heart disease
Barbados	1.63	1.12 Dishetas	1.75	0.69	3.54 Oral disorders	0.93 Osteoarthritis	0.98	0.88 Ischemic heart disease	2.66 Depressive disorders	1.08 Chronic kidney disease
Belize	1.02	1	0.77	0.74	0.9	1.19	0.89	1.04	1.07	1.39
Bermuda	1.44	Age-related hearing loss	1.58	0.69	L61	2.87	0.9	Alzheimer's disease 0.91	0.92	1.14
Cuba	Diabetes 1.51	Age-related hearing loss 1.05	Blindness and vision loss 1.24	Low back pain 0.68	Falls 1.6	Total cancers 1.83	Oral disorders 0.91	Alzheimer's disease 0.82	Depressive disorders 1.55	Osteoarthritis 1.06
Dominica	Diabetes 2.23	Age-related hearing loss 1.11	Total cancers 1.74	Blindness and vision loss 1.25	Low back pain 0,69	Prostate cancer 3.59	Oral disorders 0.93	Osteoarthritis 0.96	Alzheimer's disease 0.84	Chronic kidney disease 1.65
Dominican Republic	Age-related hearing loss 1.02	Diabetes 0.72	Blindness and vision loss 0.92	Low back pain 0.75	Oral disorders 1.01	Osteoarthritis 1.16	Alzheimer's disease 0.88	Depressive disorders 1.38	Ischemic heart disease 1.1	Road injuries 1.56
Grenada	Diabetes 1.83	Age-related hearing loss 1.05	Total cancers 2.14	Low back pain 0.7	Blindness and vision loss 0.94	Prostate cancer 4.26	Oral disorders 0.89	Osteoarthritis 1.03	Chronic kidney disease	Ischemic heart disease 0.96
Guyana	Diabetes	Age-related hearing loss	Blindness and vision lost	Low back pain	Oral disorders	Depressive disorders	Osteoarthritis	Lymphatic filariasis	Falls	Alzheimer's disease
Haiti	Diabetes	Age-related hearing loss	Blindness and Vision loss	Low blick pain	Oral disorders	Osteoarthritis	Alzheimer's disease	Nature disaster	Depressive disorders	Ischemic heart disease
Jamaica	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Alzheimer's disease	Oral disorders	Total cancers	Osteoarthritis	Ischemic heart disease	Prostate cancer
Puerto Rico	1.71 Diabetes	1.07 Age-related hearing loss	0.98 Low back pain	Blindness and vision loss	0.86 Alzheimer's disease	0.93 Osteoarthritis	1.49 Fails	1.03 Oral disorders	0.96 Ischemic heart disease	Z,85 Total cancers
Saint Kitte and Novie	2.29 Diabetes	1.2 Age-related hearing loss	Total cancers	1.59 Prostate cancer	0.9 Low back pain	0,93 Blindness and vision loss	0,74 Osteoarthritis	0.94 Oral disorders	1.25 Depressive disorders	Chronic kidney disease
Cales fuels	1.89 Diabetes	1.13 Age-related hearing loss	2.17 Blindness and vision loss	4.72 Low back pain	0.68 Total cancers	1.27 Oral disorders	0.95 Osteoarthritis	0:9 Alzheimer's disease	1.45 Prostate cancer	1.99 Chronic kidney disease
Saint Lucia	1.89 Diabetes	1.04 Age-related hearing loss	0.94 Blipdness and vision loss	0.71 Low back pain	1.76 Oral disorders	0.89 Osteoarthritis	1.05 Total cancers	0.85 Alzbeimer's disease	3,39 tschemic heart disease	1.52 Depressive disorders
Grenadines	1.71 Diabates	1.02 Assertiated hearing loss	0.51 Blindness and vision loss	0.7	0.88 Oral disorders	1.11 Osteoarthritis	1.82	0.87 Depressive disperters	0.92 Ischemic heart disease	1.13 Chronic kidney disease
Suriname	1.75	1.02	0.98	0.71	0.87	1.12	0.84	1.43	1.07	144
Trinidad and Tobago	2.37	Age-related hearing loss	0.69	1.31	0.94	0.91	1.26	0.86	2.45	13
United States Virgin Islands	Diabetes 1.95	Age-related hearing loss 1.2	Total cancers 1.5	Low back pain 0.67	Prostate cancer 3	Blindness and vision loss 1.64	Osteoarthritis 0.95	Oral disorders D.78	Other musculoskeletal 2.07	Ischemic heart disease 1.1
Central Latin America	Diabetes 1.48	Age-related hearing loss	Blindness and vision loss	Low back parm	Other musculoskeletal	Osteoarthritis	Alzheimer's disease	Oral disorders	Chronic kidney disease	Falls 1.21
Colombia	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Alzheimer's disease	Other musculoskeletal	Osteoarthritis	COPD	Oral disorders	Chronic kidney disease
Costa Rica	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Other musculoskeletal	Alzheimer's disease	Osteoarthritis	Total cancers	Dral disorders.	Chronic kidney disease
El Salvador	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Alzheimer's disease	Osteoarthritis	Chronic kidney disease	1.41 Drai disorders	Other musculoskeletal	Falls
Guatemala	1.4 Diabetes	0.99 Age-related hearing loss	1.16 Blindness and vision loss	0.67 Low back pain	0.95 Dral disorders	1.16 Falls	1.85 Osteoarthritis	0.79 Alzheimer's disease	2.83 Chronic kidney disease	1.44 Depressive disorders
Hondurar	1.57 Diabetes	1.01 Age-related hearing loss	1.05 Blindness and vision loss	0.74 Low back pain	0.9 Other musculoskeletal	2,04 Oral disorders	1.12 Osteoarthritis	0.98 Alzheimer's disease	1.97 Depressive disorders	1.2 Urinary diseases
Maning	1.66 Diabetes	1.03 Age-related hearing loss	0.78 Blindness and vision loss	0.69 Osteoarthritis	3.59 Other musculoskeletal	0.9 Low back pain	1.15 Falls	1.01 Oral disorders	1.19 Chronic kidney disease	1,81 Alzheimer's disease
Mexico	1.6 Diabetes	1.05 Age-related bearing loss	1.21 Blindness and vision loss	1.44	3.89 Other musculoskeletal	0.56 Chronic kidney divease	1.46 Osteoarthritis	0.87 Oral disorders	1.93 Alzheimer's disease	0,79 Depressive disorders
Nicaragua	1.48 Disbetes	1.02	0.91 Blindness and vision loss	0.68 Other musculockeletal	3.06	2.19 Altholmer's disease	1.16 Osteoarthritis	0.87	1.04	1.06 Depressive disorders
Panama Manamata (Pationian	1.49	1.04	1.62	A.37	0,64	0.9	1.03	U.79	1.64	1,23
Republic of)	1.29	Age-related hearing loss	0.96	4.08	0.62	0.88	1.07	0.79	1.33	1,76
Tropical Latin America	Diabetes 1.03	Age-related hearing loss D.34	Blindness and vision loss 1.19	Low back pain 0.88	Oral disorders 1.4	Alzheimer's disease	Falls 1.72	Osteoarthritis 1.13	Other musculoskeletal 3,04	Ischemic heart disease 0.97
Brazil	Diabetes 1.03	Age-related heating loss 0.84	Blindness and vision loss 1,19	Low back pain 0.88	Oral disorders 1.41	Alzheimer's disease 1.21	Falls 1.74	Osteoarthritis 1.13	Other musculoskeletal 1.03	Ischemic heart disease 0.97
Paraguay	Age-related hearing loss 1.01	Diabetes 1.01	Blindness and vision loss 1.13	Low back pain 0.85	Alzheimer's disease 1.06	Oral disorders 0.98	Other musculoskeletal 3.37	Osteoarthritis 1.07	Ischemic heart disease 1.03	Stroke UZ1
North Africa and Middle East	Diabetes 1.18	Age-related hearing loss	Blindness and vision loss 1.48	Low back pain 1.08	COPD 1.49	Alzheimer's disease	Oral disorders	Stroke	Osteoarthritis 0.94	Chronic kidney disease
North Africa and Middle	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	COPD 1.49	Alzheimer's disease	Oral disorders	Stroke	Osteoarthritis	Chronic kidney disease
Afghanistan	Blindness and vision loss	Diabetes	Conflict & terror	Age-related hearing loss	Low back pain	Oral disorders	Alzheimer's disease	Stroke	Leishmaniasis	Depressive disorders
Algeria	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Stroke	Alzheimer's disease	Oral disorders	COPD	Osteoarthritis	Chronic kidney disease
Bahrain	Diabetes	Age-related hearing loss	L44 Low back pain	Blindness and vision loss	COPD	L.3 Oral disorders	Alzheimer's disease	Chronic kidney disease	0.98 Ischemic heart disease	0steoarthritis
Fevot	3.03 Age-related hearing loss	1.09 Diabetes	0.97 Blindness and vision loss	2.11 Low back pain	1.25 COPD	1.12 Stroke	1.31 Oral disorders	2.53 Alzheimer's disease	1.29 Chronic kidney disease	0.88 Osteoarthritis
Iran (Islamic Republic	1.03 Age-related hearing loss	0.91 Diabetes	1.46 Blindness and vision loss	1.06 Low back pain	1.8 Alzheimer's disease	1.32 COPD	1.16 Oral disorders	1.26 Stroke	1.92 Osteoarthritis	1 Ischemic heart disease
of)	1.05 Diabetes	1.09 Age-related hearing loss	1.8 Blindness and vision loss	1.17 Low back pain	1.32 Stroke	1.25 Conflict & terror	1.07 Oral disorders	1.04 Alzheimer's disease	0.99 Chronic kidney disease	0.99 Ischemic heart disease
trad	1.28 Diabetes	1.02 Age-related hearing loss	1.56 Low back pain	1.01 Blindness and vision loss	1.48 Stroke	737.61 Oral disorders	1.15 Alzheimer's disease	1.26 COPD	2 12 Chronic kidney disease	1.24 Osteoarthritis
Jordan	1.38	1.09	1.01	1.55	1.52	1.24 Oral disorders	1.29 Strata	0.97	2.13	0,91
Kuwait	2.43	L23	3.07	0.95	1.37	1.22	1.18	1.43	0.78	Z,D4
Lebanon	1.67	Age-related hearing loss	1.74	1.65	0.91	1.29	1.18	1.06	1.41	1.91
Libya	Diabetes 1:64	Age-related hearing loss 1.06	Blindness and vision loss 2.04	Low back pain 0.98	COPD 1.4	Alzheimer's disease 1.25	Oral disorders 1.17	1.05	Ischemic heart disease 1.15	Osteoarthritis 0.91
Moracco	Diabetes 1.2	Age-related hearing loss 1.02	Low back pain 1.12	Blindness and vision loss 0.89	Oral disorders 1.26	Alzheimer's disease 1.38	Stroke 1.32	L27	Ischemic heart disease 1.28	Depressive disorders 1.32
Oman	Diabetes 1.74	Blindness and vision loss 4.23	Age-related hearing loss 1.12	Low back pain 0.97	Stroke 1.61	Oral disorders 1.16	Chronic kidney disease 2.58	Alzheimer's disease 1.3	Ischemic heart disease 1.44	Osteoarthritis 0.82
Palestine	Diabetes	Age-related hearing loss 0.98	Blindness and vision loss 1.03	Low back pain 1.03	Depressive disorders 2.02	Oral disorders 1.18	Stroke 1.21	Alzheimer's disease 1.33	Conflict & terror 276.53	Chronic kidney disease
Qatar	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Oral disorders	Chronic kidney disease	Stroke	Dyteoartivitis	COPD	Alzheimer's disease
Saudi Arabia	Diabetes	Blindness and vision loss	Age-related hearing loss	Falls	Low back pain	Stroke	COPD	Oral disorders	Alzheimer's disease	Osteoarthritis
Sudan	Diabetes	Blindness and vision loss	Age-related hearing loss	Low back pain	Oral disorders	Stroke	Alzheimer's disease	COPD	Osteoarthritis	Ischemic heart disease
Syrian Arab Republic	1.21 Diabetes	1.27 Age-related hearing loss	1.03 Conflict & terror	1.03 Blindness and vision loss	1.25 Low back pain	1.35 Oral disorders	1.39 Alzheimer's disease	1.06 Stroke	L.02 COPD	1.17 Ischemic heart disease
Tupicia	1.1 Diabetes	1 Age-related hearing loss	843.55 Blindness and vision loss	1.29 Low back pain	1.03 COPD	1.18 Alzheimer's disease	1.29 Oral disorders	1.11 Stroke	1.37 Depressive disorders	1.2 Osteoarthritis
Tjudiau	1.54 Age-related hearing loss	1.03 Diabetes	1.37 COPD	0.98 Low back pain	1.74 Blindness and vision loss	1.29 Alzheimer's disease	1.16 Oral disorders	1.05 Stroke	1.73 Chronic kidney disease	0.94 Ostegarthritis
likey	1.13 Diabetes	1.14 Age-related hearing loss	2:14 Stroke	1.16 Low back pain	1.47 Blindness and vision loss	1.33 COPD	1.32 Oral disorders	1.02 Chronic kidney disease	1.98 Alzheimer's disease	0:87 Osteoarthritts
United Arab Emirates	2.61 Age-related hearing loss	1.22 Blindness and vision loss	2.27 Diabetes	0.94 Low back pain	4.18 Oral disorders	0.89 Stroke	1.23 Alzheimer's disease	2.94 COPD	1.23 Depressive disorders	0.72 Osteparthritis
remen	1.06 Blindness and vision loss	1.04	0.96 Age-related hearing loss	1.03 Diabetes	1.56 Road inturfer	1,3	1.48 Faile	1.19 Dietary kon deticionen	0.9 Depressive disorders	0.93 Other musculoskal and
South Asia	1.53	3.16	0.99	0.97	3.05	0.77	2.14	4.48	1.44	2,67
South Asia	1.53 Plinds	3.16	0.99	0.97	3.05	0.71	2.14	4.48	1.44	2.67
Bangladesh	bindness and vision loss 1.17	Age-related hearing loss 0.98	24	0.83	Low back pain 1.03	Depressive disorders 1.66	Road injuries	3.56	Aizneimer's disease	2.83
Bhutan	COPD 3.01	Age-related hearing loss 0.98	Diabetes 0.95	Low back pain 1.02	Blindness and vision loss 0.71	Road Injuries 2.18	Depressive disorders 14	Falls 2.21	Alzheimer's disease 0.95	Osteoarthritis 0.99
India	Blindness and vision loss 1.61	COPD 3.38	Age-related hearing loss 0.99	Diabetes 0.97	Road Injuries 3.36	Low back pain 0.72	Falls 2,43	Dietary iron deficiency 5,01	Depressive disorders 1.44	Other musculoskeletal 2.57
Nepal	COPD 3.15	Age-related hearing loss	Blindness and vision loss	Diabetes	Low back pain	Depressive disorders	Dietary fron deficiency	Falls.	Road injuries	Osteoarthritis
Pakistan	Blindness and vision loss	Age-related hearing loss	Diabetes	COPD	Low back pain	Dietary iron deficiency	Depressive disorders	Road injuries	Osteoarthritis	Oral disorders
Southeast Asia, East Asia,	Age-related hearing loss	Stroke	Blindness and vision loss	Diabetes	COPD	Low back pain	Alzheimer's disease	Falls	Otal disorders	Osteoarthritis
East Asia	Age-related hearing loss	Stroke	COPD	Blindness and vision loss	Diabetes	Low back pain	Alzheimer's disease	Falls	Osteoarthritis	Oral disorders
China	1.19 Age-related hearing loss	1.82 Stroke	L55 Blindness and vision loss	1.12 COPD	Diabetes	Low back pain	1.16 Alzheimer's disease	1.12 Falls	0.96 Osteoarthritis	0175 Oral disorders
Democratic People's	1.19 Age-related hearing loss	1.83 Low back pain	1.14 COPD	1.58 Stroke	0.55 Diabetes	0,65 Oral disorders	1.17 Bithdowns and vision (oss	1.16 Osteoarthritis	0.96 Alzheimer's disease	0.75 Urinary diseases
Republic of Korea Taiwan (Province of	1.01 Diabetes	1.09 Age-related hearing loss	2.29 Low back pain	1.77 Stroke	LE4. Chronic kidney disease	0.75 Alzheimer's disease	II.39 Total cancers	0.96 Ostroarthritis	0.95	1.47 Utinary diseases
China)	1.32 Disherer	1.09 Age-related hearing for	1.12	1.35 Blindness and sizion torr	3.25 Stroke	0.87 Oral disorders	0.65	U.72 Ischemic heart discours	0,47 Alzheimer's diserse	2.21 Distantisition
Oceania	1.79	0.98	1.19	1.02	1.49	1.4	143	1.19	0,97	E 79
American Samoa	2.54	Age-related hearing loss 0.98	Low back pain 1.17	Stroke 1.56	bundness and vision loss	0ral disorders 1.11	iscnemic heart disease	D.85	0.75	Chronic kidney disease
Cook Islands	Diabetes 2.03	Age-related hearing loss 1.03	Low back pain 1.17	COPD 1.49	Stroke 1.75	Blindness and Vision loss 1.83	Oral disorders 1.13	Atzheimer's disease 0.87	Total cancers 0.97	Osteoarthmis 0.75
Fiji	Diabetes 2/68	Age-related hearing loss 0.94	Low back pain 1.15	Blindness and vision loss 1.42	Stroke 1.52	Oral disorders 1.09	Ischemic heart disease 1.2	Chronic kidney disease 1.9	Osteparthritis 0.81	Urinary diseases 1.53
Guam	Diabetes 1.43	Age-related hearing loss 1.11	Low back pain 1.16	Stroke 1.89	Blindness and vision loss 2.06	Oral disorders 1.14	Ischemic heart disease 1.53	Alzheimer's disease 0.89	Osteoarthritis 0.7	COPD 0.48
Kiribati	Diabetes 2,13	Age-related hearing loss 0.95	Low back pain	Stroke 2.15	Blindness and vision loss	Oral disorders 1.28	Ischemic heart disease	Osteoarthritis 0.85	Urinary diseases	Diarrheal diseases
Marshall Islands	Diabetes	Age-related hearing loss	Low back pain	Stroke	Blindness and vision loss	Oral disorders	COPD	Ischemic heart disease	Ostepanthritis	Alzheimer's disease
Micronesia (Federated	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Stroke	Oral disorders	COPD	Alzheimer's disease	Chronic kidney disease	Osteoarthritis
Nauru	Diabetes	Age-related kearing loss	Low back pain	Stroke	COPD	Blindness and vision Joss	0ral disorders	Ischemic heart disease	Alzheimer's disease	Chronic kidney disease
Niue	1.45 Diabetes	Age-related hearing loss	1.22 Low back pain	1.81 COPD	1.94 Stroke	0.91 Blindness and vision loss	1.1 Oral disorders	1.15 Ischemic heart disease	0.87 Alzheimer's disease	1.54 Chronic kidney disease
Northern Mariana	2,19 Diabetes	0.97 Age-related hearing loss	1.19 Low back pain	1.63 Stroke	1.59 Blindness and vision loss	1.25 Oral disorders	1.14 Ischemic heart disease	1.25 EOPD	0.86 Alzheimer's disease	1.66 Chronic kidney disease
Islands	1.74 Diabetes	1.07 Age-related hearing loss	1.15 Low back pain	1.72 Strake	1.72 COPD	1.13 Blindness and vision loss	1.41 Oral disorders	0.72 Falls	0.89 Ischemic heart disease	1.96 Ostroarthritis
Palau	1.93 Dishuter	1.02	1.15 Blindness and side land	2.02	1.57	1.48	1.13 Oral disperting	1.14	1.49	0.75
Papua New Guinea	1.65	0.98	1.01	1.19	1.77	1.42	1.51	3.49	1.01	1.16

Samoa	Diabetes	Age-related hearing loss	Low back pain	Stroke	Blindness and vision loss	Oral disorders	Alzheimer's disease	COPD	Ischemic heart disease	Osteoarthritis 0.85
Solomon Islands	Diabetes	Age-related hearing loss	Low back pain	Mundness and vision loss	Stroke	Oral disorders	Ischemic heart disease	COPD	Diarrheal diseases	Alzheimer's disease
Tokelau	Diabetes	Age-related hearing loss	Low back pain	COPD	Blindness and vision loss	Stroke	Oral disorders	Alzheimer's disease	Ischemic heart disease	Osteoarthritis
Tonga	Diabetes	Age-related hearing loss	Low back pain	Stroke	Oral disorders	Blindness and vision loss	Ischemic heart disease	COPD	Alzheimer's disease	Osteoerthritis
Tuvalu	1,47 Diabetes	Age-related hearing loss	1.26 Low back pain	Blindness and vision loss	COPD	Stroke	0ral disorders	1.16 Ischemic heart disease	Alzheimer's disease	Osteparthritis
Vanuatu	1.48 Diabetes	0.93 Age-related hearing loss	1.24 Low back pain	0.86 Stroke	1.79 Blindness and vision loss	1.4 Oral disorders	1.17 Ischemic heart disease	1.09 COPD	0.88 Alzheimer's disease	0.86 Osteparthritig
Southeast Asia	1.61 Diabetes	0.96 Blindness and vision loss	1.37 Age-related hearing loss	1.92 COPD	U.64 Low back pain	1.31 Stroke	1.34 Oral disorders	0.89 Alzheimer's disease	0.94 Neck pain	0.84 Ischemic heart disease
Cambodia	1.04 Diabetes	1.71 Blindness and vision loss	0.97 Age-related hearing loss	2.28 Low back pain	1.1 COPD	1.58 Stroke	0.78 Falls	0.81 Oral-disorders	2.23 Alzheimer's disease	0.9 Neck pain
Indenssia	1.42 Blindness and vision loss	1.27 Age-related hearing loss	0.97 Diabetes	1.2 Low back pain	2.04 Stroke	1,45 COPO	2.2 Oral disorders	0.87 Neck pain	0.91 Ischemic heart disease	2.11 Alzheimer's disease
Lao People's	2.56 Diabetes	0.97 Age-related hearing loss	0.81 Low back pain	1.11 COPD	1.9 Blundness and vision loss	2.18 Stroke	0.83 Alzheimer's disease	2.32 Neck pain	0.94 Dral disorders	0.77 Urinary diseases
Democratic Republic	1.45 Diabetes	0.98 Age-related hearing loss	1.17 Blindness and vision loss	1.96 Low back pain	0.7A COPD	1.74 Stroke	0.9 Oral disorders	2.07 Ischemic heart disease	0.64 Alzheimer's disease	1.52 Road injuries
Malaysia	1.36 Diabetes	1.05 Age-related hearing loss	2.16 COPD	1.03 Low back pain	1.52 Blindness and vision loss	1.54 Stroke	0.97 Alzheimer's disease	1.34 Ischemic heart disease	0.85 Oral disorders	1.87 Neck pain
Maldives	1.22 Diabates	0.95 Age-related hearing loss	2.28 Low back pain	1.12 Blindness and vision loss	0.87 COPD	1.34 Stroke	0.91 Oral disorders	1.13 Atsheimer's disease	D 74 Chronic kidney disease	2.05 Neck pain
Mauritius	2.26 Diabetes	1	1.08 Blindness and vision loss	1.65 Age-related hearing loss	1.67 Low back pain	1.35 Stroke	0.98 Falls	0,61 Attheimer's disease	1.75 Nerk pain	1.98 Deal disorders
Myanmar	1.28	3.17 Are-related hearing loss	1.24 Low back pain	0.97 Blindness and vision loss	1.05 Diabetes	171 Stroke	1.83 Oral disorders	0.87 Neck pain	2.01	0.59 Ischemic heart disease
Philippines	3.24 Diabates	0.98 Age-related hearing loss	1.2 Blindness and vision loss	1.26	179 0900	1.23 Stroke	0.95	3,02 Oral disorders	0.79 Attractive disease	0.89 Neck pain
Seychelles	2.22	1.03	1.91	1.04	1.62	1.64	1.18	0.72	0.8	1.93
Sri Lanka	2.3	Age-related hearing loss	1.65	1.05	2.12	1.35	1.2	U.SI	0.68	2.02
Thailand	1.05	Age-related hearing loss 0.98	1.04	1.88	1.32	1.12	0.82	0.77	2.62	0.93
Timor-Leste	Blindness and vision loss	Diabetes 1.24	Age-related hearing loss 0,96	Low back pain 1.09	1.89	2.04	U.8	Z:	Alzheimer's disease 0.87	138.7
Viet Nam	Liabetes 1,1	Age-related hearing loss 0.93	1.17	Blindness and vision loss	2.44	5troke 1.8	U-82	1.19	Neck pain 2.14	1.61
Sub-Saharan Africa	Age-related hearing loss 0.97	Blindness and vision loss 1.12	Diabetes 1.01	Low back pain 1.06	Depressive disorders 1.59	Road injuries	Osteoarthritis 1.17	COPD 1.07	Stroke 0.94	Alzheimer's disease 0.87
Central Sub-Saharan Africa	Diabetes 1.37	Age-related hearing loss 0.98	Low back pain 1.01	Onchocerciasis 39.44	Depressive disorders 1.71	Blindness and vision loss 0.6	COPD 1.09	Osteoarthritis 1.1	Stroke 0.93	Alzheimer's disease 1.09
Angola	Diabetes 1.3	Age-related hearing loss 0.96	Low back pain 1.04	ellindness and vision loss 0.85	Depressive disorders 1.97	Stroke 1.17	Osteoarthritis 1.13	COPD 0.97	Alzheimer's disease 1.07	Onil disorders 0,71
Central African Republic	Diabetes 1.56	Age-related hearing loss	Low back pain 0.96	Onchocerciasts 8.88	Depressive disorders 1.38	Blindness and vision loss 0.58	COPD 1.03	Osteoarthritis 1.05	Stroke 0.95	Oral disorders 1.05
Congo	Diabetes 1.21	Age-related hearing loss 0.92	Low back pain 1.03	Blindness and vision loss 0.85	Depressive disorders 2.24	Stroke 1.06	Osteoarthritis 1.17	COPD 1.09	Alzheimer's disease 1.06	Oral disorders
Democratic Republic of the Congo	Diabetes 1.41	Age-related hearing loss 0.99	Onchocerciasis 48.62	Low back pain	Depressive disorders 1.6	Blindness and vision loss 0.49	COPD 1.12	Osteoarthritis 1.08	Alzheimer's disease 1.11	Strofor
Equatorial Guinea	Diabetes 1.28	Age-related hearing loss 0.97	Blindness and vision loss 1.77	Low back pain 0.98	Depressive disorders 2.49	Stroke 1.08	Osteoarthritis 1.06	COPD 0.95	Alzheimer's disease 0.94	Oral disorders 0.6
Gabon	Diabetes 1.38	Age-related hearing loss 0.93	Low back pain 0.99	Blindness and vision loss	Depressive disorders 2.55	Stroke 1.09	Osteoarthritis 1.14	COPD 1.14	Alzheimer's disease	Road injuries 1.45-
Eastern Sub-Saharan Africa	Age-related hearing loss	Blindness and vision loss	Low back pain	Diabetes 0.94	Depressive disorders	Road Injuries	Osteoarthritis	Stroke	COPD 0.94	Alzheimer's disease
Burundi	Age-related hearing loss	Low back pain	Diabetes	Depressive disorders	Blindness and Vision loss	COPD 1.14	Road injuries	Osteoarthritis	Conflict & terror 67.74	Stroke 0.9
Comoros	Age-related hearing loss	Low back pain	Blindness and vision loss	Diabetes	Road injunes	Depressive disorders	Stroke	Osteoarthritis	COPD 0.99	Alzheimer's disease
Djibouti	Age-related hearing loss	Diabetes	Low back pain	Blindness and vision loss	Depressive disorders	Stroke	Road Injuries	Osteoarthritis	COPD	Ischemic heart disease
Eritrea	Blindness and vision loss	Age-related hearing loss	Diabetes	Low back pain	Conflict & terror	Depressive disorders	Road injuries	COPD 115	Osteoarthritis	Stroke
Ethiopia	Blindness and vision loss	Age-related hearing loss	Low back pain	Diabetes	Depressive disorders	Osteoarthritis	Road injuries	Alzheimer's disease	COPD	Ischemic heart disease
Kenya	Age-related hearing loss	Blindness and vision loss	Low back pain	Diabetes	Depressive disorders	COPD	Osteoarthritis	Stroke	Ischemic heart disease	Road injuries
Madagascar	Age-related hearing loss	Low back pain	Diabetes	Blindness and vision loss	Depressive disorders	COPD 135	Stroke	Road injuries	Osteoarthritis	Alzheimer's disease
Malawi	Diabetes	Blindness and vision loss	Age-related hearing loss	Low back pain	Depressive disorders	COPD 1.08	Stroke	Osteoarthritis	Road injuries	Ischemic heart disease
Mozambique	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Road injuries	Depressive disorders	Stroke	COPD	Osteoarthritis	HIV/AIDS
Rwanda	Age-related hearing loss	Low back pain	Diabetes	Blindness and vision loss	Depressive disorders	Road injuries	COPD	Osteoarthritis	Stroke	Conflict & terror
Somalia	Age-related hearing loss	Low back pain	Blindness and vision loss	Diabetes	Depressive disorders	Road Injunes	Osteoarthritis	COPD	Stroke	Dietary iron deficiency
South Sudan	Onchocenciasis	Blindness and vision loss	Age-related hearing loss	Low back pain	Diabetes	Depressive disorders	Road Injuries	Stroke	Osteoarthritis	COPD
Uganda	Diabetes	Low back pain	Depressive disorders	Age related hearing loss	Blindness and vision loss	Road injuries	COPD	Stroke	Osteoarthritis	Alzheimer's disease
United Republic of	Blindness and vision loss	Age-related hearing loss	Low back pain	Diabetes	Depressive disorders	Stroke	Road injuries	Osteoarthritis	Alzheimer's disease	COPD
Zambia	Age-related hearing loss	Diabetes	Blindness and vision loss	Low back pain	Depressive disorders	COPD	Osteoarthritis	Stroke	Road injuries	Alzheimer's disease
Southern Sub-Saharan	Diabetes	Age-related hearing loss	Blindness and vision loss	COPD	Low back pain	0steoarthritis	Stroke	Depressive disorders	Drat disorders	Alzheimer's disease
Botswana	Diabetes	Blindness and vision loss	Age-related hearing loss	COPD	Low back pain	1.33 Stroke	1.1 Osteoarthritis	HIV/AIDS	Depressive disorders	Endo/metab/blood/immun
Eswatini	1.19 Diabetes	Age-related hearing loss	Blindness and vision loss	COPD	Low back pain	HIV/AIDS	1.2/ Depressive disorders	Stroke	Osteoarthritis	Oral disorders
Lesotho	1.28 Blindness and vision loss	0.95 Diabetes	1.29 Age-related hearing loss	COPD	0.97 Low back pain	427.89 HIV/AIDS	1.68 Depressive disorders	1.09 Osteoarthritis	1.36 Stroke	0.72 Oral disorders
Namibia	1.26 Age-related hearing loss	1.09 Diabetes	0.98 Blindness and vision loss	2.62 COPD	0.98 Low back pain	198.63 Stroke	1.76 Osteoarthritis	1,3 Qual disprders	1.02 Depressive disorders	U.62 Alzheimer's disease
South Africa	0.98 Diabetes	0.92 Age-related hearing loss	1.34 Blindness and vision loss	2.69 COPD	1.03 Low back pain	1.15 Osteoarthritis	1.24 Stroke	D BA Depressive disorders	1.38 One disorders	0.87 Alzheimer's disease
Zimbahwa	1.17 Diabetes	1.1 Blindness and vision loss	1.61 Age-related hearing loss	2.12 Low back pain	0.86 COPD	1.35 Depressive disorders	1.12 Osteoarthritis	1.44 Stroke	0.78 Oral disorders	0.85 Alzheimer's disease
Western Sub-Saharan	1.19 Blindness and vision loss	1.14 Age-related hearing loss	0.94 Diabetes	1.13 Low back pain	1.43 Depressive disorders	1.45 Road injuries	1.26 Osteoarthritis	0.95 Stroke	0.78 COPD	0.95 Alzheimer's disease
Africa	1.22 Diabetes	0.94 Age-related hearing loss	0.95 Blindness and vision loss	1.08 Low back pain	1.56 Depressive disorders	2.02 Road injuries	1.17 Osteoarthritis	0.98 COPD	0.91 Stroke	0.78 Oral disorders
Benin	1.25 Blindness and vision loss	0.94 Age-related hearing loss	0.99 Diabetes	1.03 Low back pain	1.41 Depressive disorders	1.9 Road injuries	1.16 Osteoarthritis	1.06 Alzheimer's disease	0.98 CDPD	0.82 Stroke
Burkina Faso	1.02 Diabetes	0.98 Age-related hearing loss	1.25 Blindness and vision losi	0.98 Low back pain	1.4 Depressive disorders	1.64 Altheimer's disease	L11 Stroke	0.94 Osteoarthritis	0.72 Road Injuries	D.73 COPD
Cabo Verde	1.24 Diabetes	0.93 Age-related hearing loss	0.51 Low back pain	1.05 Windness and vision loss	2.05 Boad injuries	0.83 Depressive disorders	1.02 COPD	1.19 Osteoarthritis	1.96 Stroke	0.92 Onchocerciasis
Cameroon	1.09 Blindness and vision loss	0.9 Age-related hearing loss	1.13 Diabetes	0.83 Low back pain	3.39 Depressive disorders	1.92 Road injuries	1.28 Osteoarthritis	1.22 Stroke	0.93 COPD	68.25 Oral disorders
Chad	0.99 Diabetes	0.97 Blindness and vision loss	1.24 Age-related hearing loss	1.04 Low back pain	1.38 Road injuries	1.44 Depressive disorders	1.06 Stroke	0.92 Osteoarthritis	0.88 COPD	1.12 Oral disorders
Cote d'Ivoire	1.13 Age-related hearing loss	1.04 Blindness and vision loss	0.93 Diabetes	1.05 Low back pain	2.19 Depressive disorders	1.45 Road injuries	1.04 COPD	1.15 Osteoarthritis	0.97 Stroke	D.86 Tuberculosis
Gambia	0.94	0.98	1.05	1	1.37	1.88	1.14	1.15	1.01	4.12
Ghana	1.16	0.88	1.02	0.86	Z 15	3	1.01	1.19	1.18	D.75
Guinea	Blindness and vision loss 1.08	Age-related hearing loss 0.96	Diabetes 1.08	Low back pain 1.02	Road injuries	Depressive disorders 1.22	COPD 1.12	Osteoarthritis 1.11	0.89	Airneimer's disease 0.88
Guinea-Bissau	Blindness and vision loss 1.13	Age-related bearing loss 0.94	Diabetes 1.16	Low back pain	Depressive disorders 1.29	Road injuries 1.77	COPD 1.11	Stroke 1.01	Osteoarthritis 1.11	Dral disorders 0.83
Liberia	Diabetes 1.45	Age-related hearing loss 0.94	diindness and vision loss 0.93	Onchocerclasis 45.99	Low back pain 0.99	Depressive disorders 1.07	Road injuries 1.49	Osteoarthritis 1.16	U.81	Alzheimer's disease 0.85
Mali	Blindness and vision loss	Age-related hearing loss 0.98	Diabetes 1.06	Low back pain 0.89	COPD 1.18	Road injuries 1.32	Depressive disorders 0.85	Osteoarthritis 1.09	Alzheimer's disease 0.94	Stroke 0.79
Mauritania	Age-related hearing loss 0.93	Blindness and vision loss 1.01	Low back pain 1.1	Diabetes 0.64	Depressive disorders 1.76	Road injuries 2.51	Osteoarthritis 1.23	Stroke 0.95	0.95	Oral disorders 0.76
Niger	Age-related hearing loss	Bundriess and vision loss 0.96	Low back pain 0.95	Diabetes 0.89	Depressive disorders 0.87	Road injuries 0.98	Osteoarthritis 1.06	0.92	0.84	1.04

Nigeria	1.45	0.94	1.19	0.78	1.8	2.23	1.21	0.83	0,76	071
Sao Tome and Principe	Diabetes	COPD	Age-related hearing loss	Blindness and vision loss	Low back pain	Stroke	Road injuries	Falls	Osteoarthritis	Depressive disorders
	1.14	2.84	0.91	0.99	0.96	1.24	2.46	2.2	1.18	1.23
Senegal	Diabetes	Blindness and vision loss	Age-related hearing loss	Low back pain	Depressive disorders	Road injuries	COPD	Osteoarthritis	Stroke	Oral disorders
	1.53	1.09	0.94	0.93	1.56	1.77	1.08	1.14	0,88	0.91
Sierra Leone	Age-related hearing loss	Blindness and vision loss	Low back pain	Diabetes	Depressive disorders	Road injuries	Onchocerciasis	Stroke	Osteoarthritis	COPD
	1.01	0,92	1.01	0.68	1.3	1.68	16.64	1.01	1.12	0.99
Тодо	Age-related hearing loss	Blindness and vision loss	Low back pain	Diabetes	Depressive disorders	COPD	Road injuries	Stroke	Osteoarthritis	Oral disorders
	0.93	1.03	1.03	0.83	1.62	1.21	1.88	1.09	1.14	0.75
Values shown in brackets repr	esent the ratio of observed YL	LDs to predicted YLDs on the b	asis of Socio-Demographic Ind	lex (SDI), rounded to two (2) d	igits. Color ranges (shown belo	w) were calculated to place	a roughly equal number of cel	ls into each bin.		
COLOR KEY:	[0.00,0.64]	(0.84,0.93)	(0.93,0.98)	[0.98,1.04]	[1.04,1.12]	(1.12,1.18)	[1.18,1.29]	[1.29,1.5]	[1.5,1,93]	[1.93,]

Figure S23. Leading ten causes of total years lived with disability with ratio of observed to expected years lived with disability in 2019, among people 70 years and older, in females, for all GBD locations.

Causes are ranked based on global estimates of YLDs. Causes are color coded (shown in color key) based on the ratio of observed to expected (O:E) rates on that basis of SDI from the epidemiologic transition analysis. Shades of blue represent much lower observed deaths and YLDs than expected levels based on SDI, whereas red shows that observed deaths and YLDs exceed expected levels. When the ratio exceeds 1 means that observed levels exceeded the expected levels on the basis of SDI. O:E ratios are listed in each cell. YLDs = years of life lived with disability.

rigure 25. ceaunig to causes	1	2	3	4	5	6	7	8	9	10
Global	Age-related hearing loss 1.09	Low back pain 0.99	Diabetes 0.92	Blindness and vision loss 1.31	COPD 1.99	Stroke 1.21	Alzheimer's disease 1.05	Falls 1.24	Osteoarthritis 1.06	Oral disorders 0.92
Central Europe, Eastern	Low back pain	Age-related hearing loss	Diabetes	Alzheimer's disease	Blindness and vision loss	Stroke	Oral disorders	Osteoarthritis	Falls	Depressive disorders
Central Asia	Age-related hearing loss	Low back pain	Diabetes	Blindness and vision loss	Oral disorders	Alzheimer's disease	Depressive disorders	Stroke	Osteoarthritis	COPD
	1.02 Age-related hearing loss	1.02 Low back pain	0.95 Diabetes	1.25 Blindness and vision loss	1.28 Alzheimer's disease	1.13 Oral disorders	1.36 Depressive disorders	0.91 Osteoarthritis	1 COPD	1.04 Stroke
Armenia	1.03	1.12	0.97	1.29	1.14	1.29	1.3	0.96	1.45	0.69
Azerbaijan	Age-related hearing loss 1.02	Low back pain 1.04	Diabetes 0.91	Blindness and vision loss 1.32	Oral disorders 1.25	Alzheimer's disease 1.12	Stroke 0.97	Osteoarthritis 1.06	Depressive disorders 1.16	L.13
Georgia	Age-related hearing loss	Diabetes	Low back pain	Blindness and vision loss	Alzheimer's disease	Oral disorders	Depressive disorders	Osteoarthritis	Stroke	Falls
Kazakhstan	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Oral disorders	Stroke	Alzheimer's disease	Depressive disorders	Osteoarthritis	COPD
HULDINI SLOW	1.28 Are-related hearing loss	1.08 Low back pain	0.99 Blindness and vision loss	1.51 Alzheimer's disease	1.34 Oral disorders	1.12 Depressive disorders	1.08 Diabetes	1.43 Osteoarthritis	0.92 COPD	1.19 Stroke
Kyrgyzstan	0.97	1.07	0.93	1.21	1.31	1.47	0.53	1.08	1.46	0.63
Mongolia	Age-related hearing loss 0.95	Low back pain 1.06	Blindness and vision loss 1.09	Oral disorders 1.25	Depressive disorders 1.46	Alzheimer's disease 1.18	Osteoarthritis 1.07	Stroke 0.69	Diabetes 0.34	Falls 1.29
Tajikistan	Age-related hearing loss	Low back pain	Diabetes	Blindness and vision loss	Oral disorders	Alzheimer's disease	Depressive disorders	Osteoarthritis	51/pke	Ischemic heart disease
Turkmenistan	Age-related hearing loss	Low back pain	Blindness and vision loss	Alzheimer's disease	Diabetes	0ral disorders	Stroke	Depressive disorders	Osteoarthritis	Ischemic heart disease
Turkinemstan	1 Are-related hearing loss	1.04 Low back pain	1.33 Diabeles	1.16 Blindness and vision loss	0.72 Oral disorders	1.23 Stroke	0.94 Depressive disorders	1.36 Osteoarthritis	0.88 Alzheimer's disease	1.14 Other musculoskeletal
Uzbekistan	0.96	1.04	0,75	1.08	1.25	0.92	1.29	1.05	1.15	1.39
Central Europe	Age-related hearing loss 1.21	1.32	0.94	Alzheimer's disease	Fails 1.24	1.35	1.11	Blindness and vision loss 1.15	0.71	Depressive disorders
Albania	Age-related hearing loss	Low back pain	Alzheimer's disease	Diabetes	Oral disorders	Stroke	Blindness and vision loss 1179	Falls	Osteoarthritis 0.84	Depressive disorders
Bosnia and Herzegovina	Diabetes	Age-related hearing loss	Stroke	Low back pain	Alzheimer's disease	Oral disorders	Falls	Blindness and vision loss	Depressive disorders	Osteoarthritis
Bulante	1.5 Age-related hearing loss	1.06 Diabetes	Low back pain	0.67 Stroke	1.17 Alzheimer's disease	1.22 Oral disorders	1.32 Depressive disorders	0,9 Blindness and vision loss	1.16 Falls	Osteparthritis
bulgana	1.15 Falls	1.11 Diabetes	0.91 Age-related hearing loss	1.73 Low back pain	1.17 Alzheimer's disease	1.07 Stroke	1.25 Oral disorders	1.07 Depressive disorders	0.88 Blindness and vision loss	0.73 Osteoarthritis
Croatia	24	1.42	1.17	0.95	1.17	1.23	1.1	1.37	1.18	0.68
Czechia	Diabetes 2.23	Age-related hearing loss 1.22	D.87	Falls 1.3	Alzheimer's disease 1.16	Stroke 1.2	Oral disorders 1.15	Blindness and vision loss 1.35	Depressive disorders 1.22	Ostepartiritis 0.64
Hungary	Diabetes	Age-related hearing loss	Falls	Low back pain	Alzheimer's disease	Stroke	Oral disorders	Blindness and vision loss	Depressive disorders	Ostmanthritis
Montenegro	Diabetes	Age-related hearing loss	Low back pain	Stroke	Alzheimer's disease	Oral disorders	Falls	Blindness and vision loss	Depressive disorders	Osteoarthritis
montenegro	1.69 Diabetes	1.19 Stroke	0.89 Age-related hearing loss	1.41 Low back pain	1.18 Oral disorders	1.2 Alzheimer's disease	0.99 Falls	1.22 Blindness and vision loss	1.24 Depressive disorders	0.69 Ostroarthritis
North Macedonia	1.73	1.96	1.11	0.86	1.19	1.19	1.32	1.02	1.1	0.74
Poland	Age-related hearing loss 1.31	1.34	0.97	Alzheimer's disease	1.11	1.13	1.09	Blindness and vision loss 1.17	0.71	Ischemic heart disease
Romania	Age-related hearing loss	Low back pain	Stroke	Alzheimer's disease	Diabetes 0.85	Oral disorders	Blindness and vision loss	Falls	Osteoarthritis	Depressive disorders
Serbia	Diabetes	Age-related hearing loss	Stroke	Low back pain	Alzheimer's disease	Oral disorders	Falls	Depressive disorders	Blindness and vision loss	Ostenarthritis
	1.53 Age-related hearing loss	1.14 Low back pain	1.85 Diabetes	0.92 Falls	1.13 Alzheimer's disease	1.17 Stroke	1.13 Oral disorders	1.28 Blindness and vision loss	1.1 Depressive disorders	Osteoarthritis
Slovakia	1.22	0.86	1.16	1.35	1.17	1.37 Oral disert	1.05	1.3 Blindrau and dial	1.18	0.67
Slovenia	1.72	Age-related hearing loss	Aizrieimer's disease	0.82	1.23	1.32	L48	011000055 and vision loss 1.37	0.87	0.54
Eastern Europe	Low back pain	Age-related hearing loss	Blindness and vision loss	Alzheimer's disease	Osteoarthritis	Oral disorders	Stroke	Diabetes D.67	Depressive disorders	Falls 1970
Belarus	Low back pain	Age-related hearing loss	Alzheimer's disease	Blindness and vision loss	Stroke	Depressive disorders	Osteoarthritis	Oral disorders	Falls	Diabetes
	1.22 Age-related hearing loss	1.15 Low back pain	1.14 Alzheimer's disease	1.39 Diabetes	1.03 Depressive disorders	1.45 Bilindness and vision loss	0.97 Osteoarthritis	1.02 Oral disorders	1.05 Fails	0.57 Stroke
Estonia	1.33	1.06	1.12	0.89	1.77	1.62	0.83	1.06	0.56	D.74
Latvia	Low Back pain 1.15	Age-related hearing loss	Alzheimer's disease	Liss	0.88	1.2	1.54	0.85	0.58	0.93
Lithuania	Low back pain	Age-related hearing loss	Alzheimer's disease	Blindness and vision loss	Falls 0.82	Stroke	Depressive disorders	Osteoarthritis	Diabates	Oral disorders
Republic of Moldova	Low back pain	Age-related hearing loss	Blindness and vision loss	Alzheimer's disease	Diabetes	Osteoarthritis	Oral disorders	Strake	Depressive disorders	Falls
	1.23 Low back pain	1.07 Age-related hearing loss	1.37 Blindness and vision loss	1.15 Osteoarthritis	0.72 Alzheimer's disease	1.06 Stroke	1.02 Oral disorders	0.79 Diabotes	1.12 Faily	1 Road injuries
Russian Federation	1.35	1.3	2 Alabaimar's disease	1.18 Blindness and vision loss	1.06	1.25	1.27	0.72 Disbotos	0.66 Ostopasthritis	4 Jacksonic house discourse
Ukraine	1.35	Age-related hearing loss	1.11	1.34	1.21	1.53	0.95	0.57	0.92	1.87
High-income	Low back pain	Age-related hearing loss	Falls	Alzheimer's disease	Osteoarthritis	Diabetes	COPD 1.32	Stroke	Oral disorders	Other musculoskeletal
Australasia	Falls	Age-related hearing loss	Low back pain	Osteoarthritis	Alzheimer's disease	COPD	Diabetes	Oral disorders	Other musculoskeletal	Total cancers
Australia	E46 Falls	1.15 Age-related hearing loss	Low back pain	1.24 Osteoarthritis	1.07 Alzheimer's disease	COPD	0.95 Diabetes	1.26 Oral disorders	Other musculoskeletal	1.4 Total cancers
Australia	1.44 Falls	1.15 Age-related hearing loss	0.81	1.24 Osteparthritis	1.06 COPD	1.64 Alzbeimer's disease	0.97 Oral disorders	1.24 Diabetes	4,23 Total cancers	1,37 Atrial fibrillation
New Zealand	1.56	1.17	0.85	1.25	1.76	1.07	1.35	0.86	1.56	1.68
High-income Asia Pacific	Low back pain 1.08	Age-related hearing loss 1.74	Alzheimer's disease	Osteoarthritis	Stroke 1.58	Other musculoskeletal 4.32	Diabetes 0.83	Falls 0.56	Oral disorders 0.93	Total cancers 0(7)
Brunei Darussalam	Diabetes	Low back pain	Osteoarthritis	Stroke	Age-related hearing loss	Other musculoskeletal	COPD 1.47	Alzheimer's disease	Fails	Oral disorders
Japan	Low back pain	Alzheimer's disease	Age-related hearing loss	Osteoarthritis	Stroke	Other musculoskeletal	Falls	Diabetes	Oral disorders	Total cancers
Barris Martinese a	1.11 Osteoarthritis	1.26 Low back pain	1.24 Age-related hearing loss	1.28 Diabetes	1.6 Alzheimer's disease	4.45 Stroke	0.6 Fails	Other musculoskeletal	0.96 Oral disorders	0,74 COPD
Republic of Korea	1.51 Outpossthuitis	0.94	1.22	1.18 Dishatas	1.07	1.48	0.72 Other environmentering	3.72	0.78 Oct disenter	U.67
Singapore	1.44	1.21	0,79	1.09	1.01	1.34	4,44	0.47	0.76	1.08
High-income North America	Low back pain 1.16	2.33	Age-related hearing loss 1.39	Falls	Diabetes	Osteoarthritis 1.31	Alzheimer's disease 1.08	Stroke 1.42	Other musculoskeletal 4.59	Total cancers 1.24
Canada	Falls	Low back pain	Age-related hearing loss	Alzheimer's disease	Osteoarthritis	Other musculoskeletal	COPD	Diabetes	Total cancers	Stroke
Greenland	Fälls	Low back pain	COPD	Age-related hearing loss	Stroke	Osteoarthritis	Alzheimer's disease	Diabetes	Other musculoskeletal	Total cancers
United States of	3.16 Low back pain	1.12 COPD	3.05 Age-related hearing loss	1.08 Diabetes	1.51 Falls	1.2 Osteoarthritis	1.09 Alzheimer's disease	U.6 Stroke	3.2 Other musculoskeletal	1.57 Neck pain
America	1.2	2.45	1.41	1.5	1.1	1.35	1.09	1.48	4.65	1.81
Southern Latin America	0.98	0.95	6.37	0.82	1.47	1.05	1.01	1.04	Unit .	0.61
Argentina	Age-related hearing loss 0.94	Other musculoskeletal 6.47	Diabetes	Low back pain	Osteoarthritis	Alzheimer's disease	Oral disorders	Blinkiness and vision loss	Falls 0.97	Endo/metab/blood/immun 1.66
Chile	Diabetes	Age-related hearing loss	Other musculoskeletal	Osteoarthritis	Low back pain	Alzheimer's disease	Falls	Oral disorders	Depressive disorders	Blindness and vision loss
Hereitau	Age-related hearing loss	Low back pain	Other musculoskeletal	Osteoarthritis	Alzheimer's disease	Oral disorders	Diabetes	Falls	5troke	Blindness and vision loss
orogoay	0.97 Low back pain	0.85 Falls	6.31 Diabetes	1.54 Alzheimer's disease	1.07 Age-related hearing loss	1.06 Osteparthritis	0.57 COPD	1.33 Oral disorders	0.77 Depressive disorders	0.54 Blindness and vision loss
western Europe	1.03	1.16	1.2	1.01	0.9	1.05	1.21	1.07	1.2	1.05
Andorra	1.52	0.96	0.97	0.95	D.89	1.08	1.07	1.1	1.12	0.69
Austria	Low back pain	Falls	Diabetes	Alzheimer's disease	Osteoarthritis	Age-related bearing loss	Oral disorders	Stroke	COPD 0.84	Depressive disorders
Belgium	Falls	Low back pain	Diabetes	Alzheimer's disease	Age-related hearing loss	COPD	Osteoarthritis	Oral disorders	Strake	Total cancers
Cumur	1.71 Diabetes	0.99 Low back pain	1.21 Falls	0.96 Osteoarthritis	0.88 Age-related hearing loss	1.46 Alzheimer's disease	1.02 Oral disorders	1.25 COPD	0.7 Total cancers	1.05 Endo/metab/blood/immun
cypius	1.63	1.02	1.25	1.04 Osteoerthritik	0.82	0.99	1.12 Diabatas	1.13 Oral disordary	1.13 Depressive disorder	1.26
Denmark	1.12	1.8	0.89	1.03	0.9	0.8	0.84	1.07	1.2	0.96
Finland	Falls 1.43	Low back pain 0,89	Diabetes 1.42	Age-related hearing loss 1.03	Alzheimer's disease 0.96	Osteoarthritis 1.02	Oral disorders 1.16	Stroke 0.9	Depressive disorders 1.01	Neck pain 1.54
France	Falls	Low back pain	Alzheimer's disease	Age-related hearing loss	Osteoarthritis	Oral disorders	Depressive disorders	Diabetes.	Total cancers	Stroke
Germany	Low back pain	Diabetes	Fails	Alzheimer's disease	COPD	Age-related hearing loss	Osteoarthritis	Oral disorders	Stroke	Depressive disorders
	1.04 Low back pain	1.64 COPD	0.9 Age-related hearing loss	1.02 Alzheimer's disease	1.27 Diabetes	0.9 Osteoarthritis	0.89 Depressive disorders	1.1 Oral disorders	0.83 Falls	1.09 Stroke
GREECE	1.01	2 Osteopatheltic	0.85	L01 Falle	0.97 Alzbeimer's disease	0.98	1.63 Diabates	1.1 Oral disorder	0.79 Blindness and vision for:	0.8 Shoke
Iceland	1.01	1.28	1.73	0.86	0.98	0.86	1	1.11	1.14	0.7
Ireland	Low back pain 1.05	COPD 1.75	Falls 0.85	Osteoarthritis 1.01	Alzheimer's disease 0.98	Diabetes 1.04	Age-related hearing loss 0.86	Oral disorders 1.23	Depressive disorders 1.18	Total cancers 1.11
Israel	Low back pain	Diabetes	Osteoarthritis	Age-related hearing loss	Alzheimer's disease	Oral disorders	Falls	Depressive disorders	COPD	Stroke
Italy	Low back pain	Diabetes	Alzheimer's disease	Age-related hearing loss	Falls	Osteoarthritis	Blindness and vision loss	Oral disorders	COPD	Depressive disorders
	1.04 Low back pain	1.23 Falls	1.17 Diabetes	0.97 COPD	1.2 Osteoarthritis	1.1 Alzheimer's disease	1.27 Age-related hearing loss	1.07 Oral disorders	1.04 Depressive disorders	1.18 Total cancers
Luxembourg	1.09	1.01	1.7	1.39	0.95	0.82	0.83	1.19	1.03	0.81
Malta	Low back pain 1.19	Diabetes 1.44	Falls 1.38	Osteoarthritis 1.14	Age-related hearing loss 0.79	Alzheimer's disease 0.99	Oral disorders 0.95	Endo/metab/blood/immun 1.52	0.85	Depressive disorders 0.89
Monaco	Low back pain	Fails	Alzheimer's disease	Osteoarthritis	Age-related hearing loss	Diabetes	COPD	Total cancers	Oral disorders	Stroke
Netherlands	Falls	Low back pain	COPD	Alzheimer's disease	Osteoarthritis	Age-related hearing loss	0ral disorders	1.42 Diabetes	Total cancers	Depressive disorders
restenatus	1.29 Falls	0.89 Low back nain	1.74 Age-related hearing loss	1.03 Osteoarthritis	0.91 Diabetes	0.84 Alzheimer's disease	1.35 COPD	0.97 Oral disorders	1.15 Stroke	1.05 Total cancers
Norway	1.22	0.84	1.21	1.06	1.37	0.94	1.18	1.7	1.12	0.85
Portugal	Low back pain 1.28	Diabetes 1.28	Usteoarthritis 1.37	Alzheimer's disease	Age-related treating lass D.73	Depressive disorders 1.66	1.63	Ural disorders 1.05	Falls 1.07	0.72
San Marino	Low back pain	Alzheimer's disease	Fails 0.74	Diabetes	Osteoarthritis	Age-related hearing loss	COPD 1.15	Oral disorders	Depressive disorders	Total cancers
Spain	Diabetes	Low back pain	Age-related hearing loss	Osteoarthritis	Alzheimer's disease	Falls	Blindness and vision loss	Depressive disorders	COPD	Oral disorders
Success	1.27 Low back pain	0.91 Falls	D/H2 COPD	14 Alzheimer's disease	1 Diabetes	1.33 Osteoartmitis	1.3 Oral disorders	1.58 Age-related hearing loss	1.28 Depressive disorders	0.78 Stroke
Success	1.05	1.2	1.72 Alzheimer's discourse	0.87 Diabatat	0.96	0.77	1.06	0.61 Oral disordary	1.26 Depressive disorder	11.8 Dilal conserv
Switzerland	1.06	1.06	0.96	1.29	0.88	0.88	D.84	0.98	1.1	0.75
United Kingdom	Low back pain	Diabetes 1.34	Falls	Age-related hearing loss	COPD 1.63	Osteoarthritis	Alzheimer's disease	Oral disorders	Depressive disorders	Total cancers

Latin America and	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Oral disorders	Alzheimer's disease	Other musculoskeletal	Osteoarthritis	Depressive disorders	Falls
Andean Latin America	Age-related hearing loss	Blindness and vision loss	Diabetes	Oral disorders	Low back pain	Osteoarthritis	Alzheimer's disease	Other musculoskeletal	Depressive disorders	Endo/metab/blood/immun
Bolivia (Plurinational	1.03 Age-related hearing loss	1.24 Diabetes	0.89 Blindness and vision loss	1.42 Oral disorders	0.78 Low back pain	1.21 Osteoarthritis	0.83 Depressive disorders	3.16 Other musculoskeletal	0.87 Alzheimer's disease	1.5 Endo/metab/blood/immun
State of)	1.03 Diabetes	0.96 Age-related hearing loss	1 Oral disorders	1.48 Blindness and vision loss	0.61 Low back pain	1.23 Osteoarthritis	1.24 Other misculoskeletal	2.01 Alzheimer's disease	0.86 Depressive disorders	1,45 Endo/metab/blood/immun
Ecuador	1.2	1.06	1.32	0.92	0.74	1.42	3.29	0.85	1.01	1.52
Peru	Age-related hearing loss 1.02	Blindness and vision loss 1.46	Ural disorders 1.45	0.72	D 78	0.82	Osteoarthritis 1.11	Other musculoskeletal 3.6	0.71	Endo/metab/blood/immun 1.5
Caribbean	Diabetes 1.42	Age-related hearing loss 1.12	Low back pain 0.87	Blindness and vision loss 0.94	Falls 1.53	Oral disorders 1.06	Depressive disorders 1.24	Osteoarthritis 1	Alzheimer's disease 0.78	Stroke 0.49
Antigua and Barbuda	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Oral disorders	Osteoarthritis	Alzheimer's disease	Depressive disorders	Other musculoskeletal	Chronic kidney disease
Bahamas	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Osteoarthritis	Oral disorders	Alzheimer's disease	Depressive disorders	Other musculoskeletal	Stroke
Deskudes	1.84 Diabetes	1.33 Age-related hearing loss	0.75 Low back pain	1.39 Oral disorders	0.83 Osteoarthritis	1.01 Alzheimer's disease	D 76 Depressive disorders	1.06 Other musculoskeletal	2.3 Blindness and vision loss	0.54 Stroke
Barbados	1.83 Dishatar	1.21 Ann-related bearing loss	0.79 Low back pain	L01	0.92 Oral disorders	0.78 Ostooarthritir	1.05	2.35 Depressive disorders	U.64 Chronic kidnov disease	0.53 Other murculer keletal
Belize	1.26	1.04	0.89	0.69	1	1.17	0.83	0.99	1.44	1.52
Bermuda	Age-related hearing loss 1.36	Diabetes 1.3	Low back pain 0.77	Alzheimer's disease DEL	Osteoarthritis D.83	Blindness and vision loss 1.35	Oral disorders	Depressive disorders 1.2	Other musculoskeletal 2.55	0.99
Cuba	Age-related hearing loss	Diabetes	Falls 3.94	Low back pain	Blindness and vision loss	Depressive disorders	Oral disorders	Osteoarthritis	Alzheimer's disatase	COPD
Dominica	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Oral disorders	Alzheimer's disease	Osteoarthritis	Depressive disorders	Other musculoskeletal	Chronic kidney disease
Dominican Republic	Age-related hearing loss	Diabetes	Low back pain	Blindness and vision loss	0ral disorders	Depressive disorders	Osteoarthritis	Alzheimer's disease	Stroke	Other musculoskeletal
comment repuerte	1.04 Diabetes	0.79 Age-related hearing loss	0.81 Low back pain	0.76 Blindness and vision loss	1.14 Oral disorders	1.4 Osteoarthritis	1.15 Altheimer's disease	0.82 Depressive disorders	0.52 Stroke	1.39 Other musculoskeletal
Grenada	1.65	1.09	0.85	0.83 Departmenting dispardent	0.97	1.01	0.78 Ortegatheitic	0.96	0.55	2.2
Guyana	1.75	Age-related hearing loss	0,86	1.44	0.73	0.99	1.08	0.77	0.50	1.33
Haiti	Diabetes 2.06	Age-related hearing loss 1.08	Low back pain 0.89	Blindness and vision loss 0.65	Oral disorders 1.36	Depressive disorders 0.95	Osteoarthritis 1.05	Alzheimer's disease 0.84	Stroke 0.65	Endo/metab/blood/immun 1.24
Jamaica	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Alzheimer's disease	Oral disorders	Osteoarthritis	Depressive disorders	Other musculoskeletal	Stroke
Puerto Rico	Diabetes	Age-related hearing loss	Low back pain	Alzheimer's disease	Ostenarthritis	Blindness and vision loss	Oral disorders	Falls	Depressive disorders	Chronic kidney disease
Color Marcine Landauer I.	2.37 Diabetes	1.35 Age-related hearing loss	0,73 Low back pain	0.79 Depressive disorders	0.85 Blindness and vision loss	1.33 Osteoarthritis	0.98 Oral disorders	0.48 Alzheimer's disease	0.86 Stroke	1.86 Other musculoskeletai
Saint Kitts and Nevis	1.82 Disbates	1.22 Ann-related bearing loss	0.79 Low back pain	1.38 Blindness and vision loss	1.09 Oral disorders	091 Ottoorthritis	0.98	0.77 Depressive disorders	07.69 Styleka	2,23
Saint Lucia	2.18	1.07	0.85	0.83	0.97	1.02	0.78	0.99	0.96	2,32
Saint Vincent and the Grenadines	Diabetes 1.8	Age-related hearing loss 1.04	Low back pain 0.86	Blindnoss and vision loss 0.72	Oral disorders 0.98	Osteoarthritis 1.09	Althomor's disease	Depressive disorders 0.97	Stroke 0.55	Other musculoskeletal 2,06
Suriname	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Depressive disorders	Oral disorders	Osteoarthritis	Attheimer's disease	Stroke 0.53	Chronic kidney disease
Trinidad and Tobago	Diabetes	Age-related hearing loss	Low back pain	Blindness and vision loss	Osteoarthritis	Oral disorders	Alzheimer's disease	Depressive disorders	Other musculoskeletal	Stroke
United States Virgin	Diabetes	1.25 Age-related hearing loss	Low back pain	1.14 Osteoarthritis	Blindness and vision loss	0.99 Depressive disorders	0.76 Oral disorders	1.15 Alzheimer's disease	Other musculoskeletal	Endo/metab/blood/immun
Islands	1.99 Diabetes	1.35 Are-related hearing loss	0.75 Blindness and vision loss	0.87	1.37 Other musculoskeletal	1.17 Oral disorders	0.84 Ostenarthritis	0.77 Altheimer's dise ave	2.39 Depressive disorders	1.04 Chronic kidney disease
Central Latin America	1.41	1.04	1.07	0.85	3.8	1.04	1.19	0.82	0.94	18
Colombia	1.1	Age-related nearing loss 1.02	1.12	0.95	4,41	0.89	1.07	0.85	133	1.68
Costa Rica	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Other musculoskeletal	Alzheimer's disease	Oral disorders	Osteoarthritis	Falls	Depressive disorders
El Salvador	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Alzheimer's disease	Other musculoskeietal	Oral disorders	Osteoarthritis	Depressive disorders	Falls
Gustamala	1.19 Diabetes	1.01 Blindness and vision loss	0.97 Age-related hearing loss	0.87 Low back pain	0.92 Oral disorders	2.55 Other musculaskeletal	1.03 Depressive disorders	1.13 Osteoarthritis	1 Alzheimer's disease	1.56 Chronic kidney disease
Goduernala	1.64 Diabetes	1.15 Age-related hearing loss	1.03 Blindpett and vision loss	0.86	1.23 Other musculoskeletal	1.95 Oral disorders	1.36 Depressive disorders	1.09 Osteoarthritic	0.92 Alzheimer's disease	1.61 Endo/metab/blood/immun
Honduras	1.49	1.05	0.81	0.89	1.94	1.2	1.21	1.11	0.92	1.56
Mexico	L6	Age-related hearing loss 1.06	Blingness and vision loss 1.05	Cow back pain 0.79	4.31	Osteoarthritis 1.32	Ural disorders	2.3	Atzheimer's disease 0.75	Depressive disorders 1.03
Nicaragua	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Other musculoskeletal	Oral disorders	Osteoarthritis	Alzheimer's disease	Depressive disorders	Falls 1.49
Panama	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Other musculoskeletal	Alzheimer's disease	Oral disorders	Osteoarthritis	Depressive disorders	Endo/metab/blood/immun
Venezuela (Bolivarian	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	0.16 Other musculoskeletal	Oral disorders	Altheimer's disease	0.98 Osteoarthritis	Depressive disorders	Chronic kidney disease
Republic of)	1.23 Diabetes	1.01 Age-related hearing loss	1.03 Blindness and vision loss	0.86 Oral disorders	3.55 Low back pain	1.01 Alzheimer's disease	0.84 Other musculoskeletal	1.03 Osteoarthritis	1.07 Depressive disorders	1.48 Falls
Tropical Latin America	0.95	0.87	1.15	1.45	0.83	1.09	3.8	1.09	1.09	1.69
Brazil	0.95	0.86	1.15	1.46	0.84	1.09	3.8	1.09	1.09	1.7
Paraguay	Age-related hearing loss 1.05	Diabetes 0.95	Blindness and vision loss 1.09	Low back pain 0.8	Oral disorders 1.25	Alzheimer's disease 1.06	Other musculoskeletal 3.7	Osteoarthritis 1.06	Depressive disorders 1.1	Stroke 0.56
North Africa and Middle	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Stroke	Alzheimer's disease	Oral disorders	Osteoarthritis	COPD	Depressive disorders
North Africa and Middle	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Stroke	Alzheimer's disease	Oral disorders	Osteoarthritis	COPD	Depressive disorders
East	1.26 Blindness and vision loss	1.03 Diabetes	1.5 Age-related hearing loss	0.91 Low back pain	1.29 Leishmanlasis	1.17 Conflict & terror	0.99 Stroke	0.9 Oral disorders	1.52 Alzheimer's disease	1.01 COPD
Argnanistan	1.43 Diabates	1.91 Bijodness and vision loss	1 Are-related hearing loss	0.9 Stroke	1472.36	249.67 Alzheimer's disease	1.21 Drat disorders	1.44 Osteparthritis	1.22 Depressive disorders	1.17 Other musculaskaletal
Algeria	1.32	1,49	0.97	1.34	0.88	1.17	0.91	0.96	0.99	2.65
Bahrain	Diabetes 3.13	Age-related hearing loss 1.11	Blindness and vision loss 2.12	Low back pain 0.78	Stroke 1.1	Alzheimer's disease 1.14	COPD 1.74	Distributivities	Oral disorders 0.89	Depressive disorders 1.14
Egypt	Diabetes 1.05	Blindness and vision loss 1.64	Stroke	Age-related hearing loss 0.96	Low back pain	Oral disorders 0.91	Alzheimer's disease	Osteoarthritis	Depressive disorders 1.04	Chronic kidney disease 2.3
Iran (Islamic Republic	Diabetes	Blindness and vision loss	Age-related hearing loss	Low back pain	Alzheimer's disease	Stroke	Osteoarthritis	COPD	Depressive disorders	Oral disorders
or)	Diabetes	Blindness and vision loss	Age-related hearing loss	Stroke	Low back pain	Alzheimer's disease	Dral disorders	Osteoarthritis	Chronic kidney disease	Depressive disorders
nay	1.41 Diabetes	1.6 Stoke	0.99 Age-related hearing loss	1.64 Low back pain	0.85 Blindness and vision loss	1.14 Alzheimer's disease	0.91 Oral disorders	0.92 Depressive disorders	2.21 Osteoarthritis	0.8 Other musculoskeletal
Jordan	1.36	1.88	1.08	0.82	1.66	1.13	0.97	1.19	0.86	29
Kuwait	2.4	Age-related hearing loss	Blindness and vision loss 2.94	Low back pain 0.8	Alzheimer's disease	1.13	Osteoarthritis 0.71	0.97	Uther musculoskeletai 3.24	Depressive disorders 1.12
Lebanon	Diabetes 1.46	Age-related hearing loss 1.05	Blindness and vision loss 1.71	Stroke	Low back pain 0.75	Alzheimer's disease	2.16	Oral disorders 0.95	Osteoarthritis 0.35	Depressive disorders 1.11
Libya	Diabetes	Blindness and vision loss	Age-related hearing loss	Stroke	Low back pain	Alzheimer's disease	Oral disorders	Osteoarthritis	COPD	Depressive disorders
Morecco	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Stroke	Alzheimer's disease	Oral disorders	Depressive disorders	Osteoarthritis	Chronic kidney disease
0	1.21 Diabetes	0.97 Blindness and vision loss	0.92 Age-related hearing loss	0.95 Low back pain	1.42 Stroke	1.24 Alzheimer's disease	1.1 Chronic kidney disease	1.19 Osteoarthritis	1.02 Oral disorders	1.84 Depressive disorders
Uman	1.56 Disbates	3.33 Ann-related bearing loss	1.16 Blindners and vision loss	U.76 Stroke	1.58	1.14 Alzhaimar's disease	3.5 Depressive disorders	0.76 Oral disorders	0.92 Orteoarthritic	1.1 Chronic kidnau diraara
Palestine	1.39	0.94	1.14	1.39	0.87	1.19	1.37	0.95	1	1.93
Qatar	Diabetes 4.03	Blindness and vision loss 3.7	Low back pain 0.72	Age-related hearing loss 1.2	Stroke 1.44	Other musculoskeletal 2.52	Osteoarthritis 0.73	Oral disorders 0.88	Chronic kidney disease 3.08	Depressive disorders 1.08
Saudi Arabia	Blindness and vision loss	Diabetes	Stroke	Age-related hearing loss	Low back pain	Falls	Alzheimer's disease	Osteoarthritis	COPD 1.23	Oral disorders
Sudan	Blindness and vision loss	Age-related hearing loss	Diabetes	Stroke	Low back pain	Alzheimer's disease	Oral disorders	Osteoarthritis	Depressive disorders	Chronic kidney disease
Surian Arab Deputition	1.24 Diabetes	0.98 Blindness and vision loss	1.17 Age-related hearing loss	L53 Low back pain	0,87 Conflict & terror	1.24 Stroke	1.04 Oral disorders	1.01 Alzheimer's disease	0.87 Osteoarthritis	1.73 Depressive disorders
Synan Arab Republic	1.15 Diabatas	1.35 Are related bearing loss	0.92 Blindness and vision loss	0.88	1225.76 Althaimer's disease	1.16 Stepke	0.95 Depressive disorders	1.19 Okal dis anders	0.98 Ostopartheitis	0.91 Other onuscular kelatal
Tunisia	1.26	1.01	1.44	U,84	1.18	1.09	1.45	0,9	0.92	2.96
Turkey	Diabetes 1.24	Age-related hearing loss 1.14	Low back pain 0.92	Alzheimer's disease 1.17	Blindness and vision loss 1.42	1.87	Stroke 1.12	Oral disorders 1.17	Osteoarthritis 0.74	Falls 0.86
United Arab Emirates	Diabetes 3.21	Stroke 2.84	Blindness and vision loss 4.15	Age-related hearing loss	Low back pain	Osteoarthritis	COPD 1.17	Oral disorders	Other musculoskeletal	Chronic kidney disease
Yemen	Blindness and vision loss	Age-related hearing loss	Diabetes	Low back pain	Stroke	Alzheimer's disease	Oral disorders	Depressive disorders	Osteoarthritis	COPD
South Asia	Blindness and vision loss	COPD	Age-related hearing loss	Diabetes	Ealls	Low back pain	Dietary Iron deficiency	Other musculoskeletal	Depressive disorders	Osteoarthritis
South Aria	1.61 Blindness and vision loss	4.14 COPD	1 Age-related hearing loss	0.94 Diabetes	4.35 Falls	0.93 Low back pain	3.52 Dietary fron deficiency	2.3 Other musculoskeletal	1.23 Depressive disorders	0.98 Osteoarthritis
South Asia	1.61 Blindness and vision loss	4.14 Age-related hearing last	1 Low back pain	0.94 Other musculativation	4.35 Diabates	0.93	3.52 Depressive disordant	2.3 Distary iron deficiency	1.23 Osteparthritic	0.98 Stroke
Bangladesh	1.4	0.96	1.03	2.96	0.92	2.37	1.37	1,86	0.93	p.73
Bhutan	COPD- 3.49	Age-related hearing loss 0.98	Low back pain 1.06	Diabetes 1.01	domaniess and vision lass	Cuner musculoskeletal 2.39	Falls 2.95	Depressive disorders 1.2	Osteoarthritis 0.99	Dietary iron deficiency 1.72
India	Blindness and vision loss	COPD 45	Age-related hearing loss	Falls 4.97	Diabetes 0.92	Low back pain	Dietary iron deficiency	Other musculoskeletal 2,21	Depressive disorders	Osteoarthritis 3
Nepal	COPD	Blindness and vision loss	Low back pain	Age-related hearing loss	Diabetes	Depressive disorders	Falls	Other musculoskeletal	Dietary Iron deficiency	Osteoarthritis
Pakistan	4.2 Blindness and vision loss	1.09 Diabetes	1.14 Age-related hearing loss	COPD	1.06 Low back pain	1.48 Other musculoskeletal	Depressive disorders	0steoarthritis	Dietary iron deficiency	0.95 Struke
Pakistan Southeast Asia Fast Asia	1.62 Age, related bearing loss	1.31 Stroke	1 Blindness and vision loss	2.77	0.91 Low back pain	2.23 Alzheimer's disease	1.24 Disturbus	0.89 Osteoarthritis	1.58 Oral disorders	0.68 Falls
and Oceania	1.14	1.91	14	3.22	0.92	1.16	0.50	0.93	0.86	1.28
East Asia	Age-related hearing loss	2.04	3.57	0.86	1.23	1.22	0.52	1	0.85	1.3
China	Age-related hearing loss 1.19	Stroke 2.05	COPD 3.66	Low back pain 0.85	Blindness and vision loss 1.26	Alzheimer's disease 1.23	Diabetes 0.51	Osteoarthritis 1	Oral disorders 0.85	Fails 1.38
Democratic People's	COPD	Age-related hearing loss	Stroke	Low back pain	Diabetes	Alzheimer's disease	Blindness and vision loss	Osteoarthritis	Oral disorders	Depressive disorders
Taiwan (Province of	Low back pain	Diabetes	Age-related hearing loss	Stroke	Alzheimer's disease	Chronic kidney disease	Osteganhritis	Oral disorders	Other musculoskeletal	Blindness and vision loss
China)	1.05 Diabater	1.61 Low back ratio	1.28 Blindness and vision lass	1.71 Age-related hearing for	0.98 Stroke	3,64	0.71 Oral disorder	0.81 Falls	2.77 Alzheimer's diseases	1.17 Dietacy iron deficierent
Oceania	1.61	1.32	1.09	1	1.55	2.19	1.18	2.07	0.97	2.11
American Samoa	2,54	Low back pain 1.22	Stroke 1.85	Age-related hearing loss 1.03	Bandness and vision loss 1.43	Alzheimer's disease 0.88	Oral disorders 0.91	Ostooutintis 0(82	COPD 1.48	Z.12
Cook Islands	Diabetes 2.16	Low back pain 1.17	COPD	Age-related hearing loss	Stroke 1.79	Blindness and vision loss	Alzheimer's ditease 0.89	Oral disorders 0.93	Osteoertfillts 0.75	Chronic kidney disease
Fiji	Diabetes	Low back pain	Blindness and vision loss	Age-related hearing loss	Stroke	Oral disorders	Alzheimer's disease	Osteoarthritis	Dietary iron deficiency	Other musculoskeletal
Guam	Low back pain	1.26 Diabetes	1.56 Stroke	Age-related hearing loss	1.63 Blindness and vision loss	0.92 Alzheimer's disease	0.89 Oral disorders	0.85 Osteoarthritis	5.75 Ischemic heart disease	COPD
and the second s	1.14 Diabetes	1.45 Low back pain	2.08 Age-related hearing loss	1.21 Blindness and vision loss	2.07 Stroke	0.89 Oral disorders	0.94 Dietary iron deficiency	0.69 Osteparthritis	2.06 Alzheimer's disease	0,82 Other musculoskeletal
Kinbati	1.45	1.35	0.98	0.95	1.51 Blindauss and this	1.12	2.43	0.92	0.95	1.02
Marshall Islands	2.39	1.27	1.82	0.94	0.92	1	2.21	0.89	0.93	1
Micronesia (Federated States of)	Diabetes 1.57	Low back pain 1.31	Age-related hearing loss 0.93	Stroke	Blindness and vision loss 0.95	Oral disorders 0.99	Alzheimer's disease 0.94	Osteoarthritis 0.92	COPD 1.49	Chronic kidney disease
Nauru	Diabetes	Low back pain	Stroke	Age-related hearing loss	COPD	Blindness and vision loss	Oral disorders	Osteoarthritis	Other musculoskeletal	Alzheimer's disease
Niue	Diabetes	Low back pain	Age-related hearing loss	COPD	Stroke	Blindness and vision loss	Alzheimer's disease	Oral disorders	Osteoarthritis	Chronic kidney disease
Northern Mariana	2.15 Diabetes	1.22 Low back pain	1.02 Age-related hearing loss	3.25 Stroke	1.68 Blindness and vision loss	1.34 Alzheimer's disease	0.9 Oral disorders	0.94 Osteparthritis	0.81 Falls	2.01 Etironic kidney disease
Islands	1.75 Disharar	1.15	1.16	1.88	1.79	0.92 Blindness and skine terr	0.93 Oral disordary	0.72 Diseasethette	0.84 Alzheimm's dise	2,18 Falls
Palau	2.01	1.19	1.9	1.09	3.18	1.58	0.93	0.77	0.89	1.08
Papua New Guinea	Low back pain 1.35	Diabetes	Blindness and vision loss 1.03	Age-related hearing loss 0.99	2.59	Stroke	Pails 3.15	Oral disorders	Dietary iron deficiency L8	Alzheimer's disease

Samoa	Diabetes	Low back pain	Age-related hearing loss	Stroke	Blindness and vision loss	Alzheimer's disease	Oral disorders	COPD	Osteoarthritis	Chronic kidney disease
Solomon Islands	Low back pain	Diabetes	Age-related hearing loss	Blindness and vision loss	Stroke	Falls	Oral disorders	COPD	Dietary iron deficiency	Osteoarthritis
Tokelau	1.34 Diabetes	1.36 Low back pain	1.01 Age-related hearing loss	COPD	1.67 Stroke	5.46 Blindness and vision loss	1.34 Alzheimer's disease	1.19 Oral disorders	1.64 Osteoarthritis	Chronic kidney disease
Tonga	1.44 Diabetes	1.31 Low back pain	0.92 Age-related hearing loss	3.83 Stroke	1.47 Blindness and vision loss	1.01 Alzheimer's disease	0.93 Oral disorders	0.94 Osteoarthritis	0.9 COPD	1.6 Ischemic heart disease
Tonga	1.34 Diabetes	1.34 Low back pain	0.94 Age-related hearing loss	1.39 Stroke	0.81 Blindness and vision loss	0.93 COPD	0.95 Oral disorders	0.9 Alzheimer's disease	1.55 Osteoarthritis	1.67 Dietary iron deficiency
Tuvalu	1.56 Diabetes	1.32 Low back pain	0.93 Stroke	1.47 Age-related hearing loss	0.96 Blindnwys and vision fors	3.18 Oral disorders	0.98 COPD	0.94 Dietary iron deficiency	0.9 Alzheimer's disease	2.68 Osteoarthritis
Vanuatu	1.62 Biladoess and vision loss	1.45 Low back pain	7.11 Diabetes	0.97 Ave-related hearing loss	0.71 Stroke	1.14	1.32 Altholmer's disease	1.92 Oral disorders	0.98 Other musculoskeletal	0.9 Neck pain
Southeast Asia	1.92 Blindense and vision loss	1.16 Dishatas	1.03	1 Lou back ania	1.45 Strake	1.89	0.91	0.85 Oral disordary	25	2 Other mutaular kale tal
Cambodia	1.44	1.33	1	1.19	1.4	2.39	1	0.98	1.2	1.17
Indonesia	3.11	1.93	1.26	Age-related hearing loss	0.7	0.93	1.84	0.85	2.76	2.05
Lao People's Democratic Republic	Diabetes 1.58	Age-related hearing loss	Low back pain 1.16	Blindness and vision loss 0.86	Stroke 1.68	COPD 1.66	Alzheimer's disease 0.99	Other musculoskeletal 1.24	Neck pain 1.89	0,72
Malaysia	Diabetes 1.49	Low back pain 1.07	Blindness and vision loss 2.21	Age-related hearing loss 1.13	Stroke 1.7	Oral disorders 1.06	Alzheimer's disease 0.95	Other musculoskeletal 3	COPD 1.44	Chronic kidney disease 2.02
Maldives	4.01	Age-related hearing loss 0.96	Diabetes 1.05	Low back pain 1.07	Blindness and vision loss 0.93	Stroke 0.99	Alzheimer's disease 1.03	Oral disorders 0.81	Other musculoskeletal 1.74	Chronic kidney disease 1.82
Mauritius	Diabetes 2.28	Age-related hearing loss 1.05	Blindness and vision loss 1.81	Low back pain 0.95	Stroke 1.21	Oral disorders 1.06	Alzheimer's disease 0.89	Chronic kidney disease 2.65	Other musculoskeletal 3.22	Depressive disorders 0.95
Myanmar	Blindness and vision loss 1.43	Diabetes 1.45	COPD 3.51	Age-related hearing loss 0.99	Low back pain 1.05	Alzheimer's disease 0.98	Stroke 0.86	Falls 1.98	Other musculoskeletal 1.2	Neck pain 1.84
Philippines	Low back pain 1.36	Age-related hearing loss	Blindness and vision loss 1.36	Diabetes 0.95	Stroke	Oral disorders 1.09	Alzheimer's disease 0.89	Neck pain 2 g	COPD 17	Other musculoskeletal 2.01
Seychelles	Diabetes. 2.24	Blindness and vision loss	Age-related hearing loss	Low back pain	Stroke	Alzheimer's disease	Other musculoskeletal	Oral disorders	COPD 1.25	Chronic kidney disease
Sri Lanka	Diabetes	Age-related hearing loss	Blindness and vision loss	Low back pain	Stroke	Alzheimer's disease	COPD	Other musculoskeletal	Falls	Oral disorders
Thailand	Age-related hearing loss	Diabetes	Low back pain	Blindness and vision loss	Stroke	Alzheimer's disease	Other musculoskeletal	Oral disorders	Chronic kidney disease	COPD
Timor-Leste	Blindness and vision loss	Diabetes	Age-related hearing loss	1.43 Stroke	Low back pain	COPD	0ral disorders	Alzheimer's disease	Other musculoskeletal	1.28 Neck pain
Viet Nam	1.69 Blindness and vision loss	1.16 Diabetes	0.99 Age-related hearing loss	1.81 Low back pain	1.05 Stroke	1.56 COPD	0.88 Alzheimer's disease	0.98 Falls	1.13 Oral disorders	1.86 Neck pain
Sub-Sabaran Africa	1.35 Blindness and vision loss	1.05 Age-related hearing loss	0.92 Low back pain	1.16 Diabetes	1.33 Depressive disorders	2.27 Stroke	0.94 Osteoarthritis	1.92 Alzheimer's disease	0.72 COPD	1.96 Dral disorders
Central Sub-Saharan	1.07 Age-related hearing loss	0.96 Low back pain	0.96 Diabetes	0.96 Depressive disorders	1:46 Blindness and vision loss	0.97 Alzheimer's disease	1.08 COPD	0.98 Stroke	1.21 Osteoarthritis	0,66 Onchocerciasis
Africa	0.95 Age-related hearing loss	1.03 Low back pain	1.01 Blindmuss and vision loss	1.37 Diabetes	0.61 Depressive disorders	1.33 Stroke	1.63 Alzheimer's disease	0.92 COPD	1.05 Osteoarthritis	24.18 Dral divorders
Angola Central African	0.94 Age-related hearing loss	1.02	0.81 Diabetes	0.9 Bilimforess and sister loss	1.57 Depressive disorders	1.12 Altheimer's disease	1.33 Stroke	1.43 Opchorentiasis	1.07 COPD	0.58 Osteoarthritis
Republic	0.99	1.07 Dishetes	1.24	0.62 Blindness and vision loss	1.11 Demessive disorders	1.49 Stroke	0.96	6.39 Altheimer's disease	1.26 Osteoarthritis	1.03 Other musculoskeletal
Congo	0.89	0.89	1 Diskater	0.84	1.69	1.18	2.47	1.31	1.09	1.14
the Congo	0.96	1.03	1.05	1.31	1.65	1.33	0.53	29.61	1.04	0,84
Equatorial Guinea	Blindness and vision loss 1.77	Age-related hearing loss 0.96	Diabetes 0.92	Low back pain 0.94	Depressive disorders 1.74	Stroke 1,13	2.4	Alzheimer's disease 1.16	Osteoarthritis 0.97	Other musculoskeletal 2,16
Gabon	Age-related hearing loss 0.93	0.91	Low back pain 0.96	Blindness and vision loss 1.06	Depressive disorders 1.69	Alzheimer's disease 1.18	Stroke 1.07	Osteoarthritis 1.05	COPD 1.6	Other musculoskeletal 2.07
Eastern Sub-Saharan Africa	Blindness and vision loss 1.03	Age-related hearing loss 0.94	Low back pain 0.92	Depressive disorders 1.45	Diabetes 0.78	Stroke 0.99	Alzheimer's disease 1.08	Osteoarthritis 1.07	COPD 0.87	Dietary iron deficiency 1.28
Burundi	Age-related hearing loss 0.95	Low back pain 0.94	Depressive disorders 1.22	Diabetes 0.88	Blindness and vision loss 0.51	Stroke 1	Alzheimer's disease 1.12	Osteoarthritis 1.03	COPD 0.96	Dietary iron deficiency 1.31
Comoros	Age-related hearing loss 0.91	Blindness and vision loss 0.92	Low back pain 0.93	Depressive disorders 1/46	Stroke 1.23	Diaberes 0.66	Alzheimer's disease 1.06	Osteoarthritis 1.07	Road injuries 2.62	Dietary iron deficiency 1.48
Djibouti	Age-related hearing loss 0.89	Blindness and vision loss 0.89	Low back pain 0.85	Depressive disorders	Diabetes 0.78	Stroke	Osteoarthritis	Alzheimer's disease	Dietary iron deficiency 1.33	Road injuries 2.14
Eritrea	Blindness and vision loss	Age-related hearing loss	Depressive disorders	Losv back pain	Diabetes 0.83	Stroke 0.95	Osteoarthritis	Alzheimer's disease	Dietary iron deficiency 1.57	COPD 0.97
Ethiopia	Blindness and vision loss	Age-related hearing loss	Low back pain	Depressive disorders	Diabetes	Alzheimer's disease	Osteoarthritis	Stroke	Trachoma	Falls
Kenya	Age-related hearing loss	Blindness and vision loss	Low back pain	Depressive disorders	Stroke	Diabetes	Alzheimer's disease	Osteoarthritis	COPD	Dietary iron deficiency
Madagascar	1.18 Age-related hearing loss	1.14 Blindness and vision loss	0.92 Low back pain	1.78 Stroke	0.98 Depressive disorders	0.53 Diabetes	COPD	Osteoarthritis	1.21 Alzheimer's disease	Dietary iron deficiency
Malawi	1 Blindness and vision loss	0.76 Age-related hearing loss	0.91 Low back pain	1.43 Diabetes	1.45 Depressive disorders	U.76 Stroke	1.42 Alzheimer's disease	1.04 Osteoarthritis	1.05 Dietary iron deficiency	1.58 COPD
Manaphique	0.94 Blindness and vision loss	0.93 Age-related hearing loss	0.91 Low back pain	0.93 Depressive disorders	1.18 Diabetes	0.98 Stroke	1.08 Alzheimer's disease	1.07 Osteoarthritis	1.41 Road injuries	0.76 Dietary iron deficiency
Rwanda	0.98 Age-related hearing loss	0.94 Depressive disorders	0.96 Low back pain	1.28 Blindness and vision loss	0.93 Diabetes	1.25 Alzheimer's disease	1.09 Stroke	1.05 Osteoarthritis	2.2 COPD	1.35 Conflict & terror
Rwalloa	0.91 Age-related hearing loss	1.76 Blindness and vision loss	0.94 Low back pain	0.61 Depressive disorders	0.73 Diabetes	1.09 Stroke	0.89 Dietary iron deficiency	1.06 Osteoarthritis	1.14 Alzheimer's disease	225,07 COPD
Somalia	1 Onchocerciatis	0.73 Blindness and vision loss	0.99 Age-related hearing loss	0,87 Low back pain	1.23 Depressive disorders	0.96 Stroke	1.47 Diabetes	1.03 Alzheimer's disease	1.13 Osteoarthritis	0.69 Dietary iron deficiency
South Sudan	86.19 Depressive disorders	1.26 Low back pain	0.89 Diabetes	0,9 Blindness and vision loss	1.33 Age-rotated hearing loss	1.22 Stroke	0.81 Alzheimer's disease	1.05 Osteoarthritis	1.02 COPD	1.52 Dietary iron deficiency
Uganda United Republic of	2,72 Blindness and vision loss	0.92 Associated bearing loss	1 Low back gain	0.73 Depressive disorders	0.65 Diabetus	1.08 Stroke	1.08 Alzheimer's disease	1.06 Osteoarthritis	0.9 Dietary iron deficiency	1.21
Tanzania	1.2	0.87	0.88	1.53	0.74	1.04	1.07	1.08	1.4 Distanciona della sena	076
Zambia	0.88	0.8	0,85	0,74	1.44	1.04	1.08	1.05	1.75	1.04
Southern Sub-Saharan Africa	Diabetes 1.28	Age-related hearing loss 1.09	Blindness and vision loss 1.29	Low back pain 0.86	Depressive disorders 1.57	Stroke 1.09	2,14	Alzheimer's disease 0.95	Osteoarthritis 1	0.74
Botswana	Diabetes 1.19	Age-related hearing loss 0.97	Blindness and vision loss 1.24	Low back pain 0,89	Stroke 1.16	2.61	Depressive disorders 1.45	Alzheimer's disease 0.97	0steoarthritis 1.06	Endo/metab/blood/immun 2.26
Eswatini	Diabetes 1.26	Age-related hearing loss 0.96	Blindness and vision loss 1.11	Low back pain 0.85	Stroke 1.05	Depressive disorders 1.44	2.12	Osteoarthritis 1.14	951.16	Alzheimer's disease 0.99
Lesotho	Diabetes 1.18	Age-related hearing loss 1	Blindness and vision loss 1.06	Depressive disorders 2.05	Low back pain 0.87	COPD 2.15	HIV/AID5 417.22	Stroke 0.99	Osteoarthritis 1.09	Alzheimer's disease 1.02
Namibia	Age-related hearing loss 0.98	Diabetes 0.94	Blindness and vision loss 1.16	Low back pain 0.94	Stroke 0.99	Alzheimer's disease 0.99	COPD 2.04	Depressive disorders 1.16	Osteoarthritis 1.04	Oral disorders 0.77
South Africa	Diabetes 1.28	Age-related hearing loss 1.12	Blindness and vision loss 1.36	Low back pain 0.84	Depressive disorders 1.63	Stroke 1.1	COPD 2.26	Alzheimer's disease 0.94	Osteoarthritis 0.99	Oral disorders 0.74
Zimbabwe	Diabetes 1.5	Blindness and vision loss 1.04	Age-related hearing loss 0.96	Low back pain 1.02	Stroke	Depressive disorders 1:18	COPD 1.41	Osteoarthritis 1.07	Alzheimer's disease 1.04	Oral disorders 0.76
Western Sub-Saharan Africa	Blindness and vision loss	Age-related hearing loss	Low back pain	Diabetes 0.95	Depressive disorders	Stroke	Osteoarthritis	COPD	Alzheimer's disease 0.82	Oral disorders
Benin	Blindness and vision loss	Age-related hearing loss	Diabetes	Low back pain	Depressive disorders	Osteoarthritis	COPD 1.37	Stroke	Alzheimer's disease	Oral disorders
Burkina Faso	Blindness and vision loss	Age-related hearing loss	Diabetes	Low back pain	Depressive disorders	Osteoarthritis	Alzheimer's disease	Road Injuries	Stroke	COPD
Cabo Verde	Diabetes	Age-related hearing loss	Blindness and vision loss	Depressive disorders	Low back pain	Alzheimer's disease	Osteoarthritis	COPD	Stroke	Dret disorders
Cameroon	1.39 Age-related hearing loss	0.91 Blindness and vision loss	0,83 Diabetes	1.98 Low back pain	0.89 Depressive disorders	COPD	1.14 Osteoarthritis	1.23 Stroke	0.79 Alzheimer's disease	Road injurtes
Chad	0.89 Blindness and vision loss	0.92 Age-related hearing loss	1.03 Diabetes	0.98 Depressivé disorders	1.85 Low back pain	1.63 Stroke	1.16 Osteoarthritis	0.83 Alzheimer's disease	0.85 COPD	2.47 Oral disorders
Alter diverse	1 Blindness and vision loss	0.96 Diabetes	1.43 Age-related hearing loss	1.38 Low back pain	1.06 Depressive disorders	0.9 Stroke	1.06 Osteoarthritis	0.91 Alzheimer's disease	1.01 Oral disorders	1.22 COPD
Cote d'Ivoire	1.05 Depressive disorders	1.26 Blindness and vision loss	0,92 Age-related hearing loss	0.96 Diabetes	1:3 Low back pain	0.95 Stroke	1.12 COPD	0,68 Osteoarthritis	0.92 Alzheimer's disease	1.03 Oral disorders
Gambia	2.53 Dishatar	1.01 Blindness and vision loss	0.92	1.1 Depression disorders	0.91 Stroke	1.01	1.35 Osteoarthritik	1.11 Althelmer's diverse	0.88	0.84 Boad Injuster
Ghana	1 Blieden	1.05	0.87	173	1.21	0.77	1.13	0.82	1.06	2,49
Guinea	1.08	Age-related hearing loss 0.94	Diabetes 1.19	0.97	1.34	Usteoarthritis 1.09	1.21	Atzneimer's disease	0.82	0.92
Guinea-Bissau	Blindness and vision loss 1.17	Age-related hearing loss 0.93	Diabetes 1.23	Low back pain 0.94	Depressive disorders 1.41	Ströke 0.97	Osteoarthritis 1.08	COPD 1.19	Aizheimer's disease 0.88	Road injuries 1.87
Liberia	Blindness and vision loss 0.98	Diabetes 1:44	Age-related hearing loss 0.92	Depressive disorders 1.8	Onchocerciasis 47.25	Low back pain 0.92	Osteoarthritis 1.12	Stroke 0.8	Alzheimer's disease 0.87	COPD 1.06
Mali	Blindness and vision loss 1.35	Age-related hearing loss 0.96	Diabetes 1.39	Low back pain 0.89	Depressive disorders 0.9	COPD 1.45	Osteoarthritis 1.08	Stroke 0.85	Alzheimer's disease 0.93	Oral disorders 0.92
Mauritania	Blindness and vision loss 1.03	Age-related hearing loss 0.9	Low back pain 0.89	Diabetes 0.87	Depressive disorders 1.26	Stroke 0,99	Osteoarthritis 1.17	COPD 1.33	Alzheimer's disease 0.87	Oral disorders 0.76
Niger	Blindness and vision loss 0.94	Age-related hearing loss 0.99	Low back pain 1.01	Depressive disorders 0.99	Diabetes 1.13	Osteoarthritis 1.07	COPD 1.01	Stroke 0.81	Alzheimer's disease 0.96	Oral disorders 1,25
	Oll a damage and states 1	tout had only	and the second se	and the second se	Challenge	A	a second s	whether and an and a state of the	60.00	Company and and all as a second

nigeria	1.4	1.13	0.92	1.66	0.7	1.15	0.89	0.75	1.03	1.86
Eno Tomo and Bringing	Blindness and vision loss	Diabetes	Age-related hearing loss	COPD	Stroke	Low back pain	Depressive disorders	Osteoarthritis	Alzheimer's disease	Dral divorders
sao tome and Philope	1.01	1.11	0.9	2.66	1.39	0.83	1.4	1.13	0.86	0.65
Sanagal	Blindness and vision loss	Diabetes	Age-related hearing loss	Low back pain	Depressive disorders	Stroke	Osteoarthritis	Alzheimer's disease	Oral disorders	COPD
Seriegai	1.17	1.58	0.92	0.87	1.25	0.93	1.11	0.89	0.97	1.02
Singra Leann	Age-related hearing loss	Blindness and vision loss	Low back pain	Depressive disorders	Diabetes	Stroke	COPD	Osteoarthritis	Alzhuimer's disease	Road injuries
Sierra Leone	1	0.92	0.95	1.42	0.91	1.06	1.27	1.09	0.89	1.81
Tono	Blindness and vision loss	Age-related hearing loss	Low back pain	Depressive disorders	Diabotes	Stroke	Osteoarthritis	COPD	Alzheimer's disease	Oral disordars
1080	1.05	0.92	0.94	1.58	0.81	0.92	1.1	1.22	0.88	0,79
Values shown in brackets rep	resent the ratio of observed Yi	Ds to predicted YLDs on the b	asis of Socio-Demographic Inde	ex (SDI), rounded to two (2) a	ligits. Color ranges (shown bek	ow) were calculated to place	e a roughly equal number of cel	ls into each bin.		
COLOR KEY:	[0.00,0.82)	[0.82,0.91]	(0.91,0.97)	[0.97,1.02]	[1.02, 1.08]	[1.08,1.17]	[1.17,1.27]	[1.27,1.45]	[1.45,1.87]	[1.87)



Figure S24. Global annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019.



Figure S25. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in Low SDI quintile.



Figure S26. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in Low-middle SDI quintile.







Figure S28. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in High-middle SDI quintile.



Figure S29. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in High SDI quintile.

Figure S30. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the Central Europe, Eastern Europe and Central Asia GBD super-region.





Figure S31. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the High-income GBD super-region.

Figure S32. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the Latin America and Caribbean GBD super-region



Figure S33. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the North Africa and Middle East super-region.





Figure S34. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the South Asia GBD super-region

Figure S35. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the Southeast Asia, East Asia and Oceania GBD super-region.



Figure S36. Annualised rate of change in risk factors summary exposure values (SEV) in people aged 70 years and older, for both sexes, from 1990 to 2019 versus number of attributable DALYs by risk factor in 2019, in the Sub-Saharan Africa GBD super-region.



Supplementary Table 1. GATHER checklist of information that should be included in reports of global health estimates, with description of compliance and location of information for "Global, regional, and national burden of diseases and injuries for adults 70 years and older: a systematicanalysis for the Global Burden of Disease 2019 Study"

#	GATHER checklist item	Description of compliance	Reference
Obj	ectives and funding		•
1	Define the indicators, populations, and time periods forwhich estimates were made.	Narrative provided inpaper and appendix describing indicators, definitions, and populations	Main text methods and appendix tables
2	List the funding sources for the work.	Funding sources listedin paper	Abstract and declaration of interest (Funding)
Dat	a Inputs		
For	all data inputs from multiple sources that are synthe	sized as part of the study:	1
3	Describe how the data were identified and how the data were accessed.	Narrative description of data seeking methods provided	Main text (Methods) and appendix
4	Specify the inclusion and exclusion criteria. Identify all ad-hocexclusions.	Narrative about inclusion and exclusion criteria by data type provided	Main text (Methods) and appendix
5	Provide information on all included data sources and their main characteristics. For each data source used, report reference information or contact name/institution, population represented, data collection method, year(s) of data collection, sex and age range, diagnostic criteria or measurement method, and sample size, as relevant.	An interactive, online data source tool that provides metadata for data sources by component, geography, cause, risk, or impairment has been developed. Detailed descriptions of all cause-specific analyses	Main text (methods), appendix, accompanying publications, and online tools including GBD Input Data Sources Tool at <u>https://ghdx.healthdata.org</u>
6	Identify and describe any categories of input data that have potentially important biases (e.g., based on characteristics listed in item 5).	References on related biases are reported in the main text description	Main text (Methods) and limitations
For	data inputs that contribute to the analysis but were r	ot synthesized as part of the study:	•
7	Describe and give sources for any other data inputs.	All are included in online data sources tool	https://ghdx.healthdata.org
For	all data inputs:	-	-
8	Provide all data inputs in a file format from which data can beefficiently extracted (e.g., a spreadsheet as opposed to a PDF), including all relevant meta-data listed in item 5. For any data inputs that cannot be shared due to ethical or legal reasons, such as third-party ownership, provide a contact name or the name of the institution that retains the right to the data.	Visualization of input data available through online model visualization tools at and for download via data query tools at	<u>https://vizhub.healthdata.org</u> and <u>https://ghdx.healthdata.org</u>
Dat	a analysis		
9	Provide a conceptual overview of the data analysis method. A diagram may be helpful.	Description of the overall methodologicalprocesses, as well as of modelling processes, is provided in methods. Main text states that data analysis is followingthe GBD 2019 capstone papers	Main text (Methods)

10	Provide a detailed description of all steps of the analysis, including mathematical formulae, if necessary. This description should cover, as relevant, data cleaning, data pre-processing, data adjustments and weighting of data sources, and mathematical or statistical model(s).	Detailed methodological description of the analysed variables and statistical analysisis provided. Information on this models is following the GBD 2019 capstone papers andrelevant references have been provided.	Main text (Methods)
11	Describe how candidate models were evaluated and how the final model(s) were selected.	Information on this models is following theGBD 2019 capstone papers and relevant references have been provided	Main text (methods)
12	Provide the results of an evaluation of model performance, ifdone, as well as the results of any relevant sensitivity analysis.	Information on this models is following theGBD 2019 capstone papers and relevant references have been provided	Main text (methods)
13	Describe methods for calculating uncertainty of the estimates. State which sources of uncertainty were, and werenot, accounted for in the uncertainty analysis.	Brief Information on theuncertainty intervals is previded and is following the GBD 2019 capstone papers. Relevant referenceshave been provided	Main text (methods)
14	State how analytic or statistical source code used to generate estimates can be accessed.	Access statement provided.	Code is available upon request.
Res	sults and Discussion		
15	Provide published estimates in a file format from which data can be efficiently extracted.	Results are availablethrough online data visualization tools, the Global Health Data Exchange, and the online data query tool (https://ghdx.healthdata.org/gbd- 2019)	Main text, appendix, and online data tools (data visualization tools, dataquery tools, and the Global Health Data Exchange
16	Report a quantitative measure of the uncertainty of theestimates (e.g. uncertainty intervals).	Uncertainty intervals are provided with all results	Main text, appendix,and online data tools (data visualization tools, dataquery tools, and the Global Health Data Exchange, <u>https://ghdx.healthdata.org/gb</u> <u>d-2019</u>)
17	Interpret results in light of existing evidence. If updating a previous set of estimates, describe the reasons for changes in estimates.	Discussion of results is provided in the narrative of the article	Main text (results and Discussion)
18	Discuss limitations of the estimates. Include a discussion of any modelling assumptions or data limitations that affect interpretation of the	Discussion of limitations provided in the narrative of of the article	Main text (Limitations)

unitableUnitab
NameN
NameNormeSecondNormeSecondNormeSecondNormeSecond
NameN
MakeMayeM
NormNameN
ArmPartialNameArmsPartialMartialArmsMartial
NormN
Correst C
ControlNomeControlNomeControlNomeControlNomeNo
Arrow <th< td=""></th<>
Jord
MathM
isor
NationNati
AppAppAppApp (App (App (App (App (App (App (App
NormN
NormSoftward </td
SameSameSameMathematerialMathemater
ArrowNetwork
note of mote seriesnote seriespart of seriespart of seriesdensyseriesweekseries<
NameWalkedWalkedMax durabit of\$
NormN
CurryNamethalMarkitaliandMathematerialNamethalGurryNamethalSambaraNamethalNamethalNamethalGurryNamethalSambaraNamethalNamethalNamethalGurryNamethalSambaraNamethalNamethalNamethalGurryNamethalSambaraNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalSambara-AmethalNamethalNamethalNamethalGurryNamethalSambara-AmethalNamethalNamethalNamethalGurryNamethalSambara-AmethalNamethalNamethalNamethalGurryNamethalSambara-AmethalNamethalNamethalNamethalGurryNamethalSambara-AmethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethalNamethalNamethalGurryNamethalNamethalNamethal<
SummNewNetShipNewNetworked 1NetShipNewNetworked 1NetShipGurunNewNetShipGurun 1Gurun 1NewNetGurun 1NewNet 1GurunNewNetShipGurun 1NewNet 1NewNet 1NewNet 1NewNet 1GurunNewNetShipGurun 1NewNet 1NewNet 1NewNet 1NewNet 1GurunNewNet 1NewNet 1NewNet 1NewNet 1NewNet 1NewNet 1NewNet 1GurunNewNet 1NewNet 1NewNet 1NewNet 1NewNet 1NewNet 1NewNet 1NewNet 1NewNet 1GurunNewNet 1NewNet 1<
ContryNetworksionContry (Networksion)NetworksionNetwo
ShoryHeadShoringinShoring in SolHeineUserOracleGuoryHap DiHefferdShoring into into 3Hap DiHorecoGuorsGuorsGuoryHap DiMiddalangeShoring into into 3Hap DiHorecoGuorsGuorsGuoryHap DiMiddalangeShoring into into 3Hap DiGuorsGuorsGuorsGuoryHap DiMiddalangeShoring into into 3Hap DiGuorsGuorsGuorsGuoryHap DiShoring into into 3Hap DiShoring into into 3Hap DiShoring into into 3Hap DiGuoryHap DiShoring into into 3Hap DiShoring into into 3Hap DiShoring into into 3Hap DiGuoryHap DiShoring into into 3Hap DiShoring into into 3Hap DiShoring into into 3Hap DiGuoryHap DiShoring into into 3Hap DiShoring into into 3Hap DiShoring into into 3Hap DiGuoryHap DiShoring into into 3Hap DiHap DiShoring into into 3Hap DiHap DiHap DiGuoryHap DiShoring into into 3Hap DiHap Di <td< td=""></td<>
ConvertMarinda Marinda Marin
CorryHe Di Herdingson<
Loury Name Control Con
m.m.m.gMay BallDistBallDistBallName <td< td=""></td<>
NameN
AnotyApp and by App and by Control of a p 30Another by Another by and by Another by another
SoorsAp bitNacharakan and Ap bitSakakan SoorsCoursAp bitSocial CoursSocial CoursCoursAp bitSocial CoursSocial CoursCoursAp bitSocial CoursAp bitCoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursSocial CoursSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursSocial CoursSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial CoursAp bitSocial Cou
Monry ingle bit Moder and General Market Market Market Market Market South Young Market South Young Market Mark
Christian Christian <t< td=""></t<>
ActuryNap we ability (ConvyNap we ability (ConvyNap we (ConvyNap we (ConvyNap we (ConvyNap we (ConvyNap we
ConvyName of the Society of S
SouryNep-ads/300Sodering is also interaction of partsFundoConverSource of parts
CoreNeprode
Jaur regin . HBBJADDR WHR Substant West Hep Stat Yennen Country Regin . BBBJOD Substant West Hep Stat BBBJOD Country Hep Stat Substant West Hep Stat BBBJOD Country Hep Stat Substant West Hep Stat Hep S
AgenAgenAgenAgenAgenGerryMg/SiBalagaoMonitorial land 1Mg/SiSouth kinMg/SiGerryMg/SiBalagaoMonitorial land 1Mg/SiBalagaoBalagaoContryMg/SiBalagaoMg/SiBalagaoBalagaoComyContryMg/SiContryMg/SiMg/SiBalagaoMg/SiBalagaoContryMg/SiContryMg/SiMg/SiMg/SiMg/SiMg/SiMg/SiStatistical land 1Mg/SiSantani land 1Mg/SiMg/S
ConvyHg 50BittonHontoni Lon HHg 50Solah AliaSolah AliaHg 50ConvyHg 50ForyNorther Lon HHg 10Solahatini Lon HHg 10Solahatini Lon HHg 10ConvyHg 50ConvyHg 50ConvyHg 10Solahatini Lon HHg 10Hg 10Solahatini Lon HHg 10ConvyHg 10Solahatini Lon HHg 10Hg 10FoldaSolahatini Lon HHg 10Solahatini Lon HHg 10Solahatini Lon HHg 10Solahatini Lon HHg 10FoldaSolahatini Lon HHg 10Solahatini Lon HHg 10Hg 10Solahatini Lon HHg 10FoldaSolahatini Lon HHg 10Solahatini Lon H
curryspip0 <th< td=""></th<>
bit Appen ··· Description fait in the shore sh
CountyHep D2Catalyne Wett all Catalyne Wett all All Dan
Contry Nap So Control is identical level is identis idevel is identical level is identical level is identrev
Note of the second of the se
a lationHaltonLational laterHaltonLational laterHaltonCourtySubscient laterHajtonKoroni laterHajtonSubscient laterHajtonSubscient laterHajtonSubscient laterHajtonSubscient laterHajtonSubscient laterHajtonSubscient laterHajtonCourtySubscient laterHajtonHajtonMarchesterHajtonHajtonCourtyCourtyTauerCourtySubscient laterHajtonOldhamSubscient laterHajtonCourtyTauerCourtyTauerCourtyTauerCourtyCourtyTauerCourtyCourtyCourtyCourtyTauerCourtyTauerCourtyC
Substitution land if in all plant Knowniny Substitution land if in all plant Margin is an all plant Substitution land if in all plant Link Shiftin Substitution land if in all plant Fig. 50 Substitution land if in all plant Link Shiftin Substitution land if in all plant Fig. 50 Substitution land if in all plant Mark DSM Mark DSM Substitution land if in all plant Substitution land if in all plant Mark DSM Substitution land if in all plant Care in all plant Substitution land if in all plant Mark DSM Substitution land if in all plant Care in all plant Substitution land if in all plant Substitution land if in all plant Substitution land if in all plant Gamma Care in all plant Substitution land if in all plant Substitution land if in all plant Substitution land if in all plant Gamma Care in all plant Substitution land if in all plant Mark DSM Substitution land if in all plant Gamma Care in all plant Substitution land if in all plant Mark DSM Substitution land if in all plant Mark DSM Gamma Care in all plant Substitution land if in all plant
sketorol lord 1Hg 50LinkShireSketorol lord 3Hg 50Est kisEagSketorol lord 1Hg 50LivepoolSketorol lord 3Hg 50CorrSketorol lord 1Hg 50Mint hots forSketorol lord 3Hg 50CorrSketorol lord 1Hg 50Sketorol lord 3Hg 50Gold 1Hg 50Sketorol lord 3Hg 50S
Substatest Leet 1High 50LiverpoolSubstatest Leet 3High 50ChiraCourtySubstatest Leet 1High 50MinCriesterSubstatest Leet 3High 50CourtyDemocratic RegistryCourtySubstatest Leet 1High 50OldramSubstatest Leet 3High 50CourtyCourtySubstatest Leet 1High 50Substatest Leet 3High 50CourtyCourtySubstatest Leet 1High 50Substatest Leet 3High 50CourtyCourtySubstatest Leet 1High 50Substatest Leet 3High 50CourtyCourtySubstatest Leet 1High 50Statest Leet 3High 50CourtyCourtySubstatest Leet 1High 50Statest Leet 3High 50GaamCourtySubstatest Leet 1High 50Targe 3de Substatest Leet 3High 50GaamCourtySubstatest Leet 1High 50Targe 3de Substatest Leet 3High 50Minchest Leet 3High 50Substatest Leet 1High 50Warral Courts 1High 50Minchest Leet 3High 50Minchest Leet 3Substatest Leet 1High 50Substatest Leet 3High 50Substatest Leet 3High 50High 50Substatest Leet 1High 50Substatest Leet 3High 50Substatest Leet 3High 50High 50Substatest Leet 1High 50Substatest Leet 3High 50Substatest Leet 3High 50Substatest Leet 3High 50Substatest Leet 1High 50Substatest Leet 3 <t< td=""></t<>
Substantional Level 1 High 50 Marchester High 50 Descontal Registry a Substantional Level 3 High 50 County Chickly of Koons Taiwan (Province of Cauny Cauny Substantional Level 3 High 50 Substantional Level 3 High 50 County Chickly of Koons Taiwan (Province of Cauny Cauny Substantional Level 3 High 50 Substantional Level 3 High 50 County Cauny Cauny Substantional Level 3 High 50 Substantional Level 3 High 50 County Cauny Cauny Substantional Level 3 High 50 County Cauny Substantional Level 3 High 50 County Cauny Substantional Level 3 High 50 County Substantional Level 3 High 50 County Substantional Level 3 High 50 County Substantional Level 3 High 50 Kine 4 County Substantional Level 3 High 50 Kine 4 County Substantional Level 3 High 50 Kine 4 County Substantional Level 3 High 50 Substantional Level 3 High 50 Kine 4 County Substantional Level 3 High 50 Substantional Level 3 High 50 Kine 4 County Substantional Level 3 Hi
International and the state of the state
Accounterant reverMig DAOldshamSolutional level 1Mig DAChrini 1Chrini 1KingerSubstational level 1Migh DASafetonSolutational Level 3Migh DACock IslandsCorrerSubstational level 1Migh DASolutational Level 3Migh DACock IslandsCock IslandsSubstational Level 1Migh DASolutational Level 3Migh DAMicrosetia [Federated]Cock IslandsSubstational Level 1Migh DAWirralSubstational Level 3Migh DAMicrosetia [Federated]Cock IslandsSubstational Level 1Migh DAWirralSubstational Level 3Migh DAMicrosetia [Federated]Cock IslandsSubstational Level 1Migh DABischonal Level
Schattered Leed 1 Hip S0 Rockdale Schattered Leed 1 Hip S0 Occaria Hepen Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Convert Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Convert Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Gam Convert Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Gam Convert Schattered Leed 1 Hip S0 Transide Schattered Leed 1 Hip S0 Marchall Islands Convert Schattered Leed 1 Hip S0 Warington Schattered Leed 1 Hip S0 Marchall Schattered Leed 1 Hip S0 Convert Schattered Leed 1 Hip S0 Warington Schattered Leed 1 Hip S0 Naru Convert Schattered Leed 1 Hip S0 Warington Schattered Leed 1 Hip S0 Northern Marina Convert Schattered Leed 1 Hip S0 Barckeref Forest 1 Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Schattered Leed 1 Hip S0 Barckeref Forest 1 <
Substational level 1 High Stat Saliford Substational level 3 High Stat American Samoa Country Substational level 1 High Stat Safetan Substational level 3 High Stat Fiji Country Substational level 1 High Stat Substational level 3 High Stat Fiji Country Substational level 1 High Stat Substational level 3 High Stat Guarn Country Substational level 1 High Stat Substational level 3 High Stat Kinhadi Country Substational level 1 High Stat Warnington Substational level 3 High Stat Micronesia (Federated Sciences) Country Substational level 1 High Stat Wigan Substational level 3 High Stat Nauru Country Substational level 1 High Stat Wigan Substational level 3 High Stat Nauru Country Substational level 1 High Stat Substational level 3 High Stat Nauru Country Substational level 1 High Stat Substational level 3 High Stat Nauru Country Substational level 1 High Stat Substational level 3 High Stat Substational level 3 High Stat Substational
Substational Level 1High SDISeftonSubstational Level 3High SDICook IslandsCountrySubstational Level 1High SDISt HelensSubstational Level 3High SDIGuarnCountrySubstational Level 1High SDIStockportSubstational Level 3High SDIGuarnCountrySubstational Level 1High SDITranesideSubstational Level 3High SDIKirbaitsCountrySubstational Level 1High SDITranesideSubstational Level 3High SDIKirbaitsCountrySubstational Level 1High SDIWarningtonSubstational Level 3High SDIManhall IslandsCountrySubstational Level 1High SDIWirralSubstational Level 3High SDINuceCountrySubstational Level 1High SDIWirralSubstational Level 3High SDINuceCountrySubstational Level 1High SDISubstational Level 3High SDINuceCountrySubstational Level 1High SDIBicking JamashineSubstational Level 3High SDINuceCountrySubstational Level 1High SDIBicking JamashineSubstational Level 3High SDISubstational Level 3High SDISubstational Level 3High SDISubstational Level 1High SDIBicking JamashineSubstational Level 3High SDISubstational Level
Schwatzonal Level 1 High 501 Fiji Country Schwatzonal Level 1 High 501 Schwatzonal Level 3 High 501 Guarn Country Schwatzonal Level 1 High 501 Tarnetside Schwatzonal Level 3 High 501 Kirblati Country Schwatzonal Level 1 High 501 Tarnetside Schwatzonal Level 3 High 501 Marshall Islands Country Schwatzonal Level 1 High 501 Warrington Schwatzonal Level 3 High 501 Marshall Islands Country Schwatzonal Level 1 High 501 Warrington Schwatzonal Level 3 High 501 Marconesia [frederated] Country Schwatzonal Level 1 High 501 Wiral Schwatzonal Level 3 High 501 Nue Country Schwatzonal Level 1 High 501 Birgchorell Forest Schwatzonal Level 3 High 501 Nue Country Schwatzonal Level 1 High 501 Birgchorell Forest Schwatzonal Level 3 High 501 Palau Country Schwatzonal Level 1 High 501 Birgchorell Forest Schwatzonal Level 3 High 501 Tokalau Country <
Substantional Level 1High 501StockportSubstantional Level 3High 501GuamiGuamiSubstantional Level 3High 501TranferideSubstantional Level 3High 501Kith ballCountrySubstantional Level 1High 501WarringtonSubstantional Level 3High 501Micronesia (Federatted)CountrySubstantional Level 1High 501WirralSubstantional Level 3High 501Micronesia (Federatted)CountrySubstantional Level 1High 501WirralSubstantional Level 3High 501NiuceCountrySubstantional Level 1High 501WirralSubstantional Level 3High 501NiuceCountrySubstantional Level 1High 501Brackinell ForestSubstantional Level 3High 501NiuceCountrySubstantional Level 1High 501Brackinell ForestSubstantional Level 3High 501PalauCountrySubstantional Level 1High 501Brackinell ForestSubstantional Level 3High 501PalauCountrySubstantional Level 1High 501Brackinell Substantional Level 3High 501Salmattoonal Level 3High 501Salmattoonal Level 3High 501CountrySubstantional Level 1High 501Brackinell Substantional Level 3High 501TokelauCountrySubstantional Level 1High 501KrentSubstantional Level 3High 501TokelauCountrySubstantional Level 1High 501KrentSubstantional Level 3High 501
anouncent terms i Mg 500 Guarn Guarn Contry Substational Level 1 Mg 500 Find Substational Level 3 Mg 501 Kinbatch Contry Substational Level 1 Mg 500 Trafford Substational Level 3 Mg 501 Marshall Islands Contry Substational Level 1 Hg 500 Warrington Substational Level 3 Mg 501 Marshall Islands Contry Substational Level 1 Hg 501 Wigan Substational Level 3 Mg 501 Nauru Contry Substational Level 1 Hg 501 Wigan Substational Level 3 Hg 501 Nue Contry Substational Level 1 Hg 501 Substational Level 3 Hg 501 Nue Contry Substational Level 1 Hg 501 Substational Level 3 Hg 501 Nue Contry Substational Level 1 Hg 501 Bind Groet 1 Substational Level 3 Hg 501 Finda Contry Substational Level 1 Hg 501 Bind Groet 1 Substational Level 3 Hg 501 Substational Leve
Substational Level 1 High S04 Tameside Substational Level 3 High S04 Kinbati Country Substational Level 1 High S04 Trafford Substational Level 3 High S04 Marshall Islands Country Substational Level 1 High S04 Warrington Substational Level 3 High S04 Marshall Islands Country Substational Level 1 High S04 Warrington Substational Level 3 High S04 Naurul Country Substational Level 1 High S04 Wirral Substational Level 3 High S04 Northerm Marinana Country Substational Level 1 High S04 Substational Level 3 High S04 Northerm Marinana Country Substational Level 1 High S04 Bit S04 Substational Level 3 High S04 Palau Country Substational Level 1 High S04 Bit S04 Substational Level 3 High S04 Somon Country Substational Level 1 High S04 Bit S04 Substational Level 3 High S04 Somon Country Substational Level 1 High S04 Bit S04 Substational Level 3 High S04 Somon Country Substational Level 1 High S04 Substational Level 3 High S04 Su
Substand Level 1 High S24 Trafford Substand Level 1 High S24 Marshall Islands Country Substand Level 1 High S24 Warrington Substand Lovel 3 High S24 Marshall Islands Country Substand Level 1 High S24 Warrington Substand Lovel 3 High S24 Marshall Islands Country Substand Level 1 High S24 Warrington Substand Lovel 3 High S24 Nauru Country Substand Level 1 High S24 Warrington Substand Lovel 3 High S24 Nue Country Substand Level 1 High S24 Birds Cheel I forest Substand Lovel 3 High S24 Palau Country Substand Level 1 High S24 Birds Cheel I forest Substand Lovel 3 High S24 Palau Country Substand Level 1 High S24 Birds Cheel I forest Substand Lovel 3 High S24 Palau Country Substand Level 1 High S24 Birds Cheel I forest Substand Lovel 3 High S24 Forest Country Substand Level 1 High S24 Birds Cheel I forest Substand Lovel 3 High S24 Tokelau Country Substand Level 1 High S24 Kent Substand Lovel 3 High S24
Substational Level 1 High SD(Warrington Substational Level 3 High SD(Microne is in (referented) Country Substational Level 1 High SD(Wigan Substational Level 3 High SD(Naura Country Substational Level 1 High SD(Wirral Substational Level 3 High SD(Nuce Country Substational Level 1 High SD(Wirral Substational Level 3 High SD(Nuce Country Substational Level 1 High SD(Bracknell Forest Substational Level 3 High SD(Papau New Guinea Country Substational Level 1 High SD(Bracknell Forest Substational Level 3 High SD(Papau New Guinea Country Substational Level 1 High SD(Bracknell Forest Substational Level 3 High SD(Substational Level 3 Papau New Guinea Country Substational Level 1 High SD(Bracknell Forest Substational Level 3 High SD(Substational Level 3 Papau New Guinea Country Substational Level 1 High SD(Bracknell Forest Substational Level 3 High SD(
Substitutional level 1 High 501 Natural States off)
Advancement of the set of t
Substational Level 1 High S01 Wirral Substational Level 1 High S01 Nue Country Substational Level 1 High S01 Substational Level 3 High S01 Birgh Country Nucherm Marinam Country Substational Level 1 High S01 Birgh Count Fast England Substational Level 3 High S01 Palau Country Substational Level 1 High S01 Birgh Count Fast England Substational Level 3 High S01 Palau Country Substational Level 1 High S01 Birgh Count Fast England Substational Level 3 High S01 Palau Country Substational Level 1 High S01 Birgh Count Fast England Substational Level 3 High S01 Sanca Country Substational Level 1 High S01 Buckinghams/Hire Substational Level 3 High S01 Tokelau Country Substational Level 1 High S01 East Sussee Substational Level 3 High S01 Tokelau Country Substational Level 1 High S01 Kent Substational Level 3 High S01 Towalu Country Substational Level 1 High S01 Midton Keynes Substational Level 3 High S01 Towalu Country Substational Level 1 High S01
Substational Level 1 High 50 South East England Substational Level 2 High 50 Northern Minimal Links Country Substational Level 1 High 50 Bracknell Forest Substational Level 3 High 50 Palau Country Substational Level 1 High 50 Bracknell Forest Substational Level 3 High 50 Palau Country Substational Level 1 High 50 Bracknell Forest Substational Level 3 High 50 Substational Level 3
Substational Level 1 High SOL Bracknell Forest Substational Level 3 High SOL Palau Country Substational Level 1 High SOL Brighton and Hove Substational Level 3 High SOL Papua New Guinea Country Substational Level 1 High SOL Buckinghamshire Substational Level 3 High SOL Samoa Country Substational Level 1 High SOL East Sussex Substational Level 3 High SOL Samoa Country Substational Level 1 High SOL East Sussex Substational Level 3 High SOL Torkelau Country Substational Level 1 High SOL East Sussex Substational Level 3 High SOL Torga Country Substational Level 1 High SOL Kent Substational Level 3 High SOL Torga Country Substational Level 1 High SOL Midton Keynes Substational Level 3 High SOL Yanuatu Country Substational Level 1 High SOL OxfortShire Substational Level 3 High SOL Controda Country Substational Level 1 High SOL OxfortShire Substational Level 3 High SOL Controda Country Substational Level 1 High SOL Reading
Substational Level 1 High S01 Bighton and Hove Substational Level 3 High S01 Papus New Guinea Contray Substational Level 1 High S01 Bighton and Hove Substational Level 3 High S01 Samaa Contray Substational Level 1 High S01 East Sussex Substational Level 3 High S01 Solomation Slands Contray Substational Level 1 High S01 Isle of Wight Substational Level 3 High S01 Totelau Contray Substational Level 1 High S01 Kent Substational Level 3 High S01 Tong 3 Contray Substational Level 1 High S01 Kent Substational Level 3 High S01 Tong 3 Contray Substational Level 1 High S01 McKent Substational Level 3 High S01 Tong 3 Contray Substational Level 1 High S01 McKent Substational Level 3 High S01 Tong 3 Contray Substational Level 1 High S01 McKent Substational Level 3 High S01 Yanualtu Contray Substational Level 1 High S01 OxfordShire Substational Level 3 High S01 Controy Substational Level 1 High S01 OxfordShire Substational Level 3 <t< td=""></t<>
international level High Sol Buckinghams hire is scheational level 3 High Sol Samoa Country Subhational level 1 High Sol Buckinghams hire is scheational level 3 High Sol Samoa Country Subhational level 1 High Sol East Sussex Subhational level 3 High Sol Solonon Islands Country Subhational level 1 High Sol East Sussex Subhational level 3 High Sol Tokelau Country Subhational level 1 High Sol Kent Subhational level 3 High Sol Tong a Country Subhational level 1 High Sol Kent Subhational level 3 High Sol Vanuatu Country Subhational level 1 High Sol Milton Keynes Subhational level 3 High Sol Vanuatu Country Subhational level 1 High Sol Oxfordshilre Subhational level 3 High Sol Country Country Subhational level 1 High Sol Oxfordshilre Subhational level 3 High Sol Country Country Subhational level 1 High Sol Oxfordshilre Subhational level 3 High Sol Country Country Subhational level 1 High Sol Oxfordshilre Subhational level 3 High Sol
Substational Level 1 High SOI Buckinghame hirre Substational Level 3 High SOI Samoa Country Substational Level 1 High SOI East Sussex Substational Level 3 High SOI Solomaton Islands Country Substational Level 1 High SOI East Sussex Substational Level 3 High SOI Tokelau Country Substational Level 1 High SOI Else of Wight Substational Level 3 High SOI Torga Country Substational Level 1 High SOI Kent Substational Level 3 High SOI Torga Country Substational Level 1 High SOI Midton Keynes Substational Level 3 High SOI Yanutatu Country Substational Level 1 High SOI Midton Keynes Substational Level 3 High SOI Yanutatu Country Substational Level 1 High SOI Oxfordshine Substational Level 3 High SOI Cambodia Country Substational Level 1 High SOI Oxfordshine Substational Level 3 High SOI Cambodia Country Substational Level 1 High SOI Portsmouth Substational Level 3 High SOI Cambodia Country Substational Level 1 High SOI Portsmouth
Subrational Level 1 High S21 East Sussex Subrational Level 3 High S21 Solomon Islands Country Subrational Level 1 High S21 High S21 Subrational Level 3 High S21 Tokelau Country Subrational Level 1 High S21 High S21 Subrational Level 3 High S21 Toga Country Subrational Level 1 High S21 High S21 High S21 Toga Country Subrational Level 1 High S21 High S21 High S21 Toga Country Subrational Level 1 High S21 High S21 High S21 Vanuatu Country Subrational Level 1 High S21 High S21 High S21 Soluthast Asla Region Subrational Level 1 High S21 High S21 Soluthast Asla Region Country Subrational Level 1 High S21 High S21 High S21 Soluthast Asla Region Subrational Level 1 High S21 High S21 High S21 Indonesia Country Subrational Level 1 High S21 High S21 High S21 Subrational Level 3 High S21 Subrational Level 1 High S21 Solomational Level 3 High S21 Subrational Level 3 High S21 <td< td=""></td<>
Substational Level 1 High SOL Tokelau Country Substational Level 1 High SOL Isle of Wight Substational Level 3 High SOL Tonga Country Substational Level 1 High SOL Kent Substational Level 3 High SOL Tonga Country Substational Level 1 High SOL Kent Substational Level 3 High SOL Tonga Country Substational Level 1 High SOL Medwary Substational Level 3 High SOL Vanuatu Country Substational Level 1 High SOL OxfordShife Substational Level 3 High SOL Cambodia Country Substational Level 1 High SOL OxfordShife Substational Level 3 High SOL Country Substational Level 1 High SOL PortSmouth Substational Level 3 High SOL Indonesia Country Substational Level 1 High SOL Reading Substational Level 3 High SOL Acch Substational Level 3 Substational Level 1 High SOL Sologithes Substational Level 3 High SOL Acch Substational Level 3 Substational Level 1 High SOL Sologithes Substational Level 3 High SOL Acch Substational Level 1 Substational Level
Substational Level 1 High S01 Substational Level 3 High S01 Tonga Country Substational Level 1 High S04 Kent Substational Level 3 High S04 Tonvalu Country Substational Level 1 High S04 Medwary Substational Level 3 High S04 Vanuatu Country Substational Level 1 High S04 Medwary Substational Level 3 High S04 Vanuatu Country Substational Level 1 High S04 Milton Keynes Substational Level 3 High S04 Southeast Akia Region Substational Level 1 High S04 OxfordShire Substational Level 3 High S04 Country Substational Level 1 High S04 Portsmouth Substational Level 3 High S04 Region Country Substational Level 1 High S04 Reading Substational Level 3 High S04 Substational Level 3 High S04 Substational Level 3 Ball Substational Level 1 Ball Substational Level 3 High S04 Substational Level 3 High S04<
Image: Normal Control Mage: Normal Control Normal Control Control Substational Level 1 Mage: Normal Control Mage: Normal Control Mage: Normal Control Mage: Normal Control
Substational Level 1 High SOI Kent Substational Level 3 High SOI Turvalu Country Substational Level 1 High SOI Mcdwary Substational Level 3 High SOI Vanuatu Country Substational Level 1 High SOI Miltion Keynes Substational Level 3 High SOI Vanuatu Country Substational Level 1 High SOI Miltion Keynes Substational Level 3 High SOI Country Substational Level 1 High SOI OxfordShifte Substational Level 3 High SOI Country Substational Level 1 High SOI Portsmouth Substational Level 3 High SOI Indonesia Country Substational Level 1 High SOI Reading Substational Level 3 High SOI Substational Level 3 Substational Level 3 High SOI Substational Le
Substational Level 1 High S2I MedWary Substational Level 3 High S2I Vanuable Country Substational Level 1 High S0I Million Keynes Substational Level 3 High S0I Southeast Akia Region Substational Level 1 High S0I OxfortShilre Substational Level 3 High S0I Country Substational Level 1 High S0I Portsmouth Substational Level 3 High S0I Indonesia Country Substational Level 1 High S0I Region Substational Level 3 High S0I Aceh Substational Level 1 Substational Level 1 High S0I Region Substational Level 3 High S0I Aceh Substational Level 1 Substational Level 1 High S0I South South South Level 3 High S0I Ball Substational Level 1 Substational Level 1 High S0I South South Level 3 High S0I Ball Substational Level 1 Substational Level 1 High S0I South South Level 3 High S0I Ball Substational Level 3 Substational Level 1 High S0I South South Level 3 High S0I Ball Substational Level 3
Subnational Level 1 High SQI Milton Keynes Subnational Level 3 High SQI Southeast Asia Region Subnational Level 1 High SQI OxfordShife Subnational Level 3 High SQI Cambodia Country Subnational Level 1 High SQI Portsmouth Subnational Level 3 High SQI Indonesia Country Subnational Level 1 High SQI Reading Subnational Level 3 High SQI Aceh Subnational Level 3 Subnational Level 1 High SQI Reading Subnational Level 3 High SQI Aceh Subnational Level 3 Subnational Level 1 High SQI South Subnational Level 3 High SQI Ball Subnational Level 3 Subnational Level 1 High SQI Country Subnational Level 3 High SQI Ball Subnational Level 3
Subnational Level 1 High S01 Oxfordshire Subnational Level 3 High S01 Cambodia Country Subnational Level 1 High S01 Portsmouth Subnational Level 3 High S01 Indonesia Country Subnational Level 1 High S01 Reading Subnational Level 3 High S01 A Ceh Subnational Level 3 Subnational Level 1 High S01 Sobrational Level 3 High S01 A Ceh Subnational Level 3 Subnational Level 1 High S01 Sobrational Level 3 High S01 Ball Subnational Level 3
Answer Night SA Constraint or anotational Love 3 High SA Califizational Love 3 High SA Califizational Love 3 Indonesia Country Substational Level 1 High SA Portsmouth Substational Level 3 High SA Indonesia Country Substational Level 1 High SA Reading Substational Level 3 High SA Aceh Substational Level 3 Substational Level 1 High SA Slough Substational Level 3 High SA Ball Substational Level 3 Substational Level 1 High SA Country Country Ball Substational Level 3
Substational Level 1 High S01 Portsmouth Substational Level 3 High S01 Indionesia Country Substational Level 1 High S04 Reading Substational Level 3 High S04 Acceh Substational Level 1 High S04 Substational Level 3 High S04 Ball Substational Level 3 High S04 Substatins Level 3 <td< td=""></td<>
Substational Level 1 High SDI Reading Substational Level 3 High SDI Aceh Substational Level 1 Substational Level 1 High SDI Slough Substational Level 3 High SDI Ball Substational Level 1 Substational Level 1 High SDI Countsaverlaw Substational Level 3 High SDI Ball Substational Level 1
Subnational Level 1 High SQI Slough Subnational Level 3 High SQI Ball Subnational Level 1 Subnational Level 3 High SQI Ball Subnational Level 1 Subnational Level 1 Bally Subnating Subnational Level 1 Bally Subnating Subnationa
Substituted Level 1 High SQL Constructional Level 3 Level rate on Bangka-Beiltung
AND AND A DIVISION AND A DIVISIONA

Supplementary Table 2. GBD	ocation hierarchy, with SDI	quintile						
Geography	Level in hierarchy	SDI quintile	Geography	Level in hierarchy	SDI quintile	Geography	Level in hierarchy	SDI quintile
Okinawa	Subnational Level 1	High SDI	Surrey	Subnational Level 3	High SDI	Banten	Subnational Level 1	Middle SDI
Ösaka	Subnational Level 1	High SDI	West Berkshire	Subnational Level 3	High SDI	Bengkulu	Subnational Level 1	Middle SDI
Saga	Subnational Level 1	High SDI	West Sussex	Subnational Level 3	High SDI	Gorontalo	Subnational Level 1	Low-middle SDI
			Windsor and					
Saitama	Subnational Level 1	High SDI	Maidenhead	Subnational Level 3	High SDI	Jakarta	Subnational Level 1	High-middle SDI
Shiga	Subnational Level 1	High SDI	Wokingham	Subnational Level 3	High SDI	Jambi	Subnational Level 1	Middle SDI
Shimane	Subnational Level 1	High SDI	South West England	Subnational Level 2	High SDI	West Java	Subnational Level 1	Middle SDI
Shizuoka	Subnational Issuel 1	High SDI	Bath and North	Subnational Issuel 2	High CDI	Control Jour	Subnational Level 1	Middle SDI
SHIZOOKA	Subilitional Cerei 1	Tigh State	East Somerset	Submuturer Certer S	1180.324	Central Java	3001000101 10101 1	Mildole Joh
Tochigi	Subnational Level 1	High SDI	Bournemouth	Subnational Level 3	High SDI	East Java	Subnational Level 1	Middle SDI
Tokushima	Subnational Level 1	High SDI	Bristol, City of	Subnational Level 3	High SDI	West Kalimantan	Subnational Level 1	Low-middle SDI
Tökvö	Subnational Level 1	High SDI	Cornwall	Subnational Level 3	High SDI	South Kalimantan	Subnational Level 1	Middle SDI
Tottori	Subnational Level 1	High SDI	Devon	Subnational Level 3	High SDI	Central Kalimantan	Subnational Level 1	Middle SDI
Toyama	Subnational Level 1	High SDI	Dorset	Subnational Level 3	High SDI	East Kalimantan	Subnational Level 1	High-middle SDI
Wakayama	Subnational Level 1	High SDI	Gloucestershire	Subnational Level 3	High SDI	North Kalimantan	Subnational Level 1	High-middle SDI
Veren ente		11.1.444	North Comment		11.1.484	Diau Islanda		
TdffldgdLd	Subnational Level 1	High SDI	North Somerset	Subnational Level 3	High SDI	Ridu Isidilus	Subnational Level 1	High-middle SDI
Yamaguchi	Subnational Level 1	High SDI	Plymouth	Subnational Level 3	High SDI	Lampung	Subnational Level 1	Middle SDI
Yamanashi	Subnational Level 1	High SDI	Poole	Subnational Level 3	High SDI	Maluku	Subnational Level 1	Low-middle SDI
Republic of Korea	Country	High SDI	Somerset	Subnational Issuel 2	High SDI	North Maluku	Subnational Level 1	Law-middle SDI
Republic of Korea	country	High 301	South	Submatronal Level S	Higi Sbi	Norut Matuku	Subhational Level 1	cow-middle son
Singapore	Country	High SDI	Gloucestershire	Subnational Level 3	High SDI	West Nusa Tenggara	Subnational Level 1	Low-middle SDI
High-income North	Region		Swindon	Subnational Level 3	High SDI	East Nusa Tenggara	Subnational Level 1	Low-middle SDI
Canada	Country	High SDI	Torbay	Subnational Level 3	High SDI	Papua	Subnational Level 1	Middle SDI
Consultant'								
Greenland	Country	High-middle SDI	Wiltshire	Subnational Level 3	High SDI	West Papua	Subnational Level 1	Middle SDI
United States of America	Country	High SDI	West Midlands	Subnational Level 2	High SDI	Riau	Subnational Level 1	High-middle SDI
Alabama	Subnational Level 1	High SDI	Birmingham	Subnational Level 3	High SDI	West Sulawesi	Subnational Level 1	Low-middle SDI
Alarka	Subnational Level 1	plak chi	Courter	Subpational (1 3	High SDI	South Sularian	Subnational Level 1	Middle (D)
MIDSKO	Subnational Level 1	mgn SUI	Coventry	Subnational Level 3	nigi sui	South Sulawesi	Subnational LEVEL 1	mudle SUI
Arizona	Subnational Level 1	High SDI	Dudley	Subnational Level 3	High SDI	Central Sulawesi	Subnational Level 1	Middle SDI
Arkansas	Subnational Level 1	High SDI	Herefordshire,	Subnational Level 3	High SDI	Southeast Sulawesi	Subnational Level 1	Middle SDI
California	Subnational Level 1	High SDI	County of Sandwall	Subnational Level 3	High SDI	North Sulawasi	Subnational Level 1	Middle SDI
contonia			Sunderen			North Saldwest		
Colorado	Subnational Level 1	High SDI	Shropshire	Subnational Level 3	High SDI	West Sumatra	Subnational Level 1	Middle SDI
Connecticut	Subnational Level 1	High SDI	Solihull	Subnational Level 3	High SDI	South Sumatra	Subnational Level 1	Middle SDI
Delaware	Subnational Level 1	High SDI	Staffordshire	Subnational Level 3	High SDI	North Sumatra	Subnational Level 1	Middle SDI
					-			
District of Columbia	Subnational Level 1	High SDI	Stoke-on-Trent	Subnational Level 3	High SDI	Yogyakarta	Subnational Level 1	Middle SDI
Florida	Subnational Level 1	High SDI	Telford and Wrekin	Subnational Level 3	High SDI	Lao People's Democratic Republic	Country	Low-middle SDI
Georgia	Subnational Level 1	High SDI	Walsall	Subnational Level 3	High SDI	Malaysia	Country	High-middle SDI
Union II.	Colorational Local 1	11-1- CM	We evidentiate	Colorational Local 2	History	h de Jaliures	Country	Law and dis COL
HdWdll	Subhational Level 1	High sol	warwickshire	Submatronal Level S	Higi Sbi	Waldives	Country	Low-Initiatie sol
Idaho	Subnational Level 1	High SDI	Wolverhampton	Subnational Level 3	High SDI	Mauritius	Country	High-middle SDI
Illinois	Subnational Level 1	High SDI	Worcestershire	Subnational Level 3	High SDI	Myanmar	Country	Low-middle SDI
Indiana	Subnational Invel 1	High SDI	Yorkshire and the	Subpational Level 2	High SDI	Philippines	Country	Middle SDI
indiana			Humber			Thippines		
lowa	Subnational Level 1	High SDI	Barnsley	Subnational Level 3	High SDI	Seychelles	Country	High-middle SDI
Kansas	Subnational Level 1	High SDI	Bradford	Subnational Level 3	High SDI	Sri Lanka	Country	High-middle SDI
Kentucky	Subnational Level 1	High SDI	Calderdale	Subnational Level 3	High SDI	Thailand	Country	Middle SDI
					-			
Louisiana	Subnational Level 1	High SDI	Doncaster	Subnational Level 3	High SDI	Timor-Leste	Country	Low-middle SDI
Maine	Subnational Level 1	High SDI	East Riding of Yorkshire	Subnational Level 3	High SDI	Viet Nam	Country	Middle SDI
Maryland	Subnational Level 1	High SDI	Kingston upon	Subnational Level 3	High SDI	Sub-Saharan Africa	Super region	
Manager		11.1.444	Hull, City of		11.1.484	Central Sub-Saharan		
Massachusetts	Subnational Level 1	High SDI	KIRKIEES	Subnational Level 3	High SDI	Africa	Region	
Michigan	Subnational Level 1	High SDI	Leeds	Subnational Level 3	High SDI	Angola	Country	Low-middle SDI
Minnesota	Subnational Level 1	High SDI	North East	Subnational Level 3	High SDI	Central African Republic	Country	Low SDI
Mississioni	Subnational Level 1	High-middle SDI	North Lincoles him	Subpational Javal 2	High SDI	Conso	Country	Low-middle CDI
Iditorioliti	Submissional LEVEL 1	1=61-11=2016 3D1	North LincoldShire	Sound of Mill Level 5	118/1301	Democratic Population of	country	cow moure sor
Missouri	Subnational Level 1	High SDI	North Yorkshire	Subnational Level 3	High SDI	the Congo	Country	Low SDI
Montana	Subnational Level 1	High SDI	Rotherham	Subnational Level 3	High SDI	Equatorial Guinea	Country	Middle SDI
Nebraska	Subnational Level 1	High SDI	Sheffield	Subnational Level 3	High SDI	Gabon	Country	Middle SDI
Marianda	Coloradian 11 11	-		folgetie in the	-	Eastern Sub-Saharan	Davi	
ivevada	subnational Level 1	riigh SDI	wakefield	Substational Level 3	High SUI	Africa	Kegion	
New Hampshire	Subnational Level 1	High SDI	York	Subnational Level 3	High SDI	Burundi	Country	Low SDI
New Jersey	Subnational Level 1	High SDI	Northern Ireland	Subnational Level 1	High SDI	Comoros	Country	Low SDI
New Mexico	Subnational Level 1	plak chi	Centland	Subpational I and 1	Hist CDI	Dilbarti	Country	purmidd - CD
IVEW IVIEXICO	susmutional cevel 1	Align and	scouand	Substational Level 1	nigi sui	Djibouu	country	20WHILDUIE SUI
New York	Subnational Level 1	High SDI	Wales	Subnational Level 1	High SDI	Eritrea	Country	Low SDI
North Carolina	Subnational Level 1	High SDI	Latin America and Caribbean	Super region		Ethiopia	Country	Low SDI
North Dakota	Subnational Level 1	High SDI	Andean Latin America	Region		Kenva	Country	Low-middle SDI
			Bolivia (Plurinational					
Ohio	Subnational Level 1	High SDI	State of)	Country	Low-middle SDI	Baringo	Subnational Level 1	Low-middle SDI
Oklahoma	Subnational Level 1	High SDI	Ecuador	Country	Middle SDI	Bomet	Subnational Level 1	Low-middle SDI
Oregon	Subnational Level 1	High SDI	Peru	Country	Middle SDI	Bungoma	Subnational Level 1	Low-middle SDI
Dec. 1	Public In the second	-	0. 21				followed and a second	
Pennsylvania	subnational Level 1	High SDI	Caribbean	Region		Busia	Subnational Level 1	Low-middle SDI
Rhode Island	Subnational Level 1	High SDI	Antigua and Barbuda	Country	High-middle SDI	Elgeyo-Marakwet	Subnational Level 1	Low-middle SDI
South Carolina	Subnational Level 1	High SDI	Bahamas	Country	High-middle SDI	Embu	Subnational Level 1	Low-middle SDI
South D-linte	Coloradian 11 11	11.1.6 444	Park-d		101-10 - 100 - 100-	G	folgeting 11 - 11	terre and the second
SUUUI D'AKOTA	Subnational Level 1	High SDI	2006u is d	country	Hign-middle SDI	udrissa	subnational Level 1	Low-middle SDI
Tennessee	Subnational Level 1	High SDI	Belize	Country	Low-middle SDI	HomaBay	Subnational Level 1	Low-middle SDI
Texas	Subnational Level 1	High SDI	Bermuda	Country	High SDI	Isiolo	Subnational Level 1	Low-middle SDI
Utab	Subnational I and 1	High Shi	Cuba	Country	Middle SDI	Kailado	Subpational Level 1	low-middle SDI
oun	Submissional LEVEL 1	g. 301	C GOOD	country	modie 301	Najiduo	Submittenel LEVEL 1	cow moule sol
Vermont	Subnational Level 1	High SDI	Dominica	Country	High-middle SDI	Kakamega	Subnational Level 1	Low-middle SDI
Virginia	Subnational Level 1	High SDI	Dominican Republic	Country	Low-middle SDI	Kericho	Subnational Level 1	Low-middle SDI
Washington	Subnational Level 1	High SDI	Grenada	Country	Middle SDI	Kiambu	Subnational Level 1	Low-middle SDI
	and the second second second	. ngu 200	orchoo	country	moore soft		L Break and a second se	
Wort Winginia	AL 1. 11. 14	11 1 444	Gunana	Country	Middle CDI	Kilifi	Subnational Level 1	Louismiddle SD1

Low SDI

Country

Kirinyaga

Subnational Level 1

Low-middle SDI

High SDI

Subnational Level 1

Wisconsin

Haiti

orgenyUser lange of the lange o	Level in hierarchy Subnational Level 1 Subnational Level 1
Wong NongMeader of wireMeader	Subnational Level 1 Subnat
Adventical AmericaAgeor-Partio NicoContryHej redde NicoAgeorinaContryHej redde NicoSint Utits and HevisContryHell redde NicoChileContryHej redde NicoSint Utits and HevisContryHell redde NicoUngayContryHej redde NicoSint Utits and HevisContryHell redde NicoAderinaContryHej redde NicoSint Vicore and HeContryHell redde NicoAderinaContryHej redContryHell redde NicoHell redde NicoContryHej redContryHej redContryHell redde NicoContryHej redContryHej redContryHell redde NicoContryHej redContryHej redContryHell redde NicoContryHej redContryHej redMerceMerceFinanceContryHej redContryHell redMerceFinanceContryHej redContryHell redMerceFinanceContryHej redMerceMerceMerceFinanceContryHej redMerceMerceMerceFinanceContryHej redMerceMerceMerceFinanceContryHej redMerceMerceMerceFinanceContryHej redMerceMerceMerceFinanceContryHej redMerceMerceMerceFinanceContryHej redMerce<	Subnational Level 1 Subnat
martine martin	Submational Lend 1 Submational L
NapentionOwneyHigh methodsSint REx and HavisOwneyHigh methodsKindCinkConviryHigh methodsSint REx and HavisConviryMede StotHalipIndigatorConviryHigh methodsSint Reverse and HigConviryMede StotHalipMadriaConviryHigh MiceSarkaramConviryMede StotHalipMadriaConviryHigh MiceConviryMede StotMedeSelegiumConviryHigh MiceConviryMede StotMede StotCopusConviryHigh MiceConviryMede StotMede StotFindadConviryHigh MiceConviryMede StotMede StotFindadConviryHigh MiceConviryMede StotMede StotFindadConviryHigh MiceConviryMede StotMede StotFindadConviryHigh MiceConviryMede StotMedicFindadConviryHigh MiceConviryMede StotMiceFindadConviryHigh MiceConviryMede StotMiceFindadConviryHigh MiceConviryMedic StotMiceFindadConviryHigh MiceConviryMedic StotMiceFindadConviryHigh MiceConviryMice StotMiceFindadConviryHigh MiceConviryMice StotMiceFindadConviryHigh MiceConviryMice StotMice Stot <td>Subastional Level 1 Subnational Level 1 Subnat</td>	Subastional Level 1 Subnational Level 1 Subnat
ChieContryHigh-ridd SDShirt LickaContryMidde SDKanieJaigaayGurryHigh-ridd SDGurryMider SDGurryMider SDGurryStort TrypeHigh-ContryMider SDGurryMider SDOrderaGurryHighGurryMider SDMider SDMider SDStort TrypeGurryHighGurryHighGurryHighMider SDStort TrypeGurryHighColor TrypeHighMider SDMider SDStort TrypeGurryHighColor TrypeMider SDMider SDStort TrypeHighColor TrypeMider SDMider SDStort TrypeHighColor TrypeMider SDMider SDStort TrypeHighColor TrypeMider SDMider SDStort TrypeHighGalaterniaGurryMider SDMider SDStort Trype <td< td=""><td>Subnational Level 1 Subnational Level 1 Subnat</td></td<>	Subnational Level 1 Subnat
Jongway Courry Halphadde Stat Saint Notest and the (new address) Courry Madie Stat Ialigian Saintame Courry Halphade Stat Saintame Courry Halphade Stat Madres Stat Adadra Courry Halphade Initiad data Tabago Courry Halphade Stat Madres Stat Adadra Courry Halphade Courry Halphade Stat Madres Stat Belgium Courry Halphade Courry Halphade Stat Madres Stat Demark Courry Halphade Courry Madres Stat Madres Stat Finand Courry Halphade Courry Madres Stat Madres Stat German Courry Halphade Courry Leurendde Stat Madres Stat German Courry Halphade Stat Courry Madres Stat Madres Stat German Courry Halphade Stat Courry Madres Stat Madres Stat German Courry Halphade Stat Madres Stat Madres Stat	Subnational Level 1 Subnat
Jackgap County High midde 501 County of Made 501 Calling a Scitch Turgel Agen Scitch Turgel Agen Made 501 Calling a Scitch Turgel Agen Scitch Turgel County Made 501 Made 501 Made 501 Scitch Turgel County High 501 County High 501 Made 501	Subastional Level 1 Subast
kiter targetAgentAgentAdaraAdaraAdaraAdaraAdaraAdaraCantryAgentTrindic and TakaCantryAgentMalaraAtariaCantryAgentBalanCantryAgentMalaraCantryAgentAgentCantryAgentAgentMalaraCantryAgentAgentCantryAgentAgentMalaraCantryAgentAgentCantryAgentMalaraMalaraFranceCantryAgentCantryAgentMalaraMalaraFranceCantryAgentCantryAgentMalaraMalaraGaranyAgentMalaraCantryAgentMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalaraKaldaCantryAgentMalaraMalaraMalaraMalara <t< td=""><td>Subnational Level 1 Subnational Level 1</td></t<>	Subnational Level 1
AndoranCountryHijl S0Trinidad and TodagoCountryHijl-NolMachalosAustriaCountryHijl S0CountryHijl S0CountryHijl S0MachalosOrpusCountryHijl S0CountryMadde S0MachalosMachalosDemmarkCountryHijl S0CountryMadde S0MachalosMarabatRindraCountryHijl S0CountryCountryMadde S0MarabatRindraCountryHijl S0El StadeardCountryMadde S0MarabatGeneracCountryHijl S0GatternalaCountryMarabatMarabatRindraCountryHijl S0GatternalaCountryMarabatMarabatGeneracCountryHijl S0GatternalaCountryMarabatMarabatRindraCountryHijl S0GatternalaCountryMarabatMarabatRindraCountryHijl S0GatternalaCountryMarabatMarabatRindraCountryHijl S0GatternalaSistatson Levil Madde S0MarabatNathCountryHijl S0CountryMarabatMarabatRindraCountryHijl S0CountryMarabatMarabatNathCountryHijl S0CountryMarabatMarabatNathCountryHijl S0CountrySinatson Levil Madde S0SinatsonNathCountryHijl S0CountryMarabatMarabat	Subnational Level 1 Subnat
Andoran Country High Shi Trinidiad and Toapogo Country High Shi Madrahos Austria Country High Shi Country High Shi Country Madrahos Madrahos Cypurs Country High Shi Colorbha Country Mide Shi Madrahos Cypurs Country High Shi Colorbha Country Mide Shi Madrahos Finlard Country High Shi Colorbha Country Mide Shi Mide Shi Finlard Country High Shi Colorbha Country Mider Shi Mider Shi Germany Country High Shi Country High Shi Mider Shi Mider Shi Germany Country High Shi Mider Shi Mider Shi Mider Shi Mider Shi Iteland Country High Shi Mider Shi Mider Shi Mider Shi Mider Shi Iteland Country High Shi Country High Shi Mider Shi Mider Shi	Substational Level 1 Substatio
Akatia Contry Hg b0 United State Strigging Beiguinn Contry Hg b00 Central Latin America Repion Advades 30 Copus Country Hg b10 Colombia Country Midde 301 Midne 301 Demark Country Hg b10 Colombia Country Midde 301 Midne 301 Beiguinn Country Hg b10 Colombia Country Midne 301 Midne 301 Beiguinn Country Hg b10 Country Low and 45 50 Midne 301 France Country Hg b10 Country Low and 45 50 Midne 301 France Country Hg b10 Goaternia Country Midne 301 Midne 301 France Country Hg b10 Agaustallentria Scautry Midne 301 Midne 301 Ictalaria Country Hg b10 Agaustallentria Scautron Low 1 Midne 501 Midne 501 Ictalaria Country Hg b10 Country Hg b10 Midne 501 Midne 501 Ictalaria Scautron Low 1 Midne 501 Midne 501 Midne 501 Midne 501 Ictalaria Scautron Low 1 Midne 501 Midne 501 Midne 501 Midne 501 <	Subnational Level 1
Balance Name Name Cyprus Courty High SN Colombla Courty Maders SN Demark Courty High SN Colombla Courty Maders SN Demark Courty High SN Courty Maders SN Mager Finland Courty High SN El Salvador Courty Maders SN France Courty High SN El Salvador Courty Mager France Courty High SN Matro SN Courty Mager Germany Courty High SN Matro SN Courty Malon france Courty High SN Aglascallentes Substraturets Maders SN Nalvarage france Courty High SN Courty Malon Nalvarage Nalvarage france Courty High SN Aglascallentes Substraturets Maders SN Nalvarage france Courty High SN Colombla Substraturets Maders SN	Subnational Level 1 Subnat
Belginn Central List Andraica Region Nameter Cypuns County High SDI Colombia County Middle SDI Middle SDI Demark County High SDI County County Middle SDI Middle SDI France County High SDI County County Middle SDI Middle SDI Generanty County High SDI Gattemala County Middle SDI Middle SDI Generanty County High SDI Middle SDI Middle SDI Middle SDI Generanty County High SDI Middle SDI Middle SDI Middle SDI Generanty High SDI Middle SDI Middle SDI Middle SDI Middle SDI France County High SDI Schastranal Level 1 Middle SDI Middle SDI France County High SDI County Middle SDI Middle SDI Middle SDI France County High SDI County Middle SDI Middle SDI Middle SDI France County High SDI Colombia Schastraal Level 1 Middle SDI Schastraal Level 1 Middle SDI Kareford County High SDI County <t< td=""><td>Subnational Level 1 Subnational Level 1</td></t<>	Subnational Level 1
CynsCorbiaCorbiaCorbiaCorreryMideisolMassbiDemarkCorreryNep 50Costa RicaCorreryMideisolMideisolFranceCourryNep 50El ShadorCourryNem det 50MideisolGemarkCourryNep 50GoatemalaCourryNem det 50MideisolGemarkCourryNep 50GoatemalaCourryNem det 50MideisolGemarkCourryNep 50GoatemalaCourryNem det 50MideisolGeneraCourryNep 50AlgascallertesCourryMideisolNem det 50FeldadCourryNep 50Bigl ColforniaSastani Levi 1MideisolNem det 50FeldadCourryNep 50ColforniaSastani Levi 1MideisolNem det 50KarbaCourryNep 50ColforniaSastani Levi 1MideisolNem det 50NorwaCourryNep 50ColforniaSastani Levi 1MideisolSastani Levi 1MideisolNorwaCourryNep 50ColforniaSastani Levi 1MideisolTankiniaSastani Levi 1MideisolMideisolGoatemalaMideisolTankiniaNorwaCourryNep 50Sastani Levi 1MideisolTankiniaSastani Levi 1Nep 50Sastani Levi 1MideisolTankiniaSastani Levi 1Nep 50Sastani Levi 1MideisolTankiniaSastani Levi 1Nep 50Sastani Levi 1 <t< td=""><td>Subnational Level 1 Subnational Level 1 Subnat</td></t<>	Subnational Level 1 Subnat
DemarkCountryHigh 501Cots RicaCountryMidle 501MeruFinlandCountryHigh 501El SalvadorCountryLow midde 501MigoriFranceCountryHigh 501Guatema laCountryLow midde 501Midne 501GermanyCountryHigh 501ModurasCountryLow midde 501Midne 501GermanyCountryHigh 501MercoCountryMidne 501Midne 501ItelandCountryHigh 501Baja CaliforniaSubsational Levi 1Midne 501NardaItelandCountryHigh 501Glapa CaliforniaSubsational Levi 1Midne 501NardaItelandCountryHigh 501Chalpa Subsational Levi 1Midne 501NardaMataCountryHigh 501Chalpa Subsational Levi 1Midne 501NardaMataCountryHigh 501ColumaSubsational Levi 1Midne 501NardaMataCountryHigh 501ColumaSubsational Levi 1Midne 501Subsational Levi 1Midne 501NervayCountryHigh 501GlaunaSubsational Levi 1Midne 501Subsational Levi 1Midne 501Subsational Levi 1Midne 501San MarinoCountryHigh 501GlaunaSubsational Levi 1Midne 501TaraRakeTaraRakeSan MarinoCountryHigh 501GlaunaSubsational Levi 1Midne 501TaraRakeSan MarinoCountryHigh 501High 501Midne	Subnational Level 1 Subnat
DemminCasteryRegisterCaster KinkCaster KinkCaster KinkCaster KinkMeter KinkFinlandCountryHigh SOMEl SalvadorCountryLeve midde SOMMoleci SOMFranceCountryHigh SOMHondurasCountryLeve midde SOMMoleci SOMGerrerorCountryHigh SOMMoleci SOMMoleci SOMMoleci SOMMoleci SOMGerrerorCountryHigh SOMAguascallentesSubastional Leve 1Modele SOMNakouItelandaCountryHigh SOMBaja CaliforniaSubastional Leve 1Modele SOMNakouItelandaCountryHigh SOMGarapecheSubastional Leve 1Modele SOMNarodeItalyCountryHigh SOMChipapasSubastional Leve 1Modele SOMNarodeMaranoCountryHigh SOMChipapasSubastional Leve 1Modele SOMNarodeMaranoCountryHigh SOMChipapasSubastional Leve 1Modele SOMNarodeMaranoCountryHigh SOMColinaSubastional Leve 1Modele SOMSubastional Leve 1MaranoCountryHigh SOMColinaSubastional Leve 1Modele SOMSubastional Leve 1NorwayCountryHigh SOMGuanaguatoSubastional Leve 1Modele SOMTataFaveleSon MarinoCountryHigh SOMGuanaguatoSubastional Leve 1Modele SOMTataFaveleSon KarinoCountryHigh SOMGuanaguato<	Subational Leef 1 Subational L
Find Contry Hyp 30 E Shador Contry Lew adds 30 Frace Contry Hyp 30 Gatenala Contry Lew adds 30 General Contry Hyp 30 Hondras Contry Marka 30 General Contry Hyp 30 Marka 30 Gatenala Contry Marka 30 General Contry Hyp 30 Marka 30 Gatenala Contry Marka 30 Icalard Contry Hyp 30 Agus 30 Gatenala Marka 30 Marka 30 Icalard Contry Hyp 30 Bajla Galfonia Satesala Leal Marka 30 Marka 30 Icalard Gatory Hyp 30 Bajla Galfonia Satesala Leal Marka 30 Marka 30 Icalard Gatory Hyp 30 Bajla Galfonia Satesala Leal Marka 30 Marka 30 Icalard Gatory Hyp 30 Gatenala Satesala Leal Marka 30 Marka 30 Icalard Gatory Hyp 30 Gatenala Satesala Leal Marka 30 Marka 30 Icalard Gatory Hyp 30 Gatenala Satesala Leal Marka 30 Marka 30 Marka 3 Gatory Hyp 30 Gatenala Satesal	Subnational Level 1 Subnat
France Country High 501 Guatemala Country Lowenide S01 Montass Germany Country High 501 Honduras Country Lowenide S01 Malaro (3) Greece Country High 501 Mesico Country Midele S01 Malaro (3) Iceland Country High 501 Aguasscallentes Subastional Lowel 1 Midele S01 Nalaro (3) Ireland Country High 501 Aguasscallentes Subastional Lowel 1 Midele S01 Nandi Istrael Country High 501 Garpeche Subastional Lowel 1 Midele S01 Narde Malta Country High 501 Chipass Subastional Lowel 1 Midele S01 Narde Montass Country High 501 Chipas Subastional Lowel 1 Midele S01 Narde Morado Country High 501 Country High 501 Midele S01 Subastional Lowel 1 Midele S01 TaraNarba Sonderin Country High 501 Guanaguato Subastional Lowel 1 <td>Subnational Level 1 Subnational Level 1</td>	Subnational Level 1 Subnational Level 1
raine contry raine contry register Contry register Contry register Germany Country High Sch Moduras Country Main ang Sch Main ang Sch Gereace Country High Sch Mexico Country Main ang Sch Main ang Sch Centry High Sch Mexico Country Mide Sch Nakou relanda Country High Sch Agascalientes Subastional Levi 1 Mide Sch Nakou relanda Country High Sch Balja California Sur Subastional Levi 1 Mide Sch Nardou tata Country High Sch Congreche Subastional Levi 1 Mide Sch Nardou Maha Country High Sch Collana Subastional Levi 1 Mide Sch Subastional Levi 1 Mide Sch Nardou Moraco Country High Sch Colina Subastional Levi 1 Mide Sch Sanbaru Sanbaru Sanbaru Sanbaru Sanbaru Sanbaru Sanbaru Sanbar	Subational Leef 1 Subational L
Germany Country Hey Sol Honduras Country Mukang'a Greece Country Hey Hey Held Sol Mexico Country Mukal Sol Naindel Icelaria Country Hey Sol Agasaallentes Adaatsola Lievi II Mukal Sol Naindel Ireland Country Hey Sol Balga California Sabastola Lievi II Midel Sol Naindel Istra Country Hey Medide Sol Balga California Sabastola Lievi II Midel Sol Naindel Istra Country Hey Medide Sol Garage Che Sabastola Lievi II Midel Sol Naindel Malta Country Hey Medide Sol Chaigas Sabastola Lievi II Midel Sol Naindel Malta Country Hey Medide Sol Chaigas Sabastola Lievi II Midel Sol Naindel Malta Country Hey Medide Sol Chaigas Sabastola Lievi II Midel Sol Salastola Malta Country Hey Medide Sol Country Salastola Lievi II Midel Sol Salastola Malta Country Hey Medide Sol Country Salastola Lievi II Midel Sol Salastola Namada Country Hey Medide Sol Garangato Salas	Subastional Level 1 Subast
Greece Country High-models DJN Mexico Country Media Maintoil keland Country High-models DJN Agusscalientes Submational Level 1 Media SDN Natarda freidind Country High-models DJN Bigl California Submational Level 1 Media SDN Natarda freidind Country High-models DJN Bigl California Submational Level 1 Media SDN Narda freiding Country High-models DJN Campache Submational Level 1 Media SDN Narda Marta Country High-models DJN Campache Submational Level 1 Media SDN Narda Marta Country High-models DJN Campache Submational Level 1 Media SDN Narda Moraco Country High-models DJN Cabifula Submational Level 1 Media SDN Submational Level 1 Media SDN Submational Level 1 Media SDN Tarakalthin Norway Country High SDN Guanaj Lato C Submational Level 1 Media SDN	Subnational Level 1 Subnat
winder winder winder winder winder winder winder Icelaria Country Nigh 201 Alguistal liferia Subastional Local 1 Middle 501 Nardia Israel Country Nigh 201 Baja California Sur Subastional Local 1 Middle 501 Nardia Israel Country Nigh 201 Cappeche Subastional Local 1 Middle 501 Nardia Mata Country Nigh 201 Chilapas Subastional Local 1 Middle 501 Nardia Mata Country Nigh 501 Chilapas Subastional Local 1 Middle 501 Nardia Mata Country Nigh 501 Colina Subastional Local 1 Middle 501 Nigh 201 Norway Country Nigh 501 Colina Subastional Local 1 Middle 501 Siga 2 Sin Marino Country Nigh 501 Colina Subastional Local 1 Middle 501 TaraNiko Sin Marino Country Nigh 501 Guannyauto Subastional Local 1 Middle 501 TaraNiko Sin Marino Country Nigh 501 Guannyauto Subastional Local 1 Middle 501 TaraNiko Sin Marino Country Nigh 501 Sub	Substational Level 1 Substational Level 1
celaria Country Hep S01 Appasalientes Subastional Level 1 Medie S01 Nakaru relaria Country Hep S04 Baja California Subastional Level 1 Medie S01 Nakaru strael Country Hep S04 Baja California Sur Subastional Level 1 Medie S01 Narda taly Country Hep S04 Campeche Subastional Level 1 Medie S01 Narda Walka Country Hep S04 Chipasaha Subastional Level 1 Medie S01 Medie S01 Narda Walka Country Hep S04 Chipasaha Subastional Level 1 Medie S01 Medie S01 Narda Walka Country Hep S04 Collina Subastional Level 1 Medie S01 Tatal Tatavea Warkay Country Hep S04 Country Hep S04 Subastional Level 1 Medie S01 Tatal Tatavea Subastional Level Country Hep S04 Subastional Level 1 Medie S01 Medie S01 Tatal Tatavea Subastional Level Country Hep S04 Subastional Level 1 Medie S0	Subnational Level 1 Subnational Level 1
Internation Country High Sold Bigls California Substancia Levi 1 Medie Sold Nandi Israel Country High middle SOL Bigls California Substancia Levi 1 Middle SOL Nardic Italy Country High middle SOL Carapache Substancia Levi 1 Middle SOL Nardic Marka Country High Sold Chipapa Substancia Levi 1 Middle SOL Nardic Marka Country High Sold Chipapa Substancia Levi 1 Middle SOL Nardic Marka Country High Sold Chipapa Substancia Levi 1 Middle SOL Tarakalvini 1 Norway Country High Sold Guang Lipancia Substancia Levi 1 Middle SOL Tarakalvini 1 Substandia Country High Sold Guang Lipancia Substancia Levi 1 Middle SOL Tarakalvini 1 Substandia Country High Sold High Sold Substancia Levi 1	Subnational Level 1 Subnat
Andrew	Subnational Level 1 Subnational Level 1
shell Courty Hep-mode SOI Baje Califonia Sur Substantion Live 1 Model SOI Narrok taty Country Hep-mode SOI Campeche Substantion Live 1 Model SOI Narrok Luxembourg Country Hep-mode SOI Chipas Substantion Live 1 Model SOI Narrok Malta Country Hep-mode SOI Chipas Substantion Live 1 Model SOI Narrok Monaco Country Hep-mode SOI Country Country Country Substantion Live 1 Model SOI Substantion Live 1 Substantion Live 1 Model SOI TaraNative 1 Norway Country Hep-model SOI Country Hep-model SOI GuarangLando Substantion Live 1 Model SOI TaraNative 1 Substant Country Hep-model SOI Substantion Live 1 Model SOI TaraNative 1 Substand Country Hep-model SOI Substanti Live 1	Subnational Level 1 Subnational Level 1
taly Country High-middle Solo Campeche Subasticui Levi 1 Middle Solo Nymria Luxembourg Country High Solo Chipaza Subasticui Levi 1 Middle Solo Nymria Valta Country High Solo Chipaza Subasticui Levi 1 Middle Solo Nymria Valta Country High Solo Collibaza Subasticui Levi 1 Middle Solo Nymria Verterfands Country High Solo Colling Subasticui Levi 1 Middle Solo Saga Norway Country High Solo Colling Subasticui Levi 1 Middle Solo TaraRiver Sondanio Country High Solo Guanajuato Subasticui Levi 1 Middle Solo TaraRiver Sandario Country High Solo Guanajuato Subasticui Levi 1 Middle Solo TaraRiver Spain Country High Solo Subasticui Levi 1 Middle Solo TaraNoio Soccholm Subasticui Levi 1 Middle Solo TaraNoio TaraNoio Soccholm Subasticui Levi 1 Middle Solo TaraNoio TaraNoio Soccholm Subasticui Levi 1 Middle Solo Middle Solo UsinGishu Soccholm	Subnational Level 1 Subnational Level 1
Substitution Country High SOI Chilapas Substitutional Level 1 Middle SOI Nyndra Valita Country High SOI Chilapas Substitutional Level 1 Middle SOI Nyndra Valita Country High SOI Chilapas Substitutional Level 1 Middle SOI Nyndra Vetherfands Country High SOI Collina Substitutional Level 1 Middle SOI Sindra Vetherfands Country High SOI Collina Substitutional Level 1 Middle SOI Taita Taveta Vetherfands Country High SOI Country Ourango Substitutional Level 1 Middle SOI Taita Taveta Vetherfands Country High SOI Guanajuato Substitutional Level 1 Middle SOI Taita Taveta Sand Marino Country High SOI Guanajuato Substitutional Level 1 Middle SOI Taita Taveta Sand Marino Country High SOI Guanajuato Substitutional Level 1 Middle SOI Taita Taveta Sand Marino Country High SOI Jalisco Substitutional Level 1 Middle SOI Tarkana Substitutional Level 1 High SOI Hidalgo Substitutional Level 1 Middle SOI	Subnational Level 1 Subnational Level 1
Luxembourg Country High S01 Chipps Substitue Live 1 Middle S01 Negradama Walta Country High S01 Chipps Substitue Live 1 Middle S01 Middle S01 Middle S01 Middle S01 Middle S01 Substitue Live 1 Middle S01 Tata Taveta Norway Country High S04 Guanaj Luxe 0 Substitue Live 1 Middle S01 Tata Taveta Sondaria Country High S04 Guanaj Luxe 0 Substitue Live 1 Middle S01 TatarkNPre Singain Country High S04 Guanaj Luxe 0 Substitue Live 1 Middle S01 TatarkNPre Sondohan Country High S04 Fildago Substitue Live 1 Middle S01 TatarkNPre Sondohan Country High S04 Fildago Substitue Live 1 Middle S01 TatarkNPre Sondohan Country High S04 Fildago Substitue Live 1 Middle S01 TatarkNPre Sondohan Country High S04 Fildago Substitue Live 1	Subnational Level 1 Subnational Level 1
Alfa Contry High-middle 201 Chihuahua Subasional Levi 1 Middle 201 Syndrin Atora CO Contry High 501 Coahula Subasional Levi 1 Middle 501 Samburu ketherlands Contry High 501 Colina Subasional Levi 1 Middle 501 Salaya korway Contry High 501 Colina Subasional Levi 1 Middle 501 Taita Taveta korway Contry High 501 Gianajuato Subasional Levi 1 Middle 501 Taita Taveta ortugal Contry High 501 Gianajuato Subasional Levi 1 Middle 501 TarakAltibh pain Contry High 501 Giaerero Subasional Levi 1 Middle 501 TarakAltibh Stockholm Subastonal Levi 1 High 501 Hidelago Subastonal Levi 1 Middle 501 TarakAltibh Stockholm Subastonal Levi 1 High 501 Hidelago Subastonal Levi 1 Middle 501 TarakAltibh Stockholm Subastonal Levi 1 High 501 Hidelago Subastonal Levi 1 Middle 501 UsinGishu Stockholm Subastonal Levi 1 High 501 Medico City Subastonal Levi 1 Midel 501 Wigjir Nater Ari	Subnational Level 1 Subnational Level 1
Arrian Country Hgh S01 Collina Substand Levi 1 Midle S01 Slaga Koraco Country Hgh S01 Collina Substand Levi 1 Midle S01 Slaga Koraco Country Hgh S01 Collina Substand Levi 1 Midle S01 Slaga Koraco Country Hgh S01 Durango Substand Levi 1 Midle S01 Tata Pareta Koraco Country Hgh S01 Gianajuato Substand Levi 1 Midle S01 Tata Pareta Koraco Country Hgh S01 Gianajuato Substand Levi 1 Midle S01 Tata Pareta an Marino Country Hgh S01 Gianajuato Substand Levi 1 Midle S01 Tata Pareta salan Country Hgh S01 Gianajuato Substand Levi 1 Midle S01 Tata Pareta salan Country Hgh S01 Jalisco Subational Levi 1 Midle S01 Tata Pareta Stockholm Substand Levi 1 Hgh S01 Médico Midle S01 Tata Pareta Stockholm Substand Levi 1 Hgh S01 Médico Midle S01 UsainGishu Stockholm Substand Levi 1 Hgh S01 Médico Waji F Stockholm Country<	Subnational Level 1 Subnational Level 1
Moraco Country High S01 Confuil a Substrian Level 1 Middle S01 Sambur Neetherlands Country High S01 Collman Substrian Level 1 Middle S01 Silaya Norway Country High S01 Durango Substrian Level 1 Middle S01 Tata Taveta Norway Country High S01 Guanajuato Substriana Level 1 Middle S01 Tata River Norway Country High s01 Guanajuato Substriana Level 1 Middle S01 Tata River Singhin Country High s01 Hidalgo Substriana Level 1 Middle S01 Tata Navier Sockholm Substriana Level 1 High S01 Jallacca Substriana Level 1 Middle S01 Tata Navier Sockholm Substriana Level 1 High S01 Midelic Cly Substriana Level 1 Midelic S01 Vielage Sockholm Substriana Level 1 High S01 Midelic Cly Substriana Level 1 Midelic S01 Vielage Sockholm Substriana Level 1 High S01 <td>Subnational Level 1 Subnational Level 1</td>	Subnational Level 1 Subnational Level 1
Netherfands Country High Sol Colina Substantial Levil 1 Middle Sol Slaya Norway Country High Sol Durango Substantial Levil 1 Middle Sol Taita Taveta hortugal Country High High Sol Guanajuato Substantial Levil 1 Middle Sol Taita Taveta an Marino Country High High Sol Guanajuato Substantial Levil 1 Middle Sol Tarans/Nord gain Country High Sol Guerrero Substantianal Levil 1 Middle Sol Tarans/Nord Subscholm Country High Sol Substantianal Levil 1 Middle Sol Tarans/Nord Stockholm Substantianal Levil 1 High Sol Médico Substantianal Levil 1 Middle Sol UsinGishu Stockholm Substantianal Levil 1 High Sol Médico Substantianal Levil 1 Middle Sol Vilaga Stockholm Substantianal Levil 1 High Sol Médico City Substantianal Levil 1 Middle Sol Vilaga Stockholm Country High	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
worky Country Hgb S01 Durango Subational Levi 1 Middle S01 Tata Taveta an Marino Country Hgb neidel S00 Guanajuato Subational Levi 1 Middle S01 Tata Nitre gain Country Hgb S01 Guerrero Subational Levi 1 Middle S01 Tata Nitre gain Country Hgb S01 Guerrero Subational Levi 1 Middle S01 Tata Nitre sockholm Country Hgb S01 Hidalgo Subational Levi 1 Middle S01 Tata Nitre sockholm Country Hgb S01 JalisCo Subational Levi 1 Middle S01 Turkana sockholm Subational Levi 1 Hgb S01 Médico Cliy Subational Levi 1 Middle S01 Vilaga sockholm Country Hgb S01 Médico Cliy Subational Levi 1 Middle S01 Vilaga sockholm Country Hgb S01 Médica Cliy Subational Levi 1 Middle S01 Vilaga sockholm Country Hgb S01 Médica Cliy Subational Levi 1 Middle S01 Vilaga sockholm Country Hgb S01 Médica Cliy Subational Levi 1 Middle S01 Vilaga sockholm Country Hgb S01	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
Yorkyayi Country High S01 Durango Substatival Levi 1 Middle S01 Tatla Taveta Yorkyajal Country High S01 Guanajuato Substatival Levi 1 Middle S01 TanaRkver jain Marinoo Country High S01 Guanajuato Substatival Levi 1 Middle S01 TanaRkver jain Marinoo Country High S01 Guarero Substatival Levi 1 Middle S01 TanaRkver jain Country High S01 Hidalgo Substatival Levi 1 Middle S01 TanaNzoia skockinon Country High S01 Jallaco Substatival Levi 1 Middle S01 TanaNzoia Skockinon Substatival Levi 1 High S01 Midels C01Y Substatival Levi 1 Middle S01 UsinGichu Skockinon Substatival Levi 1 High S01 Midels C01Y Substatival Levi 1 Middle S01 Vilija Skockinon Substatival Levi 1 High S01 Midels C01Y Substatival Levi 1 Middle S01 Vilija Waterand Country High S01 Michoacind de Occompo Substatival Levi 1 Midels S01 Wilija Naterand Kingdom Country High S01 Michoacind de Occompo Substatival Levi 1 Midels S01 Wilija <td>Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1</td>	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
Portugal Country High middle SD1 Guanajuato Subastional Level 1 Middle SD1 TanaRiver ain Marino Country High S01 Guerrero Subastional Level 1 Middle SD1 TanaRiver igain Country High middle SD1 Hiddlago Subastional Level 1 Middle SD1 TanaRiver Stockholm Country High SD1 Jalisco Subastional Level 1 Middle SD1 Turkana Stockholm Subastional Level 1 High SD1 Médico Subastional Level 1 Middle SD1 UsainGishu Stockholm Subastional Level 1 High SD1 Médico Citry Subastional Level 1 Middle SD1 Vihiga Stockholm Country High SD1 Médico Citry Subastional Level 1 Middle SD1 Vihiga Middle Kingdom Country High SD1 Médico Citry Subastional Level 1 Middle SD1 Vihiga	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
Sindurino Country High S01 Country High S01 Subastional Level 1 Middle S01 Tarakal/Hill gain Country High S04 Hiddligo Subastional Level 1 Middle S01 Tarakal/Hill soccholm Sobstational Level 1 High S04 Jalls Co Subastional Level 1 Middle S01 Turakal/Hill Soccholm Sobstational Level 1 High S04 Middle S01 Middle S01 UsasinGishu Soccholm Subastional Level 1 High S04 Middle S01 Middle S01 UsasinGishu Soccholm Soccholm Sochastional Level 1 High S01 Middle S01 Vihiga Jolted Kingdom Country High S01 Middle S01 Videl S01 Vihiga	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
an Manno Country High SDI Guerrero Subastional Level 1 Middle SDI Tharakakithi gain Country High SDI Hidalgo Subastional Level 1 Middle SDI TransNabia Weden Country High SDI Jalico Subastional Level 1 Middle SDI TransNabia Stockholm Subastional Level 1 High SDI Médico City Subastional Level 1 Middle SDI Vilja Sockholm Country High SDI Medico City Subastional Level 1 Middle SDI Vilja Subcholm Country High SDI Medico City Subastional Level 1 Middle SDI Vilja	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
Spain Country High stoll Hiddago Subtrational Level 1 Middle SDI TransNazola Sweden Country High SDI Jalis Co Subtrational Level 1 Middle SDI Turka na Stockholm Suborational Level 1 High SDI Midel CO Subtrational Level 1 Midel SDI UsainGishu Sweden except Suborational Level 1 High SDI Midel CC (Ty Subbrational Level 1 Midel SDI Vihiga Sweden except Suborational Level 1 High SDI Michoscia de Country Michoscia de Country Michoscia de Country Subbrational Level 1 Midel SDI Vihiga Julied Kingdom Country High SDI Michoscia de Country Subbrational Level 1 Midel SDI WestPoloci	Subnational Level 1 Subnational Level 1 Subnational Level 1 Subnational Level 1
weden Country High S01 Jallsco Substational Level 1 Middle S01 Turkana Stockholm Substational Level 1 High S04 México Substational Level 1 Middle S01 UsalinGishu Stockholm Substational Level 1 High S04 México Substational Level 1 Middle S01 UsalinGishu Stockholm Country High S04 México Substational Level 1 Middle S01 Vihiga Julide Kingdom Country High S04 Michaesian de Country Middle S01 WestPolocit Middle S01 WestPolocit	Subnational Level 1 Subnational Level 1 Subnational Level 1
Stockfolm Substantional Level 1 High SOI Jalisco Substantional Level 1 Middle SOI Turkana Stockfolm Substantional Level 1 High SOI Médic OC ly Substantional Level 1 Middle SOI UasinGishu Stockfolm Substantional Level 1 High SOI Médic OC ly Substantional Level 1 Middle SOI Vihiga Stockfolm Country High SOI Medic OC ly Substantional Level 1 Middle SOI Wilgir Juliced Kingdom Country High SOI Morelos Substantional Level 1 Middle SDI WestPoloct	Subnational Level 1 Subnational Level 1 Subnational Level 1
Stockholm Subnational Level 1 High SOI Médico Subnational Level 1 Middle SOI UbasinGishu Sweden except Subnational Level 1 High SOI Médico City Subnational Level 1 Middle SDI Vihiga Sweden except Subnational Level 1 High SOI Médico City Subnational Level 1 Middle SDI Vihiga witterfand Country High SOI Michoaccin de Ocampo Subnational Level 1 Middle SDI Wajir Inited Kingdom Country High SOI Morelos Subnational Level 1 Middle SDI WestPolocit	Subnational Level 1 Subnational Level 1
Sweden except Stockholm Subnational Level 1 High SDI Mexico City Subnational Level 1 Middle SDI Vihiga Stockholm Country High SDI Michoacán de Ocampo Subnational Level 1 Middle SDI Wajir Inited Kingdom Country High SDI Morelos Subnational Level 1 Middle SDI Wajir	Subnational Level 1
Stockholm Substantial Leve I High SAI Metaco Liny Substantial Leve I Hiddle SDI Wildle Wajr Inited Kingdom Country High SDI Michoactan Leve I Middle SDI Wajr Inited Kingdom Country High SDI Morelos Substantial Leve I Middle SDI Wajr	Subnational Level 1
Writerfand Country High SD1 Michaelican de Ocampo Subational Level 1 Misdie SD1 Wajir Jnited Kingdom Country High SD1 Morelos Subational Level 1 Misdie SD1 WestPoloat	
United Kingdom Country High SDI Morelos Subnational Level 1 Middle SDI WestPokot	Subnational Level 1
unted kingdom country High Sul Moreids Subrabona Leve 1 Milabie Sul WestPokot	
	Subnational Level 1
England Subnational Level 1 High SDI Nayarit Subnational Level 1 Middle SDI Madagascar	Country
Part Millards Colonian Lond 2 History New New Long Colonian Lond 2 Midda (N. Miland	Country
East Middlands Subnational Level 2 High SDI Nuevo León Subnational Level 1 Middle SDI Malawi	Country
Derby Subnational Level 3 High SDI Ogxaca Subnational Level 1 Middle SDI Mozambique	Country
Déroysniré subnational Level 3 High SUI Prépia Subnational Level 1 Millione SUI KWanda	Country
Leicester Subnational Level 3 High SDI Querétaro Subnational Level 1 Middle SDI Somalia	Country
International Advances in the Adva	
Leicesterstille Subnational Level 3 High SUI Quilitatila KOO Subnational Level 1 Mildole SUI SOULIT SUULITI	Country
Lincolnshire Subnational Level 3 High SDI San Luis Potosí Subnational Level 1 Middle SDI Uganda	Country
Northamotopchira Subational Jawa 2 Mich Str. Sinalina Subational Jawa 1 Middle Str. United Republic of	Country
Not trianiptorisme subilational texes s migri son sinarioa subilational texes s migri son Tanzania	Country
Nottingham Subnational Level 3 High SDI Sonora Subnational Level 1 Middle SDI Zambia	Country
Nottinghamshire Subnational Level 3 High SQI Tahascrn Subnational Level 1 Muddle Sni	Region
	Nagion
Rutland Subnational Level 3 High SDI Tamaulipas Subnational Level 1 Middle SDI Botswana	Country
East of England Subnational Level 2 High SQI Tlavrala Subnational Level 1 Muddle GNU Environi	Country
	i y
Bedford Subnational Level 3 High SDI de la Llave 1 Middle SDI Lesotho	Country
Cambridgeshire Subnational Level 3 High SDI Yucatán Subnational Level 1 Middle SDI Namihia	Country
Central Centra	
Subnational Level 3 High SDI Zacatecas Subnational Level 1 Middle SDI South Africa	Country
Essex Subnational Level 3 High SDI Nicaragua Country Low-middle SDI Zimbabwe	Country
Wettern Sub-Sabaran	
Herritorosnine suenational Level 3 High SOI Panama Country Middle SDI Africa Africa	Region
Luton Subnational Level 3 High SDI Venezuela (Bolivarian Country Low-middle SDI Benin	
керилис от	Country
Norroix suonasional Level 3 High SOI Tropical Latin America Region - Burkina Faso	Country
Peterborough Subnational Level 3 High SDI Brazil Country Middle SDI Cabo Verde	Country
	Country Country Country
Social constrained a subnational Level 3 regn sur Acre Subnational Level 1 Low-middle SDI Cameroon	Country Country Country
Suffolk Subnational Level 3 High SDI Alagoas Subnational Level 1 Low-middle SDI Chad	Country Country Country Country
Thursde Subastian I and 2 High Sty	Country Country Country Country Country
Harrison Amapa Subrational Level 1 Middle SDI Côte d'Ivoire	Country Country Country Country Country
Constant and an a filled for the second seco	Country Country Country Country Country Country
Gambia Subnational Level 2 High SUI Amazonas Subnational Level 1 Low-middle SDI Gambia	Country Country Country Country Country Country Country
utester Lunuun avannavutaa Level 2 High Sun Amazonas Subnational Level 1 Low-middle SDI Gambia Barking and Examinational 2 High Pro	Country Country Country Country Country Country
utrester Lonizoan a sourieurstal level 2 migrista Antizzonas Substational Level 1 Love model SDI Gambia Barking and Substational Level 3 High SDI Bahia Substational Level 1 Love middle SDI Ghana	Country Country Country Country Country Country Country
Varieties: Losson Journal-dial Level 2 High SDI Amazonas Subational Level 1 Low-middle SDI Gambia Barriet Subnational Level 3 High SDI Bahia Subnational Level 1 Low-middle SDI Gitana Barriet Subnational Level 3 High SDI Ceará Subnational Level 1 Low-middle SDI Gitana	Country Country Country Country Country Country Country Country
Caretary Submitted Improvide Improvide Improvide Cambia	Country Country Country Country Country Country Country Country
Unterest Amazonas Subhational Level 2 rugs x/r Amazonas Subhational Level 1 Low-middle SDI Gambia Barking and Dagenham Subhational Level 3 High SOI Bahlia Subhational Level 1 Low-middle SDI Ghana Barnet Subhational Level 3 High SOI Ceará Subhational Level 1 Low-middle SDI Guinea Beekley Subhational Level 3 High SOI Distrito Federal Subhational Level 1 High middle SDI Guinea-Bissau	Country Country Country Country Country Country Country Country Country
Barking and Barking	Country
Barking and Dagenham Subnational Level 3 High SOL Armazona's Bahking and Dagenham Subnational Level 3 High SOL Gambia Barnet Subnational Level 3 High SOL Ceará Subnational Level 1 Low emiddle SOL Gulnea Barnet Subnational Level 3 High SOL Ceará Subnational Level 1 Low emiddle SOL Gulnea Bexley Subnational Level 3 High SOL Distrito Federal Subnational Level 4 High sol Gulnea-Bissau Brent Subnational Level 3 High SOL Espírito Santo 1 Low emiddle SDL Liberia	Country Country Country Country Country Country Country Country Country
Water control Average on a solumination level 3 Migh SA Average on Substational level 1 Lower date SAI Cambba Barking and Dagenham Substational level 3 High SAI Bahla Substational level 1 Lower date SAI Ghana Barnet Substational level 3 High SAI Ceará Substational level 1 Lower date SAI Guinea Barnet Substational level 3 High SAI Ceará Substational level 1 High middle SAI Guinea Bernet Substational level 3 High SAI Espírito Santo Substational level 1 High middle SAI Guinea Bromley Substational level 3 High SAI Golás Substational level 1 Middle SAI Liberia	Country Country Country Country Country Country Country Country Country Country
uiteatri cuituri animunitati tent 2 mignisia Amazonasis Substituri 1 Low endeti Soli Gambia Barking and Barking and Barking and Substituri 1 Substituri 1 Low endeti Soli Gambia Barking and Barking and Substituri 1 High SOl Ceará Substituri 1 Low endeti Soli Galance Barking and Barking and Substituri 1 Substituri 1 Low endeti Soli Galance Galance Barking and Barking and Substituri 1 High SOl Ceará Substituri 1 High Soli Galance Bromley Substituri 1 High SOl Espírito Santo Substituri 1 Midde Soli Liberia Bromley Substituri 1 High SOl Galás Substituri 1 Midde Soli Mali Canden Substituri 1 Substituri 1 Substituri 1 Midde Soli Mali	Country
Untractic Longan associational Level 3 Nigh Sol Amazonasis Subnational Level 1 Low-middle Sol Gambia Barking approx Subnational Level 3 Nigh Sol Bahka Subnational Level 1 Low-middle Sol Ghana Barking approx Subnational Level 3 Nigh Sol Ceará Subnational Level 1 Low-middle Sol Gulnea Barking approx Subnational Level 3 Nigh Sol Ceará Subnational Level 1 Nigh-middle Sol Gulnea-Bissau Berlet Subnational Level 3 Nigh Sol Esplitito Santo Subnational Level 1 Middle Sol Liberia Bromley Subnational Level 3 Nigh Sol Golás Subnational Level 3 Migh Sol Mali Canden Subnational Level 3 Nigh Sol Golás Subnational Level 1 Middle Sol Malai	Country Country Country Country Country Country Country Country Country Country Country
utereater currours auxinus/dit later 2 reg s2A Armazona's Substriant Level 1 Low end det SOI Gambia Barking and Barking and Barket Substriant Level 3 High SOI Caraf Substriant Level 1 Low end det SOI Galara Barket Substriant Level 3 High SOI Caraf Substriant Level 1 Low end det SOI Galara Barket Substriant Level 3 High SOI Caraf Substriant Level 1 Low end det SOI Galara-Bissau Barket Substriant Level 3 High SOI Distrito Federal Substriant Level 1 High Model 50I Galara-Bissau Bromley Substriant Level 3 High SOI Goldas Substriant Level 1 Middle 50I Mali Caraden Substriant Level 3 High SOI Maranhão Substriant Level 1 Middle 50I Maluritanta Caraden Substriant Level 3 High SOI Mato Grosso Substriantal Level 1 Middle 50I Nider	Country Country Country Country Country Country Country Country Country Country Country
utreater currour Armazonas Submittional Lovel 1 Love middle Soli Gambia Barking and Dagenham Submittional Lovel 3 High Sol Bahia Submittional Lovel 1 Love middle Soli Ghana Barnet Submittional Lovel 3 High Sol Ceará Submittional Lovel 1 Love middle Soli Gulnea Barnet Submittional Lovel 3 High Sol Ceará Submittional Lovel 1 Love middle Soli Gulnea Brentt Submittional Lovel 3 High Sol Explifito Santo Submittional Lovel 1 Middle Soli Cultera Bromley Submittional Lovel 3 High Sol Golás Submittional Lovel 1 Middle Soli Mali Canden Submittional Lovel 3 High Sol Golás Submittional Lovel 1 Middle Soli Mali Canden Submittional Lovel 3 High Sol Maranhilo Submittional Lovel 1 Middle Soli Mali Canden Submittional Lovel 3 High Sol Maranhilo Submittional Lovel 1 Lover Soli Mali Croydon Submittional Lovel 3 High Sol Mator Grossol Submittional Lovel 1 Middle Soli Niger C Ealling Submittional Lovel 3 High Sol Mator Grossol Lovel 3 Loversol Hole M	Country Country Country Country Country Country Country Country Country Country Country Country Country
Utersett cuttown associated to the 2 right SA Amazona's Substitual Lefe 1 Low middle SDI Gambia Barking and Bageham Substitual Lefe 3 High SDI Bahlia Substitual Lefe 1 Low middle SDI Ghana Barnet Substitual Lefe 3 High SDI Cearlá Substitual Lefe 1 Low middle SDI Guinea Barnet Substitual Lefe 3 High SDI Distritu Federal Substitual Lefe 1 Low middle SDI Guinea Bernet Substitual Lefe 3 High SDI Espírita Statu Substitual Lefe 1 Middle SDI Low middle SDI Bromley Substitual Lefe 3 High SDI Golás Substitual Lefe 1 Middle SDI Mali Camden Substitual Lefe 3 High SDI Golás Substitual Lefe 1 Low SDI Maluritania Carroydon Substitual Lefe 3 High SDI Matto Grosso Substitual Lefe 1 Middle SDI Nigeria Ealing Substitual Lefe 3 High SDI Matto Grosso do Sul Substitual Lefe 1 Middle SDI Nigeria	Country Country Country Country Country Country Country Country Country Country Country Country
utereter Annaconstructional Level 3 High SOL Annaconstructional Level 1 Low ended to SOL Gambia Barrier, Schunstronal Level 3 High SOL Bahlia Substrational Level 1 Low ended to SOL Galance Barrier, Schunstronal Level 3 High SOL Ceará Substrational Level 1 Low ended to SOL Galance Barrier, Schunstronal Level 3 High SOL Ceará Substrational Level 1 Low ended to SOL Galance Berrier, Schunstronal Level 3 High SOL Espírito Stato Substrational Level 1 High medde SOL Galance Bromley Substrational Level 3 High SOL Golás Substrational Level 1 Midel SDL Uberia Carnden Substrational Level 3 High SOL Golás Substrational Level 1 Midel SDL Mali Carnden Substrational Level 3 High SOL Matardaños Substrational Level 1 Midel SDL Mali Carnden Substrational Level 3 High SOL Matardaños Substrational Level 1 Midel SDL Mali Carnden Substrational Level 3 High SOL Matardaños Substrational Level 1 Midel SDL Niger? Carnden Substrational Level 3 High SOL Matardaños Substrati Level 1 Midel SDL <td>Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country</td>	Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country
utracter control associational teer 3 High SOI Amazona's Subnational teer 1 Low middle SOI Gambia Barking and Barking and B	Country Country Country Country Country Country Country Country Country Country Country Country Country Country
Garciard Louison Amitto and Barking	Country Country Country Country Country Country Country Country Country Country Country Country Country Country
uterseter (unum) anowanda tere if yerset Mig sol Antagonas Substational Level 1 Lowerdide Sol Gambia Barking and Substational Level 1 High Sol Bahka Substational Level 1 Lowerdide Sol Galana Barret Substational Level 3 High Sol Ceard Substational Level 1 Lowerdide Sol Galana Benety Substational Level 3 High Sol Ceard Substational Level 1 High midde Sol Galana-Bissau Brent Substational Level 3 High Sol Distrito Federal Substational Level 1 High midde Sol Galana-Bissau Brent Substational Level 3 High Sol Golds Substational Level 1 Midde Sol Mali Carnden Substational Level 3 High Sol Golds Substational Level 1 Midde Sol Mali Carnden Substational Level 3 High Sol Matanaño Substational Level 1 Midde Sol Mali Cer Carnden Substational Level 3 High Sol Matanaño Substational Level 1 Midde Sol Miger Ealing Substational Level 3 High Sol Mitto Grosso do Sol Substational Level 1 Midde Sol Nigerà Enfield Substational Level 3 High Sol	Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country Country

Supplementary Table 3. List o	of GBD causes, with levels
Communicable, maternal,	
neonatal, and nutritional HIV/AIDS and sexually	1
transmitted infections	2
HIV/AIDS	3
HIV/AIDS - Drug- susceptible	4
HIV/AIDS - Multidrug- resistant Tuberculosis	4
HIV/AIDS - Extensively drug-resistant	4
HIV/AIDS resulting in other diseases	4
Sexually transmitted	3
Syphilis	4
Chlamydial infection	4
chianyular mection	*
Gonococcal infection	4
Trichomoniasis	4
Genital herpes	4
Other sexually transmitted infections	4
Respiratory infections and	2
Tuberculosis	3
Latent tuberculosis	4
infection Drug-suscentible	4
tuberculosis	4
tuberculosis without	4
Extensively drug- resistant tuberculosis	4
Lower respiratory	3
Upper respiratory	3
Otitis media	3
Estado la fosti a se	-
Enteric infections	2
Diarrheal diseases	3
paratyphoid	3
Typhoid fever	4
Paratyphoid fever	4
Invasive Non-typhoidal	3
Other intestinal	3
Neglected tropical	2
diseases and malaria	-
Maiaria	3
Chagas disease	3
Leishmaniasis	3
Visceral leishmaniasis	4
Cutaneous and	4
African trypanosomiasis	3
Schistosomiasis	3
Cysticercosis	3
Cystic echinococcosis	3
Lymphatic filariasis	3
Onchocerciasis	3
Trachoma	3
Dengue	3

Cause name	Level in hierarchy
Testicular cancer	3
Kidney cancer	3
Bladder cancer	3
Brain and central	3
nervous system cancer	3
Maasthallanse	2
Mesothelioma	3
Hodgkin lymphoma	3
Non-Hodgkin lymphoma	3
Multiple myeloma	3
Leukemia	3
Acute lymphoid leukemia	4
Chronic lymphoid leukemia	4
Acute myeloid leukemia	4
Chronic myeloid	4
Other leukemia	4
Other malignant	3
Other peoplasms	3
Myelodysplastic,	4
myeloproliferative, Benign and in situ	-
intestinal neoplasms Benign and in situ	4
cervical and uterine	4
situ neoplasms	4
Cardiovascular diseases	2
Rheumatic heart disease	3
Ischemic heart disease	3
Stroke	3
Ischemic stroke	4
Intracerebral bemorrhage	4
Subarachnoid	4
Hypertensive heart	3
disease Non-rheumatic valvular	3
heart disease Non-rheumatic calcific	4
aortic valve disease Non-rheumatic	-
degenerative mitral Other non-rheumatic	4
valve diseases	4
myocarditis	3
Myocarditis	4
Alcoholic cardiomyopathy	4
Other cardiomyopathy	4
Atrial fibrillation and flutter	3
Aortic aneurysm	3
Peripheral artery disease	3
Endocarditis	3
Other cardiovascular	3
and circulatory diseases Chronic respiratory	2
diseases Chronic obstructive	2
pulmonary disease	2
Pheumoconiosis	3

Cause name	Lovel in biorarchy
Bacterial skin diseases	3
Cellulitis	4
Pyoderma	4
Cashies	
Scables	3
Fungal skin diseases	3
Viral skin diseases	3
Acne vulgaris	3
Alopecia areata	3
Pruritus	3
Urticaria	3
Decubitus ulcer	3
Other skin and subcutaneous diseases	3
Sense organ diseases	2
Blindness and vision loss	3
Glaucoma	4
Cataract	4
Age-related macular	
degeneration	4
Refraction disorders	4
Near vision loss	4
Other vision loss	4
Age-related and other hearing loss	3
Other sense organ diseases	3
Musculoskeletal disorders	2
Rheumatoid arthritis	3
Osteoarthritis	3
Osteoarthritis hip	4
Osteoarthritis knee	4
Osteoarthritis hand	4
Osteoarthritis other	4
Low back pain	3
Low back pain	3
меск раїп	3
Gout	3
disorders	3
diseases	2
Congenital birth defects	3
Neural tube defects	4
Congenital heart anomalies	4
Orofacial clefts	4
Down syndrome	4
Turner syndrome	4
Klinefelter syndrome	4
Other chromosomal	Δ
abnormalities Congenital	
musculoskeletal and Urogenital congenital	4
anomalies	4
anomalies	4

Supplementary Table 3. List of GBI	D causes, with levels
Cause name	Level in hierarchy
Yellow fever	3
Rables	3
infections	3
Ascariasis	4
Trichuriasis	4
Hookworm disease	4
Food-borne trematodiases	3
Leprosy	3
Ebola	3
Zika virus	3
Guinea worm disease	3
Other neglected tropical	3
Other infectious diseases	2
Meningitis	3
Encephalitis	3
Diphtheria	3
Whooping cough	3
Tetanus	3
Maaalaa	2
Varicella and herpes	3
zoster	3
Acute hepatitis	3
Acute hepatitis A	4
Acute hepatitis B	4
Acute hepatitis C	4
Acute hepatitis E	4
Other unspecified infectious diseases	3
Maternal and neonatal disorders	2
Maternal disorders	3
Maternal hemorrhage	4
Maternal sepsis and other maternal	4
Maternal hypertensive	4
Maternal obstructed	4
Maternal abortion and	4
Ectopic pregnancy	4
Indirect maternal	4
deaths	
Maternal deaths	-
aggravated by Other maternal	4
disorders	4
Neonatal disorders	3
Neonatal preterm birth	4
encephalopathy due to	4
Neonatal sepsis and other neonatal	4
Hemolytic disease and other neonatal	4
Other neonatal disorders	4
Nutritional deficiencies	2

Cause name	Level in hierarchy
Silicosis	4
Asbestosis	4
Coal workers	4
pneumoconiosis	*
Other pneumoconiosis	4
Asthma	3
and pulmonary	3
Other chronic respiratory diseases	3
Digestive diseases	2
Cirrhosis and other chronic liver diseases	3
Cirrhosis and other chronic liver diseases	4
Cirrhosis and other chronic liver diseases	4
Cirrhosis and other	4
Cirrhosis and other	4
chronic liver diseases Cirrhosis and other	
chronic liver diseases	4
diseases	3
Peptic ulcer disease	4
Gastritis and duodenitis	4
Gastroesophageal reflux disease	4
Appendicitis	3
Paralytic ileus and	3
Inguinal, femoral, and	3
abdominal hernia Inflammatory bowel	3
disease Vascular intestinal	-
disorders Gallbladder and biliany	3
diseases	3
Pancreatitis	3
Other digestive diseases	3
Neurological disorders	2
Alzheimer's disease and other dementias	3
Parkinson's disease	3
Idiopathic epilepsy	3
Multiple sclerosis	3
Motor neuron disease	3
Headache disorders	3
Migraine	4
Tension-type headache	4
Other neurological	3
Mental disorders	2
Schizophrenia	3
Depressive disorders	3
Major depressive	4
disorder	4
Dysulymia	4
Bipolar disorder	3
Anxiety disorders	3
Eating disorders	3
Anorexia nervosa	4

Cause name	Level in bierarchy
Other congenital birth	4
defects Urinary diseases and	3
male infertility Urinary tract infections	4
and interstitial	4
Urolithiasis Benign prostatic	4
hyperplasia	4
Male infertility	4
Other urinary diseases	4
Gynecological diseases	3
Uterine fibroids	4
Polycystic ovarian syndrome	4
Female infertility	4
Endometriosis	4
Genital prolapse	4
Premenstrual	4
Other gynecological	4
diseases Hemoglobinopathies	3
and hemolytic anemias	
Thalassemias	4
Thalassemias trait	4
Sickle cell disorders	4
Sickle cell trait	4
G6PD deficiency	4
G6PD trait	4
Other hemoglobinopathies	4
Endocrine, metabolic, blood, and immune	3
Oral disorders	3
Caries of deciduous	4
Caries of permanent	4
Periodontal diseases	4
Edentulism	4
Other and disarders	
Sudden infant death	4
syndrome	3
Injuries	1
Transport injuries	2
Road injuries	3
Pedestrian road injuries	4
Cyclist road injuries	4
Motorcyclist road	4
Injuries Motor vehicle road injuries	4
Other road injuries	4
Other transport injuries	3
Unintentional injuries	2
Falls	3
Drowning	3
Fire, heat, and hot	3
Poisonings	3
· · · · · · · · · · · · · · · · · · ·	

Supplementary Table 3. List of	GBD causes, with levels
Cause name	Level in hierarchy
malnutrition	3
lodine deficiency	3
Vitamin A deficiency	3
Dietary iron deficiency	3
Other nutritional deficiencies	3
Non-communicable diseases	1
Neoplasms	2
Lip and oral cavity cancer	3
Nasopharynx cancer	3
Other pharynx cancer	3
Esophageal cancer	3
Stomach cancer	3
Colon and rectum cancer	3
Liver cancer	3
Liver cancer due to hepatitis B	4
Liver cancer due to hepatitis C	4
Liver cancer due to alcohol use	4
Liver cancer due to NASH	4
Liver cancer due to other causes	4
Gallbladder and biliary tract cancer	3
Pancreatic cancer	3
Larynx cancer	3
Tracheal, bronchus, and lung cancer	3
Malignant skin melanoma	3
Non-melanoma skin cancer	3
Non-melanoma skin cancer (squamous-cell	4
Non-melanoma skin cancer (basal-cell	4
Breast cancer	3
Cervical cancer	3
Uterine cancer	3
Ovarian cancer	3
Prostate cancer	3

Cause name	Level in hierarchy
Bulimia nervosa	4
Autism spectrum disorders	3
Attention- deficit/hyperactivity	3
Conduct disorder	3
Idiopathic developmental	3
Other mental disorders	3
Substance use disorders	2
Alcohol use disorders	3
Drug use disorders	3
Opioid use disorders	4
Cocaine use disorders	4
Amphetamine use disorders	4
Cannabis use disorders	4
Other drug use disorders	4
Diabetes and kidney diseases	2
Diabetes mellitus	3
Diabetes mellitus type 1	4
Diabetes mellitus type 2	4
Chronic kidney disease	3
Chronic kidney disease due to diabetes	4
Chronic kidney disease due to diabetes	4
Chronic kidney disease due to hypertension	4
Chronic kidney disease due to	4
Chronic kidney disease due to other and	4
Acute glomerulonephritis	3
Skin and subcutaneous diseases	2
Dermatitis	3
Atopic dermatitis	4
Contact dermatitis	4
Seborrhoeic dermatitis	4
Psoriasis	3

Cause name	Lovel in biorarchy
Poisoning by carbon	Lever in merarchy
monoxide	4
Poisoning by other	4
Exposure to mechanical	
forces	3
Unintentional firearm	4
injuries	7
Other exposure to	4
Adverse effects of	
medical treatment	3
Animal contact	3
Venomous animal	4
contact	4
Non-venomous animal	4
contact	
Foreign body	3
Pulmonary aspiration	4
and foreign body in	
Foreign body in eyes	4
Foreign body in other	4
Environmental heat and	2
cold exposure	3
Exposure to forces of	3
Other unintentional	
injuries	3
Self-harm and	2
interpersonal violence	
Self-harm	3
Self-harm by firearm	4
Self-harm by other	4
specified means	
Interpersonal violence	3
Physical violence by	4
Physical violence by	
sharp object	4
Sexual violence	4
Physical violence by	
other means	4
Conflict and terrorism	3
Executions and police	3
conflict	
Total cancers	1
hepatitis B	1
Total burden related to	1
hepatitis C	
Non-alcoholic fatty liver	1

Supplementary Table 4. Cause-speci	ific mortality rate for 70-7	79 years, 80-94 years, and 9	95+ years in 2019, and per	centage change from 19	90 to 2019 in death numb	er and rate in 70+ years, g	lobal, for all GBD causes				
	Males						Females	Females			
		Deaths per 100.000, 2019		Percentage chang	e in 70+. 1990-2019		Deaths per 100.000. 2019		Percentage chan	ze in 70+, 1990-2019	
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate	
All causes	4510 (4220 to 4790)	12000 (11500 to 13500)	29500 (29100 to 29900)	91.8	-22.4 (-26.8 to -18.1)	3110 (2920 to 2290)	9560 (9190 to 9950)	28200 (27800 to 28700)	75.1	-19.7 (-22.4 to .15.7)	
Communicable, maternal, neonatal, and	358	1030	3520	31.7	-46.8	283	810	2640	37.5	-37	
HIV/AIDS and sexually transmitted	(321 to 424) 5.72	(903 to 1190) 2.65	(2750 to 4050) 3.62	(16.5 to 46) 250	(-52.9 to -41) 41.3	(229 to 370) 4.35	(648 to 1030) 1.83	(1970 to 3090) 2.84	(17.8 to 65.8) 227	(-46 to -24) 49.9	
HIV/AIDS	(5.02 to 6.67) 5.59	(2.17 to 3.15) 2.3	(2.15 to 5.56) 1.29	(141 to 438) 331	(-2.71 to 118) 74.4	(3.79 to 5.07) 3.93	(1.56 to 2.09) 0.976	(2.21 to 3.31) 0.586	(137 to 376) 326	(8.46 to 118) 95.1	
HIV/AIDS - Drug-susceptible	(4.89 to 6.55)	(1.84 to 2.78) 0.336	(1.17 to 1.45) 0.202	(175 to 653) 105	(11.2 to 205) -17.3	(3.37 to 4.66) 0.88	(0.795 to 1.23) 0.2	(0.504 to 0.696) 0.108	(170 to 644) 142	(23.9 to 241)	
Tuberculosis HIV/AIDS - Multidrug-resistant	(0.707 to 1.37)	(0.23 to 0.462)	(0.138 to 0.275)	(43.6 to 243)	(-41.9 to 38.6)	(0.606 to 1.21)	(0.137 to 0.274)	(0.0742 to 0.146)	(68.8 to 297)	(-22.6 to 82.1)	
drug resistance	(0.0401 to 0.186)	(0.013 to 0.0635)	(0.00716 to 0.0343)	(1000 to 5520)	(346 to 2170)	(0.032 to 0.152)	(0.00747 to 0.0363)	(0.00385 to 0.0183)	(1820 to 8210)	(779 to 3710)	
resistant Tuberculosis	(0.00148 to 0.00924)	(0.000603 to 0.00502)	(0.000541 to 0.00279)			(0.000891 to 0.00462)	(0.000241 to 0.0014)	(0.000172 to 0.00096)			
diseases	4.47 (3.75 to 5.42)	1.93 (1.45 to 2.41)	1.07 (0.938 to 1.23)	457 (235 to 903)	125 (35.6 to 306)	2.97 (2.38 to 3.7)	0.757 (0.585 to 0.992)	0.468 (0.391 to 0.575)	430 (216 to 867)	143 (45.1 to 343)	
excluding HIV	0.129 (0.0999 to 0.202)	0.358 (0.177 to 0.51)	2.33 (0.86 to 4.32)	-33.5 (-52.6 to -7.46)	-73.1 (-80.8 to -62.6)	0.424 (0.352 to 0.489)	0.854 (0.654 to 0.977)	2.26 (1.62 to 2.71)	53.7 (32.6 to 77.2)	-29.5 (-39.2 to -18.8)	
Syphilis	0.0924 (0.0724 to 0.143)	0.151 (0.0901 to 0.199)	0.688 (0.36 to 1.1)	-43.2 (-56.3 to -19.7)	-77 (-82.4 to -67.5)	0.0373 (0.0297 to 0.0441)	0.121 (0.0823 to 0.144)	0.308 (0.18 to 0.419)	85.8 (50.2 to 128)	-14.8 (-31.1 to 4.67)	
Chlamydial infection						0.064 (0.0535 to 0.0735)	0.162 (0.127 to 0.184)	0.455 (0.329 to 0.545)	55.3 (34.7 to 77.3)	-28.8 (-38.3 to -18.7)	
Gonococcal infection	0.0097 (0.00702 to 0.0159)	0.0206 (0.0098 to 0.0295)	0.0234 (0.0125 to 0.037)	-32.8 (-55.4 to 8.21)	-72.8 (-82 to -56.3)	0.226 (0.19 to 0.259)	0.41 (0.323 to 0.466)	1.22 (0.88 to 1.43)	48.8 (29.1 to 70.2)	-31.8 (-40.8 to -22)	
Trichomoniasis											
Genital herpes											
Other sexually transmitted infections	0.027	0.186	1.62	-13	-64.8	0.0964	0.161	0.276	50	-31.2	
Respiratory infections and tuberculosis	235	736	2650	50.6	-39.1	151	494	1960	57.1	-28	
Tuberculosis	(218 to 254) 80.3	(648 to 799) 130	(2070 to 2960) 161	(38.2 to 64) -14.1	(-44.1 to -33.7) -65.3	(135 to 169) 42.6	(405 to 550) 62.7	(1430 to 2230) 70.8	(39.8 to 78.1) -12.9	(-35.9 to -18.3) -60	
latent tuberculosis infection	(72.4 to 89.1)	(115 to 142)	(128 to 181)	(-25.4 to -3.86)	(-69.8 to -61.1)	(36.8 to 53.3)	(52 to 79.7)	(52 to 94.6)	(-32.8 to 37.8)	(-69.2 to -36.8)	
Dura currentible to berry desig	72.4	118	149	-21.4	-68.2	385	56.8	65.7	-20.2	-63.4	
Multidrue-resistant tuberculosis	(62.4 to 81.5)	(102 to 132)	(118 to 169)	(-33.3 to -9.83)	(-73 to -63.5)	(32.5 to 48)	(46.3 to 73.1)	(48.4 to 87.5)	(-39.2 to 26.3)	(-72.1 to -42.1)	
without extensive drug resistance	(2.76 to 14.3)	(4.4 to 21.2)	(4.64 to 20.4)	(165 to 1710)	(7.22 to 631)	(1.43 to 7.77)	(2.03 to 11)	(2.04 to 8.92)	(162 to 1740)	(20.1 to 741)	
tuberculosis	0.534 (0.224 to 1.06)	0.831 (0.358 to 1.58)	0.946 (0.419 to 1.78)			0.261 (0.105 to 0.518)	0.42 (0.178 to 0.823)	0.393 (0.175 to 0.76)			
Lower respiratory infections	154 (143 to 166)	605 (529 to 656)	2490 (1930 to 2780)	100 (83.4 to 116)	-19.1 (-25.8 to -12.7)	109 (94 to 121)	431 (351 to 479)	1880 (1380 to 2150)	90.5 (73.3 to 106)	-12.7 (-20.6 to -5.64)	
Upper respiratory infections	0.356 (0.253 to 0.665)	1.49 (0.944 to 3.48)	2.57 (1.88 to 3.83)	-53.5 (-77.5 to 134)	-81.2 (-90.9 to -5.23)	0.236 (0.15 to 0.42)	1.24 (0.717 to 3.03)	4.74 (2.7 to 10.9)	-64.3 (-84.6 to 107)	-83.6 (-92.9 to -5.22)	
Otitis media	0.0214 (0.0158 to 0.0319)	0.0425 (0.0323 to 0.0618)	0.0899 (0.0649 to 0.122)	-47.5 (-62.8 to -21.6)	-78.8 (-85 to -68.3)	0.0162 (0.0122 to 0.0254)	0.0331 (0.0252 to 0.0457)	0.0935 (0.0674 to 0.119)	-42.5 (-58.6 to 2.5)	-73.7 (-81 to -53)	
Enteric infections	73.9 (43.6 to 142)	211 (133 to 387)	592 (380 to 1000)	-4.38 (-39.3 to 34.4)	-61.3 (-75.5 to -45.7)	89.7 (34.9 to 182)	243 (106 to 467)	436 (235 to 729)	11.5 (-32.3 to 90)	-48.9 (-69 to -12.9)	
Diarrheal diseases	73 (42.6 to 141)	210 (132 to 386)	590 (379 to 998)	-4.45 (-39.7 to 34.8)	-61.4 (-75.6 to -45.5)	89 (34 to 181)	243 (105 to 466)	435 (234 to 728)	11.4 (-32.5 to 90.4)	-48.9 (-69.1 to -12.7)	
Typhoid and paratyphoid	0.424 (0.171 to 0.843)	0.427 (0.185 to 0.798)	0.589 (0.236 to 1.34)	-16.5 (-29.6 to -0.268)	-66.2 (-71.5 to -59.7)	0.363 (0.15 to 0.704)	0.316 (0.138 to 0.605)	0.279 (0.119 to 0.636)	3.42 (-14.3 to 23)	-52.6 (-60.7 to -43.6)	
Typhoid fever	0.328	0.336	0.451	-22.7 (-24.9 to -7.22)	-68.7	0.281	0.251	0.219	-1.57 (-19.2 to 17.9)	-54.9	
Paratyphoid fever	0.0954	0.091	0.138	15.8	-53.2	0.0821	0.0654	0.0606	26.1	-42.2	
Invasive Non-typhoidal Salmonella	(0.0312 to 0.211) 0.47	(0.0348 to 0.185) 0.55	(0.0579 to 0.307) 0.96	(+5.31 to 42.3) 31.8	(-61.7 to -42.5) -46.7	(0.0277 to 0.183) 0.341	(0.0249 to 0.134) 0.352	(0.0276 to 0.132) 0.458	(-0.0841 to 56) 22.8	(-54.2 to -28.5) -43.7	
Other intestinal infectious diseases	(0.247 to 0.769) 0.0124	(0.271 to 0.931) 0.0469	(0.406 to 1.97) 0.175	(9.92 to 57.5) 51	(-55.6 to -36.3) -39	(0.176 to 0.569) 0.0132	(0.162 to 0.61) 0.0582	(0.172 to 0.963) 0.254	(-0.792 to 45.8) 47.3	(-54.5 to -33.1) -32.5	
Neglected tropical diseases and	(0.000192 to 0.0309) 16.9	(0.0035 to 0.106) 10.9	(0.000118 to 0.681) 16.6	(-63.5 to 613) 44.4	(-85.3 to 188) -41.6	(0.000315 to 0.0346) 14	(0.00616 to 0.136) 8.08	(0.000782 to 0.806) 7.86	(-66.8 to 517) 60.8	(-84.8 to 183) -26.3	
malaria	(9.38 to 27.7)	(7.67 to 15.5)	(9.97 to 26.3)	(-3.74 to 103)	(-61.1 to -17.8)	(7.67 to 23.9)	(5.42 to 11.5)	(4.96 to 13)	(7.77 to 125)	(-50.6 to 3.17)	
mararra	(5.82 to 24.6)	(1.82 to 8.03)	(0.0125 to 0.0789)	(-16.7 to 146)	(-66.3 to -0.389)	(4.8 to 21.2)	(1.24 to 5.76)	(0.0163 to 0.101)	(-6.4 to 166)	(-57.1 to 21.8)	
Chagas disease	(0.348 to 1.69)	1.74 (0.758 to 3.44)	6.38 (2.48 to 14.8)	(-19.2 to 133)	-53.3 (-67.3 to -5.9)	(0.235 to 1.18)	1.34 (0.574 to 2.81)	(1.39 to 7.8)	(-21.5 to 114)	-50.4 (-64 to -1.97)	
Leishmaniasis	0.038 (0.00413 to 0.105)	0.0388 (0.00369 to 0.109)	0.0901 (0.00484 to 0.25)	-84.8 (-93 to -80.5)	-93.8 (-97.2 to -92.1)	0.0195 (0.00199 to 0.0517)	0.0167 (0.00141 to 0.0456)	0.0217 (0.000953 to 0.0599)	-82 (-91.8 to -75.7)	-91.8 (-96.3 to -88.8)	
Visceral leishmaniasis	0.038 (0.00413 to 0.105)	0.0388 (0.00369 to 0.109)	0.0901 (0.00484 to 0.25)	-84.8 (-93 to -80.5)	-93.8 (-97.2 to -92.1)	0.0195 (0.00199 to 0.0517)	0.0167 (0.00141 to 0.0456)	0.0217 (0.000953 to 0.0599)	-82 (-91.8 to -75.7)	-91.8 (-96.3 to -88.8)	
Cutaneous and mucocutaneous leishmaniasis											
African trypanosomiasis	0.0102 (0.00177 to 0.0383)	0.0093 (0.00172 to 0.036)	0.00658 (0.000684 to 0.0375)	-93.4 (-98.6 to -71.1)	-97.3 (-99.4 to -88.3)	0.00932 (0.00168 to 0.0351)	0.00712 (0.00144 to 0.0242)	0.00295 (0.000373 to 0.0121)	-92.6 (-98.3 to -68.6)	-96.6 (-99.2 to -85.6)	
Schistosomiasis	0.684 (0.575 to 0.817)	0.759 (0.626 to 0.893)	0.53 (0.325 to 0.785)	-26.3 (-39.3 to -10.3)	-70.2 (-75.5 to -63.7)	0.549 (0.457 to 0.656)	0.608 (0.489 to 0.724)	0.338 (0.212 to 0.501)	-23.9 (-36.6 to -7.4)	-65.1 (-70.9 to -57.5)	
Cysticercosis	0.0166 (0.000339 to 0.0434)	0.0257 (0.000876 to 0.0684)	0.0474 (0.0000135 to 0.168)	11.2 (-87.7 to 910)	-55 (-95 to 308)	0.0176 (0.000774 to 0.0494)	0.0268 (0.0012 to 0.0664)	0.0371 (0.0000123 to 0.139)	16.1 (-83 to 713)	-46.8 (-92.2 to 273)	
Cystic echinococcosis	0.0587	0.101	0.202	1.09 (-69.7 to 212)	-59.1 (-97.2 to 26.2)	0.0513 (0.00926 to 0.115)	0.0896	0.156	10.3	-49.5	
Lymphatic filariasis	()	((0.000 0.000 0.000)	(100.0212)	((()	()	(1000001)	(000.0000)	
Onchocerciasis											
Trachoma											
Departue	1.09	2.99	651	336	76.3	111	2.52	2.65	435	145	
Deligue	(0.24 to 1.54)	(0.641 to 3.99)	(1.83 to 9.16)	(215 to 499)	(27.3 to 142)	(0.21 to 1.55)	(0.533 to 3.55)	(0.909 to 3.91)	(209 to 725)	(41.7 to 278)	
YELLOW TEVEL	(0.00726 to 0.0445)	(0.00621 to 0.0389)	(0.00414 to 0.0298)	(-81.7 to -64.8)	(-92.6 to -85.8)	(0.00255 to 0.0162)	(0.00176 to 0.0109)	(0.000802 to 0.0063)	(-83.2 to -68.2)	(-92.3 to -85.4)	
Rabies	0.343 (0.126 to 0.534)	0.246 (0.0969 to 0.355)	0.355 (0.171 to 0.606)	-6.51 (-49.7 to 49.3)	-62.2 (-79.7 to -39.6)	0.201 (0.0984 to 0.34)	0.126 (0.0515 to 0.206)	0.25 (0.0917 to 0.438)	3.39 (-30.5 to 48.1)	-52.6 (-68.2 to -32.1)	
Intestinal nematode infections	0.0167 (0.0136 to 0.0202)	0.0273 (0.0219 to 0.033)	0.0856 (0.0575 to 0.117)	2.62 (-16.6 to 24.5)	-58.5 (-66.3 to -49.7)	0.0154 (0.0124 to 0.0186)	0.0258 (0.0204 to 0.031)	0.0615 (0.0405 to 0.0869)	8.3 (-12.9 to 32.4)	-50.4 (-60.1 to -39.3)	
Ascariasis	0.0167 (0.0136 to 0.0202)	0.0273 (0.0219 to 0.033)	0.0856 (0.0575 to 0.117)	2.62 (-16.6 to 24.5)	-58.5 (-66.3 to -49.7)	0.0154 (0.0124 to 0.0186)	0.0258 (0.0204 to 0.031)	0.0615 (0.0405 to 0.0869)	8.3 (-12.9 to 32.4)	-50.4 (-60.1 to -39.3)	
Trichuriasis											
Hookworm disease											
Food-borne trematodiases											
Leprosy											
Ebola	0.0153	0.00733	0.109			0.00411	0.0118	0.0992			
Zika virus	0.000346	0.0000303	0.0000354			0.0000146	0.00000963	0.00000644			
Guinea worm disease	(0.0000207 to 0.0000523)	(0.0000179 to 0.0000461)	(0.0000197 to 0.0000543)			(U.00000631 to 0.0000252)	(0.00000417 to 0.000017)	(U.00000266 to 0.0000116)			
Other neglected tropical diseases	0.425	0.713	2.23	111	-14.7	0.258	0.388	1.07	117	-0.416	
Other infectious diseases	(0.286 to 0.954) 16.5	(0.481 to 1.51) 30.6	(1.25 to 3.81) 59.3	(72.6 to 187) 19.3	(-30.2 to 16) -51.8	(0.142 to 0.434) 13.9	(0.228 to 0.66) 23.8	(0.568 to 1.74) 44.4	(57.6 to 187) 25.8	(-27.8 to 31.4) -42.3	
	(14.7 to 19.9)	(26.1 to 24.2)	(45.3 to 69.4)	(-1 56 to 44.6)	(-60.2 to -41.5)	(12 to 15 7)	(19.5 to 27.2)	(22.2 to 52)	(9 56 to 44 4)	(-50.2 to -22.8)	

Supplementary Table 4. Cause-speci	fic mortality rate for 7	'0-79 years, 80-94 years, and 95	5+ years in 2019, and pe	rcentage change from 19	90 to 2019 in death numb	per and rate in 70+ years,	global, for all GBD causes			
			Males					Females		
		Deaths per 100,000, 2019		Percentage chang	e in 70+, 1990-2019		Deaths per 100,000, 2019		Percentage chang	ge in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Meningitis	4.25 (3.84 to 4.82)	7.56 (6.63 to 8.63)	11.1 (8.63 to 13.3)	19.5 (4.38 to 40.8)	-51.7 (-57.8 to -43.1)	4 (3.56 to 4.43)	5.95 (4.99 to 6.68)	9.7 (7.33 to 11.4)	18.3 (-0.812 to 38)	-45.8 (-54.5 to -36.7)
Encephalitis	4.42 (3.54 to 6.75)	8.52 (6.95 to 11.2)	10.5	73.1	-30 (-48.2 to 21.7)	4.05	6.91 (5.25 to 9.97)	6.52 (4.66 to 8.1)	129 (64.1 to 222)	4.98 (-24.9 to 52.9)
Diphtheria	(3.34 (3.3.3)	(0.05 (0.11.5)	(0.04 10 14.1)	(10.1 10 101)	(40.2.10.2.2.7)	(3.23 (0 3.37)	(323/00.07)	(4.00 10 0.1)	(04.1 (0 103)	(143 (0 51.3)
Whooping cough										
Tetanus	0.62	0.815	1.36	-64.7	-85.7	0.614	0.566	0.571	-66.1	-84.5
Measles	(0.31 to 1.01) 0.152	(0.434 to 1.38) 0.257	(0.802 to 2.69) 0.386	(-76.4 to -36.7)	(-90.4 to -74.4)	(0.33 to 0.861) 0.133	(0.255 to 0.792) 0.246	(0.289 to 0.827) 0.295	(-77.8 to -41.4)	(-89.8 to -73.1)
Mariaella and harrow and a	(0.138 to 0.167) 0.413	(0.233 to 0.282)	(0.351 to 0.425)	23.5	-50.1	(0.121 to 0.146)	(0.224 to 0.271)	(0.268 to 0.324)	30.3	-40.3
varicera and ne pes zoste	(0.348 to 0.515)	(2.14 to 3.36)	(9.58 to 18.6)	(6.99 to 44.8)	(-56.7 to -41.4)	(0.323 to 0.473)	(1.96 to 3.27)	(9.01 to 20.6)	(12.5 to 49)	(-48.4 to -31.7)
Acute nepatitis	(2.42 to 3.8)	(3 to 4.67)	(3.12 to 6.16)	(-47.7 to 17.9)	(-78.9 to -52.3)	(1.61 to 2.5)	(1.96 to 3.12)	(1.42 to 2.55)	(-53.8 to 24.2)	(-78.8 to -43.1)
Acute hepatitis A	(0.759 to 1.65)	(1.2 to 2.42)	(1.18 to 3.28)	-42.3 (-60.8 to -3.29)	-76.7 (-84.2 to -60.9)	(0.498 to 1.33)	(0.789 to 1.86)	(0.652 to 1.6)	-41.8 (-61.5 to 23.9)	-73.3 (-82.3 to -43.2)
Acute hepatitis B	1.6 (1.16 to 2.27)	1.66 (1.18 to 2.31)	1.9 (1.13 to 3.02)	-0.282 (-41.4 to 81.3)	-59.7 (-76.3 to -26.7)	0.823 (0.545 to 1.26)	0.778 (0.467 to 1.29)	0.648 (0.397 to 1.05)	-19.3 (-51.6 to 60.7)	-63 (-77.8 to -26.3)
Acute hepatitis C	0.147 (0.0852 to 0.308)	0.201 (0.126 to 0.425)	0.256 (0.125 to 0.54)	-31.1 (-65.9 to 47.3)	-72.2 (-86.2 to -40.4)	0.179 (0.0965 to 0.317)	0.258 (0.16 to 0.402)	0.119 (0.0715 to 0.193)	-45.7 (-69.6 to 15.1)	-75.1 (-86.1 to -47.3)
Acute hepatitis E	0.0864 (0.0444 to 0.142)	0.126 (0.07 to 0.195)	0.31 (0.123 to 0.722)	-5.08 (-47.6 to 79.2)	-61.6 (-78.8 to -27.5)	0.036 (0.0156 to 0.0547)	0.0514 (0.0226 to 0.0801)	0.0796 (0.0363 to 0.147)	17.3 (-32.3 to 144)	-46.2 (-69 to 12.1)
Other unspecified infectious diseases	3.62 (2.41 to 4.39)	7.17 (4.38 to 8.71)	17.8 (10.4 to 23)	76.7 (18.7 to 120)	-28.6 (-52 to -11.2)	2.73 (1.78 to 3.24)	5.29 (3.34 to 6.52)	11.5 (7.51 to 14.5)	99 (58.3 to 143)	-8.76 (-27.4 to 11.3)
Maternal and neonatal disorders										
Maternal disorders										
Maternal hemorrhage										
Maternal sepsis and other maternal infections										
Maternal hypertensive disorders										
Maternal obstructed labor and										
Maternal abortion and										
Ectopic presnancy										
Indirect maternal deaths										
Maternal deaths ageravated by										
HIV/AIDS										
Other maternal disorders										
Neonatal disorders										
Neonatal preterm birth										
Neonatal encephalopathy due to birth asphyxia and trauma										
Neonatal sepsis and other neonatal infections										
Hemolytic disease and other neonatal jaundice										
Other neonatal disorders										
Nutritional deficiencies	10.1 (9.32 to 10.9)	40.8 (36.3 to 44)	196 (155 to 220)	-4.78 (-19.1 to 39.5)	-61.5 (-67.3 to -43.6)	9.4 (8.24 to 11.1)	38.6 (32.1 to 44.1)	196 (147 to 226)	14.9 (-18.9 to 87.4)	-47.3 (-62.8 to -14.1)
Protein-energy malnutrition	7.88 (7.23 to 8.58)	33 (28.8 to 35.8)	167 (129 to 189)	9.45 (-3.55 to 41.1)	-55.8 (-61 to -42.9)	6.86 (6.06 to 7.97)	31.2 (25.7 to 35.3)	169 (125 to 196)	31.5 (2.67 to 83.7)	-39.7 (-52.9 to -15.8)
lodine deficiency										
Vitamin A deficiency										
Dietary iron deficiency										
Other nutritional deficiencies	2.19	7.82	29.1	-37.6	-74.8	2.55	7.43	27	-22.5	-64.5
Non-communicable diseases	(1.88 to 2.71) 3980	(6.64 (6 9.93)	(21.9 to 44.8) 25000	(+52.8 to 31.9) 99.7	-19.3	(2.02 to 3.28)	(5.99 to 9.24) 8450	(19.5 to 39.8) 24700	(-63.8 to 117) 79.1	(-83.4 to -0.395) -17.9
Neoplasms	(3710 to 4240) 1090	(10100 to 11000) 2040	(24300 to 26000) 3270	(87.5 to 112) 133	(-24.2 to -14.1) -5.74	(2550 to 2890) 624	(8050 to 8840) 1130	(24000 to 25600) 2170	(69.8 to 88.8) 110	(-22.2 to -13.4) -3.7
Lip and oral cavity cancer	(1010 to 1170) 18	(1820 to 2180) 26.4	(2560 to 3660) 43.8	(117 to 150) 146	(-12.4 to 1.1) -0.46	(573 to 670) 8.64	(936 to 1240) 16.6	(1580 to 2470) 35.8	(94.5 to 124) 164	(-10.8 to 2.68) 21.2
Narophanuny cancer	(16.2 to 19.9) 5.68	(23.3 to 29.1) 5.77	(34.2 to 49.5) 5.5	(113 to 183) 105	(-14 to 14.3) -17	(7.75 to 9.56) 2.15	(13.6 to 18.5) 2.4	(26.2 to 41.5) 3.1	(140 to 190) 48.2	(9.96 to 32.7) -32
	(5.04 to 6.33)	(5.12 to 6.37)	(4.26 to 6.3)	(79.4 to 135)	(-27.5 to -5.15)	(1.9 to 2.43)	(1.99 to 2.73)	(2.31 to 3.6)	(26.8 to 80.5)	(-41.9 to -17.3)
other pharyix cancer	(10.4 to 13.3)	(11.2 to 14.4)	(8.62 to 12.5)	(157 to 253)	(3.95 to 42.5)	(2.7 to 3.7)	(3.18 to 4.62)	(3.22 to 5.05)	(125 to 221)	(3.35 to 47)
Esophageal cancer	(59.5 to 81.3)	(82.5 to 108)	(59.4 to 84.3)	(96.2 to 169)	(-20.7 to 8.77)	(19.1 to 27.4)	(29.4 to 43.9)	(35.6 to 55.2)	(31.7 to 78.1)	(-39.6 to -18.3)
Stomach cancer	(108 to 135)	(181 to 221)	(189 to 277)	(50.4 to 89.4)	(-39.2 to -23.4)	(48.3 to 60)	(87.5 to 120)	(146 to 233)	(21.7 to 48.9)	(-44.2 to -31.7)
Colon and rectum cancer	(107 to 123)	246 (219 to 264)	452 (352 to 506)	166 (146 to 184)	7.54 (-0.392 to 14.7)	74.7 (68.3 to 80.4)	183 (150 to 201)	441 (316 to 506)	108 (92.4 to 121)	-4.66 (-11.8 to 1.51)
Liver cancer	54 (49.4 to 58.8)	76.9 (67.9 to 83.4)	78.7 (60.4 to 89)	123 (95.3 to 155)	-10 (-21 to 3.15)	24.7 (22.2 to 27.1)	41.4 (33.5 to 46.1)	58.9 (42.6 to 68.5)	84.7 (55.8 to 112)	-15.3 (-28.6 to -2.7)
Liver cancer due to hepatitis B	18.7 (14.8 to 23.1)	20 (15.1 to 24.8)	11.9 (7.02 to 17.8)	68.1 (38.9 to 107)	-32 (-43.8 to -16.4)	4.63 (3.36 to 6.21)	5.12 (3.45 to 6.91)	4.42 (2.34 to 7.44)	39.1 (9.72 to 68.8)	-36.3 (-49.7 to -22.6)
Liver cancer due to hepatitis C	15.4 (12.3 to 18.7)	32.4 (27.1 to 38.1)	47.8 (34.1 to 58.7)	158 (133 to 188)	4.23 (-5.78 to 16.5)	11.9 (9.66 to 13.9)	25 (19.4 to 29.1)	43.1 (29.1 to 52.3)	91.7 (62.8 to 119)	-12.1 (-25.4 to 0.199)
Liver cancer due to alcohol use	14.7 (11.3 to 18.4)	16.6 (12.5 to 20.7)	11.7 (6.86 to 17.1)	169 (142 to 199)	8.57 (-2.22 to 20.7)	3.54 (2.53 to 4.89)	3.92 (2.76 to 5.26)	3.16 (1.68 to 4.88)	101 (71.4 to 127)	-8.07 (-21.4 to 4.2)
Liver cancer due to NASH	3.49 (2.6 to 4.74)	5.7 (4.08 to 7.8)	5.4 (3.03 to 8.65)	193 (155 to 236)	18.5 (3.03 to 36)	3.12 (2.34 to 4.16)	5.21 (3.69 to 6.97)	5.83 (3.29 to 9.22)	139 (101 to 177)	9.78 (-7.67 to 27.2)
Liver cancer due to other causes	1.7 (1.22 to 2.27)	2.34 (1.68 to 3.14)	1.94 (1.14 to 3.08)	100 (69.3 to 137)	-19.1 (-31.5 to -4)	1.55 (1.12 to 2.03)	2.15 (1.52 to 2.9)	2.39 (1.41 to 3.75)	65.3 (36.2 to 95.1)	-24.2 (-37.6 to -10.5)
Gallbladder and biliary tract cancer	15.1 (12.4 to 16.7)	32 (24.2 to 35.4)	54.1 (35.5 tp 63.8)	150 (96,9 to 179)	1.13 (-20.4 to 12.9)	16.4 (13.8 to 19.3)	32.5 (24.5 to 37.1)	72.5 (45.1 to 87.6)	79.8 (49.3 to 104)	-17.6 (-31.6 to -6 27)
Pancreatic cancer	55.1	91.3	125 (97 to 142)	226	31.9	44.7	83.5 (68 to 93.6)	148 (105 to 173)	188	32.2
Larynx cancer	17.2	22.4	25.1	81	-26.8	2.61	3.34	3.87	78	-18.4
Tracheal, bronchus, and lung cancer	(16 to 18.7) 296	(20 to 24.3) 434	(19.7 to 28.4) 428	(66.7 to 96.5) 140	(-32.6 to -20.5) -3.14	(2.38 to 2.88) 115	(2.8 to 3.73) 176	(2.82 to 4.46) 259	(63.4 to 97.5) 199	(-25.1 to -9.48) 36.9
Malignant skin melanoma	(269 to 324) 5.74	(385 to 469) 12.7	(331 to 482) 29.7	(115 to 164) 190	(-13.2 to 6.62) 17.4	(104 to 126) 3.47	(144 to 196) 8.07	(191 to 300) 20.3	(173 to 225) 123	(25.1 to 48.9) 2.28
Non-melanoma rivin cancer	(3.24 to 6.78) 6.11	(6.91 to 14.8) 19.1	(15 to 36.3) 75.1	(56.7 to 233) 197	(-36.7 to 34.5) 20.2	(2.27 to 4.03) 2.74	(4.98 to 9.33)	(11.5 to 24.7) 54.9	(48.1 to 147) 170	(-32.1 to 13.3) 23.8
Non-melanoma skin cancer	(5.58 to 6.57)	(16.7 to 20.5)	(58 to 84.4)	(175 to 225)	(11.2 to 31.3)	(2.41 to 3.06)	(8.77 to 12.2)	(39.1 to 63.2)	(141 to 194)	(10.6 to 35)
(squamous-cell carcinoma)	(5.58 to 6.57)	(16.7 to 20.5)	(58 to 84.4)	(175 to 225)	(11.2 to 31.3)	(2.41 to 3.06)	(8.77 to 12.2)	(39.1 to 63.2)	(141 to 194)	(10.6 to 35)

Supplementary Table 4. Cause-speci	fic mortality rate for 7	70-79 years, 80-94 years, and 95-	+ years in 2019, and pe	ercentage change from 199	90 to 2019 in death numb	er and rate in 70+ years,	global, for all GBD causes			
			Males					Females		
		Deaths per 100,000, 2019		Percentage chang	e in 70+, 1990-2019		Deaths per 100,000, 2019		Percentage change	in 70+, 1990-2019
Causes Non-melanoma skin cancer (basal- cell carcinoma)	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Breast cancer	2.04	3.74	6.99	108	-15.9	73.9	127	292	109	-4.32
	(1.79 to 2.29)	(3.24 to 4.21)	(5.48 to 8.19)	(78 to 140)	(-28.1 to -2.86)	(68.2 to 79)	(105 to 139)	(218 to 335)	(94.4 to 121)	(-10.9 to 1.46)
Cervical cancer						26 (22.6 to 29.3)	31.7 (26.1 to 35.7)	40.5 (30.1 to 46.9)	74.9 (52.6 to 93.8)	-19.8 (-30 to -11.2)
Uterine cancer						14.2 (13 to 16)	20.5 (16.9 to 23.3)	32.8 (24.5 to 37.7)	84.5 (73.4 to 98.9)	-15.4 (-20.5 to -8.8)
Ovarian cancer						26.3 (23.3 to 28.8)	35.1 (28.9 to 39)	46.5 (33.7 to 54.2)	121 (95.7 to 140)	1.44 (-10.3 to 10.2)
Prostate cancer	112 (98.1 to 138)	362 (301 to 447)	896 (626 to 1070)	121 (107 to 145)	-10.5 (-16.5 to -0.925)					
Testicular cancer	0.58 (0.529 to 0.635)	1.38 (1.19 to 1.5)	4.09 (3.16 to 4.71)	127 (106 to 152)	-8.33 (-16.5 to 1.72)					
Kidney cancer	19.4	38.5	60.7	225	31.6	9.11	18.9	34.2	150	14.4
	(18.2 to 20.6)	(33.6 to 41.3)	(47.5 to 68.7)	(203 to 252)	(22.5 to 42.2)	(8.4 to 9.71)	(15.3 to 20.9)	(24.7 to 40)	(130 to 170)	(5.45 to 23.6)
Bladder cancer	35.4	105	246	120	-11.1	9.43	28.5	75.4	95.3	-10.5
	(33.1 to 37.6)	(92.6 to 113)	(193 to 278)	(105 to 139)	(-17.2 to -3.46)	(8.63 to 10.1)	(23.3 to 31.6)	(55.4 to 87.3)	(77.7 to 112)	(-18.5 to -2.71)
Brain and central nervous system	16.7	19.7	16.7	205	23.4	12.5	14.6	16.4	174	25.5
cancer	(11.4 to 19)	(12.5 to 22.9)	(9.68 to 20.3)	(82.6 to 266)	(-26.2 to 48.1)	(7.98 to 14.4)	(8.37 to 17.7)	(9.16 to 20.7)	(45.8 to 249)	(-33.2 to 60)
Thyroid cancer	3.27	6.43	8.31	217	28.3	4.11	7.27	12.8	102	-7.41
	(2.94 to 3.55)	(5.37 to 7.08)	(5.85 to 9.66)	(162 to 257)	(5.72 to 44.5)	(3.66 to 4.47)	(5.87 to 8.09)	(8.85 to 14.9)	(78.1 to 119)	(-18.4 to 0.363)
Mesothelioma	4.73	9.03	10.6	158	4.45	1.27	1.99	2.58	83.1	-16
	(4.47 to 4.98)	(7.95 to 9.64)	(8.44 to 12.1)	(134 to 180)	(-5.46 to 13)	(0.9 to 1.42)	(1.41 to 2.3)	(1.62 to 3.21)	(33.7 to 124)	(-38.7 to 2.79)
Hodgkin lymphoma	1.67	2.17	1.68	35.9	-45.1	1.04	1.35	1.05	22	-44.1
	(1.38 to 1.99)	(1.73 to 2.44)	(1.01 to 1.98)	(20.4 to 57.7)	(-51.3 to -36.3)	(0.822 to 1.29)	(0.965 to 1.61)	(0.548 to 1.39)	(12 to 36.2)	(-48.6 to -37.6)
Non-Hodgkin lymphoma	24.1	47.4	75.3	186	15.6	16.1	32.9	57.4	139	9.47
	(22.6 to 25.5)	(41.8 to 50.7)	(58.9 to 84.5)	(167 to 205)	(8.09 to 23.2)	(14.8 to 17.2)	(26.7 to 36.3)	(41.1 to 66.1)	(122 to 154)	(1.81 to 16.5)
Multiple myeloma	(10.3 to 13.7)	24.1 (17.7 to 26.3)	38.8 (28.1 to 44.6)	180 (132 to 201)	(+6.05 to 21.7)	9.62 (8.4 to 10.9)	16.4 (12.1 to 18.3)	(12.8 to 25)	(88.4 to 144)	4.5 (-13.6 to 11.7)
Leukemia	(24.2 to 29.9)	55.7 (49.8 to 61.6)	(81.5 to 123)	(117 to 153)	-5.2 (-12.2 to 2.36)	(15.4 to 18.4)	32.8 (27.1 to 36.3)	(47.2 to 74.6)	105 (85.1 to 120)	-6.05 (-15.1 to 0.836)
Acute lymphoid leukemia	(1.27 to 1.91)	(1.86 to 2.69)	(1.94 to 3.41)	(124 to 198)	(-9.52 to 20.6)	(0.821 to 1.32)	(1.11 to 1.75)	(1.1 to 1.99)	(86.7 to 163)	(-14.4 to 20.4)
Chronic lymphoid leukemia	(4.04 to 5.34) 8.79	(10.7 to 15)	(26.4 to 44.4)	(114 to 181) 230	(-13.4 to 13.7)	(3.21 to 4.14)	(7.1 to 9.68) 8.38	(15 to 24.6)	(107 to 150)	(-4.9 to 14.8)
Acute myeloid leukemia	(6.9 to 9.66) 2.36	(11.2 to 17.3) 4.72	(9.46 to 22.2) 7.09	(152 to 271) 48	(1.82 to 50.1) -40.2	(4.43 to 5.82)	(5.95 to 9.55) 2.17	(5.8 to 13.7) 4.51	(109 to 199) 20.4	(-4.17 to 37)
Other Indemia	(2.05 to 2.76)	(4.04 to 5.55)	(5.26 to 8.71)	(30.6 to 73.4)	(-47.2 to -29.9)	(0.981 to 1.29)	(1.78 to 2.51)	(3.13 to 5.41)	(9.01 to 37.1)	(-50 to -37.2)
	10.1	21.6	44.4	109	-15.4	5.99	12.2	27.1	80	-17.5
Other malignant peoplasms	(8.6 to 11.6)	(18.5 to 24.7)	(33.1 to 53.3)	(84.2 to 144)	(-25.5 to -1.24)	(5.12 to 6.82)	(9.76 to 13.9)	(20.1 to 32.1)	(62.5 to 102)	(-25.5 to -7.22)
	31.6	55.5	83.1	143	-1.65	23.6	43.5	77.2	121	1.25
Other peoplasms	(24.4 to 36.3)	(42 to 63.6)	(60.5 to 95.6)	(107 to 179)	(-16.4 to 12.7)	(21 to 25.9)	(35.4 to 48.4)	(54.6 to 89.6)	(97 to 143)	(-9.71 to 11.6)
	6.57	23.4	62.8	183	14.3	3.6	13.8	41.8	165	21.5
Myelodysplastic,	(4.7 to 9.57)	(15.1 to 33.7)	(32.8 to 91.8)	(104 to 246)	(-17.3 to 40)	(3.21 to 3.89)	(10.5 to 15.4)	(27.7 to 49.4)	(110 to 198)	(-3.77 to 36.8)
myeloproliferative, and other	6.57	23.4	62.8	183	14.3	3.6	13.8	41.8	165	21.5
hematopoletic neoplasms Benign and in situ intestinal	(4.7 to 9.57)	(15.1 to 33.7)	(32.8 to 91.8)	(104 to 246)	(-17.3 to 40)	(3.21 to 3.89)	(10.5 to 15.4)	(27.7 to 49.4)	(110 to 198)	(-3.77 to 36.8)
Benign and in situ cervical and										
Other benign and in situ										
Cardiovascular diseases	1740 (1610 to 1870)	5070 (4540 to 5420)	12300 (9790 to 12500)	85 (72.4 to 98)	-25.2	1280 (1160 to 1280)	4510 (2780 to 4960)	13500 (10100 to 15200)	60.1 (47.6 to 72)	-26.6
Rheumatic heart disease	18.8 (15.9 to 22.2)	(4540 to 5420) 45.3 (28.6 to 52.2)	(9780 (0 13300) 80.9 (64 8 to 94 4)	(72.4 (0 58) 21.7 (.7 8 to 54 2)	-50.8 (-62.7 to -27.6)	20.8	48.2 (28 to 55.6)	(10100 (0 15300) 116 (86 5 to 126)	(47.5 (5 72)	-48.9 (-60.6 to -25.6)
Ischemic heart disease	857	2560	6730	85.3	-25.1	586	2150	6710	62	-25.7
	(795 to 920)	(2280 to 2740)	(5340 to 7470)	(72.1 to 96.7)	(-30.4 to -20.5)	(531 to 635)	(1800 to 2360)	(5090 to 7600)	(50.9 to 72.3)	(-30.8 to -21)
Stroke	668	1750	3060	78.4	-27.9	500	1550	3810	46	-33.1
	(604 to 732)	(1560 to 1880)	(2430 to 3410)	(59.8 to 97.1)	(-35.4 to -20.3)	(453 to 550)	(1300 to 1710)	(2830 to 4340)	(31.7 to 63.5)	(-39.6 to -25)
Ischemic stroke	345	1140	2320	90.7	-22.9	261	1070	2930	52.4	-30.2
	(311 to 381)	(1020 to 1230)	(1820 to 2600)	(67.8 to 108)	(-32.2 to -16)	(236 to 286)	(893 to 1180)	(2180 to 3350)	(38.5 to 68.9)	(-36.5 to -22.5)
Intracerebral hemorrhage	297	552	624	72.8	-30.1	215	431	751	44.7	-33.7
	(261 to 328)	(490 to 605)	(499 to 705)	(51.4 to 95.8)	(-38.8 to -20.9)	(190 to 238)	(360 to 482)	(571 to 860)	(24.5 to 67.1)	(-42.9 to -23.4)
Subarachnoid hemorrhage	26.2	57	123	4.21	-57.9	24.3	52.7	123	-8.66	-58.1
	(21.7 to 31.2)	(44.7 to 65.5)	(75.9 to 150)	(-21.8 to 149)	(-68.4 to 0.575)	(21.4 to 27.5)	(42.8 to 58.7)	(84.3 to 143)	(-23.8 to 11.8)	(-65.1 to -48.7)
Hypertensive heart disease	92.6	315	772	111	-14.8	92.9	356	1190	100	-8.13
	(65.6 to 105)	(211 to 352)	(500 to 880)	(70.7 to 145)	(-31 to -1.03)	(75.2 to 106)	(257 to 403)	(734 to 1390)	(57.1 to 137)	(-28 to 8.78)
Non-rheumatic valvular heart	10.1	55	273	158	4.47	8.83	62.7	358	142	10.9
disease	(9.46 to 10.8)	(46.1 to 59.4)	(201 to 343)	(136 to 176)	(-4.47 to 11.7)	(7.99 to 9.75)	(48.8 to 71.3)	(249 to 423)	(115 to 162)	(-1.31 to 20)
Non-rheumatic calcific aortic	7.87	46.7	245	176	11.5	6	51	309	175	26.1
valve disease	(7.14 to 8.48)	(38.9 to 51.2)	(179 to 309)	(152 to 201)	(1.87 to 21.5)	(5.25 to 6.89)	(39.1 to 59.5)	(217 to 372)	(147 to 199)	(13 to 37.1)
Non-rheumatic degenerative mitral	2.03	7.52	27.6	100	-19.1	2.58	10.8	48.1	65	-24.4
valve disease	(1.59 to 2.51)	(5.19 to 9.17)	(15.9 to 35.9)	(80.5 to 149)	(-27 to 0.587)	(2.16 to 3.47)	(7.18 to 15.1)	(23.4 to 87.2)	(44.7 to 124)	(-33.7 to 2.48)
Other non-rheumatic valve	0.205	0.768	0.648	68.4	-31.9	0.251	0.877	1.76	53.5	-29.6
diseases	(0.138 to 0.271)	(0.551 to 1.06)	(0.396 to 0.853)	(16.8 to 174)	(-52.8 to 10.9)	(0.182 to 0.302)	(0.617 to 1.07)	(1.09 to 2.35)	(17.6 to 107)	(-46.1 to -4.93)
Cardiomyopathy and myocarditis	22.7	74.1	283	69.1	-31.6	13.3	69	302	34.8	-38.2
	(18.3 to 26.3)	(54.5 to 83.1)	(185 to 342)	(54.5 to 116)	(-37.5 to -12.6)	(11.2 to 15.2)	(51.1 to 77.9)	(206 to 356)	(18.6 to 75.1)	(-45.6 to -19.7)
Myocarditis	1.79	7.61	21.5	248	40.8	1.24	8.1	35.4	200	37.5
	(1.07 to 2.19)	(4.16 to 9.67)	(10.2 to 29.3)	(116 to 390)	(-12.5 to 98.1)	(0.776 to 1.53)	(4.48 to 10.4)	(16.4 to 49.5)	(79.4 to 345)	(-17.8 to 104)
Alcoholic cardiomyopathy	4.8	5.23	10.9	51.2	-38.9	0.985	1.3	2.64	-53.2	-78.6
	(3.69 to 5.76)	(3.7 to 6.76)	(6.92 to 17.1)	(18.7 to 75.2)	(-52 to -29.2)	(0.742 to 1.24)	(0.814 to 1.82)	(1.65 to 3.6)	(-64.4 to -18)	(-83.7 to -62.4)
Other cardiomyopathy	16.1	61.3	251	62.5	-34.3	11	59.6	264	34.4	-38.4
	(13.4 to 19.2)	(46 to 68.5)	(165 to 302)	(46.3 to 126)	(-40.9 to -8.48)	(9.46 to 12.8)	(44 to 68)	(177 to 318)	(18.2 to 82.6)	(-45.8 to -16.3)
Atrial fibrillation and flutter	18.4	127	577	206	23.7	19.4	143	583	168	23
	(15.1 to 22.6)	(100 to 158)	(416 to 752)	(163 to 241)	(6.13 to 37.9)	(17.1 to 22)	(115 to 166)	(423 to 742)	(141 to 192)	(10.4 to 33.9)
Aortic aneurysm	21.6	56.4	119	85.8	-24.9	9.81	32.2	90.2	119	0.298
	(20.2 to 23)	(49.1 to 60.4)	(92.1 to 138)	(70 to 102)	(-31.3 to -18.5)	(8.93 to 10.5)	(25.6 to 35.8)	(64.2 to 106)	(99.2 to 132)	(-8.68 to 6.24)
Peripheral artery disease	7.18	28.8	134	171	9.7	3.78	24.5	129	150	14.7
	(3.45 to 14.6)	(12.6 to 63.5)	(49.8 to 317)	(124 to 215)	(-9.36 to 27.2)	(1.76 to 7.5)	(10.2 to 51.3)	(47 to 266)	(65.7 to 187)	(-24 to 31.8)
Endocarditis	4.16	13.3	57.1	285	55.7	3.51	15.3	76.4	250	60.4
	(2.58 to 4.86)	(6.75 to 16.3)	(20.3 to 82.8)	(106 to 404)	(-16.5 to 104)	(2.39 to 3.98)	(8.23 to 19.1)	(28.9 to 104)	(87.3 to 353)	(-14.1 to 108)
Other cardiovascular and	21.1	57.5	162	69.4	-31.5	19.1	57.2	178	67.6	-23.2
circulatory diseases	(18.9 to 24.2)	(50.1 to 64.6)	(126 to 193)	(46.4 to 86.6)	(-40.8 to -24.6)	(17.1 to 21)	(46.9 to 63.6)	(130 to 206)	(45.3 to 82.9)	(-33.4 to -16.1)
Chronic respiratory diseases	500	1420	2370	54.1	-37.7	296	853	1740	44	-34
	(452 to 552)	(1250 to 1550)	(1920 to 2620)	(35.6 to 76.8)	(-45.2 to -28.5)	(247 to 334)	(682 to 971)	(1260 to 2000)	(21.4 to 80.2)	(-44.4 to -17.4)
disease	434	1270	2110	55.5	-37.1	243	739	1540	41.4	-35.2
	(391 to 482)	(1130 to 1390)	(1680 to 2350)	(35.7 to 79.2)	(-45.1 to -27.6)	(201 to 278)	(591 to 848)	(1140 to 1790)	(18.8 to 82.5)	(-45.5 to -16.3)
Pneumoconiosis	4.05	11.4	14.3	21.5	-50.9	0.33	0.879	1.86	84.1	-15.6
	(3.59 to 4.6)	(10 to 12.9)	(11.3 to 16.1)	(2.86 to 56.4)	(-58.4 to -36.8)	(0.271 to 0.39)	(0.679 to 1.03)	(1.24 to 2.25)	(34.5 to 125)	(-38.3 to 3.16)
Silicosis	2.29	6.11	5.29	5.21	-57.5	0.0911	0.248	0.441	62.3	-25.6
	(1.91 to 2.91)	(5.26 to 8.01)	(4.04 to 6.45)	(-16.8 to 53.7)	(-66.4 to -37.9)	(0.0649 to 0.121)	(0.177 to 0.325)	(0.289 to 0.638)	(-2.47 to 117)	(-55.3 to -0.493)
Asbestosis	0.673	2.44	4.58	270	49.7	0.0727	0.211	0.485	114	-1.75
	(0.441 to 0.778)	(1.6 to 2.79)	(2.92 to 5.42)	(145 to 337)	(-0.918 to 76.6)	(0.0463 to 0.093)	(0.129 to 0.273)	(0.257 to 0.67)	(61.5 to 169)	(-26 to 23.5)
Coal workers pneumoconiosis	0.595	1.7	2.38	-21.9	-68.4	0.0361	0.096	0.285	43.8	-34.1
	(0.385 to 0.755)	(1.32 to 2.09)	(1.77 to 2.94)	(-37.1 to 11.8)	(-74.6 to -54.8)	(0.0202 to 0.0543)	(0.06 to 0.134)	(0.168 to 0.447)	(0.99 to 108)	(-53.7 to -4.65)
Other pneumoconiosis	0.484	1.12	2.08	84.5	-25.4	0.13	0.324	0.645	103	-6.82
	(0.355 to 0.672)	(0.893 to 1.45)	(1.49 to 2.55)	(39.4 to 178)	(-43.6 to 12.3)	(0.0978 to 0.169)	(0.242 to 0.413)	(0.405 to 0.861)	(49.3 to 148)	(-31.5 to 13.8)
Asthma	38.9	82.7	126	11	-55.1	37.6	78.6	118	33.3	-38.9
	(30.9 to 49.7)	(67.5 to 101)	(96.8 to 161)	(-14.8 to 38.7)	(-65.5 to -43.9)	(25.7 to 51.4)	(55 to 100)	(79.9 to 160)	(1.56 to 69.1)	(-53.4 to -22.5)
pulmonary sarcoidosis	21.1	49.2	108	222	30.4	13.8	30.9	68.1	229	51
	(12.7 to 27.4)	(27.8 to 65.2)	(48.8 to 161)	(107 to 391)	(-16.3 to 98.4)	(8.7 to 17)	(17.5 to 39.8)	(30.2 to 98.8)	(100 to 350)	(-8.11 to 106)
Other chronic respiratory diseases	1.98	5.72	18.1	81	-26.8	1.16	3.5	9.68	96.8	-9.78
	(1.42 to 2.43)	(4.17 to 6.71)	(10.3 to 22.4)	(51.9 to 156)	(-38.6 tp 3.52)	(0.722 to 1.46)	(2.15 to 4.41)	(5.34 to 12.4)	(59.7 to 146)	(-26.8 to 12.9)

Supplementary Table 4. Cause-speci	fic mortality rate for 70-3	79 years, 80-94 years, and 95	i+ years in 2019, and pe	rcentage change from 199	0 to 2019 in death numbe	er and rate in 70+ years,	global, for all GBD causes			
			Males					Females		
		Deaths per 100,000, 2019		Percentage change	e in 70+, 1990-2019		Deaths per 100,000, 2019		Percentage chang	e in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Digestive diseases	186 (175 to 200)	401 (356 to 432)	1000 (788 to 1120)	78.8 (63.5 to 95.2)	-27.7 (-33.9 to -21.1)	130 (119 to 140)	337 (279 to 369)	961 (706 to 1100)	72.8 (55.7 to 87.3)	-20.8 (-28.6 to -14.1)
Cirrhosis and other chronic liver diseases	102 (95 to 111)	153 (135 to 169)	284 (221 to 327)	87.8 (69.6 to 109)	-24.1 (-31.4 to -15.6)	62.7 (56.9 to 69.6)	101 (83.6 to 113)	185 (134 to 227)	72.6 (50.3 to 92.9)	-20.9 (-31.1 to -11.6)
Cirrhosis and other chronic liver diseases due to hepatitis B	22.1 (16 to 29.1)	33.3 (24.4 to 43.1)	51.8 (27.8 to 83)	43.6 (25 to 64.9)	-42 (-49.5 to -33.3)	11 (7.66 to 14.6)	17 (12 to 22.4)	24.1 (12.5 to 39.3)	24 (4.79 to 42.6)	-43.1 (-52 to -34.6)
Cirrhosis and other chronic liver diseases due to hepatitis C	28.5 (22.3 to 35.6)	43.7 (33.3 to 54.7)	88.9 (54.1 to 128)	107 (85.2 to 131)	-16.3 (-25.1 to -6.59)	15.5 (11.5 to 20.2)	24.8 (17.9 to 32.2)	53.3 (31.3 to 79)	87.3 (61.7 to 113)	-14.2 (-25.9 to -2.52)
Cirrhosis and other chronic liver diseases due to alcohol use	29 (22.4 to 36.2)	34.6 (25.9 to 44.6)	56.5 (32.3 to 92.5)	97.1 (79.8 to 118)	-20.3 (-27.3 to -11.8)	11.8 (8.34 to 15.9)	15 (10.8 to 20.7)	25.9 (13.8 to 45.2)	80.6 (61.3 to 101)	-17.2 (-26.1 to -7.93)
Cirrhosis and other chronic liver diseases due to NAFLD	9.63 (5.74 to 14.6)	17.2 (10.5 to 25.8)	37 (15.6 to 67.8)	125 (102 to 153)	-9.09 (-18 5 to 2 28)	8.98 (5.39 to 13.4)	16.3 (9.97 to 23.8)	30.3 (13.5 to 52.8)	104 (77.2 to 130)	-6.49 (-18.8 to 5.27)
Cirrhosis and other chronic liver diseases due to other causes	13.1	23.8 (14.2 to 26.2)	49.3	104 (81.7 to 120)	-17.5	15.5 (9.24 to 22.6)	27.5 (17.4 to 29)	51.3 (24.4 to 92.9)	84.3 (59.9 to 109)	-15.5 (-26.7 to -4.46)
Upper digestive system diseases	24.5 (22.3 to 27.2)	59.9 (52.4 to 66.5)	125	10.1 (-2.09 to 25)	-55.5	17.5 (15.6 to 19.2)	51.5 (42.8 to 57.6)	125	20.2 (7.57 to 22.7)	-44.9 (-50.7 to -28.7)
Peptic ulcer disease	21.1	50.9	110	458	-57.7	15.2	43.8	105	14.6	-47.5
Gastritis and duodenitis	3.44	(45.2 to 57.2) 8.95	(86.2 to 127)	(+8.49 to 22) 59.7	(+63 t0 -50.7) -35.4	2.32	(36.5 to 49.1) 7.69	20.2	(1.78 to 29.7) 69.7	-22.2
Gastroesophageal reflux disease	(2.24 to 4.04)	(6.66 to 10.2)	(10.9 to 17.2)	(4.28 to 138)	(-57.810-3.95)	(1.92 to 2.68)	(6.25 to 8.85)	(15.2 to 24.4)	(29 to 121)	(-40.9 to 1.15)
Appendicitis	1.83	4.01	8.28	25.3	-49.3	1.46	3.06	5.92	28.9	-40.9
Paralytic ileus and intestinal	(1.36 to 2.23) 16.3	(3.11 to 4.98) 55.2	(5.99 to 11.1) 180	(3.92 to 65) 137	(-58 to -33.3) -4.11	(1.13 to 1.68) 12.5	(2.46 to 3.53) 46.7	(4.44 to 7.05) 172	(-4.58 to 63) 120	(-56.3 to -25.3) 0.743
obstruction Inguinal, femoral, and abdominal	(13.3 to 19) 4.69	(44.8 to 64.6) 15.3	(120 to 213) 47.8	(97.2 to 176) 63.4	(-20.3 to 11.7) -33.9	(10.3 to 14.3) 2.42	(36.6 to 53.4) 9.49	(109 to 211) 30.5	(85.5 to 155) 59.3	(-15 to 17) -27
hernia	(4.05 to 5.46)	(13.2 to 17.8)	(37.2 to 57.6)	(25.1 to 95.5)	(-49.4 to -21)	(1.82 to 2.97) 2.59	(7.35 to 11.5)	(20.7 to 38.9) 45.9	(35 to 98.8)	(-38.1 to -8.85)
initiation bower of sease	(2.31 to 3.33)	(7.94 to 11.4)	(21.5 to 39.7)	(88.6 to 180)	(-23.7 to 13.1)	(2.26 to 2.81)	(8.41 to 12.3)	(31.8 to 56.9)	(77.8 to 160)	(-18.5 to 19)
Vascular intestinal disorders	(8.48 to 9.82)	(23.4 to 29.7)	(55.5 to 83.5)	(100 to 140)	(-19.1 to -2.78)	(8.65 to 10.7)	(28.8 to 39.3)	(65.7 to 110)	(91.3 to 129)	(-12.3 to 5.06)
Gallbladder and biliary diseases	9.54 (8.08 to 11.3)	(29.6 to 41.1)	(89.6 to 151)	(87.4 to 147)	-15.9 (-24.2 to -0.156)	8.95 (7.86 to 10.7)	(29.1 to 43.2)	(103 to 192)	/3.5 (54.1 to 104)	-20.5 (-29.3 to -6.59)
Pancreatitis	7.49 (6.44 to 8.6)	14.7 (12.8 to 16.5)	28.3 (22.1 to 33.1)	123 (90.6 to 155)	-10 (-22.9 to 3.19)	5.51 (4.53 to 6.46)	13.5 (11 to 15.7)	31.6 (22.9 to 39.1)	92.8 (61.9 to 124)	-11.6 (-25.8 to 2.69)
Other digestive diseases	7.44 (5.66 to 8.89)	26.2 (19.5 to 31.8)	103 (69.4 to 133)	127 (76 to 168)	-8.41 (-28.8 to 8.27)	6.82 (5.33 to 8.22)	29.5 (21.7 to 36.7)	121 (79.7 to 161)	118 (67.4 to 158)	-0.0414 (-23.2 to 18.3)
Neurological disorders	135 (79.3 to 269)	848 (373 to 1900)	3620 (1140 to 8930)	209 (189 to 231)	25.1 (16.8 to 33.7)	123 (59.1 to 277)	934 (333 to 2150)	4200 (1220 to 10300)	178 (161 to 198)	27.5 (19.7 to 36.7)
Al zheimer's disease and other dementias	72.2 (16.3 to 208)	635 (151 to 1710)	3330 (816 to 8710)	224 (206 to 250)	30.8 (23.7 to 41.3)	84.7 (19.4 to 240)	818 (208 to 2060)	4030 (1030 to 10200)	186 (168 to 213)	31 (22.6 to 43.7)
Parkinson's disease	49.9 (46 to 54.1)	190 (168 to 206)	255 (197 to 300)	180 (156 to 204)	13.1 (3.31 to 22.7)	27.9 (25 to 30)	98.6 (81 to 109)	134 (99.6 to 152)	136 (116 to 154)	8.16 (-1.1 to 16.6)
Idiopathic epilepsy	3.6 (3.23 to 4.04)	8.05 (6.92 to 8.93)	15.4 (12.2 to 17.7)	161 (137 to 205)	5.55 (+4.12 to 23.2)	3.01 (2.13 to 3.55)	6.68 (4.04 to 7.82)	13.6 (6.96 to 16.6)	182 (96.2 to 253)	29.1 (-10 to 61.9)
Multiple sclerosis	0.956 (0.664 to 1.19)	1.1 (0.777 to 1.36)	1.1 (0.571 to 1.41)	136 (44.6 to 173)	-4.63 (-41.5 to 10.5)	1.3 (0.802 to 1.62)	1.4 (0.874 to 1.71)	1.32 (0.739 to 1.68)	123 (24.4 to 166)	2.05 (-43 to 21.8)
Motor neuron disease	4.32 (4.01 to 4.57)	5.19 (4.48 to 5.63)	4.83 (3.79 tp 5.52)	236 (212 to 258)	36 (25.9 to 44.6)	3.22 (2.92 to 3.48)	3.4 (2.72 to 3.8)	2.66 (1.92 to 3.08)	180 (157 to 201)	28.5 (17.8 to 38)
Headache disorders										
Migraine										
Tension-type headache										
Other neurological disorders	3.92	8.34	17.3	186	15.6	2.99	5.86	12.8	144	11.9
Mental disorders	(3.68 t0 4.18)	(7.32 to 8.98)	(13.4 to 20.7)	(1/1 to 202)	(9.51 to 22.2)	(2.76 to 3.17)	(4.75 t0 6.45)	(9.47 to 14.6)	(129 to 160)	(4.76 t0 19.1)
Schizophrenia										
Depressive disorders										
Major depressive disorder										
Desthumia										
Binolar disorder										
Anxiety dirorderr										
Failer disarders										
Earing disorders										
Allorexta nervosa										
Bulimia nervosa										
Autism spectrum disorders										
disorder										
Conduct disorder										
intellectual disability										
Other mental disorders										
Substance use disorders	9.65 (8.41 to 10.3)	9.69 (8.47 to 10.4)	16.2 (12.8 to 18.2)	147 (125 to 167)	-0.234 (-9.08 to 7.82)	2.76 (2.56 to 2.93)	4.1 (3.4 to 4.51)	9.44 (6.94 to 10.9)	85.2 (70 to 101)	-15.1 (-22.1 to -7.9)
Alcohol use disorders	7.58 (6.33 to 8.19)	6.32 (5.24 to 6.86)	8.15 (6.03 to 9.28)	141 (113 to 166)	-2.61 (-13.8 to 7.43)	1.43 (1.31 to 1.53)	1.65 (1.4 to 1.83)	2.96 (2.18 to 3.46)	71.1 (57.1 to 82.6)	-21.6 (-28 to -16.3)
Drug use disorders	2.07 (1.91 to 2.22)	3.37 (2.99 to 3.66)	8.03 (6.38 to 9.16)	166 (133 to 200)	7.43 (-5.67 to 21.5)	1.33 (1.21 to 1.44)	2.45 (2 to 2.74)	6.47 (4.69 to 7.56)	99.4 (78.6 to 125)	-8.6 (-18.1 to 2.95)
Opioid use disorders	1.41 (1.29 to 1.52)	2.17 (1.92 to 2.37)	4.85 (3.94 to 5.56)	123 (91.2 to 152)	-9.88 (-22.7 to 1.88)	0.846 (0.774 to 0.922)	1.69 (1.37 to 1.9)	4.78 (3.46 to 5.68)	84.1 (62.6 to 108)	-15.6 (-25.5 to -4.78)
Cocaine use disorders	0.156 (0.131 to 0.174)	0.048 (0.0411 to 0.0538)	0.159 (0.121 to 0.183)	393 (203 to 491)	99.5 (22.3 to 139)	0.0253 (0.0228 to 0.0276)	0.0136 (0.0113 to 0.0152)	0.0292 (0.0215 to 0.0345)	143 (107 to 185)	11.6 (-5 to 30.8)
Amphetamine use disorders	0.0375 (0.0266 to 0.0438)	0.161 (0.13 to 0.204)	0.67 (0.46 to 0.93)	688 (521 to 865)	218 (151 to 290)	0.0385 (0.0315 to 0.047)	0.0854 (0.0685 to 0.102)	0.0731 (0.055 to 0.0882)	-26.3 (-48.1 to 8.01)	-66.2 (-76.2 to -50.5)
Cannabis use disorders								,		
Other drug use disorders	0.471	0.986	2.34	297 (218 to 2011)	60.5	0.416	0.662	1.59 (1.15 to 1.67)	214 (149 to 2001	44.1
Diabetes and kidney diseases	262	640	1790	199	20.8	219	523	1450	171	24
Diabetes mellitus	(245 10 281)	290	564	199	20.7	127	265	525	147	13.3
Diabetes mellitus type 1	(132 to 151) 3.62	(257 to 311) 3.94	(451 to 625) 10.2	(178 to 221) 111	(12.5 to 29.6) -14.7	(116 to 138) 3.58	(222 to 292) 4.24	(390 to 597) 10.6	(127 to 166) 56	(3.87 to 22.1) -28.5
Diabetes mellitus type 2	(3.03 to 5.12) 138	(3.22 to 5.25) 286	(6.97 to 14.4) 554	(64 to 168) 201	(-33.7 to 8.48) 21.7	(2.76 to 4.92) 124	(3.25 to 5.68) 261	(6.95 to 14.6) 515	(36.2 to 102) 150	(-37.6 to -7.24) 14.8
Chronic kidney disease	(129 to 147) 120	(254 to 306) 349	(441 to 614) 1220	(181 to 223) 202	(13.5 to 30.7) 21.9	(113 to 134) 90.9	(218 to 288) 257	(382 to 586) 918	(129 to 170) 206	(4.89 to 23.9) 40.1
Chronic kidney disease due to	(112 to 130) 3.57	(307 to 377) 2.51	(956 to 1370) 0.425	(168 to 229) 177	(8.28 to 33) 11.8	(82.7 to 98.3) 2.83	(210 to 283) 1.99	(668 to 1050) 0.35	(172 to 229) 165	(24.7 to 50.6) 21.5
diabetes mellitus type 1	(1.62 to 6.72)	(1.08 to 5.27)	(0.12 to 1.11)	(143 to 210)	(-1.83 tp 25.4)	(1.32 to 5.38)	(0.868 to 4.23)	(0.101 to 0.9)	(140 to 195)	(9.81 to 35.2)

Supplementary Table 4. Cause-specif	fic mortality rate for 7	70-79 vears. 80-94 vears. and 95+	vears in 2019, and	percentage change from 1990) to 2019 in death numb	er and rate in 70+ vears. a	lobal, for all GBD causes			
			Males					Females		
		Deaths per 100.000, 2019		Percentage change	in 70+. 1990-2019		Deaths per 100.000. 2019		Percentage chang	e in 70+. 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Chronic kidney disease due to diabetes mellitus type 2	39.3 (27.6 to 50.5)	94.4 (65.4 to 129)	277 (148 to 428)	220 (178 to 260)	29.4 (12.2 to 45.4)	31.1 (21.9 to 39.8)	76.2 (53 to 101)	231 (125 to 349)	223 (185 to 260)	48.2 (30.9 to 64.9)
Chronic kidney disease due to hypertension	41 (32.3 to 51.4)	144 (116 to 174)	582 (419 to 768)	204 (169 to 233)	22.7 (8.93 to 34.5)	30.1 (23.6 to 38.5)	102 (77.8 to 125)	418 (279 to 558)	208 (174 to 236)	41.2 (25.6 to 54.2)
Chronic kidney disease due to glomerulonephritis	13.6 (7.69 to 20.8)	33.7 (18.7 to 53.8)	87.2 (38.6 to 174)	176 (144 to 208)	11.7 (-1.46 to 24.6)	9 (5.16 to 14.1)	20.5 (11.3 to 32.8)	54.3 (23.5 to 112)	178 (150 to 210)	27.7 (14.4 to 42)
Chronic kidney disease due to other and unspecified causes	22.9 (13.9 to 35.3)	74.3 (46.6 to 106)	275 (142 to 426)	189 (155 to 222)	16.9 (3.1 to 30.1)	17.8 (11 to 26.4)	56 (36.4 to 78.4)	215 (113 to 325)	193 (157 to 226)	34.2 (17 9 to 49 4)
Acute glomerulonephritis	0.88	2.07	2.2 (164 to 2.66)	33.9	-45.9	0.644	1.42 (1.08 to 1.74)	2.38	29.4 (-8.17 to 64.7)	-40.7
Skin and subcutaneous diseases	6.97	22.5	99.9	153	2.16	6.65	25.3	112	162	19.9
Dermatitis	(4.48 to 10.1)	(14.4 to 34.5)	(52.8 t0 163)	(103 to 207)	(-17.8 to 24.2)	(5.06 to 8.47)	(17.8 to 34.7)	(66.4 to 162)	(132 to 194)	(6.27 t0 34.6)
Atopic dermatitis										
Contact dermatitis										
Seborrhoeic dermatitis										
Psoriasis										
Bacterial skin diseases	5.13	14	60	182	14	4.74	14.4	58.8	232	52.4
Cellulitis	(3.19 to 7.33) 1.23	(7.73 to 22) 3.53	(26.3 to 102) 16.4	(129 to 268) 222	(-7.42 to 48.9) 30	(3.66 to 6.2) 1.2	(9.94 to 20.9) 3.72	(33.2 to 89) 16.2	(180 to 291) 242	(28.2 to 79.3) 56.7
Punderma	(0.544 to 2.01) 3.91	(1.38 to 6.53) 10.5	(5.16 to 30.5) 43.6	(94.7 to 356) 171	(-21.3 to 84.5) 9.58	(0.664 to 1.71) 3.54	(2.02 to 5.84) 10.7	(7.31 to 27.3) 42.6	(166 to 295) 229	(21.9 to 81) 50.9
Scables	(2.25 to 5.38)	(5.76 to 15.8)	(19.2 to 72.2)	(120 to 269)	(-11.2 to 49.1)	(2.9 to 4.62)	(7.59 to 15)	(24.8 to 61.1)	(180 to 299)	(28.1 to 82.8)
Europal rikin dinasnar										
Viral skin diseases										
VITAL SIGN DISEASES										
Acne vuigaris										
Alopecia areata										
Pruritus										
Urticaria										
Decubitus ulcer	1.63 (0.949 to 2.68)	7.61 (4.56 to 12.5)	36.3 (17.2 to 65.2)	111 (40.2 to 204)	-14.9 (-43.3 to 23)	1.68 (1.08 to 2.05)	9.77 (6.39 to 13)	49.8 (28.2 to 65.8)	95.5 (59.3 to 131)	-10.4 (-27 to 5.81)
diseases	0.208 (0.135 to 0.323)	0.918 (0.556 to 1.53)	3.67 (1.48 to 7.15)	96.5 (23.7 to 148)	-20.6 (-50 to 0.429)	0.233 (0.18 to 0.378)	1.09 (0.731 to 1.89)	3.85 (1.8 to 6.46)	105 (46 to 146)	-5.98 (-33.1 to 12.9)
Sense organ diseases										
Blindness and vision loss										
Glaucoma										
Cataract										
Age-related macular degeneration										
Refraction disorders										
Near vision loss										
Other vision loss										
Age-related and other hearing loss										
Other sense organ diseases										
Musculoskel etal disorders	6.96 (6.15 to 7.86)	19.1 (15.6 to 21.4)	48.4 (33.5 to 57.6)	162 (137 to 203)	5.96 (-4.14 to 22.5)	10.9 (7.76 to 13.4)	27.8 (18 to 32.8)	77.1 (41.6 to 99.4)	158 (109 to 199)	18.3 (-4.29 to 37.2)
Rheumatoid arthritis	3.31 (2.84 to 3.76)	7.65 (6.44 to 8.6)	11.3 (8.22 to 13.9)	147 (119 to 193)	-0.00665 (-11.5 to 18.4)	5.79 (3.94 to 7.13)	12 (7.52 to 14.6)	17.8 (10.8 to 23.6)	124 (70.1 to 176)	2.59 (-22 to 26.5)
Osteoarthritis										
Osteoarthritis hip										
Osteoarthritis knee										
Osteoarthritis hand										
Osteoarthritis other										
Low back pain										
Neck pain										
Gout										
Other musculoskeletal disorders	3.65 (3.15 tn 4.21)	11.4 (9 to 12.9)	37.1 (25.1 to 44.5)	175 (147 to 213)	11 (-0.0193 to 26.5)	5.07 (3.51 to 6.41)	15.8 (9.67 to 19.1)	59.3 (30.6 to 75.9)	197 (152 to 247)	36.1 (15.6 to 58.9)
Other non-communicable diseases	36.6	120	494	178	12.5	30.9	105	456	203	38.7
Congenital birth defects	(50.3 (0 55.5)	(55.6 (0 132)	(358 10 303)	(149 to 203)	(0.8 (0 22.5)	(20.8 (0 55.4)	(82.6 (0 117)	(512 (0 525)	(14510227)	(14 (0 50.1)
Neural tube defects										
Congenital heart anomalies										
Orofacial clefts										
Down syndrome										
Turner syndrome										
Via setter available										
kinetete syndrome										
Congenital musculoskeletal and										
limb anomalies										
Urogenital congenital anomalies										
Digestive congenital anomalies										
Other congenital birth defects										
Urinary diseases and male infertility	23.5 (18.8 to 25.8)	85.7 (67.1 to 94.4)	356 (240 to 409)	172 (138 to 202)	10.1 (-3.59 to 22.1)	18.1 (15.1 to 19.8)	68.5 (52.4 to 76.3)	317 (216 to 365)	225 (158 to 254)	49.2 (18.1 to 62.2)
Supplementary Table 4. Cause-specif	fic mortality rate for 70-7	79 years, 80-94 years, and 95	5+ years in 2019, and per	centage change from 19	90 to 2019 in death numbe	er and rate in 70+ years, g	lobal, for all GBD causes			
--	---------------------------------	--	---	------------------------	----------------------------	---------------------------------	----------------------------------	--	-------------------------	---------------------------
			Males					Females	i.	
		Deaths per 100,000, 2019		Percentage chang	te in 70+, 1990-2019		Deaths per 100,000, 2019		Percentage chan	ge in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Urinary tract infections and interstitial nephritis	16.7 (12.9 to 18.9)	65.4 (47.9 to 73)	302 (204 to 350)	196 (145 to 229)	19.8 (-0.834 to 33)	15.6 (13.2 to 17.4)	61.7 (47.3 to 68.8)	291 (199 to 335)	239 (164 to 269)	55.3 (21.2 to 69.2)
Urolithiasis	1.31 (0.848 to 1.83)	3.25 (2.18 to 4.44)	7.42 (4.97 tp 11.3)	40.1 (2.65 to 105)	-43.3 (-58.5 to -17.2)	0.92 (0.726 tp 1.16)	2.29 (1.69 to 3.27)	8.65 (5.58 to 15.7)	64.2 (33.6 to 133)	-24.7 (-38.7 to 6.97)
Benign prostatic hyperplasia						(
Maleinfertility										
Other urinary diseases	5.41	17.1	47	150	1.04	1.57	4.55	16.8	237	54.3
Gynecological diseases	(3.84 to 7.31)	(12.9 to 22.4)	(30.9 to 60.9)	(118 to 186)	(-11.9 to 15.8)	(0.705 to 2.13) 0.773	(2.08 to 6.22) 1.7	(6.45 to 25.9) 2.59	(107 to 318) 98.3	(-5.29 to 91.6) -9.07
Uterine fibroidr						(0.364 to 1.05) 0.43	(0.884 to 2.3)	(1.71 to 3.56) 0.675	(22 to 200) 105	(-44.1 to 37.5) -5.95
Palvestia sealar sedare						(0.187 to 0.638)	(0.342 to 1.12)	(0.4 to 1.07)	(3.34 to 261)	(-52.6 to 65.6)
Polycystic ovarian synoronie										
Female intertility										
Endometriosis										
Genital prolapse						0.193 (0.0808 to 0.308)	0.406 (0.199 to 0.608)	0.575 (0.337 to 0.869)	70.3 (10.5 to 162)	-21.9 (-49.3 to 20.2)
Premenstrual syndrome										
Other gynecological diseases						0.149 (0.0773 to 0.18)	0.551 (0.31 to 0.679)	1.34 (0.866 to 1.72)	118 (61.3 to 196)	-0.256 (-26.1 to 35.7)
Hemoglobinopathies and hemolytic anemias	3.03 (2.58 to 4.06)	7.11 (6.11 to 8.95)	17.4 (13.5 to 20.3)	64.2 (42 to 81)	-33.6 (-42.6 to -26.8)	2.74 (2.38 to 3.46)	6.48 (5.18 to 7.99)	16.7 (11.6 to 21.4)	70.1 (48 to 102)	-22 (-32.1 to -7.22)
Thalassemias	0.0036 (0.00177 to 0.00641)	0.000218 (0.0000751 to 0.000512) (0	0.00000231 0.00000366 to 0.00000713)	619 (392 to 899)	191 (98.7 to 304)	0.00479 (0.00246 to 0.00823)	0.000264 (0.0001 to 0.000603)	0.00000489 (0.000000995 to 0.0000148)	442 (309 to 683)	149 (87.4 to 259)
Thalassemias trait										
Sickle cell disorders	0.00458 (0.00278 to 0.00733)	0.000479 (0.000198 to 0.000917)	0.0000595	473 (340 to 686)	132 (78 to 218)	0.0125	0.00164	0.000164 (0.0000525 to 0.000386)	384 (284 to 569)	122 (76.1 to 207)
Sickle cell trait	()	(,	(((((()	()	(,
G6PD deficiency	0.586	0.365	0.146	244	39	0.223	0.139	0.0468	292	79.9
G6PD trait	(0.339 to 0.986)	(0.197 to 0.639)	(0.06 to 0.261)	(184 to 306)	(14.7 to 64.1)	(0.126 to 0.357)	(0.0767 to 0.227)	(0.018 to 0.0854)	(239 to 383)	(55.4 to 121)
Other hemoglobinopathies and	2.44	6.75	17.2	52.9	-38.2	2.5	6.34	16.7	65.2	-24.3
hemolytic anemias Endocrine, metabolic, blood, and	(2.07 to 3.17)	(5.8 to 8.33)	(13.4 to 20.1)	(32.2 to 69.7)	(-46.6 to -31.4)	(2.16 to 3.14)	(5.06 to 7.81)	(11.6 to 21.3)	(43.5 to 96.5)	(-34.2 to -9.92)
immune disorders	(7.33 to 11.8)	(18.5 to 31.6)	(61.2 to 147)	(225 to 307)	(31.6 to 64.4)	(7.34 to 10.3)	(20.3 to 32.4)	(70 to 141)	(171 to 254)	(24.2 to 62.3)
Oral disorders										
Caries of deciduous teeth										
Caries of permanent teeth										
Periodontal diseases										
Edentulism										
Other oral disorders										
Sudden infant death syndrome										
Injuries	175 (153 to 191)	400 (344 to 437)	1020 (810 to 1160)	114 (97 to 131)	-13.5 (-20.4 to -6.59)	107 (93.2 to 119)	299 (241 to 336)	881 (653 to 1010)	103 (78.5 to 125)	-7.02 (-18.2 to 3.11)
Transport injuries	44.7 (36.3 to 49.3)	61.1 (51.9 to 67)	73.2 (58 to 85.4)	90.9 (66.3 to 110)	-22.8 (-32.8 to -15.3)	19.7 (17.9 to 21.6)	25.9 (21.7 to 28.6)	31.7 (24.1 to 36.2)	69 (56.5 to 83.8)	-22.5 (-28.3 to -15.7)
Road injuries	41.9	57.4 (48.9 to 62.9)	67.4 (53.2 to 78.1)	90 (65 5 to 109)	-23.2	18.8	24.5 (20.5 to 27.1)	29.7 (22.6 to 22.8)	68.7 (56.4 to 84)	-22.6
Pedestrian road injuries	22	32.3	34.8 (27.6 to 40.9)	77	-28.4	11 (9.92 to 12.2)	15.3 (12.7 to 17)	15.8 (12 to 18 2)	52.3 (28 8 to 66 9)	-30.2
Cyclist road injuries	3.73	3.83	0.112	148	0.105	0.956	0.741	0.0197	155	17
Motorcyclist road injuries	(2.9 to 4.41) 3.46	(3.04 to 4.53) 3.9	(0.0852 to 0.136) 3.87	(75.8 to 244) 185	(-28.9 to 39) 15.4	(0.833 to 1.1) 0.967	(0.607 to 0.852) 0.83	(0.0144 to 0.0235) 1.14	(116 to 209) 201	(-0.91 to 41.5) 38.1
Motor vehicle road injuries	(2.44 to 4.06) 12.2	(2.75 to 4.79) 16.4	(2.81 to 4.74) 27.2	(99.6 to 296) 85.5	(-19.3 to 60.1) -25	(0.677 to 1.13) 5.78	(0.599 to 0.976) 7.44	(0.815 to 1.37) 12.4	(141 to 289) 86.6	(10.7 to 78.5) -14.5
Other road injurier	(10.3 to 14.2) 0.592	(13.7 to 19.5) 0.885	(21.3 to 33.1) 1.3	(49.9 to 115) 121	(-39.4 to -12.9) -10.8	(5.14 to 6.51) 0.127	(6.15 to 8.39) 0.23	(9.16 to 14.5) 0.393	(60.4 to 112) 116	(-26.5 to -2.64) -1.03
Other teresent initials	(0.481 to 0.698)	(0.71 to 1.07)	(0.958 to 1.61)	(62.4 to 217)	(-34.4 to 28.2)	(0.106 to 0.153)	(0.187 to 0.289)	(0.288 to 0.517)	(78.6 to 181) 74.5	(-18.1 to 28.9)
one cansportinjunes	(2.22 to 3.19)	(3.12 to 4.23)	(4.6 to 7.18)	(76.8 to 137)	(-28.5 to -4.12)	(0.774 to 0.986)	(1.16 to 1.57)	(1.54 to 2.4)	(46.8 to 98.9)	(-32.7 to -8.82)
Unintentional injuries	92.7 (78.1 to 103)	(237 to 310)	875 (696 to 1010)	(118 to 162)	-2.59 (-11.7 to 6.11)	/0.4 (57.6 to 79.6)	(198 to 283)	(615 to 955)	(101 to 158)	(-7.94 to 18.3)
Falls	53.2 (42.2 to 60.4)	195 (159 to 220)	662 (526 to 779)	189 (153 to 226)	16.8 (2.31 to 31.6)	43.6 (33 to 50)	188 (145 to 214)	652 (477 to 753)	150 (116 to 187)	14.5 (-0.773 to 31.8)
Drowning	7.28 (6.04 to 8.12)	13.7 (11.3 to 15.3)	15.3 (11.7 to 17.6)	122 (76.9 to 157)	-10.3 (-28.5 to 3.71)	4.74 (4.12 to 5.34)	9.26 (7.38 to 10.7)	9.38 (6.74 to 11)	109 (72.6 to 153)	-4.02 (-20.9 to 15.9)
Fire, heat, and hot substances	4.25 (3.45 to 4.97)	11 (8.86 to 13.1)	24.7 (19 to 30)	57.6 (43.1 to 84.7)	-36.3 (-42.1 to -25.3)	3.66 (2.88 to 4.55)	9.67 (7.68 to 12)	22 (16.1 to 27.1)	61.6 (38.7 to 103)	-25.9 (-36.4 to -6.73)
Poisonings	3.07 (2.05 to 3.57)	4.86 (3.48 to 5.56)	3.52 (2.78 to 4.02)	105 (40.2 to 146)	-17.3 (-43.3 to -0.374)	1.96 (1.65 to 2.27)	3.28 (2.7 to 3.74)	2.92 (2.22 to 3.38)	106 (71.6 to 137)	-5.73 (-21.3 to 8.86)
Poisoning by carbon monoxide	1.79 (1.14 to 2.15)	2.98 (1.98 to 3.51)	2 (1.53 to 2.31)	112 (43 to 162)	-14.2 (-42.2 to 6.02)	1.15 (0.867 to 1.38)	2.07 (1.58 to 2.43)	1.76 (1.28 to 2.09)	93.3 (49.5 to 129)	-11.4 (-31.5 to 4.97)
Poisoning by other means	1.29 (0.733 to 1.77)	1.89 (1.16 to 2.65)	1.52 (1.18 to 1.83)	94.5 (19.1 to 154)	-21.4 (-51.8 to 2.71)	0.813 (0.549 to 1.08)	1.21 (0.876 to 1.58)	1.16 (0.85 to 1.45)	128 (62.2 to 191)	4.62 (-25.7 to 33.6)
Exposure to mechanical forces	3.74 (2.86 to 4.27)	5.79 (4.6 to 6.5)	11.9 (9.27 to 14.8)	81 (34.7 to 117)	-26.8 (-45.6 to -12.1)	1.78 (1.3 to 2.04)	4.01 (3.1 to 4.55)	9.29 (6.83 to 10.9)	127 (70.8 to 164)	3.84 (-21.7 to 21.1)
Unintentional firearm injuries	0.43	0.698 (0.457 to 0.891)	1.65 (1.11 to 2.44)	12 (-16.1 to 62.2)	-54.7 (-66.1 to -24.4)	0.229 (0.175 to 0.297)	0.525 (0.399 to 0.675)	1.64	41.8 (-1.51 to 99.2)	-35 (-54.8 to -8.64)
Other exposure to mechanical forces	3.31	5.09	10.2	97.1	-20.3	1.55	3.49	7.65	149	14.2
Adverse effects of medical treatment	(a.s w s.d1) 6.85	(4.05 (0 5.76)	37.9	73.8	-29.8	6.01	13.5	31.3	72.5	-20.9
Animal contact	(5.51 to 7.88) 3.68	(12.6 to 17.3) 5.04	(29 to 43.5) 6.49	(33.9 to 115) 57.9	(+45.9 to -13) -36.2	(4./1 to 6.88) 2.81	(10.5 to 15.5)	(22.6 to 37.1) 2.7	(32.6 to 101) 105	(-59.2 to -7.72) -5.85
Venomous apimal contact	(2.55 to 4.46) 3.01	(3.25 to 6.03) 4.08	(4.6 to 8.14) 4.74	(12.1 to 124) 63.7	(-54.7 to -9.4) -33.8	(1.49 to 3.72) 2.63	(1.63 to 3.42) 2.34	(1.93 to 3.59) 2.04	(38.9 to 215) 110	(-36.3 to 44.6) -3.94
Non-warranter spin-1	(1.97 to 3.71)	(2.45 to 5)	(3.19 to 6.02)	(13.7 to 139)	(-54 to -3.24) -44.7	(1.33 to 3.5) 0.178	(1.35 to 3)	(1.43 to 2.78)	(37.1 to 229) 70.1	(-37.1 to 50.9)
non-venomods animai contact	(0.541 to 0.902)	(0.771 to 1.22)	(1.33 to 2.15)	(-0.148 to 80.1)	(-59.6 to -27.2)	(0.136 to 0.244)	(0.265 to 0.449)	(0.478 to 0.848)	(34.3 to 130)	(-38.4 to 5.41)
Pulmopary aspiration and forci-	(4.99 to 5.69)	(17.3 to 21.6)	(71.5 to 104)	(168 to 203)	(8.39 to 22.5)	(3.01 to 3.49)	(11.2 to 15.6)	(61.4 to 99.4)	(158 to 203)	(18.1 to 38.8)
body in airway	5.17 (4.78 to 5.47)	19.5 (16.9 to 21)	91.3 (70.5 to 103)	196 (176 to 211)	19.6 (11.7 to 25.7)	3.14 (2.9 to 3.35)	13.7 (10.9 to 15.2)	84.8 (60.6 to 98.2)	192 (164 to 211)	33.7 (21.1 to 42.5)
Foreign body in eyes										
Foreign body in other body part	0.21 (0.152 to 0.275)	0.504 (0.376 to 0.677)	1.12 (0.789 to 1.55)	47 (14.9 to 96.6)	-40.6 (-53.6 to -20.5)	0.126 (0.0966 to 0.167)	0.326 (0.244 to 0.442)	1.08 (0.742 to 1.67)	45.6 (22.6 to 85.3)	-33.2 (-43.8 to -15)
Environmental heat and cold exposure	2.88 (1.59 to 3.54)	5.91 (3.47 to 6.99)	11.2 (8.37 to 12.8)	42.9 (18 to 66.5)	-42.2 (-52.3 to -32.7)	1.61 (0.724 to 2.26)	4.39 (2.37 to 5.75)	10 (6.79 to 12.3)	51 (4.27 to 87.2)	-30.8 (-52.2 to -14.2)
Exposure to forces of nature	0.116	0.15	0.156	-80.7	-92.2	0.0968	0.119	0.107	-74.8	-88.4

Supplementary Table 4. Cause-speci	fic mortality rate for 70-7	9 years, 80-94 years, and 9	5+ years in 2019, and per	centage change from 199	0 to 2019 in death numbe	r and rate in 70+ years, g	obal, for all GBD causes			
			Males					Females		
			warea.					Tennes		
		Deaths per 100,000, 2019		Percentage change	e in 70+, 1990-2019		Deaths per 100,000, 2019		Percentage change	in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Other unintentional injuries	2.29	3.73	9.07	49.2	-39.7	0.903	2.12	5.09	45.6	-33.2
	(1.61 to 2.56)	(2.67 to 4.18)	(6.74 to 10.8)	(13 to 74.8)	(-54.3 to -29.3)	(0.808 to 1.01)	(1.75 to 2.4)	(3.79 to 5.87)	(27.2 to 68.7)	(-41.7 to -22.7)
Self-harm and interpersonal violence	37.6	57.6	70.4	71	-30.9	17.3	22.6	18.9	24.3	-43
	(32.5 to 41.7)	(49 to 64.2)	(56.2 to 79.7)	(57.8 to 95.6)	(-36.2 to -20.9)	(15.6 to 19.1)	(18.9 to 25.5)	(14.4 to 21.6)	(11 to 37.6)	(-49.1 to -36.9)
Self-harm	30.3	51	52.6	67.6	-32.2	13.4	19.2	16.1	14.4	-47.5
	(25.3 to 34)	(42.8 to 57.3)	(41.4 to 61.3)	(52.9 to 93.8)	(-38.2 to -21.6)	(11.9 to 15.1)	(15.7 to 21.9)	(12 to 18.6)	(0.0522 to 29.2)	(-54.1 to -40.8)
Self-harm by firearm	3.16	5.54	8.5	36.2	-44.9	0.239	0.264	0.521	37.3	-37.1
	(2.71 to 3.48)	(4.69 to 6.35)	(6.73 to 11)	(14.5 to 47.9)	(-53.7 to -40.2)	(0.218 to 0.262)	(0.219 to 0.298)	(0.381 to 0.616)	(26.3 to 46.5)	(-42.1 to -32.8)
Self-harm by other specified means	27.2	45.4	44.1	72.3	-30.3	13.1	18.9	15.6	14.1	-47.7
	(21.9 to 30.9)	(37.6 to 51.4)	(34 to 51.3)	(55.5 to 104)	(-37.1 to -17.6)	(11.6 to 14.9)	(15.5 to 21.6)	(11.6 to 18.1)	(-0.353 to 29)	(-54.3 to -40.8)
Interpersonal violence	5.55	2.95	11.7	60.3	-35.2	2.46	1.46	1.55	34.7	-38.2
	(5.17 to 6.06)	(2.59 to 3.26)	(8.86 to 13.7)	(45.3 to 86.9)	(-41.3 to -24.4)	(2.27 to 2.65)	(1.23 to 1.59)	(1.17 to 1.78)	(25.9 to 45.1)	(-42.3 to -33.5)
Physical violence by firearm	1.4	0.793	4.32	85.4	-25.1	0.355	0.193	0.298	55.6	-28.7
	(1.28 to 1.53)	(0.676 to 0.89)	(3.14 to 5.27)	(64.4 to 111)	(-33.5 to -14.8)	(0.329 to 0.382)	(0.16 to 0.213)	(0.217 to 0.359)	(42.2 to 70)	(-34.8 to -22.1)
Physical violence by sharp object	1.29	0.835	3.34	56.7	-36.7	0.625	0.436	0.411	38.8	-36.4
	(1.08 to 1.48)	(0.714 to 0.965)	(2.52 to 3.93)	(36.1 to 86.7)	(+45 to -24.5)	(0.577 to 0.672)	(0.373 to 0.479)	(0.312 to 0.483)	(24.1 to 51.5)	(-43.1 to -30.5)
Sexual violence										
Physical violence by other means	2.86	1.33	4.03	51.4	-38.8	1.48	0.828	0.841	28.9	-40.9
	(2.6 to 3.19)	(1.15 to 1.51)	(3.09 to 4.66)	(34.1 to 80.1)	(-45.8 to -27.2)	(1.35 to 1.61)	(0.706 to 0.904)	(0.636 to 0.952)	(19.3 to 38.9)	(-45.3 to -36.3)
Conflict and terrorism	1.61	3.51	5.62	225	31.2	1.39	1.9	1.15	344	104
	(1.46 to 1.77)	(3.19 to 3.87)	(5.1 to 6.18)	(220 to 226)	(29.2 to 32)	(1.26 to 1.53)	(1.73 to 2.09)	(1.04 to 1.27)	(339 to 346)	(101 to 104)
Executions and police conflict	0.0776	0.117	0.524	217	27.9	0.045	0.0572	0.0587	347	105
	(0.0612 to 0.0969)	(0.0986 to 0.139)	(0.356 to 0.828)	(147 to 408)	(-0.136 to 105)	(0.0398 to 0.0547)	(0.0513 to 0.0655)	(0.0413 to 0.0937)	(239 to 446)	(55.4 to 150)
Total cancers	1080	2010	3210	133	-5.88	621	1120	2130	110	-3.89
	(1000 to 1170)	(1800 to 2160)	(2500 to 3580)	(116 to 150)	(-12.7 to 1.14)	(569 to 666)	(925 to 1230)	(1540 to 2420)	(94.1 to 124)	(-11 to 2.5)
Total burden related to hepatitis B	42.4	54.9	65.6	50.3	-39.2	16.5	22.9	29.2	24.6	-42.9
	(34.4 to 51.1)	(44.2 to 66.3)	(41.1 to 96.9)	(32.1 to 73.1)	(-46.6 to -30)	(12.6 to 20.5)	(17.1 to 28.8)	(17.2 to 44.3)	(8.1 to 44.3)	(-50.4 to -33.9)
Total burden related to hepatitis C	44	76.3	137	122	-10.1	27.5	50	96.5	86.7	-14.4
	(36.9 to 52.1)	(63.2 to 90.1)	(93.9 to 180)	(103 to 147)	(-18.1 to -0.227)	(22.8 to 32.8)	(39.1 to 58.9)	(64.3 to 127)	(64.8 to 108)	(-24.4 to -4.82)
Total burden related to Non-alcoholic	13.1	22.9	42.4	139	-3.3	12.1	21.5	36.1	112	-2.93
fatty liver disease (NAFLD)	(9.11 to 18.1)	(15.8 to 31.6)	(20.7 to 73.3)	(114 to 168)	(-13.3 to 8.2)	(8.49 to 16.5)	(14.7 to 29.3)	(18.4 to 58.4)	(86.5 to 136)	(-14.5 to 8.19)

Supplementary Table 5. Cause-speci	fic rate of YLDs for 70-79) years, 80-94 years, and 95	▶ years in 2019, and percer	tage change from 1990	to 2019 in YLD number ar	nd rate in 70+ years, globa	I, for all GBD causes			
			Males					Females		
		VI Dr. por 100 000, 2010		Porcontago change	in 70+ 1990 2010		VI Dr. ppr 100 000 - 2019		Porcontago chapag	a in 70+ 1000 2010
	70. 70	100,000, 2019	or 1	reitentage change		70. 70	100,000, 2019		Percentage change	n 707, 1990-2019
All causes	25000	31000	37900	147	-0.0825	26600	33100	41100	121	1.54
Communicable, maternal, neonatal, and	(18900 to 31800)	(23400 to 39100)	(29200 to 46900)	(145 to 149)	(-0.876 to 0.694)	(20200 to 33500)	(25200 to 41500)	(31800 to 50500)	(120 to 123)	(0.84 to 2.32)
	1150	1110	988	77.3	-28.3	1150	991	776	88.2	-13.7
HIV/AIDS and sexually transmitted	(845 to 1510)	(810 to 1440)	(720 to 1280)	(70.8 to 84)	(-30.9 to -25.6)	(856 to 1500)	(733 to 1280)	(565 to 1010)	(82 to 94.9)	(-16.6 to -10.6)
	29.4	13.8	11.7	411	107	28.1	12.9	9.2	292	79.8
HIV/AIDS	(20.2 to 41.1)	(9.15 to 20.2)	(7.9 to 16.6)	(316 to 529)	(68.1 to 154)	(18.8 to 41.2)	(7.71 to 21.7)	(5.61 to 15.3)	(210 to 415)	(42 to 136)
	24.8	9.56	7.23	614	189	18.4	5.64	3.87	767	297
HIV/AIDS - Drug-susceptible	(16.8 to 35)	(6.11 to 14.4)	(4.83 to 10.2)	(442 to 803)	(119 to 265)	(12.8 to 25.4)	(3.71 to 7.99)	(2.65 to 5.42)	(563 to 991)	(204 to 400)
	3.36	1.46	0.703	194	18.9	3.01	0.951	0.547	312	88.9
Tuberculosis HIV/AIDS - Multidrug-resistant	(2.3 to 4.52)	(1 to 1.95)	(0.489 to 0.932)	(170 to 223)	(9.12 to 30.6)	(2.08 to 4)	(0.655 to 1.26)	(0.382 to 0.722)	(279 to 350)	(73.7 to 106)
drug resistance	(0.086 to 0.276)	(0.0334 to 0.14)	(0.0176 to 0.0511)	(496 to 4610)	(141 to 1800)	(0.0726 to 0.198)	(0.0255 to 0.0776)	(0.015 to 0.0455)	(1410 to 7330)	(592 to 3310)
resistant Tuberculosis	(0.00263 to 0.0145)	(0.00106 to 0.00927)	(0.000514 to 0.00168)	(0 to 0)	(0 to 0)	(0.00158 to 0.00617)	(0.00105 (0.000473 to 0.00234)	(0.000632 (0.000311 to 0.00129)	(0 to 0)	(0 to 0)
diseases	21.3	8.03	6.5	822	273	15.3	4.64	3.3	1000	404
	(14 to 30.8)	(4.89 to 12.6)	(4.21 to 9.37)	(544 to 1150)	(160 to 406)	(10.3 to 21.6)	(2.98 to 6.9)	(2.19 to 4.78)	(674 to 1420)	(255 to 597)
excluding HIV	4.62	4.22	4.46	123	-9.65	9.64	7.3	5.33	110	-3.65
	(2.24 to 9.71)	(2.19 to 8.43)	(2.6 to 8.05)	(107 to 133)	(-16.1 to -5.74)	(3.8 to 21.1)	(2.97 to 15.3)	(2.44 to 11.4)	(103 to 114)	(-6.82 to -1.82)
Syphilis	1.16 (0.786 to 1.63)	1.34 (0.91 to 1.87) 0.00000000000000259	2.03 (1.3 to 2.93) 0.00000000000000000000000000000000000	91.1 (76.5 to 106)	-22.7 (-28.6 to -16.7)	0.391 (0.253 to 0.55)	0.51 (0.333 to 0.721) 0.0000000373	0.907 (0.57 to 1.3) 0.00000000000317	58.6 (46.1 to 72.3)	-27.3 (-33 to -21)
Chlamydial infection	0.000278 (0.00013 to 0.000519)	(0.000000000000000055 to 0.000000000000000762)	000000000378 (0.00000000000000000000000000000000000	145 (141 to 150)	-0.906 (-2.71 to 1.09)	0.0000784 (0.0000253 to 0.000188)	(0.000000012 to 0.0000000938) 0.0000000101	(0.00000000000000000000000000000000000	115 (111 to 119)	-1.47 (-3.34 to 0.47)
Gonococcal infection	0.000643 (0.000186 to 0.0017)	(0.00000000000000305 to 0.00000000399)	(0.00000000000000000000000000000000000	106 (82.8 to 130)	-16.8 (-26.1 to -6.95)	0.000046 (0.00000812 to 0.000144)	(0.0000000000765 to 0.0000000773)	(0.00000000000000000000000000000000000	102 (74.3 to 131)	-7.43 (-20.1 to 6)
Trichomoniasis	0.113	0.0659	0.0133	141	-2.67	4.02	2.43	0.764	115	-1.28
	(0.0446 to 0.26)	(0.0261 to 0.149)	(0.005 to 0.0305)	(124 to 158)	(-9.54 to 4.36)	(1.51 to 9.15)	(0.951 to 5.42)	(0.249 to 1.85)	(110 to 121)	(-3.89 to 1.53)
Genital herpes	3.34	2.81	2.42	138	-3.62	5.23	4.36	3.65	113	-2.46
	(1.01 to 8.36)	(0.838 to 7)	(0.739 to 5.87)	(134 to 143)	(-5.37 to -1.81)	(1.58 to 12.8)	(1.3 to 10.8)	(1.11 to 8.9)	(109 to 117)	(-4.29 to -0.691)
Other sexually transmitted infections	0.000384 (0.000158 to 0.00086)	0.000000000371 (0.00000000000000232 to 0.0000000156)	0.000000000000000000000000000000000000	105 (87.6 to 122)	-17.3 (-24.1 to -10.2)	0.0000519 (0.000016 to 0.000129)	0.0000000186 (0.00000000495 to 0.0000000623)	0.000000000000314 (0.00000000000000488 to 0.00000000000101)	98.3 (87.7 to 109)	-9.11 (-13.9 to -4.29)
Respiratory infections and	238	221	200	68.9	-31.7	167	153	132	64.2	-24.7
tuberculosis	(162 to 326)	(158 to 297)	(143 tp 277)	(56.9 to 83.2)	(-36.6 to -25.9)	(115 to 231)	(109 to 206)	(93.6 to 183)	(53.4 to 76.5)	(-29.7 to -19.1)
Tuberculosis	146	118	62.8	42.5	-42.4	87.7	69.7	30.9	37.4	-37
	(90 to 216)	(77.1 to 169)	(38.6 to 97.2)	(33 to 52 5)	(-46.2 to -38.3)	(53.7 to 132)	(45 to 100)	(18.8 to 46.8)	(28.3 to 46.9)	(-41 2 to -32 7)
Latent tuberculosis infection	(********	((0	0	()	((1010-10-1010)	0	0
Drug-susceptible tuberculosis	139	113	60.3	37.1	-44.6	83.5	66.5	29.6	31.8	-39.6
Multidrug-resistant tuberculosis	(84.9 to 205)	(73.8 to 162)	(36.8 to 92.7)	(26.5 to 47.4)	(-48.9 to -40.4)	(51.1 to 124)	(43.8 to 95.4)	(18.1 to 45)	(21.9 to 42)	(-44.1 to -34.9)
	6.54	5.18	2.41	573	172	4.03	3.11	1.2	690	262
Extensively drug-resistant	(2.52 to 13.7)	(2.23 to 10.3)	(1.07 to 4.66)	(115 to 2200)	(-13.1 to 828)	(1.54 to 8.32)	(1.34 to 6.28)	(0.589 to 2.2)	(168 to 2250)	(22.9 to 978)
	0.393	0.299	0.132	0	0	0.223	0.171	0.0749	0	0
tuberculosis	(0.155 to 0.886)	(0.127 to 0.631)	(0.0657 to 0.236)	(0 to 0)	(0 to 0)	(0.0991 to 0.447)	(0.0828 to 0.317)	(0.0373 to 0.135)	(0 to 0)	(0 to 0)
	25.8	43.2	73.3	123	-9.68	19	31.2	48.9	92.7	-11.7
	(17.3 to 35.9)	(29.5 to 60.3)	(50.3 to 105)	(118 to 129)	(-12 to -7.6)	(12.8 to 26.5)	(21.5 to 43.5) 41.5	(33.6 to 69.1)	(87.8 to 97.9)	(-13.9 to -9.26)
opper respiratory mections	(29.7 to 87.1)	(25.8 to 76)	(26.6 to 84.4)	(138 to 147)	(-3.95 to -0.034)	(28.1 to 82.8)	(23.5 to 69.9)	(22.5 to 71.9)	(109 to 118)	(-4.21 to -0.182)
Otitis media	(6.44 to 23.7)	(6.63 to 23.7)	(7.06 to 26.2)	(94.2 to 131)	(-21.5 to -6.51)	(5.24 to 19.6)	(5.1 to 18.6)	(5.16 to 20.4)	(77.4 to 108)	(-18.7 to -4.48)
Enteric infections	253	308	309	172	9.9	235	273	266	180	28.5
	(178 to 341)	(220 to 409)	(217 to 410)	(166 to 179)	(7.49 to 12.7)	(166 to 316)	(196 to 361)	(189 to 352)	(174 to 187)	(25.5 to 31.4)
Diarrheal diseases	253	308	308	173	10.2	235	273	265	181	28.8
	(178 to 341)	(220 to 409)	(217 to 410)	(167 to 180)	(7.8 to 13)	(166 to 316)	(196 to 361)	(189 to 352)	(174 to 187)	(25.8 to 31.6)
Typhoid and paratyphoid	0.357	0.338	0.372	-10.3	-63.7	0.292	0.243	0.156	5.18	-51.8
	(0.164 to 0.643)	(0.163 to 0.576)	(0.185 to 0.717)	(-25.9 to 6.74)	(-70 to -56.8)	(0.138 to 0.524)	(0.118 to 0.426)	(0.0742 to 0.321)	(-11 to 23.8)	(-59.2 to -43.3)
Typhoid fever	0.311	0.299	0.337	-13.2	-64.9	0.255	0.215	0.14	3.71	-52.5
	(0.143 to 0.559)	(0.141 to 0.505)	(0.165 to 0.66)	(-29.5 to 5.29)	(-71.5 to -57.4)	(0.12 to 0.466)	(0.103 to 0.374)	(0.0654 to 0.288)	(-14.3 to 24.1)	(-60.7 to -43.1)
Paratyphoid fever	0.046	0.0389	0.0346	17.3	-52.6	0.0373	0.0281	0.016	16.9	-46.4
	(0.0188 to 0.0913)	(0.0176 to 0.0699)	(0.0139 to 0.0759)	(-3.04 to 41.5)	(-60.8 to -42.8)	(0.0152 to 0.0741)	(0.0125 to 0.051)	(0.00639 to 0.0352)	(-2.56 to 40.3)	(-55.3 to -35.7)
Invasive Non-typhoidal Salmonella	0.00385	0.00392	0.00501	72.1	-30.4	0.003	0.00275	0.00283	67.6	-23.2
(INTS)	(0.00221 to 0.00654)	(0.00229 to 0.00643)	(0.0025 to 0.00843)	(53.7 to 89.4)	(-37.9 to -23.5)	(0.00169 to 0.00508)	(0.00157 to 0.00458)	(0.00138 to 0.00484)	(50.1 to 85.8)	(-31.2 to -14.8)
Other intestinal infectious diseases	0.0406	0.0655	0.147	266	47.8	0.0376	0.0602	0.127	276	72.2
	(0.0287 to 0.0548)	(0.0469 to 0.0871)	(0.103 to 0.195)	(258 to 275)	(44.6 to 51.4)	(0.0265 to 0.0504)	(0.0433 to 0.0797)	(0.0902 to 0.168)	(267 to 284)	(68.1 to 75.8)
Neglected tropical diseases and	195	182	168	4.38	-57.8	168	153	120	29.4	-40.7
malaria	(139 to 268)	(126 to 254)	(99.2 to 262)	(-6.73 to 18.4)	(-62.3 to -52.1)	(118 to 226)	(101 to 215)	(68 to 188)	(16.1 to 44.8)	(-46.8 to -33.6)
Malaria	2.95	2.6	2.01	-2.09	-60.4	4.21	3	1.96	9.67	-49.7
	(2.02 to 4.2)	(1.75 to 3.76)	(1.37 to 2.87)	(-20.8 to 17.1)	(-68 to -52.7)	(2.96 to 5.84)	(2.06 to 4.21)	(1.31 to 2.75)	(-7.3 to 28.4)	(-57.5 to -41.2)
Chagas disease	3.07	4.33	9.84	61.8	-34.6	2.05	2.65	3.93	59	-27.1
	(1.99 to 4.41)	(2.49 to 6.65)	(2.01 to 24.6)	(52.7 to 71.6)	(-38.3 to -30.6)	(1.33 to 2.94)	(1.67 to 3.91)	(0.864 to 9.31)	(48.3 to 70.6)	(-32 to -21.8)
Leishmaniasis	2.98	2.92	2.93	55.1	-37.3	4.35	3.06	2.19	75.7	-19.5
	(1.81 to 4.73)	(1.79 to 4.54)	(1.86 to 4.36)	(33.4 to 94.6)	(-46.1 to -21.3)	(2.7 to 6.66)	(1.92 to 4.66)	(1.36 to 3.35)	(55 to 123)	(-28.9 to 2.31)
Visceral leishmaniasis	0.00227	0.00222	0.00336	-84.8	-93.9	0.0011	0.000926	0.00113	-82.6	-92
Cutaneous and mucocutaneous leishmaniasis	2.98	2.91	2.93	56.2	-36.9	4.35	3.06	2.19	76.1	-19.3
African trypanosomiasis	0.00591	0.00478	0.00323	(33.8 t0 97.3) -92.6	(+45.9 t0 -20.2) -97	0.00521	0.0042	0.00276	-92.8	(-28.8 to 2.81) -96.7
Schistosomiasis	(0.000662 to 0.0215)	(0.000479 to 0.0193)	(0.00012 to 0.0164)	(-98.5 to -70)	(-99.4 to -87.9)	(0.000704 to 0.0165)	(0.000474 to 0.0157)	(0.000134 to 0.014)	(-98.4 to -68.4)	(-99.2 to -85.5)
	5.05	3.83	2.99	15.8	-53.2	4.01	2.81	2.2	14.8	-47.4
Cysticercosis	(2.46 to 9.85)	(1.9 to 7.19)	(1.38 to 5.78)	(6.65 to 25.4)	(-56.9 to -49.3)	(2.01 to 7.66)	(1.42 to 5.2)	(1.01 to 4.24)	(5.45 to 24.9)	(-51.7 to -42.8)
	75	83	92.7	104	-17.7	79.3	83.6	76.5	103	-6.88
Outlin arbitransaria	(39.8 to 119)	(42.9 to 135)	(36.6 to 172)	(78 to 136)	(-28 to -4.48)	(43.6 to 124)	(44.9 to 132)	(31.2 to 137)	(80.9 to 130)	(-17.1 to 5.52)
	0.518	0.434	0.268	75.7	-29	0.951	0.651	0.408	48.5	-31.9
lumbatic filmine	(0.264 to 0.996)	(0.211 to 0.905)	(0.0981 to 0.81)	(54 to 98.4)	(-37.8 to -19.8)	(0.551 to 1.56)	(0.367 to 1.13)	(0.193 to 0.942)	(37.4 to 60.5)	(-37 to -26.4)
cymphatic mariasis	(17.8 to 48)	(12.4 to 35.2)	(6.91 to 20.3)	(-65 to -36.4)	(-85.8 to -74.3)	(3.53 to 7.11)	(2.48 to 4.85)	(1.14 to 2.23)	(-64.7 to -51.2)	(-83.8 to -77.6)
Onchocerciasis	(9.64 to 20.2)	(4.8 to 10.4)	(3.06 to 6.81)	(-15.3 to -7.12)	(-65.8 to -62.5)	(8.79 to 18.7)	(4.19 to 8.96)	(4.33 to 9.46)	(-21.9 to -12.4)	(-64.2 to -59.9)
Trachoma	(9.32 to 25.3)	18.6 (10.9 to 29.9)	(6.24 to 22.1)	-38.8 (-43.5 to -33.4)	(-77.1 to -73.1)	(8.39 to 23.5)	14.4 (8.3 to 23.6)	8.53 (4.07 to 15.2)	-21.9 (-28.1 to -15.4)	-64.2 (-67.1 to -61.2)
Dengue	(2.48 to 10)	5.48 (2.73 to 10.8)	(6.19 to 41.7)	(108 to 445)	42.5 (-15.9 to 120)	(2.63 to 10.9)	(2.47 to 9.8)	9.15 (2.51 to 20.5)	(123 to 453)	(2.08 to 153)
Yellow fever	0.000453	0.000356	0.000265	-63.3	-85.2	0.000164	0.000113	0.0000778	-66.9	-84.8
	(0.000153 to 0.00109)	(0.000116 to 0.000845)	(0.0000845 to 0.000648)	(-71.9 to -53.6)	(-88.6 to -81.2)	(0.0000547 to 0.00038)	(0.0000388 to 0.000256)	(0.0000246 to 0.000197)	(-74.1 to -57.4)	(-88.1 to -80.5)
Rabies	0.00184	0.00128	0.00165	5.68	-57.3	0.000986	0.000604	0.00112	-11.5	-59.4
	(0.000487 to 0.0036)	(0.000432 to 0.00247)	(0.000634 to 0.00356)	(-43.8 to 59.9)	(-77.3 to -35.4)	(0.000388 to 0.00208)	(0.000208 to 0.00127)	(0.000429 to 0.00217)	(-48.8 to 49.6)	(-76.5 to -31.4)
Intestinal nematode infections	6.11	5.08	3.23	-48.6	-79.2	5.9	3.85	1.21	-48.8	-76.5
	(3.65 to 9.65)	(3.09 to 7.95)	(1.97 to 5.08)	(-54.8 to -41.3)	(-81.7 to -76.3)	(3.59 to 9.28)	(2.36 to 5.96)	(0.745 to 1.86)	(-55.1 to -42)	(-79.4 to -73.4)
Ascariasis	2.51	2.1	1.39	-42	-76.6	2.23	1.42	0.427	-46.4	-75.4
	(1.4 to 4.17)	(1.19 to 3.44)	(0.791 to 2.25)	(-52.9 to -28.1)	(-81 to -70.9)	(1.24 to 3.71)	(0.792 to 2.35)	(0.237 to 0.692)	(-56.9 to -33)	(-80.2 to -69.3)
Trichuriasis	0.491	0.335	0.228	-32.2	-72.6	0.469	0.258	0.0683	-33.3	-69.4
	(0.266 to 0.822)	(0.186 to 0.554)	(0.127 to 0.376)	(-43.7 to -19.3)	(-77.2 to -67.4)	(0.252 to 0.775)	(0.142 to 0.42)	(0.0369 to 0.114)	(-44.7 to -20.8)	(-74.6 to -63.7)
Hookworm disease	3.1	2.64	1.61	-54.4	-81.6	3.2	2.17	0.714	-51.8	-77.9
	(1.9 to 4.79)	(1.66 to 4)	(1.03 to 2.39)	(-62 to -45.8)	(-84.6 to -78.1)	(2.02 to 4.82)	(1.36 to 3.24)	(0.459 to 1.06)	(-59.8 to -43.1)	(-81.6 to -73.9)
Food-borne trematodiases	26.7 (13.3 to 46)	19.9 (9.95 to 33.7)		40.2 (19.3 to 79.5)	-43.3 (-51.8 to -27.4)	19.3 (10.6 to 33)	16.4 (9.09 to 27)		18.7 (-1.56 to 53.5)	-45.6 (-54.9 to -29.6)
Leprosy	1.16	1.07	0.991	17	-52.7	0.603	0.511	0.358	14.1	-47.7
	(0.732 to 1.68)	(0.679 to 1.52)	(0.65 to 1.43)	(4.85 to 30.1)	(-57.6 to -47.4)	(0.375 to 0.877)	(0.33 to 0.734)	(0.232 to 0.517)	(0.523 to 30.5)	(-53.9 to -40.2)
Ebola	0.00253	0.0000173	0.000213	0	0	0.00263	0.0000361	0.000433	0	0
	(0.00011 to 0.00636)	(0.000011 to 0.0000257)	(0.000135 to 0.000315)	(0 to 0)	(0 to 0)	(0.00105 to 0.00463)	(0.000023 to 0.0000535)	(0.000276 to 0.000641)	(0 to 0)	(0 to 0)
Zika virus	0.000923 (0.000507 to 0.00152)	0.000949 (0.000515 to 0.00168)	0.00144 (0.000669 to 0.00287)	0 (0 to 0)	0 (0 to 0)	0.000574	0.000381	0.00021	0 (0 to 0)	0 (0 at 0)
Guinea worm disease	0.00000965	0.00000715	0.00000409	-100	-100	0.00000713	0.00000481	0.00000313	-100	-100
Other neglected tropical diseases	6.73	(0.00000384 (0.00000119) 6.68	5.85	68.1	-32	9.11	7.28	5.06	70.8	-21.7
Other infectious diseases	28.8	28.5	(3.51 W 8.46) 27.5	(55.7 to 80.6) 79.3	-27.5	(0.46 t0 13) 31.2 (22.1 to 43)	27.1	23.2	76.1	-19.3
1	(20.2 (0 33.9)	(13.3 t0 40)	(10.0 t0 4U)	(o).o (0 91.4)	(*32.2 00 *22.0)	(ZZ-1 TD 43)	(10.0 (0.38.1)	(13.4 10 35.7)	(00.3 (0 84.1)	(-22.0 (0 -15.0)

-			Males					Females		
-		YLDs per 100,000, 2019		Percentage change	in 70+, 1990-2019		YLDs per 100,000, 2019		Percentage chang	te in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Meningitis	4.46 (3.08 to 6.02)	5.15 (3.31 to 6.95)	6.12 (3.71 to 8.25)	7.12 (1.7 to 13.5)	-56.7 (-58.9 to -54.1)	5.01 (3.48 to 6.69)	4.8 (3.15 to 6.46)	4.71 (2.88 to 6.3)	15.2 (10.2 to 21.4)	-47.2 (-49.5 to -44.4)
Encephalitis	5.24 (3.83 to 6.88)	4.71 (3.42 to 6.19)	4.48 (3.27 to 5.83)	92.1 (78.7 to 108)	-22.3 (-27.8 to -16)	5.67 (4.15 to 7.47)	3.86 (2.8 to 5.05)	2.54 (1.8 to 3.39)	114 (99.9 to 128)	-2.12 (-8.35 to 4.69)
Diphtheria				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Whooping cough				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Tetanus	0.0178 (0.00959 to 0.0279)	0.0209	0.0316	-57.6 (-68.1 to -39.4)	-82.8 (-87.1 to -75.5)	0.0174 (0.00953 to 0.0274)	0.0165 (0.0088 to 0.0267)	0.0155	-55.8 (-69 1 to -37 6)	-79.8 (-85.8 to -71.4)
Measles	()	((0	0	(((,	0	0
Varicella and herpes zoster	7.63	8.54	9.18	153	2.41	7.94	8.8	9.67	120	0.827
Acute hepatitis	(4.1 to 12.3) 3.02	(4.48 to 14.4) 2.43	(4.34 to 17.6) 1.89	(145 to 163) 130	(-1.13 to 6.12) -7.19	(4.31 to 12.8) 1.95	(4.57 to 14.6) 1.64	(4.62 to 18.7) 1.54	(111 to 129) 99.1	(-3.06 to 4.8) -8.73
Acute benatitic A	(1.66 to 5.14) 0.206	(1.28 to 4.18) 0.0562	(0.953 to 3.35) 0.00255	(52.7 to 243) 150	(-38.3 to 38.8) 0.915	(1.05 to 3.23) 0.18	(0.901 to 2.83) 0.042	(0.737 to 2.65) 0.00211	(43.4 to 182) 91.1	(-34.3 to 29.3) -12.4
Acute nepatitis A	(0.113 to 0.328)	(0.0236 to 0.116)	(0.000399 to 0.00834)	(106 to 203)	(-16.6 to 22.6)	(0.096 to 0.288)	(0.0163 to 0.0926)	(0.000263 to 0.00753)	(54.8 to 136)	(-29 to 8.29)
Acute hepatitis B	(1.17 to 4.48)	(0.793 to 3.25)	(0.343 to 2.07)	(36.8 to 270)	(-44.7 to 49.7)	(0.636 to 2.55)	(0.417 to 1.92)	(0.19 to 1.4)	(19.5 to 214)	(-45.2 to 44.1)
Acute hepatitis C	0.143 (0.0585 to 0.3)	0.215 (0.0882 to 0.44)	0.334 (0.118 to 0.744)	147 (132 to 166)	-0.191 (-6.23 to 7.58)	0.144 (0.0592 to 0.3)	0.2 (0.0814 to 0.408)	0.308 (0.108 to 0.705)	129 (118 to 147)	5.14 (-0.25 to 13)
Acute hepatitis E	0.255 (0.115 to 0.468)	0.401 (0.186 to 0.689)	0.605 (0.202 to 1.29)	158 (122 to 198)	4.4 (-10.4 to 20.3)	0.256 (0.118 to 0.479)	0.416 (0.201 to 0.739)	0.618 (0.208 to 1.26)	127 (95 to 165)	3.91 (-10.6 to 21.4)
Other unspecified infectious diseases	8.47 (5.76 to 12.3)	7.67 (5.18 to 11)	5.8 (3.85 to 8.49)	78 (66.2 to 89)	-28 (-32.8 to -23.6)	10.6 (7.25 to 14.9)	8.01 (5.5 to 11.4)	4.73 (3.09 to 6.83)	74.8 (63.6 to 86.9)	-19.9 (-25 to -14.3)
Maternal and neonatal disorders	42.4 (32.4 to 54.4)	9.42 (6.82 to 12.5)	5.07 (3.13 to 7.76)	436 (343 to 573)	117 (79.2 to 172)	74 (57.4 to 93.5)	17.6 (13.3 to 23.3)	5.14 (3.2 to 7.55)	334 (276 to 415)	99.1 (72.3 to 136)
Maternal disorders				0 (0 at 0)	0 (0 ot 0)	1.33 (0.805 tp 2.07)	0.628 (0.357 to 1)	0.208 (0.122 to 0.331)	-5.99 (-16.2 to 5.59)	-56.9 (-61.6 to -51.6)
Maternal hemorrhage				0	0	(0.000 0.000)	(0.001 10 2)	()	0	0
Maternal sepsis and other				0	0				0	(0 to 0)
Maternal hypertensive disorder				(0 to 0) 0	(0 to 0) 0	0.0000000000000000000000000000000000000	2.92e-109	7.03e-177	(0 to 0) 88.6	(0 to 0) -13.5
Maternal obstructed labor and				(0 to 0)	(0 to 0)	1 33	(5.89e-121 to 8.28e-111)	(1.99e-191 to 1.26e-178)	(-86.5 to 2940)	(-93.8 to 1290)
uterine rupture Maternal abortion and				(0 to 0)	(0 to 0)	(0.805 to 2.07)	(0.357 to 1)	(0.122 to 0.331)	(-16.2 to 5.59)	(-61.6 to -51.6)
miscarriage				(0 to 0)	(0 to 0)				(0 to 0)	(0 to 0)
Ectopic pregnancy				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Indirect maternal deaths										
Late maternal deaths										
Maternal deaths aggravated by HIV/AIDS										
Other maternal disorders				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Neonatal disorders	42.4 (32.4 to 54.4)	9.42 (6.82 to 12.5)	5.07 (3.13 to 7.76)	436 (343 to 573)	117 (79.2 to 172)	72.7 (56.1 to 92)	16.9 (12 7 to 22 7)	4.93 (3.05 to 7.23)	369 (302 to 458)	115 (84 1 to 156)
Neonatal preterm birth	20	6.54	5.05	235	35.3	35.1	9.02	4.83	206	40.3
Neonatal encephalopathy due to	(15.5 to 26.2) 4.77	(4.48 to 9.12)	0.00247	(201 to 276) 688	(21.5 to 52) 219	(27.6 to 44.2) 7.16	(6.61 to 11.9) 0.897	0.0421	(184 to 229)	(30 to 50.7)
birth asphyxia and trauma Neonatal sepsis and other	(2.93 to 7.22) 15.9	(0.115 to 0.648)	(0.000208 to 0.00966) 0.0159	(384 to 1290) 2280	(95.7 to 462) 861	(4.48 to 10.7) 27.4	(0.384 to 1.74) 6.31	(0.00708 to 0.129) 0.0573	(223 to 756) 1730	(48.2 to 293) 741
neonatal infections Hemolytic disease and other	(9.96 to 24.8)	(1.21 to 4.11)	(0.00497 to 0.0386)	(1270 to 4350)	(454 to 1700)	(17.8 to 41.4)	(3.78 to 10.6)	(0.0179 to 0.148)	(938 to 3990)	(376 to 1780)
neonatal jaundice	(1.29 to 2.2)	(0.198 to 0.381)	(0.000202 to 0.00105)	(235 to 274)	43.2 (35.5 to 51.3)	(2.3 to 3.79)	(0.529 to 0.945)	(0.00147 to 0.00548)	(173 to 202)	(25.3 to 38.3)
Other neonatal disorders				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Nutritional deficiencies	366 (255 to 512)	349 (240 to 492)	268 (185 to 378)	84 (72.6 to 96.3)	-25.6 (-30.2 to -20.6)	449 (312 to 624)	354 (249 to 498)	221 (151 to 310)	77.6 (66.8 to 89)	-18.6 (-23.5 to -13.3)
Protein-energy malnutrition	57.1 (36.2 to 82.4)	60.2 (38.7 to 85)	56.3 (36.7 to 79.5)	263 (232 to 298)	46.8 (34.3 to 60.8)	38.7 (24.9 to 54.7)	41.1 (26.7 to 57.9)	43.8 (28.8 to 61.1)	197 (179 to 218)	36.3 (28.1 to 45.8)
lodine deficiency	15.7 (9.1 to 26.1)	10.2 (5.79 to 16.9)	4.8 (2.56 to 8.2)	51.6 (33.5 to 67.3)	-38.7 (-46 to -32.3)	24.3 (13.3 to 42.9)	14.9 (8.16 to 25.9)	6.6 (3.44 to 11.6)	80.5 (57.1 to 98.5)	-17.2 (-28 to -8.98)
Vitamin A deficiency	2.27 (1.32 to 3.49)	1.5 (0.888 to 2.32)	0.584 (0.252 to 1.07)	174 (151 to 197)	10.6 (1.33 to 19.9)	1.89 (1.12 to 2.97)	1.15 (0.667 to 1.83)	0.388 (0.159 to 0.717)	176 (155 to 199)	26.6 (17 to 37)
Dietary iron deficiency	272 (195 to 292)	262 (179 to 280)	197 (127 to 299)	66.4 (52.7 to 72.8)	-32.7	372	287 (196 to 409)	163 (106 to 240)	69.3 (57.5 to 91.9)	-22.4 (-27.8 to -16.7)
Other nutritional deficiencies	18.9	15.4	9.31	111	-14.7	12.8	10.3	7.23	75.1	-19.7
on-communicable diseases	(11.9 to 27.2) 21600	(9.9 to 21.7) 27000	(6.07 to 13.1) 32700	(92.4 to 131) 151	(-22.2 to -6.43) 1.62	(8.22 to 18) 23500	(6.69 to 14.6) 29000	(4.76 to 10.1) 34900	(64.6 to 87.1) 122	(-24.5 to -14.2) 1.99
Neoplasms	(16400 to 27200) 747	(20500 to 33900) 950	(25100 to 40100) 746	(149 to 153) 191	(0.783 to 2.44)	(17800 to 29300) 441	(22100 to 36400) 541	(26900 to 42500) 531	(121 to 124) 141	(1.21 to 2.88) 10.6
Neoplas ns	(551 to 946)	(706 to 1210)	(540 to 938)	(169 to 215)	(8.7 to 27.5)	(330 to 567)	(391 to 687)	(384 to 673)	(125 to 158)	(2.93 to 18.1)
Lip and oral cavity cancer	(8.57 to 15.2)	(7.19 to 12.7)	(3.42 to 7.1)	(124 to 186)	(-9.28 to 15.4)	(4.47 to 7.91)	(4.36 to 8.38)	(2.81 to 6.17)	(135 to 182)	(7.73 to 29.1)
Nasopharynx cancer	4.48 (3.11 to 6.12)	5.18 (3.72 to 6.82)	1.32 (0.832 to 1.83)	312 (248 to 387)	66.4 (40.7 to 96.8)	1.46 (1.03 to 1.98)	2.12 (1.42 to 2.83)	0.864 (0.525 to 1.21)	158 (122 to 205)	18.1 (1.76 to 39.7)
Other pharynx cancer	4.1 (2.94 to 5.35)	3.17 (2.22 to 4.2)	1.86 (1.2 to 2.53)	253 (212 to 301)	42.7 (26.2 to 62.2)	1.18 (0.808 to 1.59)	1.02 (0.682 to 1.38)	0.825 (0.519 to 1.16)	214 (172 to 257)	43.8 (24.6 to 63.8)
Esophageal cancer	18.4 (12.7 to 24)	20.6 (14.7 to 26.5)	8.47 (5.45 to 11.2)	165 (127 to 211)	7.03 (-8.16 to 25.8)	7.09 (4.81 to 9.54)	8.74 (5.83 to 11.7)	5.58 (3.49 to 7.65)	88.3 (61.2 to 123)	-13.7 (-26.1 to 2.21)
Stomach cancer	41.4 (29.9 to 54.1)	50.8 (37.1 to 64.5)	28.8 (18.7 to 38.3)	125 (100 to 156)	-8.98 (-19.1 to 3.49)	15.9 (11.5 to 20.7)	23.9 (16.5 to 31.3)	24.4 (15.5 to 33.2)	59.9 (43.3 to 77.5)	-26.7 (-34.3 to -18.6)
Colon and rectum cancer	112	145	128	233 (207 to 262)	34.6	69.3 (61.4 to 90.1)	96.4 (68.5 to 124)	108 (75.1 to 142)	138 (119 to 159)	9.3 (-0.0718 to 18.5)
Liver cancer	12.8	16.6	9.14	175	11	5.82	8.44	6.83	114	-2.06
Liver cancer due to hepatitis B	(9.08 to 16.9) 4.19	(11.6 to 22) 3.92	(5.74 to 12.6) 1.35	(139 to 219) 110	(-3.3 to 28.9) -15.2	(4.07 to 7.82) 1.07	(5.61 to 11.5) 1.04	(4.27 to 9.5) 0.534	(81.1 to 146) 59.4	(-17 to 12.8) -26.9
liver cancer due to benatitir C	(2.74 to 5.9) 3.93	(2.5 to 5.6) 7.41	(0.713 to 2.24) 5.45	(68.6 to 160) 223	(-31.9 to 5.23) 30.7	(0.654 to 1.6) 2.85	(0.594 to 1.6) 5.1	(0.249 to 0.957) 4.91	(26.9 to 95) 125	(-41.8 to -10.6) 3.36
diver cancer due to neparative	(2.66 to 5.41)	(5.13 to 10)	(3.3 to 7.77)	(185 to 272)	(15.3 to 50.5)	(1.91 to 3.96)	(3.34 to 7.14)	(2.94 to 6.91)	(91.9 to 161)	(-12 to 19.7)
Liver cancer due to alconol use	(2.25 to 5.06)	(2.25 to 5.18)	(0.768 to 2.41)	(179 to 249)	(12.8 to 41.2)	(0.506 to 1.24)	(0.481 to 1.22)	(0.186 to 0.668)	(93.6 to 158)	(-11.2 to 18.2)
Liver cancer due to NASH	0.831 (0.511 to 1.26)	1.22 (0.747 to 1.83)	0.663 (0.328 to 1.15)	240 (197 to 290)	37.4 (20.2 to 57.6)	0.724 (0.451 to 1.07)	1.07 (0.627 to 1.61)	0.716 (0.343 to 1.2)	170 (127 to 214)	23.6 (3.92 to 43.8)
Liver cancer due to other causes	0.416 (0.258 to 0.622)	0.521 (0.321 to 0.793)	0.241 (0.123 to 0.421)	141 (102 to 185)	-2.56 (-18.1 to 15.4)	0.363 (0.229 to 0.542)	0.446 (0.264 to 0.691)	0.292 (0.146 to 0.503)	89.8 (55.7 to 125)	-13 (-28.6 to 2.99)
Gallbladder and biliary tract cancer	4.27 (2.89 to 5.7)	8.07 (5.37 to 10.7)	6.61 (3.85 to 9.22)	161 (108 to 193)	5.44 (-16.1 to 18.5)	4.4 (2.99 to 5.94)	7.78 (5.11 to 10.6)	9.71 (5.3 to 13.8)	87.1 (58.3 to 115)	-14.2 (-27.4 to -1.58)
Pancreatic cancer	10.2 (7.15 to 13.3)	15.1 (10.7 to 19.6)	12.5 (8.05 to 17)	232 (200 to 267)	34.3 (21.4 to 48.5)	8.47 (5.93 to 11.2)	14 (9.39 to 18.6)	14.8 (9.32 to 20.2)	192 (164 to 219)	33.7 (21.2 to 46.3)
Larynx cancer	13.6 (9.97 to 17.5)	12.2 (9.1 to 15.7)	6.08 (4.14 to 9.06)	131 (113 to 152)	-6.66	2.25	1.98	0.944	118 (101 to 140)	-0.086
Tracheal, bronchus, and lung cancer	71.8	(5.1 (0 15.7) 85.1	50.2	169	8.74	29.1	33.6	28.9	221	47.3
Malignant skin melanoma	(52.7 to 91.4) 10.1	(61.1 to 108) 14.9	(33.2 to 65.6) 11.6	(139 to 198) 400	(-3.23 to 20.6) 102	(20.7 to 37.1) 6.23	(23.2 to 44) 8.63	(18.2 to 39.2) 8.03	(187 to 255) 248	(31.6 to 62.7) 59.5
g	(4.72 to 14.5)	(7.09 to 20.1)	(5.66 to 16.4)	(143 to 515)	(-1.82 to 149)	(3.53 to 8.99)	(4.8 to 12)	(4.11 to 11.4)	(126 to 302)	(3.79 to 84.4)
	107	- / M	94.4	224	51.2	7.79	14.5	+2.9	113	*2.29
Non-melanoma skin cancer	18.5 (11.7 to 27.2)	(21.9 to 48.4)	(53.5 to 120)	(168 to 296)	(8.54 to 60)	(4.97 to 11.3)	(9.46 to 20.8)	(28.5 to 63.2)	(80.6 to 158)	(-17.2 to 18.1)

Supplementary Table 5. Cause-speci	fic rate of YLDs for 70-79	vears, 80-94 years, and 95+	years in 2019, and perce	entage change from 1990	to 2019 in YLD number ar	nd rate in 70+ years, glob	al, for all GBD causes			
			Males	1				Females	r.	
		YLDs per 100,000, 2019		Percentage chang	e in 70+, 1990-2019		YLDs per 100,000, 2019		Percentage change	in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Non-melanoma skin cancer (basal-	0.189	0.298	0.677	290	57.5	0.108	0.153	0.282	176	26.4
cell carcinoma)	(0.0857 to 0.353)	(0.14 to 0.552)	(0.301 to 1.33)	(251 to 341)	(41.9 to 78.3)	(0.0496 to 0.206)	(0.0707 to 0.288)	(0.12 to 0.563)	(150 to 208)	(14.4 to 41)
Breast cancer	2.89	3.73	2.83	197	20	128	143	134	125	3.33
	(2.07 to 3.87)	(2.69 to 4.94)	(1.96 to 3.82)	(162 to 235)	(5.89 to 35.3)	(90.2 to 172)	(104 to 191)	(97.1 to 180)	(108 to 144)	(-4.53 to 11.9)
Cervical cancer				0 (0 to 0)	0 (0 to 0)	9.16 (6.51 to 12)	6.87 (4.63 to 9.14)	5.06 (3.12 to 6.94)	86.7 (63.6 to 107)	-14.4 (-25 to -5.03)
Uterine cancer				0 (0 to 0)	0 (0 to 0)	23 (16.7 to 30.1)	15.8 (11.2 to 20.3)	6.32 (4.02 to 8.71)	150 (128 to 174)	14.4 (4.48 to 25.7)
Ovarian cancer				0 (0 to 0)	0 (0 to 0)	12.3 (8.84 to 16)	12.5 (8.62 to 16.6)	6.49 (3.96 to 8.85)	117 (90.3 to 143)	-0.401 (-12.7 to 11.3)
Prostate cancer	224 (159 to 315)	276 (199 to 363)	189 (135 to 244)	160 (133 to 220)	5.28 (-5.91 to 29.2)				0 (0 to 0)	0 (0 to 0)
Testicular cancer	0.91 (0.635 to 1.22)	0.629 (0.419 to 0.855)	0.535 (0.339 to 0.752)	244 (197 to 318)	39.2 (20 to 68.8)				0 (0 to 0)	0 (0 to 0)
Kidney cancer	13.3	12.5	7.91	275	51.7	6.84	6.3	4.43	175	26
	(9.74 to 17.1)	(8.98 to 16.1)	(5.17 to 10.7)	(239 to 313)	(36.9 to 67.1)	(4.97 to 8.82)	(4.38 to 8.27)	(2.72 to 6.11)	(150 to 205)	(14.4 to 39.7)
Bladder cancer	41.2	60.6	55.5	194	18.7	9.68	14.7	16.5	134	7.19
	(30.2 to 54)	(43.9 to 77.9)	(38.3 to 72.7)	(169 to 219)	(8.85 to 29.1)	(7.02 to 12.8)	(10.3 to 19.4)	(11 to 22.1)	(113 to 156)	(-2.4 to 17.5)
Brain and central nervous system	5.8	7.06	2.21	274	51.3	4.81	6	2.18	246	58.4
cancer	(3.42 to 7.87)	(3.88 to 9.83)	(1.19 to 3.18)	(110 to 359)	(-15.1 to 85.5)	(2.77 to 6.7)	(3.12 to 8.81)	(1.07 to 3.3)	(81.5 to 349)	(-16.8 to 106)
Thyroid cancer	3.12	2.5	2.52	291	58	4.77	3.12	3.99	167	22.4
	(2.2 to 4.09)	(1.67 to 3.3)	(1.5 to 3.46)	(236 to 338)	(35.8 to 76.9)	(3.41 to 6.29)	(2.13 to 4.15)	(2.42 to 5.5)	(141 to 195)	(10.4 to 35.3)
Mesothelioma	2.15	2.89	1.27	145	-0.968	0.451	0.527	0.319	74.9	-19.8
	(1.5 to 2.85)	(2.01 to 3.83)	(0.81 to 1.73)	(113 to 180)	(-13.7 to 13.2)	(0.285 to 0.613)	(0.314 to 0.733)	(0.176 to 0.458)	(26.3 to 117)	(-42.1 to -0.488)
Hodgkin lymphoma	2.15	6.08	3.58	217	28.2	1.25	3.03	2.36	204	39.2
	(1.43 to 2.86)	(3.92 to 8.16)	(2.09 to 4.94)	(155 to 259)	(3.2 to 45.2)	(0.836 to 1.73)	(1.79 to 4.26)	(1.14 to 3.67)	(163 to 241)	(20.7 to 56.3)
Non-Hodgkin lymphoma	33.7	46.4	29.6	340	78	19.7	29.4	23.7	235	53.4
	(23 to 44.8)	(30.9 to 63.4)	(18.5 to 40.6)	(296 to 387)	(60.1 to 97)	(13.5 to 26.9)	(19.3 to 41.7)	(14.6 to 33.3)	(197 to 273)	(36.4 to 71.2)
Multiple myeloma	10.5	14.2	6.43	243	38.7	7.39	9.12	3.63	169	23.2
	(7.23 to 13.9)	(9.24 to 18.8)	(4.12 to 8.68)	(178 to 289)	(12.4 to 57.1)	(5.06 to 9.85)	(5.76 to 12.4)	(1.95 to 5.15)	(121 to 207)	(1.53 to 40.8)
Leukemia	24.5	36.1	35	206	23.8	16	22.6	23.6	162	20.3
	(17.3 to 31.9)	(25.6 to 46.7)	(22.3 to 48)	(175 to 244)	(11.3 to 39)	(11.5 to 21)	(15.5 to 29.7)	(14.3 to 32.4)	(136 to 191)	(8.07 to 33.4)
Acute lymphoid leukemia	3.52	2.88	1.1	620	191	2.62	1.96	0.693	482	167
	(2.28 to 4.87)	(1.89 to 3.95)	(0.646 to 1.58)	(487 to 755)	(137 to 246)	(1.66 to 3.66)	(1.25 to 2.73)	(0.384 to 1)	(370 to 599)	(116 to 220)
Chronic lymphoid leukemia	10.5	11.9	7.83	214	26.8	6.07	7.31	5.01	157	18
	(7.36 to 14)	(8.18 to 15.7)	(4.96 to 10.9)	(174 to 291)	(10.7 to 58)	(4.31 to 8.06)	(5.04 to 9.78)	(3.1 to 6.86)	(127 to 199)	(3.95 to 37.3)
Acute myeloid leukemia	2.54	4.47	16.1	245	39.3	1.65	2.64	10.7	198	36.7
	(1.69 to 3.47)	(2.87 to 6.15)	(8.65 to 23.4)	(158 to 311)	(4.29 to 66.1)	(1.09 to 2.24)	(1.65 to 3.63)	(5.47 to 15.7)	(125 to 246)	(3.09 to 58.8)
Chronic myeloid leukemia	2.1	4.85	3.16	273	50.9	1.44	3.58	2.7	277	72.9
	(1.42 to 2.9)	(3.27 to 6.74)	(1.9 to 4.49)	(209 to 378)	(25 to 93.3)	(0.987 to 1.98)	(2.43 to 4.91)	(1.59 to 3.9)	(210 to 367)	(42.1 to 114)
Other Leukemia	5.77	12.1	6.78	118	-11.7	4.24	7.07	4.47	87.1	-14.2
	(4.04 to 7.55)	(8.51 to 15.5)	(4.34 to 9.27)	(91.3 to 156)	(-22.7 to 3.41)	(2.91 to 5.72)	(4.8 to 9.38)	(2.69 to 6.22)	(63.9 to 113)	(-24.9 to -2.43)
Other malignant neoplasms	26	33.6	34.1	296	60.2	16.8	22.5	29	228	50.2
	(18 to 34.6)	(22.8 to 44.5)	(21.5 to 45.7)	(237 to 353)	(36.3 to 83.2)	(12.2 to 22.1)	(15.3 to 29.9)	(18 to 39.5)	(186 to 265)	(31.2 to 67.1)
Other neoplasms	24.7	29.3	23.5	202	22	15.7	17.9	12.7	147	13.5
	(15.3 to 36.8)	(18.6 to 43.6)	(14.6 to 36.6)	(187 to 222)	(16.1 to 30.2)	(9.88 to 23.3)	(11.6 to 26.5)	(7.92 to 19.8)	(135 to 163)	(7.92 to 20.5)
myeloproliferative, and other	24.7	29.3	23.5	202	22	15.7	17.9	12.7	147	13.5
hematopoletic neoplasms	(15.3 to 36.8)	(18.6 to 43.6)	(14.6 to 36.6)	(187 to 222)	(16.1 to 30.2)	(9.88 to 23.3)	(11.6 to 26.5)	(7.92 to 19.8)	(135 to 163)	(7.92 to 20.5)
Benign and in situ intestinal neoplasms				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Benign and in situ cervical and uterine neoplasms				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Other benign and in situ neoplasms				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Cardiovascular diseases	2520	3490	3900	140	-2.98	2640	3890	4590	113	-2.3
	(1810 to 3260)	(2550 to 4540)	(2790 to 5170)	(135 to 145)	(-4.91 to -1.01)	(1920 to 3370)	(2900 to 4970)	(3340 to 5950)	(109 to 117)	(-4.25 to -0.353)
Rheumatic heart disease	17.5	19.9	31	139	-3.2	24.1	25.6	28.5	94.1	-11
	(11.7 to 24.4)	(13.7 to 27.5)	(20.5 to 43.8)	(127 to 153)	(-8.31 to 2.46)	(16.2 to 33.5)	(17.4 to 35.1)	(18.9 to 40)	(82.3 to 108)	(-16.4 to -4.61)
Ischemic heart disease	554	813	1060	125	-9.18	413	661	886	105	-5.81
	(357 to 788)	(530 to 1190)	(589 to 1670)	(117 to 133)	(-12.3 to -5.81)	(267 to 588)	(434 to 961)	(493 to 1430)	(97.1 to 115)	(-9.65 to -1.53)
Stroke	1100	1330	1050	151	1.48	1440	1920	1970	115	-1.65
	(780 to 1440)	(944 to 1770)	(710 to 1450)	(143 to 159)	(-1.96 to 4.88)	(1020 to 1860)	(1370 to 2480)	(1360 to 2680)	(108 to 122)	(-4.75 to 1.65)
Ischemic stroke	937	1210	896	160	5.12	1240	1710	1670	119	0.241
	(652 to 1260)	(849 to 1620)	(592 to 1280)	(150 to 170)	(1.21 to 9.23)	(859 to 1620)	(1220 to 2240)	(1120 to 2320)	(111 to 127)	(-3.3 to 4.05)
Intracerebral hemorrhage	129	88.9	77.5	95.4	-21	122	112	128	68.6	-22.7
	(87.5 to 179)	(60.1 to 120)	(49 to 113)	(88.7 to 103)	(-23.7 to -18.1)	(83.8 to 166)	(76.2 to 150)	(79.6 to 190)	(62.9 to 74.7)	(-25.3 to -19.9)
Subarachnold hemorrhage	31.5	39.2	74.1	140	-3.14	76.3	93.9	169	131	5.87
	(19.3 to 45.8)	(24.9 to 57)	(44.4 to 111)	(129 to 152)	(-7.32 to 2.07)	(49.1 to 109)	(60.8 to 134)	(105 to 248)	(120 to 143)	(1.03 to 11.4)
Hypertensive heart disease	163	257	331	150	1.14	148	280	439	154	16.5
	(86.2 to 277)	(142 to 423)	(141 to 679)	(139 to 164)	(-3.28 to 6.77)	(78.4 to 245)	(159 to 449)	(187 to 866)	(141 to 170)	(10.6 to 24)
disease	28.7	63.2	167	191	17.7	36.7	85.4	219	132	6.57
	(16 to 48.1)	(36.6 to 103)	(106 to 234)	(169 to 209)	(8.87 to 25.1)	(20.6 to 61.3)	(49.5 to 138)	(139 to 310)	(115 to 148)	(-1.62 to 13.9)
valve disease	11.1	27.1	61.2	498	142	10.3	27.8	58.4	458	156
	(6.14 to 19)	(15.2 to 45.3)	(35.5 to 92.3)	(448 to 564)	(121 to 168)	(5.64 to 17.4)	(15.8 to 47.1)	(33.9 to 88.9)	(405 to 529)	(131 to 188)
valve disease	17.4	35.7	105	115	-13	26.2	57	160	85	-15.2
	(9.58 to 29.1)	(20.3 to 57.1)	(65.8 to 150)	(97.4 to 130)	(-20.2 to -7.06)	(14.5 to 44.3)	(32.3 to 91.8)	(99.3 to 231)	(70 to 98)	(-22.1 to -9.21)
diseases	0.192	0.379	0.104	170	9.18	0.28	0.592	0.383	161	19.8
	(0.102 to 0.324)	(0.21 to 0.621)	(0.0447 to 0.204)	(156 to 187)	(3.57 to 15.8)	(0.148 to 0.472)	(0.34 to 0.949)	(0.162 to 0.761)	(144 to 179)	(11.7 to 28.1)
Cardiomyopathy and myocarditis	40 (22.3 to 66.3)	(47.4 to 121)	(74.3 to 293)	(102 to 137)	-12.5 (-18.4 to -4.31)	(14.2 to 43.2)	(35.5 to 91.9)	(56.6 to 235)	(75.4 to 108)	-13 (-19.6 to -4.78)
Myocarditis	2.69	5.36	11.1	155	3.23	2.07	5.79	13.7	137	8.5
	(1.55 to 4.24)	(3.37 to 8.05)	(5.51 to 19.9)	(142 to 172)	(-2.27 to 10)	(1.18 to 3.35)	(3.63 to 8.89)	(6.56 to 25.5)	(121 to 155)	(1.1 to 17.1)
Alcoholic cardiomyopathy	6.74 (3.85 to 11.3)	4.2 (2.6 to 6.73)	4.25 (1.96 to 8.23)	/8.1 (61.8 to 101)	-28 (-34.6 to -18.8)	(1.03 to 3.22)	(0.937 to 2.58)	(0.764 to 3.48)	36.8 (24.2 to 54.3)	-37.3 (-43.1 to -29.3)
Other cardiomyopathy	30.6	67.9	140	121	-10.8	22.1	51.7	106	89.7	-13
	(16.8 to 50.9)	(41.2 to 106)	(66.3 to 265)	(106 to 141)	(-16.8 to -2.59)	(12 to 36.7)	(30.9 to 80.4)	(49 to 205)	(75.5 to 108)	(-19.5 to -4.58)
Atrial fibrillation and flutter	(320 to 773)	(504 to 1160)	(615 to 1340)	(134 to 147)	-3.3 (-5.37 to -0.309)	433 (270 to 661)	(439 to 1020)	(471 to 1040)	(111 to 122)	-1.25 (-3.5 to 1.84)
Aortic aneurysm										
Peripheral artery disease	42 (19.2 to 77)	(29.2 to 123)	(41.9 to 224)	82.6 (77.6 to 88.7)	-26.2 (-28.2 to -23.7)	/3.3 (33.6 to 135)	(50.2 to 210)	(54.9 to 295)	68.2 (63.1 to 73.9)	-22.9 (-25.2 to -20.3)
Endocarditis Other cardiovascular and	(1.49 to 3.8)	7.26 (4.65 to 10.7)	(13.8 to 53.5)	(133 to 186)	3./1 (-5.94 to 15.8)	(1.56 to 4)	8.7 (5.47 to 12.8)	(16.1 to 63.1)	(91.4 to 140)	-2.56 (-12.2 to 9.84)
circulatory diseases	62.9 (36.4 to 96.9)	62.4 (36.3 to 97.6)	46.4 (22.7 to 85.1)	(126 to 157)	-3.17 (-8.44 to 3.92)	(28.4 to 78.9)	(26.5 to 68.1)	(18 to 64.7)	99.3 (86.4 to 116)	-8.65 (-14.5 to -1.06)
Chronic respiratory diseases	(1410 to 2090)	(2160 to 3100)	(3210 to 4620)	(116 to 133)	-9.05 (-12.6 to -5.61)	(1360 to 1930)	(1990 to 2820)	(2810 to 4100)	(107 to 125)	-0.953 (-5.3 to 3)
disease	1480 (1190 to 1730)	2350 (1880 to 2750)	3600 (2910 to 4230)	145 (139 to 151)	-1.03 (-3.57 to 1.6)	1410 (1150 to 1650)	(1760 to 2560)	3100 (2450 to 3710)	138 (132 to 144)	9.09 (6.41 to 11.7)
Pneumoconiosis	(34.1 to 71.8)	48.2 (33.4 to 67)	(15.5 to 31.2)	(127 to 163)	(-8.42 to 6.44)	4.51 (3.06 to 6.75)	6.23 (4.1 to 9.09)	(4.15 to 9.64)	(97.1 to 126)	-3.41 (-9.63 to 3.59)
Silicosis	42.8	37.2	12.7	154	2.88	2.42	3.12	2.94	120	0.982
	(28.1 to 61.2)	(25.6 to 52.6)	(8.54 to 17.7)	(131 to 178)	(-6.61 to 12.3)	(1.45 to 3.79)	(1.96 to 4.81)	(1.75 to 4.59)	(94.5 to 147)	(-10.8 to 13.1)
Asbestosis	1.67	2.69	2.38	192	18.2	0.47	0.527	0.52	140	10.1
	(1.06 to 2.49)	(1.74 to 3.92)	(1.16 to 4.15)	(151 to 244)	(1.37 to 39.1)	(0.251 to 0.788)	(0.293 to 0.845)	(0.214 to 1.04)	(108 to 178)	(-4.5 to 27.3)
Coal workers pneumoconiosis	1.87	1.54	U.163	47.4	-40.4	0.347	0.395	0.368	/1.6	-21.3
	(1.16 to 2.81)	(1.03 to 2.42)	(0.0837 to 0.288)	(34.7 to 62.3)	(-45.6 to -34.4)	(0.197 to 0.539)	(0.231 to 0.623)	(0.195 to 0.692)	(40.6 to 117)	(-35.6 to -0.426)
Other pneumoconiosis	4.55	6.69	7.49	118	-12	1.37	2.19	2.7	99.6	-8.51
	(2.84 to 6.72)	(4.21 to 9.69)	(4.71 to 11.2)	(98.7 to 138)	(-19.7 to -3.7)	(0.828 to 2.15)	(1.32 to 3.44)	(1.54 to 4.51)	(81.7 to 120)	(-16.7 to 0.779)
Asthma	198	205	2 /3	25.3	-49.3	210	208	3∠0	21	-44.5
	(120 to 298)	(133 to 295)	(172 to 410)	(16.4 to 34.2)	(-52.9 to -45.7)	(132 to 310)	(135 to 294)	(202 to 474)	(16.3 to 26.8)	(-46.7 to -41.9)
pulmonary sarcoidosis	40.1 (24.9 to 61.5)	45 (28.9 to 66.8)	46.6 (29.3 to 72.2)	(200 to 241)	29.4 (21.4 to 37.9)	33.1 (20.5 to 50.7)	32.2 (21 to 47)	32.6 (20.5 to 48.9)	177 (162 to 195)	27 (19.9 to 35.3)
utner chronic respiratory diseases	(5.59 to 8.15)	(8.59 to 12.4)	(19.6 to 28.5)	(212 to 227)	(26.2 to 32.1)	(5.2 to 7.52)	(7.94 to 11.5)	(16.4 to 24.8)	(196 to 209)	(35.6 to 41.6)

Supplementary Table 5. Cause-speci	fic rate of YLDs for 70-79	9 years, 80-94 years, and 95+	years in 2019, and perce	entage change from 1990	to 2019 in YLD number an	ıd rate in 70+ years, globa	al, for all GBD causes			į
			Males					Females		
		YLDs per 100,000, 2019		Percentage chang	e in 70+, 1990-2019		YLDs per 100,000, 2019		Percentage change	e in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Digestive diseases	464 (222 to 629)	436 (209 to 597)	421	111 (105 to 117)	-14.7	457 (214 to 624)	421 (292 to 595)	424	88.7 (92 to 94.2)	-13.5
Cirrhosis and other chronic liver diseases	24.5	20.7	10.4	129	-7.6	18.7	15	8.09	95.5	-10.4
Cirrhosis and other chronic liver	5.25	4.34	1.56	77.7	-28.2	3.33	2.5	1.12	46.7	-32.8
Cirrhosis and other chronic liver	(3.06 to 8.14)	(2.55 to 6.85)	(0.734 to 2.84)	(63.7 to 92.4)	(-33.8 to -22.2)	(1.98 to 5.28)	(1.45 to 4.15)	(0.518 to 2.1)	(33.3 to 59.5)	(-38.9 to -26.9)
	6.67	5.9	3.51	150	0.941	4.62	3.83	2.35	112	-3.01
Cirrhosis and other chronic liver	(4.05 to 10.3)	(3.52 to 9.04)	(1.89 to 5.58)	(135 to 166)	(-4.89 to 7.34)	(2.76 to 7.33)	(2.24 to 6.06)	(1.2 to 3.84)	(98.6 to 125)	(-8.95 to 3.08)
	7.57	5.68	2.65	151	1.58	3.68	2.6	1.33	117	-0.615
diseases due to alcohol use Cirrhosis and other chronic liver	(4.55 to 11.5)	(3.45 to 8.89)	(1.27 to 4.82)	(139 to 165)	(-3.53 to 7.04)	(2.06 to 5.79)	(1.47 to 4.13)	(0.579 to 2.62)	(103 to 132)	(-7.03 to 6.42)
diseases due to NAFLD	(0.959 to 3.75)	(0.932 to 3.39)	(0.349 to 2.34)	(126 to 164)	(-8.56 to 6.87)	(1.26 to 4.51)	(1.08 to 3.69)	(0.408 to 2.5)	(99.9 to 131)	(-8.38 to 5.71)
diseases due to other causes	(1.45 to 5.34)	(1.42 to 5.1)	(0.633 to 3.41)	(120 to 157)	-3.72 (-11.1 to 3.72)	4.44 (2.37 to 7.7)	(1.99 to 6.49)	(0.899 to 3.91)	(90 to 117)	-7.3 (-12.9 to -0.723)
Upper digestive system diseases	193 (116 to 309)	175 (102 to 283)	149 (81.3 to 240)	122 (112 to 129)	-10.2 (-14.3 to -7.26)	(132 to 346)	183 (109 to 292)	142 (80.8 to 227)	103 (97 to 108)	-7 (-9.67 to -4.82)
Peptic ulcer disease	16.7	18.5	14.6	48.5	-40	16.3	18.5	14.8	53	-29.8
	(10.2 to 26.1)	(11.8 to 27.1)	(8.95 to 22.1)	(41.5 to 56.4)	(-42.8 to -36.8)	(9.95 to 25.2)	(11.9 to 27.3)	(9.11 to 23.2)	(47.4 to 58.9)	(-32.4 to -27.1)
Gastritis and duodenitis	41.1	31.7	20.2	108	-16.1	59.2	39.4	24.4	99.9	-8.34
	(24 to 64.6)	(18.3 to 49.6)	(12.2 to 32)	(93.3 to 126)	(-21.9 to -8.66)	(34.1 to 93.6)	(23 to 60.5)	(14.7 to 37.7)	(87.7 to 113)	(-14 to -2.41)
Gastroesophageal reflux disease	135	125	115	143	-1.95	143	125	103	113	-2.49
	(70.4 to 244)	(62.8 to 220)	(55.7 to 202)	(138 to 148)	(-3.62 to 0.0802)	(74.2 to 256)	(63.2 to 221)	(50.2 to 181)	(109 to 117)	(-4.27 to -0.318)
Appendicitis	0.802	0.471	0.404	250	41.3	0.758	0.408	0.327	239	55.5
	(0.476 to 1.22)	(0.311 to 0.67)	(0.248 to 0.584)	(218 to 286)	(28.7 to 56.1)	(0.451 to 1.18)	(0.268 to 0.586)	(0.203 to 0.473)	(212 to 270)	(42.9 to 69.7)
Paralytic ileus and intestinal	5.58	7.96	8.96	187	16.2	4.61	6.64	7.8	131	6
obstruction	(3.7 to 7.51)	(5.48 to 10.5)	(6.41 to 11.9)	(169 to 208)	(8.81 to 24.4)	(3.12 to 6.17)	(4.64 to 8.71)	(5.48 to 10.3)	(116 to 148)	(-0.992 to 13.7)
Inguinal, femoral, and abdominal	91.5	56	30.7	89.6	-23.4	16.6	10.4	5.88	50.9	-30.8
hernia	(59.7 to 134)	(38 5 to 77 8)	(21 3 to 42 1)	(79.7 to 99.9)	(-27.3 to -19.2)	(10.7 to 24.1)	(7.11 to 14.5)	(4 to 8 32)	(41.9 to 60.5)	(-34.9 to -26.4)
Inflammatory bowel disease	18.2	14.2	13.2	77.4	-28.3	17.1	12.8	10.9	43.7	-34.1
Vascular intestinal disorders	(12 to 25.6) 3.78	(9.42 to 20.1) 5.73	(8.61 to 19.5) 4.69	(69.5 to 85.6)	(-31.5 t0 -25)	(11.4 to 23.8) 3.76	(8.37 to 18) 6.26	(7.17 t0 16.2) 5.01	(37.3 to 50.7) 86.3	(-37.1 to -30.9) -14.6
Gallbladder and biliary diseases	(2.54 to 5.24)	(3.86 to 7.64)	(3.06 to 6.5)	(105 to 134)	(-17 to -5.4)	(2.47 to 5.17)	(4.31 to 8.29)	(3.28 to 6.83)	(74.5 to 99.4)	(-20 to -8.6)
	104	125	160	103	-17.7	156	156	198	76.7	-19
Pagrenatitir	(61.6 to 161)	(79.9 to 196)	(100 to 248)	(94.1 to 115)	(-21.5 to -13.2)	(92.4 to 241)	(99.9 to 241)	(122 to 307)	(69.6 to 84.1)	(-22.2 to -15.6)
	7.91	7.82	7.16	160	5.27	7.6	8.35	8.1	113	-2.17
	(4.36 to 12.8)	(4.5 to 12.2)	(4.23 to 11.4)	(145 to 175)	(-0.871 to 11.1)	(4.19 to 12.1)	(4.85 to 13)	(4.87 to 12.8)	(100 to 125)	(-8.2 to 3.09)
Uther digestive diseases	(10.2 to 19.8)	(15.9 to 30.3)	(25.4 to 50.6)	(130 to 142)	(-7.1 to -2.17)	(9.67 to 19.6)	(15.2 to 30.7)	(25.9 to 54.5)	(108 to 120)	(-4.61 to 0.955)
Neurological disorders	(796 to 1610)	(1990 to 3910)	(4340 to 8550)	(177 to 195)	(11.9 to 19.4)	(966 to 2130)	(2570 to 5030)	(5610 to 10600)	(141 to 155)	(10.3 to 16.8)
dementias	545	2220	5790	200	21.2	701	3020	7490	161	19.9
	(363 to 773)	(1490 to 3080)	(3920 to 7910)	(191 to 208)	(17.7 to 24.6)	(479 to 995)	(2070 to 4150)	(5140 to 10100)	(155 to 168)	(16.8 to 23)
Parkinson's disease	156	257	217	199	20.7	106	171	148	136	8.05
	(106 to 214)	(178 to 343)	(139 to 324)	(188 to 211)	(16.4 to 25.7)	(71.5 to 146)	(119 to 228)	(94.7 to 216)	(128 to 144)	(4.65 to 11.9)
Idiopathic epilepsy	138	177	221	168	8.34	126	148	172	138	9.09
	(82.7 to 210)	(104 to 273)	(123 to 358)	(119 to 230)	(-11.5 to 33.2)	(75.8 to 192)	(86.9 to 232)	(94.6 to 283)	(97.3 to 187)	(-9.57 to 31.6)
Multiple sclerosis	7.46	6.81	6.36	141	-2.62	14.8	13.6	14.5	97.4	-9.52
	(5.3 to 9.78)	(4.84 to 8.98)	(4.39 to 8.53)	(127 to 157)	(-8.4 to 3.95)	(10.7 to 19.1)	(9.85 to 17.7)	(10.4 to 18.9)	(85.9 to 110)	(-14.8 to -3.64)
Motor neuron disease	2.88	3.15	2.79	185	15.1	2.17	2.25	2.03	132	6.24
	(1.87 to 4.11)	(2.08 to 4.45)	(1.61 to 4.45)	(173 to 197)	(10.5 to 20.2)	(1.42 to 3.1)	(1.47 to 3.22)	(1.17 to 3.33)	(121 to 142)	(1.54 to 11.1)
Headache disorders	303	210	113	145	-0.76	483	323	166	113	-2.33
	(108 to 611)	(70.6 to 426)	(28.2 to 290)	(137 to 153)	(-4.16 to 2.11)	(148 to 1000)	(102 to 682)	(38.6 to 368)	(99.7 to 121)	(-8.44 to 1.42)
Migraine	243	167	80.9	147	-0.309	408	270	129	115	-1.56
	(76 to 527)	(50.2 to 359)	(19.2 to 182)	(137 to 154)	(-4.03 to 2.49)	(107 to 904)	(71.2 to 595)	(24.8 to 302)	(99.1 to 123)	(-8.74 to 2.24)
Tension-type headache	59.2	42.7	32.6	141	-2.55	75.3	53	36.1	104	-6.26
Other neurological disorders	24.8	23.5	21.9	195	19.4	27.2	27.7	27	(52.1 (5 114)	15.4
Mental disorders	(17.7 to 33.6)	(16.1 to 31.7)	(15 to 29.5)	(186 to 206)	(15.7 to 23.8)	(19.2 to 37.2)	(19 to 37.7)	(18.7 to 36.1)	(146 to 159)	(12.9 to 18.6)
	1540	1330	1080	149	0.593	1940	1660	1390	115	-1.4
Schizophrenia	(1150 to 1980)	(964 to 1720)	(744 to 1480)	(146 to 152)	(-0.468 to 1.69)	(1430 to 2510)	(1220 to 2140)	(932 to 1910)	(112 to 118)	(-2.62 to -0.0042)
	145	72.5	24.3	152	1.89	142	76.9	32.2	116	-1.03
Depressive disorders	(105 to 187)	(51.6 to 95.3)	(14.7 to 35.1)	(146 to 159)	(-0.69 to 4.68)	(102 to 183)	(55.4 to 99.7)	(20.7 to 44.6)	(110 to 121)	(-3.54 to 1.34)
	710	662	599	153	2.13	1020	910	827	119	0.32
Malas deservive discodes	(484 to 966)	(449 to 918)	(357 to 905)	(148 to 157)	(0.345 to 3.94)	(695 to 1400) 848	(610 to 1240) 789	(496 to 1260)	(115 to 123)	(-1.54 to 2.35)
wajor depressive disorder	(381 to 812)	(362 to 784)	(286 to 801)	(148 to 159)	(0.404 to 4.59)	(570 to 1200)	(515 to 1100)	(423 to 1140)	(113 to 123)	(-2.57 to 2.01)
Dysthymia	(86.5 to 211)	(61.7 to 159)	(51 to 151)	(140 to 158)	(-2.99 to 4.29)	(112 to 267)	(73.1 to 183)	94,4 (52.8 to 157)	(119 to 136)	4.19 (0.393 to 8.08)
Bipolar disorder	100	67.8	42.3	133	-5.86	103	68.1	45.9	96.3	-10
	(60.1 to 157)	(40.2 to 104)	(24.4 to 67.6)	(128 to 138)	(-7.95 to -3.71)	(62.8 to 159)	(40.9 to 104)	(27 to 73.4)	(91.7 to 101)	(-12.1 to -7.73)
Anxiety disorders	291	236	122	148	0.384	474	415	285	111	-3.35
	(193 to 419)	(150 to 341)	(70.8 to 189)	(143 to 154)	(-1.65 to 2.69)	(314 to 687)	(273 to 600)	(175 to 417)	(106 to 116)	(-5.5 to -1.06)
Eating disorders				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Anorexia nervosa				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Bulimia nervosa				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Autism spectrum disorders	66	63.5	62.8	147	-0.142	18.3	17	16.2	115	-1.24
	(44.5 to 94.1)	(43.2 to 90.3)	(42.9 to 88.6)	(143 to 151)	(-1.7 to 1.34)	(12.2 to 26.2)	(11.5 to 24.5)	(11 to 23.3)	(110 to 121)	(-3.62 to 1.14)
Attention-deficit/hyperactivity disorder	0.531 (0.163 to 1.28)	0.0172 (0.00188 to 0.0616)	0.00000143 (0.00000000000877 to 0.0000137)	130 (98.8 tp 162)	-6.86 (-19.6 to 5.95)	0.253 (0.0634 tp 0.656)	0.0119 (0.00103 to 0.0461)	0.00000326 (0.0000000053 to 0.0000238)	96.2 (64 to 131)	-10 (-24.8 to 5.81)
Conduct disorder	1	1	,	0	0 (0 to 0)	0			0 (0 to 0)	0
Idiopathic developmental	19	11.2	3.78	106	-16.8	20.3	13.9	6.44	85.2	-15.1
Other mental disorders	(9.41 to 31.7)	(5.39 to 19.2)	(1.51 to 7.37)	(93 to 121)	(-22 to -10.5)	(11.1 to 32.2)	(7.98 to 21.6)	(3.52 to 10.1)	(75.3 to 93.6)	(-19.6 to -11.2)
	211	212	229	147	-0.00705	153	158	176	120	0.741
Substance use disorders	(140 to 307)	(143 to 302)	(153 to 322)	(144 to 150)	(-1.27 to 1.2)	(102 to 222)	(108 to 227)	(117 to 249)	(117 to 123)	(-0.723 to 2.27)
	256	208	258	170	9.15	125	136	215	157	17.7
Alashal usa disasalara	(181 to 350)	(150 to 282)	(174 to 377)	(161 to 180)	(5.69 to 13.4)	(87.5 to 172)	(98.3 to 181)	(144 to 311)	(146 to 169)	(12.6 to 23.2)
Accilion use discribers	(128 to 277)	(98.3 to 205)	(122 to 299)	(144 to 158)	(-1.46 to 4.47)	(33.8 to 77.5)	(39.2 to 86.3)	(71.2 to 188)	(122 to 138)	(1.96 to 9.16)
Drug use disorders	(42.4 to 94.6)	(42.6 to 88.8)	(41.5 to 98.3)	(221 to 262)	(29.6 to 46.2)	(46.9 to 106)	(51.5 to 108)	(61.6 to 150)	(163 to 203)	(20.7 to 38.8)
Opioid use disorders	55.4	56.6	54.1	265	47.7	66.5	71.1	88.8	192	34
	(34.2 to 81.8)	(35.9 to 79.8)	(32.3 to 86.3)	(242 to 293)	(38.4 to 58.8)	(41.1 to 98.3)	(45.4 to 101)	(53.9 to 138)	(172 to 218)	(24.8 to 46)
Cocaine use disorders	3.75	3.34	4.15	147	-0.33	2.46	2.42	3.07	95.4	-10.4
	(2.27 to 5.63)	(2.04 to 5.07)	(2.41 to 6.42)	(126 to 173)	(-8.63 to 10.4)	(1.44 to 3.74)	(1.4 to 3.73)	(1.72 to 4.66)	(81 to 112)	(-17 to -2.74)
Ampheta mine use disorders	1.6	1.15	2.26	144	-1.39	1.15	1.03	2.46	113	-2.14
	(0.846 to 2.67)	(0.593 to 2.08)	(0.96 to 4.4)	(135 to 156)	(-5.11 to 3.37)	(0.578 to 1.95)	(0.552 to 1.86)	(1.14 to 4.65)	(105 to 125)	(-6.02 to 3.33)
Cannabis use disorders	1.23	0.624	0.298	147	-0.342	0.608	0.265	0.115	106	-5.65
	(0.666 to 2.07)	(0.309 to 1.1)	(0.129 to 0.59)	(134 to 161)	(-5.57 to 5.51)	(0.309 to 1.06)	(0.116 to 0.51)	(0.0432 to 0.242)	(95.2 to 117)	(-10.5 to -0.4)
Other drug use disorders	3.71	3.16	4.56	148	0.442	2.61	2.52	4.07	105	-6.08
	(2.38 to 5.34)	(2.06 to 4.54)	(2.86 to 6.74)	(133 to 167)	(-5.91 to 8.06)	(1.64 to 3.82)	(1.64 to 3.63)	(2.47 to 6.03)	(92.9 to 118)	(-11.5 to 0.146)
Diabetes and kidney diseases	2640	2880	3050	250	41.4	2410	2540	2390	199	36.9
	(1860 to 3550)	(2090 to 3810)	(2190 to 4060)	(244 to 257)	(38.9 to 44.3)	(1680 to 3250)	(1830 to 3360)	(1710 to 3180)	(193 to 204)	(34.3 to 39.5)
Diabetes mellitus	2240	2250	2080	258	44.6	2000	1940	1560	203	39
	(1560 to 3060)	(1600 to 3020)	(1460 tp 2830)	(251 to 266)	(41.7 to 47.8)	(1390 to 2740)	(1370 to 2580)	(1100 to 2120)	(197 to 209)	(36.2 to 41.8)
Diabetes mellitus type 1	45.9	50.5 (33.5 to 71.2)	59.9 (39.2 to 95.1)	236 (222 to 250)	35.8	43	47.8	55.6 (36.5 to 78.9)	179	27.9 (22.8 to 22.5)
Diabetes mellitus type 2	2190	2200	2020	258	(30 t0 41.6)	1950	1890	1500	204	39.3
Chronic kidney disease	(1520 to 2990)	(1560 to 2960)	(1420 to 2750)	(251 to 266)	(41.9 to 48)	(1350 to 2690)	(1340 to 2520)	(1060 to 2050)	(198 to 210)	(36.5 to 42.1)
	403	630	966	217	28	411	602	829	181	28.8
Chronic kidney disease due to	(264 to 612)	(436 to 911)	(626 to 1490)	(203 to 231)	(22.6 to 33.7)	(273 to 618)	(419 to 853)	(531 to 1290)	(168 to 193)	(23 to 34.5)
	4.6	1.64	0.217	248	40.7	3.48	1.15	0.123	181	28.9
ciapetes mellitus type 1	(2.55 to 7.81)	(0.919 to 2.8)	(0.121 to 0.363)	(226 to 273)	(31.8 to 50.7)	(1.91 to 6.04)	(0.61 to 2.04)	(0.0662 to 0.216)	(164 to 204)	(20.9 to 39.5)

Supplementary Table 5. Cause-speci	fic rate of YLDs for 70-79	years, 80-94 years, and 954	vears in 2019, and perce	ntage change from 199	0 to 2019 in YLD number an	ıd rate in 70+ years, glob	al, for all GBD causes			
			Males					Females		
		YLDs per 100.000, 2019		Percentage chan	ge in 70+ 1990-2019		YLDs per 100.000, 2019		Percentage char	are in 70+. 1990-2019
6	70 4= 70	100,000, 1013	05 -1	Number	Beth 100, 1550 1015	70 4= 70	PO to 04	05 alua	Number	0-1-
Chronic kidney disease due to diabetes mellitus type 2	126	136	84.3	220	29.3	123	120	67 67	184	30.3
Chronic kidney disease due to	(78.6 to 196) 98.8	(91.2 to 204) 169	(55.9 to 128)	(205 to 235) 229	(23.2 to 35.6) 33.1	(77.7 to 194) 80.4	(81.4 to 179)	(43.3 to 102) 180	(171 to 198) 190	(24.5 to 36.4) 32.8
Chronic kidney disease due to	(62.3 to 153)	(113 to 252)	(172 to 427)	(215 to 246)	(27.2 to 39.7)	(51.2 to 124)	(87 to 187)	(115 to 287)	(176 to 204)	(26.7 to 39.3)
	20.9	15.7	10.2	194	18.8	16.1	11	6.86	163	20.4
giomerulonephritis	(12.5 to 33.1)	(9.8 to 24.4)	(5.14 to 20.9)	(178 to 210)	(12.4 to 25.3)	(9.51 to 25.8)	(6.94 to 17.3)	(3.35 to 14.4)	(148 to 180)	(13.6 to 28.2)
Chronic kidney disease due to	153	308	601	209	24.9	188	343	575	177	27
other and unspecified causes	(102 to 226)	(215 to 431)	(387 to 917)	(195 to 224)	(19.3 to 30.9)	(129 to 275)	(240 to 476)	(359 to 901)	(164 to 191)	(20.8 to 33.2)
Acute gromer dronepin rus	(0.0164 to 0.0534)	(0.0161 to 0.0494)	(0.0146 to 0.0517)	(27.9 to 56)	(-48.3 to -36.9)	(0.0149 to 0.0473)	(0.0127 to 0.0387)	(0.0103 to 0.0356)	(34.5 to 58.6)	(-38.4 to -27.3)
Skin and subcutaneous diseases	(380 to 893)	(415 to 1050)	(477 to 1190)	(135 to 145)	(-4.92 to -0.888)	(401 to 931)	(419 to 1040)	(500 to 1200)	(106 to 116)	(-5.49 to -1.08)
Dermatitis	127	131	139	146	-0.419	151	139	136	118	-0.0954
	(76.6 to 188)	(81.2 to 198)	(82.8 to 214)	(142 to 151)	(-2.12 to 1.59)	(91.5 to 224)	(87.8 to 210)	(80.8 to 210)	(114 to 122)	(-1.74 to 1.59)
Atopic dermatitis	66.5	78.7	91.2	151	1.64	85.3	88.7	95.5	119	0.178
	(37 to 107)	(43.4 to 130)	(50.3 to 151)	(146 to 157)	(-0.522 to 4.05)	(47.6 to 139)	(49.3 to 146)	(52.9 to 157)	(114 to 123)	(-1.95 to 2.32)
Contact dermatitis	51.6	42.7	39.8	140	-2.91	58.4	43.5	34.7	117	-0.527
	(26.7 to 90.7)	(20.9 to 71.7)	(18.5 to 75.6)	(134 to 146)	(-5.32 to -0.544)	(30.8 to 104)	(21.5 to 72.8)	(15.8 to 66.2)	(112 to 123)	(-2.99 to 2.03)
Seborrhoeic dermatitis	8.62	9.4	7.85	142	-2.22	7.23	7.32	6.09	118	-0.177
	(4.71 to 13.7)	(5.35 to 15)	(4.34 to 12.7)	(137 to 146)	(-4.03 to -0.387)	(3.97 to 11.5)	(4.15 to 11.6)	(3.36 to 9.72)	(113 to 122)	(-2.13 to 1.98)
Psoriasis	92.9	74.6	45.1	92.3	-22.3	89.6	68.7	43.4	62	-25.7
	(67.3 to 120)	(54.2 to 97.1)	(33.2 to 57.6)	(88.9 to 96.2)	(-23.6 to -20.7)	(65.5 to 117)	(49.8 to 89.2)	(32 to 55.4)	(58.9 to 65.3)	(-27.2 to -24.2)
Bacterial skin diseases	6.76	6.85	7.48	170	9.02	5.76	6.19	7.22	123	2.35
	(3.96 to 11.4)	(4.14 to 10.8)	(4.88 to 11.2)	(162 to 177)	(5.75 to 11.9)	(3.44 to 9.57)	(3.86 to 9.61)	(4.83 to 10.6)	(115 to 131)	(-1.47 to 5.87)
Cellulitis	2.97	3.69	5.39	162	5.98	2.86	3.61	5.43	110	-3.69
	(2.02 to 4.19)	(2.45 to 5.18)	(3.66 to 7.67)	(150 to 175)	(1.16 to 11.3)	(1.91 to 4.01)	(2.43 to 5.07)	(3.73 to 7.61)	(100 to 120)	(-8.21 to 0.85)
Pyoderma	3.78	3.16	2.09	177	11.9	2.91	2.58	1.79	140	10.2
	(1.54 to 7.98)	(1.3 to 6.49)	(0.851 to 4.29)	(171 to 183)	(9.75 to 14.3)	(117 to 612)	(1.06 to 5.3)	(0.728 to 3.71)	(135 to 145)	(7.93 to 12.3)
Scables	39.9	43.1	34.8	178	12.4	38.9	42.6	35.6	175	26.3
Fungal skin diseases	(20.8 to 68) 91.6	(23.3 to 71.1) 159	(17.6 t0 59.9) 245	(1/1 to 185) 151	(9.61 to 15.4)	(20.3 to 66.3) 86.9	(23.6 to 70.4) 157	(18.3 t0 61.5)	(168 to 184) 123	2.3
Viral skin diseases	(35.6 to 192)	(63.4 to 341)	(97.6 to 505)	(147 to 156)	(0.0194 to 3.3)	(33.9 to 183)	(63.3 to 337)	(96.3 to 496)	(119 to 128)	(0.288 to 4.67)
	41.1	32.5	22.1	145	-1.11	36.5	28.9	25.3	103	-6.74
Accessolateir	(26.6 to 59.8)	(21.4 to 47.3)	(14.7 to 32.2)	(142 to 148)	(-2.28 to 0.0559)	(23.4 to 52.9)	(19 to 41.8)	(16.9 to 36.5)	(101 to 106)	(-7.9 to -5.51)
	5.54	3.81	1.25	187	16.1	6.1	3.98	1.41	141	10.7
Alexania assate	(3.41 to 8.68)	(2.34 to 5.97)	(0.752 to 1.97)	(180 to 195)	(13.3 to 19.1)	(3.72 to 9.51) 9.29	(2.45 to 6.23)	(0.863 to 2.24)	(136 to 148)	(8.32 to 13.6)
A opecia areata	(2.29 to 5.34)	(1.37 to 3.1)	(0.507 to 1.18)	(138 to 157)	(-3.94 to 3.73)	(5.94 to 13.7)	(3.58 to 7.91)	(1.03 to 2.32)	(103 to 112)	(-7.09 to -2.62)
Pruritus	18.2 (8.3 to 34.2)	(8.52 to 37)	(8.79 to 37.2)	(164 to 175)	(6.73 to 11.3)	(10.4 to 43.4)	(10.1 to 42.6)	(8.61 to 36.5)	(133 to 143)	(6.74 to 11.4)
Urticaria	26.7 (17 to 40)	22 (14.6 to 32.3)	16.7 (9.5 to 27.2)	143 (138 to 149)	-1.78 (-3.89 to 0.636)	41.9 (26.6 to 62.8)	31 (20.6 to 45.3)	18.9 (10.7 to 30.4)	(107 to 116)	-3.13 (+5.08 to -0.998)
Decubitus ul cer	10.3	30.4	104	149	0.629	9.53	34.5	123	116	-0.817
	(6.91 to 14.7)	(21.2 to 41.1)	(68.1 to 154)	(137 to 164)	(-4.08 to 6.66)	(6.46 to 13.4)	(24.1 to 46.9)	(82.1 to 176)	(105 to 130)	(-5.86 to 5.38)
Other skin and subcutaneous	122	134	130	150	0.929	118	118	123	118	-0.0577
diseases	(58.6 to 221)	(64.8 to 241)	(64.3 to 233)	(148 to 151)	(0.352 to 1.48)	(56.6 to 214)	(57.2 to 213)	(61.1 to 220)	(117 to 119)	(-0.628 to 0.485)
Sense organ diseases	4000	5690	7130	136	-4.79	4000	5760	7160	117	-0.502
	(2790 to 5520)	(4080 to 7560)	(5240 to 9340)	(130 to 140)	(-6.85 to -2.84)	(2800 to 5490)	(4140 to 7600)	(5200 to 9360)	(113 to 121)	(-2.39 to 1.32)
Blindness and vision loss	1480	2060	2820	122	-10.2	1670	2250	2800	112	-3.04
	(1040 to 2050)	(1470 to 2760)	(1990 to 3790)	(115 to 129)	(-13 to -7.34)	(1180 to 2300)	(1610 to 2990)	(1980 to 3780)	(106 to 117)	(-5.34 to -0.487)
Glaucoma	92	199	408	84.8	-25.3	68.4	144	284	77.4	-18.7
	(61.5 to 135)	(132 to 279)	(267 to 600)	(78.6 to 92.6)	(-27.8 to -22.2)	(45.3 to 100)	(94.6 to 201)	(185 to 423)	(71.3 to 84.6)	(-21.5 to -15.4)
Cataract	575	936	1180	122	-10.4	718	1090	1260	118	-0.0255
	(399 to 796)	(656 to 1250)	(777 to 1620)	(112 to 133)	(-14.2 to -5.96)	(505 to 985)	(772 to 1440)	(849 to 1730)	(111 to 127)	(-3.48 to 4.16)
Age-related macular degeneration	51.6	77.9	129	124	-9.55	61.9	104	202	93	-11.5
	(34.6 to 73.5)	(53.2 to 109)	(79.8 to 196)	(116 to 133)	(-12.6 to -5.83)	(41.7 to 87.9)	(72 to 145)	(124 to 306)	(86.3 to 101)	(-14.6 to -7.7)
Refraction disorders	290	305	208	121	-10.5	306	314	220	102	-7.53
	(198 to 410)	(205 to 429)	(130 to 315)	(117 to 126)	(-12.4 to -8.51)	(209 to 428)	(212 to 439)	(138 to 333)	(97.5 to 105)	(-9.44 to -5.89)
Near vision loss	278	285	235	141	-2.56	306	310 (138 to (03)	226	125	3.34
Other vision loss	196	257	661	128	-8.02	213	290	612	108	-4.43
Age-related and other hearing loss	(137 to 275)	(179 to 354)	(438 to 929)	(122 to 133)	(-10.2 to -5.76)	(149 to 298)	(204 to 394)	(410 to 859)	(104 to 113)	(-6.35 to -2.22)
	2360	3460	4110	143	-1.75	2140	3320	4140	120	1.07
Other sense organ diseases	(1620 to 3370)	(2410 to 4670)	(2940 to 5550)	(136 to 150)	(-4.54 to 0.883)	(1470 to 3070)	(2310 to 4460)	(2960 to 5470)	(115 to 126)	(-1.62 to 3.81)
	157	174	205	162	6.06	191	193	218	128	4.64
Murculorialatal dirordare	(79.1 to 270) 4050	(93.7 to 297) 3880	(101 to 355) 3280	(156 to 170) 144	(3.47 to 9.03)	(96.4 to 326) 5620	(105 to 330) 5220	(108 to 381) 4100	(123 to 135) 118	(2.3 to 7.72) 0.111
Okaumatai di asterisi a	(2800 to 5520)	(2710 to 5380) 57.6	(2240 to 4690)	(137 to 151)	(-4.25 to 1.47)	(3910 to 7670)	(3660 to 7230)	(2790 to 5930)	(113 to 123)	(-2.2 to 2.39) 7 16
Roledinatord and intes	(48.7 to 95.2)	(40.5 to 75.4)	(20.7 to 40)	(159 to 170)	(4.65 to 9.12)	(100 to 194)	(72.6 to 134)	(40.7 to 76)	(130 to 137)	(5.56 to 8.65)
Usteoartnritis	(482 to 1980)	(539 to 2120)	(564 to 2160)	(154 to 160)	(2.7 to 5.02)	(696 to 2820)	(752 to 2960)	(781 to 2990)	(121 to 127)	(1.54 to 4.19)
Osteoarthritis hip	(33.8 to 151)	82.3 (39.1 to 171)	(47.3 to 201)	(169 to 178)	(8.94 to 12.5)	/6.4 (36.6 to 159)	(42.5 to 181)	(52.3 to 218)	(124 to 133)	4.45 (2.72 to 6.59)
Osteoarthritis knee	543	550	471	163	6.28	800	781	628	133	6.89
	(264 to 1100)	(268 to 1100)	(236 to 925)	(160 to 166)	(5.17 to 7.59)	(394 to 1620)	(385 to 1560)	(318 to 1240)	(131 to 136)	(5.69 to 8.21)
Osteoarthritis hand	209	246	316	135	-5.08	368	444	584	107	-5.21
	(101 to 422)	(123 to 498)	(159 to 642)	(128 to 142)	(-7.88 to -2.26)	(184 to 753)	(228 to 912)	(301 to 1180)	(101 to 113)	(-7.78 to -2.18)
Osteoarthritis other	144	177	212	164	6.57	130	166	201	128	4.67
	(71.2 to 295)	(90.8 to 364)	(110 to 414)	(160 to 168)	(5.04 to 8.16)	(64.9 to 267)	(84.2 to 334)	(104 to 390)	(125 to 132)	(3.26 to 6.16)
Low back pain	1680	1820	1480	108	-15.9	2300	2460	1910	92.7	-11.7
	(1120 to 2380)	(1220 to 2550)	(982 to 2150)	(103 to 114)	(-17.7 to -13.7)	(1530 to 3230)	(1680 to 3380)	(1270 to 2770)	(89 to 97.2)	(-13.4 to -9.6)
Neck pain	519	433	423	146	-0.579	644	498	412	117	-0.734
	(301 to 851)	(244 to 719)	(238 to 732)	(135 to 158)	(-4.86 to 4.22)	(374 to 1050)	(278 to 827)	(233 to 686)	(107 to 127)	(-4.9 to 4.04)
Gout	146	159	178	205	23.5	52.3	65.3	79.3	173	25
	(83.7 to 219)	(96.7 to 249)	(104 to 277)	(196 to 218)	(19.7 to 28.4)	(30.6 to 78.4)	(40 to 100)	(45.9 to 123)	(162 to 188)	(20.1 to 31.8)
Other musculoskeletal disorders	661	353	70.8	286	55.9	1110	611	124	204	39.2
	(364 to 1080)	(137 to 651)	(6.92 to 227)	(240 to 388)	(37.6 to 97.2)	(675 to 1680)	(321 to 991)	(23.8 to 370)	(182 to 239)	(29.2 to 55.3)
Other non-communicable diseases	1840 (1330 to 2630)	1880 (1280 to 2640)	1680 (1110 to 2260)	130 (126 to 124)	-7.01	2110	2010	1810	92.4 (88.6 to 96.2)	-11.8 (13.5 to -10)
Congenital birth defects	34.9	27.5	19.6	115	-13.1	34.1	25.6	19.3	100	-8.15
Neural tube defects	0.562	0.44	0.321	315	67.8	0.669	0.517	0.424	250	60.5
Congenital heart anomalies	(0.344 to 0.815)	(0.274 to 0.654)	(0.183 to 0.487)	(284 to 347)	(55.3 to 80.8)	(0.419 to 0.948)	(0.325 to 0.756)	(0.244 to 0.631)	(229 to 273)	(50.8 to 71.1)
	3.51	3.42	3.18	171	9.49	3.5	3.13	3.23	130	5.39
Orofacial clefts	(1.39 to 6.17)	(1.38 to 6.03)	(1.26 to 5.56)	(158 to 183)	(4.49 to 14.5)	(1.43 to 6.1)	(1.28 to 5.53)	(1.32 to 5.67)	(120 to 140)	(0.762 to 9.85)
	2.77	2.5	2.01	157	3.93	2.6	2.27	1.79	150	14.5
David standar	(1.74 to 4.11)	(1.57 to 3.66)	(1.24 to 2.95)	(138 to 180)	(-3.66 to 13)	(1.61 to 3.88)	(1.41 to 3.39)	(1.12 to 2.62)	(128 to 175)	(4.54 to 26.1)
oown synarome				(0 to 0)	(0 to 0)	0.0554	0.0397	0.0393	(0 to 0)	(0 to 0)
Turner syndrome				(0 to 0)	(0 to 0)	(0.0203 to 0.106)	(0.0147 to 0.0751)	(0.0102 to 0.0576)	(93.5 to 103)	-9.18 (-11.3 to -7.01)
Klinefelter syndrome	0.00229 (0.000981 to 0.00444)	0.00127 (0.000511 to 0.00251)	0.000661 (0.00023 to 0.00143)	91 (84.1 to 97.6)	-22.8 (-25.6 to -20.1)				0 (0 to 0)	0 (0 to 0)
Other chromosomal abnormalities				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Congenital musculoskeletal and limb anomalies	12.7 (7.93 to 18.3)	7.84 (4.71 to 11.8)	4.91 (2.78 to 8.01) 0.0000000204	161 (149 to 173)	5.37 (0.487 to 10.4)	15.4 (9.81 to 21.8)	9.43 (5.81 to 14.1)	6.22 (3.62 to 10.1)	112 (104 to 121)	-2.75 (-6.4 to 1.37)
Urogenital congenital anomalies	0.000946	(0.00000000298 to	(0.000000000000128 to	140	-3.09	0.00182	0.0000139	(0.0000000000000306 to	104	-6.69
	(0.0000258 to 0.00477)	0.0000206)	0.000000197)	(120 to 204)	(-11.2 to 22.9)	(0.00016 to 0.00673)	(0.0000000838 to 0.000119)	0.00000115)	(82.1 to 124)	(-16.5 to 2.73)
Digestive congenital anomalies	0.291	0.304	0.339	90.9	-22.8	0.381	0.418	0.521	58.1	-27.5
	(0.177 to 0.444)	(0.187 to 0.467)	(0.204 to 0.529)	(70.3 to 111)	(-31.2 to -14.7)	(0.235 to 0.575)	(0.25 to 0.644)	(0.309 to 0.814)	(44.5 to 73.5)	(-33.7 to -20.5)
Other congenital birth defects	15.1	13	8.83	74.5	-29.5	11.6	9.78	7.06	71.8	-21.3
	(6.67 to 31)	(5.68 to 27.1)	(3.69 to 19.6)	(52.2 to 92.5)	(-38.5 to -22.2)	(4.91 to 25.1)	(4.14 to 21.5)	(2.89 to 16.5)	(50.4 to 87.2)	(-31.1 to -14.2)
Urinary diseases and male infertility	463	417	203	146	-0.696	10.9	8.13	8.3	99.5	-8.56
	(273 to 715)	(249 to 638)	(123 to 313)	(138 to 156)	(-3.7 to 3.38)	(6.93 to 15.6)	(5.22 to 11.4)	(5.22 to 12.7)	(91.5 to 108)	(-12.2 to -4.78)

Supplementary Table 5. Cause-specif	fic rate of YLDs for 70-79	years, 80-94 years, and 95+	years in 2019, and percer	itage change from 199	0 to 2019 in YLD number an	d rate in 70+ years, globa	l, for all GBD causes			
			Males					Females		
		VLDs per 100.000, 2019		Percentage char	are in 70± 1990-2019		YI Ds per 100 000 2019		Percentage chan	re in 70± 1990-2019
C	70 += 70	80 to 04	05 alua	Number	0-1-	70 += 70	1205 pc1 100,000, 1015	or elve	Number	Beta
Urinary tract infections and	2.02	2.47	4.62	169	8.69	5.08	5.06	6.77	112	-2.84
Urolithiasis	9.27	5.19	2.45	73.7	-29.8	3.96	1.97	0.914	86.6	-14.5
Benign prostatic hyperplasia	(5.33 to 14.9) 450	(3.1 to 8.12) 408	(1.39 to 3.91) 196	(64 to 86.8) 148	(-33.7 to -24.5) 0.208	(2.23 to 6.63)	(1.12 to 3.1)	(0.504 to 1.51)	(75.8 to 101) 0	(-19.4 to -7.91) 0
Male infertility	(260 to 696)	(242 to 628)	(116 to 304)	(140 to 160) 0	(-2.98 to 5.02) 0				(0 to 0) 0	(0 to 0) 0
	2.28	125	0.568	(0 to 0)	(0 to 0)	1.81	111	0.618	(0 to 0)	(0 to 0)
oucleaning distance	(1.38 to 3.52)	(0.796 to 1.8)	(0.376 to 0.815)	(65.2 to 90.6)	(-33.2 to -23)	(1.16 to 2.63)	(0.709 to 1.57)	(0.389 to 0.947)	(82.2 to 98.1)	(-16.5 to -9.21)
Gynecological diseases				(0 to 0)	(0 to 0)	(208 to 471)	(166 to 389)	(124 to 377)	(65.9 to 78.6)	(-23.9 to -18.1)
Uterine fibroids				(0 to 0)	(0 to 0)	(5.82 to 26.3)	(2.64 to 11.5)	(1.15 to 4.92)	(82.5 to 97.5)	-13.1 (-16.4 to -9.44)
Polycystic ovarian syndrome				0 (0 to 0)	(0 to 0)				0 (0 to 0)	0 (0 to 0)
Female infertility				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Endometriosis				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Genital prolapse				0 (0 to 0)	0 (0 to 0)	31.1 (14.6 to 57.2)	31 (14.1 to 57.6)	31.2 (14.7 to 60.5)	88.7 (84 to 94.3)	-13.5 (-15.7 to -10.9)
Premenstrual syndrome				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Other gynecological diseases				0 (0 to 0)	0 (0 to 0)	283 (178 to 415)	228 (139 to 342)	193 (94.6 to 343)	69.4 (63.3 to 76.7)	-22.3 (-25.2 to -19)
Hemoglobinopathies and hemolytic anemias	76.9 (52 to 111)	85 (58.6 to 121)	117 (77.4 to 167)	83.7 (72.9 to 95)	-25.7 (-30.1 to -21.2)	96.1 (65.4 to 135)	82.5 (56.7 to 119)	63.7 (43.1 to 91)	85.9 (75.2 to 96.7)	-14.8 (-19.7 to -9.84)
Thalassemias	0.000788 (0.000419 to 0.00133)	0.0000453	0.000000976	178 (144 to 229)	12.2 (-1 36 to 33)	0.00144 (0.000781 to 0.00244)	0.0000854 (0.0000392 to 0.000176)	0.00000319 (0.00000112 to 0.00000857)	171 (135 to 216)	24 (7.52 to 44.7)
Thalassemias trait	30	31.3	20.7	102 (97.2 to 119)	-18.3	34.9 (22.9 to 51.9)	32.6 (21.9 to 49.4)	21.3	92.1 (78.8 to 106)	-11.9
Sickle cell disorders	0.00158	0.000213	0.0000535	391	98.4	0.00521	0.000915	0.000205	214	44
Sickle cell trait	(0.00077 tb 0.00289)	10.3	6.89	(290 to 550) 144	-1.32	(0.00278 to 0.00889)	(0.00037118 0.00169)	6.01	(1/1 to 2/6)	(24.3 to 72.4)
G6PD deficiency	(7.36 to 16) 0.331	(6.83 to 14.6) 0.328	(4.47 to 9.67) 0.272	(129 to 160) 150	(-7.37 to 5.06) 1.03	(9.98 to 20.9) 0.118	(7.47 to 15.5) 0.0929	(3.97 to 8.43) 0.0595	(140 to 162) 169	(9.82 to 20.2) 23.5
G6PD trait	(0.219 to 0.469)	(0.221 to 0.471)	(0.174 to 0.394)	(134 to 168) 0	(-5.56 to 8.32) 0	(0.0785 to 0.167) 0.00374	(0.0625 to 0.132) 0.00355	(0.0395 to 0.0861) 0.00264	(160 to 179) 127	(19.3 to 27.8) 3.98
Other hemoglobinopathies and	25.2	42.1	90	(0 to 0)	(0 to 0)	(0.00251 to 0.00538)	(0.00233 to 0.00526)	(0.00173 to 0.00389)	(118 to 137)	(-0.119 to 8.47)
hemolytic anemias	(24 to 50.7)	(29.4 to 61.4)	(58.2 to 129)	(49.7 to 70.8)	(-39.5 to -31)	(31.7 to 64.9)	(26 to 55.3)	(24.5 to 53.2)	(57 to 80)	(-28 to -17.5)
immune disorders	(247 to 607)	(200 to 494)	(143 to 398)	(126 to 147)	(-8.46 to -0.222)	(363 to 899)	(243 to 605)	(155 to 439)	(90.4 to 106)	(-12.7 to -5.36)
Oral disorders	867 (535 to 1330)	1030 (644 to 1530)	1100 (684 to 1610)	126 (121 to 131)	-8.66 (-10.6 to -6.67)	1060 (665 to 1590)	1240 (795 to 1780)	1220 (774 to 1760)	96.2 (91.5 to 101)	-10.1 (-12.2 to -7.91)
Caries of deciduous teeth				0 (0 to 0)	0 (0 to 0)				0 (0 to 0)	0 (0 to 0)
Caries of permanent teeth	24.7 (10.4 to 49.3)	19.8 (8.12 to 39.2)	12.2 (4.29 to 27.8)	129 (124 to 136)	-7.3 (-9.47 to -4.77)	26.2 (11.2 to 52.4)	20.4 (8.34 to 40)	12 (4.18 to 27.3)	106 (101 to 112)	-5.59 (-7.94 to -3)
Periodontal diseases	171 (68.7 to 347)	145 (56 to 297)	122 (44.6 to 263)	161 (156 to 167)	5.41 (3.37 to 8.07)	153 (61.6 to 312)	126 (47.7 to 257)	109 (40.1 to 234)	139 (132 to 148)	9.43 (6.18 to 13.7)
Edentulism	621 (376 to 945)	837 (523 to 1260)	941 (564 to 1390)	118 (114 to 123)	-11.9 (-13.6 to -9.86)	823 (502 to 1230)	1060 (674 to 1560)	1070 (662 to 1570)	89.7 (85.2 to 94.9)	-13 (-15.1 to -10.7)
Other oral disorders	50.8 (31.8 to 75)	30.6 (19.2 to 44.1)	22.3 (13.7 to 33.7)	142 (140 to 145)	-2 (-3.03 to -0.936)	57.9 (35.9 to 85.3)	35.8 (22.4 to 50.8)	27.2 (16.7 to 39.8)	113 (111 to 116)	-2.23 (-3.21 to -1.17)
Sudden infant death syndrome										
Injuries	2240 (1600 to 3030)	2890 (2020 to 3930)	4280 (2990 to 5880)	154 (149 to 158)	2.52 (0.741 to 4.3)	1940 (1410 to 2600)	3140 (2260 to 4240)	5450 (3820 to 7450)	129 (126 to 132)	5.1 (3.77 to 6.55)
Transport injuries	690 (495 to 920)	659 (464 to 882)	587 (416 to 790)	173 (169 to 178)	10.4 (8.64 to 12.2)	454 (332 to 605)	431 (308 to 574)	362 (255 to 486)	107 (104 to 110)	-5.13 (-6.52 to -3.83)
Road injuries	661 (474 to 882)	626 (440 to 829)	526 (271 to 710)	179 (175 to 184)	13 (11 1 to 14 9)	427 (212 to 569)	396 (280 to 521)	290 (204 to 296)	110 (106 to 112)	-3.87
Pedestrian road injuries	175	177	138	146	-0.674	144	150	105	94.1	-11
Cyclist road injuries	140	127	95	200	21.2	78.4	69.1	46.9	118	-0.179
Motorcyclist road injuries	(99 to 189) 193	(88.1 to 172) 176	(65.7 to 130) 148	(195 to 206) 284	(19.1 to 23.6) 55.1	(56 to 105) 85.5	(48.5 to 93) 68.2	(32.4 to 64.3) 48	(114 to 121) 235	(-1.94 to 1.39) 53.7
Motor vehicle road injuries	(136 to 263) 143	(121 to 242) 136	(102 to 205) 136	(274 to 294) 122	(51.3 to 59.3) -10.2	(60.3 to 115) 112	(47.9 to 93.4) 102	(33.4 to 67) 85.5	(227 to 245) 76.1	(50.1 to 58.2) -19.3
Other road injurier	(102 to 196) 10.6	(96 to 187) 10.7	(94.4 to 187) 9.96	(118 to 126) 185	(-11.8 to -8.68) 15.1	(79.9 to 152) 7.43	(72.1 to 139) 6.9	(59.3 to 118) 5.42	(73.4 to 78.6) 106	(-20.5 to -18.1) -5.37
Other teacement in justice	(7.35 to 14.6)	(7.33 to 14.8)	(6.81 to 14)	(181 to 189)	(13.7 to 16.7)	(5.12 to 10.2)	(4.72 to 9.55)	(3.68 to 7.66)	(103 to 110) 75.4	(-7.16 to -3.62)
oue transportinjunes	(20.5 to 38.1)	(24.3 to 45.1)	(43.1 to 83.6)	(80.3 to 86.4)	(-27.1 to -24.6)	(19.3 to 36.1)	(25.2 to 47)	(49.4 to 97.9)	(72.8 to 78.3)	(-20.8 to -18.3)
Unintentional injuries	(997 to 1940)	(1470 to 2900)	(2470 to 4910)	(144 to 156)	(-1.45 to 3.3)	(1000 to 1900)	(1870 to 3590)	(3510 to 6870)	(135 to 142)	(7.56 to 11.1)
Falls	(655 to 1250)	(1070 to 2090)	(1880 to 3730)	(179 to 193)	(12.8 to 18.3)	(748 to 1410)	(1560 to 2980)	(3100 to 6030)	(152 to 160)	(15.5 to 19.2)
Drowning	4.74 (3.32 to 6.43)	7.76 (5.44 to 10.6)	12.5 (8.55 to 17.4)	126 (116 to 137)	-8.55 (-12.8 to -4.2)	7.01 (4.85 to 9.55)	14.5 (10.1 to 20)	29.8 (19.9 to 41.3)	254 (239 to 269)	62.1 (55.4 to 69.2)
Fire, heat, and hot substances	50.9 (29 to 83)	56.3 (32.3 to 93.2)	76.2 (44.7 to 122)	85 (81.5 to 88)	-25.2 (-26.6 to -24)	54.1 (32.2 to 86.9)	56.8 (32.8 to 93.3)	66.1 (38.3 to 107)	76.4 (72.3 to 79.6)	-19.1 (-21 to -17.7)
Poisonings	6.26 (4.21 to 8.59)	6.94 (4.77 to 9.44)	8.84 (6.17 to 12)	90.4 (84.5 to 96.8)	-23 (-25.4 to -20.5)	7.28 (4.97 to 9.99)	8.34 (5.8 to 11.4)	10.6 (7.39 to 14.4)	60.7 (56.1 to 65)	-26.3 (-28.5 to -24.4)
Poisoning by carbon monoxide	1.33 (0.835 to 1.98)	1.35 (0.883 to 1.97)	1.27 (0.85 to 1.8)	155 (144 to 166)	2.95 (-1.36 to 7.48)	1.5 (0.953 to 2.22)	1.66 (1.08 to 2.41)	1.87 (1.24 to 2.68)	93.3 (87.7 to 98.6)	-11.4 (-14 to -8.96)
Poisoning by other means	4.93 (3.23 to 6.88)	5.59 (3.69 to 7.83)	7.57 (5.13 to 10.5)	78.6 (73.6 to 83.6)	-27.8 (-29.8 to -25.8)	5.78 (3.79 to 8.1)	6.68 (4.42 to 9.29)	8.77 (5.91 to 12.3)	54.1 (49.9 to 58.1)	-29.4 (-31.3 to -27.5)
Exposure to mechanical forces	239 (155 to 351)	280 (182 to 410)	371 (241 to 546)	93.1 (90.9 to 95.2)	-22 (-22.8 to -21.1)	112 (75.3 to 161)	137 (91.5 to 196)	191 (126 to 275)	93.2 (91 to 95.2)	-11.4 (-12.4 to -10.5)
Unintentional firearm injuries	8.73 (5.9 to 12.6)	9.94 (6.74 to 14.4)	17.8 (11.9 to 26.1)	84.5 (80.6 to 88.5)	-25.4 (-27 to -23.8)	6 (4.15 to 8.32)	6.55 (4.53 to 9.19)	8.94 (5.98 to 13)	101 (97.7 to 104)	-7.99 (-9.34 to -6.66)
Other exposure to mechanical forces	231 (149 to 339)	270 (174 to 396)	354 (229 to 519)	93.4 (91.1 to 95.6)	-21.8 (-22.7 to -20.9)	106 (70.6 to 153)	131 (87.2 to 186)	182 (120 to 263)	92.8 (90.6 to 94.8)	-11.6 (-12.6 to -10.7)
Adverse effects of medical treatment	8.22 (4.4 to 13.9)	8.53 (4,84 to 13.9)	12.6 (6.21 to 23)	224 (210 to 242)	31.1	6.98 (3.76 to 11.6)	6.55	8.16	132	6.17
Animal contact	16.2	(4.04 00 15.9)	23	76.3	(23.2 to 38.1) -28.7	(3.76 to 11.8) 15.1	(5.74 to 10.6) 15.6	(4 to 15.1) 18.7	(121 to 143) 82.2	-16.5
Venomous animal contact	(10.7 to 23.9) 4.98	(11.6 to 25.8) 5.01	(15.3 to 34.2) 6.16	(70.4 to 81.3) 64.2	(-31.1 to -26.7) -33.6	(10 to 22.2) 4.57	(10.3 to 23) 4.34	(12.3 to 27.8) 4.55	(/7.8 to 85.9) 71.2	(-18.5 to -14.8) -21.5
Non-venomous animal contact	(3.42 to 6.89) 11.2	(3.48 to 6.94) 12.4	(4.31 to 8.6) 16.9	(59.4 to 68.6) 82.1	(-35.6 to -31.8) -26.4	(3.11 to 6.35) 10.5	(3.01 to 6) 11.2	(3.17 to 6.35) 14.1	(67.3 to 75) 87.2	(-23.3 to -19.8) -14.2
Foreign body	(6.88 to 17.3) 41.6	(7.8 to 19.2) 48.2	(10.7 to 25.7) 74.8	(75.6 to 87) 124	(-29 to -24.4) -9.47	(6.46 to 16.2) 29	(7.01 to 17.4) 34.2	(8.8 to 21.9)	(83 to 90.7) 94.2	(-16.1 to -12.6) -11
Pulmonary aspiration and foreign	(29 to 57.4)	(34.5 to 66.9)	(52.6 to 104)	(121 to 127)	(-10.7 to -8.16)	(20.7 to 39.2)	(24.6 to 46.6)	(36.9 to 71.6)	(91.6 to 96.6)	(-12.1 to -9.85)
body in airway	1.87 (1.33 to 2.53)	(2.14 to 4.14)	(4.42 to 9.45)	(89.6 to 102)	-21.1 (-23.3 to -18.5)	(1.81 to 3.35)	3.4b (2.44 to 4.63)	0.17 (4.23 to 8.77)	/3.1 (69.7 to 77.2)	-20.6 (-22.2 to -18.8)
Foreign body in eyes	15.2 (9.8 to 22.2)	14.5 (9.74 to 21.1)	12.6 (8.68 to 17.7)	122 (118 to 126)	-10.2 (-11.7 to -8.67)	8.41 (5.42 to 12.4)	8.63 (5.78 to 12.5)	9.25 (6.41 to 13)	100 (97.2 to 103)	-8.15 (-9.59 to -6.76)
Foreign body in other body part	24.5 (17.1 to 33.4)	30.6 (21.6 to 42.5)	55.8 (38.9 to 78.2)	128 (123 to 132)	-7.93 (-9.77 to -6.07)	18.1 (12.9 to 24.2)	22.1 (16 to 30.2)	36.6 (25.7 to 51.1)	95.1 (91.2 to 98.8)	-10.6 (-12.3 to -8.86)
Environmental heat and cold exposure	25.8 (17 to 36.4)	34.3 (23.2 to 48.1)	67.6 (45.3 to 94.7)	104 (99.9 to 108)	-17.6 (-19.2 to -16.1)	19.2 (12.8 to 27.2)	25.6 (17.5 to 36)	44.4 (29.9 to 61.8)	88.7 (85.5 to 91.4)	-13.5 (-15 to -12.2)
Exposure to forces of nature	9.45 (6.92 to 12.4)	8.04 (5.86 to 10.6)	7.22 (5.13 to 9.91)	721 (552 to 950)	232 (164 to 324)	6.28 (4.41 to 8.78)	5.09 (3.59 to 7.02)	4.04 (2.77 to 5.68)	612 (469 to 794)	226 (161 to 310)

Supplementary Table 5. Cause-speci	fic rate of YLDs for 70-79	vears, 80-94 years, and 95	+ years in 2019, and perce	ntage change from 1990 (to 2019 in YLD number an	ud rate in 70+ vears, globa	al. for all GBD causes			i i
		,,,	Malaa			,,		Complex.		
			IVId les					remaies		
		YLDs per 100,000, 2019		Percentage change	e in 70+, 1990-2019		YLDs per 100,000, 2019		Percentage change	e in 70+, 1990-2019
Causes	70 to 79	80 to 94	95 plus	Number	Rate	70 to 79	80 to 94	95 plus	Number	Rate
Other unintentional injuries	99.9	123	190	88.9	-23.6	96.6	126	196	74.4	-20
	(67 to 145)	(82.1 to 177)	(132 to 267)	(87.2 to 90.8)	(-24.3 to -22.9)	(64.8 to 138)	(85.8 to 177)	(137 to 271)	(71.3 to 76.5)	(-21.5 to -19.1)
Self-harm and interpersonal violence	134	127	148	118	-12.1	88.7	81.3	64.7	82.4	-16.4
	(98.5 to 177)	(93.3 to 167)	(109 to 197)	(109 to 126)	(-15.5 to -8.53)	(68.6 to 112)	(62.2 to 103)	(47.5 to 86.1)	(75.8 to 89.6)	(-19.4 to -13.1)
Self-harm	18	18.7	19.1	104	-17.6	24.1	23.2	20.9	60.1	-26.6
	(12.8 to 24.3)	(13.2 to 25.3)	(13.3 to 26.2)	(99.7 to 108)	(-19.3 to -15.8)	(17.3 to 31.8)	(16.6 to 31.1)	(14.7 to 28.8)	(56.8 to 63.5)	(-28.1 to -25.1)
Self-harm by firearm	2.65	2.96	2.67	105	-17	2.36	2.22	1.3	111	-3.41
	(1.9 to 3.61)	(2.06 to 4.12)	(1.77 to 3.81)	(99.7 to 109)	(-19.3 to -15.3)	(1.72 to 3.16)	(1.59 to 3.03)	(0.88 to 1.83)	(104 to 116)	(-6.33 to -0.954)
Self-harm by other specified means	15.4	15.7	16.4	104	-17.7	21.7	21	19.6	56.1	-28.4
	(10.7 to 20.7)	(10.9 to 21.4)	(11.3 to 22.8)	(99.1 to 108)	(-19.5 to -15.8)	(15.3 to 28.8)	(14.9 to 28.2)	(13.8 to 27)	(53 to 59.2)	(-29.9 to -27)
Interpersonal violence	92.2	85.1	103	115	-12.9	52.3	46.7	35.3	94.8	-10.7
	(67.8 to 124)	(61.9 to 117)	(72.9 to 143)	(112 to 119)	(-14.3 to -11.5)	(40.1 to 66.8)	(35.4 to 60.3)	(25.4 to 49.2)	(89.2 to 102)	(-13.2 to -7.41)
Physical violence by firearm	5.16	5.11	9.72	195	19.4	1.68	1.74	2.38	141	10.5
	(3.61 to 7.12)	(3.5 to 7.23)	(6.54 to 13.7)	(190 to 201)	(17.3 to 21.7)	(1.18 to 2.25)	(1.21 to 2.42)	(1.59 to 3.4)	(137 to 145)	(8.64 to 12.5)
Physical violence by sharp object	13.9	14.2	24.4	86.3	-24.7	4.66	5.05	6.1	57.1	-28
	(9.65 to 19.7)	(9.7 to 20.3)	(16.5 to 34.9)	(82 to 90.2)	(-26.4 to -23.1)	(3.26 to 6.45)	(3.48 to 7.05)	(4.13 to 8.69)	(53.4 to 60.8)	(-29.7 to -26.3)
Sexual violence	7.64	5.46	0.272	161	5.63	16	11.3	0.753	147	13.1
	(4.87 to 11.3)	(3.5 to 8.12)	(0.148 to 0.47)	(159 to 165)	(4.51 to 6.94)	(10.3 to 23.6)	(7.36 to 16.6)	(0.419 to 1.29)	(144 to 150)	(11.9 to 14.4)
Physical violence by other means	65.4	60.3	68.7	114	-13.5	29.9	28.6	26.1	81.5	-16.8
	(45.6 to 90.5)	(41.8 to 84.1)	(48.3 to 96.5)	(111 to 117)	(-14.9 to -12.1)	(21.3 to 40.7)	(20.1 to 39.3)	(18.4 to 36.2)	(78 to 85)	(-18.4 to -15.2)
Conflict and terrorism	23.8	23.1	25.2	135	-4.91	12.1	11.1	8.15	81.5	-16.8
	(15 to 39.7)	(15.5 to 34.7)	(17.3 to 35.2)	(91.7 to 189)	(-22.5 to 16.9)	(7.45 to 20.4)	(7.07 to 16.8)	(5.35 to 11.9)	(50.1 to 120)	(-31.2 to 1.01)
Executions and police conflict	0.448	0.493	0.642	720	231	0.221	0.291	0.288	388	124
	(0.258 to 0.803)	(0.314 to 0.785)	(0.4 to 1)	(526 to 994)	(153 to 342)	(0.136 to 0.36)	(0.181 to 0.455)	(0.176 to 0.46)	(221 to 593)	(47.2 to 218)
Total cancers	723	921	723	191	17.5	425	523	518	141	10.5
	(530 to 913)	(681 to 1170)	(521 to 913)	(168 to 216)	(8.4 to 27.8)	(318 to 546)	(377 to 665)	(373 to 658)	(124 to 158)	(2.55 to 18.2)
Total burden related to hepatitis B	11.8	10	3.86	96.5	-20.6	5.76	4.53	2.27	57.6	-27.8
	(7.97 to 16.8)	(6.81 to 14.6)	(2.32 to 5.97)	(72.4 to 125)	(-30.3 to -9.16)	(3.73 to 8.45)	(2.92 to 6.73)	(1.28 to 3.64)	(39.2 to 80)	(-36.2 to -17.5)
Total burden related to hepatitis C	10.7	13.5	9.3	176	11.8	7.62	9.13	7.57	118	-0.0976
	(7.13 to 15.2)	(9.39 to 18.3)	(6.2 to 13.1)	(159 to 198)	(4.7 to 20.6)	(5.1 to 11)	(6.2 to 12.8)	(5.12 to 10.6)	(102 to 135)	(-7.59 to 7.95)
Total burden related to Non-alcoholic	2.91	3.1	1.7	168	8.36	3.34	3.2	1.88	126	3.69
fatty liver disease (NAFLD)	(1.65 to 4.68)	(1.8 to 4.9)	(0.862 to 3.18)	(148 to 195)	(0.441 to 19.1)	(1.84 to 5.33)	(1.85 to 5.09)	(0.96 to 3.43)	(110 to 144)	(-3.6 to 12)

Supplementary Table 6:	Life expectancy,	Health-adjusted	life expectancy, a	and proportion o	f years spent in	ill health in all re	porting locations	s, in 1990, 2005, 2	2019
location	1990	LE-70	2019	1990	HALE-70	2019	1990	PYIH-70	2019
Global	11.8	12.8	14.1	8.48	9.18	10.1	0.28	0.28	0.29
	(11.7 to 12)	(12.7 to 12.9)	(13.9 to 14.4)	(7.57 to 9.29)	(8.24 to 10)	(9.01 to 11)	(0.22 to 0.35)	(0.22 to 0.35)	(0.23 to 0.35)
Low SDI	9.53	10.3	11.5	6.79	7.32	8.2	0.29	0.29	0.29
	(9.34 to 9.74)	(10.1 to 10.5)	(11.2 to 11.8)	(6.07 to 7.48)	(6.55 to 8.07)	(7.31 to 9.04)	(0.23 to 0.35)	(0.23 to 0.35)	(0.24 to 0.35)
Low-middle SDI	10	11.1	12.3	7.09	7.8	8.62	0.29	0.3	0.3
	(9.88 to 10.2)	(10.9 to 11.2)	(11.9 to 12.7)	(6.33 to 7.81)	(6.94 to 8.57)	(7.66 to 9.55)	(0.24 to 0.36)	(0.24 to 0.36)	(0.25 to 0.36)
Middle SDI	11.2	11.9	13.3	8.06	8.59	9.49	0.28	0.28	0.28
	(10.9 to 11.5)	(11.7 to 12.1.)	(12.8 to 13.7)	(7.19 to 8.83)	(7.72 to 9.39)	(8 54 to 10 4)	(0.23 to 0.34)	(0.22 to 0.34)	(0.24 to 0.34)
High-middle SDI	11.8	12.6	14.5	8.55	9.14	10.4	0.28	0.28	0.28
	(11.7 to 12)	(12.5 to 12.7)	(14.1 to 14.8)	(7.66 to 9.35)	(8.21 to 9.97)	(9.38 to 11.4)	(0.22 to 0.34)	(0.22 to 0.34)	(0.23 to 0.34)
High SDI	13.8	15.5	16.7	9.81	11.1	11.8	0.29	0.29	0.29
	(13.7 to 13.8)	(15.5 to 15.5)	(16.6 to 16.8)	(8.76 to 10.8)	(9.87 to 12.1)	(10.5 to 13)	(0.22 to 0.36)	(0.22 to 0.36)	(0.23 to 0.37)
Central Europe, Eastern	11.6	11.4 (11.4 to 11.4)	13.2	8.43	8.34	9.62	0.27	0.27	0.27
Central Asia	12.1	9.84	11	9.1	7.46	8.26	0.25	0.24	0.25
A i	(12 to 12.2)	(9.76 to 9.93)	(10.6 to 11.4) 12.9	8.92	(6.8 to 8.07) 8.85	(7.49 to 9.04) 9.61	0.26	0.19 to 0.3)	0.21 to 0.29)
Armenia	(11.9 to 12.1)	(11.8 to 12)	(12.1 to 13.8)	(8.1 to 9.68)	(8.02 to 9.6)	(8.58 to 10.6)	(0.2 to 0.32)	(0.2 to 0.32)	(0.23 to 0.29)
Azerbaijan	(12.1 to 12.8)	(9.65 to 10.1)	(9.83 to 10.9)	(8.63 to 10.3)	(6.85 to 8.17)	(7.07 to 8.66)	(0.2 to 0.29)	(0.19 to 0.29)	(0.21 to 0.28)
Georgia	(10.8 to 11.5)	11.4 (11.1 to 11.7)	12.4 (11.5 to 13.3)	8.47 (7.68 to 9.18)	8.62 (7.83 to 9.37)	9.18 (8.17 to 10.2)	0.24 (0.2 to 0.29)	0.25 (0.2 to 0.29)	0.26 (0.23 to 0.29)
Kazakhstan	11.8	10.4	11.9	8.75	7.73	8.77	0.26	0.26	0.26
	(11.7 to 12)	(10.3 to 10.5)	(11.3 to 12.5)	(7.88 to 9.53)	(6.97 to 8.42)	(7.86 to 9.72)	(0.21 to 0.33)	(0.2 to 0.32)	(0.22 to 0.3)
Kyrgyzstan	12.7	10.9	12.9	9.48	8.31	9.79	0.25	0.24	0.24
	(12.5 to 12.9)	(10.9 to 11)	(12.3 to 13.5)	(8.57 to 10.3)	(7.58 to 8.96)	(8.85 to 10.7)	(0.2 to 0.31)	(0.18 to 0.3)	(0.2 to 0.28)
Mongolia	9.85	9.28	10.8	7.48	7.08	8.28	0.24	0.24	0.24
	(9.19 to 10.6)	(8.72 to 9.93)	(9.74 to 11.9)	(6.66 to 8.29)	(6.32 to 7.87)	(7.19 to 9.38)	(0.22 to 0.28)	(0.21 to 0.27)	(0.21 to 0.26)
Tajikistan	13.2	9.96	9.61	10	7.65	7.36	0.24	0.23	0.23
	(12.9 to 13.6)	(9.64 to 10.3)	(8.7 to 10.5)	(9.11 to 10.9)	(6.95 to 8.33)	(6.44 to 8.3)	(0.2 to 0.29)	(0.19 to 0.28)	(0.21 to 0.26)
Turkmenistan	11.7	10.8	12.4	8.87	8.22	9.48	0.24	0.24	0.24
Uzbekistan	12.7	7.75	8.73	9.71	5.98	6.69	0.24	0.23	0.23
Central Europe	(12.7 to 12.8) 11.3	(7.61 to 7.9)	(8.18 to 9.33) 13.9	(8.84 to 10.5) 8.15	(5.47 to 6.44) 9.03	(5.98 to 7.39)	0.28	0.27	0.21 to 0.27)
Central Europe	(11.2 to 11.3)	(12.4 to 12.4)	(13.2 to 14.6)	(7.3 to 8.9)	(8.1 to 9.85)	(8.97 to 11.2)	(0.21 to 0.35)	(0.21 to 0.34)	(0.23 to 0.32)
	12.1	13.2	14.2	9.11	9.96	10.7	0.25	0.25	0.25
Albania	(12 to 12.2)	(13.1 to 13.3)	(12.7 to 15.8)	(8.28 to 9.85)	(9.06 to 10.8)	(9.3 to 12.2)	(0.19 to 0.31)	(0.19 to 0.31)	(0.23 to 0.27)
Bosnia and Herzegovina	11.9	11.9	12.8	8.77	8.69	9.28	0.27	0.27	0.28
	(11.8 to 12.1)	(11.8 to 12)	(11.7 to 14.1)	(7.91 to 9.54)	(7.81 to 9.49)	(8.06 to 10.5)	(0.21 to 0.33)	(0.21 to 0.34)	(0.25 to 0.31)
Bulgaria	10.3	10.7	11.9	7.67	7.99	8.86	0.26	0.26	0.26
	(10.2 to 10.5)	(10.6 to 10.9)	(10.9 to 13)	(6.93 to 8.35)	(7.23 to 8.69)	(7.75 to 10)	(0.2 to 0.32)	(0.2 to 0.32)	(0.23 to 0.29)
Croatia	11.3	12.5	14.2	8.07	8.96	10	0.28	0.28	0.29
	(11 to 11.5)	(12.4 to 12.6)	(13 to 15.4)	(7.2 to 8.87)	(7.99 to 9.85)	(8.71 to 11.4)	(0.23 to 0.35)	(0.22 to 0.36)	(0.26 to 0.33)
Czechia	10.8	13.1	14.8	7.69	9.28	10.4	0.29	0.29	0.3
	(10.8 to 10.9)	(13 to 13.2)	(13.8 to 15.9)	(6.83 to 8.46)	(8.23 to 10.2)	(9.09 to 11.8)	(0.22 to 0.37)	(0.22 to 0.37)	(0.26 to 0.34)
Hungary	11.1	12.5	13.9	7.81	8.87	9.98	0.29	0.29	0.28
	(11 to 11.1)	(12.4 to 12.5)	(12.9 to 15)	(6.94 to 8.6)	(7.9 to 9.76)	(8.74 to 11.2)	(0.22 to 0.37)	(0.22 to 0.36)	(0.25 to 0.32)
Montenegro	13.2	12.1	12.5	9.73	8.97	9.16	0.26	0.26	0.27
	(12.9 to 13.4)	(11.9 to 12.3)	(11.7 to 13.3)	(8.77 to 10.7)	(8.08 to 9.77)	(8.08 to 10.2)	(0.21 to 0.32)	(0.21 to 0.32)	(0.23 to 0.31)
North Macedonia	10.6	10.2	10.9	7.78	7.44	7.99	0.27	0.27	0.27
Roland	(10.4 to 10.7)	(10 to 10.3)	(9.99 to 11.9)	(7 to 8.5)	(6.68 to 8.13)	(6.96 to 9.05)	(0.21 to 0.33)	(0.21 to 0.33)	(0.24 to 0.3)
	11.7	13.5	14.9	8.4	9.78	10.9	0.28	0.27	0.27
Polunu	(11.6 to 11.7)	(13.4 to 13.5)	(14 to 15.9)	(7.5 to 9.21)	(8.75 to 10.7)	(9.54 to 12.1)	(0.21 to 0.36)	(0.21 to 0.35)	(0.24 to 0.32)
Romania	(11.1 to 11.2)	(11.9 to 12)	(12.5 to 14.5)	(7.4 to 8.92)	(8.06 to 9.65)	(8.78 to 11.1)	(0.2 to 0.33)	(0.19 to 0.32)	(0.23 to 0.3)
Serbia	10.9	10.7	12.2	7.98	7.86	8.85	0.26	0.26	0.27
	(10.8 to 10.9)	(10.6 to 10.7)	(11.2 to 13.1)	(7.22 to 8.68)	(7.09 to 8.55)	(7.75 to 9.96)	(0.2 to 0.33)	(0.2 to 0.33)	(0.24 to 0.31)
Slovakia	11.4	12.6	14.1	8.33	9.2	10.3	0.27	0.27	0.27
	(11.3 to 11.5)	(12.5 to 12.7)	(12.9 to 15.4)	(7.49 to 9.09)	(8.24 to 10)	(8.92 to 11.6)	(0.21 to 0.34)	(0.21 to 0.34)	(0.24 to 0.31)
Slovenia	12.4	14.5	16.3	8.8	10.3	11.6	0.29	0.29	0.29
	(11 to 13.8)	(14.4 to 14.7)	(14.7 to 17.7)	(7.53 to 10.2)	(9.07 to 11.3)	(9.95 to 13.2)	(0.26 to 0.32)	(0.23 to 0.37)	(0.25 to 0.33)
Eastern Europe	11.8	11.1	13.3	8.49	8.09	9.73	0.28	0.27	0.27
	(11.7 to 11.8)	(11.1 to 11.1)	(12.8 to 13.9)	(7.59 to 9.29)	(7.24 to 8.83)	(8.62 to 10.7)	(0.21 to 0.35)	(0.21 to 0.35)	(0.22 to 0.33)
Belarus	12.4	11.5	13	9.07	8.47	9.63	0.27	0.26	0.26
	(12.3 to 12.4)	(11.5 to 11.6)	(11.7 to 14.3)	(8.15 to 9.89)	(7.63 to 9.21)	(8.27 to 11)	(0.2 to 0.34)	(0.2 to 0.33)	(0.23 to 0.29)
Estonia	11.5	13	15	8.5	9.63	11.1	0.26	0.26	0.26
	(11.4 to 11.7)	(12.9 to 13.2)	(13.8 to 16.4)	(7.67 to 9.24)	(8.65 to 10.5)	(9.73 to 12.5)	(0.21 to 0.33)	(0.21 to 0.33)	(0.23 to 0.3)
Latvia	, 11.8 (11.7 to 11.9)	, 12.4 (12.3 to 12.5)	14.2 (13.2 to 15.1)	8.55 (7.65 to 9.36)	9.07 (8.12 to 9.9)	10.4 (9.17 to 11.6)	0.27 (0.21 to 0.35)	0.27 (0.21 to 0.34)	0.27 (0.23 to 0.3)
Lithuania	12.5	12.9	14.5	9.12	9.33	10.7	0.27	0.28	0.27
	(12.4 to 12.6)	(12.8 to 13)	(13.6 to 15.6)	(8.16 to 9.97)	(8.38 to 10.2)	(9.38 to 11.9)	(0.21 to 0.34)	(0.21 to 0.34)	(0.24 to 0.31)
Republic of Moldova	11.1	11.2	13.7	8.13	8.29	10.2	0.26	0.26	0.26
Russian Federation	11.7	11	13.3	8.44	7.99	9.69	0.28	0.28	0.27
	(11.7 to 11.7) 11.7	(11 to 11)	(12.6 to 14.1) 13.1	(7.54 to 9.24) 8.49	(7.13 to 8.73) 8.12	(8.48 to 10.7) 9.67	(0.21 to 0.36) 0.28	(0.21 to 0.35) 0.26	(0.24 to 0.33) 0.26
Ukraine	(11.7 to 11.7)	(11 to 11)	(12.4 to 13.8)	(7.61 to 9.27)	(7.31 to 8.84)	(8.64 to 10.7)	(0.21 to 0.35)	(0.2 to 0.33)	(0.22 to 0.3)

Supplementary Table 6:	Life expectancy,	Health-adjusted	life expectancy,	and proportion o	of years spent in	ill health in all re	porting location	s, in 1990, 2005, i	2019
location	1990	LE-70	2010	1000	HALE-70	2010	1990	PYIH-70	2010
High-income	13.8	15.6	16.7	9.87	11.1	11.8	0.29	0.29	0.29
	(13.8 to 13.8)	(15.6 to 15.6)	(16.7 to 16.7)	(8.82 to 10.8)	(9.92 to 12.2)	(10.6 to 13)	(0.22 to 0.36)	(0.22 to 0.36)	(0.22 to 0.37)
Australasia	13.8	16.1	17.1	9.8	11.3	12	0.29	0.3	0.3
	(13.7 to 13.8)	(16 to 16.1)	(17 to 17.2)	(8.74 to 10.8)	(10.1 to 12.5)	(10.6 to 13.2)	(0.22 to 0.36)	(0.23 to 0.37)	(0.23 to 0.37)
Australia	13.8	16.2	17.2	9.86	11.4	12.1	0.29	0.3	0.3
	(13.8 to 13.9)	(16.1 to 16.2)	(17.1 to 17.3)	(8.79 to 10.8)	(10.1 to 12.5)	(10.7 to 13.3)	(0.22 to 0.36)	(0.23 to 0.37)	(0.23 to 0.37)
New Zealand	13.4	15.4	16.5	9.53	11	11.7	0.29	0.29	0.29
	(13.4 to 13.5)	(15.4 to 15.5)	(16.4 to 16.7)	(8.49 to 10.5)	(9.84 to 12.1)	(10.4 to 12.9)	(0.22 to 0.36)	(0.22 to 0.36)	(0.23 to 0.37)
High-income Asia Pacific	14.4 (14.4 to 14.4)	16.9 (16.9 to 16.9)	18.3 (18.3 to 18.4)	10.6 (9.53 to 11.5)	(3.67 to 12.17) 12.4 (11.2 to 13.5)	13.5 (12.2 to 14.7)	0.27 (0.2 to 0.34)	0.27 (0.2 to 0.34)	0.26 (0.2 to 0.33)
Brunei Darussalam	8.98	10.3	11.4	6.34	7.32	8.14	0.29	0.29	0.28
	(8.66 to 9.35)	(9.94 to 10.7)	(10.8 to 11.8)	(5.65 to 7.03)	(6.47 to 8.13)	(7.25 to 9)	(0.25 to 0.35)	(0.24 to 0.35)	(0.24 to 0.33)
Japan	14.9	17.3	18.6	10.9	12.7	13.7	0.27	0.27	0.26
	(14.9 to 14.9)	(17.2 to 17.3)	(18.5 to 18.7)	(9.84 to 11.9)	(11.4 to 13.8)	(12.4 to 14.9.)	(0.2 to 0.34)	(0.2 to 0.34)	(0.2 to 0.33)
Republic of Korea	11.7 (11.7 to 11.7)	14.6	(16.5 to 16.7)	8.5 (7.66 to 9.29.)	10.7	12.4 (11.2 to 13.5)	0.27	0.27 (0.21 to 0.34)	0.27 (0.21 to 0.33)
Singapore	12.9 (12.8 to 12.9)	16.1	18.2	9.46	(10.8 to 12.9)	13.7 (12.4 to 14.8)	0.26	0.26	0.25
High-income North	14.3	15.2	(18.1 (0 18.4) 16 (16 to 16 1)	9.72	10.3	10.5	0.32	0.32	0.34
Canada	14.3	15.9	17.1	10.3	(11.5	12.1	0.28	0.28	0.29
Greenland	(14.3 to 14.3) 10.3	(15.9 to 16) 11.8	(1/ to 1/.2) 13	(9.24 to 11.3) 7.1	(10.3 to 12.5) 8.21	(10.9 to 13.3) 8.99	0.31	0.3	0.31
United States of	(9.89 to 10.7)	(11.3 to 12.1)	(12.2 to 14)	(6.3 to 7.9)	(7.26 to 9.03)	(7.85 to 10.2)	(0.26 to 0.36)	(0.25 to 0.36)	(0.27 to 0.36)
	14.3	15.1	15.9	9.66	10.1	10.4	0.32	0.33	0.35
America	(14.3 to 14.3)	(15.1 to 15.1)	(15.9 to 16)	(8.48 to 10.7)	(8.89 to 11.3)	(9 to 11.6)	(0.25 to 0.4)	(0.26 to 0.41)	(0.27 to 0.43)
	12.8	14	14.6	9.56	10.4	10.8	0.25	0.26	0.26
Argonting	(12.8 to 12.8)	(13.9 to 14)	(14.5 to 14.8)	(8.65 to 10.4)	(9.37 to 11.3)	(9.73 to 11.8)	(0.19 to 0.32)	(0.19 to 0.33)	(0.2 to 0.33)
	12.8	13.8	14.1	9.56	10.3	10.5	0.25	0.26	0.26
Argentina	(12.7 to 12.8) 12.8	(13.7 to 13.8) 14.6	(14 to 14.2) 15.9	(8.66 to 10.4) 9.45	(9.27 to 11.1) 10.7	(9.48 to 11.4) 11.5	(0.19 to 0.32)	(0.19 to 0.33)	(0.2 to 0.32) 0.28
Chile	(12.8 to 12.8)	(14.6 to 14.7)	(15.8 to 16.1)	(8.53 to 10.3)	(9.61 to 11.7)	(10.3 to 12.6)	(0.2 to 0.33)	(0.2 to 0.34) 0.25	(0.22 to 0.34)
Uruguay	(12.9 to 13)	(13.7 to 13.9)	(14.6 to 15)	(8.81 to 10.5)	(9.35 to 11.2)	(9.85 to 11.9)	(0.19 to 0.32)	(0.19 to 0.32)	(0.21 to 0.33)
Western Europe	(13.4 to 13.5)	(15.4 to 15.4)	(16.5 to 16.6)	(8.82 to 10.7)	(10 to 12.2)	(10.8 to 13.1)	(0.21 to 0.34)	(0.21 to 0.35)	(0.21 to 0.35)
Andorra	(13.2 to 16.1)	(15.1 to 17.4)	(15.4 to 18.2)	(9.4 to 12.4)	(10.5 to 13.3)	(10.6 to 13.7)	(0.23 to 0.29)	(0.24 to 0.3)	(0.25 to 0.31)
Austria	(13.2 to 13.3)	(15.1 to 15.2)	(16.5 to 16.7)	9.64 (8.66 to 10.5)	(9.77 to 11.9)	(10.7 to 13.1)	(0.21 to 0.34)	(0.22 to 0.35)	(0.22 to 0.35)
Belgium	13.2	15	16.2	9.65	10.8	11.6	0.27	0.28	0.28
	(13.2 to 13.3)	(15 to 15.1)	(16.1 to 16.4)	(8.67 to 10.5)	(9.64 to 11.8)	(10.4 to 12.8)	(0.21 to 0.34)	(0.22 to 0.36)	(0.22 to 0.36)
Cyprus	11.3	13	14.8	8.37	9.46	10.8	0.26	0.27	0.27
	(11.2 to 11.4)	(12.9 to 13.2)	(14.4 to 15.3)	(7.54 to 9.11)	(8.49 to 10.3)	(9.67 to 11.8)	(0.2 to 0.33)	(0.21 to 0.34)	(0.23 to 0.33)
Denmark	13	14.2	15.8	9.5	10.4	11.6	0.27	0.27	0.27
	(13 to 13.1)	(14.2 to 14.3)	(15.7 to 16)	(8.54 to 10.4)	(9.41 to 11.4)	(10.5 to 12.6)	(0.21 to 0.34)	(0.21 to 0.34)	(0.21 to 0.33)
Finland	13.1	15.4	16.6	9.51	11	12	0.27	0.29	0.28
	(13 to 13.2)	(15.3 to 15.5)	(16.4 to 16.8)	(8.51 to 10.4)	(9.78 to 12.1)	(10.7 to 13.1)	(0.21 to 0.35)	(0.22 to 0.36)	(0.22 to 0.35)
France	14.4	16.3	17.7	10.6	12.1	13.1	0.26	0.26	0.26
	(14.4 to 14.5)	(16.3 to 16.3)	(17.6 to 17.8)	(9.56 to 11.6)	(10.9 to 13.1)	(11.8 to 14.2)	(0.2 to 0.34)	(0.2 to 0.33)	(0.2 to 0.33)
Germany	13	15.1	15.9	9.5	11	11.5	0.27	0.27	0.28
	(13 to 13)	(15.1 to 15.1)	(15.8 to 16)	(8.57 to 10.3)	(9.89 to 12)	(10.3 to 12.6)	(0.2 to 0.34)	(0.21 to 0.34)	(0.21 to 0.35)
Greece	13.3	14.5	15.8	9.82	10.6	11.6	0.26	0.27	0.26
	(13.3 to 13.4)	(14.5 to 14.6)	(15.7 to 16)	(8.9 to 10.7)	(9.61 to 11.6)	(10.6 to 12.7)	(0.2 to 0.33)	(0.21 to 0.34)	(0.21 to 0.33)
Iceland	14.3	16	17.9	10.5	11.5	13	0.27	0.28	0.27
	(14.1 to 14.5)	(15.6 to 16.3)	(17.4 to 18.4)	(9.46 to 11.4)	(10.4 to 12.7)	(11.7 to 14.3)	(0.21 to 0.33)	(0.22 to 0.34)	(0.23 to 0.33)
Ireland	12	14.4	16.1	8.87	10.5	11.7	0.26	0.27	0.27
	(11.9 to 12.1)	(14.3 to 14.5)	(15.9 to 16.3)	(8.01 to 9.63)	(9.48 to 11.5)	(10.6 to 12.8)	(0.2 to 0.33)	(0.21 to 0.34)	(0.22 to 0.33)
Israel	13.6	15.2	16.9	10.2	11.2	12.5	0.25	0.27	0.26
	(13.6 to 13.7)	(15.2 to 15.3)	(16.7 to 17)	(9.22 to 11)	(10.1 to 12.2)	(11.3 to 13.5)	(0.19 to 0.32)	(0.2 to 0.33)	(0.2 to 0.32)
Italy	13.8	15.7	16.9	9.81	11.2	12.1	0.29	0.29	0.28
	(13.8 to 13.8)	(15.7 to 15.7)	(16.9 to 17)	(8.72 to 10.8)	(9.95 to 12.3)	(10.8 to 13.3)	(0.22 to 0.37)	(0.22 to 0.37)	(0.22 to 0.36)
Luxembourg	12.9	14.9	17.1	9.43	10.8	12.2	0.27	0.28	0.29
	(12.7 to 13)	(14.7 to 15.2)	(16.4 to 17.7)	(8.49 to 10.3)	(9.67 to 11.8)	(10.8 to 13.5)	(0.21 to 0.33)	(0.22 to 0.34)	(0.24 to 0.34)
Malta	12.8	14.8	16.8	9.4	10.8	12.3	0.26	0.27	0.27
	(12.6 to 12.9)	(14.6 to 15)	(16.3 to 17.4)	(8.48 to 10.2)	(9.75 to 11.8)	(11 to 13.5)	(0.21 to 0.33)	(0.21 to 0.33)	(0.23 to 0.33)
Monaco	14.3	14.8	15.5	10.7	11	11.4	0.26	0.26	0.27
	(13.5 to 15.7)	(14.1 to 16.2)	(14.8 to 16.6)	(9.47 to 12.1)	(9.7 to 12.3)	(10.1 to 12.7)	(0.23 to 0.3)	(0.24 to 0.31)	(0.24 to 0.32)
Netherlands	13.5	14.7	16	9.98	10.8	11.5	0.26	0.26	0.28
	(13.5 to 13.6)	(14.7 to 14.8)	(15.8 to 16.1)	(9.05 to 10.9)	(9.82 to 11.8)	(10.4 to 12.6)	(0.2 to 0.33)	(0.2 to 0.33)	(0.22 to 0.34)
Norway	13.6	15.3	16.7	9.7	10.9	11.8	0.29	0.29	0.3
	(13.5 to 13.6)	(15.3 to 15.4)	(16.6 to 16.8)	(8.62 to 10.6)	(9.74 to 12)	(10.5 to 12.9)	(0.22 to 0.36)	(0.22 to 0.36)	(0.23 to 0.37)
Portugal	12.4	14.7	16.3	8.99	10.6	11.9	0.27	0.28	0.27
	(12.4 to 12.4)	(14.6 to 14.7)	(16.2 to 16.5)	(8.09 to 9.83)	(9.51 to 11.6)	(10.7 to 13)	(0.21 to 0.34)	(0.21 to 0.35)	(0.21 to 0.34)
San Marino	15.1	16.1	16.6	11.1	11.9	12.2	0.26	0.26	0.26
	(14.3 to 15.9)	(14.6 to 17.5)	(14.6 to 18.9.)	(9.97 to 12.3)	(10.3 to 13.4)	(10.3 to 14.3.)	(0.23 to 0.3)	(0.23 to 0.3)	(0.24 to 0.29)
Spain	13.9 (13.9 to 13.9)	15.7 (15.7 to 15.7)	17.2 (17 to 17 3)	10.1 (9.1 to 11)	(10.3 to 12.5)	12.5 (11.2 to 13.6)	0.27 (0.21 to 0.34)	0.27 (0.21 to 0.34)	0.27 (0.21 to 0.34)
1	,, , ,, , ,, , ,, , ,, , , , , , , , , , , , , , , , , , , ,	(((()))	. =	, ,	,	, (0 10.0 /	,	,	, 0

Supplementary Table 6:	Life expectancy,	Health-adjusted	life expectancy,	and proportion o	of years spent in i	ill health in all re	porting location	s, in 1990, 2005, 2	2019
	1000	LE-70	2010	1000	HALE-70	2010	4000	PYIH-70	1 2010
Sweden	1990 14 (14 to 14 1)	15.6	16.7	1990 10.3	11.3 (10.2 to 12.3)	12.1 (10.9 to 13.2.)	0.26	0.27 (0.21 to 0.35)	0.27 (0.21 to 0.35)
Switzerland	14.4 (14.4 to 14.5)	16.4 (16.3 to 16.4)	17.6 (17.5 to 17.8)	10.4 (9.32 to 11.4)	(10.2 to 12.5) 11.9 (10.6 to 13)	12.8 (11.4 to 14)	0.28 (0.21 to 0.35)	0.28 (0.21 to 0.35)	0.27 (0.21 to 0.35)
United Kingdom	13	14.8	15.8	9.48	10.7	11.3	0.27	0.28	0.28
	(12.9 to 13)	(14.8 to 14.8)	(15.7 to 15.9)	(8.53 to 10.3)	(9.62 to 11.7)	(10.1 to 12.4)	(0.2 to 0.34)	(0.21 to 0.35)	(0.22 to 0.36)
Latin America and	13.1	14.6	15.2	9.44	10.6	11	0.28	0.27	0.27
Caribbean	(13 to 13.1)	(14.5 to 14.6)	(14.7 to 15.7)	(8.45 to 10.3)	(9.51 to 11.6)	(9.91 to 12.1)	(0.21 to 0.35)	(0.21 to 0.34)	(0.23 to 0.33)
Andean Latin America	(13.1 to 13.9)	14.8 (14.4 to 15.2)	(14.4 to 16.5)	(9.05 to 11)	(9.89 to 12)	(10.1 to 12.7)	(0.25 (0.21 to 0.31)	(0.26 (0.21 to 0.31)	(0.23 to 0.3)
State of)	(10.3 to 11.2)	(11.4 to 12.2)	(11.1 to 12.6)	(7.11 to 8.74)	(7.84 to 9.62)	(7.7 to 9.83)	(0.22 to 0.31)	(0.21 to 0.31)	(0.22 to 0.31)
Ecuador	13.8	14.4	14.6	10.4	10.7	10.8	0.25	0.26	0.26
	(13.7 to 14)	(14 to 14.8)	(13.4 to 15.8)	(9.39 to 11.2)	(9.59 to 11.6)	(9.37 to 12.2)	(0.2 to 0.32)	(0.21 to 0.31)	(0.23 to 0.3)
Peru	14.2	16.1	17.1	10.6	12	12.7	0.25	0.25	0.26
	(13.5 to 15)	(15.3 to 16.9)	(15.4 to 18.8)	(9.49 to 11.8)	(10.7 to 13.2)	(11 to 14.4)	(0.21 to 0.3)	(0.22 to 0.3)	(0.23 to 0.29)
Caribbean	13.2	14.1	14.6	9.89	10.5	10.7	0.25	0.26	0.26
	(13.1 to 13.3)	(13.9 to 14.3)	(13.8 to 15.4)	(8.95 to 10.7)	(9.48 to 11.4)	(9.54 to 11.8)	(0.19 to 0.32)	(0.2 to 0.32)	(0.23 to 0.31)
Antigua and Barbuda	13.2	13.7	13.5	10	10.3	10	0.24	0.25	0.26
	(12.9 to 13.5)	(13.5 to 14)	(12.9 to 14.1)	(9.08 to 10.8)	(9.25 to 11.2)	(8.93 to 11.1)	(0.2 to 0.3)	(0.2 to 0.31)	(0.22 to 0.31)
Bahamas	13.1	14.2	14.3	9.97	10.7	10.7	0.24	0.25	0.25
	(12.8 to 13.5)	(13.9 to 14.6)	(13.2 to 15.4)	(9.07 to 10.9)	(9.66 to 11.7)	(9.39 to 12)	(0.2 to 0.29)	(0.2 to 0.3)	(0.22 to 0.29)
Barbados	13.2	13.6	13.8	10	10.2	10.3	0.24	0.25	0.25
	(13 to 13.4)	(13.4 to 13.8)	(13 to 14.7)	(9.12 to 10.8)	(9.25 to 11.1)	(9.16 to 11.5)	(0.19 to 0.3)	(0.19 to 0.31)	(0.22 to 0.29)
Belize	13.9	13.9	14.9	10.6	10.5	11.2	0.24	0.25	0.25
	(13.6 to 14.2)	(13.7 to 14.1)	(14.2 to 15.7)	(9.6 to 11.5)	(9.47 to 11.3)	(10 to 12.4)	(0.19 to 0.29)	(0.19 to 0.31)	(0.21 to 0.29)
Bermuda	12.1	15.2	16.5	9.23	11.5	12.3	0.24	0.25	0.25
	(11.9 to 12.3)	(14.5 to 15.9)	(15.4 to 17.3)	(8.41 to 9.96)	(10.3 to 12.6)	(11 to 13.6)	(0.19 to 0.29)	(0.21 to 0.29)	(0.21 to 0.29)
Cuba	13.7	14.6	15.1	10.2	10.8	11	0.26	0.26	0.27
	(13.6 to 13.7)	(14.5 to 14.7)	(14 to 16.3)	(9.18 to 11)	(9.71 to 11.7)	(9.62 to 12.4)	(0.2 to 0.33)	(0.2 to 0.33)	(0.24 to 0.31)
Dominica	11.8	12.5	12.4	8.89	9.31	9.16	0.24	0.26	0.26
	(11.5 to 12.2)	(12 to 13.1)	(11.5 to 13.1)	(8.05 to 9.67)	(8.36 to 10.2)	(8.06 to 10.3)	(0.2 to 0.3)	(0.22 to 0.3)	(0.22 to 0.3)
Dominican Republic	15.1	14.6	14	11.5	11.1	10.6	0.24	0.24	0.24
	(14.5 to 15.7)	(13.9 to 15.4)	(12.8 to 15.1)	(10.4 to 12.5)	(9.99 to 12.1)	(9.32 to 11.9)	(0.2 to 0.28)	(0.21 to 0.28)	(0.21 to 0.27)
Grenada	11.3	11.5	12.4	8.55	8.57	9.16	0.25	0.25	0.26
	(11 to 11 7)	(11.3 to 11.7)	(12.1 to 12.8)	(7.69 to 9.36)	(773 to 933)	(8.21 to 10.)	(0.2 to 0.3)	(0.2 to 0.31)	(0.22 to 0.32)
Guyana	9.39 (8.88 to 10)	10.9 (10.4 to 11.4)	(11.4 (10.3 to 12.7)	6.93 (6.15 to 7.67)	(7.06 to 8.84)	8.37 (7.19 to 9.64)	0.26 (0.23 to 0.31)	0.26 (0.23 to 0.32)	0.27 (0.24 to 0.3)
Haiti	9.48	10.4	10.9	7.12	7.76	8.11	0.25	0.25	0.26
	(9.23 to 9.87)	(9.85 to 11)	(9.65 to 12.1)	(6.41 to 7.79)	(6.92 to 8.59)	(6.86 to 9.29)	(0.21 to 0.31)	(0.22 to 0.3)	(0.23 to 0.29)
Jamaica	14.4	15.7	14.6	10.9	11.7	10.8	0.24	0.25	0.26
	(14.2 to 14.5)	(15.3 to 16)	(13.3 to 16)	(9.94 to 11.8)	(10.5 to 12.7)	(9.48 to 12.3)	(0.19 to 0.3)	(0.2 to 0.31)	(0.23 to 0.29)
Puerto Rico	14 (13.9 to 14.1.)	15.8 (15.7 to 16.)	17.4 (15.9 to 18.9.)	10.4 (9.44 to 11.4)	11.6 (10.5 to 12.7)	12.7 (11 1 to 14 4)	0.25 (0.19 to 0.32)	0.27 (0.2 to 0.33)	0.27
Saint Kitts and Nevis	9.52 (9.25 to 9.8)	11.8 (11.5 to 12.1)	(15.5 to 15.5) 12 (11.4 to 12.4)	7.12 (6.43 to 7.78)	8.71 (7.81 to 9.54)	8.84 (7.84 to 9.73)	0.25	0.26 (0.21 to 0.32)	0.27 (0.21 to 0.31)
Saint Lucia	11.4 (11.2 to 11.7)	13.6	(11.10012.17) 14 (12.2 to 14.8)	8.44 (7.59.to 9.24)	9.99 (8 98 to 10 9)	10.2	0.26	0.27	0.27
Saint Vincent and the	(11.2 (0 11.7) 11.6	(13.4 to 13.8) 13.5 (12.2 to 12.7)	12.6	(7.39 to 9.24) 8.74	10.1	9.35	0.25	0.26	0.26
Grendames	12.9	13.5	14	9.68	9.93	10.2	0.25	0.26	0.27
Suriname	(12.7 to 13.1) 11.6	(13.3 to 13.7) 13.4	(13.1 to 15) 14.5	(8.76 to 10.5)	(8.95 to 10.9) 9.94	(8.99 to 11.4) 10.7	(0.2 to 0.31)	(0.21 to 0.33)	(0.24 to 0.31)
Trinidad and Tobago	(11.4 to 11.7)	(13.2 to 13.5)	(12.9 to 16.2)	(7.8 to 9.4)	(8.97 to 10.9)	(9.14 to 12.3)	(0.2 to 0.32)	(0.2 to 0.32)	(0.24 to 0.29)
United States Virgin Islands	(12.9 (12.4 to 13.7)	13.4 (12.9 to 13.8)	12.9 (12.6 to 13.5)	9.87 (8.92 to 10.8)	10.1 (9.08 to 10.9)	9.64 (8.68 to 10.6)	0.24 (0.21 to 0.28)	(0.25 (0.21 to 0.3)	0.25 (0.22 to 0.31)
Central Latin America	13.3	14.7	15.4	9.55	10.7	11.1	0.28	0.27	0.28
	(13.3 to 13.4)	(14.7 to 14.8)	(14.6 to 16.1)	(8.52 to 10.5)	(9.58 to 11.7)	(9.82 to 12.3)	(0.22 to 0.36)	(0.21 to 0.35)	(0.24 to 0.33)
Colombia	13.7	15.8	17.5	9.93	11.5	12.8	0.27	0.27	0.27
	(13.6 to 13.7)	(15.8 to 15.9)	(15.9 to 19.1)	(8.89 to 10.8)	(10.4 to 12.6)	(11.2 to 14.5)	(0.21 to 0.35)	(0.21 to 0.34)	(0.24 to 0.3)
Costa Rica	14.9	16.1	16.6	10.8	11.8	12.1	0.27	0.27	0.27
	(14.6 to 15.1)	(16 to 16.3)	(15.2 to 18.1)	(9.69 to 11.8)	(10.5 to 12.9)	(10.5 to 13.7)	(0.22 to 0.34)	(0.21 to 0.34)	(0.24 to 0.31)
El Salvador	15.1	15.3	15.5	11	11.2	11.3	0.27	0.27	0.27
	(15 to 15.2)	(15.2 to 15.4)	(14 to 17.2)	(9.87 to 12)	(9.99 to 12.2)	(9.73 to 12.9)	(0.21 to 0.34)	(0.21 to 0.34)	(0.25 to 0.3)
Guatemala	10.4	12.5	13.9	7.62	9.06	10	0.27	0.28	0.28
	(9.92 to 10.9)	(12 to 13.1)	(12.7 to 15)	(6.78 to 8.45)	(8.07 to 10)	(8.75 to 11.3)	(0.22 to 0.32)	(0.23 to 0.33)	(0.24 to 0.31)
Honduras	14.1	12.9	11.9	10.3	9.53	8.75	0.27	0.26	0.27
	(13.5 to 14.9)	(11.7 to 14.2)	(11.4 to 12.1)	(9.18 to 11.5)	(8.21 to 10.8)	(7.84 to 9.56)	(0.23 to 0.32)	(0.24 to 0.3)	(0.21 to 0.31)
Mexico	13.1	14.5	14.9	9.24	10.4	10.6	0.3	0.28	0.29
	(13.1 to 13.2)	(14.4 to 14.5)	(14.4 to 15.4)	(8.19 to 10.2)	(9.32 to 11.4)	(9.43 to 11.8)	(0.23 to 0.38)	(0.21 to 0.35)	(0.24 to 0.35)
Nicaragua	15.3	12.2	13	11.1	9.05	9.54	0.28	0.26	0.26
	(15.1 to 15.5)	(12.1 to 12.3)	(12.3 to 13.8)	(9.94 to 12.1)	(8.18 to 9.84)	(8.48 to 10.6)	(0.22 to 0.34)	(0.2 to 0.32)	(0.23 to 0.31)
Panama	15.6	16.3	17.3	11.4	11.9	12.6	0.27	0.27	0.27
	(15.4 to 15.8)	(16.1 to 16.5.)	(15.8 to 18.9)	(10.2 to 12.4)	(10.8 to 13.)	(11 to 14.3)	(0.21 to 0.33)	(0.21 to 0.33)	(0.24 to 0.31)
Venezuela (Bolivarian	13.8	15	14.8	10	10.9	10.9	0.27	0.27	0.27
Republic of)	(13.7 to 13.8)	(14.9 to 15)	(13.2 to 16.4)	(8.99 to 10.9)	(9.83 to 11.9)	(9.34 to 12.5)	(0.21 to 0.34)	(0.21 to 0.34)	(0.24 to 0.29)
Tropical Latin America	(12.5 to 12.6)	(14.4 to 14.5)	(15.1 to 15.4)	(8.01 to 9.86)	(9.32 to 11.4)	(9.94 to 12.1)	(0.22 to 0.36)	(0.21 to 0.35)	(0.22 to 0.34)

Supplementary Table 6:	Life expectancy,	, Health-adjusted	life expectancy, a	and proportion o	of years spent in	ill health in all re	porting location	s, in 1990, 2005,	2019
	1000	LE-70	2010	1000	HALE-70	2010	4000	PYIH-70	2010
location	1990	2005	15.3	8 92	2005	2019	0.29	2005	0.27
Brazil	(12.4 to 12.6)	(14.3 to 14.5)	(15.1 to 15.4)	(7.96 to 9.8)	(9.3 to 11.4)	(9.94 to 12.1)	(0.22 to 0.36)	(0.21 to 0.35)	(0.22 to 0.34)
Paraguay	15.3	15.2	15.1	11.3	11.2	11.2	0.26	0.26	0.26
	(14.8 to 15.9)	(14.7 to 15.6)	(13.6 to 16.7)	(10.2 to 12.5)	(10.1 to 12.3)	(9.68 to 12.8)	(0.22 to 0.31)	(0.21 to 0.31)	(0.24 to 0.29)
North Africa and Middle	11.3	12.4	13	8.23	9.01	9.33	0.27	0.28	0.28
East	(11.1 to 11.5)	(12.2 to 12.7)	(12.5 to 13.4)	(7.38 to 9.04)	(8.11 to 9.88)	(8.35 to 10.3)	(0.21 to 0.33)	(0.22 to 0.33)	(0.23 to 0.33)
North Africa and Middle	11.3	12.4	13	8.23	9.01	9.33	0.27	0.28	0.28
EdSL	9.15	9.37	9.77	6.49	6.61	6.75	0.29	0.29	0.31
Afghanistan	(8.5 to 9.88)	(8.55 to 10.2)	(9.11 to 10.8)	(5.63 to 7.29)	(5.68 to 7.52)	(5.82 to 7.76)	(0.26 to 0.34)	(0.26 to 0.34)	(0.28 to 0.36)
Algeria	10.6	12.3	13.3	7.9	9.06	9.71	0.26	0.26	0.27
	(9.96 to 11.3)	(11.5 to 13.1)	(12.6 to 14.1)	(6.96 to 8.83)	(8.1 to 10.1)	(8.58 to 10.8)	(0.22 to 0.3)	(0.23 to 0.3)	(0.24 to 0.32)
Bahrain	9.1	9.54	12	6.48	6.7	8.36	0.29	0.3	0.3
	(8.64 to 9.6)	(9.1 to 9.95)	(11.1 to 13)	(5.74 to 7.21)	(5.93 to 7.48)	(7.24 to 9.51)	(0.25 to 0.34)	(0.25 to 0.35)	(0.27 to 0.35)
Egypt	10.1	10.2	10.7	7.51	7.55	7.88	0.25	0.26	0.27
	(10 to 10.1)	(10.1 to 10.2)	(9.62 to 11.9)	(6.81 to 8.14)	(6.84 to 8.2)	(6.81 to 9.02)	(0.19 to 0.32)	(0.2 to 0.33)	(0.24 to 0.29)
Iran (Islamic Republic	11.8	13.1	14.3	8.42	9.41	10.2	0.29	0.28	0.29
of)	(11.7 to 12)	(13 to 13.2)	(14.2 to 14.5)	(7.52 to 9.26)	(8.44 to 10.3)	(9.12 to 11.2)	(0.23 to 0.36)	(0.22 to 0.35)	(0.22 to 0.36)
Iraq	11.8	11.5	12.5	8.21	8.25	9.01	0.3	0.29	0.28
	(11 to 12.6)	(10.5 to 12.6)	(11.8 to 13.5)	(7.19 to 9.24)	(7.1 to 9.41)	(7.98 to 10.2)	(0.27 to 0.35)	(0.25 to 0.32)	(0.25 to 0.33)
lordan	11.4	12.3	14.5	8.34	8.93	10.5	0.27	0.27	0.27
Jordan	(10.8 to 12)	(11.8 to 12.8)	(13.6 to 15.4)	(7.47 to 9.24)	(7.93 to 9.85)	(9.32 to 11.7)	(0.23 to 0.31)	(0.23 to 0.33)	(0.24 to 0.32)
Kuwait	14.7	15.5	16.4	10.7	11.1	11.8	0.27	0.28	0.28
	(14.5 to 14.9)	(15.3 to 15.6)	(15.5 to 17.4)	(9.65 to 11.8)	(9.96 to 12.2)	(10.4 to 13.2)	(0.21 to 0.33)	(0.22 to 0.35)	(0.24 to 0.33)
Lebanon	11.6	12.7	13.5	8.45	9.2	9.54	0.27	0.28	0.29
	(10.9 to 12.1)	(12.3 to 13.2)	(13 to 14)	(7.51 to 9.33)	(8.24 to 10.1)	(8.43 to 10.6)	(0.23 to 0.31)	(0.23 to 0.33)	(0.24 to 0.35)
Libya	13.9	15.3	14.5	10	10.9	10.3	0.28	0.29	0.29
	(12.9 to 14.8)	(15.1 to 15.5)	(13.3 to 15.8)	(8.89 to 11.2)	(9.72 to 12)	(8.9 to 11.7)	(0.24 to 0.31)	(0.22 to 0.36)	(0.26 to 0.33)
Morocco	11.5	12.2	11.9	8.49	8.92	8.69	0.26	0.27	0.27
	(11.2 to 11.8)	(11.3 to 13)	(11.4 to 13)	(7.66 to 9.3)	(7.86 to 10)	(7.74 to 9.84)	(0.21 to 0.31)	(0.23 to 0.31)	(0.24 to 0.32)
Oman	9.5	10.6	10.7	6.87	7.55	7.6	0.28	0.28	0.29
Palestine	(8.62 to 10.6)	(10.3 to 10.8)	(10.3 to 11.1)	(5.94 to 7.9)	(6.69 to 8.33)	(6.73 to 8.4)	(0.25 to 0.31)	(0.23 to 0.35)	(0.24 to 0.34)
	10.5	11.4	11.8	7.64	8.25	8.45	0.27	0.28	0.28
	(9.47 to 11.6)	(11 to 11.7)	(11.1 to 12.5)	(6.61 to 8.71)	(7.37 to 9.08)	(7.44 to 9.45)	(0.25 to 0.3)	(0.23 to 0.33)	(0.25 to 0.33)
	9.56	9.91	10.9	6.82	6.87	7.65	0.29	0.31	0.3
Qatar	(8.91 to 10.3)	(9.26 to 10.6) 11.7	(9.97 to 11.9) 13.2	(5.97 to 7.7) 7.73	(5.97 to 7.72) 8.18	(6.55 to 8.76) 9.11	(0.25 to 0.33)	(0.27 to 0.35) 0.3	(0.26 to 0.34) 0.31
Saudi Arabia	(10.4 to 11.9)	(11.4 to 12.1)	(12.5 to 14)	(6.78 to 8.75)	(7.17 to 9.1)	(7.94 to 10.2)	(0.27 to 0.35)	(0.24 to 0.37)	(0.27 to 0.37)
Sudan	(9.93 to 10.9)	(10.5 to 12.4)	(11.1 to 12.5)	(6.84 to 8.46)	(7.31 to 9.3)	8.65 (7.62 to 9.59)	(0.27 (0.23 to 0.31)	(0.25 to 0.3)	(0.23 to 0.31)
Syrian Arab Republic	11.6	12.3	11.9	8.58	9.08	8.55	0.26	0.26	0.28
	(10.7 to 12.6)	(11.7 to 12.9)	(10.7 to 13)	(7.54 to 9.59)	(8.03 to 10)	(7.31 to 9.77)	(0.24 to 0.3)	(0.23 to 0.32)	(0.25 to 0.32)
Tunisia	12.8	13.2	14.1	9.45	9.6	10.1	0.26	0.27	0.28
	(12.3 to 13.4)	(12 to 14.5)	(12.6 to 15.6)	(8.38 to 10.4)	(8.37 to 11)	(8.69 to 11.6)	(0.23 to 0.32)	(0.24 to 0.31)	(0.26 to 0.31)
Turkey	12.6	15.1	14.6	9.25	10.8	10.5	0.27	0.28	0.28
	(12.1 to 13.1)	(14.6 to 15.6)	(13.5 to 15.9)	(8.25 to 10.2)	(9.7 to 11.9)	(9.18 to 11.9)	(0.22 to 0.32)	(0.23 to 0.34)	(0.25 to 0.32)
United Arab Emirates	9.42	8.19	12.1	6.76	5.85	8.5	0.28	0.29	0.3
	(8.96 to 9.92)	(7.76 to 8.68)	(11.2 to 12.9)	(6.01 to 7.51)	(5.15 to 6.52)	(7.37 to 9.59)	(0.24 to 0.33)	(0.25 to 0.34)	(0.26 to 0.34)
Yemen	10.4 (9.55 to 11.1.)	11.1 (10.3 to 12)	11.4 (10.5 to 12.)	7.57	8.16 (7.2 to 9.16)	8.35 (7.24 to 9.31.)	0.27 (0.24 to 0.31)	0.27 (0.24 to 0.3)	0.27
Cauth Asia	9.49	10.8	12.4	6.51	7.37	8.46	0.31	0.31	0.32
South Asia	(9.29 to 9.69)	(10.5 to 11)	(11.8 to 13)	(5.77 to 7.24)	(6.5 to 8.18)	(7.41 to 9.5)	(0.25 to 0.38)	(0.26 to 0.38)	(0.27 to 0.37)
South Asia	(9.29 to 9.69)	(10.5 to 11)	(11.8 to 13)	(5.77 to 7.24)	(6.5 to 8.18)	(7.41 to 9.5)	(0.25 to 0.38)	(0.26 to 0.38)	(0.27 to 0.37)
Bangladesh	10.4	11.6	14	7.51	8.39	10.1	0.28	0.28	0.28
	(10.1 to 10.8)	(11.3 to 11.9)	(12.9 to 15.1)	(6.73 to 8.26)	(7.49 to 9.22)	(8.88 to 11.3)	(0.24 to 0.33)	(0.23 to 0.34)	(0.25 to 0.31)
Bhutan	10.7	12	12.4	7.72	8.64	8.89	0.28	0.28	0.28
	(10 to 11.3)	(11.5 to 12.7)	(11.9 to 13.3)	(6.87 to 8.58)	(7.75 to 9.53)	(7.93 to 9.92)	(0.24 to 0.32)	(0.25 to 0.33)	(0.25 to 0.33)
India	9.16	10.7	12.3	6.19	7.26	8.34	0.32	0.32	0.32
	(8.92 to 9.4)	(10.4 to 11)	(11.6 to 13)	(5.45 to 6.94)	(6.37 to 8.09)	(7.23 to 9.43)	(0.26 to 0.39)	(0.26 to 0.39)	(0.28 to 0.38)
Nepal	10.1	11.6	11.4	7.11	8.16	8.11	0.3	0.29	0.29
	(9.43 to 10.7)	(11.3 to 12)	(11 to 12.3)	(6.26 to 7.95)	(7.31 to 8.95)	(7.14 to 9.17)	(0.26 to 0.34)	(0.26 to 0.36)	(0.26 to 0.35)
Pakistan	10.6	10.2	11.2	7.55	7.16	7.92	0.29	0.3	0.3
	(10.3 to 11)	(9.88 to 10.5)	(10.5 to 12)	(6.79 to 8.33)	(6.37 to 7.92)	(6.91 to 8.94)	(0.24 to 0.34)	(0.25 to 0.36)	(0.26 to 0.34)
Southeast Asia, East Asia,	10.8	11.7	13.4	7.84	8.47	9.62	0.27	0.28	0.28
and Oceania	(10.5 to 11.2)	(11.5 to 12)	(12.8 to 14)	(7.02 to 8.62)	(7.63 to 9.26)	(8.62 to 10.6)	(0.23 to 0.33)	(0.23 to 0.33)	(0.24 to 0.33)
	10.6	11.6	13.5	7.76	8.45	9.76	0.27	0.27	0.28
Last Asid	(10.2 to 11.2)	(11.3 to 12)	(12.8 to 14.3)	(6.96 to 8.56)	(7.61 to 9.24)	(8.69 to 10.8)	(0.23 to 0.32)	(0.23 to 0.33)	(0.24 to 0.32)
	10.6	11.6	13.5	7.72	8.4	9.72	0.27	0.27	0.28
China	(10.1 to 11.1)	(11.2 to 11.9)	(12.7 to 14.3)	(6.91 to 8.53)	(7.57 to 9.2)	(8.65 to 10.8)	(0.23 to 0.32)	(0.23 to 0.33)	(0.24 to 0.32)
Democratic People's	11.6	11.5	12.8	8.53	8.47	9.37	0.27	0.27	0.27
Republic of Korea	(11 to 12.4)	(11.3 to 12.2)	(12.1 to 13.3)	(7.68 to 9.42)	(7.7 to 9.3)	(8.41 to 10.3)	(0.24 to 0.3)	(0.24 to 0.32)	(0.23 to 0.31)
Taiwan (Province of	13	15	16.1	9.53	11	11.9	0.27	0.27	0.26
China)	(12.9 to 13)	(14.9 to 15)	(14.6 to 17.6)	(8.64 to 10.4)	(9.95 to 11.9)	(10.3 to 13.5)	(0.2 to 0.33)	(0.2 to 0.33)	(0.24 to 0.29)
Oceania	10.3	10.3	10.7	7.34	7.35	7.6	0.29	0.29	0.29
American Samoa	11.5	(9.7 (0 10.9)	12.3	8.12	8.33	8.48	0.29	0.3	0.31
American Sumou	(11.3 to 11.8)	(11.6 to 12.3)	(11.6 to 12.9)	(7.21 to 8.96)	(7.34 to 9.21)	(7.37 to 9.5)	(0.24 to 0.36)	(0.25 to 0.37)	(0.26 to 0.37)

Supplementary Table 6: I	Life expectancy	, Health-adjusted	life expectancy, a	and proportion o	of years spent in	ill health in all re	porting locations	s, in 1990, 2005, 2	2019
lasation	1000	LE-70	2010	1000	HALE-70	2010	1000	PYIH-70	2010
Cook Islands	10.9	12.7	13.6	7.76	8.81	9.43	0.29	0.3	0.31
Fiji	10.1	(12.2 (0 13.1))	10.5	(6.94 (0 8.53)	7.09	7.29	0.29	0.31	0.31
Guam	(9.39 to 10.9)	(10.1 to 10.3)	(9.5 to 11.6)	(6.29 to 8.12)	(6.26 to 7.87)	(6.21 to 8.4)	(0.25 to 0.33)	(0.24 to 0.38)	(0.27 to 0.35)
	12.3	16.1	16	8.96	11.6	11.5	0.27	0.28	0.28
	(11.9 to 12.7)	(15.6 to 16.7)	(15 to 17)	(8.08 to 9.77)	(10.4 to 12.8)	(10.1 to 12.8)	(0.23 to 0.32)	(0.23 to 0.33)	(0.24 to 0.33)
	8.01	8.37	8.84	5.8	6.03	6.33	0.28	0.28	0.28
KIRIDATI	(7.49 to 8.63) 9.22	(7.87 to 8.98) 9.58	(8.11 to 9.69) 10.1	(5.09 to 6.56)	(5.32 to 6.77)	(5.48 to 7.21) 7.14	(0.24 to 0.32)	(0.25 to 0.32)	(0.26 to 0.32) 0.29
Marshall Islands	(8.9 to 9.57)	(9.14 to 10.1)	(9.05 to 11.2)	(5.88 to 7.32)	(6.01 to 7.62)	(6.03 to 8.25)	(0.24 to 0.34)	(0.25 to 0.34)	(0.26 to 0.33)
Micronesia (Federated	9.19	9.56	9.51	6.7	6.88	6.84	(0.24 to 0.31)	0.28	0.28
States of)	(8.45 to 9.97)	(9.07 to 10.1)	(8.69 to 10.5)	(5.86 to 7.56)	(6.09 to 7.63)	(5.91 to 7.83)		(0.25 to 0.33)	(0.25 to 0.32)
Nauru	9.18	8.32	9.44	6.65	6.04	6.72	0.28	0.27	0.29
	(8.49 to 10)	(7.69 to 9.07)	(8.79 to 10.1)	(5.82 to 7.5)	(5.33 to 6.85)	(5.88 to 7.51)	(0.25 to 0.31)	(0.24 to 0.31)	(0.26 to 0.33)
Niue	11.1	11.1	11.7	7.89	7.76	8.12	0.29	0.3	0.31
	(10.3 to 11.6)	(10.6 to 11.5)	(11.1 to 12.5)	(6.92 to 8.79)	(6.89 to 8.6)	(7.09 to 9.09)	(0.24 to 0.33)	(0.25 to 0.35)	(0.27 to 0.36)
Northern Mariana	11.7	12.3	12.5	8.46	8.83	8.93	0.28	0.28	0.29
Islands	(11 to 12.1)	(11.7 to 12.9)	(12.1 to 13.2)	(7.53 to 9.33)	(7.88 to 9.75)	(7.91 to 9.9)	(0.23 to 0.31)	(0.24 to 0.33)	(0.25 to 0.34)
Palau	10.1	10.6	10.8	7.22	7.42	7.53	0.28	0.3	0.3
	(9.16 to 10.9)	(9.76 to 11.5)	(9.78 to 11.9)	(6.28 to 8.18)	(6.48 to 8.4)	(6.45 to 8.66)	(0.25 to 0.31)	(0.27 to 0.34)	(0.27 to 0.34)
Papua New Guinea	10.5	10.3	10.7	7.45	7.31	7.56	0.29	0.29	0.29
	(9.91 to 11.1)	(9.49 to 11.1)	(9.68 to 11.5)	(6.53 to 8.27)	(6.34 to 8.24)	(6.52 to 8.6)	(0.26 to 0.34)	(0.26 to 0.33)	(0.25 to 0.33)
Samoa	10.6	11.3	11.7 (10.8 to 12.4)	7.64	8.09 (7.14 to 9.02)	8.31 (7.26 to 9.33.)	0.28 (0.23 to 0.33)	0.29	0.29
Solomon Islands	7.78	7.83	8.22	5.79	5.77	5.99	0.26	0.26	0.27
Takelau	10.9	(7.33 (0 8.43)	12.3	7.92	(5.1 (0 6.45) 8.19	8.71	0.28	0.28	0.29
Tonga	(10.2 to 11.4)	(10.6 to 12.3)	(11.2 to 13.2)	(7.02 to 8.75)	(7.16 to 9.2)	(7.56 to 9.77)	(0.23 to 0.31)	(0.25 to 0.32)	(0.26 to 0.33)
	12.3	12.6	12.7	8.91	9.09	9.14	0.28	0.28	0.28
- i	(11.7 to 13)	(12.1 to 13.2)	(11.9 to 13.7)	(7.94 to 9.84)	(8.12 to 10)	(8.01 to 10.2)	(0.24 to 0.32)	(0.24 to 0.33)	(0.25 to 0.32)
	9.6	10.3	10.9	6.97	7.41	7.75	0.27	0.28	0.29
Tuvalu	(9 to 10.3) 9.57	(9.6 to 10.9) 9.72	(9.62 to 12) 10.1	(6.19 to 7.77) 6.98	(6.56 to 8.26) 7.09	(6.53 to 8.95) 7.29	(0.24 to 0.31)	(0.24 to 0.32)	(0.26 to 0.32) 0.28
Vanuatu	(8.7 to 10.3)	(8.8 to 10.5)	(9.02 to 11)	(6.06 to 7.86)	(6.19 to 8.02)	(6.2 to 8.29)	(0.24 to 0.3)	(0.24 to 0.3)	(0.24 to 0.31)
Southeast Asia	(11.3 to 11.7)	(11.8 to 12.2)	(12.4 to 13.3)	8.14 (7.26 to 8.94)	(7.68 to 9.42)	(8.08 to 10)	(0.24 to 0.36)	(0.23 to 0.35)	(0.25 to 0.35)
Cambodia	9.86	10.8	11.4	7.04	7.73	8.05	0.29	0.28	0.29
	(9.52 to 10.3)	(10.4 to 11.3)	(11 to 12.2)	(6.22 to 7.81)	(6.87 to 8.54)	(7.11 to 9.07)	(0.24 to 0.35)	(0.24 to 0.34)	(0.26 to 0.35)
Indonesia	11.1	11.2	11.4	7.69	7.78	7.98	0.31	0.3	0.3
	(10.8 to 11.5)	(10.8 to 11.5)	(11 to 12.3)	(6.78 to 8.56)	(6.88 to 8.67)	(7.03 to 8.98)	(0.25 to 0.37)	(0.25 to 0.36)	(0.27 to 0.36)
Lao People's	9.28	10.3	11.3	6.77	7.53	8.2	0.27	0.27	0.28
Democratic Republic	(8.69 to 9.98)	(9.89 to 10.9)	(10.7 to 12.1)	(6 to 7.61)	(6.74 to 8.29)	(7.29 to 9.17)	(0.24 to 0.31)	(0.24 to 0.32)	(0.24 to 0.32)
Malaysia	12.1	12.1	12.7	8.57	8.62	9.07	0.29	0.29	0.29
	(12 to 12.2)	(12.1 to 12.2)	(11.5 to 13.9)	(7.65 to 9.43)	(7.7 to 9.47)	(7.85 to 10.3)	(0.23 to 0.37)	(0.22 to 0.36)	(0.26 to 0.32)
Maldives	10.5	13.2	14.9	7.63	9.61	10.7	0.27	0.27	0.28
	(10.3 to 10.7)	(12.9 to 13.6)	(14 to 15.9)	(6.88 to 8.35)	(8.67 to 10.5)	(9.45 to 12)	(0.22 to 0.33)	(0.22 to 0.33)	(0.25 to 0.32)
Mauritius	11.6 (11.5 to 11.8)	12.9 (12.7 to 13.)	14.3 (13.1 to 15.5.)	8.27 (7.42 to 9.1)	9.01 (8 to 9 94)	9.96 (8.61 to 11.3.)	0.29 (0.23 to 0.35)	0.3	0.3 (0.27 to 0.34.)
Myanmar	9.59	10.4	11.6	6.86 (6to 7.7)	7.41	8.19	0.28	0.28	0.29
Philippines	12.4	12.4	12.6	8.82	8.85	9.01	0.29	0.28	0.29
Sevenelles	(12 to 12.7)	(12 to 12.7)	(11.7 to 13.6)	(7.83 to 9.71)	(7.89 to 9.71)	(7.99 to 10.1)	(0.24 to 0.35)	(0.24 to 0.34)	(0.26 to 0.32)
	12.1	12.2	12.8	8.78	8.71	9.01	0.27	0.29	0.3
Sciencies	(11.8 to 12.3)	(11.9 to 12.5)	(12.3 to 13.3)	(7.87 to 9.59)	(7.76 to 9.62)	(7.98 to 9.99)	(0.22 to 0.34)	(0.23 to 0.35)	(0.25 to 0.35)
	11.5	12.6	14.1	8.33	8.84	9.8	0.28	0.3	0.31
Shi Lanka	(11.3 to 11.8)	(12.1 to 13.1)	(12.7 to 15.7)	(7.46 to 9.15)	(7.78 to 9.88)	(8.33 to 11.4)	(0.23 to 0.34)	(0.25 to 0.35)	(0.28 to 0.34)
	13.2	15.2	16.7	9.47	11	12.1	0.28	0.28	0.27
Thailand	(12.8 to 13.8)	(14.5 to 15.9)	(15 to 18.5)	(8.47 to 10.5)	(9.8 to 12.1)	(10.4 to 13.8)	(0.24 to 0.34)	(0.24 to 0.33)	(0.25 to 0.3)
Timor-Leste	(10.5 to 11.5)	(11.2 to 12.1)	(11 to 12.2)	(7.01 to 8.76)	(7.38 to 9.13)	(7.05 to 9.1)	(0.24 to 0.33)	(0.24 to 0.34)	(0.26 to 0.36)
Viet Nam	(11 to 12.2)	12.3 (11.6 to 12.6)	12.8 (12.4 to 13.6)	8.47 (7.61 to 9.36)	9.01 (8.08 to 9.87)	9.24 (8.22 to 10.2)	(0.23 to 0.31)	(0.27 (0.21 to 0.3)	0.28 (0.25 to 0.34)
Sub-Saharan Africa	10.1	10.4	11.5	7.33	7.54	8.39	0.28	0.27	0.27
	(9.88 to 10.3)	(10.1 to 10.6)	(11.1 to 11.8)	(6.59 to 8.04)	(6.79 to 8.24)	(7.55 to 9.2)	(0.22 to 0.33)	(0.22 to 0.33)	(0.22 to 0.32)
Central Sub-Saharan	9.32	9.83	10.9	6.73	7.13	7.96	0.28	0.27	0.27
Africa	(8.83 to 9.79)	(9.4 to 10.3)	(10.1 to 11.6)	(6 to 7.47)	(6.4 to 7.86)	(7.01 to 8.89)	(0.24 to 0.32)	(0.24 to 0.32)	(0.23 to 0.3)
Angola	8.92	9.79	11.1	6.54	7.17	8.17	0.27	0.27	0.27
	(8.39 to 9.55)	(9.3 to 10.3)	(10.4 to 11.6)	(5.81 to 7.29)	(6.41 to 7.92)	(7.23 to 9)	(0.24 to 0.31)	(0.23 to 0.31)	(0.22 to 0.3)
Central African Republic	8.29	8.15	8.8	5.97	5.9	6.42	0.28	0.28	0.27
	(7.8 to 8.79)	(7.42 to 9.05)	(7.83 to 9.89)	(5.27 to 6.67)	(5.11 to 6.78)	(5.44 to 7.47)	(0.24 to 0.32)	(0.25 to 0.31)	(0.24 to 0.31)
Congo	8.81	9.81	10.6	6.45	7.15	7.8	0.27	0.27	0.27
	(8.23 to 9.54)	(9.2 to 10.5)	(9.91 to 11.2)	(5.74 to 7.23)	(6.31 to 7.91)	(6.87 to 8.67)	(0.24 to 0.3)	(0.25 to 0.31)	(0.22 to 0.31)
Democratic Republic of	9.51	9.91	11 (10 to 11 9)	6.84	7.17	8 (7.01 to 9.00.)	0.28	0.28	0.27
Equatorial Guinea	8.69	11.2	11.5	6.16	7.98	8.3	0.29	0.29	0.28
Gabon	(7.94 to 9.42)	(10.1 to 12.7)	(10.4 to 12.5)	(5.36 to 6.95)	(6.86 to 9.23)	(/.16 to 9.43)	(0.26 to 0.33)	(0.27 to 0.32)	(0.25 to 0.31)
	9.93	10.4	11.2	7.27	7.57	8.21	0.27	0.27	0.27
Gubon	(9.43 to 10.4)	(9.78 to 11)	(10.7 to 12.1)	(6.49 to 8.02)	(6.72 to 8.38)	(7.31 to 9.17)	(0.23 to 0.31)	(0.24 to 0.31)	(0.24 to 0.32)

Supplementary Table 6:	Life expectancy,	Health-adjusted	life expectancy, a	nd proportion of	f years spent in i	ill health in all rep	orting locations	s, in 1990, 2005, 2	2019
		LE-70			HALE-70			PYIH-70	1
location Eastern Sub-Sabaran	9 37	2005	11.4	1990 6.81	2005	8 34	1990 0.27	2005	0.27
Africa	(9.16 to 9.59)	(10 to 10.4)	(11.1 to 11.7)	(6.11 to 7.45)	(6.68 to 8.12)	(7.51 to 9.1)	(0.22 to 0.33)	(0.22 to 0.33)	(0.22 to 0.32)
Burundi	8.51	9.35	10.7	6.3	6.89	7.94	0.26	0.26	0.26
	(7.88 to 9.02)	(8.82 to 9.97)	(9.69 to 11.6)	(5.54 to 6.99)	(6.15 to 7.63)	(6.9 to 8.96)	(0.23 to 0.3)	(0.23 to 0.3)	(0.23 to 0.29)
Comoros	9.95	11.1	11.8	7.34	8.24	8.79	0.26	0.26	0.26
	(9.35 to 10.7)	(10.5 to 11.5)	(10.9 to 12.2)	(6.53 to 8.22)	(7.4 to 9.05)	(7.76 to 9.65)	(0.23 to 0.3)	(0.22 to 0.3)	(0.21 to 0.29)
Djibouti	10.5	10.8	11.5	7.81	8.04	8.56	0.26	0.25	0.26
	(9.65 to 11.3)	(9.82 to 12)	(10.5 to 12.1)	(6.88 to 8.7)	(7.05 to 9.15)	(7.53 to 9.4)	(0.23 to 0.29)	(0.23 to 0.28)	(0.22 to 0.28)
Eritrea	8.54	9.5	10.2	6.26	6.96	7.53	0.27	0.27	0.26
	(8.04 to 9.06)	(8.66 to 10.5)	(9.22 to 11.1)	(5.57 to 6.97)	(6.12 to 7.88)	(6.51 to 8.5)	(0.23 to 0.31)	(0.25 to 0.29)	(0.23 to 0.29)
Ethiopia	8.2	10.1	11.8	5.93	7.34	8.7	0.28	0.27	0.26
	(7.95 to 8.45)	(9.7 to 10.4)	(11.3 to 12.4)	(5.28 to 6.53)	(6.54 to 8.08)	(7.75 to 9.6)	(0.23 to 0.34)	(0.22 to 0.33)	(0.23 to 0.32)
Kenya	11.1	10.7	11.4	7.92	7.72	8.32	0.28	0.28	0.27
	(10.7 to 11.4)	(10.5 to 11)	(11 to 12)	(7.1 to 8.73)	(6.94 to 8.46)	(7.43 to 9.19)	(0.24 to 0.34)	(0.23 to 0.34)	(0.24 to 0.32)
Madagascar	10.3	10.1	10.9	7.55	7.46	8.09	0.26	0.26	0.26
	(9.82 to 10.8)	(9.61 to 10.7)	(9.84 to 12)	(6.77 to 8.32)	(6.66 to 8.21)	(7.02 to 9.18)	(0.23 to 0.31)	(0.23 to 0.31)	(0.24 to 0.29)
Malawi	9.48	9.95	11.3	6.9	7.26	8.32	0.27	0.27	0.26
	(9.15 to 9.84)	(9.45 to 10.4)	(10.7 to 11.9)	(6.2 to 7.57)	(6.4 to 8.01)	(7.42 to 9.16)	(0.23 to 0.32)	(0.23 to 0.32)	(0.23 to 0.31)
Mozambique	9.54	10	10.4	6.87	7.2	7.54	0.28	0.28	0.27
	(9.18 to 9.86)	(9.58 to 10.5)	(9.49 to 11.1)	(6.11 to 7.58)	(6.41 to 7.96)	(6.55 to 8.43)	(0.23 to 0.33)	(0.24 to 0.33)	(0.24 to 0.31)
Rwanda	8.54 (8.1 to 8.93)	10.5	11.7 (11 to 12 1)	6.29	7.66	8.65	0.26	0.27 (0.23 to 0.31)	0.26
Somalia	8.54 (7.85 to 9.26)	9.04	9.71 (8 53 to 10 7)	6.35	6.71	7.22 (6 15 to 8 23)	0.26 (0.23 to 0.28)	0.26 (0.23 to 0.28)	0.26
South Sudan	10	10.6	11.4	7	7.38	7.94	0.3	0.31	0.3
Uaanda	9.81	10.2	11.5	7.11	7.47	8.47	0.28	0.27	0.26
United Republic of	(9.36 to 10.4)	(9.85 to 10.6)	(11.1 to 12.2)	(6.35 to 7.9)	(6.71 to 8.18)	(7.59 to 9.3)	(0.24 to 0.32)	(0.23 to 0.32)	(0.24 to 0.31)
	10.2	10.9	11.8	7.48	7.97	8.69	0.27	0.27	0.26
Tanzania	(9.79 to 10.6)	(10.6 to 11.3)	(11.3 to 12.4)	(6.73 to 8.2)	(7.14 to 8.75)	(7.81 to 9.48)	(0.23 to 0.31)	(0.23 to 0.32)	(0.23 to 0.31)
Zambia	9.24	9.22	10.7	6.84	6.81	7.99	0.26	0.26	0.26
	(8.91 to 9.7)	(8.72 to 9.74)	(9.89 to 11.4)	(6.1 to 7.58)	(6.08 to 7.49)	(7.03 to 8.9)	(0.22 to 0.32)	(0.23 to 0.3)	(0.22 to 0.29)
Southern Sub-Saharan	12.9	10.9	12.4	9.19	7.78	8.82	0.29	0.29	0.29
Africa	(12.7 to 13.1)	(10.8 to 11.1)	(12.2 to 12.6)	(8.24 to 10.1)	(6.99 to 8.55)	(7.92 to 9.71)	(0.23 to 0.35)	(0.23 to 0.35)	(0.23 to 0.35)
Botswana	10.2	9.52	10.8	7.38	6.85	7.66	0.28	0.28	0.29
	(9.25 to 10.9)	(8.38 to 11.1)	(9.71 to 11.7)	(6.39 to 8.33)	(5.77 to 8.08)	(6.58 to 8.69)	(0.24 to 0.31)	(0.27 to 0.31)	(0.26 to 0.32)
Eswatini	10.2	8.42	10.2	7.36	6.01	7.31	0.28	0.29	0.29
	(9.64 to 10.9)	(7.58 to 9.35)	(9.03 to 11.6)	(6.56 to 8.18)	(5.16 to 6.88)	(6.16 to 8.45)	(0.25 to 0.32)	(0.26 to 0.32)	(0.27 to 0.32)
Lesotho	10.5	8.61	9.06	7.6	6.21	6.49	0.27	0.28	0.28
	(9.93 to 10.8)	(7.98 to 9.26)	(8.06 to 10.2)	(6.8 to 8.35)	(5.44 to 7)	(5.52 to 7.52)	(0.23 to 0.31)	(0.24 to 0.32)	(0.26 to 0.31)
Namibia	10.1	9.84	11.2	7.3	7.07	8.08	0.28	0.28	0.28
	(9.72 to 10.5)	(9.25 to 10.4)	(10.4 to 12)	(6.5 to 8.08)	(6.28 to 7.87)	(7.04 to 9.14)	(0.23 to 0.33)	(0.24 to 0.32)	(0.24 to 0.32)
South Africa	13.7	11.4	13	9.75	8.12	9.22	0.29	0.29	0.29
	(13.5 to 14)	(11.3 to 11.5)	(12.8 to 13.2)	(8.74 to 10.7)	(7.29 to 8.92)	(8.28 to 10.1)	(0.23 to 0.35)	(0.23 to 0.36)	(0.23 to 0.35)
Zimbabwe	10.7	9.42	10.2	7.81	6.83	7.39	0.27	0.28	0.27
	(10.4 to 11.1)	(8.87 to 9.95)	(9.37 to 11.1)	(7.02 to 8.56)	(6.09 to 7.59)	(6.45 to 8.34)	(0.23 to 0.32)	(0.24 to 0.31)	(0.25 to 0.31)
Western Sub-Saharan	10.2	10.4	11.5	7.4	7.65	8.42	0.27	0.27	0.27
Africa	(9.84 to 10.5)	(10 to 10.9)	(11 to 11.9)	(6.63 to 8.11)	(6.87 to 8.4)	(7.54 to 9.27)	(0.23 to 0.33)	(0.23 to 0.32)	(0.22 to 0.31)
Benin	10	10.5	11.3	7.29	7.72	8.32	0.27	0.26	0.26
	(9.61 to 10.4)	(9.83 to 11)	(10.4 to 12)	(6.56 to 8)	(6.92 to 8.53)	(7.32 to 9.27)	(0.23 to 0.32)	(0.23 to 0.3)	(0.23 to 0.3)
Burkina Faso	9.77	10.1	10.8	7.11	7.45	8.03	0.27	0.26	0.26
Cabo Verde	14	13.8	12.5	10.4	10.2	9.24	0.25	0.26	0.26
Cameroon	(13.6 to 14.3) 10.3	(13.2 to 14.4) 9.89	(12.2 to 12.9)	(9.41 to 11.3) 7.44	(9.15 to 11.3) 7.12	(8.33 to 10.1) 8.16	0.28	0.22 to 0.31)	0.22 to 0.32)
Chad	(9.84 to 10.7)	(9.45 to 10.5)	(10.2 to 11.9)	(6.65 to 8.22)	(6.34 to 7.95)	(7.12 to 9.12)	(0.23 to 0.32)	(0.24 to 0.33)	(0.24 to 0.3)
	9.93	9.71	10.6	7.29	7.07	7.79	0.27	0.27	0.27
Chùà	(9.55 to 10.3)	(9.27 to 10.2)	(9.85 to 11.3)	(6.54 to 8.03)	(6.32 to 7.82)	(6.87 to 8.67)	(0.22 to 0.32)	(0.23 to 0.32)	(0.23 to 0.3)
Côte d'Ivoire	(9.4 to 10.2)	(9.23 to 10.2)	(10.5 to 11.8)	(6.16 to 7.78)	(6.37 to 7.91)	(7.26 to 9.08)	(0.24 to 0.34)	(0.23 to 0.31)	(0.23 to 0.31)
Gambia	(9.64 to 11.1)	(10.1 to 11.3)	(10.2 to 11.8)	(6.78 to 8.55)	(6.96 to 8.65)	8.05 (7.14 to 8.92)	(0.23 to 0.3)	(0.23 to 0.31)	(0.24 to 0.3)
Ghana	10.3	10.4	11.3	7.64	7.73	8.41	0.26	0.26	0.26
	(9.63 to 10.9)	(10 to 10.9)	(10.7 to 11.6)	(6.81 to 8.48)	(6.93 to 8.5)	(7.48 to 9.22)	(0.22 to 0.29)	(0.22 to 0.31)	(0.21 to 0.3)
Guinea	10	10.1	10.7	7.43	7.49	7.9	0.26	0.26	0.26
	(9.6 to 10.4)	(9.62 to 10.6)	(9.85 to 11.5)	(6.67 to 8.19)	(6.75 to 8.23)	(6.93 to 8.9)	(0.21 to 0.31)	(0.22 to 0.3)	(0.23 to 0.3)
Guinea-Bissau	8.51	9.21	10.1	6.27	6.8	7.47	0.26	0.26	0.26
	(7.99 to 9.09)	(8.71 to 9.67)	(9.18 to 11)	(5.57 to 6.98)	(6.08 to 7.46)	(6.53 to 8.41)	(0.23 to 0.3)	(0.23 to 0.3)	(0.24 to 0.29)
Liberia	9.92	10.6	11.6	7.13	7.63	8.31	0.28	0.28	0.28
	(9.42 to 10.3)	(10.1 to 11.2)	(10.6 to 12.3)	(6.32 to 7.9)	(6.74 to 8.48)	(7.21 to 9.35)	(0.24 to 0.33)	(0.24 to 0.33)	(0.24 to 0.32)
Mali	9.67	10.6	11.3	7.08	7.81	8.37	0.27	0.27	0.26
	(9.33 to 10.1)	(10.2 to 11)	(10.4 to 12)	(6.33 to 7.81)	(7.03 to 8.56)	(7.37 to 9.28)	(0.22 to 0.32)	(0.22 to 0.31)	(0.23 to 0.29)
Mauritania	10	11.6	12.4	7.48	8.68	9.25	0.25	0.25	0.25
	(9.61 to 10.5)	(10.9 to 12.1)	(11.6 to 12.7)	(6.72 to 8.21)	(7.76 to 9.52)	(8.33 to 10.1)	(0.22 to 0.3)	(0.21 to 0.29)	(0.2 to 0.28)
Niger	9.6	10.3	11.1	7.18	7.75	8.31	0.25	0.25	0.25
	(9.29 to 9.95)	(9.97 to 10.7)	(10.2 to 11.8)	(6.47 to 7.83)	(7.06 to 8.46)	(7.36 to 9.2)	(0.21 to 0.3)	(0.21 to 0.29)	(0.22 to 0.28)
Nigeria	10.3	10.6	11.8	7.48	7.78	8.63	0.28	0.27	0.27
	(9.8 to 10.9)	(9.87 to 11.5)	(11 to 12.7)	(6.64 to 8.31)	(6.84 to 8.73)	(7.64 to 9.69)	(0.24 to 0.32)	(0.24 to 0.31)	(0.24 to 0.3)

Supplementary Table 6:	Life expectancy,	Health-adjusted	life expectancy, a	and proportion o	f years spent in i	ill health in all re	porting locations	, in 1990, 2005, 2	2019
		LE-70			HALE-70			PYIH-70	
location	1990	2005	2019	1990	2005	2019	1990	2005	2019
Sao Tome and Principe	11.3	11.1	11.2	8.34	8.1	8.17	0.26	0.27	0.27
	(10.8 to 11.7)	(10.7 to 11.4)	(11.1 to 11.9)	(7.5 to 9.12)	(7.34 to 8.89)	(7.36 to 9.03)	(0.22 to 0.31)	(0.22 to 0.32)	(0.24 to 0.33)
Senegal	10.2	11	11.7	7.52	8.02	8.6	0.27	0.27	0.27
	(9.89 to 10.5)	(10.7 to 11.3)	(10.9 to 12.1)	(6.76 to 8.23)	(7.14 to 8.8)	(7.6 to 9.46)	(0.22 to 0.32)	(0.22 to 0.33)	(0.22 to 0.3)
Sierra Leone	9.67	9.78	11.1	7.16	7.2	8.16	0.26	0.26	0.26
	(9.16 to 10.3)	(9.35 to 10.2)	(10.1 to 11.6)	(6.4 to 7.95)	(6.47 to 7.92)	(7.12 to 9.07)	(0.23 to 0.3)	(0.22 to 0.31)	(0.22 to 0.3)
Тодо	10.2	10.3	11.4	7.57	7.64	8.42	0.26	0.26	0.26
	(9.74 to 10.7)	(9.72 to 10.8)	(10.5 to 11.8)	(6.79 to 8.31)	(6.83 to 8.42)	(7.4 to 9.29)	(0.22 to 0.3)	(0.22 to 0.3)	(0.22 to 0.3)

Supplementary Table 7:	Life expectancy	, Health-adjusted	life expectancy,	and proportion o	f years spent in i	ll health in all repo	orting locations, i	n 1990, 2005, 201	19, Males
location	1990	2005	2019	1990	2005	2019	1990	2005	2019
Global	10.6	11.5	12.9	7.72	8.4	9.35	0.27	0.27	0.27
	(10.4 to 10.8)	(11.4 to 11.7)	(12.5 to 13.3)	(6.92 to 8.42)	(7.58 to 9.18)	(8.43 to 10.3)	(0.22 to 0.34)	(0.22 to 0.33)	(0.23 to 0.33)
Low SDI	8.99	9.66	11	6.48	6.95	7.92	0.28	0.28	0.28
	(8.74 to 9.26)	(9.42 to 9.92)	(10.6 to 11.4)	(5.81 to 7.11)	(6.22 to 7.65)	(7.06 to 8.76)	(0.23 to 0.34)	(0.23 to 0.34)	(0.23 to 0.33)
Low-middle SDI	9.56	10.4	11.6	6.86	7.46	8.28	0.28	0.28	0.28
	(9.34 to 9.81)	(10.2 to 10.7)	(11 to 12.1)	(6.15 to 7.54)	(6.67 to 8.2)	(7.36 to 9.21)	(0.23 to 0.34)	(0.23 to 0.35)	(0.24 to 0.33)
Middle SDI	10.5	11	12.1	7.7	8.11	8.89	0.26	0.26	0.27
	(10 to 10.9)	(10.7 to 11.3)	(11.6 to 12.7)	(6.9 to 8.45)	(7.33 to 8.83)	(8.01 to 9.82)	(0.22 to 0.31)	(0.22 to 0.32)	(0.23 to 0.31)
High-middle SDI	10.5	(11.1	13	7.7	8.19	9.57	0.26	0.26	0.26
	(10.2 to 10.7)	(11.to 11.3)	(12.5 to 13.5)	(6.93 to 8.38)	(7.39 to 8.92)	(8.61 to 10.5)	(0.22 to 0.32)	(0.21 to 0.33)	(0.22 to 0.31)
High SDI	11.9 (11.9 to 11.9)	13.9 (13.9 to 13.9)	15.2 (15.1 to 15.3)	8.62 (7.74 to 9.42)	10 (8.98 to 10.9)	(9.78 to 11.9)	0.28 (0.21 to 0.35)	0.28 (0.21 to 0.35)	0.28 (0.22 to 0.35)
Central Europe, Eastern	9.99	9.82	11.5	7.26	7.18	8.44	0.27	0.27	0.27
Europe, and Central Asia	(9.97 to 10)	(9.8 to 9.84)	(11.1 to 12.1)	(6.49 to 7.93)	(6.45 to 7.83)	(7.48 to 9.27)	(0.21 to 0.35)	(0.2 to 0.34)	(0.23 to 0.32)
Central Asia	10.6 (10.4 to 10.7)	8.71 (8.61 to 8.8)	9.68	8.02	6.66 (6.09 to 7.17)	7.34	0.24	0.24	0.24 (0.2 to 0.28)
Armenia	10.9	10.8	11.8	8.13	8.13	8.83	0.25	0.25	0.25
Azerbaijan	(10.8 to 11)	(10.7 to 10.9)	(10.9 to 12.7)	(7.37 to 8.82)	(7.38 to 8.8)	(7.86 to 9.82)	(0.2 to 0.32)	(0.19 to 0.31)	(0.22 to 0.28)
	10.7	9.28	9.66	8.23	7.15	7.41	0.23	0.23	0.23
Coorein	(10.3 to 11.2)	(8.94 to 9.62)	(8.79 to 10.5)	(7.45 to 8.98)	(6.51 to 7.79)	(6.49 to 8.32)	(0.2 to 0.28)	(0.19 to 0.27)	(0.21 to 0.26)
	9.76	9.89	10.5	7.47	7.51	7.8	0.23	0.24	0.26
Georgia	(9.35 to 10.2)	(9.47 to 10.3)	(9.73 to 11.4)	(6.74 to 8.17)	(6.77 to 8.19)	(6.93 to 8.72) 7 58	(0.2 to 0.28)	(0.21 to 0.28)	(0.23 to 0.29)
Kazakhstan	(9.83 to 10.2)	(8.65 to 9.04)	(9.57 to 10.8)	(6.77 to 8.13)	(6.03 to 7.24)	(6.75 to 8.41)	(0.2 to 0.31)	(0.2 to 0.3)	(0.22 to 0.29)
Kyrgyzstan	10.8	9.76	11.6	8.14	7.49	8.91	0.24	0.23	0.23
	(10.5 to 11)	(9.69 to 9.83)	(11 to 12.2)	(7.37 to 8.85)	(6.85 to 8.06)	(8.04 to 9.78)	(0.2 to 0.3)	(0.18 to 0.29)	(0.2 to 0.27)
Mongolia	8.38	7.88	9.31	6.41	6.03	7.14	0.24	0.23	0.23
	(7.69 to 9.17)	(7.29 to 8.57)	(8.29 to 10.3)	(5.63 to 7.17)	(5.37 to 6.76)	(6.13 to 8.14)	(0.22 to 0.27)	(0.21 to 0.26)	(0.21 to 0.26)
Tajikistan	11.8	9.42	8.8	8.97	7.3	6.82	0.24	0.22	0.23
	(11.3 to 12.3)	(9.05 to 9.81)	(7.93 to 9.67)	(8.09 to 9.81)	(6.61 to 7.97)	(5.93 to 7.7)	(0.2 to 0.28)	(0.19 to 0.27)	(0.2 to 0.25)
Turkmenistan	10.4	9.34	11	7.98	7.22	8.52	0.23	0.23	0.23
	(10.3 to 10.5)	(9.26 to 9.41)	(9.91 to 12.2)	(7.29 to 8.59)	(6.6 to 7.74)	(7.4 to 9.64)	(0.18 to 0.29)	(0.18 to 0.29)	(0.21 to 0.25)
Uzbekistan	11.4 (11.3 to 11.4)	6.9 (6.76 to 7.05)	7.88 (7.32 to 8.5)	8.73 (7.96 to 9.4)	5.36 (4.91 to 5.78)	6.09 (5.43 to 6.78)	0.23	0.22 (0.18 to 0.27)	0.23 (0.2 to 0.26)
Central Europe	9.97	10.9	12.3	7.2	7.91	8.9	0.28	0.28	0.28
Albania	(9.93 to 10)	(10.9 to 11)	(11.7 to 13.1)	(6.43 to 7.88)	(7.09 to 8.65)	(7.86 to 9.93)	(0.21 to 0.35)	(0.21 to 0.35)	(0.24 to 0.33)
	10.1	11.9	12.8	7.56	8.93	9.57	0.25	0.25	0.25
Bosnia and	(10 to 10.3)	(11.8 to 12.1)	(11.3 to 14.3)	(6.85 to 8.21) 8.09	(8.1 to 9.69)	(8.22 to 11) 8.51	(0.2 to 0.32) 0.27	(0.2 to 0.31)	(0.23 to 0.27)
Herzegovina	(11 to 11.2)	(10.7 to 10.9)	(10.7 to 13.1)	(7.28 to 8.83)	(7 to 8.54)	(7.32 to 9.76)	(0.21 to 0.34)	(0.22 to 0.34)	(0.26 to 0.31)
Bulgaria	9.42	9.56	10.6	6.93	7.06	7.8	0.26	0.26	0.26
	(9.19 to 9.67)	(9.33 to 9.8)	(9.54 to 11.7)	(6.2 to 7.58)	(6.37 to 7.71)	(6.77 to 8.91)	(0.22 to 0.33)	(0.21 to 0.32)	(0.24 to 0.29)
Croatia	9.79	10.9	12.7	6.99	7.74	8.95	0.29	0.29	0.29
	(9.45 to 10.1)	(10.8 to 11)	(11.5 to 13.9)	(6.22 to 7.75)	(6.86 to 8.52)	(7.72 to 10.2)	(0.23 to 0.34)	(0.23 to 0.36)	(0.26 to 0.33)
Czechia	9.17	11.6	13.3	6.56	8.14	9.29	0.28	0.3	0.3
	(9.11 to 9.22)	(11.5 to 11.7)	(12.2 to 14.4)	(5.86 to 7.2)	(7.18 to 8.98)	(8.01 to 10.5)	(0.22 to 0.36)	(0.23 to 0.38)	(0.27 to 0.35)
Hungary	9.61 (9.56 to 9.66)	10.7 (10.7 to 10.8)	12.3 (11.2 to 13.3)	6.8 (6.03 to 7.48)	/.5/ (6.74 to 8.34)	8.7 (7.54 to 9.85)	(0.23 to 0.37)	0.29 (0.23 to 0.37)	0.29 (0.26 to 0.33)
Montenegro	11.7	10.8	11.1	8.6	7.98	8.14	0.27	0.26	0.27
	(11.4 to 12)	(10.6 to 11.1)	(10.3 to 12)	(7.73 to 9.43)	(7.14 to 8.74)	(7.11 to 9.17)	(0.22 to 0.32)	(0.21 to 0.32)	(0.24 to 0.31)
North Macedonia	10.2	9.5	10.3	7.5	6.97	7.51	0.27	0.27	0.27
	(10 to 10.4)	(9.31 to 9.69)	(9.31 to 11.3)	(6.74 to 8.2)	(6.23 to 7.63)	(6.49 to 8.59)	(0.21 to 0.33)	(0.21 to 0.33)	(0.24 to 0.3)
Poland	10	11.6	13	7.18	8.39	9.43	0.28	0.28	0.28
	(9.98 to 10)	(11.6 to 11.6)	(11.8 to 14.4)	(6.42 to 7.86)	(7.52 to 9.19)	(8.14 to 10.8)	(0.22 to 0.36)	(0.21 to 0.35)	(0.25 to 0.31)
Romania	10.3	10.9	12	7.51	8.01	8.81	0.27	0.26	0.27
	(10.3 to 10.4)	(10.8 to 10.9)	(11 to 13)	(6.74 to 8.19)	(7.22 to 8.71)	(7.7 to 9.91)	(0.21 to 0.34)	(0.2 to 0.33)	(0.24 to 0.3)
Serbia	10.8 (10.7 to 10.8)	10.1	11.5	7.86	7.38	8.31	0.27	0.27	0.28
Slovakia	9.95	10.8	12.5	7.19	7.76	8.99	0.28	0.28	0.28
Claugaia	(9.87 to 10)	(10.7 to 10.9)	(11.3 to 13.8)	(6.42 to 7.87)	(6.91 to 8.52)	(7.75 to 10.3)	(0.22 to 0.35)	(0.22 to 0.35)	(0.25 to 0.31)
	10.8	12.5	14.3	7.63	8.74	10.2	0.3	0.3	0.29
Sioveniu	(9.54 to 12.3)	(12.3 to 12.7) 9.29	(12.8 to 15.6)	(6.43 to 8.91) 7.17	(7.72 to 9.68)	(8.66 to 11.6) 8.49	(0.27 to 0.33)	(0.24 to 0.37)	(0.25 to 0.33)
Eastern Europe	(9.88 to 9.91)	(9.28 to 9.3)	(10.8 to 12.3)	(6.4 to 7.83)	(6.07 to 7.39)	(7.41 to 9.42)	(0.21 to 0.35)	(0.21 to 0.35)	(0.24 to 0.32)
Belarus	(10.6 to 10.7)	(9.26 to 9.36)	(9.53 to 12.1)	(7.01 to 8.52)	(6.1 to 7.42)	(6.72 to 9.21)	(0.2 to 0.34)	(0.27 (0.21 to 0.34)	(0.24 to 0.3)
Estonia	9.76	10.7	13.1	7.15	7.85	9.66	0.27	0.27	0.26
	(9.63 to 9.89)	(10.6 to 10.9)	(11.9 to 14.5)	(6.39 to 7.81)	(7.04 to 8.57)	(8.36 to 11.1)	(0.21 to 0.34)	(0.21 to 0.33)	(0.24 to 0.3)
Latvia	10.1	10.1	12.3	7.27	7.36	9.03	0.28	0.27	0.27
	(9.94 to 10.2)	(10 to 10.2)	(11.1 to 13.6)	(6.49 to 7.97)	(6.56 to 8.06)	(7.79 to 10.3)	(0.22 to 0.35)	(0.21 to 0.34)	(0.24 to 0.3)
Lithuania	10.9	10.8	12.5	7.86	7.78	9.13	0.28	0.28	0.27
	(10.8 to 11)	(10.7 to 10.9)	(11.5 to 13.6)	(7 to 8.62)	(6.96 to 8.53)	(7.95 to 10.3)	(0.22 to 0.35)	(0.22 to 0.35)	(0.24 to 0.31)
Republic of Moldova	10.1	9.88	12.4	7.38	7.33	9.17	0.27	0.26	0.26
	(9.97 to 10.1)	(9.8 to 9.96)	(11.7 to 13.1)	(6.62 to 8.03)	(6.62 to 7.97)	(8.16 to 10.2)	(0.21 to 0.34)	(0.2 to 0.32)	(0.22 to 0.3)
Russian Federation	9.7	9.15	11.6	7	6.65	8.52	0.28	0.27	0.27
	(9.69 to 9.72)	(9.14 to 9.16)	(10.6 to 12.7)	(6.24 to 7.66)	(5.92 to 7.27)	(7.32 to 9.62)	(0.21 to 0.36)	(0.21 to 0.35)	(0.24 to 0.31)
Ukraine	10.1	9.46	11.3	7.34	6.97	8.37	0.27	0.26	0.26
	(10.1 to 10.1)	(9.44 to 9.48)	(10.3 to 12.3)	(6.58 to 8)	(6.27 to 7.57)	(7.33 to 9.46)	(0.21 to 0.35)	(0.2 to 0.34)	(0.23 to 0.29)
High-income	12	13.9	15.2	8.7	10	10.9	0.28	0.28	0.28
Australasia	12 (0 12)	14.6	15.9	8.6	10.4	11.3	0.28	0.21 (0 0.35)	0.22 (00.35)
Australi	(12 to 12)	(14.6 to 14.7)	(15.8 to 16)	(7.69 to 9.43)	(9.25 to 11.4)	(10 to 12.4)	(0.22 to 0.36)	(0.22 to 0.37)	(0.23 to 0.36)
	12.1	14.7	16	8.64	10.4	11.3	0.28	0.29	0.29
Australia	(12 to 12.1)	(14.7 to 14.8)	(15.8 to 16.1)	(7.71 to 9.46)	(9.27 to 11.4)	(10.1 to 12.4)	(0.22 to 0.36)	(0.23 to 0.37)	(0.23 to 0.36)

Supplementary Table 7:	Life expectancy	, Health-adjusted	life expectancy,	and proportion o	f years spent in i	ll health in all repo	rting locations,	in 1990, 2005, 201	19, Males
location	1990	2005	2019	1990	2005	2019	1990	2005	2019
New Zealand	11.7	14.2	15.5	8.42	10.2	11	0.28	0.28	0.29
	(11.6 to 11.8)	(14.1 to 14.3)	(15.3 to 15.6)	(7.52 to 9.23)	(9.12 to 11.2)	(9.85 to 12.1)	(0.22 to 0.35)	(0.22 to 0.35)	(0.22 to 0.36)
High-income Asia Pacific	12.6	14.6	16.3	9.36	10.8	12.2	0.26	0.26	0.25
	(12.6 to 12.6)	(14.5 to 14.6)	(16.2 to 16.4)	(8.49 to 10.1)	(9.82 to 11.7)	(11.1 to 13.2)	(0.2 to 0.32)	(0.2 to 0.32)	(0.2 to 0.32)
Brunei Darussalam	7.1	9.2	9.72	5.06	6.52	7.01	0.29	0.29	0.28
	(6.82 to 7.41)	(8.79 to 9.59)	(9.16 to 10.3)	(4.51 to 5.61)	(5.76 to 7.27)	(6.17 to 7.81)	(0.24 to 0.34)	(0.24 to 0.34)	(0.24 to 0.33)
Japan	13	14.8	16.5	9.66	11	12.3	0.26	0.26	0.25
	(13 to 13)	(14.8 to 14.8)	(16.4 to 16.6)	(8.76 to 10.5)	(10 to 11.9)	(11.2 to 13.3)	(0.2 to 0.32)	(0.2 to 0.32)	(0.2 to 0.31)
Republic of Korea	9.89	12.8	15.1	7.35	9.48	11.2	0.26	0.26	0.26
	(9.87 to 9.92)	(12.8 to 12.9)	(14.9 to 15.4)	(6.66 to 7.97)	(8.6 to 10.3)	(10.2 to 12.2)	(0.2 to 0.32)	(0.2 to 0.33)	(0.21 to 0.32)
Singapore	11.3	14.5	16.7	8.42	10.8	12.7	0.25	0.25	0.24
	(11.2 to 11.4)	(14.4 to 14.5)	(16.6 to 16.9)	(7.65 to 9.12)	(9.81 to 11.7)	(11.6 to 13.7)	(0.2 to 0.32)	(0.2 to 0.32)	(0.19 to 0.3)
High-income North	12.4	13.9	14.8	8.5	9.47	9.81	0.31	0.32	0.34
America	(12.4 to 12.4)	(13.9 to 13.9)	(14.7 to 14.8)	(7.51 to 9.4)	(8.39 to 10.5)	(8.59 to 10.9)	(0.24 to 0.39)	(0.25 to 0.39)	(0.26 to 0.42)
Canada	12.4	14.4	15.8	8.98	10.5	11.3	0.27	0.27	0.28
	(12.3 to 12.4)	(14.4 to 14.4)	(15.7 to 15.9)	(8.06 to 9.81)	(9.46 to 11.4)	(10.1 to 12.4)	(0.21 to 0.35)	(0.21 to 0.34)	(0.22 to 0.35)
Greenland	9.78	11.2	12	6.76	7.91	8.39	0.31	0.29	0.3
	(9.46 to 10.2)	(10.9 to 11.5)	(11.4 to 13)	(6 to 7.53)	(7.03 to 8.74)	(7.38 to 9.53)	(0.26 to 0.37)	(0.24 to 0.36)	(0.27 to 0.35)
United States of	12.4	13.8	14.6	8.45	9.35	9.63	0.32	0.32	0.34
America	(12.4 to 12.4)	(13.8 to 13.8.)	(14.6 to 14.7.)	(7.46 to 9.36)	(8.27 to 10.3.)	(8.42 to 10.8)	(0.25 to 0.4)	(0.25 to 0.4)	
Southern Latin America	11.3	12.3	13.1	8.57	9.22	9.79	0.24	0.25	0.25
Argenting	11.2	(12.3 (0 12.3)	12.5	8.51	9.01	9.39	0.24	0.25	0.25
Chilo	(11.2 to 11.2)	(11.9 to 12)	(12.4 to 12.6)	(7.76 to 9.18)	(8.18 to 9.76)	(8.53 to 10.2)	(0.18 to 0.3)	(0.19 to 0.31)	(0.19 to 0.31)
	11.8	13.4	14.8	8.82	9.9	10.9	0.25	0.26	0.27
Chine	(11.7 to 11.8)	(13.3 to 13.4)	(14.6 to 14.9)	(7.99 to 9.55)	(8.94 to 10.8)	(9.78 to 11.8)	(0.19 to 0.32)	(0.2 to 0.33)	(0.21 to 0.33)
	11.2	11.9	13	8.5	9	9.67	0.24	0.25	0.26
Uruguay	(11.2 to 11.3)	(11.8 to 12)	(12.8 to 13.2)	(7.73 to 9.19)	(8.19 to 9.71)	(8.76 to 10.5)	(0.19 to 0.31)	(0.19 to 0.31)	(0.2 to 0.32)
Western Europe	(11.7 to 11.7)	(13.7 to 13.7)	(15.1 to 15.2)	(7.83 to 9.4)	(9.12 to 11)	(10.1 to 12.1)	(0.19 to 0.33)	(0.2 to 0.33)	(0.2 to 0.33)
Andorra	13.1	14.5	15.2	9.85	10.8	11.3	0.25	0.26	0.26
	(11.7 to 14.3)	(13.5 to 15.4)	(14.1 to 16.5)	(8.49 to 11.1)	(9.5 to 11.9)	(10 to 12.7)	(0.22 to 0.27)	(0.22 to 0.3)	(0.23 to 0.29)
Austria	11.5	13.6	15.2	8.41	9.79	11.1	0.27	0.28	0.27
	(11.4 to 11.5)	(13.5 to 13.6)	(15.1 to 15.3)	(7.55 to 9.17)	(8.77 to 10.7)	(9.88 to 12.1)	(0.21 to 0.34)	(0.21 to 0.35)	(0.21 to 0.35)
Belgium	11.2	13.2	14.7	8.27	9.66	10.7	0.26	0.27	0.27
	(11.2 to 11.3)	(13.2 to 13.3)	(14.6 to 14.9)	(7.47 to 9)	(8.67 to 10.5)	(9.62 to 11.7)	(0.2 to 0.33)	(0.21 to 0.34)	(0.21 to 0.34)
Cyprus	11.5 (11.3 to 11.6.)	11.9 (117 to 121)	14.1 (13.5 to 14.6.)	8.58 (7.79 to 9.3)	8.79 (7.92 to 9.57)	10.4 (933 to 114)	0.25	0.26	0.26
Denmark	11.2	12.8	14.6	8.41	9.62	10.9	0.25	0.25	0.25
Finland	(11.2 to 11.3)	(12.7 to 12.9)	(14.4 to 14.7)	(7.64 to 9.11)	(8.75 to 10.4)	(9.91 to 11.8)	(0.19 to 0.32)	(0.19 to 0.31)	(0.2 to 0.31)
	11.1	13.5	15.1	8.17	9.75	11.1	0.26	0.28	0.27
	(11 to 11.2)	(13.5 to 13.6)	(14.9 to 15.3)	(7.36 to 8.89)	(8.71 to 10.7)	(9.92 to 12.1)	(0.2 to 0.33)	(0.21 to 0.35)	(0.21 to 0.33)
	12.3	14.3	16	9.29	10.8	12.1	0.25	0.24	0.24
France	(12.3 to 12.3)	(14.2 to 14.3) 13.6	(15.8 to 16.1)	(8.43 to 10.1)	(9.81 to 11.7)	(11 to 13)	(0.18 to 0.31)	(0.18 to 0.31)	(0.19 to 0.31)
Germany	(11.1 to 11.1)	(13.6 to 13.7)	(14.5 to 14.7)	(7.51 to 8.97)	(9.09 to 11)	(9.7 to 11.7)	(0.19 to 0.32)	(0.2 to 0.33)	(0.2 to 0.33)
Greece	(12.4 to 12.6)	(13.7 to 13.8)	(14.7 to 15)	(8.53 to 10.1)	(9.22 to 11)	(10.1 to 12)	(0.19 to 0.31)	(0.2 to 0.33)	(0.2 to 0.32)
Iceland	12.9	14.5	16.1	9.69	10.7	12	0.25	0.26	0.26
	(12.6 to 13.2)	(14.2 to 14.8)	(15.6 to 16.6)	(8.83 to 10.5)	(9.59 to 11.6)	(10.8 to 13.1)	(0.2 to 0.3)	(0.21 to 0.32)	(0.21 to 0.31)
Ireland	10.5	12.9	14.9	7.89	9.59	11.1	0.25	0.26	0.26
	(10.4 to 10.5)	(12.8 to 13)	(14.7 to 15.1)	(7.2 to 8.54)	(8.69 to 10.4)	(10 to 12)	(0.19 to 0.31)	(0.2 to 0.32)	(0.21 to 0.32)
Israel	13	14.5	16	9.93	10.8	12.1	0.24	0.25	0.24
	(12.9 to 13.1)	(14.4 to 14.6)	(15.8 to 16.1)	(9.05 to 10.7)	(9.82 to 11.7)	(11 to 13)	(0.18 to 0.3)	(0.19 to 0.32)	(0.19 to 0.3)
Italy	12.1	13.8	15.4	8.74	9.93	11.2	0.28	0.28	0.28
	(12.1 to 12.1)	(13.8 to 13.9)	(15.3 to 15.5)	(7.83 to 9.57)	(8.87 to 10.9)	(10 to 12.2)	(0.21 to 0.35)	(0.21 to 0.36)	(0.21 to 0.35)
Luxembourg	10.9	13.2	15.7	8.12	9.7	11.5	0.25	0.27	0.27
	(10.7 to 11.1)	(13 to 13.4)	(15 to 16.4)	(7.35 to 8.82)	(8.74 to 10.6)	(10.2 to 12.7)	(0.2 to 0.31)	(0.22 to 0.33)	(0.23 to 0.32)
Malta	11.3 (11.1 to 11.5)	13 (12.7 to 13.2.)	15.3	8.46	9.65	11.3 (10.2 to 12.4.)	0.25	0.26	0.26
Monaco	12.5	13.4	14.3	9.43	10.1	10.6	0.25	0.25	0.26
Netherlands	(11.8 to 13.6)	(12.8 to 14.5)	(13.8 to 15)	(8.44 to 10.5)	(8.99 to 11.2)	(9.6 to 11.7)	(0.23 to 0.28)	(0.22 to 0.3)	(0.22 to 0.3)
	11.3	12.9	14.7	8.48	9.62	10.8	0.25	0.26	0.26
Neeueu	(11.3 to 11.4)	(12.9 to 13)	(14.5 to 14.8)	(7.73 to 9.18)	(8.77 to 10.4)	(9.86 to 11.7)	(0.19 to 0.31)	(0.2 to 0.32)	(0.21 to 0.32)
	11.7	13.6	15.5	8.41	9.78	11.1	0.28	0.28	0.29
Norway	(11.6 to 11.8)	(13.5 to 13.7) 13.1	(15.3 to 15.7) 14.8	(7.5 to 9.22) 8.15	(8.73 to 10.7) 9.66	(9.88 to 12.1) 11	(0.22 to 0.35) 0.26	(0.22 to 0.35) 0.26	(0.22 to 0.36) 0.25
Portugal	(11 to 11.1) 13.4	(13 to 13.2) 14.7	(14.6 to 14.9) 15.2	(7.37 to 8.86) 10.1	(8.73 to 10.5) 11	(9.95 to 11.9) 11.4	(0.2 to 0.33)	(0.2 to 0.33) 0.25	(0.2 to 0.32) 0.25
San Marino	(12.8 to 14.2)	(13.4 to 16.2)	(13.5 to 17.6)	(9.03 to 11)	(9.58 to 12.4)	(9.67 to 13.4)	(0.22 to 0.29)	(0.23 to 0.29)	(0.24 to 0.28)
Spain	(12.2 to 12.3)	(13.8 to 13.9)	(15.4 to 15.6)	9.01 (8.15 to 9.81)	(9.28 to 11.1)	(10.4 to 12.4)	(0.2 to 0.33)	(0.2 to 0.33)	(0.2 to 0.32)
Sweden	12.2	14	15.6	9.17	10.4	11.6	0.25	0.26	0.26
	(12.2 to 12.3)	(13.9 to 14.1)	(15.4 to 15.7)	(8.3 to 9.93)	(9.42 to 11.3)	(10.5 to 12.5)	(0.19 to 0.32)	(0.2 to 0.32)	(0.2 to 0.32)
Switzerland	12.4	14.7	16.3	9.09	10.8	12.1	0.27	0.26	0.26
	(12.4 to 12.5)	(14.6 to 14.7)	(16.2 to 16.5)	(8.19 to 9.91)	(9.72 to 11.7)	(10.9 to 13.2)	(0.21 to 0.34)	(0.2 to 0.33)	(0.2 to 0.33)
United Kingdom	11.2	13.5	14.7	8.29	9.86	10.7	0.26	0.27	0.27
	(11.1 to 11.2)	(13.4 to 13.5)	(14.6 to 14.8)	(7.52 to 8.99)	(8.88 to 10.7)	(9.64 to 11.7)	(0.2 to 0.33)	(0.2 to 0.34)	(0.21 to 0.34)
Latin America and	12.3 (12.2 to 12.4.)	13.6 (13.5 to 13.7)	14.1 (13.6 to 14.7)	8.98 (8.05 to 9.81)	9.98	10.3 (9.24 to 11.4.)	0.27 (0.21 to 0.34)	0.27 (0.21 to 0.34)	0.27
Andean Latin America	12.9	14.3	14.9	9.7	10.8	11.1	0.25	0.25	0.25
Bolivia (Plurinational	(12.4 to 13.3)	(13.8 to 14.9)	(13.8 to 16.1)	(8.71 to 10.6)	(9.66 to 11.7)	(9.8 to 12.5)	(0.2 to 0.3)	(0.21 to 0.3)	(0.23 to 0.29)
	10.2	11.6	11.5	7.62	8.64	8.6	0.26	0.26	0.25
State of)	(9.73 to 10.7)	(11 to 12.1)	(10.7 to 12.6)	(6.81 to 8.42)	(7.71 to 9.49)	(7.48 to 9.8)	(0.22 to 0.3)	(0.21 to 0.3)	(0.22 to 0.3)

Supplementary Table 7:	Life expectancy	, Health-adjusted	life expectancy,	and proportion o	f years spent in i	ll health in all repo	rting locations, i	in 1990, 2005, 20	19, Males
location	1990	2005	2019	1990	2005	2019	1990	PYIH-70 2005	2019
Ecuador	13.6 (13.5 to 13.7)	13.7 (13.1 to 14.3)	13.9 (12.6 to 15.2)	10.2 (9.3 to 11.1)	10.2 (9.16 to 11.2)	10.3 (8.91 to 11.7)	0.25 (0.19 to 0.31)	0.26 (0.22 to 0.3)	0.26 (0.23 to 0.29)
Peru	13.3	15.6	16.5	10.1	11.8	12.4	0.24	0.25	0.25
Caribbean	12.5	13.2	13.5	9.38	9.85	9.97	0.25	0.25	0.26
Antique and Darbuda	(12.3 to 12.6) 11.1	(12.9 to 13.4) 13.1	(12.7 to 14.4) 12.8	(8.52 to 10.2) 8.41	(8.92 to 10.7) 9.81	(8.84 to 11.1) 9.51	(0.19 to 0.31) 0.24	(0.2 to 0.31) 0.25	(0.23 to 0.3) 0.26
Antigua ana Barbuaa	(10.8 to 11.3) 11.4	(12.7 to 13.5) 12.9	(12 to 13.6) 12.9	(7.65 to 9.12) 8.68	(8.81 to 10.7) 9.71	(8.42 to 10.6) 9.72	(0.2 to 0.29) 0.24	(0.21 to 0.31) 0.24	(0.22 to 0.3) 0.25
Bahamas	(11 to 11.8)	(12.5 to 13.3)	(11.8 to 14)	(7.86 to 9.44)	(8.77 to 10.6)	(8.47 to 10.9)	(0.2 to 0.29)	(0.2 to 0.3)	(0.22 to 0.28)
Barbados	(11.9 to 12.4)	(12.4 to 12.9)	(12.2 to 14)	(8.43 to 10.1)	(8.71 to 10.4)	(8.65 to 10.9)	(0.19 to 0.29)	(0.19 to 0.3)	(0.22 to 0.29)
Belize	13.8 (13.4 to 14.3)	13.1 (12.8 to 13.4)	14 (13.3 to 14.8)	10.6 (9.6 to 11.5)	9.95 (8.99 to 10.8)	10.6 (9.47 to 11.7)	0.23 (0.19 to 0.28)	0.24 (0.19 to 0.3)	0.24 (0.21 to 0.29)
Bermuda	10.1 (9.97 to 10.3)	13 (12.5 to 13.5)	14 (13.1 to 14.7)	7.74 (7.07 to 8.36)	9.8 (8.81 to 10.7)	10.4 (9.26 to 11.5)	0.24 (0.19 to 0.29)	0.25 (0.2 to 0.29)	0.25 (0.22 to 0.29)
Cuba	12.9 (12.8 to 13)	13.6 (13.5 to 13.7)	13.9 (12.8 to 15.2)	9.67 (8.75 to 10.5)	10.2 (9.16 to 11)	10.2 (8.92 to 11.5)	0.25 (0.19 to 0.32)	0.25 (0.2 to 0.32)	0.27 (0.24 to 0.3)
Dominica	10.5 (10.2 to 10.9)	11.2 (10.5 to 11.8)	11.3 (10.4 to 12.1)	7.94 (7.13 to 8.65)	8.26 (7.33 to 9.16)	8.29 (7.21 to 9.35)	0.24 (0.21 to 0.3)	0.26 (0.23 to 0.3)	0.27 (0.23 to 0.3)
Dominican Republic	14.6 (13.9 to 15.3.)	13.4 (12.6 to 14.4.)	12.9 (11.7 to 14.2.)	11.1 (10 to 12 2)	10.3 (9.09 to 11.3)	9.82 (8.51 to 11.2.)	0.24	0.24	0.24 (0.21 to 0.27)
Grenada	9.68	8.1	11.1	7.32	6	8.12	0.24	0.26	0.27
Guvana	8.58	10.2	10.5	6.36	7.52	7.7	0.26	0.26	0.27
	(7.97 to 9.3) 9.09	(9.5 to 10.9) 10.5	(9.36 to 11.8) 10.8	(5.61 to 7.09) 6.83	(6.6 to 8.42) 7.84	(6.57 to 8.94) 8.06	(0.24 to 0.3) 0.25	(0.23 to 0.3) 0.25	(0.24 to 0.3) 0.25
Haiti	(8.73 to 9.59)	(9.63 to 11.5)	(9.56 to 12)	(6.1 to 7.55)	(6.9 to 8.87)	(6.86 to 9.25)	(0.21 to 0.3)	(0.23 to 0.28)	(0.23 to 0.28)
Jamaica	(13.4 to 13.8)	(14.3 to 15)	(12.1 to 14.8)	(9.43 to 11.2)	(9.86 to 12)	(8.69 to 11.4)	(0.19 to 0.29)	(0.2 to 0.31)	(0.23 to 0.28)
Puerto Rico	(12.7 to 13)	(14.2 to 14.6)	(14.5 to 17.7)	(8.68 to 10.4)	(9.5 to 11.5)	(10.1 to 13.4)	(0.2 to 0.32)	(0.21 to 0.33)	(0.24 to 0.3)
Saint Kitts and Nevis	8.89 (8.55 to 9.28)	10.5 (10.2 to 10.8)	10.8 (10.4 to 11)	6.69 (6.02 to 7.32)	7.74 (6.96 to 8.49)	7.84 (6.99 to 8.6)	0.25 (0.21 to 0.3)	0.26 (0.21 to 0.32)	0.27 (0.22 to 0.33)
Saint Lucia	10.3 (10.1 to 10.6)	12.2 (11.9 to 12.4)	12.4 (11.6 to 13.2)	7.68 (6.91 to 8.41)	8.95 (8.03 to 9.81)	9.11 (8.02 to 10.2)	0.25 (0.2 to 0.31)	0.26 (0.21 to 0.32)	0.27 (0.23 to 0.31)
Saint Vincent and the Grenadines	11 (10.6 to 11.3)	12.7 (12.4 to 13)	12 (11.5 to 12.6)	8.26 (7.47 to 9.05)	9.47 (8.53 to 10.3)	8.92 (7.92 to 9.84)	0.25 (0.2 to 0.3)	0.25 (0.2 to 0.31)	0.26 (0.22 to 0.31)
Suriname	12.2	12	12.8	9.2	8.95	9.42	0.25	0.26	0.27
Trinidad and Tobago	10.6	12.2	13.2	7.95	9.02	9.73	0.25	0.26	0.26
United States Virgin	(10.4 to 10.8) 12.2	(12 to 12.4) 12.3	(11.6 to 14.9) 11.1	(7.19 to 8.62) 9.33	(8.15 to 9.85) 9.27	(8.24 to 11.3) 8.24	(0.2 to 0.31) 0.24	(0.2 to 0.32) 0.25	(0.24 to 0.29) 0.26
Islands	(11.5 to 13) 12.9	(11.7 to 13) 14	(10.9 to 11.6) 14.5	(8.38 to 10.3) 9.33	(8.31 to 10.1) 10.2	(7.4 to 9.06) 10.5	(0.21 to 0.27) 0.28	(0.22 to 0.29) 0.27	(0.22 to 0.32) 0.27
Central Latin America	(12.8 to 13)	(13.9 to 14)	(13.7 to 15.3)	(8.35 to 10.2)	(9.21 to 11.2)	(9.3 to 11.7)	(0.21 to 0.35)	(0.2 to 0.34)	(0.23 to 0.32)
Colombia	(13.2 to 13.3)	(15 to 15.1)	(14.8 to 18.3)	(8.66 to 10.6)	(9.91 to 12)	(10.5 to 13.9)	(0.2 to 0.34)	(0.2 to 0.34)	(0.24 to 0.29)
Costa Rica	(13.8 to 14.2)	(15 to 15.4)	(13.9 to 16.9)	(9.27 to 11.2)	(10.1 to 12.2)	(9.73 to 12.9)	(0.21 to 0.33)	(0.21 to 0.33)	(0.24 to 0.3)
El Salvador	14.2 (14 to 14.3)	13.7 (13.6 to 13.8)	14.3 (12.8 to 16)	10.4 (9.32 to 11.3)	10 (8.99 to 11)	10.4 (8.88 to 12)	0.27 (0.21 to 0.34)	0.27 (0.21 to 0.34)	0.27 (0.25 to 0.3)
Guatemala	10.1 (9.38 to 10.9)	11.8 (11.2 to 12.6)	13.1 (12 to 14.2)	7.5 (6.57 to 8.44)	8.68 (7.74 to 9.63)	9.55 (8.31 to 10.8)	0.26 (0.23 to 0.3)	0.27 (0.23 to 0.31)	0.27 (0.24 to 0.3)
Honduras	13.1 (12.2 to 14.1)	13.2 (11.9 to 14.8)	11.3 (11.1 to 11.6)	9.73 (8.57 to 10.9)	9.8 (8.4 to 11.3)	8.4 (7.54 to 9.2)	0.26 (0.23 to 0.3)	0.26 (0.24 to 0.29)	0.26 (0.21 to 0.32)
Mexico	12.9 (12.9 to 12.9)	14 (14 to 14)	14.2 (13.5 to 15)	9.2 (8.2 to 10.1)	10.2 (9.2 to 11.2)	10.2 (9.08 to 11.4)	0.29 (0.22 to 0.36)	0.27 (0.21 to 0.34)	0.28 (0.24 to 0.33)
Nicaragua	12.2 (12 to 12.4)	11.2	11.5 (10.6 to 12.6)	9.04	8.34	8.52 (7.41 to 0.7.)	0.26	0.25	0.26
Panama	14.7	15.2	16.1	10.8	11.2	11.8	0.26	0.26	0.27
Venezuela (Bolivarian	(14.5 to 15) 12.9	(14.9 to 15.4) 12.9	(14.5 to 17.7) 13.4	(9.77 to 11.8) 9.52	(10.1 to 12.2) 9.61	(10.2 to 13.4) 9.91	(0.21 to 0.32) 0.26	(0.21 to 0.32) 0.26	(0.24 to 0.3) 0.26
Republic of)	(12.8 to 13) 11.6	(12.9 to 13) 13.2	(11.8 to 15) 14	(8.58 to 10.3) 8.34	(8.67 to 10.4) 9.56	(8.44 to 11.5) 10.2	(0.2 to 0.33) 0.28	(0.2 to 0.33) 0.27	(0.24 to 0.28) 0.27
Tropical Latin America	(11.5 to 11.7)	(13 to 13.3)	(13.7 to 14.2)	(7.46 to 9.15) 8.28	(8.57 to 10.5) 9.53	(9.16 to 11.1)	(0.22 to 0.35)	(0.21 to 0.34)	(0.22 to 0.33)
Brazil	(11.4 to 11.6)	(13 to 13.2)	(13.7 to 14.2)	(7.4 to 9.09)	(8.54 to 10.4)	(9.15 to 11.1)	(0.22 to 0.35)	(0.21 to 0.34)	(0.22 to 0.33)
Paraguay	(13.8 to 15.2)	(13.4 to 14.8)	(12.2 to 15.4)	(9.73 to 12)	(9.45 to 11.6)	(8.75 to 11.8)	(0.21 to 0.3)	(0.21 to 0.29)	(0.23 to 0.28)
North Africa and Middle East	10.9 (10.6 to 11.1)	11.9 (11.6 to 12.2)	12.6 (12.1 to 13.1)	8.05 (7.26 to 8.81)	8.78 (7.94 to 9.61)	9.19 (8.25 to 10.1)	0.26 (0.21 to 0.31)	0.26 (0.21 to 0.32)	0.27 (0.23 to 0.32)
North Africa and Middle East	10.9 (10.6 to 11.1)	11.9 (11.6 to 12.2)	12.6 (12.1 to 13.1)	8.05 (7.26 to 8.81)	8.78 (7.94 to 9.61)	9.19 (8.25 to 10.1)	0.26 (0.21 to 0.31)	0.26 (0.21 to 0.32)	0.27 (0.23 to 0.32)
Afghanistan	8.95 (8.3 to 9.71)	9.3 (8.67 to 10.1)	9.95 (9.47 to 10.9)	6.5 (5.61 to 7.28)	6.71 (5.84 to 7.57)	6.99 (6.1 to 7.94)	0.27 (0.25 to 0.32)	0.28 (0.25 to 0.33)	0.3 (0.28 to 0.36)
Algeria	10.3	12.2	13.5 (12.6 to 14.5.)	7.8 (6.83 to 8.76)	9.13	9.93	0.25	0.25	0.26
Bahrain	8.41	9.15	11.8	6.07	6.48	8.27	0.28	0.29	0.3
Favnt	(7.93 to 8.94) 10.3	(8.62 to 9.66) 10.5	(10.8 to 12.8) 11.4	(5.38 to 6.75) 7.79	(5.7 to 7.27) 7.91	(7.12 to 9.44) 8.49	(U.25 to 0.32) 0.24	(U.25 to 0.34) 0.25	(U.26 to 0.34) 0.26
Iran (Islamic Republic	(10.2 to 10.3) 11.3	(10.5 to 10.5) 12.7	(10.2 to 12.8) 14.1	(7.1 to 8.41) 8.16	(7.22 to 8.55) 9.25	(7.31 to 9.77) 10.2	(0.18 to 0.31) 0.28	(0.19 to 0.31) 0.27	(0.24 to 0.28) 0.28
of)	(11 to 11.6)	(12.6 to 12.9)	(13.8 to 14.3)	(7.3 to 8.95)	(8.31 to 10.1)	(9.14 to 11.1)	(0.23 to 0.34)	(0.22 to 0.34)	(0.22 to 0.34)

Supplementary Table 7:	Life expectancy	, Health-adjusted	life expectancy,	and proportion o	f years spent in il	l health in all repo	rting locations, i	n 1990, 2005, 20:	19, Males
location	1000	LE-70	2010	1000	HALE-70	2010	1000	PYIH-70	2010
Iraq	11.1 (10.1 to 12.2.)	10.8 (9.75 to 12.)	11.4 (10.9 to 12.6.)	7.81	7.84	8.35 (7.42 to 9.42)	0.3 (0.27 to 0.34)	0.27 (0.25 to 0.31)	0.27 (0.25 to 0.32)
Jordan	12.1 (11.3 to 13.)	13.8 (13 to 14 7)	14.5 (13.3 to 15.9.)	9.01 (8.05 to 10.)	10.2 (897 to 11 3)	10.7 (9.3 to 12.1)	0.26 (0.23 to 0.29)	0.26	0.27 (0.24 to 0.3)
Kuwait	14.9	14.6 (14.5 to 14.8)	15.5 (14.3 to 16.7.)	11 (9.91 to 12.1)	10.6 (9.52 to 11.6)	(9.15 to 12.17)	0.26	0.27	0.28
Lebanon	10.8 (10 to 11 5)	(14.5 to 14.5) 11.9 (11.2 to 12.5)	(14.5 to 10.7) 12 (11.5 to 12.7)	7.99 (7.08 to 8.88.)	8.7 (7.72 to 9.64)	8.6 (7.61 to 9.57)	0.26	0.27	0.29
Libya	13.2	14.5	13.9	9.71	10.5	9.98 (8.61 to 11.4.)	0.27	0.28	0.28
Morocco	11 (105 to 116)	(14.2 to 14.3) 12.5 (11.2 to 13.7)	(12.7 to 13.3) 11.3 (10.8 to 12.7)	8.33 (7.46 to 9.2.)	9.24 (8.02 to 10.5.)	(0.01 (0 11.4) 8.32 (7.41 to 9.5)	0.25	0.26	0.26
Oman	8.85	10.2 (9.93 to 10.5)	10.2 (9.59 to 10.7)	6.46 (5.57 to 7.45)	7.35	7.3 (6.42 to 8.13.)	0.27 (0.25 to 0.3)	0.28	0.28
Palestine	9.62	10.2 (9.75 to 10.6)	(10.5 to 10.7) 11.2 (10.5 to 11.8)	7.15 (6.2 to 8.18.)	7.48 (6.7 to 8.24.)	8.08 (7.14 to 9.)	0.26	0.26	0.28
Qatar	9.02	10.7 (9.78 to 11.7)	11.5 (10.4 to 12.6)	6.54	7.48	8.11 (6.94 to 9.31.)	0.27	0.3	0.29
Saudi Arabia	10.8	11.1	12.8	7.68	7.88	8.94	0.29	0.29	0.3
Sudan	(10.1 to 11.8) 9.81	(10.8 to 11.4) 10.8	(12.3 to 13.4) 11.5	(6.73 to 8.71) 7.33	(6.94 to 8.71) 7.99	(7.84 to 9.98) 8.43	(0.26 to 0.33) 0.25	(0.24 to 0.36) 0.26	(0.26 to 0.36) 0.26
500011	(9.23 to 10.4)	(9.83 to 12)	(10.6 to 12.2)	(6.55 to 8.11)	(7.03 to 9.03)	(7.41 to 9.36)	(0.22 to 0.29)	(0.25 to 0.28)	(0.23 to 0.3)
Syrian Arab Republic	(10.6 to 12.8)	(11.6 to 13.5)	(10.5 to 13.2)	(7.68 to 9.83)	(8.26 to 10.4)	(7.37 to 9.95)	(0.23 to 0.28)	(0.23 to 0.29)	(0.25 to 0.3)
Tunisia	12.1 (11.5 to 12.7)	12.2 (11.1 to 13.6)	13 (11.5 to 14.6)	8.98 (7.96 to 9.87)	8.94 (7.71 to 10.2)	9.43 (8.03 to 10.9)	0.26 (0.22 to 0.31)	0.27 (0.24 to 0.3)	0.28 (0.26 to 0.3)
Turkey	11.7 (11.1 to 12.4)	13.3 (12.7 to 14)	13.8 (12.7 to 15.1)	8.75 (7.8 to 9.65)	9.76 (8.71 to 10.8)	10.1 (8.81 to 11.4)	0.25 (0.22 to 0.3)	0.27 (0.23 to 0.32)	0.27 (0.25 to 0.3)
United Arab Emirates	9.2 (8.54 to 10)	9.02 (8.49 to 9.64)	11.6 (10.9 to 12.4)	6.71 (5.89 to 7.57)	6.51 (5.73 to 7.28)	8.26 (7.2 to 9.32)	0.27 (0.24 to 0.31)	0.28 (0.25 to 0.33)	0.29 (0.25 to 0.34)
Yemen	9.4 (8.56 to 10.3)	10.4 (9.58 to 11.5)	10.8 (9.87 to 11.5)	7.05 (6.16 to 7.94)	7.8 (6.86 to 8.79)	8.03 (6.97 to 8.96)	0.25 (0.23 to 0.28)	0.25 (0.23 to 0.28)	0.26 (0.22 to 0.29)
South Asia	9.26 (8.97 to 9.56)	10.3 (10 to 10.7)	11.9 (11.1 to 12.8)	6.48 (5.78 to 7.2)	7.21 (6.37 to 8.02)	8.34 (7.23 to 9.47)	0.3 (0.25 to 0.36)	0.3 (0.25 to 0.36)	0.3 (0.26 to 0.35)
South Asia	9.26 (8.97 to 9.56)	10.3 (10 to 10.7)	11.9 (11.1 to 12.8)	6.48 (5.78 to 7.2)	7.21 (6.37 to 8.02)	8.34 (7.23 to 9.47)	0.3 (0.25 to 0.36)	0.3 (0.25 to 0.36)	0.3 (0.26 to 0.35)
Bangladesh	9.97 (9.52 to 10.4)	11.3 (10.9 to 11.7)	13.7 (12.6 to 14.8)	7.29 (6.55 to 8.03)	8.3 (7.42 to 9.12)	10 (8.82 to 11.2)	0.27 (0.23 to 0.31)	0.27 (0.22 to 0.32)	0.26 (0.24 to 0.3)
Bhutan	10.5 (9.66 to 11.3)	11.7 (11.2 to 12.6)	12.1 (11.4 to 13.1)	7.75 (6.82 to 8.64)	8.62 (7.73 to 9.53)	8.82 (7.82 to 9.92)	0.26 (0.23 to 0.29)	0.27 (0.24 to 0.31)	0.27 (0.24 to 0.31)
India	8.94 (8.58 to 9.31)	10.3 (9.88 to 10.7)	11.8 (10.8 to 12.9)	6.17 (5.45 to 6.92)	7.09 (6.24 to 7.93)	8.19 (7.02 to 9.39)	0.31 (0.26 to 0.36)	0.31 (0.26 to 0.37)	0.31 (0.27 to 0.35)
Nepal	9.66 (8.96 to 10.4)	11.1 (10.8 to 11.7)	10.7 (10.2 to 11.7)	6.91 (6.07 to 7.77)	7.93 (7.12 to 8.74)	7.77 (6.83 to 8.88)	0.28 (0.25 to 0.32)	0.28 (0.25 to 0.34)	0.27 (0.24 to 0.33)
Pakistan	10.4 (9.89 to 10.9)	9.82 (9.24 to 10.4)	10.9 (9.75 to 12.3)	7.49 (6.71 to 8.3)	7.02 (6.23 to 7.84)	7.87 (6.76 to 9.05)	0.28 (0.24 to 0.32)	0.29 (0.25 to 0.33)	0.28 (0.26 to 0.31)
Southeast Asia, East Asia,	9.88	10.5	11.8	7.37	7.82	8.82	0.25	0.25	0.26
East Asia	9.68	10.3	(11.1 to 12.7) 11.9 (10.9 to 12.9)	7.3 (652 to 8 16)	7.78	(7.89 to 9.83) 8.91 (7.91 to 10.)	0.25	0.25 (0.21 to 0.29)	0.25
China	9.63	10.3 (9.84 to 10.7)	11.8 (10.9 to 12.8)	7.26	7.72	8.87 (7.87 to 10.)	0.25	0.25	0.25
Democratic People's Republic of Korea	10.2	10 (9.72 to 11)	10.9 (10.5 to 11.3)	7.84	7.7 (7.03 to 8.53.)	8.33 (7.61 to 9.06.)	0.23	0.23	0.23 (0.2 to 0.28)
Taiwan (Province of	12.3	14	14.7	9.29	10.5	11.1	0.24	0.25	0.25
China)	(12.2 to 12.4) 9.44	(13.9 to 14.1) 9.56	(13.1 to 16.2) 10	(8.46 to 10) 6.89	(9.56 to 11.4) 6.95	(9.52 to 12.6) 7.29	(0.19 to 0.31) 0.27	(0.19 to 0.31) 0.27	(0.22 to 0.28) 0.27
occania	(8.91 to 10) 10.4	(8.98 to 10.2) 10.8	(9.27 to 10.8) 11.5	(6.1 to 7.7) 7.46	(6.11 to 7.72) 7.64	(6.34 to 8.23) 8.12	(0.23 to 0.32) 0.28	(0.24 to 0.32) 0.29	(0.24 to 0.32) 0.29
American Samoa	(10.2 to 10.7)	(10.5 to 11.1)	(11.3 to 11.8)	(6.64 to 8.2)	(6.75 to 8.49)	(7.18 to 9.05)	(0.23 to 0.35)	(0.24 to 0.36)	(0.23 to 0.36)
Cook Islands	(9.67 to 10.4)	(10.9 to 11.9)	(11.9 to 13.1)	(6.55 to 8.02)	(7.18 to 8.93)	(7.82 to 9.84)	(0.22 to 0.32)	(0.25 to 0.34)	(0.25 to 0.34)
Fiji	9.22 (8.53 to 9.89)	(8.87 to 9.11)	9.39 (8.48 to 10.4)	(5.75 to 7.47)	6.32 (5.57 to 6.99)	(5.6 to 7.59)	(0.24 to 0.33)	(0.23 to 0.37)	(0.27 to 0.34)
Guam	11.3 (10.9 to 11.8)	14.2 (13.6 to 14.8)	14.7 (13.8 to 15.7)	8.49 (7.68 to 9.24)	10.5 (9.43 to 11.5)	10.8 (9.64 to 12)	0.25 (0.22 to 0.29)	0.26 (0.22 to 0.31)	0.26 (0.23 to 0.3)
Kiribati	7.37 (6.85 to 8.02)	7.81 (7.19 to 8.56)	8.32 (7.56 to 9.17)	5.39 (4.7 to 6.11)	5.64 (4.93 to 6.49)	5.99 (5.17 to 6.87)	0.27 (0.24 to 0.31)	0.28 (0.24 to 0.31)	0.28 (0.25 to 0.32)
Marshall Islands	8.31 (7.98 to 8.66)	9.66 (9.2 to 10.2)	10.1 (9.06 to 11.2)	6.06 (5.41 to 6.69)	6.97 (6.17 to 7.76)	7.28 (6.17 to 8.37)	0.27 (0.23 to 0.32)	0.28 (0.24 to 0.33)	0.28 (0.25 to 0.32)
Micronesia (Federated States of)	8.79 (8.07 to 9.46)	9.24 (8.74 to 9.8)	9.19 (8.33 to 10.2)	6.51 (5.72 to 7.33)	6.78 (6.02 to 7.49)	6.75 (5.82 to 7.75)	0.26 (0.22 to 0.29)	0.27 (0.24 to 0.31)	0.27 (0.24 to 0.3)
Nauru	8.72 (7.99 to 9.57)	8 (7.37 to 8.74)	8.95 (8.09 to 9.94)	6.44 (5.6 to 7.28)	5.89 (5.19 to 6.69)	6.51 (5.61 to 7.49)	0.26 (0.24 to 0.3)	0.26 (0.23 to 0.3)	0.27 (0.25 to 0.31)
Niue	10 (9.47 to 10.5)	10 (9.73 to 10.4)	10.5 (10.3 to 10.8)	7.31 (6.48 to 8.13)	7.19 (6.36 to 7.95)	7.43 (6.59 to 8.26)	0.27 (0.23 to 0.32)	0.28 (0.24 to 0.35)	0.29 (0.23 to 0.36)
Northern Mariana Islands	11.5 (10.9 to 11.9)	11.7 (11.4 to 12)	11.4 (11 to 11.8)	8.49 (7.57 to 9.33)	8.54 (7.63 to 9.33)	8.29 (7.41 to 9.13)	0.26 (0.22 to 0.31)	0.27 (0.22 to 0.33)	0.27 (0.23 to 0.33)
Palau	9.45	10.1 (9.3 to 10.7)	10.2	6.89 (6.06 to 7.67)	7.19	7.3 (6.28 to 8.36)	0.27	0.29	0.29
Papua New Guinea	9.61	9.56	10.1	7	6.95	7.31	0.27	0.27	0.27
Samoa	9.61	10.8	(9.19 (0 10.9)	7.06	7.86	8.33	0.27	0.27	0.27
	(9.27 to 9.98)	(10.5 to 10.9)	(11 to 11.7)	(0.32 to 7.79)	(/.U/ to 8.62)	(7.44 to 9.18)	(U.22 to 0.32)	(U.21 to 0.33)	(U.21 to 0.32)

Supplementary Table 7:	Life expectancy	, Health-adjusted	life expectancy,	and proportion o	of years spent in	ill health in all repo	rting locations, i	in 1990, 2005, 20	19, Males
location	1990	2005	2019	1990	2005	2019	1990	2005	2019
Solomon Islands	7.62	7.71	8.13	5.76	5.75	6.01	0.24	0.25	0.26
	(7 to 8.41)	(7.15 to 8.36)	(7.43 to 8.94)	(5.04 to 6.53)	(5.07 to 6.44)	(5.24 to 6.86)	(0.22 to 0.28)	(0.23 to 0.29)	(0.23 to 0.3)
Tokelau	11.5	12.2	13.2	8.53	8.94	9.55	0.26	0.27	0.27
	(11.1 to 11.9)	(11.7 to 12.6)	(12.3 to 13.6)	(7.67 to 9.33)	(8 to 9.81)	(8.49 to 10.5)	(0.21 to 0.31)	(0.22 to 0.32)	(0.23 to 0.31)
Tonga	10.8	10.7	11	8.03	7.89	8.12	0.26	0.26	0.26
	(10.3 to 11.4)	(10.2 to 11.1)	(10.4 to 11.8)	(7.16 to 8.83)	(7.1 to 8.63)	(7.23 to 9.01)	(0.23 to 0.3)	(0.23 to 0.31)	(0.23 to 0.31)
Tuvalu	8.83	10.2	10.8	6.6	7.49	7.9	0.25	0.26	0.27
	(8.53 to 9.27)	(9.56 to 10.6)	(9.55 to 11.6)	(5.93 to 7.24)	(6.71 to 8.25)	(6.71 to 8.97)	(0.22 to 0.3)	(0.22 to 0.3)	(0.23 to 0.3)
Vanuatu	9.21	9.33	9.76	6.81	6.93	7.18	0.26	0.26	0.26
	(8.4 to 9.76)	(8.5 to 9.83)	(8.72 to 10.4)	(5.93 to 7.61)	(6.1 to 7.68)	(6.16 to 8.04)	(0.22 to 0.29)	(0.22 to 0.28)	(0.23 to 0.29)
Southeast Asia	10.6	11.1	11.7	7.61	8	8.4	0.28	0.28	0.28
	(10.3 to 10.9)	(10.8 to 11.4)	(11.2 to 12.3)	(6.8 to 8.36)	(7.18 to 8.78)	(7.47 to 9.29)	(0.23 to 0.34)	(0.23 to 0.34)	(0.24 to 0.33)
Cambodia	8.91	9.75	10.2	6.47	7.09	7.31	0.27	0.27	0.28
	(8.59 to 9.38)	(9.41 to 10.2)	(9.85 to 11.2)	(5.75 to 7.16)	(6.34 to 7.83)	(6.47 to 8.28)	(0.24 to 0.33)	(0.24 to 0.33)	(0.26 to 0.34)
Indonesia	10.6	10.6	10.6	7.46	7.56	7.55	0.29	0.29	0.29
	(10.1 to 11.1)	(10.1 to 11.3)	(9.81 to 11.7)	(6.63 to 8.33)	(6.63 to 8.42)	(6.58 to 8.67)	(0.25 to 0.34)	(0.25 to 0.34)	(0.26 to 0.33)
Lao People's	8.42	9.46	10.5	6.24	7.01	7.71	0.26	0.26	0.27
Democratic Republic	(7.87 to 9.13)	(9.05 to 10.1)	(9.93 to 11.4)	(5.55 to 7.01)	(6.27 to 7.72)	(6.86 to 8.64)	(0.23 to 0.3)	(0.23 to 0.31)	(0.24 to 0.31)
Malaysia	11.5	11.7	12.2	8.18	8.35	8.79	0.29	0.29	0.28
Maldives	(11.4 to 11.5)	(11.6 to 11.8)	(11 to 13.5)	(7.32 to 8.96)	(7.45 to 9.17)	(7.6 to 10.1)	(0.22 to 0.36)	(0.22 to 0.36)	(0.25 to 0.31)
	10.5	13.1	14.5	7.73	9.61	10.5	0.27	0.26	0.27
indianes	(10.3 to 10.7)	(12.7 to 13.4)	(13.5 to 15.5)	(6.99 to 8.45)	(8.69 to 10.5)	(9.31 to 11.8)	(0.21 to 0.32)	(0.22 to 0.32)	(0.24 to 0.31)
	10.2	11.3	13	7.33	7.96	9.15	0.28	0.29	0.3
Mauritius	(10 to 10.4)	(11.1 to 11.5)	(11.9 to 14.2)	(6.61 to 8.05)	(7.1 to 8.77)	(7.88 to 10.4)	(0.23 to 0.34)	(0.24 to 0.36)	(0.27 to 0.34)
Myanmar	(7.9 to 9.22)	(8.83 to 9.81)	(9.77 to 10.7)	(5.39 to 6.92)	(5.98 to 7.44)	(6.6 to 8.22)	(0.25 to 0.32)	(0.24 to 0.32)	(0.23 to 0.32)
Philippines	11.8	11.4	11.5	8.54	8.31	8.35	0.28	0.27	0.28
	(11.3 to 12.4)	(10.9 to 12)	(10.1 to 13.1)	(7.59 to 9.44)	(7.41 to 9.15)	(7 to 9.73)	(0.24 to 0.33)	(0.24 to 0.32)	(0.26 to 0.31)
Seychelles	9.92	10.1	11.5	7.26	7.26	8.1	0.27	0.28	0.29
	(9.66 to 10.2)	(9.86 to 10.4)	(10.8 to 12.1)	(6.52 to 7.93)	(6.49 to 8.04)	(7.11 to 9.08)	(0.22 to 0.33)	(0.23 to 0.34)	(0.25 to 0.34)
Sri Lanka	10.5	11.4	13	7.61	8.02	9.03	0.28	0.3	0.31
	(10.2 to 10.9)	(10.9 to 12)	(11.5 to 14.6)	(6.81 to 8.4)	(7.04 to 8.95)	(7.62 to 10.6)	(0.23 to 0.33)	(0.25 to 0.35)	(0.28 to 0.34)
Thailand	12.1	14.5	15.5	8.73	10.5	11.3	0.28	0.27	0.27
	(11.5 to 12.7)	(13.6 to 15.3)	(13.8 to 17.5)	(7.77 to 9.7)	(9.42 to 11.7)	(9.72 to 13.1)	(0.24 to 0.32)	(0.24 to 0.31)	(0.25 to 0.29)
Timor-Leste	11.1	11.5	10.8	7.98	8.18	7.67	0.28	0.29	0.29
	(10.3 to 11.7)	(10.9 to 12.1)	(10.3 to 11.8)	(7.02 to 8.84)	(7.27 to 9.11)	(6.73 to 8.76)	(0.24 to 0.32)	(0.25 to 0.33)	(0.26 to 0.35)
Viet Nam	10	10.5	10.7	7.49	7.8	7.83	0.25	0.26	0.27
	(9.43 to 10.6)	(9.97 to 10.8)	(10.4 to 11.4)	(6.7 to 8.25)	(7.04 to 8.48)	(6.98 to 8.65)	(0.22 to 0.29)	(0.21 to 0.29)	(0.24 to 0.33)
Sub-Saharan Africa	9.28	9.51	10.7	6.79	6.97	7.88	0.27	0.27	0.26
Central Sub-Saharan Africa	8.35	8.82	9.91	6.08	6.42	7.28	0.27	0.27	0.27
Angola	(7.91 to 8.83)	(8.45 to 9.28)	(9.24 to 10.5)	(5.41 to 6.76)	(5.74 to 7.08)	(6.42 to 8.11)	(0.23 to 0.32)	(0.24 to 0.32)	(0.23 to 0.31)
	7.89	8.81	9.99	5.82	6.49	7.36	0.26	0.26	0.26
Central African	(7.4 to 8.54)	(8.38 to 9.36)	(9.31 to 10.4)	(5.16 to 6.53)	(5.81 to 7.18)	(6.53 to 8.11)	(0.24 to 0.3)	(0.23 to 0.31)	(0.22 to 0.3)
	7.05	7.08	7.64	5.11	5.12	5.58	0.28	0.28	0.27
Republic	(6.83 to 7.38)	(6.77 to 7.55)	(7.15 to 8.31)	(4.55 to 5.66)	(4.56 to 5.7)	(4.9 to 6.32)	(0.23 to 0.33)	(0.25 to 0.33)	(0.24 to 0.31)
	7.89	9.38	10.2	5.8	6.87	7.57	0.27	0.27	0.26
Democratic Republic of	(7.61 to 8.24)	(8.96 to 9.95)	(9.81 to 10.6)	(5.24 to 6.38)	(6.09 to 7.56)	(6.74 to 8.34)	(0.23 to 0.31)	(0.24 to 0.32)	(0.21 to 0.31)
	8.59	8.86	10	6.23	6.43	7.33	0.27	0.27	0.27
the Congo	(8.03 to 9.18)	(8.47 to 9.37)	(9.25 to 10.8)	(5.5 to 6.98)	(5.73 to 7.13)	(6.42 to 8.23)	(0.24 to 0.31)	(0.24 to 0.32)	(0.24 to 0.31)
	7.4	10.3	10.7	5.28	7.42	7.76	0.29	0.28	0.27
Equatorial Guinea	(6.96 to 7.99)	(9.41 to 11.6)	(9.72 to 11.7)	(4.61 to 5.92)	(6.42 to 8.54)	(6.74 to 8.78)	(0.26 to 0.34)	(0.26 to 0.32)	(0.25 to 0.31)
Gabon	(8.05 to 8.87)	(8.85 to 9.59)	(9.41 to 10.5)	(5.51 to 6.84)	(5.94 to 7.34)	(6.33 to 7.98)	(0.23 to 0.32)	(0.23 to 0.33)	(0.24 to 0.33)
Eastern Sub-Saharan	8.6	9.23	10.5	6.28	6.75	7.75	0.27	0.27	0.26
Africa	(8.37 to 8.84)	(9.03 to 9.44)	(10.2 to 10.9)	(5.65 to 6.87)	(6.06 to 7.37)	(6.97 to 8.51)	(0.22 to 0.32)	(0.22 to 0.33)	(0.22 to 0.31)
Burundi	7.6	8.55	9.95	5.65	6.31	7.4	0.26	0.26	0.26
	(7.18 to 8.02)	(8.08 to 9.12)	(9.01 to 10.8)	(5.03 to 6.25)	(5.64 to 6.96)	(6.46 to 8.35)	(0.22 to 0.3)	(0.24 to 0.3)	(0.23 to 0.28)
Comoros	9.3	10.7	11.3	6.87	7.94	8.43	0.26	0.25	0.26
	(8.71 to 10.1)	(10 to 11.2)	(10.4 to 11.8)	(6.07 to 7.79)	(7.09 to 8.76)	(7.41 to 9.26)	(0.23 to 0.3)	(0.22 to 0.29)	(0.22 to 0.29)
Djibouti	9.67	9.86	10.8	7.25	7.4	8.03	0.25	0.25	0.25
	(8.79 to 10.6)	(8.99 to 11)	(9.85 to 11.3)	(6.33 to 8.17)	(6.5 to 8.45)	(7.06 to 8.83)	(0.23 to 0.28)	(0.23 to 0.28)	(0.22 to 0.28)
Eritrea	7.31	8.17	9.26	5.39	5.99	6.78	0.26	0.27	0.27
	(7.07 to 7.64)	(7.78 to 8.71)	(8.74 to 9.79)	(4.86 to 5.92)	(5.38 to 6.63)	(6.04 to 7.51)	(0.23 to 0.31)	(0.24 to 0.31)	(0.23 to 0.31)
Ethiopia	7.62	9.57	11.2	5.56	7.05	8.33	0.27	0.26	0.26
	(7.29 to 7.99)	(9.08 to 10)	(10.4 to 12.2)	(4.94 to 6.16)	(6.27 to 7.78)	(7.33 to 9.43)	(0.23 to 0.32)	(0.23 to 0.31)	(0.23 to 0.29)
Kenya	10.4	9.31	10.4	7.49	6.69	7.53	0.28	0.28	0.27
	(9.76 to 11.1)	(8.95 to 9.68)	(9.71 to 11.3)	(6.62 to 8.39)	(5.93 to 7.37)	(6.69 to 8.55)	(0.24 to 0.32)	(0.24 to 0.34)	(0.24 to 0.31)
Madagascar	9.67	9.61	10.5	7.16	7.1	7.87	0.26	0.26	0.25
	(9.22 to 10.2)	(9.09 to 10.1)	(9.59 to 11.6)	(6.4 to 7.89)	(6.33 to 7.82)	(6.86 to 8.92)	(0.22 to 0.31)	(0.23 to 0.3)	(0.23 to 0.28)
Malawi	8.72	8.38	9.82	6.38	6.09	7.22	0.27	0.27	0.26
	(8.35 to 9.13)	(8.05 to 8.67)	(9.29 to 10.3)	(5.71 to 7.02)	(5.38 to 6.72)	(6.45 to 7.95)	(0.23 to 0.32)	(0.22 to 0.33)	(0.23 to 0.31)
Mozambique	8.62	8.32	8.82	6.23	5.97	6.35	0.28	0.28	0.28
	(8.23 to 8.99)	(8.03 to 8.59)	(8.33 to 9.25)	(5.55 to 6.89)	(5.35 to 6.57)	(5.61 to 7.07)	(0.23 to 0.33)	(0.24 to 0.33)	(0.24 to 0.33)
Rwanda	7.74	9.31	10.7	5.71	6.84	7.92	0.26	0.26	0.26
	(7.43 to 8.08)	(8.83 to 9.71)	(10 to 11.2)	(5.15 to 6.27)	(6.14 to 7.55)	(7.07 to 8.65)	(0.22 to 0.31)	(0.22 to 0.3)	(0.23 to 0.3)
Somalia	7.64	7.92	8.73	5.74	5.92	6.51 (5.64 to 7.41)	0.25 (0.23 to 0.28)	0.25	0.25 (0.23 to 0.29)
South Sudan	9.33	9.91	10.7	6.63	7.01	7.61	0.29	0.29	0.29
Haanda	(8.52 to 10.3)	(8.96 to 11.2)	(9.74 to 12)	(5.73 to 7.58)	(6.04 to 8.17)	(6.5 to 8.81)	(U.27 to 0.33)	(U.27 to 0.33)	(U.27 to 0.33)
	8.55	8.75	10.1	6.22	6.38	7.43	0.27	0.27	0.26
United Republic of	(8.17 to 9.05)	(8.33 to 9.19)	(9.68 to 10.8)	(5.57 to 6.87)	(5.7 to 7.02)	(6.66 to 8.22)	(0.24 to 0.32)	(0.24 to 0.32)	(0.24 to 0.31)
	9.39	9.82	11.1	6.93	7.24	8.22	0.26	0.26	0.26
Tanzania	(8.94 to 9.84)	(9.47 to 10.2)	(10.6 to 11.8)	(6.22 to 7.6)	(6.46 to 7.93)	(7.38 to 9.04)	(0.23 to 0.3)	(0.23 to 0.32)	(0.24 to 0.3)

Supplementary Table 7:	Life expectancy,	Health-adjusted	life expectancy,	and proportion o	f years spent in ill	l health in all repo	porting locations, in 1990, 2005, 2019, Males			
		LE-70			HALE-70			PYIH-70		
location	1990	2005	2019	1990	2005	2019	1990	2005	2019	
Zambia	8.68	8.13	9.67	6.45	6	7.2	0.26	0.26	0.26	
	(8.38 to 9.14)	(7.8 to 8.53)	(9.08 to 10.3)	(5.76 to 7.14)	(5.36 to 6.6)	(6.39 to 8.01)	(0.22 to 0.31)	(0.23 to 0.31)	(0.22 to 0.3)	
Southern Sub-Saharan	11.5	9.62	11.2	8.27	6.91	8.02	0.28	0.28	0.28	
Africa	(11.2 to 11.7)	(9.47 to 9.74)	(11 to 11.4)	(7.45 to 9.06)	(6.22 to 7.54)	(7.19 to 8.79)	(0.23 to 0.34)	(0.23 to 0.34)	(0.23 to 0.34)	
Botswana	8.72	7.72	9.44	6.29	5.5	6.67	0.28	0.29	0.29	
	(8.29 to 9.28)	(7.27 to 8)	(8.88 to 10.1)	(5.54 to 7.06)	(4.84 to 6.09)	(5.83 to 7.5)	(0.24 to 0.33)	(0.24 to 0.34)	(0.26 to 0.34)	
Eswatini	8.48	7.1	8.28	6.12	5.01	5.87	0.28	0.29	0.29	
	(8.09 to 9.12)	(6.6 to 7.6)	(7.68 to 8.6)	(5.47 to 6.81)	(4.33 to 5.61)	(5.1 to 6.53)	(0.25 to 0.32)	(0.26 to 0.34)	(0.24 to 0.34)	
Lesotho	8.49	7.09	7.7	6.21	5.13	5.53	0.27	0.28	0.28	
	(8.02 to 8.8)	(6.8 to 7.34)	(7.12 to 8.13)	(5.56 to 6.83)	(4.58 to 5.66)	(4.84 to 6.16)	(0.22 to 0.31)	(0.23 to 0.33)	(0.24 to 0.32)	
Namibia	8.8	8.44	9.54	6.37	6.06	6.86	0.28	0.28	0.28	
	(8.5 to 9.18)	(8.17 to 8.65)	(9.1 to 9.95)	(5.68 to 7.04)	(5.43 to 6.69)	(6.08 to 7.63)	(0.23 to 0.33)	(0.23 to 0.33)	(0.23 to 0.33)	
South Africa	12.4	10.3	11.8	8.93	7.36	8.46	0.28	0.28	0.29	
	(12.1 to 12.8)	(10.1 to 10.4)	(11.6 to 12.1)	(8.02 to 9.79)	(6.62 to 8.05)	(7.56 to 9.26)	(0.23 to 0.34)	(0.23 to 0.34)	(0.24 to 0.35)	
Zimbabwe	9.44	8.01	9.03	6.95	5.84	6.62	0.26	0.27	0.27	
	(9.08 to 9.84)	(7.65 to 8.32)	(8.65 to 9.61)	(6.24 to 7.61)	(5.21 to 6.46)	(5.89 to 7.32)	(0.23 to 0.31)	(0.22 to 0.32)	(0.24 to 0.32)	
Western Sub-Saharan	9.62	9.85	10.9	7.09	7.29	8.08	0.26	0.26	0.26	
Africa	(9.06 to 10.2)	(9.21 to 10.6)	(10.1 to 11.6)	(6.25 to 7.9)	(6.42 to 8.19)	(7.15 to 9)	(0.23 to 0.31)	(0.23 to 0.3)	(0.22 to 0.3)	
Benin	9.27	9.44	10.4	6.83	7.04	7.74	0.26	0.25	0.26	
	(8.83 to 9.74)	(8.79 to 10)	(9.49 to 11.3)	(6.11 to 7.52)	(6.29 to 7.77)	(6.75 to 8.71)	(0.23 to 0.31)	(0.23 to 0.28)	(0.23 to 0.29)	
Burkina Faso	9.04	9.26	9.82	6.64	6.88	7.34	0.27	0.26	0.25	
	(8.58 to 9.52)	(8.82 to 9.69)	(9.2 to 10.4)	(5.91 to 7.37)	(6.17 to 7.56)	(6.54 to 8.1)	(0.23 to 0.31)	(0.22 to 0.3)	(0.22 to 0.29)	
Cabo Verde	13.1	11.9	10.6	9.85	8.85	7.94	0.25	0.25	0.25	
	(12.8 to 13.4)	(11.2 to 12.7)	(10.5 to 10.9)	(8.93 to 10.7)	(7.89 to 9.85)	(7.18 to 8.63)	(0.2 to 0.3)	(0.22 to 0.29)	(0.21 to 0.31)	
Cameroon	9.67	8.94	10.3	7.05	6.47	7.53	0.27	0.28	0.27	
	(9.17 to 10.1)	(8.58 to 9.5)	(9.44 to 11)	(6.28 to 7.81)	(5.79 to 7.22)	(6.58 to 8.42)	(0.23 to 0.32)	(0.24 to 0.32)	(0.24 to 0.3)	
Chad	9.43	9.07	10.2	6.99	6.66	7.5	0.26	0.27	0.26	
	(8.91 to 9.95)	(8.58 to 9.62)	(9.36 to 10.9)	(6.24 to 7.77)	(5.93 to 7.36)	(6.6 to 8.38)	(0.22 to 0.3)	(0.23 to 0.31)	(0.23 to 0.29)	
Côte d'Ivoire	8.88	8.68	10.3	6.38	6.37	7.57	0.28	0.27	0.26	
	(8.44 to 9.27)	(8.24 to 9.05)	(9.64 to 10.9)	(5.65 to 7.11)	(5.7 to 7.02)	(6.68 to 8.38)	(0.23 to 0.33)	(0.22 to 0.31)	(0.23 to 0.31)	
Gambia	9.49	9.7	10.2	7.18	7.29	7.66	0.24	0.25	0.25	
	(8.74 to 10.3)	(9.22 to 10.4)	(9.66 to 11)	(6.32 to 8.02)	(6.54 to 8.07)	(6.84 to 8.46)	(0.22 to 0.28)	(0.22 to 0.29)	(0.23 to 0.29)	
Ghana	9.59	9.35	10.1	7.22	7	7.56	0.25	0.25	0.25	
	(8.92 to 10.3)	(8.98 to 9.8)	(9.59 to 10.5)	(6.43 to 8.08)	(6.29 to 7.67)	(6.76 to 8.28)	(0.21 to 0.28)	(0.22 to 0.3)	(0.21 to 0.3)	
Guinea	10	9.55	10.2	7.51	7.17	7.59	0.25	0.25	0.25	
	(9.48 to 10.5)	(9.02 to 10.1)	(9.39 to 11)	(6.72 to 8.29)	(6.45 to 7.89)	(6.64 to 8.56)	(0.21 to 0.29)	(0.22 to 0.29)	(0.22 to 0.29)	
Guinea-Bissau	7.54	8.11	9.19	5.61	6.07	6.87	0.26	0.25	0.25	
	(7.09 to 8.09)	(7.7 to 8.52)	(8.51 to 9.95)	(5 to 6.24)	(5.45 to 6.63)	(6.06 to 7.7)	(0.23 to 0.3)	(0.22 to 0.29)	(0.23 to 0.29)	
Liberia	9.75	10.4	11.4	7.12	7.6	8.27	0.27	0.27	0.28	
	(9.13 to 10.3)	(9.8 to 11.1)	(10.4 to 12.1)	(6.31 to 7.89)	(6.71 to 8.46)	(7.17 to 9.31)	(0.23 to 0.31)	(0.23 to 0.31)	(0.23 to 0.31)	
Mali	9.57	10.7	11.3	7.07	7.9	8.44	0.26	0.26	0.25	
	(9.12 to 10.1)	(10.1 to 11.2)	(10.3 to 12.2)	(6.32 to 7.83)	(7.11 to 8.7)	(7.39 to 9.43)	(0.22 to 0.31)	(0.22 to 0.3)	(0.22 to 0.28)	
Mauritania	9.77	11.8	12.5	7.38	8.88	9.42	0.24	0.25	0.24	
	(9.37 to 10.3)	(11 to 12.3)	(11.8 to 13)	(6.65 to 8.11)	(7.92 to 9.79)	(8.47 to 10.3)	(0.21 to 0.29)	(0.21 to 0.28)	(0.21 to 0.28)	
Niger	9.19	10	10.7	6.95	7.6	8.12	0.24	0.24	0.24	
	(8.82 to 9.61)	(9.59 to 10.5)	(9.76 to 11.6)	(6.27 to 7.6)	(6.88 to 8.29)	(7.15 to 9.06)	(0.21 to 0.29)	(0.21 to 0.28)	(0.22 to 0.27)	
Nigeria	9.83	10.2	11.4	7.22	7.56	8.46	0.27	0.26	0.26	
	(8.73 to 11.1)	(8.88 to 11.9)	(9.94 to 13.1)	(6.12 to 8.39)	(6.36 to 8.87)	(7.15 to 9.85)	(0.25 to 0.3)	(0.26 to 0.28)	(0.25 to 0.28)	
Sao Tome and Principe	11	10.6	10.6	8.17	7.84	7.77	0.25	0.26	0.27	
	(10.3 to 11.6)	(10.2 to 11)	(10.4 to 11.3)	(7.28 to 9.01)	(7.07 to 8.61)	(6.97 to 8.57)	(0.22 to 0.29)	(0.22 to 0.31)	(0.24 to 0.33)	
Senegal	9.55	10.3	11.1	7.07	7.57	8.22	0.26	0.27	0.26	
	(9.06 to 10.1)	(9.87 to 10.8)	(10.3 to 11.6)	(6.36 to 7.82)	(6.73 to 8.38)	(7.27 to 9.07)	(0.22 to 0.3)	(0.22 to 0.32)	(0.22 to 0.29)	
Sierra Leone	8.97	9.22	10.7	6.69	6.84	7.97	0.25	0.26	0.25	
	(8.4 to 9.64)	(8.74 to 9.71)	(9.73 to 11.3)	(5.97 to 7.46)	(6.11 to 7.54)	(6.95 to 8.89)	(0.23 to 0.29)	(0.22 to 0.3)	(0.22 to 0.29)	
Тодо	9.56	8.99	10	7.15	6.73	7.51	0.25	0.25	0.25	
	(8.99 to 10.1)	(8.52 to 9.39)	(9.35 to 10.6)	(6.41 to 7.89)	(6.05 to 7.4)	(6.64 to 8.27)	(0.22 to 0.29)	(0.21 to 0.29)	(0.22 to 0.29)	

Supplementary Table 8:	Life expectancy	, Health-adjusted	life expectancy,	and proportion o	of years spent in	ill health in all re	porting location	s, in 1990, 2005,	2019, Females
location	1990	LE-70 2005	2019	1990	HALE-70 2005	2019	1990	PYIH-70 2005	2019
Global	12.8	13.9	15.2	9.1	9.85	10.7	0.29	0.29	0.3
	(12.7 to 13)	(13.8 to 14)	(14.9 to 15.6)	(8.12 to 10)	(8.8 to 10.8)	(9.52 to 11.8)	(0.23 to 0.36)	(0.23 to 0.36)	(0.24 to 0.36)
Low SDI	10.1	10.9	12	7.13	7.72	8.47	0.3	0.29	0.29
	(9.91 to 10.3)	(10.7 to 11.1)	(11.7 to 12.3)	(6.32 to 7.85)	(6.87 to 8.49)	(7.57 to 9.35)	(0.24 to 0.36)	(0.24 to 0.36)	(0.24 to 0.35)
Low-middle SDI	10.5	11.7	12.9	7.33	8.15	8.94	0.31	0.3	0.31
	(10.3 to 10.8)	(11.5 to 11.9)	(12.4 to 13.5)	(6.52 to 8.1)	(7.23 to 9.01)	(7.91 to 9.94)	(0.25 to 0.37)	(0.25 to 0.37)	(0.26 to 0.36)
Middle SDI	11.8	12.8	14.3	8.37	9.06	10.1	0.29	0.29	0.3
	(11.5 to 12.2)	(12.6 to 13)	(13.8 to 14.9)	(7.44 to 9.26)	(8.06 to 9.94)	(8.96 to 11.2)	(0.24 to 0.35)	(0.24 to 0.36)	(0.25 to 0.35)
High-middle SDI	12.7	13.7	15.6	9.16	9.87	11.2	0.28	0.28	0.29
	(12.6 to 13)	(13.6 to 13.9)	(15.1 to 16.1)	(8.2 to 10.1)	(8.83 to 10.8)	(9.94 to 12.3)	(0.22 to 0.35)	(0.22 to 0.35)	(0.24 to 0.34)
High SDI	(15.1 to 15.1)	(16.8 to 16.8)	(17.9 to 18.1)	(9.51 to 11.8)	(10.6 to 13)	(11.2 to 13.9)	(0.22 to 0.37)	(0.22 to 0.37)	(0.23 to 0.38)
Central Europe, Eastern	12.5	12.4	14.2	9.06	9.08	10.4	0.28	0.27	0.27
Europe, and Central Asia	(12.5 to 12.5)	(12.4 to 12.4)	(13.7 to 14.7)	(8.13 to 9.9)	(8.16 to 9.9)	(9.27 to 11.4)	(0.21 to 0.35)	(0.2 to 0.34)	(0.22 to 0.32)
Central Asia	13	10.7	12	9.71	8.04	8.93	0.25	0.25	0.25
	(12.9 to 13.1)	(10.6 to 10.8)	(11.6 to 12.4)	(8.82 to 10.5)	(7.31 to 8.7)	(8.1 to 9.78)	(0.2 to 0.31)	(0.19 to 0.31)	(0.21 to 0.3)
Armenia	12.7	12.7	13.8	9.4	9.39	10.2	0.26	0.26	0.26
	(12.5 to 12.8)	(12.5 to 12.8)	(12.9 to 14.6)	(8.53 to 10.2)	(8.5 to 10.2)	(9.1 to 11.2)	(0.2 to 0.32)	(0.2 to 0.32)	(0.23 to 0.3)
Azerbaijan	13.5	10.4	11	10.2	7.89	8.26	0.24	0.24	0.25
	(13.1 to 13.9)	(10.1 to 10.7)	(10.3 to 11.7)	(9.21 to 11.1)	(7.15 to 8.58)	(7.34 to 9.16)	(0.2 to 0.29)	(0.2 to 0.29)	(0.22 to 0.28)
Georgia	11.8	12.5	13.7	9.01	9.39	10.2	0.24	0.25	0.26
	(11.5 to 12.3)	(12.1 to 12.9)	(12.8 to 14.7)	(8.17 to 9.77)	(8.49 to 10.3)	(9.05 to 11.3)	(0.2 to 0.29)	(0.2 to 0.3)	(0.23 to 0.3)
Kazakhstan	12.7	11.4	13	9.37	8.42	9.5	0.26	0.26	0.27
	(12.5 to 12.9)	(11.2 to 11.6)	(12.4 to 13.6)	(8.43 to 10.2)	(7.57 to 9.15)	(8.5 to 10.5)	(0.21 to 0.33)	(0.21 to 0.33)	(0.23 to 0.31)
Kyrgyzstan	13.8	11.8	13.8	10.2	8.91	10.4	0.26	0.24	0.24
	(13.5 to 14)	(11.7 to 11.9)	(13.2 to 14.4)	(9.25 to 11.1)	(8.12 to 9.64)	(9.42 to 11.4)	(0.2 to 0.32)	(0.19 to 0.3)	(0.21 to 0.28)
Mongolia	11.1	10.4	12.1	8.4	7.93	9.22	0.24	0.24	0.24
	(10.4 to 11.9)	(9.8 to 11.1)	(11 to 13.2)	(7.48 to 9.31)	(7.07 to 8.77)	(8.03 to 10.4)	(0.22 to 0.28)	(0.21 to 0.28)	(0.22 to 0.27)
Tajikistan	14.3	10.5	10.4	10.8	7.99	7.92	0.25	0.24	0.24
	(13.8 to 14.8)	(10.1 to 10.8)	(9.52 to 11.3)	(9.81 to 11.7)	(7.26 to 8.71)	(6.96 to 8.89)	(0.21 to 0.29)	(0.2 to 0.28)	(0.21 to 0.27)
Turkmenistan	12.4	11.8	13.5	9.4	8.94	10.2	0.25	0.24	0.24
Uzbekistan	(12.3 to 12.6) 13.6	(11.7 to 11.9) 8.42	(12.2 to 14.7) 9.38	(8.53 to 10.1)	(8.15 to 9.69) 6.46	(8.86 to 11.5) 7.16	0.24	0.23	(0.22 to 0.27) 0.24
Central Europe	12.2	13.4	15	8.85	9.83	(0.4 (0 7.87)	0.27	0.27	0.27
	(12.2 to 12.2)	(13.4 to 13.5)	(14.3 to 15.7)	(7.95 to 9.68)	(8.85 to 10.7)	(9.76 to 12.1)	(0.21 to 0.35)	(0.2 to 0.34)	(0.23 to 0.32)
	14	14.4	15.6	10.6	10.9	11.8	0.24	0.24	0.24
Albania	(13.8 to 14.2)	(14.2 to 14.6)	(14.2 to 17.2)	(9.64 to 11.5)	(9.91 to 11.8)	(10.4 to 13.3)	(0.19 to 0.3)	(0.19 to 0.3)	(0.22 to 0.27)
Bosnia and Herzegovina	12.5	12.8	13.6	9.23	9.33	9.87	0.26	0.27	0.27
	(12.4 to 12.7)	(12.6 to 12.9)	(12.5 to 14.8)	(8.32 to 10.1)	(8.4 to 10.2)	(8.64 to 11.2)	(0.21 to 0.33)	(0.21 to 0.33)	(0.25 to 0.31)
Bulgaria	11.1	11.7	12.9	8.33	8.76	9.66	0.25	0.25	0.25
	(10.9 to 11.3)	(11.5 to 11.9)	(11.9 to 14)	(7.54 to 9.05)	(7.93 to 9.53)	(8.5 to 10.8)	(0.2 to 0.31)	(0.2 to 0.31)	(0.23 to 0.29)
Croatia	12.2	13.6	15.3	8.77	9.8	10.8	0.28	0.28	0.29
	(11.9 to 12.5)	(13.5 to 13.8)	(14.2 to 16.4)	(7.83 to 9.61)	(8.78 to 10.7)	(9.45 to 12.2)	(0.23 to 0.34)	(0.22 to 0.35)	(0.26 to 0.33)
Czechia	12	14.1	16	8.51	10.1	11.3	0.29	0.29	0.29
	(11.9 to 12.1)	(14 to 14.3)	(15 to 17.1)	(7.53 to 9.38)	(8.95 to 11.1)	(9.92 to 12.7)	(0.23 to 0.37)	(0.22 to 0.36)	(0.25 to 0.34)
Hungary	12.1	13.6	15	8.53	9.74	10.8	0.29	0.29	0.28
	(12 to 12.2)	(13.5 to 13.7)	(14 to 16)	(7.58 to 9.4)	(8.68 to 10.7)	(9.51 to 12.1)	(0.23 to 0.37)	(0.22 to 0.36)	(0.24 to 0.32)
Montenegro	14.3	13.2	13.6	10.6	9.79	10	0.26	0.26	0.26
	(14 to 14.6)	(12.9 to 13.4)	(12.9 to 14.2)	(9.57 to 11.6)	(8.83 to 10.7)	(8.9 to 11)	(0.2 to 0.31)	(0.2 to 0.32)	(0.22 to 0.31)
North Macedonia	11	10.7	11.5	8.06	7.86	8.41	0.27	0.27	0.27
	(10.8 to 11.2)	(10.6 to 10.9)	(10.6 to 12.5)	(7.26 to 8.78)	(7.04 to 8.6)	(7.34 to 9.46)	(0.22 to 0.33)	(0.21 to 0.33)	(0.24 to 0.31)
Poland	12.8	14.7	16.3	9.24	10.7	11.9	0.28	0.27	0.27
	(12.8 to 12.9)	(14.7 to 14.8)	(15.1 to 17.5)	(8.25 to 10.1)	(9.6 to 11.7)	(10.4 to 13.3)	(0.21 to 0.35)	(0.21 to 0.35)	(0.24 to 0.31)
Romania	11.8	12.7	14.5	8.71	9.55	10.8	0.26	0.25	0.25
Serbia	(11.7 to 11.8) 11 (10.9 to 11.1)	(12.7 to 12.8) 11.1 (11 to 11.2)	(13.6 to 13.5) 12.7 (11.8 to 13.6)	(7.3 to 3.46) 8.1 (7.3 to 8.8)	(8.69 to 10.5) 8.22 (7.43 to 8.94)	9.3 (8.19 to 10.4.)	0.26	0.26	0.27 (0.24 to 0.31)
Slovakia	12.6 (12.4 to 12.7)	(11 to 11.2) 13.8 (13 6 to 13 9)	(11.0 to 10.0) 15.2 (14 to 16.4)	9.22 (8.31 to 10.)	10.2	(9.8 to 12.5)	0.27 (0.21 to 0.33)	0.26 (0.2 to 0.33)	0.26
Slovenia	13.3 (12 to 14 7)	15.8 (15.6 to 16.1.)	17.8 (16.3 to 19.2.)	9.54 (8.22 to 11)	(3.17 to 11.17) 11.2 (9.93 to 12.4)	(11 to 14 4)	0.28 (0.25 to 0.32)	0.29 (0.23 to 0.36)	0.29 (0.25 to 0.33)
Eastern Europe	12.6	12.1	14.3	9.07	8.84	10.4	0.28	0.27	0.27
	(12.5 to 12.6)	(12.1 to 12.1)	(13.6 to 15.)	(8.14 to 9.93.)	(7.93 to 9.64)	(9.26 to 11.5)	(0.21 to 0.35)	(0.21 to 0.35)	(0.23 to 0.32)
Belarus	13.2	12.8	14.3	9.67	9.45	10.6	0.27	0.26	0.26
Estonia	(13.1 to 13.3) 12.5 (12.3 to 13.7)	(12.7 to 12.9) 14.4	(13 (0 15.5))	(8.71 (0 10.5) 9.2	(8.54 to 10.3) 10.6	(9.18 to 12) 12	0.26	0.26	0.26
Latvia	(12.5 to 12.7) 12.7	(14.1 (0 14.0) 13.7 (12 5 to 12.0)	(15 (017.4) 15.2	9.22 (8.27 to 10.1)	(9.59 (0 11.6) 10	(10.5 to 13.4) 11.2	0.27	0.27	0.26
Lithuania	13.5 (12.5 to 12.9)	(13.5 to 13.9) 14.1	(15.8 to 16.5) 15.7 (14.8 to 16.7)	(8.27 to 10.1) 9.87	(8.99 to 10.9) 10.2	(5.72 to 12.6) 11.6	0.27	0.27	0.26
Republic of Moldour	11.7	12	14.6	8.62	8.93	10.2 (0 12.8)	0.26	0.26	0.26
περαδιίε ο <u></u> ινισίαονα	(11.6 to 11.8)	(11.9 to 12.2)	(13.9 to 15.3)	(7.79 to 9.39)	(8.07 to 9.71) 8 74	(9.66 to 12)	(0.2 to 0.33)	(0.2 to 0.32)	(0.22 to 0.31)
Russian Federation	(12.5 to 12.6)	(12 to 12.1)	(13.4 to 15.3)	(8.08 to 9.89)	(7.82 to 9.55)	(9.11 to 11.6)	(0.21 to 0.35)	(0.21 to 0.35)	(0.24 to 0.32)
Ukraine	12.5	11.9	14.1	9.02	8.79	10.4	0.28	0.26	0.26
	(12.4 to 12.5)	(11.9 to 11.9)	(13.1 to 15.1)	(8.1 to 9.86)	(7.93 to 9.57)	(9.24 to 11.6)	(0.21 to 0.35)	(0.2 to 0.33)	(0.23 to 0.3)

Supplementary Table 8:	Life expectancy,	Health-adjusted	life expectancy,	and proportion o	of years spent in	ill health in all re	porting locations	s, in 1990, 2005, 2	2019, Females
location	1000	LE-70	2019	1000	HALE-70	2019	1000	PYIH-70	2010
	1550	16.9	18	1990	11.9	12.6	0.29	0.29	0.3
High-Income	(15.1 to 15.2)	(16.9 to 16.9)	(17.9 to 18)	(9.56 to 11.8)	(10.6 to 13.1)	(11.2 to 13.9)	(0.22 to 0.37)	(0.22 to 0.37)	(0.23 to 0.38)
Australasia	15.2	17.3	18.2	10.8	12.1	12.7	0.29	0.3	0.3
	(15.2 to 15.3)	(17.2 to 17.3)	(18.1 to 18.3)	(9.59 to 11.9)	(10.8 to 13.4)	(11.2 to 14)	(0.22 to 0.37)	(0.23 to 0.37)	(0.23 to 0.38)
Australia	15.3	17.4	18.3	10.8	12.2	12.7	0.29	0.3	0.3
	(15.2 to 15.4)	(17.4 to 17.5)	(18.2 to 18.4)	(9.67 to 11.9)	(10.8 to 13.5)	(11.3 to 14.1)	(0.22 to 0.37)	(0.23 to 0.38)	(0.24 to 0.38)
New Zealand	14.8	16.5	17.6	10.4	11.7	12.3	0.3	0.29	0.3
	(14.7 to 14.9)	(16.4 to 16.6)	(17.4 to 17.7)	(9.25 to 11.5)	(10.4 to 12.8)	(10.9 to 13.6)	(0.23 to 0.37)	(0.22 to 0.36)	(0.23 to 0.37)
High-income Asia Pacific	15.8	18.7	20.1	11.5	13.6	14.6	0.27	0.27	0.27
	(15.8 to 15.8)	(18.7 to 18.7)	(20 to 20.1)	(10.3 to 12.5)	(12.3 to 14.9)	(13.1 to 15.9)	(0.21 to 0.35)	(0.21 to 0.34)	(0.21 to 0.34)
Brunei Darussalam	11	11.3	12.8	7.71	8.03	9.1	0.3	0.29	0.29
	(10.6 to 11.4)	(11 to 11.7)	(12.3 to 13.2)	(6.85 to 8.56)	(7.13 to 8.92)	(8.09 to 10.1)	(0.25 to 0.35)	(0.23 to 0.35)	(0.24 to 0.34)
Japan	16.3	19.2	20.4	11.9	14	14.9	0.27	0.27	0.27
	(16.3 to 16.4)	(19.2 to 19.2)	(20.3 to 20.5)	(10.7 to 13)	(12.6 to 15.3)	(13.3 to 16.2)	(0.21 to 0.35)	(0.21 to 0.34)	(0.21 to 0.34)
Republic of Korea	12.8	15.8	18.3	9.25	11.4	13.3	0.28	0.27	0.27
	(12.8 to 12.9)	(15.7 to 15.8)	(18.1 to 18.5)	(8.3 to 10.1)	(10.3 to 12.5)	(12 to 14.6)	(0.21 to 0.35)	(0.21 to 0.35)	(0.21 to 0.34)
Singapore	14.2	17.4	19.4	10.3	12.8	14.5	0.27	0.26	0.25
	(14.1 to 14.3)	(17.2 to 17.5)	(19.3 to 19.6)	(9.3 to 11.3)	(11.6 to 13.9)	(13.1 to 15.8)	(0.21 to 0.34)	(0.2 to 0.33)	(0.2 to 0.32)
High-income North	15.7	16.2	17.2	10.6	10.9	11.2	0.32	0.33	0.35
America	(15.7 to 15.7)	(16.2 to 16.2)	(17.1 to 17.2)	(9.34 to 11.8)	(9.58 to 12.1)	(9.69 to 12.5)	(0.25 to 0.4)	(0.25 to 0.41)	(0.27 to 0.43)
Canada	15.9	17.1	18.2	11.4	12.3	12.8	0.28	0.28	0.3
	(15.8 to 15.9)	(1/.1 to 1/.2)	(18.2 to 18.3)	(10.2 to 12.5)	(11 to 13.4)	(11.4 to 14.1)	(0.22 to 0.36)	(0.22 to 0.36)	(0.23 to 0.37)
	10.7	12.3	14.2	7.36	8.48	9.69	0.31	0.31	0.32
Greenland	(10.1 to 11.4)	(11.6 to 12.9)	(13.1 to 15.1)	(6.49 to 8.29)	(7.48 to 9.42)	(8.44 to 11)	(0.27 to 0.36)	(0.27 to 0.36)	(0.27 to 0.36)
America	(15.7 to 15.7)	(16.1 to 16.1)	(17 to 17.1)	(9.26 to 11.8)	(9.42 to 12)	(9.5 to 12.4)	(0.25 to 0.41)	(0.26 to 0.41)	(0.28 to 0.44)
Southern Latin America	(14 to 14)	(15.3 to 15.3)	(15.7 to 16)	(9.35 to 11.3)	(10.2 to 12.3)	(10.4 to 12.7)	(0.2 to 0.33)	(0.2 to 0.33)	(0.21 to 0.34)
Argentina	14.1	15.2	15.4	10.4	11.2	11.4	0.26	0.26	0.26
	(14 to 14.1)	(15.2 to 15.2)	(15.3 to 15.5)	(9.42 to 11.3)	(10.2 to 12.2)	(10.3 to 12.4)	(0.2 to 0.33)	(0.2 to 0.33)	(0.2 to 0.33)
Chile	13.7	15.7	16.9	9.98	11.4	12.1	0.27	0.28	0.28
Uruauav	(13.6 to 13.7)	(15.6 to 15.7)	(16./to1/)	(8.98 to 10.9)	(10.2 to 12.4)	(10.8 to 13.3)	(0.21 to 0.34)	(0.21 to 0.35)	(0.22 to 0.35)
	14.4	15.3	16.2	10.7	11.4	11.9	0.26	0.26	0.27
Western Furone	(14.3 to 14.5)	(15.2 to 15.4)	(16.1 to 16.4)	(9.66 to 11.6)	(10.3 to 12.4)	(10.7 to 13)	(0.2 to 0.33)	(0.2 to 0.33)	(0.21 to 0.33)
	14.7	16.7	17.7	10.6	12	12.7	0.28	0.28	0.29
inestern Latope	(14.7 to 14.8)	(16.6 to 16.7)	(17.7 to 17.8)	(9.52 to 11.6)	(10.7 to 13.1)	(11.3 to 13.9)	(0.21 to 0.35)	(0.21 to 0.36)	(0.22 to 0.36)
	16.8	18.7	18.3	12.2	13.4	13.1	0.27	0.28	0.29
Andorra	(14.9 to 18.2)	(16.9 to 19.8)	(16.7 to 20.1)	(10.5 to 13.9)	(11.6 to 15)	(11.3 to 14.9)	(0.24 to 0.3)	(0.24 to 0.31)	(0.26 to 0.33)
Austria	(14.2 to 14.3)	(16.2 to 16.4)	(17.7 to 17.9)	(9.33 to 11.4)	(10.5 to 12.8)	(11.4 to 14)	(0.21 to 0.34)	(0.22 to 0.36)	(0.22 to 0.35)
Belgium	(14.7 to 14.8)	(16.3 to 16.5)	(17.4 to 17.7)	(9.57 to 11.7)	(10.4 to 12.8)	(11 to 13.7)	(0.21 to 0.35)	(0.22 to 0.36)	(0.23 to 0.37)
Cyprus	11.3	14	15.6	8.26	10	11.3	0.27	0.28	0.28
	(11.2 to 11.4)	(13.8 to 14.1)	(15.2 to 16)	(7.41 to 9.02)	(8.95 to 11)	(10.1 to 12.4)	(0.21 to 0.34)	(0.22 to 0.35)	(0.23 to 0.34)
Denmark	14.5	15.4	17	10.4	11.1	12.2	0.28	0.28	0.28
	(14.4 to 14.6)	(15.3 to 15.5)	(16.8 to 17.1)	(9.29 to 11.4)	(9.95 to 12.1)	(10.9 to 13.3)	(0.22 to 0.36)	(0.22 to 0.35)	(0.22 to 0.35)
Finland	14.3	16.7	17.9	10.3	11.9	12.8	0.28	0.29	0.28
	(14.2 to 14.4)	(16.6 to 16.8)	(17.7 to 18.1)	(9.21 to 11.3)	(10.5 to 13.1)	(11.4 to 14.1)	(0.21 to 0.35)	(0.22 to 0.36)	(0.22 to 0.36)
France	16	17.9	19.2	11.7	13	13.9	0.27	0.27	0.27
	(16 to 16.1)	(17.9 to 17.9)	(19.1 to 19.3)	(10.4 to 12.7)	(11.7 to 14.2)	(12.5 to 15.2)	(0.21 to 0.35)	(0.21 to 0.35)	(0.21 to 0.35)
Germany	14.1	16.2	17	10.2	11.7	12.1	0.27	0.28	0.29
	(14.1 to 14.1)	(16.2 to 16.2)	(16.9 to 17.1)	(9.19 to 11.2)	(10.5 to 12.8)	(10.8 to 13.3)	(0.21 to 0.35)	(0.21 to 0.35)	(0.22 to 0.36)
Greece	14	15.2	16.7	10.2	11.1	12.1	0.27	0.27	0.27
	(13.9 to 14.1)	(15.2 to 15.3)	(16.5 to 16.8)	(9.21 to 11.1)	(9.97 to 12.1)	(11 to 13.3)	(0.21 to 0.34)	(0.21 to 0.34)	(0.21 to 0.34)
Iceland	15.5	17.3	19.7	11.2	12.3	14.1	0.28	0.29	0.29
Ireland	(15.2 (0 15.8)	15.7	(19.2 (0 20.2)	9.74	(11 to 13.6)	12.3	0.27	0.28	0.28
Israel	(13.3 to 13.5)	(15.6 to 15.8)	(17 to 17.4)	(8.78 to 10.6)	(10.2 to 12.3)	(11.1 to 13.5)	(0.21 to 0.34)	(0.22 to 0.35)	(0.22 to 0.35)
	14.2	15.8	17.6	10.4	11.5	12.8	0.27	0.28	0.27
Italy	(14.1 to 14.3)	(15.8 to 15.9)	(17.5 to 17.8)	(9.37 to 11.3)	(10.3 to 12.5)	(11.5 to 14)	(0.21 to 0.34)	(0.21 to 0.35)	(0.21 to 0.34)
	15.1	17.1	18.2	10.6	12.1	12.9	0.3	0.29	0.29
lung	(15.1 to 15.2)	(17.1 to 17.2)	(18.1 to 18.3)	(9.44 to 11.7)	(10.8 to 13.4)	(11.5 to 14.2)	(0.23 to 0.37)	(0.22 to 0.37)	(0.22 to 0.36)
	14.3	16.2	18.2	10.4	11.5	12.8	0.27	0.29	0.3
Luxembourg	(14.1 to 14.5)	(15.9 to 16.5) 16.4	(17.5 to 18.8)	(9.3 to 11.3)	(10.3 to 12.6)	(11.4 to 14.2)	(0.22 to 0.34)	(0.23 to 0.35) 0.28	(0.24 to 0.35)
Malta	(13.8 to 14.3)	(16.1 to 16.7)	(17.6 to 18.8)	(9.16 to 11.2)	(10.5 to 12.9)	(11.6 to 14.4)	(0.22 to 0.34)	(0.22 to 0.34)	(0.23 to 0.34)
Monaco	(14.8 to 17.4)	(15.2 to 17.8)	(15.7 to 18.2)	(10.3 to 13.2)	(10.3 to 13.3)	(10.6 to 13.6)	(0.24 to 0.3)	(0.25 to 0.32)	(0.25 to 0.33)
Netherlands	15.3	16.1	17.1	11.1	11.8	12.2	0.27	0.27	0.29
	(15.2 to 15.3)	(16 to 16.2)	(17 to 17.3)	(10.1 to 12.2)	(10.6 to 12.8)	(10.9 to 13.4)	(0.21 to 0.34)	(0.21 to 0.34)	(0.23 to 0.36)
Norway	15.1	16.7	17.8	10.8	11.9	12.4	0.29	0.29	0.3
	(15 to 15.2)	(16.6 to 16.8)	(17.7 to 17.9)	(9.57 to 11.8)	(10.6 to 13)	(11 to 13.7)	(0.22 to 0.36)	(0.22 to 0.36)	(0.24 to 0.38)
Portugal	13.5	15.9	17.6	9.66	11.3	12.6	0.28	0.29	0.28
	(13.4 to 13.5)	(15.8 to 16)	(17.5 to 17.7)	(8.68 to 10.6)	(10.1 to 12.4)	(11.2 to 13.8)	(0.22 to 0.35)	(0.22 to 0.36)	(0.22 to 0.36)
San Marino	16.4	17.3	18	12.1	12.7	13.1	0.27	0.27	0.27
	(15.7 to 17.3)	(15.6 to 18.9)	(15.7 to 20.2)	(10.8 to 13.3)	(10.9 to 14.4)	(11 to 15.2)	(0.23 to 0.31)	(0.24 to 0.3)	(0.25 to 0.3)
Spain	15.1	17.2	18.6	10.9	12.4	13.3	0.28	0.28	0.28
	(15.1 to 15.2)	(17.2 to 17.3)	(18.5 to 18.7)	(9.78 to 11.9)	(11.1 to 13.6)	(11.9 to 14.6)	(0.21 to 0.35)	(0.21 to 0.35)	(0.22 to 0.36)

Supplementary Table 8:	Life expectancy,	Health-adjusted	life expectancy,	and proportion o	of years spent in	ill health in all re	porting location	s, in 1990, 2005, 1	2019, Females
location	1990	LE-70 2005	2019	1990	HALE-70 2005	2019	1990	PYIH-70 2005	2019
Sweden	15.5	16.9	17.7	11.3	12.1	12.6	0.27	0.28	0.29
	(15.4 to 15.6)	(16.8 to 17)	(17.6 to 17.8)	(10.1 to 12.3)	(10.8 to 13.2)	(11.2 to 13.8)	(0.21 to 0.35)	(0.22 to 0.36)	(0.22 to 0.36)
Switzerland	16	17.7	18.7	11.4	12.7	13.4	0.29	0.28	0.29
	(15.9 to 16.1)	(17.6 to 17.7)	(18.6 to 18.9)	(10.2 to 12.5)	(11.3 to 13.9)	(12 to 14.7)	(0.22 to 0.36)	(0.22 to 0.36)	(0.22 to 0.36)
United Kingdom	14.3	15.9	16.8	10.4	11.4	11.9	0.27	0.28	0.29
	(14.3 to 14.3)	(15.8 to 15.9)	(16.7 to 16.9)	(9.31 to 11.3)	(10.2 to 12.5)	(10.6 to 13.1)	(0.21 to 0.35)	(0.21 to 0.35)	(0.22 to 0.37)
Latin America and	13.7	15.4	16.1	9.86	11.2	11.7	0.28	0.28	0.28
Caribbean	(13.7 to 13.8)	(15.4 to 15.5)	(15.7 to 16.6)	(8.8 to 10.8)	(10 to 12.2)	(10.4 to 12.8)	(0.22 to 0.36)	(0.21 to 0.35)	(0.23 to 0.33)
Andean Latin America	(13.8 to 14.5)	(14.9 to 15.7)	(15 to 16.9)	(9.37 to 11.4)	(10.1 to 12.4)	(10.4 to 13)	(0.21 to 0.32)	(0.21 to 0.32)	(0.23 to 0.31)
Bolivia (Plurinational	11.2	12.1	12.1	8.21	8.92	8.88	0.27	0.26	0.26
State of)	(10.8 to 11.6)	(11.7 to 12.4)	(11.5 to 12.6)	(7.36 to 9.05)	(7.99 to 9.76)	(7.86 to 9.86)	(0.22 to 0.32)	(0.21 to 0.32)	(0.22 to 0.31)
Ecuador	14	15.1	15.3	10.4	11.1	11.2	0.26	0.26	0.27
	(13.9 to 14.1)	(14.6 to 15.5)	(14.2 to 16.4)	(9.45 to 11.3)	(10 to 12.2)	(9.77 to 12.5)	(0.2 to 0.32)	(0.21 to 0.32)	(0.24 to 0.31)
Peru	15.1	16.6	17.7	11.2	12.2	13	0.26	0.26	0.26
	(14.5 to 15.8)	(15.8 to 17.4)	(16.1 to 19.3)	(9.97 to 12.4)	(10.9 to 13.5)	(11.4 to 14.7)	(0.22 to 0.31)	(0.22 to 0.31)	(0.24 to 0.29)
Caribbean	13.9	15	15.6	10.4	11.1	11.4	0.25	0.26	0.27
	(13.8 to 14)	(14.8 to 15.2)	(14.8 to 16.3)	(9.38 to 11.3)	(10 to 12.1)	(10.2 to 12.6)	(0.2 to 0.32)	(0.21 to 0.32)	(0.23 to 0.31)
Antigua and Barbuda	15.1	14.3	14.1	11.4	10.7	10.5	0.24	0.25	0.26
	(14.6 to 15.5)	(13.8 to 14.6)	(13.6 to 14.6)	(10.3 to 12.4)	(9.59 to 11.7)	(9.42 to 11.5)	(0.2 to 0.29)	(0.2 to 0.3)	(0.21 to 0.31)
Bahamas	14.5	15.2	15.5	11	11.4	11.6	0.24	0.25	0.25
	(14.2 to 14.9)	(14.8 to 15.6)	(14.4 to 16.5)	(9.96 to 12)	(10.3 to 12.5)	(10.2 to 12.9)	(0.2 to 0.3)	(0.2 to 0.3)	(0.22 to 0.29)
Barbados	13.9	14.2	14.4	10.6	10.7	10.8	0.24	0.25	0.25
	(13.7 to 14.2)	(13.9 to 14.5)	(13.7 to 15.3)	(9.64 to 11.5)	(9.65 to 11.7)	(9.59 to 11.9)	(0.19 to 0.29)	(0.2 to 0.31)	(0.22 to 0.3)
Belize	14	14.7	16	10.6	11	11.9	0.24	0.25	0.25
	(13.6 to 14.4)	(14.4 to 14.9)	(15.3 to 16.7)	(9.58 to 11.5)	(9.98 to 11.9)	(10.7 to 13.1)	(0.2 to 0.3)	(0.2 to 0.31)	(0.21 to 0.3)
Bermuda	13.7	17.1	18.7	10.5	12.9	14.1	0.24	0.24	0.25
	(13.5 to 13.9)	(16.2 to 18)	(17.5 to 19.6)	(9.51 to 11.3)	(11.5 to 14.2)	(12.5 to 15.5)	(0.19 to 0.3)	(0.21 to 0.29)	(0.21 to 0.28)
Cuba	14.5	15.5	16.2	10.7	11.4	11.7	0.26	0.27	0.28
	(14.4 to 14.6)	(15.4 to 15.6)	(15.2 to 17.4)	(9.6 to 11.6)	(10.2 to 12.4)	(10.3 to 13.1)	(0.2 to 0.33)	(0.21 to 0.34)	(0.24 to 0.32)
Dominica	12.7	13.6	13.4	9.58	10.2	9.99	0.24	0.25	0.26
	(12.3 to 13.2)	(13 to 14.3)	(12.6 to 14.1)	(8.66 to 10.5)	(9.13 to 11.2)	(8.85 to 11.1)	(0.2 to 0.3)	(0.22 to 0.3)	(0.21 to 0.3)
Dominican Republic	15.6	15.8	15.1	11.9	12	11.4	0.24	0.24	0.25
	(15 to 16.1)	(15.1 to 16.6)	(14 to 16)	(10.8 to 13)	(10.7 to 13.1)	(10.1 to 12.6)	(0.2 to 0.28)	(0.21 to 0.29)	(0.21 to 0.28)
Grenada	12.7	14.5	13.5	9.59	10.8	10	0.25	0.25	0.26
	(12.3 to 13.1)	(14.1 to 14.8)	(13.1 to 13.9)	(8.61 to 10.5)	(9.73 to 11.8)	(8.97 to 11)	(0.2 to 0.3)	(0.2 to 0.31)	(0.21 to 0.32)
Guyana	10.2	11.5	12.3	7.52	8.44	8.97	0.26	0.27	0.27
	(9.65 to 10.9)	(11 to 12.1)	(11.2 to 13.5)	(6.64 to 8.39)	(7.46 to 9.36)	(7.76 to 10.3)	(0.23 to 0.31)	(0.23 to 0.32)	(0.24 to 0.31)
Haiti	9.81	10.3	11.1	7.36	7.7	8.16	0.25	0.25	0.26
	(9.43 to 10.2)	(9.68 to 10.9)	(9.69 to 12.2)	(6.63 to 8.11)	(6.82 to 8.56)	(6.88 to 9.35)	(0.21 to 0.3)	(0.22 to 0.3)	(0.24 to 0.29)
Jamaica	15.1	16.6	15.7	11.4	12.4	11.7	0.24	0.26	0.26
	(14.9 to 15.3)	(16.3 to 16.9)	(14.5 to 17)	(10.4 to 12.4)	(11.1 to 13.5)	(10.3 to 13.2)	(0.19 to 0.3)	(0.2 to 0.32)	(0.22 to 0.29)
Puerto Rico	15.1	17.1	18.4	11.2	12.5	13.5	0.25	0.27	0.27
	(14.9 to 15.2)	(16.9 to 17.3)	(17 to 19.9)	(10.2 to 12.2)	(11.3 to 13.8)	(11.8 to 15.2)	(0.2 to 0.32)	(0.21 to 0.33)	(0.24 to 0.31)
Saint Kitts and Nevis	10	12.9	13.3	7.47	9.54	9.82	0.26	0.26	0.26
	(9.68 to 10.4)	(12.5 to 13.3)	(12.5 to 13.9)	(6.72 to 8.2)	(8.52 to 10.5)	(8.7 to 10.9)	(0.21 to 0.31)	(0.21 to 0.32)	(0.22 to 0.3)
Saint Lucia	12.4	14.9	15.5	9.08	10.9	11.2	0.27	0.27	0.28
	(12.1 to 12.6)	(14.6 to 15.3)	(14.7 to 16.3)	(8.11 to 9.95)	(9.81 to 12)	(9.93 to 12.5)	(0.21 to 0.33)	(0.21 to 0.33)	(0.23 to 0.33)
Saint Vincent and the	12.1	14.2	13.3	9.1	10.5	9.82	0.25	0.26	0.26
Grenadines	(11.9 to 12.3)	(13.9 to 14.5)	(12.7 to 13.9)	(8.24 to 9.87)	(9.5 to 11.5)	(8.71 to 10.9)	(0.2 to 0.31)	(0.21 to 0.31)	(0.22 to 0.31)
Suriname	13.5	14.9	15	10.1	10.9	10.9	0.26	0.27	0.27
Trinidad and Tohago	(13.3 to 13.8)	(14.6 to 15.2)	(14.2 to 15.9)	(9.08 to 11)	(9.81 to 11.9)	(9.65 to 12.2)	(0.21 to 0.32)	(0.21 to 0.33)	(0.24 to 0.32)
	12.5	14.6	15.7	9.32	10.8	11.6	0.26	0.26	0.26
	(12.3 to 12.7)	(14.3 to 14.8)	(14.1 to 17.3)	(8.4 to 10.1)	(9.72 to 11.8)	(10 to 13.3)	(0.2 to 0.32)	(0.2 to 0.32)	(0.23 to 0.29)
Islands	13.5 (13 to 14.2)	14.2 (13.9 to 14.5)	14.6 (14.1 to 15.2)	10.3 (9.32 to 11.2)	10.7 (9.72 to 11.7)	(9.84 to 12)	0.24 (0.21 to 0.28)	(0.2 to 0.3)	0.25 (0.21 to 0.3)
Central Latin America	(13.7 to 13.8)	(15.4 to 15.5)	(15.5 to 16.9)	9.76 (8.67 to 10.8)	(9.94 to 12.2)	(10.3 to 12.8)	(0.22 to 0.37)	(0.21 to 0.35)	(0.24 to 0.34)
Colombia	14.1	16.5	18.3	10.2	12	13.4	0.28	0.27	0.27
	(14 to 14.1)	(16.4 to 16.5)	(16.9 to 19.8)	(9.12 to 11.1)	(10.8 to 13.1)	(11.8 to 15.1)	(0.21 to 0.35)	(0.21 to 0.34)	(0.24 to 0.3)
Costa Rica	15.7	17	17.8	11.3	12.3	12.8	0.28	0.28	0.28
	(15.5 to 15.9)	(16.8 to 17.2)	(16.4 to 19.2)	(10.1 to 12.4)	(11 to 13.5)	(11.2 to 14.5)	(0.22 to 0.35)	(0.22 to 0.34)	(0.24 to 0.31)
El Salvador	15.9	16.8	16.5	11.6	12.2	12	0.28	0.28	0.27
	(15.8 to 16.1)	(16.7 to 17)	(15 to 18.2)	(10.4 to 12.7)	(11 to 13.4)	(10.4 to 13.7)	(0.21 to 0.34)	(0.21 to 0.34)	(0.25 to 0.31)
Guatemala	10.7	13.1	14.6	7.74	9.42	10.4	0.28	0.28	0.28
	(10.2 to 11.2)	(12.5 to 13.7)	(13.5 to 15.7)	(6.88 to 8.64)	(8.33 to 10.5)	(9.13 to 11.8)	(0.23 to 0.33)	(0.24 to 0.34)	(0.25 to 0.32)
Honduras	15.5	12.7	12.5	11.1	9.29	9.07	0.28	0.27	0.27
	(14.7 to 16.3)	(11.6 to 13.8)	(11.7 to 12.8)	(9.83 to 12.4)	(8.05 to 10.5)	(8.04 to 9.96)	(0.24 to 0.33)	(0.24 to 0.31)	(0.22 to 0.31)
Mexico	13.4	14.9	15.6	9.28	10.6	11	0.31	0.29	0.29
	(13.3 to 13.4)	(14.9 to 14.9)	(14.9 to 16.2)	(8.18 to 10.3)	(9.45 to 11.6)	(9.69 to 12.3)	(0.23 to 0.39)	(0.22 to 0.36)	(0.24 to 0.35)
Nicaragua	18.5	13.2	14.3	13.2	9.75	10.5	0.29	0.26	0.27
	(18.2 to 18.7)	(13.1 to 13.4)	(13.8 to 14.9)	(11.8 to 14.5)	(8.81 to 10.6)	(9.39 to 11.5)	(0.22 to 0.35)	(0.21 to 0.33)	(0.23 to 0.32)
Panama	16.5	17.4	18.5	12	12.7	13.4	0.27	0.27	0.28
	(16.2 to 16.7)	(17.2 to 17.7)	(17.1 to 19.9)	(10.7 to 13.1)	(11.4 to 13.9)	(11.7 to 15.1)	(0.22 to 0.34)	(0.21 to 0.34)	(0.24 to 0.31)
Venezuela (Bolivarian Republic of)	14.5 (14.5 to 14.6)	16.9 (16.8 to 17)	16.2	10.5 (9.38 to 11.5)	12.2 (11 to 13.4.)	11.7 (10.2 to 13.4.)	0.28 (0.21 to 0.35.)	0.28	0.27
Tropical Latin America	13.4 (13.3 to 13.5)	15.5 (15.4 to 15.6)	16.3 (16.1 to 16.5)	9.56 (8.52 to 10.5)	(9.95 to 12.2)	11.8 (10.6 to 12.9)	0.29 (0.22 to 0.36)	0.28 (0.22 to 0.35)	0.28 (0.22 to 0.34)

Supplementary Table 8:	Life expectancy,	Health-adjusted	life expectancy,	and proportion o	of years spent in	ill health in all re	porting locations	s, in 1990, 2005, 2	2019, Females
location	1990	LE-70 2005	2019	1990	HALE-70 2005	2019	1990	PYIH-70 2005	2019
Brazil	13.4	15.5	16.3	9.5	11.1	11.8	0.29	0.28	0.28
_	(13.3 to 13.5) 16	(15.4 to 15.6) 16.1	(16.1 to 16.5) 16.4	(8.4/to10.5) 11.8	(9.94 to 12.2) 11.9	(10.6 to 12.9) 12	(0.22 to 0.36) 0.27	(0.22 to 0.36) 0.26	(0.22 to 0.34) 0.27
Paraguay	(15.4 to 16.7)	(15.5 to 16.7)	(15 to 17.9)	(10.4 to 13)	(10.6 to 13.1)	(10.5 to 13.6)	(0.22 to 0.32)	(0.22 to 0.31)	(0.24 to 0.3)
North Africa and Middle East	(11.5 to 11.9)	13 (12.7 to 13.2)	13.3 (12.9 to 13.8)	8.42 (7.52 to 9.26)	9.26 (8.28 to 10.2)	9.47 (8.43 to 10.5)	0.28 (0.22 to 0.35)	0.29 (0.23 to 0.35)	0.29 (0.24 to 0.35)
North Africa and Middle East	11.7 (11.5 to 11.9)	13 (12.7 to 13.2)	13.3 (12.9 to 13.8)	8.42 (7.52 to 9.26)	9.26 (8.28 to 10.2)	9.47 (8.43 to 10.5)	0.28 (0.22 to 0.35)	0.29 (0.23 to 0.35)	0.29 (0.24 to 0.35)
Afghanistan	9.39	9.44	9.61	6.47	6.5	6.53	0.31	0.31	0.32
Algeria	10.9	12.4	13.2	7.97	8.99	9.49	0.27	0.27	0.28
Aigena	(10.3 to 11.4) 9.91	(11.7 to 13.1) 9.97	(12.6 to 13.8)	(7.06 to 8.86) 6.96	(8.03 to 10)	(8.4 to 10.5) 8.45	(0.23 to 0.32)	(0.23 to 0.32)	(0.24 to 0.33)
Bahrain	(9.45 to 10.4)	(9.52 to 10.4)	(11.4 to 13.1)	(6.15 to 7.73)	(6.12 to 7.79)	(7.34 to 9.56)	(0.26 to 0.35)	(0.25 to 0.36)	(0.27 to 0.36)
Egypt	9.91 (9.88 to 9.94)	9.86 (9.83 to 9.89)	9.88 (8.97 to 10.9)	7.26 (6.53 to 7.92)	7.18 (6.46 to 7.84)	7.15 (6.2 to 8.16)	0.27 (0.2 to 0.34)	0.27 (0.21 to 0.34)	0.28 (0.25 to 0.31)
Iran (Islamic Republic of)	12.4 (12.1 to 12.6)	13.6 (13.5 to 13.8)	14.6 (14.4 to 14.8)	8.7 (7.73 to 9.61)	9.61 (8.57 to 10.6)	10.2 (9.07 to 11.3)	0.3 (0.24 to 0.36)	0.3 (0.23 to 0.37)	0.3 (0.23 to 0.37)
Iraq	12.5	12.3	13.7	8.63	8.66	9.67	0.31	0.29	0.29
lorden	10.9	(11.2 (0 13.3)	(12.9 to 14.5) 14.5	7.83	7.89	(8.5 (0 10.8)	0.28	0.28	0.28
Jordan	(10.3 to 11.5)	(10.4 to 11.6)	(13.3 to 15.5)	(6.92 to 8.71)	(6.97 to 8.81)	(9.05 to 11.7)	(0.24 to 0.33)	(0.24 to 0.33)	(0.25 to 0.32)
Kuwait	(14.3 to 14.8)	(16.8 to 17.3)	(17.2 to 19.4)	(9.4 to 11.6)	(10.8 to 13.3)	(11.4 to 14.7)	(0.22 to 0.34)	(0.23 to 0.36)	(0.24 to 0.34)
Lebanon	12.4 (11.7 to 12.9)	13.7 (13.3 to 14.1)	14.9 (14.5 to 15.3)	8.9 (7.89 to 9.84)	9.79 (8.73 to 10.8)	10.5 (9.24 to 11.6)	0.28 (0.23 to 0.33)	0.29 (0.24 to 0.34)	0.3 (0.24 to 0.36)
Libya	14.5 (13.7 to 15.5)	16.2 (16 to 16.6)	15.2 (14.1 to 16.4)	10.4 (9.14 to 11.6)	11.4 (10.1 to 12.7)	10.7 (9.24 to 12.1)	0.29 (0.25 to 0.33)	0.3 (0.24 to 0.36)	0.3 (0.26 to 0.34)
Morocco	11.9 (11.7 to 12.3)	12 (11 3 to 12 6)	12.6 (12.1 to 13.5.)	8.67 (7 79 to 9 53)	8.64	9.06 (8.05 to 10.2.)	0.27 (0.22 to 0.33)	0.28 (0.23 to 0.32)	0.28 (0.24 to 0.33)
Oman	10.1	10.9	11.3	7.24	7.76	7.97	0.28	0.29	0.29
oman	(9.22 to 11.2) 11.3	(10.6 to 11.2) 12.5	(10.7 to 11.8) 12.3	(6.29 to 8.3) 8.13	(6.86 to 8.58) 8.95	(7.03 to 8.91) 8.74	(0.26 to 0.32) 0.28	(0.23 to 0.35) 0.29	(0.25 to 0.34) 0.29
Palestine	(10.3 to 12.6)	(12.1 to 13)	(11.6 to 13)	(7.03 to 9.31)	(7.94 to 9.85)	(7.71 to 9.8)	(0.26 to 0.32)	(0.24 to 0.34)	(0.25 to 0.34)
Qatar	10.2 (9.43 to 11)	8.8 (8.16 to 9.5)	9.66 (8.99 to 10.4)	7.13 (6.24 to 8.08)	6.01 (5.17 to 6.84)	6.68 (5.77 to 7.6)	0.3 (0.26 to 0.34)	0.32 (0.28 to 0.37)	0.31 (0.27 to 0.36)
Saudi Arabia	(10.8 to 12.1)	12.5 (12.1 to 12.8)	13.7 (12.6 to 14.9)	(6.82 to 8.81)	8.54 (7.44 to 9.56)	9.41 (8.07 to 10.7)	0.32 (0.27 to 0.37)	0.31 (0.25 to 0.38)	0.31 (0.28 to 0.36)
Sudan	11.2 (10.8 to 11.6)	12.1 (11.4 to 12.9)	12.5 (11.8 to 12.8)	8.06 (7.2 to 8.87)	8.67 (7.67 to 9.63)	8.95 (7.89 to 9.92)	0.28 (0.23 to 0.33)	0.28 (0.25 to 0.33)	0.28 (0.23 to 0.33)
Syrian Arab Republic	11.6	11.9	11.8	8.44	8.69	8.42	0.27	0.27	0.29
Tunisia	13.7	14.3	15.1	10	10.4	10.8	0.27	0.27	0.28
, unitid	(13.2 to 14.3) 13.5	(13.2 to 15.6) 16.8	(13.8 to 16.5) 15.3	(8.93 to 11) 9.71	(9.06 to 11.8) 11.9	(9.38 to 12.3) 10.9	(0.23 to 0.32) 0.28	(0.25 to 0.31) 0.3	(0.26 to 0.32) 0.29
Turkey	(12.9 to 14.1)	(16.1 to 17.6)	(14.2 to 16.5)	(8.6 to 10.8)	(10.5 to 13.2)	(9.53 to 12.3)	(0.24 to 0.33)	(0.25 to 0.35)	(0.25 to 0.33)
United Arab Emirates	9.69 (9.13 to 10.3)	7.32 (6.97 to 7.71)	13 (11.9 to 13.9)	6.83 (6.01 to 7.68)	5.14 (4.51 to 5.73)	8.93 (7.67 to 10.1)	0.3 (0.25 to 0.34)	0.3 (0.26 to 0.35)	0.31 (0.27 to 0.35)
Yemen	11.1 (10.3 to 11.7)	11.9 (11 to 12.5)	12.1 (11.1 to 12.7)	7.95 (6.99 to 8.83)	8.53 (7.55 to 9.57)	8.68 (7.5 to 9.7)	0.28 (0.24 to 0.32)	0.28 (0.23 to 0.32)	0.28 (0.24 to 0.32)
South Asia	9.73 (9.47 to 10)	11.2 (10.9 to 11.4)	12.8 (12 to 13.7)	6.54 (5.74 to 7.33)	7.53 (6.59 to 8.39)	8.59 (7.47 to 9.76)	0.33 (0.27 to 0.39)	0.33 (0.27 to 0.39)	0.33 (0.29 to 0.38)
South Asia	9.73	11.2	12.8	6.54	7.53	8.59	0.33	0.33	0.33
Panaladash	11.1	12	(12 (0 13.7)	7.83	8.52	10.2	0.29	0.29	0.29
bungiaaesii	(10.7 to 11.5) 10.9	(11.6 to 12.4)	(13.3 to 15.4)	(6.93 to 8.65)	(7.58 to 9.44) 8.65	(8.94 to 11.5) 8.96	(0.25 to 0.35)	(0.24 to 0.34)	(0.25 to 0.33) 0.29
Bhutan	(10.3 to 11.2)	(11.8 to 12.7)	(12.4 to 13.4)	(6.86 to 8.5)	(7.76 to 9.55)	(7.99 to 9.9)	(0.24 to 0.33)	(0.25 to 0.34)	(0.26 to 0.36)
India	9.38 (9.09 to 9.7)	11.1 (10.8 to 11.5)	12.7 (11.8 to 13.8)	6.22 (5.42 to 7.01)	7.43 (6.5 to 8.32)	8.49 (7.31 to 9.74)	0.34 (0.28 to 0.4)	0.33 (0.27 to 0.4)	0.33 (0.29 to 0.38)
Nepal	10.6 (9.97 to 11)	12.1 (11.9 to 12.5)	12.1 (11.7 to 12.9)	7.33 (6.47 to 8.19)	8.41 (7.51 to 9.26)	8.47 (7.47 to 9.51)	0.31 (0.26 to 0.35)	0.3 (0.26 to 0.37)	0.3 (0.26 to 0.36)
Pakistan	11 (10.6 to 11.3)	10.6 (10.3 to 11.1)	11.6 (10.4 to 12.5)	7.64 (6.76 to 8.46)	7.35 (6.45 to 8.19)	8 (6.89 to 9.17)	0.3 (0.25 to 0.36)	0.31 (0.26 to 0.37)	0.31 (0.27 to 0.34)
Southeast Asia, East Asia,	11.6	12.9	14.8	8.25	9.1	10.4	0.29	0.29	0.3
and Oceania	(11.2 to 12.2) 11.4	(12.5 to 13.2) 12.9	(14 to 15.7) 15.1	(7.31 to 9.15) 8.15	(8.09 to 10) 9.12	(9.21 to 11.6) 10.6	(0.25 to 0.34) 0.29	(0.24 to 0.35) 0.29	(0.26 to 0.34) 0.3
East Asia	(10.9 to 12.2)	(12.4 to 13.3)	(14.1 to 16.2)	(7.2 to 9.09)	(8.08 to 10.1)	(9.33 to 12)	(0.25 to 0.34)	(0.25 to 0.35)	(0.26 to 0.34)
China	(10.8 to 12.1)	(12.4 to 13.3)	(14.1 to 16.3)	(7.16 to 9.05)	(8.04 to 10)	(9.3 to 11.9)	(0.25 to 0.34)	(0.25 to 0.35)	(0.27 to 0.34)
Democratic People's Republic of Korea	12.3 (11.7 to 13)	12.2 (11.9 to 12.8)	13.8 (12.7 to 14.5)	8.86 (7.98 to 9.76)	8.79 (7.97 to 9.64)	9.94 (8.82 to 11)	0.28 (0.25 to 0.31)	0.28 (0.25 to 0.33)	0.28 (0.24 to 0.31)
Taiwan (Province of Ching)	13.7 (13.6 to 13.8)	16.1 (16 to 16 2)	17.5 (16 to 18 9)	9.8 (8.82 to 10.7)	11.6 (10.4 to 12.7)	12.6 (11 to 14 2)	0.28 (0.22 to 0.35)	0.28	0.28 (0.25 to 0.31)
Oceania	11.2	11.2	11.5	7.86	7.78	7.94	0.3	0.3	0.31
	(10.7 to 11.7) 12.7	(10.5 to 11.8) 13.1	(10.4 to 12.3) 13	(6.95 to 8.73) 8.82	(6.81 to 8.71) 8.99	(6.84 to 9.03) 8.85	(0.25 to 0.35) 0.3	(0.26 to 0.35) 0.32	(0.27 to 0.34) 0.32
American Samoa	(12.3 to 13.1)	(12.6 to 13.5)	(12 to 14)	(7.8 to 9.75)	(7.88 to 9.97)	(7.56 to 10.1)	(0.26 to 0.37)	(0.26 to 0.38)	(0.28 to 0.37)

Supplementary Table 8:	Life expectancy,	, Health-adjusted	life expectancy, a	and proportion o	of years spent in	ill health in all re	porting location	s, in 1990, 2005, I	2019, Females
location	1000	LE-70	2010	1000	HALE-70	2010	1000	PYIH-70	2010
Cook Islands	1990	14.4	14.7	8.32	9.76	9.99	0.31	0.32	0.32
	(11.3 to 12.5)	(13.8 to 14.8)	(13.6 to 15.8)	(7.27 to 9.28)	(8.62 to 10.9)	(8.58 to 11.4)	(0.26 to 0.36)	(0.26 to 0.38)	(0.28 to 0.37)
	11.2	11.4	11.5	7.84	7.81	7.93	0.3	0.31	0.31
Fiji	(10.4 to 12)	(11.2 to 11.5)	(10.4 to 12.7)	(6.85 to 8.89)	(6.86 to 8.71)	(6.76 to 9.13)	(0.26 to 0.34)	(0.24 to 0.39)	(0.28 to 0.35)
Guam	(12.7 to 13.5)	(17.6 to 18.7)	(16.1 to 18.1)	9.4 (8.41 to 10.3)	(11.4 to 14.1)	(10.6 to 13.5)	(0.24 to 0.34)	(0.24 to 0.35)	(0.25 to 0.34)
Kiribati	8.46	8.74	9.15	6.09	6.3	6.54	0.28	0.28	0.29
	(7.88 to 9.18)	(8.23 to 9.42)	(8.45 to 10)	(5.34 to 6.89)	(5.54 to 7.04)	(5.67 to 7.42)	(0.25 to 0.32)	(0.25 to 0.33)	(0.26 to 0.33)
Marshall Islands	10.1	9.5	10.1	7.15	6.64	6.97	0.29	0.3	0.31
	(9.75 to 10.5)	(9.07 to 10)	(9.05 to 11.2)	(6.34 to 7.96)	(5.84 to 7.47)	(5.87 to 8.13)	(0.24 to 0.35)	(0.26 to 0.36)	(0.27 to 0.35)
Micronesia (Federated	9.55	9.81	9.77	6.88	6.96	6.92	0.28	0.29	0.29
States of)	(8.79 to 10.4)	(9.32 to 10.4)	(8.98 to 10.7)	(5.98 to 7.8)	(6.12 to 7.74)	(5.97 to 7.9)	(0.25 to 0.32)	(0.26 to 0.34)	(0.26 to 0.33)
Nauru	9.67	8.98 (8.27 to 0.72)	9.8	6.88	6.38 (5.62 to 7.21)	6.84	0.29	0.29	0.3
Niue	11.8	12	12.7	8.29	8.28	8.63	0.3	0.31	0.32
Northern Mariana	(10.8 to 12.6)	(11 to 12.7)	(11.5 to 13.8)	(7.19 to 9.32)	(7.19 to 9.35)	(7.38 to 9.86)	(0.26 to 0.34)	(0.26 to 0.35)	(0.28 to 0.36)
	11.8	13	13.7	8.44	9.17	9.63	0.29	0.3	0.3
Islands	(10.8 to 12.9)	(12.1 to 14)	(12.6 to 14.7)	(7.36 to 9.62) 7.56	(8.06 to 10.3)	(8.31 to 10.8)	(0.25 to 0.32)	(0.26 to 0.34)	(0.26 to 0.34)
Palau	(9.68 to 12)	(10.2 to 12.3)	(10.3 to 12.8)	(6.5 to 8.75)	(6.65 to 8.79)	(6.61 to 9.07)	(0.27 to 0.33)	(0.29 to 0.35)	(0.29 to 0.36)
Papua New Guinea	(10.8 to 12.1)	(10.2 to 11.9)	11.4 (10.2 to 12.3)	7.98 (6.99 to 8.92)	(6.66 to 8.7)	7.87 (6.75 to 8.98)	0.3 (0.27 to 0.36)	0.31 (0.27 to 0.35)	0.31 (0.27 to 0.34)
Samoa	11.5	11.8	11.9	8.21	8.3	8.31	0.29	0.3	0.3
	(10.5 to 12)	(10.7 to 12.8)	(10.7 to 13.1)	(7.09 to 9.16)	(7.12 to 9.46)	(7.09 to 9.52)	(0.24 to 0.33)	(0.26 to 0.33)	(0.28 to 0.34)
Solomon Islands	8.02	7.98	8.32	5.84	5.78	5.97	0.27	0.28	0.28
	(7.49 to 8.7)	(7.54 to 8.53)	(7.75 to 8.97)	(5.16 to 6.58)	(5.11 to 6.44)	(5.22 to 6.71)	(0.24 to 0.31)	(0.25 to 0.32)	(0.25 to 0.33)
Tokelau	10.4	11	11.5	7.41	7.7	8	0.29	0.3	0.3
	(9.43 to 11.2)	(9.88 to 12.1)	(10.3 to 12.8)	(6.42 to 8.37)	(6.59 to 8.82)	(6.8 to 9.22)	(0.25 to 0.32)	(0.27 to 0.33)	(0.28 to 0.34)
Tonga	14	14.7	14.4	9.91	10.4	10.1	0.29	0.29	0.3
	(13.3 to 14.7)	(14 to 15.4)	(13.1 to 15.5)	(8.78 to 11)	(9.22 to 11.6)	(8.74 to 11.4)	(0.25 to 0.34)	(0.25 to 0.34)	(0.26 to 0.33)
Tuvalu	10.1	10.4	10.9	7.22	7.36	7.63	0.29	0.3	0.3
Vanuatu	10.1	10.2	10.5	7.23	7.29	7.42	0.28	0.29	0.3
Coutheast Asia	(9.12 to 11.4)	(9.17 to 11.6)	(9.37 to 11.8)	(6.23 to 8.31)	(6.29 to 8.45)	(6.24 to 8.65)	(0.27 to 0.32)	(0.27 to 0.31)	(0.27 to 0.33)
	12.3	12.8	13.7	8.61	9.06	9.67	0.3	0.29	0.3
Southeast Asia	(12 to 12.5)	(12.5 to 13.1)	(13.2 to 14.3)	(7.66 to 9.52)	(8.09 to 10)	(8.59 to 10.7)	(0.24 to 0.36)	(0.24 to 0.35)	(0.25 to 0.35)
Cambodia	(10.3 to 11.2)	(11.2 to 12.1)	(11.9 to 13)	(6.63 to 8.35)	(7.29 to 9.12)	(7.57 to 9.59)	(0.25 to 0.36)	(0.25 to 0.35)	(0.26 to 0.36)
Indonesia	11.7	11.6	12.1	7.91	7.98	8.36	0.32	0.32	0.31
	(11.2 to 12)	(11.2 to 12.1)	(11.5 to 13.2)	(6.87 to 8.83)	(7 to 8.94)	(7.32 to 9.4)	(0.27 to 0.39)	(0.26 to 0.37)	(0.29 to 0.36)
Lao People's	10.1	11.2	12.1	7.28	8.05	8.67	0.28	0.28	0.28
Democratic Republic	(9.5 to 10.8)	(10.7 to 11.7)	(11.5 to 12.9)	(6.47 to 8.2)	(7.19 to 8.89)	(7.69 to 9.64)	(0.24 to 0.32)	(0.24 to 0.33)	(0.25 to 0.33)
Malaysia	12.8	12.6	13.3	8.95	8.87	9.35	0.3	0.29	0.29
	(12.7 to 12.8)	(12.5 to 12.6)	(12.2 to 14.4)	(7.95 to 9.87)	(7.92 to 9.77)	(8.14 to 10.6)	(0.23 to 0.37)	(0.23 to 0.37)	(0.27 to 0.33)
Maldives	10.5 (10.3 to 10.6)	13.4 (13.1 to 13.8.)	15.3 (14.4 to 16.4.)	7.45	9.58 (8.6 to 10.5.)	10.9 (9.6 to 12.2)	0.29 (0.23 to 0.35)	0.29	0.29
Mauritius	12.8	14.2	15.2	9.02	9.88	10.6	0.29	0.3	0.31
Myanmar	(12.5 to 13)	(13.9 to 14.4)	(14.1 to 16.4)	(8.04 to 9.98)	(8.71 to 10.9)	(9.16 to 12)	(0.23 to 0.36)	(0.24 to 0.37)	(0.27 to 0.35)
	10.6	11.4	12.6	7.51	8.06	8.79	0.29	0.29	0.3
	(9.92 to 11.3)	(10.9 to 12)	(12.2 to 12.9)	(6.55 to 8.41)	(7.17 to 8.97)	(7.76 to 9.72)	(0.26 to 0.34)	(0.25 to 0.34)	(0.24 to 0.36)
	12.8	13.2	13.5	9.07	9.31	9.54	0.29	0.29	0.29
Philippines	(12.4 to 13.2)	(12.8 to 13.6)	(12.3 to 14.7)	(8 to 10)	(8.25 to 10.3)	(8.35 to 10.9)	(0.24 to 0.36)	(0.24 to 0.35)	(0.26 to 0.32)
Seychelles	(13.6 to 14.3)	13.9 (13.5 to 14.2)	13.9 (13.3 to 14.6)	10.1 (9 to 11.1)	9.88 (8.78 to 10.9)	9.78 (8.59 to 10.9)	(0.28 (0.23 to 0.34)	(0.23 to 0.35)	0.3 (0.25 to 0.35)
Sri Lanka	12.7	13.7	15	9.17	9.59	10.4	0.28	0.3	0.31
	(12.4 to 13.1)	(13.1 to 14.2)	(13.6 to 16.6)	(8.15 to 10.1)	(8.46 to 10.7)	(8.88 to 12)	(0.23 to 0.34)	(0.25 to 0.36)	(0.28 to 0.35)
Thailand	14.2	15.8	17.6	10.1	11.3	12.7	0.29	0.28	0.28
	(13.6 to 14.8)	(15.2 to 16.5)	(16 to 19.3)	(9.03 to 11.2)	(10.1 to 12.6)	(11 to 14.4)	(0.25 to 0.34)	(0.24 to 0.33)	(0.25 to 0.31)
Timor-Leste	11.1	12	12	7.83	8.41	8.43	0.3	0.3	0.3
	(10.6 to 11.4)	(11.6 to 12.2)	(11.6 to 12.7)	(6.94 to 8.66)	(7.45 to 9.26)	(7.4 to 9.48)	(0.24 to 0.35)	(0.24 to 0.36)	(0.25 to 0.36)
Viet Nam	12.6	13.7	14.3	9.17	9.96	10.3	0.27	0.27	0.28
	(12.1 to 13.2)	(12.9 to 14.1)	(13.8 to 15.2)	(8.24 to 10.1)	(8.84 to 10.9)	(9.1 to 11.4)	(0.23 to 0.32)	(0.22 to 0.31)	(0.25 to 0.34)
Sub-Saharan Africa	10.9	(11.0 to 11.2)	12.2	7.86	8.09	8.86	0.28	0.28	0.27
Central Sub-Saharan	10.4	10.9 (0 11.5)	11.6	7.45	7.68	8.47	0.28	0.28	0.27
Africa	(9.86 to 10.9) 10.1	(10.1 to 11.1) 10.7	(10.7 to 12.4) 12.1	(6.63 to 8.26) 7.33	(6.89 to 8.47) 7.82	(7.43 to 9.45) 8.85	(0.24 to 0.33) 0.27	(0.24 to 0.32) 0.27	(0.24 to 0.3)
Angola	(9.48 to 10.6)	(10.2 to 11.3)	(11.2 to 12.6)	(6.51 to 8.15)	(6.98 to 8.63)	(7.81 to 9.78)	(0.23 to 0.31)	(0.23 to 0.31)	(0.22 to 0.3)
Central African Republic	9.4 (8.61 to 10.1)	8.99 (7.89 to 10.3)	(8.3 to 11)	(5.85 to 7.61)	6.52 (5.48 to 7.71)	(5.79 to 8.29)	(0.25 to 0.32)	(0.25 to 0.31)	(0.25 to 0.3)
Congo	9.59	10.1	11	7.01	7.35	7.99	0.27	0.27	0.27
	(8.75 to 10.7)	(9.36 to 10.9)	(9.98 to 11.7)	(6.13 to 8.04)	(6.42 to 8.16)	(6.96 to 8.95)	(0.25 to 0.3)	(0.25 to 0.31)	(0.23 to 0.3)
Democratic Republic of	10.6	10.7	11.6	7.55	7.72	8.47	0.29	0.28	0.27
the Congo	(9.99 to 11.1)	(10.2 to 11.2)	(10.6 to 12.6)	(6.68 to 8.4)	(6.91 to 8.56)	(7.41 to 9.53)	(0.25 to 0.33)	(0.24 to 0.32)	(0.24 to 0.3)
Equatorial Guinea	9.82	11.8	12.2	6.93	8.36	8.7	0.29	0.29	0.28
	(8.75 to 10.7)	(10.6 to 13.4)	(10.8 to 13.2)	(5.97 to 7.84)	(7.19 to 9.7)	(7.43 to 9.9)	(0.26 to 0.32)	(0.27 to 0.32)	(0.25 to 0.31)
Gabon	11.2	11.3	12.4	8.21	8.22	9.09	0.27	0.27	0.27
	(10.7 to 11.6)	(10.4 to 12.1)	(11.6 to 13.4)	(7.33 to 9.04)	(7.23 to 9.17)	(8.06 to 10.2)	(0.22 to 0.31)	(0.24 to 0.3)	(0.24 to 0.3)

Supplementary Table 8:	Life expectancy,	Health-adjusted	life expectancy, a	and proportion o	of years spent in	ill health in all re	porting locations	, in 1990, 2005, 2	2019, Females
	1000	LE-70	2010	1000	HALE-70	2010	1000	PYIH-70	1 2010
IOCATION	1990	2005	12.2	1990	8 17	2019	1990	0.28	2019
Africa	(10 to 10.5)	(11 to 11.5)	(11.8 to 12.5)	(6.62 to 8.11)	(7.32 to 8.92)	(8.02 to 9.71)	(0.23 to 0.34)	(0.23 to 0.34)	(0.22 to 0.32)
Burundi	9.44	10.2	11.5	6.95	7.48	8.53	0.26	0.26	0.26
	(8.58 to 10.1)	(9.53 to 10.9)	(10.5 to 12.4)	(6.04 to 7.76)	(6.6 to 8.31)	(7.4 to 9.61)	(0.23 to 0.3)	(0.24 to 0.31)	(0.23 to 0.29)
Comoros	10.6	11.5	12.2	7.82	8.5	9.08	0.26	0.26	0.26
	(10 to 11.3)	(10.9 to 11.8)	(11.2 to 12.6)	(7 to 8.69)	(7.64 to 9.29)	(8.03 to 9.95)	(0.23 to 0.3)	(0.22 to 0.3)	(0.21 to 0.28)
Djibouti	11.3	11.7	12.3	8.34	8.7	9.16	0.26	0.26	0.26
	(10.5 to 11.9)	(10.7 to 12.9)	(11.2 to 12.9)	(7.39 to 9.17)	(7.64 to 9.83)	(8.03 to 10.1)	(0.23 to 0.3)	(0.24 to 0.29)	(0.22 to 0.28)
Eritrea	9.26	10.3	10.8	6.77	7.54	7.98	0.27	0.27	0.26
	(8.54 to 9.94)	(9.12 to 11.5)	(9.5 to 11.9)	(5.94 to 7.59)	(6.48 to 8.65)	(6.77 to 9.13)	(0.24 to 0.3)	(0.25 to 0.29)	(0.23 to 0.29)
Ethiopia	8.97	10.8	12.6	6.43	7.74	9.15	0.28	0.28	0.27
	(8.56 to 9.4)	(10.3 to 11.2)	(12.3 to 13.1)	(5.71 to 7.12)	(6.84 to 8.61)	(8.17 to 10)	(0.24 to 0.33)	(0.23 to 0.33)	(0.24 to 0.34)
Kenya	11.8	12	12.4	8.41	8.65	9.01	0.29	0.28	0.27
	(11.4 to 12.2)	(11.6 to 12.6)	(11.6 to 13.3)	(7.47 to 9.24)	(7.72 to 9.51)	(7.91 to 10)	(0.24 to 0.34)	(0.24 to 0.33)	(0.24 to 0.32)
Madagascar	11	10.7	11.2	8.06	7.82	8.3	0.27	0.27	0.26
	(10.6 to 11.5)	(10.1 to 11.2)	(10 to 12.4)	(7.22 to 8.88)	(6.98 to 8.59)	(7.14 to 9.44)	(0.23 to 0.32)	(0.23 to 0.31)	(0.24 to 0.29)
Malawi	10.2	11.3	12.4	7.39	8.24	9.16	0.28	0.27	0.26
	(9.92 to 10.5.)	(10.6 to 11.9.)	(11.8 to 13.1.)	(6.62 to 8.12)	(7.26 to 9.13.)	(8.16 to 10.1.)	(0.23 to 0.33)	(0.23 to 0.32)	(0.23 to 0.31)
Mozambique	10.4	11.6	11.6 (10.2 to 12.7)	7.48	8.35	8.49	0.28	0.28	0.27
	9.29	11.4	12.4	6.83	8.29	9.14	0.26	0.27	0.26
Rwanda	(8.72 to 9.72)	(10.8 to 11.8)	(11.7 to 12.8)	(6.09 to 7.54)	(7.43 to 9.14)	(8.21 to 10)	(0.22 to 0.3)	(0.23 to 0.31)	(0.22 to 0.3)
Somalia	9.43	9.85	10.4	6.96	7.28	7.69	0.26	0.26	0.26
	(8.52 to 10.2)	(8.6 to 10.8)	(8.91 to 11.5)	(6.1 to 7.79)	(6.22 to 8.3)	(6.43 to 8.77)	(0.24 to 0.28)	(0.23 to 0.28)	(0.24 to 0.28)
South Sudan	10.9	11.7	12.3	7.43	7.95	8.39	0.32	0.32	0.32
	(10.3 to 11.6)	(10.9 to 13)	(11.5 to 13.5)	(6.46 to 8.39)	(6.9 to 9.17)	(7.25 to 9.61)	(0.28 to 0.37)	(0.29 to 0.37)	(0.29 to 0.37)
Uganda	11.2	11.6	12.6	8.1	8.45	9.28	0.28	0.27	0.26
	(10.7 to 12.1)	(10.9 to 12)	(12.2 to 13.3)	(7.21 to 9.07)	(7.55 to 9.3)	(8.34 to 10.2)	(0.25 to 0.32)	(0.23 to 0.31)	(0.24 to 0.32)
United Republic of	11.1	11.9	12.4	8.05	8.65	9.1	0.27	0.27	0.27
Tanzania	(10.7 to 11.4)	(11.5 to 12.4)	(12 to 12.9)	(7.24 to 8.83)	(7.75 to 9.51)	(8.2 to 9.94)	(0.23 to 0.32)	(0.23 to 0.33)	(0.23 to 0.32)
Zambia	10 (9.67 to 10.5)	10.7 (9.87 to 11.4)	11.8 (10.6 to 12.6)	7.41 (6.61 to 8.18)	7.89 (7.01 to 8.74.)	8.74 (7.61 to 9.78)	0.26	0.26	0.26
Southern Sub-Saharan	13.9	11.8 (11.6 to 12.)	(10.0 to 12.0) 13.2 (12.9 to 13.5)	9.89	8.36 (7.51 to 9.21)	9.37 (8.4 to 10.3.)	0.29	0.29 (0.23 to 0.35)	0.29
Botswana	11.4 (10 to 12.3)	10.8	11.7 (10.2 to 12.9)	8.3 (7.04 to 9.41)	7.83	8.37 (7.04 to 9.57.)	0.27 (0.23 to 0.3)	0.27 (0.28 to 0.3)	0.29
Eswatini	11.4 (10.7 to 12.2)	9.37 (8.23 to 10.7)	(10.2 to 12.5) 11.4 (9.78 to 13.8)	8.26 (7.36 to 9.18)	6.72 (5.69 to 7.83)	8.19 (6.76 to 9.9)	0.28	0.28	0.28
Lesotho	11.9	9.6	9.92	8.59	6.92	7.11	0.28	0.28	0.28
Namihia	(11.3 (0 12.2)	11.1	12.5	8.18	7.95	9.04	0.28	0.28	0.27
South Africa	(10.9 to 11.8)	(10.1 to 12.2)	(11.3 to 13.7)	(7.29 to 9.06)	(6.95 to 9.11)	(7.81 to 10.4)	(0.23 to 0.33)	(0.25 to 0.31)	(0.24 to 0.31)
	14.7	12.2	13.8	10.4	8.6	9.73	0.29	0.29	0.29
Zimbabwa	(14.4 to 15)	(12.1 to 12.3)	(13.6 to 14)	(9.22 to 11.4)	(7.71 to 9.45)	(8.69 to 10.7)	(0.24 to 0.36)	(0.23 to 0.36)	(0.24 to 0.36)
	11.8	10.7	11	8.61	7.71	7.97	0.27	0.28	0.28
Zimbabwe	(11.3 to 12.3)	(9.71 to 11.7)	(9.81 to 12.2)	(7.72 to 9.52)	(6.68 to 8.74)	(6.77 to 9.18)	(0.23 to 0.32)	(0.25 to 0.31)	(0.25 to 0.31)
Western Sub-Saharan	10.7	11.1	12	7.69	8.06	8.77	0.28	0.27	0.27
Africa	(10.3 to 11.1)	(10.7 to 11.7)	(11.5 to 12.6)	(6.88 to 8.46)	(7.19 to 8.88)	(7.81 to 9.68)	(0.24 to 0.33)	(0.24 to 0.33)	(0.23 to 0.32)
Benin	10.8	11.4	12.1	7.82	8.37	8.82	0.28	0.27	0.27
	(10.5 to 11.1)	(10.8 to 12)	(11.3 to 12.6)	(7 to 8.57)	(7.51 to 9.24)	(7.78 to 9.73)	(0.23 to 0.34)	(0.23 to 0.31)	(0.23 to 0.31)
Burkina Faso	10.5	10.9	11.8	7.59	8.05	8.67	0.28	0.26	0.26
	(10.1 to 10.9)	(10.6 to 11.3)	(11.2 to 12.1)	(6.75 to 8.38)	(7.24 to 8.83)	(7.8 to 9.47)	(0.23 to 0.33)	(0.22 to 0.32)	(0.22 to 0.31)
Cabo Verde	14.7	15.4	14	10.9	11.2	10.3	0.26	0.27	0.27
	(14.3 to 15.1)	(14.7 to 15.8)	(13.5 to 14.6)	(9.79 to 11.8)	(9.99 to 12.4)	(9.21 to 11.3)	(0.22 to 0.31)	(0.22 to 0.32)	(0.23 to 0.32)
Cameroon	10.9	10.9	12.1	7.84	7.78	8.76	0.28	0.28	0.27
	(10.5 to 11.2)	(10.3 to 11.5)	(10.9 to 12.7)	(7.01 to 8.64)	(6.91 to 8.7)	(7.58 to 9.78)	(0.23 to 0.34)	(0.25 to 0.33)	(0.23 to 0.31)
Chad	10.5	10.5	11.3	7.63	7.55	8.18	0.27	0.28	0.28
	(10.1 to 10.7)	(10.1 to 10.9)	(10.5 to 11.8)	(6.88 to 8.38)	(6.73 to 8.33)	(7.23 to 9.05)	(0.22 to 0.32)	(0.23 to 0.33)	(0.23 to 0.31)
Côte d'Ivoire	11.1	11.2	12.3	7.78	8.13	8.94	0.3	0.27	0.27
	(10.7 to 11.5)	(10.5 to 11.8)	(11.5 to 12.7)	(6.81 to 8.67)	(7.22 to 9.03)	(7.9 to 9.84)	(0.25 to 0.36)	(0.23 to 0.31)	(0.23 to 0.31)
Gambia	11.3	11.4	11.6	8.21	8.25	8.41	0.27	0.28	0.28
	(10.6 to 11.8)	(10.8 to 12.1.)	(10.7 to 12.4.)	(7.25 to 9.11)	(735 to 92)	(7.42 to 9.33)	(0.23 to 0.32)	(0.24 to 0.32)	(0.25 to 0.31)
Ghana	10.9	11.5	12.3 (11.6 to 12.6)	8.03	8.42	9.1	0.26	0.27	0.26
Guinea	10	10.6	11.2	7.35	7.81	8.25	0.27	0.27	0.27
Guinea-Bissau	(9.72 to 10.3)	(10.2 to 11.1)	(10.4 to 12.1)	(6.6 to 8.07)	(7.04 to 8.56)	(7.23 to 9.27)	(0.22 to 0.32)	(0.23 to 0.31)	(0.23 to 0.3)
	9.7	10.2	10.9	7.08	7.44	7.96	0.27	0.27	0.27
Liberia	(9.09 to 10.3)	(9.57 to 10.7)	(9.71 to 11.9)	(6.25 to 7.9)	(6.63 to 8.18)	(6.89 to 8.99)	(0.23 to 0.31)	(0.24 to 0.31)	(0.24 to 0.29)
	10.1	10.8	11.8	7.15	7.66	8.35	0.29	0.29	0.29
Liberia	(9.78 to 10.4)	(10.3 to 11.3)	(10.8 to 12.5)	(6.36 to 7.92)	(6.77 to 8.48)	(7.23 to 9.43)	(0.24 to 0.35)	(0.25 to 0.35)	(0.24 to 0.33)
	9.76	10.6	11.3	7.08	7.7	8.29	0.27	0.27	0.27
Mali	(9.53 to 10)	(10.3 to 10.9)	(10.6 to 11.8)	(6.34 to 7.78)	(6.94 to 8.46)	(7.37 to 9.14)	(0.23 to 0.34)	(0.22 to 0.32)	(0.22 to 0.31)
Mauritania	10.2	11.4	12.3	7.56	8.47	9.08	0.26	0.26	0.26
	(9.81 to 10.7)	(10.9 to 11.8)	(11.6 to 12.4)	(6.78 to 8.3)	(7.6 to 9.28)	(8.14 to 9.89)	(0.22 to 0.31)	(0.21 to 0.3)	(0.21 to 0.3)
Niger	10	10.7	11.5	7.42	7.93	8.51	0.26	0.26	0.26
	(9.81 to 10.3)	(10.4 to 10.9)	(10.8 to 11.9)	(6.7 to 8.08)	(7.19 to 8.65)	(7.56 to 9.33)	(0.22 to 0.32)	(0.21 to 0.31)	(0.22 to 0.3)
Nigeria	10.7	11.2	12.2	7.7	8.08	8.86	0.28	0.28	0.27
	(10.1 to 11.6)	(10.3 to 12.6)	(11.3 to 13.6)	(6.79 to 8.68)	(7.06 to 9.23)	(7.71 to 10.1)	(0.25 to 0.32)	(0.27 to 0.32)	(0.25 to 0.32)

Supplementary Table 8:	upplementary Table 8: Life expectancy, Health-adjusted life expectancy, and proportion of years spent in ill health in all reporting locations, in 1990, 2005, 2019, Females									
	LE-70				HALE-70			PYIH-70		
location	1990	2005	2019	1990	2005	2019	1990	2005	2019	
Sao Tome and Principe	11.6	11.5	11.8	8.46	8.36	8.55	0.27	0.27	0.28	
	(11.3 to 11.8)	(11.2 to 11.8)	(11.5 to 12.4)	(7.61 to 9.25)	(7.55 to 9.15)	(7.7 to 9.44)	(0.22 to 0.33)	(0.22 to 0.32)	(0.24 to 0.33)	
Senegal	11	11.7	12.3	8.05	8.5	8.97	0.27	0.28	0.27	
	(10.7 to 11.3)	(11.4 to 12)	(11.4 to 12.7)	(7.16 to 8.83)	(7.57 to 9.33)	(7.95 to 9.86)	(0.22 to 0.33)	(0.22 to 0.33)	(0.22 to 0.3)	
Sierra Leone	10.6	10.4	11.4	7.76	7.6	8.34	0.27	0.27	0.27	
	(10.2 to 11.2)	(10 to 10.8)	(10.5 to 11.9)	(6.98 to 8.59)	(6.83 to 8.32)	(7.3 to 9.27)	(0.23 to 0.31)	(0.23 to 0.32)	(0.22 to 0.31)	
Тодо	10.9	11.5	12.2	7.98	8.43	9	0.27	0.27	0.26	
	(10.5 to 11.2)	(10.8 to 12.1)	(11.3 to 12.7)	(7.17 to 8.74)	(7.53 to 9.32)	(7.9 to 9.95)	(0.22 to 0.32)	(0.23 to 0.3)	(0.22 to 0.3)	

Supplementary T	able 9. Data cov	verage inde>	c for all risk	factors for	204 report	ing
locations, 1990	–2005, 2005–20	19 and in to	otal by all a	iges and for	the 70+ ag	е
	199	0-2005	200	5-2019	199	0-2019
	All ages	70+	All ages	70+	All ages	70+
Armenia	58.54%	46.34%	63.41%	56.10%	65.85%	56.10%
Azerbaijan	56.10%	48.78%	60.98%	53.66%	60.98%	56.10%
Georgia	56.10%	51.22%	63.41%	53.66%	63.41%	53.66%
Kazakhstan	63.41%	58.54%	60.98%	53.66%	68.29%	58.54%
Kyrgyzstan	51.22%	48.78%	63.41%	53.66%	63.41%	53.66%
Mongolia	53.66%	46.34%	58.54%	51.22%	60.98%	51.22%
Tajikistan	48.78%	39.02%	56.10%	48.78%	58.54%	48.78%
Turkmenistan	41.46%	24.39%	36.59%	36.59%	51.22%	36.59%
Uzbekistan	53.66%	46.34%	56.10%	41.46%	58.54%	53.66%
Albania	56.10%	46.34%	63.41%	53.66%	68.29%	53.66%
Bosnia and Herzegovina	53.66%	53.66%	58.54%	53.66%	58.54%	56.10%
Bulgaria	53.66%	51.22%	60.98%	56.10%	63.41%	58.54%
Croatia	60.98%	56.10%	58.54%	53.66%	70.73%	60.98%
Czechia	63.41%	58.54%	56.10%	51.22%	65.85%	58.54%
Hungary	63.41%	58.54%	63.41%	58.54%	70.73%	60.98%
Vontenegro	41.46%	36.59%	58.54%	53.66%	60.98%	53.66%
North Macedonia	48.78%	41.46%	63.41%	51.22%	65.85%	51.22%
Poland	58.54%	51.22%	63.41%	56.10%	65.85%	56.10%
Romania	60.98%	51.22%	65.85%	58.54%	68.29%	58.54%
Serbia	53.66%	41.46%	70.73%	60.98%	75.61%	60.98%
Slovakia	58.54%	58.54%	63.41%	56.10%	68.29%	60.98%
Slovenia	60.98%	56.10%	63.41%	56.10%	68.29%	60.98%
Belarus	51.22%	48.78%	60.98%	53.66%	60.98%	53.66%
Estonia	58.54%	53.66%	63.41%	58.54%	70.73%	63.41%
atvia	53.66%	53.66%	65.85%	56.10%	70.73%	60.98%
ithuania	46.34%	39.02%	63.41%	58.54%	65.85%	58.54%
Republic of Moldova	56.10%	46.34%	60.98%	53.66%	60.98%	53.66%
Russian Federation	68.29%	60.98%	65.85%	58.54%	75.61%	60.98%
Jkraine	60.98%	58.54%	65.85%	58.54%	68.29%	60.98%
Australia	78.05%	60.98%	65.85%	53.66%	78.05%	60.98%
New Zealand	63.41%	51.22%	63.41%	53.66%	70.73%	58.54%
Brunei Darussalam	43.90%	41.46%	43.90%	36.59%	46.34%	41.46%
apan	70.73%	58.54%	58.54%	53.66%	70.73%	58.54%
Republic of Korea	63.41%	56.10%	65.85%	56.10%	65.85%	58.54%
Singapore	46.34%	43.90%	46.34%	43.90%	48.78%	43.90%
Canada	75.61%	51.22%	65.85%	51.22%	75.61%	53.66%
Greenland	9.76%	0.00%	17.07%	14.63%	21.95%	14.63%
Inited States of America	82.93%	73.17%	73.17%	65.85%	82.93%	75.61%
Argentina	75 61%	56 10%	65.85%	58 54%	78.05%	60.98%
î î î î î î î î î î î î î î î î î î î	65.85%	60.98%	56 10%	51 22%	70 73%	63 41%
Iruguay	56 10%	51 22%	60.98%	53.66%	63 41%	56 10%
Andorra	1/ 63%	12 20%	9.76%	/ 88%	17 07%	12 20%
Alluotta	14.05% 65.95%	58 540/	65 950/	50 E 10/	70 72%	62 /110/
Austria	05.85%	58.54%	05.85%	58.54%	10.73%	03.41%

Supplementary Table	e 9. Data cov	erage index	for all risk	factors for	204 report	ing
locations, 1990–2005,	2005–2019 a	and in total	by all ages	and for the	70+ age gi	roup
	1990)-2005	200	5-2019	1990	0-2019
	All ages	70+	All ages	70+	All ages	70+
Belgium	56.10%	51.22%	63.41%	56.10%	65.85%	56.10%
Cyprus	46.34%	39.02%	58.54%	53.66%	60.98%	53.66%
Denmark	70.73%	56.10%	68.29%	56.10%	75.61%	58.54%
Finland	70.73%	56.10%	68.29%	56.10%	73.17%	58.54%
France	73.17%	56.10%	65.85%	56.10%	75.61%	60.98%
Germany	65.85%	56.10%	70.73%	60.98%	73.17%	63.41%
Greece	65.85%	58.54%	68.29%	60.98%	70.73%	63.41%
Iceland	46.34%	43.90%	53.66%	43.90%	56.10%	48.78%
Ireland	63.41%	58.54%	63.41%	58.54%	70.73%	63.41%
Israel	63.41%	51.22%	53.66%	51.22%	65.85%	53.66%
italy	73.17%	65.85%	65.85%	56.10%	73.17%	65.85%
Luxembourg	48.78%	43.90%	58.54%	53.66%	60.98%	53.66%
Malta	41.46%	39.02%	58.54%	53.66%	58.54%	53.66%
Monaco	0.00%	0.00%	14.63%	0.00%	14.63%	0.00%
Netherlands	65.85%	53.66%	70.73%	58.54%	73.17%	58.54%
Norway	68.29%	53.66%	63.41%	53.66%	70.73%	58.54%
Portugal	58.54%	58.54%	68.29%	60.98%	68.29%	60.98%
San Marino	12.20%	0.00%	14.63%	2.44%	14.63%	2.44%
Spain	78.05%	73.17%	70.73%	63.41%	78.05%	73.17%
Sweden	65.85%	60.98%	68.29%	60.98%	70.73%	65.85%
Switzerland	58.54%	51.22%	58.54%	48.78%	63.41%	51.22%
United Kingdom	65.85%	48.78%	58.54%	51.22%	68.29%	53.66%
Bolivia (Plurinational State of)	60.98%	51.22%	58.54%	46.34%	63.41%	51.22%
Ecuador	60.98%	56.10%	63.41%	51.22%	68.29%	56.10%
Peru	65.85%	56.10%	68.29%	60.98%	70.73%	60.98%
Antigua and Barbuda	48.78%	41.46%	41.46%	36.59%	48.78%	41.46%
Bahamas	46.34%	41.46%	41.46%	36.59%	46.34%	41.46%
Barbados	48.78%	43.90%	56.10%	51.22%	56.10%	51.22%
Belize	53.66%	48.78%	58.54%	58.54%	60.98%	58.54%
Bermuda	36.59%	34.15%	41.46%	39.02%	41.46%	39.02%
Cuba	56.10%	43.90%	53.66%	43.90%	60.98%	46.34%
Dominica	48.78%	41.46%	29.27%	21.95%	48.78%	41.46%
Dominican Republic	58.54%	56.10%	60.98%	56.10%	63.41%	58.54%
Grenada	46.34%	41.46%	46.34%	29.27%	46.34%	41.46%
Guyana	53.66%	46.34%	56.10%	36.59%	56.10%	48.78%
Haiti	58.54%	46.34%	46.34%	39.02%	60.98%	51.22%
lamaica	58.54%	46.34%	56.10%	51.22%	63.41%	51.22%
Puerto Rico	36.59%	34.15%	36.59%	29.27%	41.46%	36.59%
Saint Kitts and Nevis	34.15%	17.07%	21.95%	17.07%	34.15%	17.07%
Saint Lucia	51.22%	46.34%	53.66%	36.59%	53.66%	48.78%
Saint Vincent and the Grenadines	34.15%	29.27%	41.46%	26.83%	46.34%	31.71%
Suriname	48.78%	43.90%	51.22%	46.34%	51.22%	46.34%
Trinidad and Tobago	48.78%	48.78%	53.66%	46.34%	53.66%	51.22%
initiada ana robago					20.00/0	2112/0

Supplementary Table 9. Data coverage index for all risk factors for 204 reporting										
locations, 1990–2005, 2	005–2019	and in total	by all ages	and for the	70+ age g	roup				
	1990-2005 2005-2019 1990 All ages 70+ All ages 70+ All ages									
	All ages	70+	All ages	70+	All ages	70+				
United States Virgin Islands	9.76%	9.76%	12.20%	9.76%	14.63%	12.20%				
Colombia	68.29%	58.54%	70.73%	58.54%	70.73%	60.98%				
Costa Rica	60.98%	56.10%	60.98%	56.10%	68.29%	60.98%				
El Salvador	58.54%	51.22%	58.54%	51.22%	58.54%	53.66%				
Guatemala	65.85%	56.10%	60.98%	48.78%	65.85%	56.10%				
Honduras	58.54%	46.34%	63.41%	53.66%	65.85%	53.66%				
Mexico	60.98%	60.98%	70.73%	58.54%	70.73%	63.41%				
Nicaragua	60.98%	51.22%	58.54%	53.66%	60.98%	58.54%				
Panama	58.54%	51.22%	56.10%	51.22%	60.98%	51.22%				
Venezuela (Bolivarian Republic of)	65.85%	58.54%	53.66%	48.78%	68.29%	60.98%				
Brazil	68.29%	60.98%	70.73%	60.98%	73.17%	63.41%				
Paraguay	56.10%	51.22%	58.54%	48.78%	60.98%	53.66%				
Afghanistan	29.27%	24.39%	63.41%	36.59%	63.41%	36.59%				
Algeria	53.66%	48.78%	51.22%	39.02%	56.10%	51.22%				
Bahrain	24.39%	21.95%	21.95%	14.63%	26.83%	21.95%				
Egypt	68.29%	58.54%	70.73%	58.54%	73.17%	60.98%				
Iran (Islamic Republic of)	51.22%	41.46%	58.54%	48.78%	60.98%	48.78%				
Iraq	58.54%	48.78%	58.54%	51.22%	60.98%	53.66%				
Jordan	58.54%	48.78%	60.98%	39.02%	63.41%	51.22%				
Kuwait	46.34%	29.27%	48.78%	36.59%	51.22%	41.46%				
Lebanon	53.66%	41.46%	48.78%	34.15%	58.54%	41.46%				
Libya	39.02%	31.71%	48.78%	34.15%	53.66%	36.59%				
Morocco	63.41%	56.10%	60.98%	48.78%	68.29%	58.54%				
Oman	51.22%	48.78%	43.90%	39.02%	53.66%	48.78%				
Palestine	53.66%	43.90%	58.54%	51.22%	58.54%	51.22%				
Qatar	21.95%	17.07%	26.83%	19.51%	29.27%	19.51%				
Saudi Arabia	58.54%	48.78%	58.54%	48.78%	63.41%	48.78%				
Sudan	17.07%	9.76%	34.15%	12.20%	36.59%	12.20%				
Syrian Arab Republic	53.66%	48.78%	53.66%	46.34%	53.66%	51.22%				
Tunisia	56.10%	43.90%	58.54%	41.46%	63.41%	48.78%				
Turkey	75.61%	60.98%	68.29%	60.98%	75.61%	63.41%				
United Arab Emirates	63.41%	58.54%	51.22%	43.90%	65.85%	58.54%				
Yemen	58.54%	46.34%	56.10%	51.22%	60.98%	51.22%				
Bangladesh	68.29%	48.78%	65.85%	51.22%	70.73%	51.22%				
Bhutan	12.20%	9.76%	36.59%	31.71%	39.02%	34.15%				
India	75.61%	63.41%	80.49%	63.41%	80.49%	65.85%				
Nepal	56.10%	51.22%	63.41%	51.22%	65.85%	53.66%				
Pakistan	58.54%	53.66%	65.85%	56.10%	68.29%	58.54%				
China	75.61%	65.85%	73.17%	58.54%	78.05%	68.29%				
Democratic People's Republic of Korea	34.15%	29.27%	39.02%	34.15%	39.02%	34.15%				
Taiwan (Province of China)	65.85%	51.22%	58.54%	48.78%	65.85%	51.22%				
American Samoa	29.27%	14.63%	19.51%	14.63%	29.27%	14.63%				
Cook Islands	7.32%	2.44%	19.51%	2.44%	19.51%	2.44%				

Supplementary Table 9. Data coverage index for all risk factors for 204 reporting locations, 1990–2005, 2005–2019 and in total by all ages and for the 70+ age group									
	199	0-2005	2005	5-2019	199	0-2019			
	All ages	70+	All ages	70+	All ages	70+			
Fiji	53.66%	39.02%	51.22%	29.27%	56.10%	39.02%			
Guam	19.51%	7.32%	19.51%	7.32%	19.51%	7.32%			
Kiribati	41.46%	34.15%	46.34%	39.02%	48.78%	39.02%			
Marshall Islands	21.95%	14.63%	21.95%	17.07%	26.83%	17.07%			
Vicronesia (Federated States of)	12.20%	4.88%	21.95%	4.88%	26.83%	4.88%			
Nauru	4.88%	0.00%	19.51%	2.44%	19.51%	2.44%			
Niue	17.07%	2.44%	7.32%	4.88%	19.51%	4.88%			
Northern Mariana Islands	17.07%	14.63%	17.07%	2.44%	17.07%	14.63%			
Palau	17.07%	2.44%	14.63%	2.44%	17.07%	4.88%			
Papua New Guinea	48.78%	41.46%	48.78%	26.83%	56.10%	43.90%			
Samoa	56.10%	41.46%	46.34%	41.46%	56.10%	41.46%			
Solomon Islands	39.02%	21.95%	51.22%	29.27%	53.66%	29.27%			
Гokelau	0.00%	0.00%	4.88%	2.44%	4.88%	2.44%			
Tonga	21.95%	17.07%	14.63%	7.32%	29.27%	19.51%			
- Fuvalu	14.63%	0.00%	19.51%	2.44%	19.51%	2.44%			
/anuatu	29.27%	24.39%	53.66%	46.34%	56.10%	46.34%			
Cambodia	60.98%	48.78%	63.41%	51.22%	65.85%	51.22%			
ndonesia	68.29%	58.54%	68.29%	58.54%	73.17%	60.98%			
ao People's Democratic Republic	46.34%	41.46%	56.10%	36.59%	58.54%	41.46%			
Valaysia	68.29%	63.41%	58.54%	48.78%	73.17%	63.41%			
Maldives	48.78%	39.02%	58.54%	48.78%	60.98%	48.78%			
Mauritius	53.66%	51.22%	56.10%	48.78%	60.98%	53.66%			
Myanmar	56.10%	51.22%	58.54%	36.59%	60.98%	51.22%			
Philippines	63.41%	60.98%	73.17%	58.54%	75.61%	60.98%			
Seychelles	29.27%	12.20%	34.15%	26.83%	34.15%	26.83%			
Sri Lanka	60.98%	53.66%	56.10%	41.46%	65.85%	53.66%			
Fhailand	70.73%	60.98%	70.73%	60.98%	75.61%	65.85%			
limor-Leste	41.46%	31.71%	56.10%	43.90%	58.54%	43.90%			
/iet Nam	63.41%	58.54%	73.17%	58.54%	73.17%	60.98%			
Angola	53.66%	46.34%	51.22%	31.71%	56.10%	46.34%			
Central African Republic	41.46%	34.15%	43.90%	36.59%	46.34%	36.59%			
Congo	36.59%	34.15%	48.78%	31.71%	51.22%	36.59%			
Democratic Republic of the Congo	34.15%	29.27%	56.10%	36.59%	58.54%	36.59%			
Equatorial Guinea	12.20%	9.76%	9.76%	4.88%	17.07%	12.20%			
Gabon	46.34%	43.90%	53.66%	34.15%	53.66%	43.90%			
Burundi	41.46%	36.59%	56.10%	34.15%	58.54%	36.59%			
Comoros	39.02%	39.02%	43.90%	36.59%	43.90%	41.46%			
Djibouti	43.90%	29.27%	39.02%	36.59%	51.22%	36.59%			
ritrea	24.39%	14.63%	12.20%	9.76%	24.39%	17.07%			
Ethiopia	60.98%	51.22%	63.41%	51.22%	65.85%	53.66%			
Kenya	58.54%	39.02%	56.10%	39.02%	70.73%	41.46%			
Madagascar	58.54%	48.78%	58.54%	46.34%	63.41%	48.78%			
Malawi	60.98%	53.66%	58.54%	53.66%	60.98%	56.10%			

Supplementary Table	9. Data cov	verage index	for all risk	factors for	204 report	ing
locations, 1990–2005,	2005–2019	and in total	by all ages	and for the	70+ age g	roup
	199	0-2005	200	5-2019	199	0-2019
	All ages	70+	All ages	70+	All ages	70+
Mozambique	60.98%	48.78%	60.98%	51.22%	65.85%	53.66%
Rwanda	53.66%	46.34%	58.54%	48.78%	58.54%	48.78%
Somalia	31.71%	26.83%	41.46%	34.15%	41.46%	34.15%
South Sudan	9.76%	9.76%	26.83%	12.20%	26.83%	12.20%
Uganda	63.41%	51.22%	68.29%	51.22%	68.29%	53.66%
United Republic of Tanzania	63.41%	51.22%	68.29%	51.22%	68.29%	53.66%
Zambia	60.98%	53.66%	58.54%	48.78%	63.41%	56.10%
Botswana	58.54%	46.34%	53.66%	53.66%	60.98%	56.10%
Eswatini	41.46%	39.02%	60.98%	36.59%	60.98%	41.46%
Lesotho	56.10%	43.90%	53.66%	46.34%	58.54%	46.34%
Namibia	60.98%	51.22%	58.54%	51.22%	63.41%	53.66%
South Africa	68.29%	63.41%	73.17%	63.41%	75.61%	68.29%
Zimbabwe	63.41%	43.90%	60.98%	51.22%	65.85%	53.66%
Benin	48.78%	36.59%	56.10%	51.22%	60.98%	51.22%
Burkina Faso	56.10%	48.78%	58.54%	48.78%	58.54%	51.22%
Cabo Verde	29.27%	24.39%	46.34%	29.27%	48.78%	29.27%
Cameroon	46.34%	39.02%	58.54%	48.78%	60.98%	53.66%
Chad	41.46%	41.46%	43.90%	41.46%	46.34%	43.90%
Côte d'Ivoire	48.78%	39.02%	65.85%	36.59%	68.29%	41.46%
Gambia	41.46%	34.15%	58.54%	48.78%	60.98%	48.78%
Ghana	63.41%	53.66%	65.85%	53.66%	68.29%	53.66%
Guinea	41.46%	36.59%	41.46%	34.15%	46.34%	39.02%
Guinea-Bissau	39.02%	34.15%	36.59%	31.71%	39.02%	34.15%
Liberia	34.15%	24.39%	60.98%	51.22%	63.41%	51.22%
Mali	58.54%	53.66%	58.54%	36.59%	60.98%	53.66%
Mauritania	36.59%	36.59%	51.22%	34.15%	51.22%	39.02%
Niger	51.22%	31.71%	53.66%	39.02%	53.66%	39.02%
Nigeria	56.10%	46.34%	65.85%	51.22%	68.29%	56.10%
Sao Tome and Principe	46.34%	41.46%	56.10%	46.34%	58.54%	46.34%
Senegal	56.10%	43.90%	60.98%	56.10%	65.85%	58.54%
Sierra Leone	48.78%	46.34%	58.54%	51.22%	58.54%	51.22%
Тодо	39.02%	34.15%	60.98%	36.59%	60.98%	39.02%

Supplementary Table 10. Data coverage index for all reporting locations for 69 risk factors, 1990–2005,											
2005–2019 and in tot	al by all ag	es and for t	he 70+ age	group							
	1990)-2005	2005	5-2019	1990)-2019					
	All ages	70+	All ages	70+	All ages	70+					
Unsafe water source	68.97%	68.47%	76.35%	75.37%	83.25%	82.76%					
Unsafe sanitation	68.97%	68.97%	61.08%	61.08%	75.86%	75.86%					
No access to handwashing facility	8.37%	4.93%	32.51%	31.53%	34.98%	32.02%					
Ambient particulate matter pollution	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%					
Household air pollution from solid fuels	100.00%	65.02%	100.00%	68.97%	100.00%	78.33%					
Ambient ozone pollution	100.00%	1.48%	100.00%	0.99%	100.00%	1.48%					
High temperature	90.15%	1.48%	90.15%	1.97%	90.15%	1.97%					
Low temperature	90.15%	1.48%	90.15%	1.97%	90.15%	1.97%					
Residential radon	25.12%	4.43%	19.70%	0.49%	33.50%	4.43%					
Lead exposure	0.00%	0.00%	100.00%	0.00%	100.00%	0.00%					
Occupational exposure to asbestos	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%					
Occupational exposure to arsenic	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to benzene	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to beryllium	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to cadmium	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to chromium	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to diesel engine exhaust	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to formaldehyde	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to nickel	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to polycyclic aromatic hydrocarbons	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to silica	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to sulfuric acid	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational exposure to trichloroethylene	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational asthmagens	100.00%	76.85%	100.00%	73.89%	100.00%	82.76%					
Occupational particulate matter, gases, and fumes	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational noise	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Occupational injuries	83.25%	75.37%	90.15%	71.92%	95.57%	81.28%					
Occupational ergonomic factors	100.00%	71.92%	100.00%	69.95%	100.00%	77.83%					
Non-exclusive breastfeeding	67.49%	66.50%	66.50%	65.52%	79.80%	79.80%					
Discontinued breastfeeding	62.56%	61.08%	61.58%	60.59%	74.88%	74.38%					
Child underweight	100.00%	0.00%	62.07%	0.00%	100.00%	0.00%					
Child wasting	100.00%	0.00%	63.05%	0.00%	100.00%	0.00%					
Child stunting	100.00%	0.00%	63.05%	0.00%	100.00%	0.00%					
Short gestation	84.24%	0.00%	91.63%	0.00%	94.09%	0.00%					
Low birth weight	84.24%	0.00%	91.63%	0.00%	94.09%	0.00%					
Iron deficiency	64.04%	15.76%	41.87%	4.93%	73.40%	17.73%					
Vitamin A deficiency	44.33%	4.93%	8.37%	0.00%	45.32%	4.93%					
Zinc deficiency	85.71%	85.71%	85.71%	85.71%	85.71%	85.71%					
Smoking	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%					
Chewing tobacco	23.65%	12.81%	90.64%	40.39%	90.64%	41.87%					
Secondhand smoke	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%					
Alcohol use	100.00%	43.35%	100.00%	33.50%	100.00%	54.19%					
Drug use	14.78%	2.96%	33.50%	1.48%	36.95%	3.94%					
Diet low in fruits	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%					
Diet low in vegetables	100.00%	88.18%	100.00%	88.18%	100.00%	88.18%					

Supplementary Table 10. Data coverage index for all reporting locations for 69 risk factors, 1990–2005, 2005–									
2019 and in total b	oy all ages	and for the	70+ age gr	oup					
	1990	0-2005	2005	5-2019	1990)-2019			
	All ages	70+	All ages	70+	All ages	70+			
Diet low in legumes	83.25%	82.27%	82.27%	82.27%	83.25%	82.27%			
Diet low in whole grains	89.66%	89.66%	92.12%	92.12%	92.12%	92.12%			
Diet low in nuts and seeds	79.31%	79.31%	79.31%	79.31%	79.31%	79.31%			
Diet low in milk	88.67%	88.67%	88.67%	88.67%	88.67%	88.67%			
Diet high in red meat	89.16%	89.16%	89.16%	89.16%	89.16%	89.16%			
Diet high in processed meat	28.57%	28.57%	34.48%	33.50%	34.48%	33.50%			
Diet high in sugar-sweetened beverages	28.57%	28.57%	33.50%	32.51%	33.99%	33.00%			
Diet low in fiber	100.00%	100.00%	89.66%	89.66%	100.00%	100.00%			
Diet low in calcium	87.19%	87.19%	86.70%	86.70%	87.19%	87.19%			
Diet low in seafood omega-3 fatty acids	88.18%	87.68%	87.68%	87.68%	88.18%	87.68%			
Diet low in polyunsaturated fatty acids	100.00%	87.68%	87.19%	87.19%	100.00%	87.68%			
Diet high in trans fatty acids	33.99%	33.99%	34.98%	34.48%	34.98%	34.48%			
Diet high in sodium	100.00%	4.93%	100.00%	9.85%	100.00%	11.82%			
Intimate partner violence	41.38%	22.17%	60.10%	31.53%	64.53%	36.45%			
Childhood sexual abuse	26.60%	6.90%	22.66%	4.93%	33.99%	9.36%			
Bullying victimization	22.17%	0.00%	56.65%	0.00%	59.61%	0.00%			
Unsafe sex	16.75%	16.75%	46.80%	46.80%	47.29%	47.29%			
Low physical activity	47.78%	18.23%	50.74%	25.12%	64.04%	29.06%			
High fasting plasma glucose	37.44%	26.60%	49.75%	31.03%	59.61%	39.90%			
High LDL cholesterol	39.41%	26.60%	53.20%	28.08%	67.98%	38.92%			
High systolic blood pressure	50.25%	38.92%	68.97%	39.41%	79.31%	52.71%			
High body-mass index	79.31%	52.22%	87.68%	46.31%	92.61%	63.05%			
Low bone mineral density	20.69%	19.21%	10.84%	9.36%	22.66%	21.67%			
Kidney dysfunction	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%			
Supplementary Table 11. Data coverage index for all non-fatal causes for 204 locations, 1990–									
---	----------	--------	----------	---------------------	----------	--------	--	--	
2005, 2005–2019 and in total by all ages and for the 70+ age group									
	199	0-2005	200	2005-2019 1990-2019		0-2019			
	All ages	70+	All ages	70+	All ages	70+			
Armenia	7.58%	2.53%	7.58%	2.53%	8.59%	3.03%			
Azerbaijan	7.07%	3.03%	6.57%	2.02%	8.08%	3.54%			
Georgia	7.58%	4.55%	23.74%	20.71%	25.25%	22.22%			
Kazakhstan	8.08%	4.55%	6.57%	3.54%	9.09%	5.56%			
Kyrgyzstan	7.58%	3.03%	10.61%	7.07%	12.12%	8.08%			
Mongolia	9.60%	5.05%	9.09%	5.05%	10.61%	6.06%			
Tajikistan	6.06%	2.53%	6.57%	2.02%	7.07%	3.03%			
Turkmenistan	5.05%	2.53%	5.56%	1.52%	5.56%	2.53%			
Uzbekistan	7.07%	3.03%	6.06%	1.52%	7.07%	3.03%			
Albania	6.06%	2.02%	10.61%	5.56%	11.62%	6.57%			
Bosnia and Herzegovina	10.61%	5.56%	9.60%	4.55%	11.62%	6.57%			
Bulgaria	24.75%	20.20%	22.73%	20.20%	26.77%	21.72%			
Croatia	39.90%	36.87%	39.39%	36.36%	39.90%	36.87%			
Czechia	26.26%	22.22%	39.90%	37.37%	42.42%	38.89%			
Hungary	24.24%	19.70%	22.22%	19.19%	25.76%	21.21%			
Montenegro	3.03%	0.51%	6.06%	2.02%	6.06%	2.02%			
North Macedonia	5.56%	1.52%	6.06%	2.02%	6.57%	2.02%			
Poland	34.34%	30.30%	33.84%	31.82%	35.35%	32.32%			
Romania	10.61%	4.04%	34.34%	31.82%	38.89%	32.32%			
Serbia	23.23%	18.69%	32.32%	29.80%	34.34%	31.31%			
Slovakia	32.32%	29.80%	31.31%	29.80%	33.33%	30.81%			
Slovenia	37.88%	35.86%	38.38%	36.87%	39.39%	37.37%			
Belarus	20.71%	18.18%	22.22%	18.18%	23.23%	19.19%			
Estonia	24.75%	21.21%	25.25%	21.72%	27.78%	24.24%			
Latvia	32.32%	29.80%	32.83%	31.31%	33.84%	31.82%			
Lithuania	34.85%	30.81%	33.84%	30.81%	35.35%	31.82%			
Republic of Moldova	5.56%	3.03%	7.58%	4.04%	8.08%	4.55%			
Russian Federation	11.11%	6.57%	11.11%	9.60%	15.15%	11.11%			
Ukraine	17.68%	15.15%	16.67%	13.13%	18.69%	15.66%			
Australia	39.90%	33.84%	35.86%	31.31%	41.41%	35.86%			
New Zealand	30.30%	25.25%	30.30%	25.76%	33.33%	28.79%			
Brunei Darussalam	5.56%	3.54%	20.71%	18.18%	21.21%	18.69%			
Japan	26.26%	22.73%	26.26%	23.23%	28.79%	25.25%			
Republic of Korea	33.84%	27.78%	34.85%	29.29%	38.38%	32.83%			
Singapore	30.81%	24.24%	30.81%	27.27%	33.84%	28.28%			
Canada	33.84%	29.80%	32.32%	29.29%	36.36%	32.83%			
Greenland	15.66%	14.14%	18.18%	16.16%	18.18%	16.16%			
United States of America	54.55%	46.46%	56.06%	49.49%	58.59%	50.51%			
Argentina	30.81%	26.26%	29.80%	26.77%	33.33%	28.79%			
Chile	44.44%	40.40%	43.94%	40.91%	47.98%	43.94%			
Uruguav	27.27%	22.73%	24.24%	20.20%	28.79%	24.24%			
Andorra	2.53%	1.01%	3.54%	1.52%	3.54%	1.52%			
Austria	33 33%	31.31%	34.85%	31.31%	35.86%	32.32%			

Supplementary Table 11. Data coverage index for all non-fatal causes for 204 locations, 1990–								
2005, 2005–2019 and in total by all ages and for the 70+ age group								
	1990	1990-2005 2005-2019 1990-2019						
	All ages	70+	All ages	70+	All ages	70+		
Belgium	42.93%	38.38%	41.41%	38.38%	44.95%	40.40%		
Cyprus	31.82%	29.29%	34.85%	31.31%	35.35%	31.82%		
Denmark	42.42%	38.38%	40.91%	37.88%	42.93%	39.39%		
Finland	47.98%	42.93%	42.93%	40.40%	48.48%	43.43%		
France	36.36%	30.30%	35.35%	29.29%	39.90%	33.84%		
Germany	36.36%	31.31%	42.93%	39.39%	45.45%	41.41%		
Greece	13.64%	9.09%	16.16%	9.09%	19.19%	12.12%		
Iceland	28.28%	22.73%	33.84%	31.31%	36.87%	32.83%		
Ireland	30.30%	22.73%	28.28%	22.73%	31.82%	25.76%		
Israel	31.82%	25.25%	29.80%	23.74%	33.84%	27.27%		
Italy	27.78%	24.24%	30.81%	28.28%	34.85%	31.82%		
Luxembourg	15.66%	13.64%	16.67%	14.14%	17.68%	15.15%		
Malta	32.32%	29.29%	38.38%	35.86%	39.39%	36.36%		
Monaco	1.01%	0.00%	1.52%	0.00%	1.52%	0.00%		
Netherlands	40.91%	33.84%	39.39%	33.84%	43.94%	37.37%		
Norway	30.30%	24.75%	30.81%	24.75%	33.33%	27.78%		
Portugal	27.78%	24.24%	43.94%	41.41%	46.97%	43.43%		
San Marino	1.52%	0.00%	1.52%	0.00%	1.52%	0.00%		
Spain	38.89%	33.84%	38.89%	31.82%	44.95%	36.36%		
Sweden	40.91%	37.88%	43.43%	40.91%	43.94%	40.91%		
Switzerland	42.42%	38.89%	40.91%	39.39%	43.94%	40.40%		
United Kingdom	5.05%	2.53%	19.19%	18.18%	20.71%	18.69%		
Bolivia (Plurinational State of)	11.11%	6.06%	8.59%	4.55%	11.62%	7.07%		
Ecuador	36.87%	33.84%	37.37%	34.34%	39.39%	36.87%		
Peru	29.29%	23.23%	30.81%	25.25%	33.33%	27.78%		
Antigua and Barbuda	3.54%	1.52%	4.04%	2.02%	4.04%	2.02%		
Bahamas	4.55%	2.02%	5.56%	3.54%	6.06%	3.54%		
Barbados	6.57%	3.54%	7.07%	4.55%	8.59%	5.05%		
Belize	6.06%	2.53%	8.59%	4.55%	9.09%	5.05%		
Bermuda	7.07%	6.06%	10.10%	9.09%	10.10%	9.09%		
Cuba	27.78%	23.74%	28.79%	25.76%	31.31%	27.27%		
Dominica	3.54%	1.52%	5.56%	3.03%	5.56%	3.03%		
Dominican Republic	12.12%	6.57%	9.60%	5.56%	13.13%	8.08%		
Grenada	16.67%	14.65%	6.06%	3.54%	19.19%	16.67%		
Guyana	7.07%	3.54%	8.59%	4.04%	8.59%	4.55%		
Haiti	7.58%	3.03%	8.08%	4.55%	9.60%	5.56%		
Jamaica	22.22%	18.18%	23.23%	20.20%	24.24%	20.20%		
Puerto Rico	22.22%	18.69%	25.25%	23.23%	26.77%	23.23%		
Saint Kitts and Nevis	1.52%	0.00%	3.54%	2.02%	3.54%	2.02%		
Saint Lucia	4.04%	2.02%	6.57%	2.53%	6.57%	2.53%		
Saint Vincent and the Grenadines	4.04%	2.02%	5.56%	3.03%	5.56%	3.03%		
Suriname	6.06%	2.02%	7.07%	3.03%	7.58%	3.54%		
Trinidad and Tobago	21.72%	18.18%	21.72%	19.19%	22.73%	19.19%		

Supplementary Table 11. Data coverage index for all non-fatal causes for 204 locations, 1990–							
2005, 2005–2019 and in total by all ages and for the 70+ age group							
	1990	0-2005	200	5-2019	1990	0-2019	
	All ages	70+	All ages	70+	All ages	70+	
United States Virgin Islands	3.03%	0.51%	6.06%	3.54%	6.06%	3.54%	
Colombia	31.82%	22.73%	31.31%	23.23%	33.84%	25.76%	
Costa Rica	25.25%	20.71%	24.75%	21.21%	26.77%	21.72%	
El Salvador	8.08%	3.54%	9.09%	5.56%	9.60%	5.56%	
Guatemala	12.63%	7.58%	10.10%	6.57%	13.64%	9.09%	
Honduras	9.09%	5.05%	9.09%	5.56%	10.61%	6.57%	
Mexico	17.68%	13.64%	18.69%	14.65%	22.22%	18.69%	
Nicaragua	8.08%	2.53%	9.09%	4.04%	10.10%	4.55%	
Panama	24.24%	18.69%	25.25%	20.71%	26.77%	21.21%	
Venezuela (Bolivarian Republic of)	11.62%	6.57%	11.62%	8.08%	14.65%	9.60%	
Brazil	14.14%	9.60%	15.15%	9.60%	18.69%	13.13%	
Paraguay	11.62%	6.57%	8.08%	4.55%	12.12%	7.58%	
Afghanistan	5.05%	2.02%	7.07%	4.04%	7.07%	4.04%	
Algeria	23.23%	18.18%	22.73%	19.19%	25.76%	20.71%	
Bahrain	19.70%	16.67%	22.22%	19.19%	22.22%	19.19%	
Egypt	31.82%	24.75%	28.79%	21.72%	35.86%	27.78%	
Iran (Islamic Republic of)	34.85%	30.30%	34.85%	27.78%	41.41%	32.83%	
Iraq	7.58%	1.52%	25.76%	21.21%	27.78%	21.72%	
Jordan	22.22%	17.68%	29.29%	26.77%	31.31%	27.27%	
Kuwait	26.77%	22.22%	23.74%	19.70%	27.78%	23.23%	
Lebanon	19.19%	15.66%	25.25%	20.20%	27.78%	22.22%	
Libya	20.71%	17.68%	21.72%	18.69%	22.73%	19.19%	
Morocco	22.73%	18.18%	18.69%	15.15%	27.27%	23.23%	
Oman	22.22%	18.18%	24.24%	19.70%	25.76%	20.20%	
Palestine	4.55%	1.01%	21.21%	18.69%	21.72%	18.69%	
Qatar	28.28%	25.76%	32.32%	28.79%	33.33%	28.79%	
Saudi Arabia	27.78%	21.21%	26.26%	20.71%	31.31%	22.73%	
Sudan	7.58%	4.04%	8.59%	5.05%	10.10%	6.06%	
Syrian Arab Republic	6.57%	1.01%	6.57%	2.02%	7.58%	2.02%	
Tunisia	24.24%	20.71%	23.74%	19.70%	27.27%	22.73%	
Turkey	35.35%	26.77%	40.91%	34.85%	46.46%	38.38%	
United Arab Emirates	11.11%	4.04%	6.57%	4.04%	12.12%	5.56%	
Yemen	8.08%	2.53%	24.75%	19.70%	26.26%	20.20%	
Bangladesh	20.20%	9.09%	12.63%	8.08%	22.22%	11.62%	
Bhutan	6.06%	2.53%	6.57%	3.54%	7.58%	3.54%	
India	44.44%	32.32%	54.04%	47.98%	57.58%	49.49%	
Nepal	14.65%	8.59%	29.80%	25.76%	32.83%	27.27%	
Pakistan	12.63%	7.07%	10.10%	5.05%	15.15%	8.59%	
China	17.17%	11.62%	18.18%	14.65%	23.23%	18.18%	
Democratic People's Republic of Korea	4.55%	1.52%	4.55%	1.52%	5.05%	2.02%	
Taiwan (Province of China)	33.84%	28.28%	46.46%	42.93%	47.98%	43.94%	
American Samoa	3.54%	1.01%	5.05%	2.53%	5.56%	2.53%	
Cook Islands	3.03%	1.01%	3.03%	1.52%	3.54%	1.52%	

Supplementary Table 11. Data coverage index for all non-fatal causes for 204 locations, 1990–							
2005, 2005–2019 and in total by all ages and for the 70+ age group							
	1990	0-2005	200	5-2019	1990)-2019	
	All ages	70+	All ages	70+	All ages	70+	
Fiji	22.73%	17.68%	22.73%	19.19%	24.75%	19.70%	
Guam	3.03%	1.01%	4.55%	2.02%	4.55%	2.02%	
Kiribati	5.05%	2.53%	4.55%	2.53%	5.05%	2.53%	
Marshall Islands	5.05%	2.53%	5.05%	2.53%	6.06%	3.03%	
Micronesia (Federated States of)	6.06%	3.54%	5.05%	3.03%	6.57%	4.04%	
Nauru	2.02%	0.51%	2.02%	1.01%	2.53%	1.01%	
Niue	1.52%	0.51%	2.02%	1.01%	2.02%	1.01%	
Northern Mariana Islands	2.53%	0.51%	3.54%	1.52%	3.54%	1.52%	
Palau	1.52%	0.51%	2.53%	1.01%	2.53%	1.01%	
Papua New Guinea	7.58%	2.53%	7.58%	4.04%	9.09%	4.55%	
Samoa	5.56%	3.03%	4.04%	2.53%	5.56%	3.03%	
Solomon Islands	4.04%	2.02%	6.57%	3.54%	6.57%	3.54%	
Tokelau	0.00%	0.00%	0.51%	0.51%	0.51%	0.51%	
Tonga	8.59%	5.05%	6.57%	4.04%	9.60%	5.56%	
Tuvalu	1.52%	0.51%	1.52%	0.51%	1.52%	0.51%	
Vanuatu	6.06%	3.54%	7.07%	3.03%	7.58%	3.54%	
Cambodia	12.63%	7.58%	8.59%	5.05%	13.13%	8.59%	
Indonesia	9.09%	4.04%	9.09%	6.57%	11.62%	7.58%	
Lao People's Democratic Republic	9.09%	5.56%	9.09%	5.05%	12.63%	8.08%	
Malaysia	27.78%	23.23%	27.78%	23.23%	31.31%	26.26%	
Maldives	6.06%	2.53%	7.58%	3.54%	8.59%	3.54%	
Mauritius	19.70%	15.66%	17.68%	15.15%	21.21%	17.17%	
Myanmar	8.59%	5.05%	7.07%	3.03%	9.60%	5.56%	
Philippines	12.12%	6.06%	24.75%	21.21%	27.78%	22.73%	
Seychelles	4.04%	1.52%	21.21%	18.69%	21.72%	18.69%	
Sri Lanka	28.79%	22.73%	22.73%	16.67%	30.81%	24.24%	
Thailand	37.37%	31.31%	28.79%	24.75%	39.90%	33.84%	
Timor-Leste	6.06%	2.53%	8.08%	4.04%	8.59%	4.55%	
Viet Nam	33.33%	25.76%	41.41%	36.87%	46.46%	40.91%	
Angola	8.08%	2.02%	9.09%	4.55%	10.61%	4.55%	
Central African Republic	9.09%	4.04%	9.09%	5.56%	11.11%	6.57%	
Congo	10.61%	6.06%	9.60%	4.04%	14.14%	8.08%	
Democratic Republic of the Congo	8.08%	3.54%	11.62%	7.58%	12.12%	8.08%	
Equatorial Guinea	6.06%	1.52%	6.57%	3.03%	7.58%	3.03%	
Gabon	7.07%	2.53%	10.61%	3.54%	12.63%	4.04%	
Burundi	7.58%	3.54%	8.59%	3.54%	10.10%	5.05%	
Comoros	8.59%	4.55%	6.57%	3.03%	9.60%	5.05%	
Djibouti	5.05%	1.52%	5.05%	2.02%	5.56%	2.02%	
Eritrea	5.05%	1.01%	7.58%	4.04%	8.59%	4.04%	
Ethiopia	13.13%	8.08%	13.13%	7.58%	16.67%	11.62%	
Kenya	25.76%	21.72%	13.64%	6.06%	27.78%	23.23%	
Madagascar	8.59%	3.03%	8.59%	4.04%	11.11%	5.56%	
Malawi	28.28%	23.23%	28.28%	24.24%	31.82%	27.27%	

Supplementary Table 11. Data coverage index for all non-fatal causes for 204 locations, 1990– 2005, 2005–2019 and in total by all ages and for the 70+ age group								
	199	0-2005	200	5-2019	199	0-2019		
	All ages	70+	All ages	70+	All ages	70+		
Mozambique	12.12%	6.06%	11.11%	4.55%	15.66%	8.59%		
Rwanda	6.57%	2.02%	13.64%	7.07%	14.14%	7.07%		
Somalia	4.04%	1.01%	5.05%	2.02%	5.56%	2.02%		
South Sudan	6.57%	2.02%	9.60%	4.55%	10.10%	5.05%		
Uganda	27.78%	21.21%	31.82%	25.25%	33.33%	25.76%		
United Republic of Tanzania	15.66%	7.07%	18.69%	11.11%	22.22%	13.64%		
Zambia	10.61%	5.56%	10.10%	5.56%	13.13%	8.59%		
Botswana	28.28%	24.24%	29.80%	25.76%	31.31%	26.77%		
Eswatini	8.59%	4.55%	7.58%	3.03%	11.11%	5.56%		
Lesotho	6.57%	2.02%	7.58%	3.54%	8.59%	4.04%		
Namibia	23.74%	18.18%	21.72%	17.68%	25.76%	20.20%		
South Africa	26.26%	21.21%	28.79%	25.76%	31.82%	27.78%		
Zimbabwe	27.78%	21.21%	24.75%	20.71%	29.80%	23.74%		
Benin	10.10%	4.55%	12.12%	7.07%	13.13%	7.58%		
Burkina Faso	12.63%	7.07%	13.64%	8.59%	16.16%	10.61%		
Cabo Verde	6.06%	2.02%	6.57%	3.54%	8.59%	4.04%		
Cameroon	23.23%	18.69%	22.73%	17.68%	26.26%	20.71%		
Chad	10.61%	5.56%	8.59%	4.04%	12.12%	7.07%		
Côte d'Ivoire	12.12%	6.06%	10.61%	5.05%	14.14%	8.08%		
Gambia	24.75%	19.19%	20.71%	16.16%	27.27%	21.21%		
Ghana	16.16%	7.07%	21.72%	12.63%	23.23%	13.13%		
Guinea	23.23%	18.18%	21.21%	16.67%	25.76%	20.71%		
Guinea-Bissau	6.06%	2.02%	9.60%	5.56%	9.60%	5.56%		
Liberia	5.05%	1.52%	8.59%	3.54%	9.09%	3.54%		
Mali	28.79%	20.20%	22.73%	16.67%	33.84%	24.24%		
Mauritania	8.59%	4.55%	7.58%	5.05%	10.61%	7.58%		
Niger	21.21%	15.15%	21.21%	15.66%	22.73%	16.16%		
Nigeria	15.15%	8.59%	13.64%	9.09%	19.70%	13.13%		
Sao Tome and Principe	5.05%	1.52%	7.07%	2.53%	7.58%	2.53%		
Senegal	13.13%	7.07%	12.63%	6.06%	16.67%	9.60%		
Sierra Leone	6.57%	2.02%	9.60%	5.05%	9.60%	5.05%		
Тодо	8.59%	3.54%	9.60%	5.05%	11.11%	6.06%		

Supplementary Table 12. Data coverage index for all locations for 286 non-fatal causes, 1990–2005, 2005–2019 and in total by						
all ages and for the 70+ age group						
	1990-2005		200	5-2019	199	0-2019
	All ages	70+	All ages	70+	All ages	70+
HIV/AIDS - Drug-susceptible Tuberculosis	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
HIV/AIDS - Multidrug-resistant Tuberculosis without extensive drug resistance	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
HIV/AIDS - Extensively drug-resistant Tuberculosis	26.89%	26.89%	63.45%	63.45%	63.87%	63.87%
HIV/AIDS resulting in other diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Syphilis	100.00%	16.39%	100.00%	21.43%	100.00%	21.85%
Chlamydial infection	40.76%	3.36%	100.00%	3.78%	100.00%	5.88%
Gonococcal infection	36.55%	1.68%	100.00%	2.52%	100.00%	2.94%
Trichomoniasis	12.61%	0.84%	100.00%	2.94%	100.00%	3.36%
Genital herpes	27.31%	13.03%	13.03%	3.36%	29.83%	15.13%
Other sexually transmitted infections	2.10%	1.26%	0.84%	0.42%	2.10%	1.26%
Latent tuberculosis infection	14.71%	1.26%	11.76%	0.84%	19.75%	1.68%
Drug-susceptible tuberculosis	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Multidrug-resistant tuberculosis without extensive drug resistance	77.73%	77.73%	80.67%	80.67%	81.09%	81.09%
Extensively drug-resistant tuberculosis	0.84%	0.84%	34.45%	34.45%	35.29%	35.29%
Lower respiratory infections	51.68%	13.03%	71.85%	34.45%	73.53%	34.45%
Upper respiratory infections	22.27%	0.42%	22.69%	0.42%	29.41%	0.42%
Otitis media	7.56%	1.26%	100.00%	1.26%	100.00%	1.68%
Diarrheal diseases	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Typhoid fever	5.88%	5.88%	6.72%	6.30%	8.82%	8.40%
Paratyphoid fever	8.40%	8.40%	7.98%	7.56%	11.34%	10.92%
Invasive Non-typhoidal Salmonella (iNTS)	5.04%	3.36%	7.14%	5.88%	8.40%	6.30%
Other intestinal infectious diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Malaria	100.00%	1 26%	100.00%	0.00%	100.00%	1 26%
	3.78%	2.52%	8.82%	8.82%	8.82%	8.82%
Viscoral leishmaniasis	21.85%	21 43%	29.41%	29.41%	29.83%	29.83%
Cutanoous and musecutanoous leishmaniasis	20.59%	19 75%	30.25%	30.25%	30.25%	30.25%
	12 61%	10 50%	12 18%	10.92%	12 61%	11 76%
Chietocomiacie	65 13%	58.40%	64 29%	58.40%	68 91%	62 18%
Curticorcosis	4 62%	4 20%	2 94%	2 52%	5.46%	5.04%
	81 93%	17 23%	81 93%	18 91%	81 93%	22 69%
	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	12 61%	1 68%	12.61%	0.84%	12 61%	1 68%
Trashoma	9.66%	9.66%	10 75%	10 33%	21.01%	21.03%
Desque	28 00%	28 00%	100.00%	100.00%	100.00%	100.00%
Deligue Velleur ferrer	7/ 79%	74 79%	81 93%	21 Q3%	81 Q3%	81 93%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Acception	57.98%	57 1/1%	57 56%	56 30%	58.40%	57 1/1%
Ascalidasis	57.98%	57 1/1%	57 56%	56 30%	58 40%	57 1/1%
	57.56%	57.14%	57.50%	50.30%	50.40%	57.14%
	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	52 10%	52 10%	100.00%	100.00%	100.00%	100.00%
Leprosy	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
zika virus	0.00%	0.00%	02.01%	7.000/	02.01%	7.00%
Guinea worm disease	7.98%	7.98%	7.98%	7.98%	7.98%	7.98%
Utner neglected tropical diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	100.00%	20.59%	100.00%	25.63%	100.00%	29.41%
Encephalitis	100.00%	11.76%	100.00%	10.81%	100.00%	18.49%
Diphtheria	100.00%	3.78%	100.00%	2.10%	100.00%	4.62%
Whooping cough	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%
Tetanus	100.00%	5.46%	100.00%	2.94%	100.00%	5.88%
Measles	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%

Supplementary Table 12. Data coverage index for all locations for 286 non-fatal causes, 1990–2005, 2005–2019 and in total by						
all ages and for the 70+ age group						
	1990-2005 2005-2019			1990-2019		
	All ages	70+	All ages	70+	All ages	70+
Varicella and herpes zoster	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Acute hepatitis A	39.08%	21.85%	19.33%	9.66%	43.28%	25.63%
Acute hepatitis B	34.45%	17.65%	26.89%	8.82%	44.54%	23.11%
Acute hepatitis C	35.71%	20.17%	22.27%	17.65%	43.70%	28.99%
Acute hepatitis E	15.97%	11.34%	2.94%	2.52%	17.23%	12.18%
Other unspecified infectious diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Maternal hemorrhage	21.85%	0.00%	28.99%	0.00%	34.45%	0.00%
Maternal sepsis and other maternal infections	16.81%	0.00%	24.37%	0.00%	28.57%	0.00%
Maternal hypertensive disorders	28.15%	0.00%	38.66%	0.00%	42.86%	0.00%
Maternal obstructed labor and uterine rupture	17.65%	0.00%	22.27%	0.42%	26.89%	0.42%
Maternal abortion and miscarriage	12.61%	0.00%	21.01%	0.00%	21.43%	0.00%
Ectopic pregnancy	9.24%	0.00%	18.07%	0.00%	18.49%	0.00%
Other maternal disorders	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Neonatal preterm birth	50.84%	0.00%	61.76%	0.00%	65.55%	0.00%
Neonatal encephalopathy due to birth asphyxia and trauma	18.49%	0.00%	19.33%	0.00%	22.27%	0.00%
Neonatal sepsis and other neonatal infections	13.87%	0.00%	18.49%	0.00%	19.75%	0.00%
Hemolytic disease and other neonatal jaundice	33.19%	0.00%	100.00%	0.00%	100.00%	0.00%
Other neonatal disorders	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Protein-energy malnutrition	59.24%	0.00%	56.30%	0.00%	64.29%	0.00%
lodine deficiency	30.67%	11.34%	3.36%	0.84%	30.67%	11.34%
Vitamin A deficiency	37.39%	4.20%	7.14%	0.00%	38.66%	4.20%
Dietary iron deficiency	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%
Other nutritional deficiencies	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Lip and oral cavity cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Nasopharynx cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Other pharynx cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Esophageal cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Stomach cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Colon and rectum cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Liver cancer due to hepatitis B	23.95%	22.69%	34.03%	33.19%	41.18%	39.50%
Liver cancer due to hepatitis C	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liver cancer due to alcohol use	7.14%	6.72%	22.69%	22.69%	25.21%	24.79%
Liver cancer due to NASH	7.14%	6.72%	23.53%	23.53%	25.21%	24.79%
Hepatoblastoma	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%
Liver cancer due to other causes (internal)	5.88%	5.88%	21.43%	21.43%	22.69%	22.69%
Gallbladder and biliary tract cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Pancreatic cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Larynx cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Tracheal, bronchus, and lung cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Malignant skin melanoma	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Non-melanoma skin cancer (squamous-cell carcinoma)	31.51%	31.51%	26.05%	26.05%	33.61%	33.61%
Non-melanoma skin cancer (basal-cell carcinoma)	29.41%	29.41%	23.53%	23.53%	31.51%	31.51%
Soft tissue and other extraosseous sarcomas	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Malignant neoplasm of bone and articular cartilage	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Breast cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Cervical cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Uterine cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Ovarian cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Prostate cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Testicular cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Kidney cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

Supplementary Table 12. Data coverage index for all locations for 286 non-fatal causes, 1990–2005, 2005–2019 and in total by							
all ages and for the 70+ age group							
	199	1990-2005 2005-2019			1990-2019		
	All ages	70+	All ages	70+	All ages	70+	
Bladder cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Brain and central nervous system cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Retinoblastoma	100.00%	0.00%	100.00%	0.00%	100.00%	0.00%	
Other eye cancers	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Neuroblastoma and other peripheral nervous cell tumors	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Thyroid cancer	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Mesothelioma	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Hodgkin lymphoma	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Burkitt lymphoma	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Other non-Hodgkin lymphoma	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Multiple myeloma	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Acute lymphoid leukemia	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Chronic lymphoid leukemia	2.94%	2.94%	100.00%	100.00%	100.00%	100.00%	
Acute myeloid leukemia	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Chronic myeloid leukemia	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Other leukemia	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Other malignant neoplasms (internal)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	
Myelodysplastic, myeloproliferative, and other hematopoietic neoplasms	8.82%	8.82%	13.87%	13.87%	14.29%	14.29%	
Benign and in situ intestinal neoplasms	9.24%	9.24%	14.71%	14.71%	15.13%	15.13%	
Benign and in situ cervical and uterine neoplasms	8.82%	8.82%	13.87%	13.87%	14.29%	14.29%	
Other benign and in situ neoplasms	9.24%	9.24%	14.71%	14.71%	15.13%	15.13%	
Rheumatic heart disease	13.45%	7.14%	15.13%	10.08%	20.17%	10.92%	
Ischemic heart disease	97.48%	97.48%	97.48%	97.48%	97.48%	97.48%	
Ischemic stroke	22.27%	21.85%	23.53%	22.69%	28.99%	28.15%	
Intracerebral hemorrhage	21.85%	21.43%	23.11%	22.69%	28.99%	28.15%	
Subarachnoid hemorrhage	17.65%	17.23%	18.91%	18.49%	23.95%	23.11%	
Hypertensive heart disease	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Non-rheumatic calcific aortic valve disease	8.40%	8.40%	11.76%	11.76%	12.18%	12.18%	
Non-rheumatic degenerative mitral valve disease	6.72%	6.72%	10.50%	10.50%	10.50%	10.50%	
Other non-rheumatic valve diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Myocarditis	7.56%	7.56%	12.61%	12.61%	12.61%	12.61%	
Alcoholic cardiomyopathy	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Other cardiomyopathy	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Pulmonary Arterial Hypertension	7.98%	7.14%	9.66%	9.24%	10.08%	9.66%	
Atrial fibrillation and flutter	13.03%	13.03%	15.97%	15.97%	18.49%	18.49%	
Peripheral artery disease	3.78%	3.78%	2.94%	2.94%	5.88%	5.88%	
Endocarditis	9.24%	9.24%	13.87%	13.87%	13.87%	13.87%	
Other cardiovascular and circulatory diseases (internal)	0.42%	0.42%	0.42%	0.42%	0.42%	0.42%	
Chronic obstructive pulmonary disease	12.18%	10.08%	17.65%	16.39%	21.85%	20.17%	
Silicosis	7.98%	7.98%	13.03%	13.03%	13.03%	13.03%	
Asbestosis	8.40%	8.40%	12.18%	12.18%	12.18%	12.18%	
Coal workers pneumoconiosis	7.98%	7.98%	10.92%	10.92%	11.34%	11.34%	
Other pneumoconiosis	8.40%	8.40%	13.03%	13.03%	13.45%	13.45%	
Asthma	54.20%	30.25%	23.95%	16.39%	58.40%	36.97%	
Interstitial lung disease and pulmonary sarcoidosis	13.87%	13.03%	15.97%	15.97%	18.91%	18.07%	
Other chronic respiratory diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Cirrhosis and other chronic liver diseases due to hepatitis B	9.24%	9.24%	4.62%	4.62%	10.08%	10.08%	
Cirrhosis and other chronic liver diseases due to hepatitis C	10.50%	10.08%	4.62%	4.62%	11.34%	10.92%	
Cirrhosis and other chronic liver diseases due to alcohol use	5.88%	5.88%	5.04%	5.04%	7.14%	7.14%	
Cirrhosis and other chronic liver diseases due to NAFLD	5.04%	5.04%	7.14%	5.88%	8.82%	7.56%	
Cirrhosis and other chronic liver diseases due to other causes	4.20%	3.78%	4.20%	3.78%	5.04%	4.62%	

Supplementary Table 12. Data coverage index for all locations for 286 non-fatal causes, 1990–2005, 2005–2019 and in total by						
all ages and for the 70+ age group						
	1990-2005 2005-2019			1990-2019		
	All ages	70+	All ages	70+	All ages	70+
Peptic ulcer disease	10.92%	9.66%	16.81%	15.97%	18.07%	16.39%
Gastritis and duodenitis	9.66%	9.66%	15.13%	15.13%	15.55%	15.55%
Gastroesophageal reflux disease	15.13%	14.71%	15.97%	14.71%	18.49%	17.23%
Appendicitis	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%
Paralytic ileus and intestinal obstruction	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%
Inguinal, femoral, and abdominal hernia	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%
Inflammatory bowel disease	29.41%	28.57%	27.73%	24.79%	35.29%	34.03%
Vascular intestinal disorders	9.24%	9.24%	14.29%	14.29%	14.71%	14.71%
Gallbladder and biliary diseases	12.61%	12.61%	15.13%	15.13%	18.49%	18.49%
Pancreatitis	12.61%	12.61%	20.17%	20.17%	21.01%	21.01%
Other digestive diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Alzheimer's disease and other dementias	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Parkinson's disease	11.76%	9.66%	100.00%	7.14%	100.00%	13.03%
Idiopathic epilepsy	100.00%	100.00%	24.79%	22.27%	100.00%	100.00%
Multiple sclerosis	14.29%	11.34%	14.29%	10.92%	18.91%	15.55%
Motor neuron disease	5.04%	4.62%	2.94%	2.94%	5.46%	5.04%
Migraine	25.21%	23.11%	14.29%	11.76%	34.03%	30.67%
Tension-type headache	19.33%	18.49%	9.24%	4.20%	26.47%	21.85%
Other neurological disorders	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Schizophrenia	10.92%	6.72%	7.56%	4.62%	12.61%	7.98%
Major depressive disorder	100.00%	100.00%	27.73%	22.27%	100.00%	100.00%
Dysthymia	8.40%	5.04%	8.40%	5.88%	12.61%	8.82%
Bipolar disorder	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Anxiety disorders	17.65%	13.45%	17.23%	12.18%	23.53%	18.91%
Anorexia nervosa	9.24%	1.26%	7.98%	1.68%	12.18%	2.52%
Bulimia nervosa	9.66%	3.78%	7.98%	2.52%	13.45%	5.46%
Autism spectrum disorders	14.71%	0.42%	10.08%	0.42%	19.33%	0.42%
Attention-deficit/hyperactivity disorder	100.00%	0.42%	12.18%	1.26%	100.00%	1.26%
Conduct disorder	100.00%	0.42%	5.04%	0.42%	100.00%	0.42%
Idiopathic developmental intellectual disability	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Other mental disorders	0.84%	0.84%	0.42%	0.42%	0.84%	0.84%
Alcohol use disorders	18.07%	7.98%	17.65%	8.82%	22.69%	13.03%
Opioid use disorders	10.50%	1.68%	100.00%	100.00%	100.00%	100.00%
Cocaine use disorders	21.43%	6.30%	23.53%	2.10%	28.15%	7.56%
Amphetamine use disorders	16.81%	2.52%	20.17%	1.68%	23.95%	3.36%
Cannabis use disorders	32.35%	9.24%	45.38%	5.04%	50.00%	10.92%
Other drug use disorders	0.84%	0.84%	0.84%	0.84%	0.84%	0.84%
Diabetes mellitus type 1	27.73%	2.10%	13.45%	2.94%	28.99%	3.36%
Diabetes mellitus type 2	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Chronic kidney disease due to diabetes mellitus type 1	5.46%	5.46%	10.08%	10.08%	10.92%	10.92%
Chronic kidney disease due to diabetes mellitus type 2	5.46%	5.46%	10.08%	10.08%	10.92%	10.92%
Chronic kidney disease due to hypertension	14.29%	13.87%	20.59%	20.59%	22.27%	22.27%
Chronic kidney disease due to glomerulonephritis	14.29%	13.87%	20.59%	20.59%	22.27%	22.27%
Chronic kidney disease due to other and unspecified causes	14.29%	13.87%	20.59%	20.59%	22.27%	22.27%
Acute glomerulonephritis	7.56%	7.56%	12.61%	12.61%	13.03%	13.03%
Atopic dermatitis	50.84%	2.52%	24.37%	4.20%	53.78%	5.46%
Contact dermatitis	2.94%	1.68%	4.20%	2.10%	5.46%	2.94%
Seborrhoeic dermatitis	3.78%	1.68%	6.30%	2.94%	8.40%	4.20%
Psoriasis	26.47%	13.03%	8.82%	6.72%	29.41%	15.97%
Cellulitis	9.24%	9.24%	14.71%	14.71%	15.13%	15.13%
Pyoderma	10.50%	8.82%	15.97%	13.87%	17.23%	14.71%

Supplementary Table 12. Data coverage index for all locations for 286 non-fatal causes, 1990–2005, 2005–2019 and in total by						
all ages and for the 70+ age group						
	199	1990-2005 2005-2019		199	0-2019	
	All ages	70+	All ages	70+	All ages	70+
Scabies	8.40%	5.46%	9.24%	5.46%	12.18%	8.40%
Fungal skin diseases	6.72%	2.52%	7.56%	2.52%	10.08%	3.78%
Viral skin diseases	7.14%	2.52%	7.14%	3.78%	10.08%	5.88%
Acne vulgaris	5.88%	2.94%	9.24%	2.94%	11.76%	5.46%
Alopecia areata	2.10%	1.26%	5.04%	2.10%	5.46%	2.94%
Pruritus	2.52%	1.26%	3.36%	3.36%	5.04%	3.78%
Urticaria	5.46%	3.78%	5.04%	2.94%	8.40%	6.30%
Decubitus ulcer	9.24%	9.24%	14.29%	14.29%	14.71%	14.71%
Other skin and subcutaneous diseases	0.42%	0.00%	0.84%	0.42%	0.84%	0.42%
Glaucoma	12.18%	12.18%	28.15%	28.15%	32.35%	32.35%
Cataract	15.55%	15.13%	29.83%	29.83%	34.87%	34.87%
Age-related macular degeneration	10.50%	10.50%	27.73%	27.73%	31.09%	31.09%
Refraction disorders	26.47%	12.61%	27.73%	27.73%	40.76%	31.09%
Near vision loss	1.26%	1.26%	5.04%	4.62%	5.88%	5.46%
Other vision loss	8.40%	8.40%	22.69%	22.69%	26.05%	26.05%
Age-related and other hearing loss	10.08%	1.26%	2.94%	0.42%	11.34%	1.26%
Other sense organ diseases	0.42%	0.00%	0.84%	0.42%	0.84%	0.42%
Rheumatoid arthritis	9.66%	9.24%	9.24%	9.24%	14.29%	13.87%
Osteoarthritis hip	3.78%	3.78%	3.78%	3.78%	6.30%	6.30%
Osteoarthritis knee	2.94%	2.94%	5.88%	5.46%	7.56%	7.14%
Osteoarthritis hand	6.30%	2.94%	16.39%	5.04%	18.49%	6.72%
Osteoarthritis other	0.42%	0.00%	0.42%	0.00%	0.42%	0.00%
Low back pain	36.55%	32.35%	28.57%	22.69%	43.70%	40.34%
Neck pain	18.91%	18.91%	19.33%	19.33%	19.75%	19.75%
Gout	6.30%	6.30%	5.46%	5.46%	9.66%	9.66%
Other musculoskeletal disorders	4.62%	4.62%	4.20%	4.20%	6.72%	6.72%
Neural tube defects	100.00%	100.00%	100.00%	18.49%	100.00%	100.00%
Congenital heart anomalies	100.00%	100.00%	100.00%	15.55%	100.00%	100.00%
Orofacial clefts	25.21%	9.24%	31.93%	14.29%	35.29%	14.71%
Down syndrome	100.00%	100.00%	26.05%	3.78%	100.00%	100.00%
Turner syndrome	100.00%	100.00%	14.71%	10.92%	100.00%	100.00%
Klinefelter syndrome	100.00%	100.00%	14.29%	10.92%	100.00%	100.00%
Other chromosomal abnormalities	100.00%	100.00%	24.37%	16.81%	100.00%	100.00%
Congenital musculoskeletal and limb anomalies	25.63%	8.82%	31.51%	14.29%	35.29%	14.71%
Urogenital congenital anomalies	100.00%	8.40%	33.19%	13.45%	100.00%	13.87%
Digestive congenital anomalies	27.73%	9.24%	28.57%	13.87%	32.35%	14.29%
Other congenital birth defects	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Urinary tract infections	9.24%	9.24%	14.71%	14.71%	15.13%	15.13%
Urolithiasis	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%
Benign prostatic hyperplasia	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%
Male infertility	36.97%	0.00%	26.47%	0.00%	42.02%	0.00%
Other urinary diseases	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Uterine fibroids	10.08%	9.24%	17.23%	14.29%	18.07%	14.71%
Polycystic ovarian syndrome	5.04%	0.00%	16.81%	0.00%	17.23%	0.00%
Female infertility	36.97%	0.00%	26.47%	0.00%	42.02%	0.00%
Endometriosis	10.50%	0.00%	15.55%	0.00%	16.39%	0.00%
Genital prolapse	11.34%	10.50%	16.39%	15.97%	17.65%	16.39%
Premenstrual syndrome	5.04%	0.00%	5.04%	0.00%	7.98%	0.00%
Other gynecological diseases	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%
Thalassemias	34.45%	2.52%	34.87%	5.46%	35.29%	5.46%
Thalassemias trait	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Supplementary Table 12: Data coverage index for all locations for 286 non-fatal causes, 1990–2005, 2005–2019 and in total by							
all ages and for the 70+ age group							
	1990-2005		200	5-2019	199	0-2019	
	All ages	70+	All ages	70+	All ages	70+	
Sickle cell disorders	40.34%	9.66%	44.96%	15.13%	45.38%	16.39%	
Sickle cell trait	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
G6PD deficiency	100.00%	13.87%	100.00%	9.24%	100.00%	17.23%	
G6PD trait	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Other hemoglobinopathies and hemolytic anemias	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Endocrine, metabolic, blood, and immune disorders	9.24%	9.24%	15.13%	15.13%	15.55%	15.55%	
Caries of deciduous teeth	23.11%	0.00%	23.95%	0.00%	32.77%	0.00%	
Caries of permanent teeth	24.79%	5.04%	25.63%	5.88%	34.45%	8.82%	
Periodontal diseases	14.29%	7.56%	6.72%	5.04%	16.81%	10.92%	
Edentulism and severe tooth loss	33.19%	32.35%	23.53%	22.69%	37.82%	37.39%	
Other oral disorders	0.42%	0.00%	0.42%	0.00%	0.42%	0.00%	
Pedestrian road injuries	3.78%	3.36%	7.14%	5.88%	7.14%	6.30%	
Cyclist road injuries	3.78%	3.36%	6.72%	5.88%	7.14%	6.30%	
Motorcyclist road injuries	3.36%	3.36%	6.72%	5.88%	7.14%	6.30%	
Motor vehicle road injuries	3.78%	3.36%	6.72%	5.88%	7.14%	6.30%	
Other road injuries	3.36%	3.36%	5.04%	5.04%	5.46%	5.46%	
Other transport injuries	3.78%	3.78%	5.88%	5.88%	6.30%	6.30%	
Falls	9.24%	7.98%	11.34%	10.08%	14.29%	12.61%	
Drowning	9.24%	8.40%	13.87%	13.45%	14.71%	14.29%	
Fire, heat, and hot substances	7.14%	6.30%	10.50%	9.24%	12.61%	11.34%	
Poisoning by carbon monoxide	3.36%	3.36%	5.46%	5.46%	5.88%	5.88%	
Poisoning by other means	3.78%	3.78%	5.88%	5.88%	6.30%	6.30%	
Unintentional firearm injuries	3.78%	3.78%	5.46%	5.46%	5.88%	5.88%	
Other exposure to mechanical forces	3.78%	3.78%	6.30%	6.30%	6.72%	6.72%	
Adverse effects of medical treatment	8.82%	8.82%	14.29%	14.29%	14.71%	14.71%	
Venomous animal contact	3.78%	3.78%	6.30%	6.30%	6.72%	6.72%	
Non-venomous animal contact	3.78%	3.78%	5.88%	5.88%	6.30%	6.30%	
Pulmonary aspiration and foreign body in airway	4.20%	4.20%	6.30%	6.30%	6.72%	6.72%	
Foreign body in eyes	4.20%	4.20%	6.30%	6.30%	6.30%	6.30%	
Foreign body in other body part	4.62%	4.62%	7.14%	7.14%	7.56%	7.56%	
Environmental heat and cold exposure	4.20%	3.78%	5.88%	5.88%	6.72%	6.30%	
Exposure to forces of nature	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Other unintentional injuries	3.78%	3.78%	5.88%	5.88%	6.72%	6.72%	
Self-harm by firearm	6.30%	6.30%	9.66%	9.24%	9.66%	9.24%	
Self-harm by other specified means	3.36%	3.36%	5.88%	5.46%	6.30%	5.88%	
Physical violence by firearm	7.98%	7.98%	10.50%	10.50%	11.76%	11.76%	
Physical violence by sharp object	4.20%	4.20%	8.82%	8.82%	9.24%	9.24%	
Sexual violence	9.24%	0.42%	26.05%	1.68%	28.57%	1.68%	
Physical violence by other means	3.78%	3.78%	6.30%	6.30%	6.72%	6.72%	
Conflict and terrorism	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
Executions and police conflict	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	